<SEC-DOCUMENT>0001213900-24-025615.txt : 20240325
<SEC-HEADER>0001213900-24-025615.hdr.sgml : 20240325
<ACCEPTANCE-DATETIME>20240325172307
ACCESSION NUMBER:		0001213900-24-025615
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240325
DATE AS OF CHANGE:		20240325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silo Pharma, Inc.
		CENTRAL INDEX KEY:			0001514183
		STANDARD INDUSTRIAL CLASSIFICATION:	APPAREL & OTHER FINISHED PRODS OF FABRICS & SIMILAR MATERIAL [2300]
		ORGANIZATION NAME:           	04 Manufacturing
		IRS NUMBER:				462137136
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41512
		FILM NUMBER:		24780208

	BUSINESS ADDRESS:	
		STREET 1:		677 N. WASHINGTON BLVD
		CITY:			SARASOTA
		STATE:			FL
		ZIP:			34236
		BUSINESS PHONE:		(718) 400-9031

	MAIL ADDRESS:	
		STREET 1:		677 N. WASHINGTON BLVD
		CITY:			SARASOTA
		STATE:			FL
		ZIP:			34236

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Uppercut Brands, Inc.
		DATE OF NAME CHANGE:	20190808

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Point Capital, Inc.
		DATE OF NAME CHANGE:	20130130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gold Swap Inc
		DATE OF NAME CHANGE:	20110301
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0201957-10k_silopharma.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 20:01:04 UTC 2024 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:silo="http://www.silopharma.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>



</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-14802">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-14803">&#9746;</ix:nonNumeric>&#160;ANNUAL REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended: <span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-14804"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-14805">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-14806">2023</ix:nonNumeric></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-14807">&#9744;</ix:nonNumeric>&#160;TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-14808">001-41512</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 100%; font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-62"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">SILO PHARMA, INC</span></b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of Registrant as Specified in Its Charter)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-76"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-81"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>27-3046338</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<br/>
Incorporation or Organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%; border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-99"><b>677 N. Washington Boulevard</b></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-14809">Sarasota</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince" id="ixv-14810">FL</ix:nonNumeric></b></p></td> <td style="width: 1%; text-align: center; font-size: 10pt">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-108"><b>34236</b></ix:nonNumeric></p></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</span></td> <td style="text-align: center; font-size: 10pt">&#160;</td> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code<b>:&#160;<ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-14811">(718)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-14812">400-9031</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 33%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading symbol(s)</b></span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 33%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-143"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock, $0.0001 par value per share</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-148"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SILO</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-14813">Nasdaq</ix:nonNumeric> Stock Market LLC</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-14814">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-14815">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-14816">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-14817">Yes</ix:nonNumeric>
&#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and
&#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-14818">Non-accelerated filer</ix:nonNumeric> &#9746;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller Reporting Company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-14819">&#9746;</ix:nonNumeric></span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging Growth Company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-14820">&#9744;</ix:nonNumeric></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-14821">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If securities are registered pursuant to Section 12(b) of the Act,
indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to
previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-14822">&#9744;</ix:nonNumeric> &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b) &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined by Rule 12b-2 of the Exchange Act) Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-14823">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the voting stock
and non-voting common equity held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently
completed second fiscal quarter ended June 30, 2023 was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd" id="ixv-14824">5,962,382</ix:nonFraction> based upon the closing price of the registrant&#8217;s common stock
of $2.05 on the NASDAQ as of that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of shares of common stock outstanding
as of March 23, 2024 was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14825">2,843,634</ix:nonFraction> (315,462 shares held in treasury).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Documents incorporated by reference: <ix:nonNumeric contextRef="c0" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="ixv-14826">None</ix:nonNumeric>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM 10-K</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 10%; text-align: center">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 82%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">PART I</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk Factors</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved Staff Comments</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Cybersecurity</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Properties</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Legal Proceedings</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_009">PART II</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">[Reserved]</a></span></td>
    <td style="vertical-align: bottom; text-align: center">29</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Financial Statements and Supplementary Data</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Other Information</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">Disclosure regarding foreign jurisdictions that prevent inspections</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_019">PART III</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Executive Compensation</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">Principal Accountant Fees and Services</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_025">PART IV</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">Exhibits, Financial Statement Schedules</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_027">Form 10-K Summary</a></span></td>
    <td style="vertical-align: bottom; text-align: center">56</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_028">Signatures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Annual Report on Form 10-K contains forward-looking
statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this
report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects,
plans and objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221;
&#8220;expect,&#8221; &#8220;plan,&#8221;, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221;
&#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221;
&#8220;ongoing&#8221; or the negative of these terms or other comparable terminology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any forward-looking statements are qualified in
their entirety by reference to the risk factors discussed throughout this Annual Report on Form 10-K. Some of the risks, uncertainties
and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements
include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain additional funds for our operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our financial performance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks related to market acceptance of products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intellectual property risks;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of government regulation and developments relating to our competitors or our industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our competitive position;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our industry environment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our anticipated financial and operating results, including anticipated sources of revenues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.3pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assumptions regarding the size of the available market, benefits of our products, product pricing and timing of product launches;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates of our expenses, losses, future revenue and capital requirements, including our needs for additional financing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to attract and retain qualified key management and technical personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements regarding our goals, intensions, plans and expectations, including the introduction of new products and markets; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our cash needs and financing plans.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These statements relate to future events or our
future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied
by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among
other things, those listed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any forward-looking statement in this report reflects
our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our
business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking
statements. No forward-looking statement is a guarantee of future performance. You should read this report completely and with the understanding
that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report also contains estimates, projections
and other information concerning our industry, our business and our markets, including data regarding the estimated size of those markets
and their projected growth rates. Information that is based on estimates, forecasts, projections or similar methodologies is inherently
subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.
Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies
and similar data prepared by third parties, industry, and general publications, government data and similar sources. While we believe
that the reports, research surveys, studies and similar data prepared by third parties are reliable, we have not independently verified
the data contained in them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You are cautioned not to place undue reliance
on any forward-looking statements, which speak only as of the date of this report. Except as required by law, we do not undertake any
obligation to update or release any revisions to these forward-looking statements to reflect any events or circumstances, whether as a
result of new information, future events, changes in assumptions or otherwise, after the date hereof. New factors emerge from time to
time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our
business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained
in any forward-looking statements. We qualify all of the information presented in this Annual Report on Form 10-K, and particularly our
forward-looking statements, by these cautionary statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RISK FACTOR SUMMARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is subject to significant risks and
uncertainties that make an investment in us speculative and risky. Below we summarize what we believe are the principal risk factors but
these risks are not the only ones we face, and you should carefully review and consider the full discussion of our risk factors in the
section titled &#8220;Risk Factors,&#8221; together with the other information in this Annual Report on Form 10-K. If any of the following
risks actually occurs (or if any of those listed elsewhere in this Annual Report on Form 10-K occur), our business, reputation, financial
condition, results of operations, revenue, and future prospects could be seriously harmed. Additional risks and uncertainties that we
are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Financial Position and
Need for Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have only a limited history upon which an evaluation of our prospects and future performance can be made and have no history of profitable operations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">We will require additional financing in the future to fund
our operations; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
additional capital may cause dilution to holders of our stockholders, restrict our operations or require us to relinquish certain rights</span></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Rare Disease Therapeutics
Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of any future therapeutic candidates are prolonged or delayed, we or our current or future collaborators may be unable to obtain required regulatory approvals, and therefore we will be unable to commercialize our future therapeutic candidates on a timely basis or at all, which will adversely affect our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any therapeutic candidates we may develop in the future may be subject to controlled substance laws and regulations in the territories where the product will be marketed, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations and our financial condition.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Psilocybin and psilocin are listed as Schedule I controlled
substances under the Controlled Substances Act in the U.S., and similar controlled substance legislation in other countries and any significant
breaches in our compliance with these laws and regulations, or changes in the laws and regulations may result in interruptions to our
development activity or business continuity.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates may contain controlled substances, the use of which may generate public controversy. Adverse publicity or public perception
regarding psilocybin or our current or future investigational therapies using psilocybin may negatively influence the success of these
therapies.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if any of our future therapeutic candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense or penalties if we fail to comply with regulatory requirements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will depend on enrollment of patients in our clinical trials for our future therapeutic candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never commercialized a therapeutic candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our therapies on our own or with suitable collaborators.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The future commercial success of our future therapeutic candidates will depend on the degree of market access and acceptance of our potential therapies among healthcare professionals, patients, healthcare payors, health technology assessment bodies and the medical community at large.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may become exposed to costly and damaging liability claims, and our product liability insurance may not cover all damages from such claims.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize any of our future therapeutic candidates and could have a material adverse effect on our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers may be subject, directly or indirectly, to U.S. federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, other healthcare laws and regulations and other foreign privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to Our Intellectual Property
Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">The failure to obtain or maintain patents, licensing agreements
and other intellectual property could materially impact our ability to compete effectively.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; padding-bottom: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain and maintain patent protection for our products, or if the scope of the patent protection obtained is not sufficiently broad, competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products could be impaired.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never paid cash dividends and have no plans to pay cash dividends in the future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to remain current in our reporting requirements, we could be removed from the NASDAQ which would limit the ability of broker-dealers to sell our securities and the ability of stockholders to sell their securities in the secondary market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock could be subject to extreme volatility. Market and economic conditions may negatively impact our business, financial condition and share price.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future sales and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The majority of our cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in non-interest-bearing and interest-bearing operating accounts may exceed the Federal Deposit Insurance Corporation (&#8220;<b>FDIC</b>&#8221;) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. Any material loss that we may experience in the future could have an adverse effect on our ability to pay our operational expenses or make other payments. To mitigate our risk, in March 2023 we began transferring our cash to other banks to ensure that our exposure is limited or reduced to the FDIC protection limits.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Throughout this Annual Report on Form 10-K, the
&#8220;Company,&#8221; &#8220;Silo,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refers to Silo Pharma, Inc. and its
subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. BUSINESS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a developmental stage biopharmaceutical
company developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia,
and central nervous system (CNS) diseases. We are focused on developing novel therapies that include conventional drugs and psychedelic
formulations. The Company&#8217;s lead program, SPC-15, is an intranasal drug targeting PTSD and stress-induced anxiety disorders. SP-26
is a time-release ketamine-based loaded implant for fibromyalgia and chronic pain relief. Silo&#8217;s two preclinical programs are SPC-14,
an intranasal compound for the treatment of Alzheimer&#8217;s disease, and SPU-16, a CNS-homing peptide targeting the central nervous
system with initial research indication in multiple sclerosis (MS).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Rare Disease Therapeutics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, ketamine, and the potential benefits they may have in certain cases involving depression, mental health issues and
neurological disorders. We are focused on developing traditional therapeutics and psychedelic medicine. The company concentrates on the
development and commercialization of therapies for unmet needs from indications such as depression, post-traumatic stress disorder (&#8220;PTSD&#8221;),
and other rare neurological disorders. Our mission is to identify assets to license and fund the research which we believe will be transformative
to the well-being of patients and the health care industry.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Psilocybin is considered a serotonergic hallucinogen
and is an active ingredient in some species of mushrooms. Recent industry studies using psychedelics, such as psilocybin, have been promising,
and we believe there is a large unmet need with many people suffering from depression, mental health issues and neurological disorders.
While classified as a Schedule I substance under the Controlled Substances Act (&#8220;CSA&#8221;), there is an accumulating body of evidence
that psilocybin may have beneficial effects on depression and other mental health conditions. Therefore, the U.S. Food and Drug Administration
(&#8220;FDA&#8221;) and U.S. Drug Enforcement Agency (&#8220;DEA&#8221;) have permitted the use of psilocybin in clinical studies for
the treatment of a range of psychiatric conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential of psilocybin therapy in mental
health conditions has been demonstrated in a number of academic-sponsored studies over the last decade. In these early studies, it was
observed that psilocybin therapy provided rapid reductions in depression symptoms after a single high dose, with antidepressant effects
lasting for up to at least six months for a number of patients. These studies assessed symptoms related to depression and anxiety through
a number of widely used and validated scales. The data generated by these studies suggest that psilocybin is generally well-tolerated
and may have the potential to treat depression when administered with psychological support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged in discussions with a number of
world-renowned educational institutions and advisors regarding potential opportunities and have formed a scientific advisory board that
is intended to help advise management regarding potential acquisition and development of products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as more fully described below, we
have entered into a license agreement with the University of Maryland, Baltimore, and are developing a Ketamine polymer implant. In addition,
we have recently entered into a sponsored research agreement with Columbia University pursuant to which we have been granted an option
to license certain patents and inventions relating to the treatment of Alzheimer&#8217;s disease and stress-induced affective disorders
using Ketamine in combination with certain other compounds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to actively pursue the acquisition and/or
development of intellectual property or technology rights to treat rare diseases, and to ultimately expand our business to focus on this
new line of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently focusing on four product candidates:
(i) SPC-15 for treatment of depression disorders; (ii) SP-26 for treatments of chronic pain; (iii)SPC-14 for the treatment of Alzheimer&#8217;s
disease and (iv) SPU-16 for the treatment of CNS disorders with an initial indication for multiple sclerosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SPC-15</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into a sponsored research agreement
with Columbia University pursuant to which the Company has been granted an option to license certain assets currently under development,
including assets related to SPC-15 for the treatment of depression disorders. On September 22, 2022, we entered into a First Amendment
to Sponsored Research Agreement with Columbia to extend the term of the Columbia Agreement to conduct further research studies, which
extension runs through March 31, 2024. On April 11, 2023, the assets under development for which we have the option to license as described
above were issued a patent from the U.S. Patent &amp; Trademark Office (USPTO) for &#8220;Biomarkers for Efficacy of Prophylactic Treatments
Against Stress-Induced Affective Disorders&#8221; (US 11,622,948, B2). The Company exercised its option for an exclusive license agreement
for SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD pursuant to which the Company will
be granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. The Company expects to have the complete
license agreement with Columbia completed in the first half of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SPC-15 is a targeted prophylactic therapeutic
composition for the treatment and prevention for stress-induced affective disorders including PTSD. The treatment predicts levels of severity
or progression of such disorders and their metabolomic biomarkers&#8217; response to pharmacological treatments. We intend to develop
SPC-15 under the Section 505(b)(2) regulatory pathway of the FDA rules. Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act
(&#8220;FDCA&#8221;) was enacted to enable sponsors to seek New Drug Application (&#8220;NDA&#8221;) approval for novel repurposed drugs
without the need for such sponsors to undertake time consuming and expensive pre-clinical safety studies and Phase 1 safety studies. Proceeding
under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission
to the FDA for marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 15, 2023, the Company entered an exclusive
license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, as the delivery mechanism for
SPC-15, which agreement has an effective date of October 31, 2023. Preclinical and formulation studies are expected to be completed in
the first quarter of 2024 and the Company intends to submit a pre-IND meeting request to FDA in the first half of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SP-26 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2023, the Company filed a provisional
patent application with the USPTO to use SP-26 for treatment of chronic pain, including fibromyalgia. Fibromyalgia is a chronic condition
causing pain to the connective tissues through the body including muscles, ligaments, and tendons. Musculoskeletal pain is often accompanied
by sleep difficulties, fatigue, mood disorders, and problems with memory and concentration. Fibromyalgia affects about 4 million American
adults, or about 2% of the adult population.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to develop SP-26 following the Section
505(b)(2) regulatory pathway of the FDA rules. Section 505(b)(2) of the FDCA was enacted to enable sponsors to seek NDA approval for novel
repurposed drugs without the need for such sponsors to undertake time consuming and expensive pre-clinical safety studies and Phase 1
safety studies. Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active
ingredient in our NDA submission to the FDA for marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SPC-14</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into a
sponsored research agreement with Columbia University (&#8220;Columbia&#8221;) pursuant to which Columbia shall conduct two different
studies related to the use of SPC-14 for the treatment of Alzheimer&#8217;s. See &#8220;Investigator-Sponsored Study Agreements between
the Company and Vendors---Sponsored Research Agreement with Columbia University for the Study of Ketamine in Combination with Other Drugs
for Treatment of Alzheimer&#8217;s and Depression Disorders.&#8221; for additional details. In addition, Company has been granted an option
to license certain assets currently under development, including SPC-14 for the treatment of Alzheimer&#8217;s disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SPC-14 is a novel drug combining two approved
therapeutics, so we intend to develop SPC-14 following the Section 505(b)(2) regulatory pathway of the FDA rules. Section 505(b)(2) of
the FDCA was enacted to enable sponsors to seek NDA approval for novel repurposed drugs without the need for such sponsors to undertake
time consuming and expensive pre-clinical safety studies and Phase 1 safety studies. Proceeding under this regulatory pathway, we will
be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2022, the Company extended the
term of the sponsored research agreement with Columbia to conduct further research studies into the mechanism of action of SPC-14 in the
treatment of Alzheimer&#8217;s disease. We expect the results from further preclinical studies in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SPU-16</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, we entered into a Master
License Agreement (the &#8220;UMB License Agreement&#8221;) with the University of Maryland, Baltimore (&#8220;UMB&#8221;) pursuant to
which UMB granted us an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual property (i) to make, have
made, use, sell, offer to sell, and import certain licensed products and (ii) to use the invention titled &#8220;Central nervous system-homing
peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology,&#8221;
or SPU-16. See &#8220;License Agreements between the Company and Vendors--Vendor License Agreement with the University of Maryland, Baltimore
for CNS Homing Peptide&#8221; for additional details. On April 11, 2023 certain intellectual property under the UMB License Agreement
described above were issued a patent from the U.S. Patent &amp; Trademark Office (USPTO) for &#8220;Peptide-Targeted Liposomal Delivery
For Treatment, Diagnosis, and Imaging of Diseases and Disorders&#8221; (US 11,766,403, B2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SPU-16 is a novel peptide homing specifically
to inflamed CNS areas. It may be used to diagnose neuroinflammation in patients, and target delivery of drugs into the spinal cord. The
initial indication is for multiple sclerosis (MS). The peptides have been tested in the EAE mouse model of human MS, where they show homing
specifically to inflamed CNS areas.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Product Development Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our product development
pipeline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company and
Vendor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Vendor License Agreement with the University
of Maryland, Baltimore for CNS Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, we entered into a Master
License Agreement (the &#8220;UMB License Agreement&#8221;) with the University of Maryland, Baltimore (&#8220;UMB&#8221;) pursuant to
which UMB granted us an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual property (i) to make, have
made, use, sell, offer to sell, and import certain licensed products and (ii) to use the invention titled, &#8220;Central nervous system-homing
peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#8221;
(the &#8220;Invention&#8221;) and UMB&#8217;s confidential information to develop and perform certain licensed processes for the therapeutic
treatment of neuroinflammatory disease. The term of the License Agreement shall commence on the UMB Effective Date and shall continue
until the latest of (i) ten years from the date of First Commercial Sale (as defined in the Sublicense Agreement) of the Licensed Product
in such country and (ii) the date of expiration of the last to expire claim of the Patent Rights (as defined in the UMB License Agreement)
covering such Licensed Product in such country, or (iii) the expiration of data protection, new chemical entity, orphan drug exclusivity,
regulatory exclusivity, or other legally enforceable market exclusivity, if applicable, unless terminated earlier pursuant to the terms
of the agreement. Pursuant to the UMB License Agreement, we agreed to pay UMB (i) a license fee of $75,000, (ii) certain event-based milestone
payments, (iii) royalty payments, depending on net revenues, (iv) minimum royalty payments, and (v) a tiered percentage of sublicense
income. The UMB License Agreement will remain in effect until the later of: (a) the last patent covered under the UMB License Agreement
expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally
enforceable market exclusivity, if applicable, or (c) ten years after the first commercial sale of a licensed product in that country,
unless earlier terminated in accordance with the provisions of the UMB License Agreement. The term of the UMB License Agreement shall
expire 15 years after the effective date in which (a) there were never any patent rights, (b) there was never any data protection, new
chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity or (c) there was never
a first commercial sale of a licensed product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described below, the Company has entered into
an investigator sponsored research agreement with UMB related to a clinical study to examine a novel peptide-guided drug delivery approach
for the treatment of Multiple Sclerosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Commercial Evaluation License and Option Agreement
with UMB for Joint Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into a commercial
evaluation license and option agreement (&#8220;License Agreement&#8221;), which granted the Company an exclusive, non-sublicensable,
non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use in the investigation
and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate and obtain an
exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive Option&#8221;) with respect to the subject technology. The License
Agreement had a term of six months from the effective date. Both parties could have terminated the License Agreement within thirty days
by giving a written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company entered into a First
Amendment Agreement (&#8220;Amended License Agreement&#8221;) with UMB to extend the term of the original License Agreement by an additional
six months such that the Amended License Agreement was effective until February 25, 2022 however, if the Company exercises the Exclusive
Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution
of a master license agreement, whichever occurs first. The Company paid a license fee of $10,000 to UMB in March 2021 pursuant to the
License Agreement, which was expensed, since the Company could not conclude that such costs would be recoverable for this early-stage
venture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, the Company and University
of Maryland, Baltimore entered into a second amendment to the License Agreement dated February 26, 2021 (&#8220;Second Amendment&#8221;).
The Second Amendment extended the term of the License Agreement until December 31, 2022. However, if the Company exercises the Exclusive
Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution
of a master license agreement, whichever occurs first.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 22, 2022, the Company and UMB entered
into a third amendment to the License Agreement dated February 26, 2021 under which UMB agreed, to expand the scope of the license granted
in the CELA to add additional Patent Rights with respect to an invention generally known as &#8220;Peptide-Targeted Liposomal Delivery
for Treatment Diagnosis, and Imaging of Diseases and Disorders.&#8221; On December 16, 2022, the Company and UMB entered into a fourth
amendment to License Agreement (the &#8220;Fourth Amendment&#8221;) dated February 26, 2021 to extend the term of the License Agreement
until March 31, 2023. In addition, the parties agreed in the Fourth Amendment to allow the Company to extend the term of the License Agreement
to June 30, 2023 by paying UMB a fee of $1,000 on or before February 28, 2023. This fee was paid and thus the term of the License Agreement
was extended to June 30, 2023. We let this license expire by its terms on December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Joint Venture Agreement with Zyl&#246; Therapeutics,
Inc. for Z-pod&#8482; Technology</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021, the Company entered into a
Joint Venture Agreement with Zyl&#246; Therapeutics, Inc. (&#8220;ZTI&#8221;) pursuant to which the parties agreed to form a joint venture
entity, to be named Ketamine Joint Venture, LLC, to, among other things, focus on the clinical development of ketamine using ZTI&#8217;s
Z-pod&#8482; technology. Pursuant to the Joint Venture Agreement, the Company shall act as the manager of the Joint Venture. The Venture
shall terminate if the development program does not meet certain specifications and milestones as set forth in the Joint Venture Agreement
within 30 days of the date set forth in the Joint Venture Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion,
terminate the Venture at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Joint Venture
Agreement,&#160;(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and
(B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the
know-how and trade secrets with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be used
for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the Joint Venture
Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture
shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing,
in no event shall either party own more than 60% of the interest in the Joint Venture. As of December 31, 2022 and as of the current date
of this Annual Report, the joint venture entity has not been formed yet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the terms of the JV Agreement,
ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#8220;License Agreement&#8221;) with Albert Einstein
College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating that the patented
technology (the &#8220;Patented Technology&#8221;) licensed to ZTI pursuant to the License Agreement is needed to advance the development
of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant to the JV Agreement,
ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development of psilocybin using ZTI&#8217;s
Z-pod&#8482; technology on the same terms and conditions set forth in the JV Agreement, which option shall expire 24 months after the
JV Effective Date. We do not intend to continue with Zylo and have entered into an agreement to develop a polymer implant for dosage and
time release of Ketamine for chronic pain and Fibromyalgia</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exclusive License Agreement between Medspray
Pharma BV and the Company</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 15, 2023, we entered into an Exclusive
License Agreement (the &#8220;Medspray License Agreement&#8221;) with Medspray Pharma BV (&#8220;Medspray&#8221;) pursuant to which Medspray
granted us an exclusive, non-revocable, worldwide royalty bearing license for Medspray&#8217;s proprietary patented soft mist nasal spray
technology for marketing, promotion, sale and distribution of the products licensed by Medspray to us under the Medspray License Agreement.
The Medspray License Agreement has an effective date of October 31, 2023 and expires on the earlier of (i) termination of the Medspray
License Agreement or expiry of all Medspray license rights in the United States, Germany, United Kingdom, Spain, Italy and France. In
consideration of the exclusive rights granted by Medspray to us, we agreed to pay Medspray a royalty on a quarterly basis equal to 5%
of net sales. The term of the agreement commences on the effective date and continues until the earlier of (i) expiration of the last
to expire of Medspray&#8217;s patent rights or (ii) December 31, 2023 (the &#8220;Initial Term&#8221;) at which time, the Medspray License
Agreement will automatically renew for a successive period of three (3) years, unless terminated by either party upon one year prior written
notice prior to the end of any term; provided, however, the Medspray may terminate the Medspray License Agreement immediately if fail
to have any licensed product under the Medspray License Agreement registered with the FDA or EMA by July 1, 2028 or has filed to reach
the point of first sale of any licensed product under the Medspray License Agreement by July 1, 2028.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investigator-Sponsored Study Agreements between
the Company and Vendors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with Columbia
University for the Study of Ketamine in Combination with Other Drugs for Treatment of Alzheimer&#8217;s and Depression Disorders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into a sponsored research agreement
with Columbia University (&#8220;Columbia&#8221;) pursuant to which Columbia shall conduct two different studies related to all uses of
Ketamine or its metabolites in combination with Prucalopride, one of which is related to Alzheimer&#8217;s and the other of which is related
to Depression, PTSD and Stress Projects. In addition, Company has been granted an option to license certain assets currently under development,
including Alzheimer&#8217;s disease. The term of the option will commence on the effective date of this agreement and will expire upon
the earlier of (i) 90 days after the date of the Company&#8217;s receipt of a final research report for each specific research proposal
as defined in the agreement or (ii) termination of the research. If the Company elects to exercise the option, both parties will commence
negotiation of a license agreement and will execute a license agreement no later than 3 months after the date of the exercise of the option.
The Company exercised its option for an exclusive license agreement for SPC-15, a prophylactic treatment for stress-induced affective
disorders including anxiety and PTSD pursuant to which the Company will be granted an exclusive license to further develop, manufacture,
and commercialize SPC-15 worldwide. The Company expects to have the complete license agreement with Columbia completed in the first half
of 2024. Columbia University and the Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer&#8217;s
disease to posttraumatic stress disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082
to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four
and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of
the project. On October 13, 2022, the Company entered into an amendment of the sponsored research agreement pursuant to which the parties
agreed to extend the payment schedule until March 31, 2024. The Company paid the first payment of $430,825 in November 2021 and the second
payment of $430,825 in July 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with University
of Maryland, Baltimore for the Study of Targeted liposomal drug delivery for rheumatoid arthritis</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, we entered into a sponsored research
agreement (the &#8220;July 2021 Sponsored Research Agreement&#8221;) with UMB pursuant to which UMB shall&#160;evaluate the pharmacokinetics
of dexamethasone delivered to arthritic rats via liposome. The research pursuant to the July 2021 Sponsored Research Agreement commenced
on September 1, 2021 and will continue until the substantial completion thereof, subject to renewal upon written consent of the parties
with a project timeline of twelve months. The July 2021 Sponsored Research Agreement may be terminated by either party upon 30 days&#8217;
prior written notice to the other party. In addition, if either party commits any material breach of or defaults with respect to any terms
or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within 10 business days after written
notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement as of the date of receipt
of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for any reason other than an uncured
material breach by UMB, we shall relinquish any and all rights it may have in the Results (as defined in the July 2021 Sponsored Research
Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated early, we, among other things, will pay all
costs incurred and accrued by UMB as of the date of termination. Pursuant to the terms of the July 2021 Sponsored Research Agreement,
UMB granted us an option (the &#8220;Option&#8221;) to negotiate and obtain an exclusive license to any UMB Arising IP (as defined in
the July 2021 Sponsored Research Agreement) and UMB&#8217;s rights in any Joint Arising IP (as defined in the July 2021 Sponsored Research
Agreement) (collectively, the &#8220;UMB IP&#8221;). We may exercise the Option by giving UMB written notice within 60 days after it receives
notice from UMB of the UMB IP. We shall pay total fees of $276,285 as set forth in the July 2021 Sponsored Research Agreement. The Company
paid the first payment of $92,095 on September 1, 2021 and on August 31, 2022, the Company paid the second payment of $92,095.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with The Regents
of the University of California for the Effect of Psilocybin on Inflammation in the Blood</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company entered into a sponsored
research agreement (&#8220;Sponsored Research Agreement&#8221;) with The Regents of the University of California, on behalf of its San
Francisco Campus (&#8220;UCSF&#8221;) pursuant to which UCSF shall conduct a study to examine psilocybin&#8217;s effect on inflammatory
activity in humans to accelerate its implementation as a potential treatment for Parkinson&#8217;s Disease, chronic pain, and bipolar
disorder. The purpose of this is to show what effect psilocybin has on inflammation in the blood. The Company believes that this study
will help support the UMB homing peptide study. Pursuant to the Agreement, we shall pay UCSF a total fee of $342,850 to conduct the research
over the two-year period. The Agreement shall be effective for a period of two years from the effective date, subject to renewal or earlier
termination as set forth in the Sponsored Research Agreement. During the years ended December 31, 2022 and 2021, pursuant to the Sponsored
Research Agreement, the Company paid to UCSF $181,710 and $100,570, respectively. We have notified UCSF we do not plan to continue this
study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investigator-Sponsored Study Agreement with
UMB for CNS Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, we entered into an investigator-sponsored
study agreement with UMB. The research project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment
of Multiple Sclerosis (&#8220;MS&#8221;). More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can
effectively deliver dexamethasone to the central nervous system and (2) whether MS-1-displaying liposomes are superior to plain liposomes,
also known as free drug, in inhibiting the relapses and progression of Experimental Autoimmune Encephalomyelitis. Pursuant to the agreement,
the research commenced on March 1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent
of the parties.&#160;The total cost under the investigator-sponsored study agreement shall not exceed $81,474. which is payable in two
equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated
project timeline of nine months. The Company paid $40,737 on January 13, 2021. This project has been postponed until further notice and
the second payment is not due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>COVID-19</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The outbreak of the novel Coronavirus (COVID-19)
evolved into a global pandemic. The Coronavirus has spread to many regions of the world. The extent to which the Coronavirus impacts the
Company&#8217;s business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted,
including new information that may emerge concerning the Coronavirus and the actions to contain the Coronavirus or treat its impact, among
others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the continuing spread of the Coronavirus,
certain aspects of the Company&#8217;s business operations may be delayed or subject to interruptions. Specifically, as a result of the
shelter-in-place orders and other mandated local travel restrictions, among other things, the research and development activities of certain
of the Company&#8217;s partners may be affected, which may result in delays to the Company&#8217;s clinical trials, and the Company can
provide no assurance as to when such trials, if delayed, will resume at this time or the revised timeline to complete trials once resumed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, site initiation, participant recruitment
and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be delayed due to
changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic
efforts, or other reasons related to the pandemic. If the Coronavirus continues to spread, some participants and clinical investigators
may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required)
may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and the Company may be unable
to conduct its clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Infections and deaths related to the pandemic
may disrupt the United States&#8217; healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources
away from, or materially delay U.S. Food and Drug Administration review and/or approval with respect to the Company&#8217;s clinical trials.
It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of the Company&#8217;s
clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of the
Company&#8217;s product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The spread of the Coronavirus, which has caused
a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have
a material economic effect on the Company&#8217;s business. While the potential economic impact brought by and the duration of the pandemic
may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial
markets, which may negatively impact the Company&#8217;s ability to access capital on favorable terms, if at all. In addition, a recession,
depression or other sustained adverse market event resulting from the spread of the Coronavirus could materially and adversely affect
the Company&#8217;s business and the value of its common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultimate impact of the current pandemic, or
any other health epidemic, is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays
or impacts on its business, its clinical trials, its research programs, healthcare systems or the global economy as a whole. However,
these effects could have a material impact on the Company&#8217;s operations, and the Company will continue to monitor the situation closely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our goal is to obtain, maintain and enforce patent
protection for our products, formulations, processes, methods and other proprietary technologies, preserve our trade secrets, and operate
without infringing on the proprietary rights of other parties. Our policy is to actively seek the broadest intellectual property protection
possible for our products, proprietary information and proprietary technology through a combination of contractual arrangements and patents.
Specifically, we try to ensure that we own intellectual property created for us by signing agreements with employees, independent contractors,
consultants, companies, and any other third party that create intellectual property for us or that assign any intellectual property rights
to us. In addition, we have established business procedures designed to maintain the confidentiality of our proprietary information, including
the use of confidentiality agreements with employees, independent contractors, consultants and entities with which we conduct business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, our owned and licensed intellectual property includes 4 issued
patents and 19 pending patent applications in the U.S. and abroad. Our owned intellectual property includes six pending U.S. patent applications
related to the use of the central nervous system-homing peptides covered by the UMB License Agreement to deliver certain compounds, including
a nonsteroidal anti-inflammatory drug and/or psilocybin, for the treatment of arthritis, central nervous system diseases, neurological
diseases as well as cancer. Among our licensed intellectual property, there is one issued U.S. patent covering certain central nervous
system homing peptides and uses thereof, one issued U.S. patent covering certain peptides capable of selectively targeting inflamed synovial
tissue and uses thereof, and two issued U.S. patents covering the treatment or prevention of stress-induced affective disorders or stress-induced
psychopathology.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the rare disease therapeutics
segment of our business, our industry is characterized by many newly emerging and innovative technologies, intense competition and a strong
emphasis on proprietary product rights. We face potential competition from many different sources, including major pharmaceutical, specialty
pharmaceutical and biotechnology companies, academic institutions, governmental agencies and medical research organizations. Any product
candidates that we may successfully develop and commercialize will compete with the standard of care and new therapies that may become
available in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of the pharmaceutical, biopharmaceutical
and biotechnology companies with whom we may compete have established markets for their therapies and have substantially greater financial,
technical, human and other resources than we do and may be better equipped to develop, manufacture and market superior products or therapies.
In addition, many of these potential competitors have significantly greater experience than we have in undertaking non-clinical studies
and human clinical trials of new therapeutic substances and in obtaining regulatory approvals of human therapeutic products. Accordingly,
our competitors may succeed in obtaining regulatory approvals for alternative or superior products. In addition, many competitors have
greater name recognition and more extensive collaborative relationships. Smaller and earlier-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large, established companies. An increasing number of companies are
increasing their efforts in the discovery of new psychedelic compounds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA and other regulatory authorities at federal,
state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing,
manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval,
advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs. We, along with any potential our vendors,
contract research organizations and contract manufacturers, will be required to navigate the various preclinical, clinical, manufacturing
and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek
approval of our product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate
federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, the US Food and Drug Administration
(FDA) regulates drug products under the Federal Food, Drug, and Cosmetic Act (FDCA), its implementing regulations and other laws. If we
fail to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or
any other legal requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising,
promotion, packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions or
other legal consequences. These sanctions or consequences could include, among other things, the FDA&#8217;s refusal to approve pending
applications, issuance of clinical holds for ongoing studies, suspension or revocation of approved applications, warning or untitled letters,
product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution,
injunctions, fines, civil penalties or criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process required by the FDA before any product
candidates are approved as drugs for therapeutic indications and may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-right: 0.8pt">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of the manufacture, under current good manufacturing practice (cGMP) requirements, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to the FDA of an investigational new drug application (&#8220;IND&#8221;) which must become effective before clinical trials may begin;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval by an institutional review board or independent ethics committee at each clinical trial site before each trial may be initiated;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations,&#160;good clinical practice (GCP) requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to the FDA of a New Drug Application (&#8220;NDA&#8221;);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of user fees for FDA review of the NDA;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A determination by the FDA within 60 days of its receipt of an NDA, to accept the filing for review;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially, satisfactory completion of FDA audit of the clinical trial sites that generated the data in support of the NDA; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Controlled Substances</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal Controlled Substances Act (CSA) and
its implementing regulations establish a &#8220;closed system&#8221; of regulations for controlled substances. The CSA imposes registration,
security, recordkeeping and reporting, storage, manufacturing, distribution, importation and other requirements under the oversight of
the DEA. The DEA is the federal agency responsible for regulating controlled substances, and requires those individuals or entities that
manufacture, import, export, distribute, research, or dispense controlled substances to comply with the regulatory requirements in order
to prevent the diversion of controlled substances to illicit channels of commerce.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The DEA categorizes controlled substances into
one of five schedules&#8201;&#8212;&#8201;Schedule I, II, III, IV or V&#8201;&#8212;&#8201;with varying qualifications for listing
in each schedule. Schedule I substances by definition have a high potential for abuse, have no currently accepted medical use in treatment
in the United States and lack accepted safety for use under medical supervision. Pharmaceutical products having a currently accepted medical
use that are otherwise approved for marketing may be listed as Schedule II, III, IV or V substances, with Schedule II substances presenting
the highest potential for abuse and physical or psychological dependence, and Schedule V substances presenting the lowest relative potential
for abuse and dependence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Facilities that manufacture, distribute, import
or export any controlled substance must register annually with the DEA. The DEA registration is specific to the particular location, activity(ies)
and controlled substance schedule(s).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The DEA inspects all manufacturing facilities
to review security, recordkeeping, reporting and handling prior to issuing a controlled substance registration. The specific security
requirements vary by the type of business activity and the schedule and quantity of controlled substances handled. The most stringent
requirements apply to manufacturers of Schedule I and Schedule II substances. Required security measures commonly include background checks
on employees and physical control of controlled substances through storage in approved vaults, safes and cages, and through use of alarm
systems and surveillance cameras. Once registered, manufacturing facilities must maintain records documenting the manufacture, receipt
and distribution of all controlled substances. Manufacturers must submit periodic reports to the DEA of the distribution of Schedule I
and II controlled substances, Schedule III narcotic substances, and other designated substances. Registrants must also report any controlled
substance thefts or significant losses, and must obtain authorization to destroy or dispose of controlled substances. Imports of Schedule
I and II controlled substances for commercial purposes are generally restricted to substances not already available from a domestic supplier
or where there is not adequate competition among domestic suppliers. In addition to an importer or exporter registration, importers and
exporters must obtain a permit for every import or export of a Schedule I and II substance or Schedule III, IV and V narcotic, and submit
import or export declarations for Schedule III, IV and V non-narcotics. In some cases, Schedule III non-narcotic substances may be subject
to the import/export permit requirement, if necessary, to ensure that the United States complies with its obligations under international
drug control treaties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For drugs manufactured in the United States, the
DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II that may be manufactured or produced
in the United States based on the DEA&#8217;s estimate of the quantity needed to meet legitimate medical, scientific, research and industrial
needs. The quotas apply equally to the manufacturing of the active pharmaceutical ingredient and production of dosage forms. The DEA may
adjust aggregate production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during the
year, although the DEA has substantial discretion in whether or not to make such adjustments for individual companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The states also maintain separate controlled substance
laws and regulations, including licensing, recordkeeping, security, distribution, and dispensing requirements. State authorities, including
boards of pharmacy, regulate use of controlled substances in each state. Failure to maintain compliance with applicable requirements,
particularly as manifested in the loss or diversion of controlled substances, can result in enforcement action that could have a material
adverse effect on our business, operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations,
or initiate proceedings to revoke those registrations. In certain circumstances, violations could lead to criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 23, 2024, we employed a total of
three full-time employees. We are not a party to any collective bargaining agreements. We believe that we maintain good relations with
our employees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate History</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We were incorporated as Gold Swap, Inc. (&#8220;Gold Swap&#8221;) under
the laws of the State of New York on July 13, 2010.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 11, 2012, stockholders approved changing
our state of incorporation from New York to Delaware via the merger of Gold Swap with and into our wholly-owned subsidiary, Point Capital,
Inc., and to change our name from &#8220;Gold Swap Inc.&#8221; to &#8220;Point Capital, Inc&#8221;. The merger was effective on January
24, 2013.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2019, we amended our Certificate of
Incorporation to change our name to &#8220;Uppercut Brands, Inc,&#8221; and on September 24, 2020, we&#160;amended our Certificate of
Incorporation to change our name to &#8220;Silo Pharma, Inc.&#8221;.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through September 28, 2018, we were a closed-end,
non-diversified investment company that had elected to be regulated as a business development company under the Investment Company Act
of 1940 (the &#8220;Investment Company Act&#8221;).&#160;As a business development company, we were required to comply with certain regulatory
requirements.&#160;For instance, we generally had to invest at least 70% of our total assets in &#8220;qualifying assets&#8221;, including
securities of private U.S. companies, cash, cash equivalents, U.S. government securities and high-quality debt investments that mature
in one year or less.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 29, 2018, we filed Form N-54C, Notification
of Withdrawal of election to be Subject to Section 55 through 65 of the Investment Company Act, because we changed the nature of our business
so as to cease to be a business development company. Accordingly, as of December 31, 2018, our consolidated financial statements of have
been prepared in accordance with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of this change in status, we discontinued
applying the guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standard Codification (&#8220;ASC&#8221;)
Topic 946 - Financial Services &#8211; Investment Company and account for the change in our status prospectively by accounting for our
equity investments in accordance with ASC Topics 320 - Investments&#8212;Debt and Equity Securities as of the date of the change in status.
In addition, the presentation of the financial statements is that of a commercial company rather than that of an investment company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 946, we made this change
to our financial reporting prospectively, and did not restate periods prior to our change in status to a non-investment company effective
September 29, 2018. Accordingly, we may refer to both accounting in accordance with U.S. generally accepted accounting principles applicable
to corporations (&#8220;Corporation Accounting&#8221;), which applied commencing September 29, 2018 and to that applicable to investment
companies under the Investment Company Act (&#8220;Investment Company Accounting&#8221;) which applied to prior periods. We determined
that there is no cumulative effect of the change from Investment Company Accounting to Corporation Accounting on periods prior to those
presented, and that there is no effect on our financial position or results of operations as a result of this change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to maintain our status as a non-investment
company, we will continue to operate so as to fall outside the definition of an &#8220;investment company&#8221; or within an applicable
exception. We expect to continue to operate outside the definition of an &#8220;investment company&#8221; as a developmental stage company
primarily engaged in merging traditional therapeutics with psychedelic research.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through March 31, 2017, we elected to be treated
as a regulated investment company (&#8220;RIC&#8221;) under Subchapter M of the Internal Revenue Code of 1986, as amended, and operated
in a manner so as to qualify for the tax treatment applicable to RICs. On March 31, 2017, we failed the diversification test since our
investment in Ipsidy Inc. accounted for over 25% of our total assets. We did not cure our failure to retain our status as a RIC and we
will not seek to obtain RIC status again. Accordingly, beginning in 2017, we became subject to income taxes at corporate tax rates. The
loss of our status as an RIC did not have any impact on our financial position or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, we are not making any new equity investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 29, 2018, we entered into an Asset
Purchase Agreement with Blind Faith Concepts Holdings, Inc. pursuant to which we completed the acquisition of 100% of the assets of NFID
from the seller which consisted of three trademarks related to the NFID brand, the NFID website, shoe designs and samples, and the assumption
of a one-year Brand Ambassador Agreement in exchange for 2,000,000 shares of our common stock. NFID is a recently developed unisex clothing
brand. We plan on continuing product development to fully launch the product. Our acquisition of the NFID assets gives us access to the
growing market for unisex products.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 5, 2018, we entered into 14 separate
Return to Treasury Agreements, whereby certain stockholders holding an aggregate of 28,734,901 shares of our common stock agreed to return
a portion of their respective holdings to treasury in exchange for cash payments aggregating $2,872. As a result, the total issued and
outstanding number of our common stock was reduced by 28,734,901 shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2020, we incorporated a wholly-owned
subsidiary, Silo Pharma Inc.,&#160;in the State of Florida.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 19, 2023, we changed our state of
incorporation from Delaware to Nevada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Corporate Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated as in the State of New York
on July 13, 2010. On January 24, 2013, the Company changed its state of incorporation from New York to Delaware. On December 19, 2023,
the Company changed its state of incorporation from Delaware to Nevada. Our principal executive offices are located at 677 N Washington
Blvd Sarasota Fl 34236 and our telephone number is (718) 400-9031.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Available Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our website address is <i>www.silopharma.com</i>.
The contents of, or information accessible through, our website is not part of this Annual Report on Form 10-K, and our website address
is included in this document as an inactive textual reference only. We make our filings with the U.S. Securities and Exchange Commission
(&#8220;SEC&#8221;), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments
to those reports, available free of charge on our website as soon as reasonably practicable after we file such reports with, or furnish
such reports to, the SEC. The public may read and copy the materials we file with the SEC at the SEC&#8217;s Public Reference Room at
100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the
SEC at 1-800-SEC-0330. Additionally, the SEC maintains an internet site that contains reports, proxy and information statements and other
information. The address of the SEC&#8217;s website is <i>www.sec.gov</i>. The information contained in the SEC&#8217;s website is not
intended to be a part of this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1A. RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>An investment in our common stock involves
a high degree of risk. You should carefully consider the following risk factors and the other information in this Annual Report on Form
10-K before investing in our common stock. Our business and results of operations could be seriously harmed by any of the following risks.
The risks set out below are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently
deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. If any of the following
events occur, our business, financial condition and results of operations could be materially adversely affected. In such case, the value
and trading price of our common stock could decline, and you may lose all or part of your investment.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Financial Position and
Need for Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have only a limited history upon which
an evaluation of our prospects and future performance can be made and have no history of profitable operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated in 2010 but starting operating
under our current business plan in September 2020 and have a limited history upon which an evaluation of our prospects and future performance
can be made and have no history of profitable operations. We may sustain losses in the future as we implement our business plan. We have
not yet achieved positive cash flow on a monthly basis during any fiscal year including the fiscal year ended December 31, 2023, and there
can be no assurance that we will ever generate revenues or operate profitably.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will require additional financing in
the future to fund our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need additional capital in the future
to continue to execute our business plan. Therefore, we will be dependent upon additional capital in the form of either debt or equity
to continue our operations. At the present time, we do not have arrangements to raise all of the needed additional capital, and we will
need to identify potential investors and negotiate appropriate arrangements with them. Our ability to obtain additional financing will
be subject to a number of factors, including market conditions, our operating performance and investor sentiment. If we are unable to
raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital may cause dilution
to our stockholders, restrict our operations or require us to relinquish certain rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may seek additional capital through a combination
of equity offerings, debt financings, strategic collaborations and alliances or licensing arrangements. To the extent that we raise additional
capital through the sale of equity, convertible debt securities or other equity-based derivative securities, your ownership interest will
be diluted and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Any indebtedness
we incur could involve restrictive covenants, such as limitations on our ability to incur additional debt, acquire or license intellectual
property rights, declare dividends, make capital expenditures and other operating restrictions that could adversely impact our ability
to conduct our business. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such
issuance, may cause the market price of our common stock to decline. If we raise additional funds through strategic collaborations and
alliances or licensing arrangements with third parties, we may have to relinquish valuable rights including to future therapeutic candidates
or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and
prospects. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise additional
funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts
or grant rights to develop and market our future therapeutic candidates that we would otherwise prefer to develop and market ourselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Rare Disease Therapeutics
Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical drug development is a lengthy and
expensive process with uncertain timelines and uncertain outcomes. If clinical trials of any future therapeutic candidates are prolonged
or delayed, we or our current or future collaborators may be unable to obtain required regulatory approvals, and therefore we will be
unable to commercialize our future therapeutic candidates on a timely basis or at all, which will adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical testing is expensive and can take many
years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future
clinical trial results may not be successful. We may experience delays in initiating or completing our clinical trials. We may also experience
numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize
any future therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cannot provide any assurance that any
product candidates will successfully complete clinical trials or receive regulatory approval, which is necessary before they can be commercialized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no therapies that are approved
for commercial sale and may never be able to develop marketable therapies. We entered into the Option Agreement with UMB pursuant to which,
UMB has granted us an exclusive, non-sublicensable, non-transferable license with respect to the exploration of the potential use of central
nervous system-homing peptides in vivo and their use for the investigation and treatment of MS and other neuroinflammatory pathology.
Accordingly, our business may depend on the successful regulatory approval of potential in-licensed product candidates. We cannot be certain
that any of our product candidates will receive regulatory approval or that our therapies will be successfully commercialized even if
we receive regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research, testing, manufacturing, safety,
efficacy, labeling, approval, sale, marketing, and distribution of any in-licensed product is, and will remain, subject to comprehensive
regulation by the FDA, the DEA, the European Medicines Agency (&#8220;EMA&#8221;), the Medicines and Healthcare Products Regulatory Agency
(&#8220;MHRA&#8221;) and foreign regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any therapeutic candidates we may develop
in the future may be subject to controlled substance laws and regulations in the territories where the product will be marketed, and failure
to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results
of our business operations and our financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, psychedelics, or psilocybin,
and its active metabolite, psilocin, are listed by the DEA as a Schedule I substance, under the CSA. The DEA regulates chemical compounds
as Schedule I, II, III, IV or V substances. Schedule I substances by definition have a high potential for abuse, have no currently accepted
medical use&#8221; in the United States, lack accepted safety for use under medical supervision, and may not be prescribed marketed or
sold in the United States. Pharmaceutical products approved for use in the United States may be listed as Schedule II, III, IV or V, with
Schedule II substances considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative
risk of abuse among such substances. Schedule I and II substances are subject to the strictest controls under the CSA, including manufacturing
and procurement quotas, security requirements and criteria for importation. In addition, dispensing of Schedule II substances is further
restricted. For example, they may not be refilled without a new prescription and may have a black box warning. Further, most, if not all,
state laws in the United States classify psilocybin and psilocin as Schedule I controlled substances. For any product containing psilocybin
to be available for commercial marketing in the United States, psilocybin and psilocin must be rescheduled, or the product itself must
be scheduled, by the DEA to Schedule II, III, IV or V. Commercial marketing in the United States will also require scheduling-related
legislative or administrative action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Scheduling determinations by the DEA are dependent
on FDA approval of a substance or a specific formulation of a substance. Therefore, while psilocybin and psilocin are Schedule I controlled
substances, products approved by the FDA for medical use in the United States that contain psilocybin or psilocin should be placed in
Schedules II-V, since approval by the FDA satisfies the &#8220;accepted medical use&#8221; requirement. If one of our product candidates
receives FDA approval, we anticipate that the DEA may make a scheduling determination and place it in a schedule other than Schedule I
in order for it to be prescribed to patients in the United States. This scheduling determination will be dependent on FDA approval and
the FDA&#8217;s recommendation as to the appropriate schedule. During the review process, and prior to approval, the FDA may determine
that it requires additional data, either from non-clinical or clinical studies, including with respect to whether, or to what extent,
the substance has abuse potential. This may introduce a delay into the approval and any potential rescheduling process. That delay would
be dependent on the quantity of additional data required by the FDA. This scheduling determination will require DEA to conduct notice
and comment rule making including issuing an interim final rule. Such action will be subject to public comment and requests for hearing
which could affect the scheduling of these substances. There can be no assurance that the DEA will make a favorable scheduling decision.
Even assuming categorization as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), at the federal level, such
substances would also require scheduling determinations under state laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, therapeutic candidates containing
controlled substances are subject to DEA regulations relating to manufacturing, storage, distribution and physician prescription procedures,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DEA registration and inspection of facilities.</b>&#160;Facilities conducting research, manufacturing, distributing, importing or exporting, or dispensing controlled substances must be registered (licensed) to perform these activities and have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent drug loss and diversion. All these facilities must renew their registrations annually, except dispensing facilities, which must renew every three years. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances. Obtaining and maintaining the necessary registrations may result in delay of the importation, manufacturing or distribution of product candidates. Furthermore, failure to maintain compliance with the CSA, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect on our business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>State-controlled substances laws.</b>&#160;Individual U.S. states have also established controlled substance laws and regulations. Though state-controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule product candidates. While some states automatically schedule a drug based on federal action, other states schedule drugs through rule making or a legislative action. State scheduling may delay commercial sale of any product for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the commercial attractiveness of such product. We or any partners must also obtain separate state registrations, permits or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal law.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical trials.</b>&#160;Because any product candidates may contain psilocybin, to conduct clinical trials in the United States prior to approval, each of our research sites must submit a research protocol to the DEA and obtain and maintain a DEA researcher registration that will allow those sites to handle and dispense such product candidates and to obtain the product from our importer. If the DEA delays or denies the grant of a researcher registration to one or more research sites, the clinical trial could be significantly delayed, and we could lose clinical trial sites.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Importation.</b>&#160;If any of our product candidates is approved and classified as a Schedule II, III or IV substance, an importer can import it for commercial purposes if it obtains an importer registration and files an application for an import permit for each import. The DEA provides annual assessments/estimates to the International Narcotics Control Board, which guides the DEA in the amounts of controlled substances that the DEA authorizes to be imported. The failure to identify an importer or obtain the necessary import authority, including specific quantities, could affect the availability of our product candidates and have a material adverse effect on our business, results of operations and financial condition. In addition, an application for a Schedule II importer registration must be published in the Federal Register, and there is a waiting period for third-party comments to be submitted. It is always possible that adverse comments may delay the grant of an importer registration.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacture.</b>&#160;If, because of a Schedule II classification or voluntarily, we were to conduct manufacturing or repackaging/relabeling in the United States, our contract manufacturers would be subject to the DEA&#8217;s annual manufacturing and procurement quota requirements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Distribution.</b>&#160;If any of our product candidates is scheduled as Schedule II, III or IV, we would also need to identify wholesale distributors with the appropriate DEA registrations and authority to distribute any future therapeutic candidates. These distributors would need to obtain Schedule II, III or IV distribution registrations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The potential reclassification of psilocybin
and psilocin in the United States could create additional regulatory burdens on our operations and negatively affect our results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If psilocybin and/or psilocin, other than the
FDA-approved formulation, is rescheduled under the CSA as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), the
ability to conduct research on psilocybin and psilocin would most likely be improved. However, rescheduling psilocybin and psilocin may
materially alter enforcement policies across many federal agencies, primarily the FDA and DEA. The FDA is responsible for ensuring public
health and safety through regulation of food, drugs, supplements, and cosmetics, among other products, through its enforcement authority
pursuant to the FDCA. The FDA&#8217;s responsibilities include but are not limited to regulating the ingredients as well as the marketing
and labeling of drugs sold in interstate commerce. Because it is currently illegal under federal law to produce and sell psilocybin and
psilocin, and because there are no federally recognized medical uses, the FDA has historically deferred enforcement related to psilocybin
and psilocin to the DEA. If psilocybin and psilocin were to be rescheduled to a federally controlled, yet legal, substance, the FDA would
likely play a more active regulatory role. The DEA would continue to be active in regulating manufacturing, distribution and dispensing
of such substances. The potential for multi-agency enforcement post-rescheduling could threaten or have a materially adverse effect on
our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Psilocybin and psilocin are listed as Schedule
I controlled substances under the CSA in the U.S., and similar controlled substance legislation in other countries and any significant
breaches in our compliance with these laws and regulations, or changes in the laws and regulations may result in interruptions to our
development activity or business continuity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Psilocybin and psilocin are categorized as Schedule
I controlled substances under the CSA, and are similarly categorized by most states and foreign governments. Even assuming any future
therapeutic candidates containing psilocybin or psilocin are approved and scheduled by regulatory authorities to allow their commercial
marketing, the ingredients in such therapeutic candidates would likely continue to be Schedule I, or the state or foreign equivalent.
Violations of any federal, state or foreign laws and regulations could result in significant fines, penalties, administrative sanctions,
convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal
charges and penalties, including, but not limited to, disgorgement of profits, seizure of product, cessation of business activities, divestiture
or prison time. This could have a material adverse effect on us, including on our reputation and ability to conduct business, our financial
position, operating results, profitability or liquidity, the potential listing of our shares or the market price of our shares. In addition,
it is difficult for us to estimate the time or resources that would be needed for the investigation or defense of any such matters or
our final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information
requested by the applicable authorities involved, and such time or resources could be substantial. It is also illegal to aid or abet such
activities or to conspire or attempt to engage in such activities. An investor&#8217;s contribution to and involvement in such activities
may result in federal civil and/or criminal prosecution, including, but not limited to, forfeiture of his, her or its entire investment,
fines and/or imprisonment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various federal, state, provincial and local laws
govern our business in any jurisdictions in which we may operate, and to which we may export our products, including laws relating to
health and safety, the conduct of our operations, and the production, storage, sale and distribution of our products. Complying with these
laws requires that we comply concurrently with complex federal, state, provincial and/or local laws. These laws change frequently and
may be difficult to interpret and apply. To ensure our compliance with these laws, we will need to invest significant financial and managerial
resources. It is impossible for us to predict the cost of such laws or the effect they may have on our future operations. A failure to
comply with these laws could negatively affect our business and harm our reputation. Changes to these laws could negatively affect our
competitive position and the markets in which we operate, and there is no assurance that various levels of government in the jurisdictions
in which we operate will not pass legislation or regulation that adversely impacts our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, even if we or third parties were
to conduct activities in compliance with U.S. state or local laws or the laws of other countries and regions in which we conduct activities,
potential enforcement proceedings could involve significant restrictions being imposed upon us or third parties, while diverting the attention
of key executives. Such proceedings could have a material adverse effect on our business, revenue, operating results and financial condition
as well as on our reputation and prospects, even if such proceedings conclude successfully in our favor. In the extreme case, such proceedings
could ultimately involve the criminal prosecution of our key executives, the seizure of corporate assets, and consequently, our inability
to continue business operations. Strict compliance with state and local laws with respect to psilocybin and psilocin does not absolve
us of potential liability under U.S. federal law or EU law, nor provide a defense to any proceeding which may be brought against us. Any
such proceedings brought against us may adversely affect our operations and financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite the current status of psilocybin and psilocin
as Schedule I controlled substances in the United States, there may be changes in the status of psilocybin or psilocin under the laws
of certain U.S. cities or states. For instance, the city of Denver voted to decriminalize the possession of psilocybin in 2019 and five
other cities have decriminalized psilocybin since (Oakland, California; Santa Cruz, California; Ann Arbor, Michigan; Cambridge, Massachusetts;
and Somerville, Massachusetts). Moreover, in the November 2020 election, Oregon passed Measure 109 which legalizes medical use of &#8220;psilocybin
products,&#8221; including magic mushrooms, to treat mental health conditions in licensed facilities with registered therapists.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The legalization of psilocybin without regulatory
oversight may lead to the setup of clinics without proper therapeutic infrastructure or adequate clinical research, which could put patients
at risk and bring reputational and regulatory risk to the entire industry, making it harder for us to achieve regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may contain controlled
substances, the use of which may generate public controversy. Adverse publicity or public perception regarding psilocybin or our current
or future investigational therapies using psilocybin may negatively influence the success of these therapies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therapies containing controlled substances may
generate public controversy. Political and social pressures and adverse publicity could lead to delays in approval of, and increased expenses
for any future therapeutic candidates we may develop. Opponents of these therapies may seek restrictions on marketing and withdrawal of
any regulatory approvals. In addition, these opponents may seek to generate negative publicity in an effort to persuade the medical community
to reject these therapies. For example, we may face media-communicated criticism directed at our clinical development program. Adverse
publicity from psilocybin misuse may adversely affect the commercial success or market penetration achievable by our product candidates.
Anti-psychedelic protests have historically occurred and may occur in the future and generate media coverage. Political pressures and
adverse publicity could lead to delays in, and increased expenses for, and limit or restrict the introduction and marketing of any future
therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our clinical trials may fail to demonstrate
substantial evidence of the safety and effectiveness of future product candidates that we may identify and pursue, which would prevent,
delay or limit the scope of regulatory approval and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before obtaining regulatory approvals for the
commercial sale of future therapeutic candidates, we must demonstrate through lengthy, complex and expensive nonclinical studies, preclinical
studies and clinical trials that the applicable therapeutic candidate is both safe and effective for use in each target indication. A
therapeutic candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended
use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical testing is expensive and can take many
years to complete, and its outcome is inherently uncertain. Most product candidates that begin clinical trials are never approved by regulatory
authorities for commercialization. We have limited experience in designing clinical trials and may be unable to design and execute a clinical
trial to support marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that any clinical trials
will be successful. In some instances, there can be significant variability in safety or efficacy results between different clinical trials
of the same therapeutic candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in
the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical
trial participants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if any of our future therapeutic candidates
obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant
additional expense. Additionally, any such therapeutic candidates, if approved, could be subject to labeling and other restrictions and
market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems
with any of our future therapeutic candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the FDA, the EMA, the MHRA or a comparable
foreign regulatory authority approves any of our future therapeutic candidates, the manufacturing processes, labeling, packaging, distribution,
adverse event reporting, storage, advertising, promotion and recordkeeping for the therapy and underlying therapeutic substance will be
subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information
and reports, registration, as well as continued compliance with current good manufacturing practice (&#8220;cGMP&#8221;) and with good
clinical practice (&#8220;GCP&#8221;) for any clinical trials that we conduct post-approval, all of which may result in significant expense
and limit our ability to commercialize such therapies. The FDA may also place other conditions on approvals, including the requirement
for a risk evaluation and mitigation strategy (&#8220;REMS&#8221;), to assure the safe use of the drug. Later discovery of previously
unknown problems with any approved therapeutic candidate, including adverse events of unanticipated severity or frequency, or with our
third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the labeling, distribution, marketing or manufacturing of our future therapeutic candidates, withdrawal of the product from the market or product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled and warning letters or holds on clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA, the EMA, the MHRA or other foreign regulatory body to approve pending applications or supplements to approved applications we filed or suspension or revocation of license approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements to conduct post-marketing studies or clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on coverage by third-party payors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, restitution or disgorgement of profits or revenue;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal of marketing approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention or refusal to permit the import or export of the product; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, any regulatory approvals that we
receive for our future therapeutic candidates may also be subject to limitations on the approved indicated uses for which the therapy
may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase
IV clinical trials, and surveillance to monitor the safety and efficacy of such therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If there are changes in the application of legislation,
regulations or regulatory policies or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements,
the regulators could take various actions. These include imposing fines on us, imposing restrictions on the therapeutic or its manufacture
and requiring us to recall or remove the therapeutic from the market. The regulators could also suspend or withdraw our marketing authorizations,
requiring us to conduct additional clinical trials, change our therapeutic labeling or submit additional applications for marketing authorization.
If any of these events occurs, our ability to sell such therapy may be impaired, and we may incur substantial additional expense to comply
with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and development of drugs targeting
the central nervous system is particularly difficult, which makes it difficult to predict and understand why the drug has a positive effect
on some patients but not others.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Discovery and development of new drugs targeting
central nervous system disorders are particularly difficult and time-consuming, evidenced by the higher failure rate for new drugs for
central nervous system disorders compared with most other areas of drug discovery. For example, in 2019, both Rapastinel and SAGE-217,
two new drugs targeting major depressive disorder (&#8220;MDD&#8221;), failed to meet their primary endpoints in Phase III trials. ALKS
5461, another new drug targeting MDD, was rejected by FDA in 2019 after its Phase III trials as FDA required additional clinical data
to provide substantial evidence of effectiveness. Any such setbacks in our clinical development could have a material adverse effect on
our business and operating results. In addition, our later stage clinical trials may present challenges related to conducting adequate
and well-controlled clinical trials, including designing an appropriate comparator arm in trials given the potential difficulties related
to maintaining the blinding during the trial or placebo or nocebo effects. Due to the complexity of the human brain and the central nervous
system, it can be difficult to predict and understand why a drug may have a positive effect on some patients but not others and why some
individuals may react to the drug differently from others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The results of preclinical studies and early-stage
clinical trials of our future therapeutic candidates may not be predictive of the results of later stage clinical trials. Initial success
in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therapeutic candidates in later stages of clinical
trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical
trials. Furthermore, there can be no assurance that any of our clinical trials will ultimately be successful or support further clinical
development of any of our future therapeutic candidates. There is a high failure rate for drugs proceeding through clinical trials. A
number of companies in the pharmaceutical industry have suffered significant setbacks in clinical development even after achieving promising
results in earlier studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will depend on enrollment of patients
in our clinical trials for our future therapeutic candidates. If we are unable to enroll patients in our clinical trials, our research
and development efforts and business, financial condition and results of operations could be materially adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Identifying and qualifying patients to participate
in our clinical trials will be critical to our success. Patient enrollment depends on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and enrolling eligible patients, including those willing to discontinue use of their existing medications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the clinical protocol and the patient eligibility and exclusion criteria for the trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety profile, to date, of the therapeutic candidate under study;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness or availability of patients to participate in our trials, including due to the perceived risks and benefits, stigma or other side effects of use of a controlled substance;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived risks and benefits of our approach to treatment of indication;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients to clinical sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of competing clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of new drugs approved for the indication the clinical trial is investigating;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217; and patients&#8217; perceptions of the potential advantages of the drug being studied in relation to other available therapies, including any new therapies that may be approved for the indications we are investigating; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain patient informed consents.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even once enrolled, we may be unable to retain a sufficient number
of patients to complete any of our trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, any negative results we may report
in clinical trials may make it difficult or impossible to recruit and retain patients in other clinical trials of that same therapeutic
candidate. Delays in the enrollment for any clinical trial will likely increase our costs, slow down the approval process and delay or
potentially jeopardize our ability to commence sales of our future therapeutic candidates and generate revenue. In addition, some of the
factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of
regulatory approval of any future therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never commercialized a therapeutic
candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our therapies on our own
or with suitable collaborators.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have limited organizational experience in the
sale or marketing of therapeutic candidates. To achieve commercial success for any approved therapy, we must develop or acquire a sales
and marketing organization, outsource these functions to third parties or enter into partnerships.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we enter into arrangements with third parties
to perform market access and commercial services for any approved therapies, the revenue or the profitability of these revenue to us could
be lower than if we were to commercialize any therapies that we develop ourselves. Such collaborative arrangements may place the commercialization
of any approved therapies outside of our control and would make us subject to a number of risks including that we may not be able to control
the amount or timing of resources that our collaborative partner devotes to our therapies or that our collaborator&#8217;s willingness
or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations
or significant changes in our collaborator&#8217;s business strategy. We may not be successful in entering into arrangements with third
parties to commercialize our therapies or may be unable to do so on terms that are favorable to us. Acceptable third parties may fail
to devote the necessary resources and attention to commercialize our therapies effectively, to set up sufficient number of treatment centers
in third-party therapy sites, or to recruit, train and retain adequate number of therapists to administer our therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not establish commercial capabilities
successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our therapies, which
in turn would have a material adverse effect on our business, prospects, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The future commercial success of our future
therapeutic candidates will depend on the degree of market access and acceptance of our potential therapies among healthcare professionals,
patients, healthcare payors, health technology assessment bodies and the medical community at large.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may never have a therapy that is commercially
successful. To date, we have no therapy authorized for marketing. Furthermore, if approved, our future therapies may not achieve an adequate
level of acceptance by payors, health technology assessment bodies, healthcare professionals, patients and the medical community at large,
and we may not become profitable. The level of acceptance we ultimately achieve may be affected by negative public perceptions and historic
media coverage of psychedelic substances, including psilocybin. Because of this history, efforts to educate the medical community and
third-party payors and health technologies assessment bodies on the benefits of our future therapies may require significant resources
and may never be successful, which would prevent us from generating significant revenue or becoming profitable. Market acceptance of our
future therapies by healthcare professionals, patients, healthcare payors and health technology assessment bodies will depend on a number
of factors, many of which are beyond our control, including, but not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
by healthcare professionals, patients and healthcare payors of each therapy as safe, effective and cost-effective;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in the standard of care for the targeted indications for any therapeutic candidate;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
strength of sales, marketing and distribution support;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
product liability claims;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
therapeutic candidate&#8217;s relative convenience, ease of use, ease of administration and other perceived advantages over alternative
therapies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
prevalence and severity of adverse events or publicity;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations,
precautions or warnings listed in the summary of therapeutic characteristics, patient information leaflet, package labeling or instructions
for use;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost of treatment with our therapy in relation to alternative treatments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
ability to manufacture our product in sufficient quantities and yields;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
availability and amount of coverage and reimbursement from healthcare payors, and the willingness of patients to pay out of pocket in
the absence of healthcare payor coverage or adequate reimbursement;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
willingness of the target patient population to try, and of healthcare professionals to prescribe, the therapy;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
potential unfavorable publicity, including negative publicity associated with recreational use or abuse of psilocybin;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
extent to which therapies are approved for inclusion and reimbursed on formularies of hospitals and managed care organizations; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
our therapies are designated under physician treatment guidelines or under reimbursement guidelines as a first-line, second-line, third-line
or last-line therapy.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our future therapeutic candidates fail to gain
market access and acceptance, this will have a material adverse impact on our ability to generate revenue to provide a satisfactory, or
any, return on our investments. Even if some therapies achieve market access and acceptance, the market may prove not to be large enough
to allow us to generate significant revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in methods of therapeutic candidate
manufacturing or formulation may result in additional costs or delay.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As therapeutic candidates are developed through
preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects
of the development program, such as manufacturing methods and formulation, may be altered along the way in an effort to optimize processes
and results. Any of these changes could cause any of our future therapeutic candidates to perform differently and affect the results of
planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes
may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct
of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of any of
our future therapeutic candidates and jeopardize our ability to commence product sales and generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become exposed to costly and damaging
liability claims, either when testing our future therapeutic candidates in the clinic or at the commercial stage, and our product liability
insurance may not cover all damages from such claims.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will be exposed to potential product liability
and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of therapeutic substances.
Currently, we have no therapies that have been approved for commercial sale; however, any future therapeutic candidates by us and our
corporate collaborators in clinical trials, and the potential sale of any approved therapies in the future, may expose us to liability
claims. These claims might be made by patients who use our therapies, healthcare providers, pharmaceutical companies, our corporate collaborators
or other third parties that sell our therapies. Any claims against us, regardless of their merit, could be difficult and costly to defend
and could materially adversely affect the market for our future therapeutic candidates or any prospects for commercialization of our future
therapeutic candidates. Although the clinical trial process is designed to identify and assess potential side effects, it is always possible
that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our future therapeutic candidates causes adverse
side effects during clinical trials or after regulatory approval, we may be exposed to substantial liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Physicians and patients may not comply with warnings
that identify known potential adverse effects and describe which patients should not use any of our future therapeutic candidates. Regardless
of the merits or eventual outcome, liability claims may cause, among other things, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
demand for our therapies due to negative public perception;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
to our reputation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
of clinical trial participants or difficulties in recruiting new trial participants;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
of investigations by regulators;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
to defend or settle the related litigation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
diversion of management&#8217;s time and our resources;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
monetary awards to trial participants or patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls,
withdrawals or labeling, marketing or promotional restrictions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
of revenue from therapeutic sales; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
inability to commercialize any of our future therapeutic candidates, if approved.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may not be able to obtain or maintain
insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If
a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities,
our assets may not be sufficient to cover such claims and our business, financial condition and results of operations could be materially
adversely affected. Liability claims resulting from any of the events described above could have a material adverse effect on our business,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Enacted and future legislation may increase
the difficulty and cost for us to obtain marketing approval of and commercialize any of our future therapeutic candidates and could have
a material adverse effect on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, there have been a number
of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there
have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve
the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and
Education Reconciliation Act of 2010 (collectively, &#8220;ACA&#8221;), substantially changed the way healthcare is financed by both governmental
and private insurers, and significantly impacted the U.S. biopharmaceutical industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Among the provisions of the ACA of importance
to our potential therapeutic candidates are the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs, apportioned among these entities
according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products
approved exclusively for orphan indications;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
of eligibility criteria for Medicaid programs, a Federal and state program which extends healthcare to low-income individuals and other
groups, by, among other things, allowing states to offer Medicaid coverage to certain individuals and adding new eligibility categories
for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s
Medicaid rebate liability;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
of manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program, which requires that drug manufacturers provide rebates
to states in exchange for state Medicaid coverage for most of the manufacturers&#8217; drugs by increasing the minimum rebate for both
branded and generic drugs and revising the definition of &#8220;average manufacturer price,&#8221; for calculating and reporting Medicaid
drug rebates on outpatient prescription drug prices and extending rebate liability to prescriptions for individuals enrolled in Medicare
Advantage plans (i.e., a type of Medicare healthcare plan offered by private companies);</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for products that are inhaled,
infused, instilled, implanted or injected;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
of the types of entities eligible for the 340B drug discount program, which requires drug manufacturers to provide outpatient drugs to
eligible healthcare organizations and covered entities at significantly reduced prices;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
of the Medicare Part D coverage gap discount program, which requires manufacturers to provide a 50% point-of-sale-discount (increased
to 70% pursuant to the Bipartisan Budget Act of 2018, or BBA, effective as of January 1, 2019) off the negotiated price of applicable
products to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217; outpatient products to
be covered under Medicare Part D;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">creation
of a new non-profit, nongovernmental institute, called the Patient-Centered Outcomes Research Institute, to oversee, identify priorities
in and conduct comparative clinical effectiveness research, along with funding for such research; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
of the Center for Medicare and Medicaid Innovation within Centers for Medicare &amp; Medicaid to test innovative payment and service
delivery models to lower Medicare and Medicaid spending, potentially including prescription product spending.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since its enactment, there have been numerous
judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional
challenges and amendments to the ACA in the future. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended.
We cannot predict what affect further changes to the ACA would have on our business. This uncertainty is heightened by President&#160;Biden&#8217;s
January 28, 2021 Executive Order on Strengthening Medicaid and the&#160;Affordable Care&#160;Act which indicated that the Biden&#160;Administration
may significantly modify the ACA and potentially revoke any changes implemented by the Trump Administration. It is also possible that
President Biden will further reform the ACA and other federal programs in manner that may impact our operations. The Biden Administration
has indicated that a goal of its administration is to expand and support Medicaid and the ACA and to make high-quality healthcare accessible
and affordable. The potential increase in patients covered by government funded insurance may impact our pricing. Further, it is possible
that the Biden Administration may further increase the scrutiny on drug pricing. The ACA continues to be challenged in court and it is
unclear how any future litigation and the healthcare reform measures of the&#160;Biden&#160;administration will impact the ACA. In August
2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications
for pharmaceutical manufacturers and Medicare beneficiaries, including allowing the federal government to negotiate drug prices for certain
high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price
negotiation requirements, requiring drug companies to pay rebates for all Medicare Part B and Part D drugs, with limited exceptions, if
their drug prices increase faster than inflation, capping out-of-pocket spending for Medicare Part D enrollees and making additional changes
to Medicare Part D to further reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. The Biden administration
released an additional executive order on October 14, 2022, requiring the U.S. Department of Health &amp; Human Services (&#8220;HHS&#8221;)
to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for
lowering drug costs for Medicare and Medicaid beneficiaries. We cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional
state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state
governments will pay for health care products and services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third-party payors are increasingly challenging
the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and
efficacy. To obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive
studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs
expended to obtain regulatory approvals. Third-party payors may not consider our product or product candidates to be medically necessary
or cost-effective compared to other available therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the containment of healthcare costs
(including drug prices) has become a priority of federal and state governments. The U.S. government, state legislatures, and foreign governments
have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and
requirements for substitution by generic products. For example, the Biden&#160;Administration, including his nominee for Secretary of
DHHS, has indicated that lowering prescription drug prices is a priority, but we do not yet know what steps the administration will take
or whether such steps will be successful. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies
in jurisdictions with existing controls and measures, could limit our net revenue and results. If these third-party payors do not consider
our products to be cost-effective compared to other therapies, they may not cover our products or product candidates if approved as a
benefit under their plans or, if they do, the level of reimbursement may not be sufficient to allow us to sell our products on a profitable
basis. Decreases in third-party reimbursement for our products once approved or a decision by a third-party payor to not cover our products
could reduce or eliminate utilization of our products and have an adverse effect on our sales, results of operations, and financial condition.
In addition, state and federal healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts
that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products
or product candidates once approved or additional pricing pressures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, new laws and additional health reform
measures may result in additional reductions in Medicare and other healthcare funding, which may adversely affect customer demand and
affordability for our future therapeutic candidates and, accordingly, the results of our financial operations.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business operations and current and
future relationships with investigators, health care professionals, consultants, third-party payors and customers may be subject, directly
or indirectly, to U.S. federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws,
other healthcare laws and regulations and other foreign privacy and security laws. If we are unable to comply, or have not fully complied,
with such laws, we could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we do not currently have any therapies
on the market, our current and future operations may be directly, or indirectly through our relationships with investigators, health care
professionals, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including,
without limitation, the U.S. federal Anti-Kickback Statute or the federal Anti-Kickback Statute. Healthcare providers, physicians and
others play a primary role in the recommendation and prescription of any therapies for which we obtain marketing approval. These laws
impact, among other things, our research activities and proposed sales, marketing and education programs and constrain our business and
financial arrangements and relationships with third-party payors, healthcare professionals who participate in our clinical research program,
healthcare professionals and others who recommend, purchase, or provide our approved therapies, and other parties through which we market,
sell and distribute our therapies for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security
regulation by both the U.S. federal government and the states in which we conduct our business, along with foreign regulators (including
European data protection authorities). Finally, our current and future operations will be subject to additional healthcare-related statutory
and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. These
laws include, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering,
receiving or paying any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly,
in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of,
any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs
such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate
it in order to have committed a violation. Violations are subject to significant civil and criminal fines and penalties for each violation,
plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government
may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a
false or fraudulent claim for purposes of the civil False Claims Act (&#8220;FCA&#8221;). The definition of the &#8220;remuneration&#8221;
under the federal Anti-Kickback Statute has been interpreted to include anything of value. Further, courts have found that if &#8220;one
purpose&#8221; of remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. The Anti-Kickback Statute has been
interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary
managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
prosecution; but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection;</span></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal civil and criminal false claims laws, such as the FCA, which prohibits individuals or entities from, among other things, knowingly
presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal
healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent
claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding
or decreasing or concealing an obligation to pay money to the U.S. federal government. Manufacturers can be held liable under the FCA
even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or
fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the
federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated
the FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation
in Medicare, Medicaid and other federal healthcare programs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer or remuneration to
a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s
selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless
an exception applies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical
Health Act of 2009 and their implementing regulations (collectively referred to as &#8220;HIPAA&#8221;) as well as numerous other federal
and state laws and regulations, govern the collection, dissemination, use, privacy, security, confidentiality, integrity and availability
of personally identifiable information (&#8220;PII&#8221;), including protected health information (&#8220;PHI&#8221;). HIPAA applies
national privacy and security standards for PHI to covered entities, including certain types of health care entities and their service
providers that access PHI, known as business associates. HIPAA requires covered entities and business associates to maintain policies
and procedures governing PHI that is used or disclosed, and to implement administrative, physical and technical safeguards to protect
PHI, including PHI maintained, used and disclosed in electronic form. These safeguards include employee training, identifying business
associates with whom covered entities need to enter into HIPAA-compliant contractual arrangements and various other measures. While we
shall undertake substantial efforts to secure the PHI we maintain, use and disclose in electronic form, a cyber-attack or other intrusion
that bypasses our information security systems causing an information security breach, loss of PHI, PII or other data subject to privacy
laws or a material disruption of our operational systems could result in a material adverse impact on our business, along with potentially
substantial fines and penalties. Ongoing implementation and oversight of these security measures involves significant time, effort and
expense. HIPAA requires covered entities and their business associates to report breaches of unsecured PHI to affected individuals without
unreasonable delay and in no case later than 60 days after the discovery of the breach by the covered entity or its agents. Notification
must also be made to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and, in certain situations involving large
breaches, to the media. The HIPAA rules created a presumption that all non-permitted uses or disclosures of unsecured PHI are breaches
unless the covered entity establishes that there is a low probability the information has been compromised. A data breach affecting sensitive
personal information, including health information, also could result in significant legal and financial exposure and reputational damages
that could potentially have an adverse effect on our business.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDCA, which governs the production, sale, distribution and promotion of drugs, biologics and medical devices and prohibits, among other
things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, and its implementing regulations, which requires certain
manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s
Health Insurance Program to report annually to the CMS information related to certain payments and other transfers of value to physicians
(defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and
investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will
extend to include transfers of value made during the previous year to certain non-physician providers such as physician assistants and
nurse practitioners; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
state laws and regulations, including the following: state anti-kickback and false claims laws, which may be broader in scope than their
federal equivalents, and which may apply to our business practices, including research, distribution, sales and marketing arrangements
and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require
pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance
guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other
potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing
information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities;
state and local laws that require the registration of pharmaceutical sales representatives and state laws governing the privacy and security
of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted
by HIPAA, thus complicating compliance efforts.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The distribution of pharmaceutical products is
subject to additional requirements and regulations, including licensing, extensive record-keeping, storage and security requirements intended
to prevent the unauthorized sale of pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The scope and enforcement of each of these laws
is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable
precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare
companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare
industry. Even if precautions are taken, it is possible that governmental authorities will conclude that our business practices may not
comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations.
If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may
be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion of drugs
from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become
subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational
harm and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom
we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to significant criminal,
civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales
or withdrawal of future marketed products could materially affect business in an adverse way.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Efforts to ensure that our business arrangements
with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for
violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our
management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain
robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the
possibility that a healthcare company may run afoul of one or more of the requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with health and data protection
laws and regulations could lead to U.S. federal and state government enforcement actions, including civil or criminal penalties, private
litigation, and adverse publicity and could negatively affect our operating results and business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We and any potential collaborators may be subject
to U.S. federal and state data protection laws and regulations, such as laws and regulations that address privacy and data security. In
the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information
privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related
and other personal information. In addition, we may obtain health information from third parties, including research institutions from
which we obtain clinical trial data, which are subject to privacy and security requirements under HIPAA, as amended by HITECH. To the
extent that we act as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the
privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health
information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires
the reporting of certain security breaches to healthcare provider customers with respect to such information. Additionally, many states
have enacted similar laws that may impose more stringent requirements on entities like ours. Depending on the facts and circumstances,
we could be subject to significant civil, criminal, and administrative penalties if we obtain, use, or disclose individually identifiable
health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compliance with U.S. and foreign privacy and data
protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect,
use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and
regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private
litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects,
employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who
share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217;
privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable,
could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The successful commercialization of any
of our future therapeutic candidates will depend in part on the extent to which governmental authorities and health insurers establish
adequate reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for any of our future
therapeutic candidates, if approved, could limit our ability to market those therapies and decrease our ability to generate revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The availability and adequacy of coverage and
reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors
are essential for most patients to be able to afford therapies. As Schedule I substances under the CSA, psilocybin and psilocin are deemed
to have no accepted medical use and therapies that use psilocybin or psilocin are precluded from reimbursement in the United States. Our
products must be scheduled as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V) before they can be commercially
marketed. Our ability to achieve acceptable levels of coverage and reimbursement for therapies by governmental authorities, private health
insurers and other organizations will have an effect on our ability to successfully commercialize, and attract additional collaboration
partners to invest in the development of our future therapeutic candidates. Even if we obtain coverage for a given therapy by third-party
payors, the resulting reimbursement payment rates may not be adequate or may require patient out-of-pocket costs that patients may find
unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any therapy
that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, third-party payors are increasingly
challenging prices charged for therapeutic substances and services, and many third-party payors may refuse to provide coverage and reimbursement
for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor
may consider our future therapeutic candidates as substitutable and only offer to reimburse patients for the less expensive therapy. These
payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed therapies
at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is
not available or is available only at limited levels, we may not be able to successfully commercialize our future therapeutic candidates,
and may not be able to obtain a satisfactory financial return on therapeutic candidates that we may develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is significant uncertainty related to the
insurance coverage and reimbursement of newly approved therapies. In the United States, third-party payors, including private and governmental
payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered.
The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their
coverage and reimbursement policies for drugs. Some third-party payors may require pre-approval of coverage for new or innovative devices
or drug therapies before they will reimburse health care providers who use such therapies. It is difficult to predict at this time what
third-party payors will decide with respect to the coverage and reimbursement for our future therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, obtaining and maintaining reimbursement
status is time-consuming and costly. No uniform policy for coverage and reimbursement for drug therapies exists among third-party payors
in the United States. Therefore, coverage and reimbursement for drug therapies can differ significantly from payor to payor. As a result,
the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical
support for the use of our therapies to each payor separately, with no assurance that coverage and adequate reimbursement will be applied
consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some
cases at short notice, and we believe that changes in these rules and regulations are likely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outside the United States, international operations
are generally subject to extensive governmental price controls and other market regulations. Other countries allow companies to fix their
own prices for medical therapies, but monitor and control company profits. Additional foreign price controls or other changes in pricing
regulation could restrict the amount that we are able to charge for our future therapeutic candidates. Accordingly, in markets outside
the United States, the reimbursement for our therapies may be reduced compared with the United States and may be insufficient to generate
commercially reasonable revenue and profits.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will be subject to environmental, health
and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance
or remediation activities which may adversely affect our business and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations, including our research, development,
testing and manufacturing activities, will be subject to numerous foreign, federal, state and local environmental, health and safety laws
and regulations. These laws and regulations govern, among other things, the controlled use, manufacture, handling, release and disposal
of and the maintenance of a registry for, hazardous materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic
compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may incur significant costs to comply with
these current or future environmental and health and safety laws and regulations. Furthermore, if we fail to comply with such laws and
regulations, we could be subject to fines or other sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to Our Intellectual Property
Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The failure to obtain or maintain patents,
licensing agreements and other intellectual property could materially impact our ability to compete effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for our business to be viable and to
compete effectively, we need to develop and maintain, and we will heavily rely on, a proprietary position with respect to our intellectual
property. However, there are significant risks associated with our actual or proposed intellectual property. The risks and uncertainties
that we face with respect to our rights principally include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending
patent applications we have filed or will file may not result in issued patents or may take longer than we expect to result in issued
patents;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be subject to interference proceedings;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be subject to reexamination proceedings;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be subject to post grant review proceedings;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be subject to&#160;<i>inter partes&#160;</i>review proceedings;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be subject to derivation proceedings;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be subject to opposition proceedings in foreign countries;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
patents that are issued or licensed to us may not provide us with any competitive advantages or meaningful protection;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may not be able to develop additional proprietary technologies that are patentable;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
companies may challenge patents licensed or issued to us;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
companies may have independently developed and patented (or may in the future independently develop and patent) similar or alternative
technologies, or duplicate our technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
companies may design around technologies we have licensed or developed;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement
of patents is complex, uncertain and very expensive and we may not be able to secure,&#160;enforce and defend our patents;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
the event that we were to ever seek to enforce our patents in ligation, there is some risk that they could be deemed invalid, not infringed,
or unenforceable; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
patents of others may have an adverse effect on our business.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that any patents will be
issued as a result of any pending or future applications, or that any patents, once issued, will provide us with adequate protection from
competing products. For example, issued patents may be circumvented or challenged, declared invalid or unenforceable, or narrowed in scope.
In addition, since publication of discoveries in scientific or patent literature often lags behind actual discoveries, we cannot be certain
that we or our licensors were the first to invent or to file patent applications covering them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is also possible that others may have or may
obtain issued patents that could prevent us from commercializing our products or require us to obtain licenses requiring the payment of
significant fees or royalties in order to enable us to conduct our business. There is no guarantee that such licenses will be available
based on commercially reasonable terms. As to those patents that we have licensed, our rights depend on maintaining our obligations to
the licensor under the applicable license agreement, and we may be unable to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
patent protection for our products, or if the scope of the patent protection obtained is not sufficiently broad, competitors could develop
and commercialize products similar or identical to ours, and our ability to successfully commercialize our products could be impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent prosecution process is expensive and
time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a
timely manner, or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our development output
before it is too late to obtain patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent position of life science companies
generally is highly uncertain, involves complex legal and factual questions and has in past years been the subject of much litigation.
In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States and we may fail
to seek or obtain patent protection in all major markets. For example, unlike the U.S., European patent law restricts the patentability
of methods of treatment of the human body. Our pending and future patent applications may not result in patents being issued which protect
our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and
products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish
the value of our patents or narrow the scope of our patent protection, even post-grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent reform legislation has increased the uncertainties
and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September 16, 2011,
the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant
changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and may also affect
patent litigation. The U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) recently developed new regulations and procedures to govern
administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular,
the first to file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith
Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and
costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
have a material adverse effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, we may be subject to a third-party pre-issuance
submission of prior art to the USPTO, or become involved in opposition, derivation, reexamination,&#160;<i>inter partes&#160;</i>review,
post-grant review or interference proceedings challenging our patent rights (whether licensed or otherwise held) or the patent rights
of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent
rights (whether licensed or otherwise held), allow third parties to commercialize our products and compete directly with us, without payment
to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition,
if the breadth or strength of protection provided by our patents and patent applications (whether licensed or otherwise held) is threatened,
it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if our patent applications (whether licensed
or otherwise held) result in the issuance of patents, they may not issue in a form that will provide us with any meaningful protection,
prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent
our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of a patent is not conclusive as
to its inventorship, scope, validity or enforceability, and our licensed or owned patents may be challenged in the courts or patent offices
in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed,
invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar
or identical products, or limit the duration of the patent protection of our products. Given the amount of time required for the development,
testing and regulatory review of new life science product candidates, patents protecting such candidates might expire before or shortly
after such candidates are commercialized. As a result, our intellectual property rights portfolio may not provide us with sufficient rights
to exclude others from commercializing products similar or identical to ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become involved in lawsuits to protect
or enforce our intellectual property rights, which could be expensive, time-consuming and ultimately unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competitors may infringe our intellectual property.
To counter infringement or unauthorized use, we may be required to sue a third party, or otherwise make a claim, alleging infringement
or other violation of patents, trademarks, trade dress, copyrights, trade secrets, domain names or other intellectual property rights
that we either own or license from a third party. If we do not prevail in enforcing our intellectual property rights in this type of litigation,
we may be subject to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">paying
monetary damages related to the legal expenses of the third party;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facing
additional competition that may have a significant adverse effect on our product pricing, market share, business operations, financial
condition, and the commercial viability of our product; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restructuring
our Company or delaying or terminating select business opportunities, including, but not limited to, research and development, clinical
trial, and commercialization activities, due to a potential deterioration of our financial condition or market competitiveness.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any claims we assert against perceived infringers
could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property or that our intellectual
property is invalid or unenforceable. The result of these challenges may narrow the scope or claims of or invalidate or found unenforceable
patents that are integral to our product or product candidate. In addition, in a patent infringement proceeding, a court may decide that
a licensed or owned patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse
to stop the other party from using the technology at issue on the grounds that our patents do not cover that technology. Moreover, lawsuits
to protect or enforce our intellectual property rights could be expensive, time-consuming and ultimately unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third parties may initiate legal proceedings
alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success depends upon our ability
to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties. There is considerable
intellectual property litigation in the life sciences industry. We cannot guarantee that our product candidates will not infringe third-party
patents or other proprietary rights. We may become party to, or threatened with, future adversarial proceedings or litigation regarding
intellectual property rights with respect to our products and technology, including&#160;<i>inter partes&#160;</i>review, post-grant review,
interference, or derivation proceedings before the USPTO and similar proceeding before similar bodies in other countries. Third parties
may assert infringement claims against us based on existing intellectual property rights and intellectual property rights that may be
granted in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are found to infringe a third party&#8217;s
intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our
products. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able
to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could
be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable
for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding
of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which
could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our own patent protection could be reduced or eliminated for noncompliance with these requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Periodic maintenance fees and annuities on any
issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO
and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar
provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by
other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of
the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events
that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official
actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event,
our competitors might be able to enter our markets, which could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims by third parties
asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own
intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may retain employees and contractors that were
previously employed at universities or other companies, including potential competitors. Although we will try to ensure that our employees
and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these
employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s
former employer. Litigation may be necessary to defend against these claims, and any such litigation could have an unfavorable outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, while it is our policy to require
our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual
property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that
we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring
claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual
property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail in prosecuting or defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful
in prosecuting or defending against such claims, litigation could result in substantial costs and adverse results, and be a distraction
to management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with our obligations
in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our
business relationships with our licensors, we could lose rights that are important to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have licensed and may enter into or may be
required to enter into intellectual property license agreements that are important to our business. These license agreements may impose
various diligence, milestone payment, royalty and other obligations on us. For example, we may enter into exclusive license agreements
with various universities and research institutions, we may be required to use commercially reasonable efforts to engage in various development
and commercialization activities with respect to licensed products, and may need to satisfy specified milestone and royalty payment obligations.
If we fail to comply with any obligations under our agreements with any of these licensors, we may be subject to termination of the license
agreement in whole or in part, increased financial obligations to our licensors or loss of exclusivity in a particular field or territory,
in which case our ability to develop or commercialize products covered by the license agreement will be impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, disputes may arise regarding intellectual
property subject to a license agreement, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
scope of rights granted under the license agreement and other interpretation-related&#160;issues;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
extent to which our processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
diligence obligations under the license agreement and what activities satisfy those obligations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
a third-party&#160;expresses interest in an area under a license that we are not pursuing, under the terms of certain of our license
agreements, we may be required to sublicense rights in that area to a third party, and that sublicense could harm our business; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
ownership of inventions and know-how&#160;resulting from the joint creation or use of intellectual property by our licensors and us.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disputes over intellectual property that we have
licensed may prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, and we may be unable to
successfully develop and commercialize our product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property litigation could cause
us to spend substantial resources and distract our personnel from their normal responsibilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if resolved in our favor, litigation or other
legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical
and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings,
motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it
could have an adverse effect on the price of our common stock. Such litigation or proceedings could increase our operating losses and
reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient
financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the
costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting
from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may spend considerable resources developing
and maintaining patents, license agreements and other intellectual property that may later be abandoned or may otherwise never result
in products brought to market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not all technologies and candidate products that
initially show potential as the basis for future products will ultimately meet the rigors of our development process and as a result may
be abandoned and/or never otherwise result in products brought to market.&#160;In some cases, prior to abandonment we may be required
to incur significant costs developing and maintaining intellectual property and/or maintaining license agreements and our business could
be harmed by such costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are not able to adequately prevent
disclosure of trade secrets and other proprietary information, the value of our technology and product could be significantly diminished.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on trade secrets to protect our proprietary
technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult
to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored
researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent
disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential
information. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part
of its transparency initiative, is currently considering whether to make additional information publicly available on a routine basis,
including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time
how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming&#160;litigation could be necessary
to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely
affect our competitive business position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on information technology, and if
we are unable to protect against service interruptions, data corruption, cyber-based attacks or network security breaches, our operations
could be disrupted, and our business could be negatively affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on information technology networks and
systems to process, transmit and store electronic and financial information; to coordinate our business; and to communicate within our
Company and with customers, suppliers, partners and other third-parties. These information technology systems may be susceptible to damage,
disruptions or shutdowns, hardware or software failures, power outages, computer viruses, cyber-attacks, telecommunication failures, user
errors or catastrophic events. If our information technology systems suffer severe damage, disruption or shutdown, and our business continuity
plans do not effectively resolve the issues in a timely manner, our operations could be disrupted, and our business could be negatively
affected. In addition, cyber-attacks could lead to potential unauthorized access and disclosure of confidential information, and data
loss and corruption. There is no assurance that we will not experience these service interruptions or cyber-attacks in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in hiring and retaining
key employees, including executive officers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success materially depends upon the expertise,
experience and continued service of our management and other key personnel, including, but not limited to, Eric Weisblum, our Chief Executive
Officer. If we lose the services of Mr. Weisblum or any of other member of management, our business would be materially and adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future success also depends upon our ability
to attract and retain highly qualified management personnel and other employees. There can be no assurance that these professionals will
be available in the market, or that we will be able to retain existing professionals or to meet or to continue to meet their compensation
requirements. Furthermore, the cost base in relation to such compensation, which may include equity compensation, may increase significantly,
which could have a material adverse effect on us. Failure to establish and maintain an effective management team and work force could
adversely affect our ability to operate, grow and manage our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unfavorable global economic, business or
political conditions could adversely affect our business, financial condition or results of operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our results of operations could be adversely affected
by general conditions in the global economy and in the global financial markets, including conditions that are outside of our control,
including the impact of health and safety concerns, such as those relating to the current COVID-19 outbreak. The most recent global financial
crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result
in a variety of risks to our business, including weakened demand for our products and our ability to raise additional capital when needed
on acceptable terms, if at all. A weak or declining economy could strain our domestic and international customers, possibly resulting
in delays in customer payments. Any of the foregoing could harm our business and we cannot anticipate all the ways in which the current
economic climate and financial market conditions could adversely impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to Our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Certificate of Incorporation grants
our board of directors, without any action or approval by our stockholders, the power to designate and issue preferred stock with rights,
preferences and privileges that may be adverse to the rights of the holders of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total number of preferred stock that we are
authorized to issue is 5,000,000 shares, none of which are issued and outstanding as of March 23, 2024. Pursuant to authority granted
by our Certificate of Incorporation, our board of directors, without any action or approval by our stockholders, may issue&#160;preferred
stock in one or more series, the terms of which may be determined at the time of issuance by our board of directors without further action
by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular
matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions.&#160;The rights of holders
of other classes or series of capital stock, including preferred stock that may be issued could be superior to the rights of the holders
of shares of our common stock. The designation and issuance of shares of capital stock having preferential rights could materially adversely
affect&#160;the rights of the holders of our&#160;common stock.&#160;In addition, any issuances of additional capital stock (common or
preferred) will dilute the percentage of ownership interest of our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid cash dividends and have
no plans to pay cash dividends in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of shares of our common stock are entitled
to receive such dividends as may be declared by our board of directors. To date, we have paid no cash dividends on our capital stock and
we do not expect to pay cash dividends in the foreseeable future. We intend to retain future earnings, if any, to provide funds for operations
of our business. Therefore, any return investors in our capital stock may have will be in the form of appreciation, if any, in the market
value of their shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our compliance with complicated U.S. regulations
concerning corporate governance and public disclosure is expensive and diverts management&#8217;s attention from our core business, which
could adversely affect our business, results of operations, and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a publicly reporting company, we are faced
with expensive, complicated and evolving disclosure, governance and compliance laws, regulations and standards relating to corporate governance
and public disclosure, including the Sarbanes-Oxley Act and the Dodd-Frank Act, and Nasdaq rules. As a result of the complexity involved
in complying with the applicable rules and regulations, our management&#8217;s attention may be diverted from other business concerns,
which could harm our business, results of operations and financial condition. We may need to hire more personnel in the future or engage
outside consultants, which will increase our operating expenses, to assist us in complying with these requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, changing laws, regulations and standards
relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance
costs, and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in
many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided
by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated
by ongoing revisions to disclosure and governance practices. We intend to invest substantial resources to comply with evolving laws, regulations
and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time
and attention from business operations to compliance activities. If our efforts to comply with new laws, regulations and standards differ
from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory
authorities may initiate legal proceedings against us, and our business may be harmed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our common stock could be subject to extreme
volatility.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading price of our common stock may be affected
by a number of factors, including events described in the risk factors set forth herein and in our other reports filed with the SEC from
time to time, as well as our operating results, financial condition and other events or factors. In addition to the uncertainties relating
to future operating performance and the profitability of operations, factors such as variations in interim financial results or various,
and unpredictable, factors, many of which are beyond our control, may have a negative effect on the market price of our common stock.
In recent years, broad stock market indices, in general, and smaller capitalization companies, in particular, have experienced substantial
price fluctuations. In a volatile market, we may experience wide fluctuations in the market price of our common stock and wide bid-ask
spreads. These fluctuations may have a negative effect on the market price of our common stock. In addition, the securities market has,
from time to time, experienced significant price and volume fluctuations that are not related to the operating performance of particular
companies. These market fluctuations may have a material adverse effect the market price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Market and economic conditions may negatively
impact our business, financial condition and share price.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concerns over inflation, energy costs, geopolitical
issues, the U.S. mortgage market and a declining real estate market, unstable global credit markets and financial conditions, and volatile
oil prices have led to periods of significant economic instability, diminished liquidity and credit availability, declines in consumer
confidence and discretionary spending, diminished expectations for the global economy and expectations of slower global economic growth
going forward, increased unemployment rates, and increased credit defaults in recent years. Our general business strategy may be adversely
affected by any such economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions.
If these conditions continue to deteriorate or do not improve, it may make any necessary debt or equity financing more difficult to complete,
more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material
adverse effect on our growth strategy, financial performance, and share price and could require us to delay or abandon development or
commercialization plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales and issuances of our securities
could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that significant additional capital
will be needed in the future to continue our planned operations, including research and development, increased marketing, hiring new personnel,
commercializing our products, and continuing activities as an operating public company. To the extent we raise additional capital by issuing
equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity
securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible
securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales
may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be at risk of securities class action litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.15pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be at risk of securities class action litigation.
In the past, biotechnology and pharmaceutical companies have experienced significant stock price volatility, particularly when associated
with binary events such as clinical trials and product approvals. If we face such litigation, it could result in substantial costs and
a diversion of management&#8217;s attention and resources, which could harm our business and results in a decline in the market price
of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial reporting obligations of being
a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time
to compliance matters.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a publicly traded company we incur significant
legal, accounting and other expenses. The obligations of being a public company in the United States require significant expenditures
and places significant demands on our management and other personnel, including costs resulting from public company reporting obligations
under the Exchange Act and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley
Act of 2002, as amended (&#8220;Sarbanes-Oxley&#8221;) and the Dodd-Frank Wall Street Reform and Consumer Protection Act. These rules
require the establishment and maintenance of effective disclosure and financial controls and procedures, internal control over financial
reporting and changes in corporate governance practices, among many other complex rules that are often difficult to implement, monitor
and maintain compliance with. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply
with all of these requirements and to keep pace with new regulations, otherwise we may fall out of compliance and risk becoming subject
to litigation among other potential problems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to maintain effective internal control
over our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could cause our financial reports to be inaccurate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.8pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are required pursuant to Section 404 of the
Sarbanes-Oxley Act, or Section 404, to maintain internal control over financial reporting and to assess and report on the effectiveness
of those controls. This assessment includes disclosure of any material weaknesses identified by our management in our internal control
over financial reporting. Although we prepare our financial statements in accordance with accounting principles generally accepted in
the United States, our internal accounting controls may not meet all standards applicable to companies with publicly traded securities.
If we fail to implement any required improvements to our disclosure controls and procedures, we may be obligated to report control deficiencies
and our independent registered public accounting firm may not be able to certify the effectiveness of our internal controls over financial
reporting. In either case, we could become subject to regulatory sanction or investigation. Further, these outcomes could damage investor
confidence in the accuracy and reliability of our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management has concluded that our internal
controls over financial reporting were, and continue to be, ineffective, as December 31, 2022 as a result of the following: (i) we lack
segregation of duties within accounting functions duties as a result of our limited financial resources to support hiring of personnel,
and; (ii) we not have not implemented adequate system and manual controls. While management intends to remediate the material weakness,
there is no assurance that such changes, when economically feasible and sustainable, will remediate the identified material weaknesses
or that the controls will prevent or detect future material weaknesses. If we are not able to maintain effective internal control over
financial reporting, our financial statements, including related disclosures, may be inaccurate, which could have a material adverse effect
on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Capital Market may subsequently delist
our common stock if we fail to comply with ongoing listing standards.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Capital Market will require us to meet
certain financial, public float, bid price and liquidity standards on an ongoing basis in order to continue the listing of our common
stock. If we fail to meet these continued listing requirements, our common stock may be subject to delisting. If our common stock are
delisted and we are not able to list such common stock or warrants on another national securities exchange, we expect our securities would
be quoted on an over-the-counter market; However, if this were to occur, our stockholders could face significant material adverse consequences,
including limited availability of market quotations for our common stock and reduced liquidity for the trading of our securities. In addition,
in the event of such delisting, we could experience a decreased ability to issue additional securities and obtain additional financing
in the future. Even if our common stock is listed on the Nasdaq Capital Market, there can be no assurance that an active trading market
for our common stock will develop or be sustained after our initial listing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1B. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1C. CYBERSECURITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe cybersecurity is critical to advancing
our technological advancements. As a biopharmaceutical company, we face a multitude of cybersecurity threats that range from attacks common
to most industries, such as ransomware and denial-of service. Our customers, suppliers, subcontractors, and business partners face similar
cybersecurity threats, and a cybersecurity incident impacting us or any of these entities could materially adversely affect our operations,
performance, and results of operations. These cybersecurity threats and related risks make it imperative that we expend resources on cybersecurity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors oversees management&#8217;s
processes for identifying and mitigating risks, including cybersecurity risks, to help align our risk exposure with our strategic objectives.
Senior leadership, including our cybersecurity consultant, regularly briefs the Board of Directors on our cybersecurity and information
security posture and the Board of Directors is apprised of cybersecurity incidents deemed to have a moderate or higher business impact,
even if immaterial to us. The full Board retains oversight of cybersecurity because of its importance. In the event of an incident, we
intend to follow our detailed incident response playbook, which outlines the steps to be followed from incident detection to mitigation,
recovery, and notification, including notifying functional areas (e.g., legal), as well as senior leadership and the Board, as appropriate.
Our Cybersecurity consultant has extensive information technology and program management experience. We have implemented a governance
structure and processes to assess, identify, manage, and report cybersecurity risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a biopharmaceutical company, we must comply
with extensive regulations, including requirements imposed by the Federal Drug Administration related to adequately safeguarding patient
information and reporting cybersecurity incidents to the SEC. We work with our cybersecurity consultant on assessing cybersecurity risk
and on policies and practices aimed at mitigating these risks. We believe we are positioned to meet the requirements of the SEC. In addition
to following SEC guidance and implementing pre-existing third party frameworks, we have developed our own practices and frameworks, which
we believe enhance our ability to identify and manage cybersecurity risks. Third parties also play a role in our cybersecurity. We engage
third-party services to conduct evaluations of our security controls, whether through penetration testing, independent audits, or consulting
on best practices to address new challenges. Assessing, identifying, and managing cybersecurity related risks are factored into our overall
business approach.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely heavily on our supply chain to deliver
our products and services, and a cybersecurity incident at a supplier, subcontractor or business partner could materially adversely impact
us. We require that our subcontractors report cybersecurity incidents to us so that we can assess the impact of the incident on us. Notwithstanding
the extensive approach we take to cybersecurity, we may not be successful in preventing or mitigating a cybersecurity incident that could
have a material adverse effect on us. While we maintain cybersecurity insurance, the costs related to cybersecurity threats or disruptions
may not be fully insured.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. PROPERTIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located at
677 N. Washington Boulevard Sarasota, FL. We pay approximately $80 per month to rent for such space on a month-to-month lease basis. We
believe that our current office space will be adequate for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3. LEGAL PROCEEDINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may become involved in various
lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an
adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such
legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition
or operating results.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. MINE SAFETY DISCLOSURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 27, 2022 our common stock began trading
on The Nasdaq Capital Market under the symbol &#8220;SILO.&#8221; Prior to that time, our common stock was quoted on the OTCQB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Security Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 17, 2024, there were 97 stockholders
of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders, and includes
stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not declared or paid dividends on our
common stock since our formation. Declaration or payment of dividends, if any, in the future, will be at the discretion of our Board of
Directors and will depend on our then current financial condition, results of operations, capital requirements and other factors deemed
relevant by the board of directors. There are no contractual restrictions on our ability to declare or pay dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Repurchase Program</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 26, 2023, our Board of Directors authorized
a stock repurchase plan to repurchase up to $1.0&#160;million of the Company&#8217;s issued and outstanding common stock, from time to
time, with such plan to be in place until December 31, 2023. On January 9, 2024, the Board of Directors of the Company approved an extension
of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the Company&#8217;s common stock
until March 31, 2024. Through December 31, 2023, we purchased 252,855 shares of our common stock for a cost of $471,121, which is reflected
in treasury stock on the accompanying consolidated balance sheet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of our common stock
repurchases during the quarterly period ended December 31, 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> number of<br/> shares<br/> purchased</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average<br/> price paid<br/> per share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> number of<br/> shares<br/> purchased<br/> as part of<br/> publicly<br/> announced<br/> program</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum<br/> number (or<br/> approximate<br/> dollar value)<br/> of shares<br/> that may<br/> yet be<br/> purchased<br/> under the<br/> program</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">October 1, 2023 through October 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">54,475</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">54,475</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>November 1, 2023 through November 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">December 1, 2023 through December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,335</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,335</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">123,562</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.57</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">123,562</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">528,879</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Sales of Unregistered Securities</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;6. [RESERVED]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>You should read the following discussion and
analysis of our financial condition and plan of operations together with and our consolidated financial statements and the related notes
appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking
statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors
that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the
section titled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report on Form 10-K. All amounts in this report are in U.S.
dollars, unless otherwise noted.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a developmental stage biopharmaceutical
company developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia,
and central nervous system (CNS) diseases. We are focused on developing novel therapies that include conventional drugs and psychedelic
formulations. The Company&#8217;s lead program, SPC-15, is an intranasal drug targeting PTSD and stress-induced anxiety disorders. SP-26
is a time-release ketamine-based loaded implant for fibromyalgia and chronic pain relief. Silo&#8217;s two preclinical programs are SPC-14,
an intranasal compound for the treatment of Alzheimer&#8217;s disease, and SPU-16, a CNS-homing peptide targeting the central nervous
system with initial research indication in multiple sclerosis (MS).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Rare Disease Therapeutics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, ketamine, and the potential benefits they may have in certain cases involving depression, mental health issues and
neurological disorders. We are focused on developing traditional therapeutics and psychedelic medicine. The company concentrates on the
development and commercialization of therapies for unmet needs from indications such as depression, post-traumatic stress disorder (&#8220;PTSD&#8221;),
, and other rare neurological disorders. Our mission is to identify assets to license and fund the research which we believe will be transformative
to the well-being of patients and the health care industry.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Psilocybin is considered a serotonergic hallucinogen
and is an active ingredient in some species of mushrooms. Recent industry studies using psychedelics, such as psilocybin, have been promising,
and we believe there is a large unmet need with many people suffering from depression, mental health issues and neurological disorders.
While classified as a Schedule I substance under the Controlled Substances Act (&#8220;CSA&#8221;), there is an accumulating body of evidence
that psilocybin may have beneficial effects on depression and other mental health conditions. Therefore, the U.S. Food and Drug Administration
(&#8220;FDA&#8221;) and U.S. Drug Enforcement Agency (&#8220;DEA&#8221;) have permitted the use of psilocybin in clinical studies for
the treatment of a range of psychiatric conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential of psilocybin therapy in mental
health conditions has been demonstrated in a number of academic-sponsored studies over the last decade. In these early studies, it was
observed that psilocybin therapy provided rapid reductions in depression symptoms after a single high dose, with antidepressant effects
lasting for up to at least six months for a number of patients. These studies assessed symptoms related to depression and anxiety through
a number of widely used and validated scales. The data generated by these studies suggest that psilocybin is generally well-tolerated
and may have the potential to treat depression when administered with psychological support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged in discussions with a number of
world-renowned educational institutions and advisors regarding potential opportunities and have formed a scientific advisory board that
is intended to help advise management regarding potential acquisition and development of products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as more fully described below, we
have entered into a license agreement with the University of Maryland, Baltimore, and developing a Ketamine polymer implant. In addition,
we have recently entered into a sponsored research agreement with Columbia University pursuant to which we have been granted an option
to license certain patents and inventions relating to the treatment of Alzheimer&#8217;s disease and stress-induced affective disorders
using Ketamine in combination with certain other compounds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to actively pursue the acquisition and/or
development of intellectual property or technology rights to treat rare diseases, and to ultimately expand our business to focus on this
new line of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently focusing on four product candidates:
(i) SPC-15 for treatment of depression disorders; (ii) SP-26 for treatments of chronic pain; (iii)SPC-14 for the treatment of Alzheimer&#8217;s
disease and (iv) SPU-16 for the treatment of CNS disorders with an initial indication for multiple sclerosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SPC-15</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into a sponsored research agreement
with Columbia University pursuant to which the Company has been granted an option to license certain assets currently under development,
including assets related to SPC-15 for the treatment of depression disorders. On September 22, 2022, we entered into a First Amendment
to Sponsored Research Agreement with Columbia to extend the term of the Columbia Agreement to conduct further research studies, which
extension runs through March 31, 2024. On April 11, 2023 the assets under development for which we have the option to license as described
above were issued a patent from the U.S. Patent &amp; Trademark Office (USPTO) for &#8220;Biomarkers for Efficacy of Prophylactic Treatments
Against Stress-Induced Affective Disorders&#8221; (US 11,622,948, B2). The Company exercised its option for an exclusive license agreement
for SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD pursuant to which the Company will
be granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. The Company expects to have the complete
license agreement with Columbia completed in the first half of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SPC-15 is a targeted prophylactic therapeutic
composition for the treatment and prevention for stress-induced affective disorders including PTSD. The treatment predicts levels of severity
or progression of such disorders and their metabolomic biomarkers&#8217; response to pharmacological treatments. We intend to develop
SPC-15 under the Section 505(b)(2) regulatory pathway of the FDA rules. Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act
(&#8220;FDCA&#8221;) was enacted to enable sponsors to seek New Drug Application (&#8220;NDA&#8221;) approval for novel repurposed drugs
without the need for such sponsors to undertake time consuming and expensive pre-clinical safety studies and Phase 1 safety studies. Proceeding
under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission
to the FDA for marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 15, 2023, the Company entered an exclusive
license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, as the delivery mechanism for
SPC-15, which agreement has an effective date of October 31, 2023. Preclinical and formulation studies are expected to be completed in
the first quarter of 2024 and the Company intends to submit a pre-IND meeting request to FDA in the first half of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SP-26 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2023, the Company filed a provisional
patent application with the USPTO to use SP-26 for treatment of chronic pain, including fibromyalgia Fibromyalgia is a chronic condition
causing pain to the connective tissues through the body including muscles, ligaments, and tendons. Musculoskeletal pain is often accompanied
by sleep difficulties, fatigue, mood disorders, and problems with memory and concentration. Fibromyalgia affects about 4 million American
adults, or about 2% of the adult population.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to develop SP-26 following the Section
505(b)(2) regulatory pathway of the FDA rules. Section 505(b)(2) of the FDCA was enacted to enable sponsors to seek NDA approval for novel
repurposed drugs without the need for such sponsors to undertake time consuming and expensive pre-clinical safety studies and Phase 1
safety studies. Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active
ingredient in our NDA submission to the FDA for marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SPC-14</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into a
sponsored research agreement with Columbia University (&#8220;Columbia&#8221;) pursuant to which Columbia shall conduct two different
studies related to the use of SPC-14 for the treatment of Alzheimer&#8217;s. See &#8220;Investigator-Sponsored Study Agreements between
the Company and Vendors---Sponsored Research Agreement with Columbia University for the Study of Ketamine in Combination with Other Drugs
for Treatment of Alzheimer&#8217;s and Depression Disorders.&#8221; for additional details. In addition, Company has been granted an option
to license certain assets currently under development, including SPC-14 for the treatment of Alzheimer&#8217;s disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SPC-14 is a novel drug combining two approved
therapeutics, so we intend to develop SPC-14 following the Section 505(b)(2) regulatory pathway of the FDA rules. Section 505(b)(2) of
the FDCA was enacted to enable sponsors to seek NDA approval for novel repurposed drugs without the need for such sponsors to undertake
time consuming and expensive pre-clinical safety studies and Phase 1 safety studies. Proceeding under this regulatory pathway, we will
be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2022, the Company extended the
term of the sponsored research agreement with Columbia to conduct further research studies into the mechanism of action of SPC-14 in the
treatment of Alzheimer&#8217;s disease. We expect the results from further preclinical studies in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SPU-16</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, we entered into a Master
License Agreement (the &#8220;UMB License Agreement&#8221;) with the University of Maryland, Baltimore (&#8220;UMB&#8221;) pursuant to
which UMB granted us an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual property (i) to make, have
made, use, sell, offer to sell, and import certain licensed products and (ii) to use the invention titled &#8220;Central nervous system-homing
peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology,&#8221;
or SPU-16. See &#8220;License Agreements between the Company and Vendors--Vendor License Agreement with the University of Maryland, Baltimore
for CNS Homing Peptide&#8221; for additional details. On April 11, 2023 certain intellectual property under the UMB License Agreement
described above were issued a patent from the U.S. Patent &amp; Trademark Office (USPTO) for &#8220;Peptide-Targeted Liposomal Delivery
For Treatment, Diagnosis, and Imaging of Diseases and Disorders&#8221; (US 11,766,403, B2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SPU-16 is a novel peptide homing specifically
to inflamed CNS areas. It may be used to diagnose neuroinflammation in patients, and targeted delivery of drugs into the spinal cord.
The initial indication is for multiple sclerosis (MS). The peptides have been tested in the EAE mouse model of human MS, where they show
homing specifically to inflamed CNS areas.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Product Development Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our product development
pipeline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_002.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company and
Vendor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Vendor License Agreement with the University
of Maryland, Baltimore for CNS Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, we entered into a Master
License Agreement (the &#8220;UMB License Agreement&#8221;) with the University of Maryland, Baltimore (&#8220;UMB&#8221;) pursuant to
which UMB granted us an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual property (i) to make, have
made, use, sell, offer to sell, and import certain licensed products and (ii) to use the invention titled, &#8220;Central nervous system-homing
peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#8221;
(the &#8220;Invention&#8221;) and UMB&#8217;s confidential information to develop and perform certain licensed processes for the therapeutic
treatment of neuroinflammatory disease. The term of the License Agreement shall commence on the UMB Effective Date and shall continue
until the latest of (i) ten years from the date of First Commercial Sale (as defined in the Sublicense Agreement) of the Licensed Product
in such country and (ii) the date of expiration of the last to expire claim of the Patent Rights (as defined in the UMB License Agreement)
covering such Licensed Product in such country, or (iii) the expiration of data protection, new chemical entity, orphan drug exclusivity,
regulatory exclusivity, or other legally enforceable market exclusivity, if applicable, unless terminated earlier pursuant to the terms
of the agreement. Pursuant to the UMB License Agreement, we agreed to pay UMB (i) a license fee of $75,000, (ii) certain event-based milestone
payments, (iii) royalty payments, depending on net revenues, (iv) minimum royalty payments, and (v) a tiered percentage of sublicense
income. The UMB License Agreement will remain in effect until the later of: (a) the last patent covered under the UMB License Agreement
expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally
enforceable market exclusivity, if applicable, or (c) ten years after the first commercial sale of a licensed product in that country,
unless earlier terminated in accordance with the provisions of the UMB License Agreement. The term of the UMB License Agreement shall
expire 15 years after the effective date in which (a) there were never any patent rights, (b) there was never any data protection, new
chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity or (c) there was never
a first commercial sale of a licensed product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described below, the Company has entered into
an investigator sponsored research agreement with UMB related to a clinical study to examine a novel peptide-guided drug delivery approach
for the treatment of Multiple Sclerosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Commercial Evaluation License and Option Agreement
with UMB for Joint Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into a commercial
evaluation license and option agreement (&#8220;License Agreement&#8221;), which granted the Company an exclusive, non-sublicensable,
non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use in the investigation
and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate and obtain an
exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive Option&#8221;) to with respect to the subject technology. The License
Agreement had a term of six months from the effective date. Both parties could have terminated the License Agreement within thirty days
by giving a written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company entered into a First
Amendment Agreement (&#8220;Amended License Agreement&#8221;) with UMB to extend the term of the original License Agreement by an additional
six months such that the Amended License Agreement was effective until February 25, 2022 however, if the Company exercises the Exclusive
Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution
of a master license agreement, whichever occurs first. The Company paid a license fee of $10,000 to UMB in March 2021 pursuant to the
License Agreement, which was expensed, since the Company could not conclude that such costs would be recoverable for this early-stage
venture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, the Company and University
of Maryland, Baltimore entered into a second amendment to the License Agreement dated February 26, 2021 (&#8220;Second Amendment&#8221;).
The Second Amendment extended the term of the License Agreement until December 31, 2022. However, if the Company exercises the Exclusive
Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution
of a master license agreement, whichever occurs first.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 22, 2022, the Company and UMB entered
into a third amendment to the License Agreement dated February 26, 2021 under which UMB agreed, to expand the scope of the license granted
in the CELA to add additional Patent Rights with respect to an invention generally known as &#8220;Peptide-Targeted Liposomal Delivery
for Treatment Diagnosis, and Imaging of Diseases and Disorders.&#8221; On December 16, 2022, the Company and UMB entered into a fourth
amendment to License Agreement (the &#8220;Fourth Amendment&#8221;) dated February 26, 2021 to extend the term of the License Agreement
until March 31, 2023. In addition, the parties agreed in the Fourth Amendment to allow the Company to extend the term of the License Agreement
to June 30, 2023 by paying UMB a fee of $1,000 on or before February 28, 2023. This fee was paid and thus the term of the License Agreement
was extended to June 30, 2023. We let this license expire by its terms on December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Joint Venture Agreement with Zyl&#246; Therapeutics,
Inc. for Z-pod&#8482; Technology</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021, the Company entered into a
Joint Venture Agreement with Zyl&#246; Therapeutics, Inc. (&#8220;ZTI&#8221;) pursuant to which the parties agreed to form a joint venture
entity, to be named Ketamine Joint Venture, LLC, to, among other things, focus on the clinical development of ketamine using ZTI&#8217;s
Z-pod&#8482; technology. Pursuant to the Joint Venture Agreement, the Company shall act as the manager of the Joint Venture. The Venture
shall terminate if the development program does not meet certain specifications and milestones as set forth in the Joint Venture Agreement
within 30 days of the date set forth in the Joint Venture Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion,
terminate the Venture at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Joint Venture
Agreement,&#160;(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and
(B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the
know-how and trade secrets with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be used
for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the Joint Venture
Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture
shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing,
in no event shall either party own more than 60% of the interest in the Joint Venture. As of December 31, 2022 and as of the current date
of this Annual Report, the joint venture entity has not been formed yet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the terms of the JV Agreement,
ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#8220;License Agreement&#8221;) with Albert Einstein
College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating that the patented
technology (the &#8220;Patented Technology&#8221;) licensed to ZTI pursuant to the License Agreement is needed to advance the development
of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant to the JV Agreement,
ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development of psilocybin using ZTI&#8217;s
Z-pod&#8482; technology on the same terms and conditions set forth in the JV Agreement, which option shall expire 24 months after the
JV Effective Date. We do not intend to continue with Zylo and have entered into an agreement to develop a polymer implant for dosage and
time release of Ketamine for chronic pain and Fibromyalgia</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exclusive License Agreement between Medspray
Pharma BV and the Company</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 15, 2023, we entered into an Exclusive
License Agreement (the &#8220;Medspray License Agreement&#8221;) with Medspray Pharma BV (&#8220;Medspray&#8221;) pursuant to which Medspray
granted us an exclusive, non-revocable, worldwide royalty bearing license for Medspray&#8217;s proprietary patented soft mist nasal spray
technology for marketing, promotion, sale and distribution of the products licensed by Medspray to us under the Medspray License Agreement.
The Medspray License Agreement has an effective date of October 31, 2023 and expires on the earlier of (i) termination of the Medspray
License Agreement or expiry of all Medspray license rights in the United States, Germany, United Kingdom, Spain, Italy and France. In
consideration of the exclusive rights granted by Medspray to us, we agreed to pay Medspray a royalty on a quarterly basis equal to 5%
of net sales. The term of the agreement commences on the effective date and continues until the earlier of (i) expiration of the last
to expire of Medspray&#8217;s patent rights or (ii) December 31, 2023 (the &#8220;Initial Term&#8221;) at which time, the Medspray License
Agreement will automatically renew for a successive period of three (3) years, unless terminated by either party upon one year prior written
notice prior to the end of any term; provided, however, the Medspray may terminate the Medspray License Agreement immediately if fail
to have any licensed product under the Medspray License Agreement registered with the FDA or EMA by July 1, 2028 or has filed to reach
the point of first sale of any licensed product under the Medspray License Agreement by July 1, 2028.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investigator-Sponsored Study Agreements between
the Company and Vendors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with Columbia
University for the Study of Ketamine in Combination with Other Drugs for Treatment of Alzheimer&#8217;s and Depression Disorders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into a sponsored research agreement
with Columbia University (&#8220;Columbia&#8221;) pursuant to which Columbia shall conduct two different studies related to all uses of
Ketamine or its metabolites in combination with Prucalopride, one of which is related to Alzheimer&#8217;s and the other of which is related
to Depression, PTSD and Stress Projects. In addition, Company has been granted an option to license certain assets currently under development,
including Alzheimer&#8217;s disease. The term of the option will commence on the effective date of this agreement and will expire upon
the earlier of (i) 90 days after the date of the Company&#8217;s receipt of a final research report for each specific research proposal
as defined in the agreement or (ii) termination of the research. If the Company elects to exercise the option, both parties will commence
negotiation of a license agreement and will execute a license agreement no later than 3 months after the dated of the exercise of the
option. The Company exercised its option for an exclusive license agreement for SPC-15, a prophylactic treatment for stress-induced affective
disorders including anxiety and PTSD pursuant to which the Company will be granted an exclusive license to further develop, manufacture,
and commercialize SPC-15 worldwide. The Company expects to have the complete license agreement with Columbia completed in the first half
of 2024. Columbia University and the Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer&#8217;s
disease to posttraumatic stress disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082
to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four
and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of
the project. On October 13, 2022, the Company entered into an amendment of the sponsored research agreement pursuant to which the parties
agreed to extend the payment schedule until March 31, 2024. The Company paid the first payment of $430,825 in November 2021 and the second
payment of $430,825 in July 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with University
of Maryland, Baltimore for the Study of Targeted liposomal drug delivery for rheumatoid arthritis</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, we entered into a sponsored research
agreement (the &#8220;July 2021 Sponsored Research Agreement&#8221;) with UMB pursuant to which UMB shall&#160;evaluate the pharmacokinetics
of dexamethasone delivered to arthritic rats via liposome.&#160; The research pursuant to the July 2021 Sponsored Research Agreement commenced
on September 1, 2021 and will continue until the substantial completion thereof, subject to renewal upon written consent of the parties
with a project timeline of twelve months. The July 2021 Sponsored Research Agreement may be terminated by either party upon 30 days&#8217;
prior written notice to the other party. In addition, if either party commits any material breach of or defaults with respect to any terms
or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within 10 business days after written
notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement as of the date of receipt
of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for any reason other than an uncured
material breach by UMB, we shall relinquish any and all rights it may have in the Results (as defined in the July 2021 Sponsored Research
Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated early, we, among other things, will pay all
costs incurred and accrued by UMB as of the date of termination. Pursuant to the terms of the July 2021 Sponsored Research Agreement,
UMB granted us an option (the &#8220;Option&#8221;) to negotiate and obtain an exclusive license to any UMB Arising IP (as defined in
the July 2021 Sponsored Research Agreement) and UMB&#8217;s rights in any Joint Arising IP (as defined in the July 2021 Sponsored Research
Agreement) (collectively, the &#8220;UMB IP&#8221;). We may exercise the Option by giving UMB written notice within 60 days after it receives
notice from UMB of the UMB IP. We shall pay total fees of $276,285 as set forth in the July 2021 Sponsored Research Agreement. The Company
paid the first payment of $92,095 on September 1, 2021 and on August 31, 2022, the Company paid the second payment of $92,095.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with The Regents
of the University of California for the Effect of Psilocybin on Inflammation in the Blood</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company entered into a sponsored
research agreement (&#8220;Sponsored Research Agreement&#8221;) with The Regents of the University of California, on behalf of its San
Francisco Campus (&#8220;UCSF&#8221;) pursuant to which UCSF shall conduct a study to examine psilocybin&#8217;s effect on inflammatory
activity in humans to accelerate its implementation as a potential treatment for Parkinson&#8217;s Disease, chronic pain, and bipolar
disorder. The purpose of this is to show what effect psilocybin has on inflammation in the blood. The Company believe that this study
will help support the UMB homing peptide study. Pursuant to the Agreement, we shall pay UCSF a total fee of $342,850 to conduct the research
over the two-year period. The Agreement shall be effective for a period of two years from the effective date, subject to renewal or earlier
termination as set forth in the Sponsored Research Agreement. During the years ended December 31, 2022 and 2021, pursuant to the Sponsored
Research Agreement, the Company paid to UCSF $181,710 and $100,570, respectively. We have notified UCSF we do not plan to continue this
study</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investigator-Sponsored Study Agreement with
UMB for CNS Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, we entered into an investigator-sponsored
study agreement with UMB. The research project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment
of Multiple Sclerosis (&#8220;MS&#8221;). More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can
effectively deliver dexamethasone to the central nervous system and (2) whether MS-1-displaying liposomes are superior to plain liposomes,
also known as free drug, in inhibiting the relapses and progression of Experimental Autoimmune Encephalomyelitis. Pursuant to the agreement,
the research commenced on March 1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent
of the parties.&#160;The total cost under the investigator-sponsored study agreement shall not exceed $81,474. which is payable in two
equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated
project timeline of nine months. The Company paid $40,737 on January 13, 2021. This project was postponed until further notice and the
second payment is not due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Repurchase Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 26, 2023, the Company&#8217;s Board
of Directors authorized a stock repurchase plan to repurchase up to $1,000,000 of our issued and outstanding common stock, from time to
time, with such program to be in place until December 31, 2023. On January 9, 2024, the Board of Directors of the Company approved an
extension of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the Company&#8217;s common
stock until March 31, 2024. Through December 31, 2023, the Company purchased 252,855 shares of common stock for a cost of $471,121, which
is reflected in treasury stock on the accompanying consolidated balance sheet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Short-Term Investments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our portfolio of short-term investments consists
of marketable debt securities which are comprised solely of that are all highly rated U.S. government securities with maturities of more
than three months, but less than one year. We classify these as available-for-sale at purchase date and will reevaluate such designation
at each period end date. We may sell these marketable debt securities prior to their stated maturities depending upon changing liquidity
requirements. These debt securities are classified as current assets in the consolidated balance sheet and recorded at fair value, with
unrealized gains or losses included in accumulated other comprehensive gain and as a component of the consolidated statements of comprehensive
loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification method and are
reported in other income (expense), net in the consolidated statements of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An impairment loss may be recognized when the
decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary
declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis
of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and
the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security,
such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required
to sell the security before recovery of its amortized cost basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 31, 2023, short-term investments,
at fair value, amounted to $4,140,880.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 31, 2023 and 2022, we had equity investments,
at fair value, of $0 and $3,118, respectively, which were comprised mainly of marketable common stock. Equity investments are carried
at fair value with unrealized gains or losses which are recorded as net unrealized gain (loss) on equity investments in the accompanying
consolidated statement of operations and comprehensive loss.&#160;Realized gains and losses are determined on a specific identification
basis which is recorded as net realized gain (loss) on equity investments in the consolidated statement of operations and comprehensive
loss. The Company reviews equity investments, at fair value for impairment whenever circumstances and situations change such that there
is an indication that the carrying amounts may not be recovered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of Our Results of Operations for the Years Ended December
31, 2023 and 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the results of
operations for the years ending December 31, 2023 and 2022 and were based primarily on the comparative audited financial statements, footnotes
and related information for the periods identified and should be read in conjunction with the consolidated financial statements and the
notes to those statements that are included elsewhere in this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Years Ended <br/> December 31,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">72,102</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">72,102</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of revenues</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">5,838</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">5,838</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">66,264</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">66,264</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating expenses</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">3,921,856</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">3,693,920</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss from continuing operations</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,855,592</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,627,656</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income (expense), net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">224,509</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(279,732</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for income taxes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from discontinued operations, net of tax</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(69,600</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(1,163</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 8.1pt">Net income (loss)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(3,700,683</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(3,908,551</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022,
we generated minimal revenues from operations. For the year ended December 31, 2023 and 2022, revenues amounted to $72,102 and $72,102,
respectively. Such revenues are related to the Aikido License and Sublicense Agreement and are recognized over the term of the related
license agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023 and 2022,
cost of revenues amounted to $5,838 and $5,838, respectively, and consisted of license fees related to the UMB License and Sublicense
Agreement, which are being amortized into cost of revenues over the terms of their respective agreement.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023 and 2022,
total operating expenses consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Compensation expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">871,625</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">577,651</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,726,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,496,687</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">845,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,286,434</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,889</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling, general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">390,071</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">227,259</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,921,856</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,693,920</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Compensation Expense</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2023 and 2022, compensation expense was $871,625 and $577,651, respectively, an increase of $293,974, or 50.9%. This increase resulted from, an increase in Board of Director fees of $25,000, an increase in payroll expense and related benefits of $265,863, and an increase in executive bonus pay of $100,000, offset by a decrease in stock-based compensation of $96,889.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Professional Fees</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2023 and 2022, professional fees were $1,726,061 and $1,496,687 and, respectively, an increase of $229,374, or 15.3%. The increase was primarily attributable to an increase in other consulting fees of $187,818, an increase in stock-based consulting fees of $45,033 related to the amortization of prepaid expense on previously issued shares to consultants for business advisory and strategic planning services, and an increase in legal fees of $274,220, offset by a decrease in investor relations fees of $262,936, and a decrease in accounting and auditing fees of $14,761. During the year ended December 31, 2023, we reimbursed Columbia University $255,163 related to patent related legal fees incurred by them on our behalf.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Research and Development:</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023 and 2022, we incurred research and development expense of $845,092 and $1,286,434, respectively, a decrease of $441,342, or 34.1%. The decrease was a result of a decrease in research and development costs in connection with the Investigator-sponsored Study Agreement with UCSF, UMB, Columbia University, and other parties.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Insurance Expense</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023 and 2022, insurance expense was $89,007 and $125,889, respectively, a decrease of $36,882, or 29.3%. This decrease was a result of decrease in the cost of renewal of the D&amp;O insurance policy.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Bad Debt Expense (Recovery):</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023 and 2022, we recorded bad debt recovery of $0 and $20,000. In 2022, we recorded bad debt recovery from the collection of a previously written off note receivable deemed uncollectible.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Selling, General and Administrative Expenses</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling, general and administrative expenses include advertising and promotion, patent related expenses, public company expenses, custodian fees, bank service charges, travel, and other office expenses.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023 and 2022, selling, general and administrative expenses were $390,071 and $227,259, respectively, an increase of $162,812, or 71.6%. The increase was primarily attributed to an increase in Delaware franchise taxes of $208,264 resulting from a reverse split in our outstanding shares, without a change in our authorized shares, offset by a net decrease in other general and administrative expenses of $45,452.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Loss from Continuing Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023 and 2022,
loss from continuing operations&#160;amounted to $3,855,592 and $3,627,656, respectively, an increase of $227,936, or 6.3%. The increase
was primarily a result of the changes in operating expenses discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Income (Expenses), net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023 and 2022,
other income (expense), net amounted to $224,509 and $(279,732), respectively, a positive change of $504,241, or 180.3%. The positive
change in other income (expenses), net was primarily due to an increase in interest and dividend income of $325,893, a decrease in net
realized and unrealized loss on equity investment of $432,785, offset by an increase in interest expense of $2,670, an increase in penalty
expense of $166,034 which was incurred due to the early termination of a certificate of deposit, and a decrease in other income recorded
during the 2022 period from equity shares earned for lock up agreement of $85,733.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Loss from Discontinued Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023 and 2022,
loss from discontinued operations amounted to $69,600 and $1,163, respectively, an increase of $68,437. As of December 31, 2023, we recognized
an allowance for loss on the NFID. LLC note receivable and accrued interest receivable in an amount equal to the estimated probable losses,
and accordingly, we recorded bad debt expense of $69,600.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, net loss
amounted to $3,700,683 or $1.20 per common share (basic and diluted), as compared to net loss of $3,908,551, or $1.71 per common share
(basic and diluted) for the year ended December 31, 2022, a decrease of $207,868, or 5.3%. The change was primarily a result of the changes
discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity is the ability of an enterprise to generate
adequate amounts of cash to meet its needs for cash requirements. We had working capital of $6,905,568, $4,140,880 in short-term investments,
and $3,524,308 in cash and cash equivalents as of December 31, 2023, and working capital of $11,135,738 and $11,367,034 in cash and cash
equivalents as of December 31, 2022, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Working<br/> Capital<br/> Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage<br/> Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Working capital:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Total current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,681,158</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,572,056</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,890,898</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(34</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(775,590</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(436,318</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(339,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(78</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Working capital:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,905,568</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,135,738</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,230,170</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">(38</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The decrease in working capital of $4,230,170 was primarily attributable
to a decrease in current assets of $3,890,898 primarily due to a decrease in cash of $7.8 million, an increase in short-term investments
of $4,180,880, a decrease in prepaid expenses and other current assets of $119,924, and a decrease in note receivable of $69,600, and
an increase in current liabilities of $339,272.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of cash flow activities is summarized as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,224,498</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,497,622</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net cash (used in) provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,147,107</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,707</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash (used in) provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(471,121</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,940,948</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net (decrease) increase in cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,842,726</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,530,033</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Cash Used in Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities for the
years ended December 31, 2023 and 2022 were $3,224,498 and $3,497,622, respectively, a decrease of $273,124, or 8%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the year ended December 31, 2023 primarily reflected a net loss of $3,700,6837, adjusted for the
add-back of non-cash items such as net unrealized loss on equity investments of $3,118, bad debt expense of $69,600, stock-based
compensation of $14,125, and amortization of prepaid stock-based professional fees of $90,067, and changes in operating asset and liabilities
primarily consisting of a decrease in prepaid expenses and other current assets of $35,695, an increase of interest receivable of $3,590,
an increase in accounts payable and accrued expenses of $339,272, and a decrease in deferred revenue of $72,102.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the year ended December 31, 2022 primarily reflected a net loss of $3,908,551, adjusted for the
add-back of non-cash items such net realized loss on equity investments of $104,700, net unrealized loss on equity investments of $331,203,
bad debt recovery of $20,000, stock-based compensation of $156,047, and equity shares earned for lock up agreement of $85,733, and changes
in operating asset and liabilities primarily consisting of a decrease in prepaid expenses and other current assets of $55,335, an increase
of interest receivable of $4,800, a decrease in accounts payable and accrued expenses of $53,721 and a decrease in deferred revenue of
$72,102.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Cash (Used in) Provided by Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash (used in) provided by investing activities
for the years ended December 31, 2023 and 2022 were $(4,147,107) and $86,707, respectively, a change of $4,233,814, or 4,883%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities for the year ended December 31, 2023 was $4,147,107 which consisted of aggregate payments for the purchase
of short-term investments of $4,147,107.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities for the year ended December 31, 2022 was $86,707 which consisted of aggregate proceeds from sale
of equity investments in Aikido of $66,707 and proceeds from collection of previously written off notes receivable of $20,000.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Cash (Used in) Provided by Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash (used in) provided by financing activities
for the years ended December 31, 2023 and 2022 were $(471,121) and $4,940,948, respectively, a change of $5,412,069, or 110%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities for the year ended December 31, 2032 was $471,121, which consisted of the purchase of treasury stock.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities for the year ended December 31, 2022 was $4,940,948, which consisted of net proceeds from the sale
of common stock of $4,940,948.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that our current cash and cash equivalent
amount and short-term investment amount will provide sufficient cash required to meet our obligations for a minimum of twelve months from
the date of this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than cash requirements pursuant to research
and development agreements, we currently have no other material commitments for any capital expenditures.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying consolidated
financial statements, we generated a net loss of $3,700,683 and used cash in operations of $3,224,498 during the year ended December 31,
2023. Additionally, we have an accumulated deficit of $10,871,811 on December 31, 2023. As of December 31, 2023, we had working capital
of $6,905,568.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The positive working capital serves to mitigate
the conditions that historically raised substantial doubt about our ability to continue as a going concern. We believe that the Company
has sufficient cash to meet its obligations for a minimum of twelve months from the date of this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2022, the Russian Federation and Belarus
commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have
instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on
the world economy is not determinable as of the date of these condensed consolidated financial statements, and the specific impact on
the Company&#8217;s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2022, the Inflation Reduction Act
of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise
tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded
foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its
shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased
at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the
fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition,
certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been given authority
to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management continues to evaluate the impact of
the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect
on the Company&#8217;s financial position and results of its operations, the specific impact is not readily determinable as of the date
of these financial statements. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation is accounted for based
on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211; Stock Compensation&#8221;, which requires recognition in the financial
statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the
period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting
period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award
based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under Accounting
Standards Update (&#8220;ASU&#8221;) 2016-09 Improvements to Employee Share-Based Payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 730-10, <i>&#8220;Research
and Development-Overall,&#8221;</i> research and development costs are expensed when incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>ITEM 7A. QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">As a smaller reporting
company, we are not required to provide the information required by this item.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>ITEM 8. FINANCIAL STATEMENTS AND
SUPPLEMENTARY DATA</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The financial statements
and the reports of our independent registered public accounting firm required pursuant to this Item are included in Item 15 of this report
and are presented beginning on page F-1.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>ITEM 9. CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>ITEM 9A. CONTROLS AND PROCEDURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Evaluation of
Disclosure Controls and Procedures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">We maintain &#8220;disclosure
controls and procedures,&#8221; as that term is defined in Rule 13a-15(e) and 15d-15(e), promulgated by the SEC pursuant to the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Disclosure controls and procedures include controls and procedures
designed to ensure that information required to be disclosed in our company&#8217;s reports filed under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is
accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely
decisions regarding required disclosure. Our management, with the participation of our principal executive officer and principal financial
officer, evaluated our company&#8217;s disclosure controls and procedures as of the end of the period covered by this annual report on
Form 10-K. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of December 31,
2023, our disclosure controls and procedures were not effective. The ineffectiveness of our disclosure controls and procedures was due
to material weaknesses, which we identified, in our report on internal control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Management&#8217;s
Report on Internal Control Over Financial Reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our management,
including our principal executive officer and principal financial officer, is responsible for establishing and maintaining adequate internal
control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our management, with the participation of our
principal executive officer and principal financial officer, evaluated the effectiveness of our internal control over financial reporting
as of December 31, 2023. Our management&#8217;s evaluation of our internal control over financial reporting was based on the 2013 framework
in Internal Control-Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this
evaluation, our management concluded that as of December 31, 2023, our internal control over financial reporting was not effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The ineffectiveness
of our internal control over financial reporting was due to the following material weaknesses which we identified in our internal control
over financial reporting:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We lack segregation of
    duties within accounting functions duties as a result of our limited financial resources to support hiring of personnel.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not implemented
    adequate system and manual controls.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">A material weakness
is a deficiency or a combination of control deficiencies in internal control over financial reporting such that there is a reasonable
possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely
basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Limitations
on Effectiveness of Controls</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our principal executive
officer and principal financial officer does not expect that our disclosure controls or our internal control over financial reporting
will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact
that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent
limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of
fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making
can be faulty, and that breakdowns can occur because of a simple error or mistake. Additional controls can be circumvented by the individual
acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls
also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes
in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a
cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">This annual report
does not include an attestation report by our independent registered public accounting firm regarding internal control over financial
reporting. As a smaller reporting company, our management&#8217;s report was not subject to attestation by our registered public accounting
firm pursuant to rules of the Securities and Exchange Commission that permit us to provide only management&#8217;s report in this annual
report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Because of its
inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance with respect to financial
statement preparation and presentation and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Changes in Internal
Control Over Financial Reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">There were no changes
in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s last fiscal quarter that has
materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>ITEM&#160;9B.
OTHER INFORMATION.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">During our last
fiscal quarter ended December 31, 2023, none of our directors or executive officers <ix:nonNumeric contextRef="c37" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-14827"><ix:nonNumeric contextRef="c37" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-14828">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c37" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-14829"><ix:nonNumeric contextRef="c37" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-14830">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1
trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement&#8221; as such terms are defined under Item 408 of Regulation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>ITEM 9C. DISCLOSURE
REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Not applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>PART III</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>ITEM&#160;10. DIRECTORS, EXECUTIVE
OFFICERS AND CORPORATE GOVERNANCE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The following table
sets forth the names, positions and ages of our directors and executive officers as of the date of this report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">All directors shall
serve until the next 2024 annual meeting of stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 30%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 58%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Weisblum</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, Chief Executive Officer, President, and Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Ryweck</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne D. Linsley</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Kevin Mu&#241;oz</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff Pavell</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The business background
and certain other information about our directors and executive officers is set forth below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Eric Weisblum</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Eric Weisblum is
the founder and Chief Executive Officer of Silo Pharma Inc. Prior to Silo Pharma Mr. Weisblum was a private investor, board member, and
advisor to several companies. Mr. Weisblum has experience in both licensing therapeutic assets and assisting in their development. As
a result, Mr. Weisblum brings with him nearly 20 years of experience in structuring and trading financial instruments. Mr. Weisblum was
a registered representative with Domestic Securities, a New Jersey-based broker-dealer. While with Domestic Securities, Mr. Weisblum
held the Series 7 - General Securities Representative, the Series 63 &#8211; Uniform Securities Agent State Law Examination, and the
Series 55 &#8211; Registered Equity Trader securities registrations.&#160;From 1993 to 2002, Mr. Weisblum originated, structured, traded,
and placed structured financing transactions at M.H. Meyerson &amp; Co. Inc., a publicly-traded registered investment bank. He holds
a B.A. from the University of Hartford&#8217;s Barney School of Business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Daniel Ryweck</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Mr. Ryweck has
served as Chief Financial Officer of the Company since September 27, 2022. Since January 2020, Mr. Ryweck has served as Controller at
Mill City Ventures III Ltd. (NASDAQ: MCVT), a non-bank lender and specialty finance company. From. June 2014 to December 2019, he served
as Chief Compliance Officer of Mill City Ventures III Ltd. Mr. Ryweck holds a Bachelor of Science degree in Accounting from the Carlson
School of Management at the University of Minnesota.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Wayne D. Linsley</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Wayne D. Linsley
has served as a director of the Company since January 2020. Mr. Linsley has over 40 years of experience in business management. Since
April 2020, Mr. Linsley has served as a member of the board of directors of Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage
biopharmaceutical company. Since August 2021, Mr. Linsley has served as a member of the board of directors of DatChat, Inc. (NASDAQ:
DATS), a communication software company. From 2014 to September 2021, Mr. Linsley served as the Vice President of Operations at CFO Oncall,
Inc., a company that provides financial reporting and controller services on an outsourced basis and previously, from 2012 to 2014, Mr.
Linsley worked at CFO Oncall, Inc. as an independent contractor. Mr. Linsley holds a Bachelor of Science degree in Business Administration
from Siena College. We believe that Mr. Linsley is qualified to serve as a member of our board of directors because of his experience
as a director of public companies and background in financial reporting.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Dr. Kevin Mu&#241;oz</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Dr. Kevin Mu&#241;oz
has served as a director of the Company since October 2020. Since December 2021, Dr. Mu&#241;oz has taught Biomedical Science and Medical
Intervention at Passaic County Technical Institute. Since June 2008, Dr. Mu&#241;oz has served as the Director of Operations and Medical
Assistant at The Physical Medicine and Rehabilitation Center, P.A., a diagnostic and treatment facility that specializes in treating
sports, spine, orthopedic and neuromuscular conditions. Dr. Mu&#241;oz holds a Doctor of Medicine degree from Xavier University School
of Medicine and a Bachelor of Science degree in Kinesiology from the University of Michigan. We believe that Dr. Mu&#241;oz is qualified
to serve as a member of our board of directors because of his medical background and experience in business operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Dr. Jeff Pavell
&#8211; Director</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Dr. Pavell has
served as our director since September 27, 2022. Dr. Pavell has over 20 years of medical experience. Since January 2021, Dr. Pavell has
served as a director of FoxWayne Enterprises Acquisition Corp. (NASDAQ: FOXW), a blank check company incorporated for the purpose of
effecting a business combination. Since October 1999, Dr. Pavell has served as an Attending Physician at the Physical Medicine and Rehabilitation
Center, P.A., a diagnostic and treatment facility that specializes in treating sports, spine, orthopedic and neuromuscular conditions.
Since January 2000, Dr. Pavell has served as the Chief of Rehabilitation Medicine at Englewood Hospital and Medical Center. Since April
2002, Dr. Pavell has served as the Associate Director of Pain Medicine at the Center for Advanced Surgery in Paramus, New Jersey. Since
April 2002, Dr. Pavell has been an Instructor in Clinical Rehabilitation at Columbia University&#8217;s College of Physicians &amp; Surgeons.
Dr. Pavell holds a Doctor of Medicine degree from the New York College of Osteopathic Medicine and a Bachelor of Art degree in Political
Science from John Hopkins University. We believe that Dr. Pavell is qualified to serve as a member of our board of directors due to his
medical background and experience practicing in the healthcare industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.1pt; text-align: justify; text-indent: -8.1pt"><span style="font-size: 10pt"><b>Family
Relationships</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.1pt; text-align: justify; text-indent: -8.1pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">There are no family
relationships among any of our executive officers or directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Arrangements
between Officers and Directors</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Except as set forth
herein, to our knowledge, there is no arrangement or understanding between any of our officers or directors and any other person pursuant
to which the officer or director was selected to serve as an officer or director.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Involvement
in Certain Legal Proceedings</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">We are not aware
of any of our directors or officers being involved in any legal proceedings in the past ten years relating to any matters in bankruptcy,
insolvency, criminal proceedings (other than traffic and other minor offenses), or being subject to any of the items set forth under
Item 401(f) of Regulation S-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.1pt; text-align: justify; text-indent: -8.1pt"><span style="font-size: 10pt"><b>Committees
of Our Board of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.1pt; text-align: justify; text-indent: -8.1pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our board of directors
directs the management of our business and affairs, as provided by Delaware law, and conducts its business through meetings of the board
of directors and its standing committees. We have a standing audit committee and compensation committee. In addition, from time to time,
special committees may be established under the direction of the board of directors when necessary to address specific issues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our board of directors
has determined that all members of the audit committee and the compensation committee are independent as defined under the applicable
rules of The Nasdaq Capital Market, including, in the case of all the members of our audit committee, the independence requirements contemplated
by Rule 10A-3 under the Exchange Act. In making such determination, the board of directors considered the relationships that each director
has with our Company and all other facts and circumstances that the board of directors deemed relevant in determining director independence,
including the beneficial ownership of our capital stock by each director.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Audit Committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our audit committee
is responsible for, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving and retaining
    the independent registered public accounting firm to conduct the annual audit of our consolidated financial statements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the proposed
    scope and results of the audit;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and pre-approval
    of audit and non-audit fees and services;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing accounting and
    financial controls with the independent registered public accounting firm and our financial and accounting staff;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving
    transactions between us and our directors, officers and affiliates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures
    for complaints received by us regarding accounting matters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing internal audit
    functions, if any; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing the report of
    the audit committee that the rules of the Securities and Exchange Commission require to be included in our annual meeting proxy statement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our audit committee
consists of Wayne D. Linsley, Jeff Pavel and Dr. Kevin Mu&#241;oz,&#160;with Mr. Linsley serving as chair. Each member of our audit
committee meets the financial literacy requirements of the Nasdaq rules. In addition, our board of directors has determined that Mr.
Linsley qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.1pt; text-align: justify; text-indent: -8.1pt"><span style="font-size: 10pt"><b>Compensation
Committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.1pt; text-align: justify; text-indent: -8.1pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our compensation
committee is responsible for, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending
    the compensation arrangements for management, including the compensation for our president and chief executive officer;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and reviewing
    general compensation policies with the objective to attract and retain superior talent, to reward individual performance and to achieve
    our financial goals;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering our stock
    incentive plans; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing the report of
    the compensation committee that the rules of the Securities and Exchange Commission require to be included in our annual meeting
    proxy statement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our compensation
committee consists of Wayne D. Linsley, Jeff Pavell and Dr. Kevin Mu&#241;oz, with Mr. Linsley serving as chair.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt"><b>Nominating
and Corporate Governance Committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">Our
nominating and corporate governance committee, among other things, will be responsible for:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">reviewing and
    assessing the development of the executive officers and considering and making recommendations to the Board</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">regarding promotion
    and succession issues;</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating and reporting
    to the Board on the performance and effectiveness of the directors, committees and the Board as a whole;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">working with
    the Board to determine the appropriate and desirable mix of characteristics, skills, expertise and experience, including</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">diversity considerations,
    for the full Board and each committee;</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annually presenting to
    the Board a list of individuals recommended to be nominated for election to the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing, evaluating,
    and recommending changes to the Company&#8217;s Corporate Governance Principles and Committee Charters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the Board
    individuals to be elected to fill vacancies and newly created directorships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing the Company&#8217;s
    compliance program, including the Code of Conduct; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">overseeing
    and evaluating how the Company&#8217;s corporate governance and legal and regulatory compliance policies and practices, including
    leadership, structure, and succession planning, may affect the Company&#8217;s major risk exposures.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">Our
nominating and corporate governance committee consists of Wayne Linsley, Kevin Munoz and Jeff Pavell, with Mr. Linsley serving as chair.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-size: 10pt"><b><i>Compensation
Committee Interlocks and Insider Participation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-size: 10pt">None
of the Company&#8217;s executive officers serves, or in the past has served, as a member of the board of directors or compensation committee,
or other committee serving an equivalent function, of any entity that has one or more executive officers who serve as members of the
Company&#8217;s board of directors or its compensation committee. None of the members of the Company&#8217;s compensation committee is,
or has ever been, an officer or employee of the company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Scientific Advisory
Board</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">We have formed
a scientific advisory board that is intended to help advise management regarding potential acquisition and development of products. The
members of such board are as follows: Dr. Josh Woolley MD/Ph.D.; and Dr. Charles Nemeroff.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Dr. Josh Woolley
MD/Ph.D. is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco
(&#8220;UCSF&#8221;). He is also a licensed psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He received both
his MD and his Ph.D. in Neuroscience from UCSF and completed his psychiatry residency training at UCSF. Dr. Woolley is the director and
founder of the Bonding and Attunement in Neuropsychiatric Disorders (&#8220;BAND&#8221;) Laboratory. The mission of the BAND Lab is to
understand why people with mental illnesses, including schizophrenia, posttraumatic stress disorder, mood disorders, and substance use
disorders, have trouble with social connection, and to develop and test novel treatments for these deficits. His laboratory is actively
investigating psilocybin therapy for multiple disorders including major depressive disorder, bipolar depression, chronic pain, and mood
symptoms associated with Parkinson&#8217;s Disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Dr. Charles Nemeroff
is chair and professor with the Department of Psychiatry and Behavioral Sciences. He also directs the Institute for Early Life Adversity
Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. Prior to joining
Dell Med, Dr. Nemeroff was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging
at the University of Miami Miller School of Medicine in Miami, Florida. He received his medical degree and doctorate degrees in neurobiology
from the University of North Carolina (&#8220;UNC&#8221;) School of Medicine. After psychiatry residency training at UNC and Duke University,
he held faculty positions at Duke University Medical Center and at Emory University School of Medicine before relocating to the University
of Miami in 2009. He has served as president of the American College of Psychiatrists and the American College of Neuropsychopharmacology
and sits on the Scientific Advisory Board of the Brain and Behavior Research Foundation. He is President-elect of the Anxiety and Depression
Association of America and a member of the National Academy of Medicine.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Delinquent Section 16(a) Reports</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Section 16(a) of
the Exchange Act requires our directors and executive officers, and persons who own more than 10% of a registered class of our equity
securities, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity
securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">To our knowledge,
based solely upon a review of Forms 3, 4, and 5 filed with the SEC during the fiscal year ended December 31, 2023, we believe that our
directors, executive officers, and greater than 10% beneficial owners have complied with all applicable filing requirements during the
fiscal year ended December 31, 2023.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Code of Ethics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.1pt; text-indent: -8.1pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">We have adopted
a Code of Business Ethics that applies to all of our directors, officers and employees. A copy of the Code of Business Ethics is incorporated
by reference as an exhibit. Disclosure regarding any amendments to, or waivers from, provisions of the code of conduct and ethics that
apply to our directors, principal executive and financial officers will be posted on our website at&#160;<i>www.silopharma.com</i> or
will be included in a Current Report on Form 8-K, which we will file within four business days following the date of the amendment or
waiver.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Changes in Nominating
Procedures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Board Diversity</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Diversity Matrix (As of March 25, 2024)</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Number of Directors</span></td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="width: 55%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 10%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 10%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 10%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 10%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part I: Gender Identity</b></span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 1.5pt; vertical-align: top; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Female</span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Male</span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Binary</span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did Not <br/>
Disclose <br/>
Gender</span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part II: Demographic Background</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">African American or Black</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alaskan Native or Native America</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asian</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hispanic or Latinx</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Native Hawaiian or Pacific Islander</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">White</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two or More Races or Ethnicities</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did Not Disclose Demographic Background</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>ITEM&#160;11.
EXECUTIVE COMPENSATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The following table
provides certain information regarding compensation awarded to, earned by or paid to persons serving as our principal executive officer
and our principal financial officer during the year ended December 31, 2023 and 2022 (each a &#8220;named executive officer&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Summary Compensation
Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Name
    and<br/> Principal<br/> Position</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Salary<br/>
    ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Bonus<br/>
    ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock<br/>
    Awards<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Option<br/>
    Awards<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-Equity<br/>
    Incentive<br/> Plan<br/> Compensation<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-<br/>
    Qualified<br/> Deferred<br/> Compensation<br/> Earnings<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">All
    Other<br/> Compensation<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total<br/>
    ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(a)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(b)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(c)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(d)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(e)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(f)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(g)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(h)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(i)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(j)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; padding-left: 0.125in; text-indent: -0.125in; width: 19%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Eric
    Weisblum,<br/> Chief Executive</span></td><td style="white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">350,151</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3)</span></td><td style="white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">200,000</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18,858</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5)</span></td><td style="white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">569,009</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">222,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">9,750</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">332,250</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Daniel Ryweck,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">59,923</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,769</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">62,692</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Chief
    Financial Officer (since September 28, 2022)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            October 12, 2022, the Company entered into an employment agreement with Eric Weisblum (the
                                            &#8220;Weisblum Employment Agreement&#8221;) pursuant to which Mr. Weisblum&#8217;s (i) base
                                            salary will be $350,000 per year, (ii) Mr. Weisblum will be paid a one-time signing bonus
                                            of $100,000, and (iii) Mr. Weisblum shall be entitled to receive an annual bonus of up to
                                            $350,000, subject to the sole discretion of the Compensation Committee of the Board of Directors
                                            of the Company.&#160;&#160;On January 18, 2021, the Company and Mr. Weisblum entered into
                                            the first amendment (the &#8220;Amendment&#8221;) to the Employment Agreement, effective
                                            as of January 1, 2021. Pursuant to the Amendment Mr. Weisblum&#8217;s base salary was increased
                                            from $120,000 per year to $180,000 per year and all the terms and provisions of the Employment
                                            Agreement shall remain in full force and effect.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pursuant to the Weisblum Employment Agreement entered into between
    the Company and Mr. Weisblum on October 12, 2022, Mr. Weisblum received a signing bonus of $100,000.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On January 18, 2021, the Company and Mr. Weisblum entered into the
    first amendment (the &#8220;Amendment&#8221;) to the Employment Agreement, effective as of January 1, 2021. Pursuant to the Amendment
    Mr. Weisblum&#8217;s base salary was increased from $120,000 per year to $180,000 per year and all the terms and provisions of the
    Employment Agreement shall remain in full force and effect. On October 12, 2022, we entered into a new employment agreement with
    Mr. Weisblum pursuant to which Mr. Weisblum&#8217;s base salary will be $350,000 per year.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On September 28, 2022, the Company entered into an Employment Agreement
    with Mr. Ryweck under which it agreed to pay a base salary of $42,000 per year. On October 12, 2022, the Company entered into an
    amendment to this employment agreement under which it increased his base salary to $60,000 per year.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(6)</span></td>
    <td><span style="font-size: 10pt">During 2023 and 2022, the Company contributed funds for each executive to the Company&#8217;s 401(k)
    plan.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">Narrative
Disclosure to Summary Compensation Table</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Except as otherwise
described below, there are no compensatory plans or arrangements, including payments to be received from the Company with respect to
any named executive officer, that would result in payments to such person because of his or her resignation, retirement or other termination
of employment with the Company, or our subsidiaries, any change in control, or a change in the person&#8217;s responsibilities following
a change in control of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Employment Agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Eric Weisblum</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">On October 12,
2022, the Company entered into an employment agreement with Eric Weisblum (the &#8220;Weisblum Employment Agreement&#8221;) pursuant
to which Mr. Weisblum&#8217;s (i) base salary will be $350,000 per year, (ii) Mr. Weisblum will be paid a one-time signing bonus of $100,000,
and (iii) Mr. Weisblum shall be entitled to receive an annual bonus of up to $350,000, subject to the sole discretion of the Compensation
Committee of the Board of Directors of the Company (the &#8220;Compensation Committee&#8221;), and upon the achievement of additional
criteria established by the Compensation Committee from time to time (the &#8220;Annual Bonus&#8221;). In addition, pursuant to the Weisblum
Employment Agreement, upon termination of Mr. Weisblum&#8217;s employment for death or Total Disability (as defined in the Weisblum Employment
Agreement), in addition to any accrued but unpaid compensation and vacation pay through the date of his termination and any other benefits
accrued to him under any Benefit Plans (as defined in the Weisblum Employment Agreement) outstanding at such time and the reimbursement
of documented, unreimbursed expenses incurred prior to such termination date (collectively, the &#8220;Weisblum Payments&#8221;), Mr.
Weisblum shall also be entitled to the following severance benefits: (i) 24 months of his then base salary; (ii) if Mr. Weisblum elects
continuation coverage for group health coverage pursuant to COBRA Rights (as defined in the Weisblum Employment Agreement), then for
a period of 24 months following Mr. Weisblum&#8217;s termination he will be obligated to pay only the portion of the full COBRA Rights
cost of the coverage equal to an active employee&#8217;s share of premiums (if any) for coverage for the respective plan year; and (iii)
payment on a pro-rated basis of any Annual Bonus or other payments earned in connection with any bonus plan to which Mr. Weisblum was
a participant as of the date of his termination (together with the Weisblum Payments, the &#8220;Weisblum Severance&#8221;). Furthermore,
pursuant to the Weisblum Employment Agreement, upon Mr. Weisblum&#8217;s termination (i) at his option (A) upon 90 days prior written
notice to the Company or (B) for Good Reason (as defined in the Weisblum Employment Agreement), (ii) termination by the Company without
Cause (as defined in the Weisblum Employment Agreement) or (iii) termination of Mr. Weisblum&#8217;s employment within 40 days of the
consummation of a Change in Control Transaction (as defined in the Weisblum Employment Agreement), Mr. Weisblum shall receive the Weisblum
Severance; provided, however, Mr. Weisblum shall be entitled to a pro-rated Annual Bonus of at least $200,000. In addition, any equity
grants issued to Mr. Weisblum shall immediately vest upon termination of Mr. Weisblum&#8217;s employment by him for Good Reason or by
the Company at its option upon 90 days prior written notice to Mr. Weisblum, without Cause.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Daniel Ryweck</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">On September 28,
2022, the Company entered into an employment agreement (the &#8220;Ryweck Employment Agreement&#8221;) with Daniel Ryweck. Pursuant to
the terms of the Employment Agreement, Mr. Ryweck will (i) receive a base salary at an annual rate of $42,000 (the &#8220;Base Compensation&#8221;)
payable in equal monthly installments, and (ii) be eligible to receive an annual discretionary bonus. The term of Mr. Ryweck&#8217;s
engagement under the Employment Agreement commences on the Effective Date (as defined in the Employment Agreement) and continues until
September 28, 2023, unless earlier terminated in accordance with the terms of the Employment Agreement. The term of Mr. Ryweck&#8217;s
Employment Agreement is automatically renewed for successive one-year periods until terminated by Mr. Ryweck or the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">On October 12,
2022, the Company entered into an amendment (the &#8220;Ryweck Amendment&#8221;) to the employment agreement by and between the Company
and Daniel Ryweck dated September 27, 2022, pursuant to which Mr. Ryweck&#8217;s base salary will increase to $60,000 per year.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Potential Payment Upon Termination&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If Mr. Weisblum
dies or has a total disability, resigns, is terminated for good reason (as defined in the agreement), without cause (as defined in the
agreement) or within 40 days of a change of control (as defined in the agreement, then he is entitled to 24 months&#8217; severance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The following table
sets forth quantitative information with respect to potential payments to be made to Mr. Weisblum upon termination in various circumstances.
The potential payments are based on the terms of Mr. Weisblum&#8217;s employment agreement discussed above. For a more detailed description
of Mr. Weisblum&#8217;s employment agreement, see the &#8220;Employment Agreements&#8221; section above:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-size: 10pt">Name</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Potential<br/>
    Payment Upon<br/>
    Termination</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-size: 10pt">Eric Weisblum</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">700,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">(1)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Weisblum is entitled to 24 months&#8217; severance at the applicable base salary rate. Mr.
                                            Weisblum&#8217;s current base salary is $350,000 per annum.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Outstanding Equity Awards at Fiscal
Year-End Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The following table
provides information regarding option and restricted stock unit awards held by each of our named executive officers that were outstanding
as of December 31, 2023. There were no stock awards or other equity awards outstanding as of December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Stock
    Awards</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="23" style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Number
    of<br/>
    Securities<br/>
    Underlying<br/>
    Unexercised<br/>
    Options (#)<br/>
    (Exercisable)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Number
    of<br/>
    Securities<br/>
    Underlying<br/>
    Unexercised<br/>
    Options (#)<br/>
    (Unexercisable)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="4" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Equity<br/>
    Incentive<br/>
    Plan<br/>
    Awards:<br/>
    Number of<br/>
    Securities<br/>
    Underlying<br/>
    Unexercised<br/>
    Unearned<br/>
    Options (#)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Option<br/>
    Exercise<br/>
    Price<br/>
    ($)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Option<br/>
    Expiration<br/>
    Date</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Number
    of<br/>
    Shares or<br/>
    Units of<br/>
    Stock That<br/>
    Have Not<br/>
    Vested<br/>
    (#)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Market<br/>
    Value&#160;of<br/>
    Shares or<br/>
    Units of<br/>
    Stock That<br/>
    Have Not<br/>
    Vested (#)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Equity<br/>
    Incentive<br/>
    Plan Awards:<br/>
    Number&#160;of<br/>
    Unearned<br/>
    Shares, <br/>
Units<br/>
    or Other<br/>
    Rights that<br/>
    Have Not<br/>
    Vested<br/>
    (#)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Equity<br/>
    Incentive<br/>
    Plan Awards:<br/>
    Market or<br/>
    Payout <br/>
Value&#160;of <br/>
Unearned<br/>
    Shares, Units<br/>
    or Other<br/>
    Rights that<br/>
    Have Not<br/>
    Vested<br/>
    ($)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>(a)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>(b)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>(c)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="4" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>(d)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>(e)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>(f)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>(g)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>(h)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>(i)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>(j)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Eric Weisblum,</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">2,000</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">0.005</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;04/15/2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Chief
    Executive Officer</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">2,000</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">2,000</span></p></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(2)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(3)</span></p></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></p></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">0.005</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">0.005</span></p></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;07/15/2024</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">10/15/2024</span></p></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></p></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The options were fully
    vested on the date of grants (4/15/19)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The options were granted
    on April 15, 2019 and vested 100% on July 15, 2019.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The options were fully
    vested on the date of grant (10/15/19).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Amended and
Restated 2020 Omnibus Equity Incentive Plan</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The following is
a summary of the material features of the Amended and Restated 2020 Omnibus Equity Incentive Plan (the &#8220;Amended and Restated 2020
Plan&#8221;). This summary is qualified in its entirety by the full text of the Amended and Restated 2020 Plan, a copy of which was filed
as an Appendix to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed with the SEC on October 23, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Types of Awards</i>.
The Amended and Restated 2020 Plan provides for the issuance of incentive stock options, non-statutory stock options, stock appreciation
rights (&#8220;SARs&#8221;), restricted stock, restricted stock units (&#8220;RSUs&#8221;), and other stock-based awards. Items described
above in the Section called &#8220;Shares Available; Certain Limitations&#8221; are incorporated herein by reference.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Administration</i>.
The Amended and Restated 2020 Plan will be administered by the Board, or if the Board does not administer the Amended and Restated 2020
Plan, any committee of the Board or any other committee or subcommittee of the Board that complies with the applicable requirements of
Section 16 of the Exchange Act, as amended from time to time, and any other applicable legal or stock exchange listing requirements (each
of the Board, or such committee or such subcommittee, the &#8220;plan administrator&#8221;). The plan administrator may interpret the
Amended and Restated 2020 Plan and may prescribe, amend and rescind rules and make all other determinations necessary or desirable for
the administration of the Amended and Restated 2020 Plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The Amended and
Restated 2020 Plan permits the plan administrator to select the eligible recipients who will receive awards, to determine the terms and
conditions of those awards, including, but not limited to, the exercise price or other purchase price of an award, the number of shares
of common stock or cash or other property subject to an award, the term of an award and the vesting schedule applicable to an award,
and to amend the terms and conditions of outstanding awards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Restricted Stock
and Restricted Stock Units</i>. Restricted stock and RSUs may be granted under the Amended and Restated 2020 Plan. The plan administrator
will determine the purchase price, vesting schedule and performance goals, if any, and any other conditions that apply to a grant of
restricted stock and RSUs. If the restrictions, performance goals or other conditions determined by the plan administrator are not satisfied,
the restricted stock and RSUs will be forfeited. Subject to the provisions of the Amended and Restated 2020 Plan and the applicable award
agreement, the plan administrator has the sole discretion to provide for the lapse of restrictions in installments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Unless the applicable
award agreement provides otherwise, participants with restricted stock will generally have all of the rights of a shareholder; provided
that dividends will only be paid if and when the underlying restricted stock vests. RSUs will not be entitled to dividends prior to vesting,
but may be entitled to receive dividend equivalents if the award agreement provides for them. The rights of participants granted restricted
stock or RSUs upon the termination of employment or service to us will be set forth in the award agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Options</i>.
Incentive stock options and non-statutory stock options may be granted under the Amended and Restated 2020 Plan. An &#8220;incentive
stock option&#8221; means an option intended to qualify for tax treatment applicable to incentive stock options under Section 422 of
the Internal Revenue Code of 1986, as amended (&#8220;Code&#8221;). A &#8220;non-statutory stock option&#8221; is an option that is not
subject to statutory requirements and limitations required for certain tax advantages that are allowed under specific provisions of the
Code. A non-statutory stock option under the Amended and Restated 2020 Plan is referred to for federal income tax purposes as a &#8220;non-qualified&#8221;
stock option. Each option granted under the Amended and Restated 2020 Plan will be designated as a non-qualified stock option or an incentive
stock option. At the discretion of the plan administrator, incentive stock options may be granted only to our employees, employees of
our &#8220;parent corporation&#8221; (as such term is defined in Section 424I of the Code) or employees of our subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The exercise period
of an option may not exceed ten years from the date of grant and the exercise price may not be less than 100% of the fair market value
of a share of common stock on the date the option is granted (110% of fair market value in the case of incentive stock options granted
to 10% stockholders). The exercise price for shares of common stock subject to an option may be paid in cash, or as determined by the
plan administrator in its sole discretion, (i) through any cashless exercise procedure approved by the plan administrator (including
the withholding of shares of common stock otherwise issuable upon exercise), (ii) by tendering unrestricted shares of common stock owned
by the participant, (iii) with any other form of consideration approved by the plan administrator and permitted by applicable law or
(iv) by any combination of these methods. The option holder will have no rights to dividends or distributions or other rights of a shareholder
with respect to the shares of the Company&#8217;s common stock subject to an option until the option holder has given written notice
of exercise and paid the exercise price and applicable withholding taxes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">In the event of
a participant&#8217;s termination of employment or service, the participant may exercise his or her option (to the extent vested as of
such date of termination) for such period of time as specified in his or her option agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Stock Appreciation
Rights.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">SARs may be granted
either alone (a &#8220;Free-Standing SAR&#8221;) or in conjunction with all or part of any option granted under the Amended and Restated
2020 Plan (a &#8220;Related Right&#8221;). A Free-Standing SAR will entitle its holder to receive, at the time of exercise, an amount
per share up to the excess of the fair market value (at the date of exercise) of a share of common stock over the base price of the Free-Standing
SAR (which shall be no less than 100% of the fair market value of the related shares of common stock on the date of grant) multiplied
by the number of shares in respect of which the SAR is being exercised. A Related Right will entitle its holder to receive, at the time
of exercise of the SAR and surrender of the applicable portion of the related option, an amount per share up to the excess of the fair
market value (at the date of exercise) of a share of common stock over the exercise price of the related option multiplied by the number
of shares in respect of which the SAR is being exercised. The exercise period of a Free-Standing SAR may not exceed ten years from the
date of grant. The exercise period of a Related Right will also expire upon the expiration of its related option.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The holder of a
SAR will have no rights to dividends or any other rights of a shareholder with respect to the shares of the Company&#8217;s common stock
subject to the SAR until the holder has given written notice of exercise and paid the exercise price and applicable withholding taxes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">In the event of
a participant&#8217;s termination of employment or service, the holder of a SAR may exercise his or her SAR (to the extent vested as
of such date of termination) for such period of time as specified in his or her SAR agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Other Stock-Based
Awards</i>. The plan administrator may grant other stock-based awards under the Amended and Restated 2020 Plan, valued in whole or in
part by reference to, or otherwise based on, shares of common stock. The plan administrator will determine the terms and conditions of
these awards, including the number of shares of common stock to be granted pursuant to each award, the manner in which the award will
be settled, and the conditions to the vesting and payment of the award (including the achievement of performance goals). The rights of
participants granted other stock-based awards upon the termination of employment or service to us will be set forth in the applicable
award agreement. In the event that a bonus is granted in the form of shares of common stock, the shares of common stock constituting
such bonus shall, as determined by the plan administrator, be evidenced in uncertificated form or by a book entry record or a certificate
issued in the name of the participant to whom such grant was made and delivered to such participant as soon as practicable after the
date on which such bonus is payable. Any dividend or dividend equivalent award issued under the Amended and Restated 2020 Plan shall
be subject to the same restrictions, conditions and risks of forfeiture that apply to the underlying award.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Equitable Adjustment
and Treatment of Outstanding Awards Upon a Change in Control</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Equitable Adjustments</i>.
In the event of a merger, consolidation, reclassification, recapitalization, spin-off, spin-out, repurchase, reorganization, special
or extraordinary dividend or other extraordinary distribution (whether in the form of common shares, cash or other property), combination,
exchange of shares, or other change in corporate structure affecting our common stock, an equitable substitution or proportionate adjustment
shall be made in (i) the aggregate number and kind of securities reserved for issuance under the Amended and Restated 2020 Plan, (ii)
the kind and number of securities subject to, and the exercise price of, any outstanding options and SARs granted under the Amended and
Restated 2020 Plan, (iii) the kind, number and purchase price of shares of common stock, or the amount of cash or amount or type of property,
subject to outstanding restricted stock, RSUs and other stock-based awards granted under the Amended and Restated 2020 Plan and (iv)
the terms and conditions of any outstanding awards (including any applicable performance targets). Equitable substitutions or adjustments
other than those listed above may also be made as determined by the plan administrator. In addition, the plan administrator may terminate
all outstanding awards for the payment of cash or in-kind consideration having an aggregate fair market value equal to the excess of
the fair market value of the shares of common stock, cash or other property covered by such awards over the aggregate exercise price,
if any, of such awards, but if the exercise price of any outstanding award is equal to or greater than the fair market value of the shares
of common stock, cash or other property covered by such award, the plan administrator may cancel the award without the payment of any
consideration to the participant. With respect to awards subject to foreign laws, adjustments will be made in compliance with applicable
requirements. Except to the extent determined by the plan administrator, adjustments to incentive stock options will be made only to
the extent not constituting a &#8220;modification&#8221; within the meaning of Section 424(h)(3) of the Code.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Change in Control</i>.
The Amended and Restated 2020 Plan provides that, unless otherwise determined by the plan administrator and evidenced in an award agreement,
employment, services or other agreement, if a &#8220;change in control&#8221; (as defined below) occurs and a participant is employed
by, or otherwise providing services to the Company or any of its affiliates immediately prior to the consummation of the change in control,
then the plan administrator, in its sole and absolute discretion, may (i) provide that any unvested or unexercisable portion of an award
carrying a right to exercise will become fully vested and exercisable; and (ii) cause the restrictions, deferral limitations, payment
conditions and forfeiture conditions applicable to any award granted under the Amended and Restated 2020 Plan to lapse, and the awards
will be deemed fully vested and any performance conditions imposed with respect to such awards will be deemed to be fully achieved at
target performance levels. The plan administrator shall have discretion in connection with such change in control to provide that all
outstanding and unexercised options and SARs shall expire upon the consummation of such change in control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">For purposes of
the Amended and Restated 2020 Plan, a &#8220;change in control&#8221; means, in summary, the occurrence of any of the following events:
(i) a person or entity becomes the beneficial owner of more than 50% of our voting power; (ii) an unapproved change in the majority membership
of our Board; (iii) a merger or consolidation of us or any of our subsidiaries, other than (A) a merger or consolidation that results
in our voting securities continuing to represent 50% or more of the combined voting power of the surviving entity or its parent and our
Board immediately prior to the merger or consolidation continuing to represent at least a majority of the Board of the surviving entity
or its parent or (B) a merger or consolidation effected to implement a recapitalization in which no person is or becomes the beneficial
owner of our voting securities representing more than 50% of our combined voting power; or (iv) shareholder approval of a plan of our
complete liquidation or dissolution or the consummation of an agreement for the sale or disposition of substantially all of our assets,
other than (A) a sale or disposition to an entity, more than 50% of the combined voting power of which is owned by our stockholders in
substantially the same proportions as their ownership of us immediately prior to such sale or (B) a sale or disposition to an entity
controlled by our Board. However, a change in control will not be deemed to have occurred as a result of any transaction or series of
integrated transactions following which our stockholders, immediately prior thereto, hold immediately afterward the same proportionate
equity interests in the entity that owns all or substantially all of our assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Tax Withholding</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Each participant
will be required to make arrangements satisfactory to the plan administrator regarding payment of up to the maximum statutory tax rates
in the participant&#8217;s applicable jurisdiction with respect to any award granted under the Amended and Restated 2020 Plan, as determined
by us. We have the right, to the extent permitted by applicable law, to deduct any such taxes from any payment of any kind otherwise
due to the participant. With the approval of the plan administrator, the participant may satisfy the foregoing requirement by either
electing to have us withhold from delivery of shares of common stock, cash or other property, as applicable, or by delivering already
owned unrestricted shares of common stock, in each case, having a value not exceeding the applicable taxes to be withheld and applied
to the tax obligations. We may also use any other method of obtaining the necessary payment or proceeds, as permitted by applicable law,
to satisfy our withholding obligation with respect to any award.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Amendment and
Termination of the Amended and Restated 2020 Plan</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The Amended and
Restated 2020 Plan provides our Board with authority to amend, alter or terminate the Amended and Restated 2020 Plan, but no such action
may impair the rights of any participant with respect to outstanding awards without the participant&#8217;s consent. The plan administrator
may amend an award, prospectively or retroactively, but no such amendment may materially impair the rights of any participant without
the participant&#8217;s consent. Shareholder approval of any such action will be obtained if required to comply with applicable law.
The Amended and Restated 2020 Plan will terminate on the tenth anniversary of the Effective Date (although awards granted before that
time will remain outstanding in accordance with their terms).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Clawback</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If the Company
is required to prepare a financial restatement due to the Company&#8217;s material non-compliance with any financial reporting requirement
under the securities law, then the plan administrator may require any Section 10D-1(d) of the Exchange Act &#8220;executive officer&#8221;
to repay or forfeit to us that part of the cash or equity incentive compensation received by that Section 10D-1(d) executive officer
during the preceding three completed fiscal years that the plan administrator determines was in excess of the amount that such Section
10D-1(d) executive officer would have received had such cash or equity incentive compensation been calculated based on the restated amounts
reported in the restated financial statement. The plan administrator may take into account any factors it deems reasonable in determining
whether to seek recoupment of previously paid cash or equity incentive compensation and how much of such compensation to recoup from
each Section 10D-1(d) executive officer (which shall be made irrespective of any fault, misconduct or responsibility of each Section
10D-1(d) executive officer). The amount and form of the incentive compensation to be recouped shall be determined by the plan administrator
in its sole and absolute discretion and calculated on a pre-tax basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Disclosure of Equity Awards Based
on Material Nonpublic Information</b>: None</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Pay Versus Performance Disclosure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">In accordance with
the SEC&#8217;s disclosure requirements regarding pay versus performance, or PVP, this section presents the SEC-defined &#8220;Compensation
Actually Paid,&#8221; or CAP of our NEOs for each of the fiscal years ended December 31, 2023 and 2022, and our financial performance.
Also required by the SEC, this section compares CAP to various measures used to gauge performance at TLSS for each such fiscal year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Pay versus
Performance Table - Compensation Definitions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Salary, Bonus,
Stock Awards, and All Other Compensation are each calculated in the same manner for purposes of both CAP and Summary Compensation Table,
or SCT values. The primary difference between the calculation of CAP and SCT total compensation is the calculation of the value of &#8220;Stock
Awards,&#8221; with the table below describing the differences in how these awards are valued for purposes of SCT total and CAP:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Pay Versus Performance Table</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16.2pt"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year (1)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary<br/>
    Compensation<br/>
    Table Total<br/>
    for PEO</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation<br/>
    Actually Paid<br/>
    to PEO (2)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average<br/>
    Summary<br/>
    Compensation<br/>
    Table Total for<br/>
    Non-PEO<br/>
    NEOs</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average<br/>
    Compensation<br/>
    Actually Paid<br/>
    to Non-PEO<br/>
    NEOs (2)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value
    of<br/>
    Initial Fixed<br/>
    $100<br/>
    Investment<br/>
    Based On<br/>
    Total<br/>
    Shareholder<br/>
    Return</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
    Income (Loss)</b> &#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(h)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">569,009</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">569,009</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,692</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,692</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.79</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,700,683</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">332,250</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">332,250</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,000</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,000</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.83</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,908,551</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">345,000</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">345,000</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.57</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,903,741</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PEO (CEO) in the 2023,
    2022 and 2021 reporting year is Eric Weisblum. The non-PEO NEOs in the 2023 and 2022 reporting year is Dan Ryweck.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CAP was calculated
    beginning with the PEO&#8217;s SCT total. No amounts were deducted from or added to the applicable SCT total compensation. Since
    all equity awards were fully vested prior to 2021, no reconciliation to with respect to equity awards for summary compensation numbers
    was required.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.1pt; text-indent: -8.1pt"><span style="font-size: 10pt"><b>Non-Employee
Director Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.1pt; text-indent: -8.1pt"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The following table
presents the total compensation for each person who served as a non-employee member of our board of directors and received compensation
for such service during the fiscal year ended December&#160;31, 2023. Other than as set forth in the table and described more fully below,
we did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee
members of our board of directors in 2022.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Director Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt"><b>Name</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Fees<br/> earned or<br/>
    paid in<br/> cash ($)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Stock<br/> awards ($)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Option<br/> awards ($)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Non-equity<br/> incentive<br/>
    plan<br/> compensation ($)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Nonqualified<br/> deferred<br/>
    compensation<br/> earnings ($)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>All other<br/> compensation
    ($)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Total <br/>
    ($)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt"><b>(a)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>(b)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>(c)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>(d)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>(e)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>(f)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>(g)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>(h)</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left"><span style="font-size: 10pt">Wayne Linsley</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 10pt">45,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;<span style="font-size: 10pt">-</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right">&#160;&#160;<span style="font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right">&#160;&#160;<span style="font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt">-</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 10pt">45,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Dr. Kevin Mu&#241;oz</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">25,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">25,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Jeff Pavel (3)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">25,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">25,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Director Compensation
Program</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our current director
compensation program is designed to align our director compensation program with the long-term interests of our stockholders by implementing
a program comprised of cash and equity compensation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">In setting director
compensation, we consider the amount of time that directors expend in fulfilling their duties to the Company as well as the skill level
and experience required by our board of directors. We also consider board compensation practices at similarly situated companies, while
keeping in mind the compensation philosophy of us and the stockholders&#8217; interests. The directors also receive reimbursement for
expenses, including reasonable travel expenses to attend board and committee meetings, reasonable outside seminar expenses, and other
special board-related expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>ITEM 12. SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The following table
sets forth certain information regarding beneficial ownership of shares of our common stock as of March 23, 2023 by (i) each person known
to beneficially own more than 5% of our outstanding common stock, (ii) each of our directors, (iii) each of our named executive officers
and (iv) all of our directors and named executive officers as a group.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The percentage
ownership information is based on 2,843,634 issued outstanding (315,462 shares held in treasury as of March 23, 2024). Information with
respect to beneficial ownership has been furnished by each director, officer or beneficial owner of more than 5% of our common stock.
We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership
of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the
rules attribute beneficial ownership of securities as of a particular date to persons who hold convertible preferred stock, options or
warrants to purchase shares of common stock and that are exercisable within 60 days of such date. These shares are deemed to be outstanding
and beneficially owned by the person holding those convertible preferred stock, options or warrants for the purpose of computing the
percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of
any other person. Except as otherwise indicated, the persons named in the table below have sole voting and investment power with respect
to all shares beneficially owned, subject to community property laws, where applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Except as otherwise
noted below, the address for each person or entity listed in the table is c/o Silo Pharma, Inc., 677 N. Washington Boulevard Sarasota,
FL 34236.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-size: 10pt">Name and Address of Beneficial Owner</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Number
    of<br/>
    shares<br/>
    beneficially<br/>
    owned</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Percentage
    of <br/>
    shares<br/>
    beneficially<br/>
    owned</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 10pt">Directors and Named Executive Officers:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Eric Weisblum</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">175,924</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"><sup>(1)</sup></span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">6.17</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">Wayne D. Linsley</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,425</span></td><td style="text-align: left"><span style="font-size: 10pt"><sup>(2)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Kevin Munoz</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,425</span></td><td style="text-align: left"><span style="font-size: 10pt"><sup>(2)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">Daniel Ryweck</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">5,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Jeff Pavell</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">All executive officers and directors as a group (5
    persons)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">187,774</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.56</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            beneficial ownership of less than 1% of the outstanding shares of our common stock.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 6,000 shares of
    common stock issuable upon exercise of presently exercisable options.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 3,425 shares of common
    stock, all of which are presently exercisable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>SECURITIES AUTHORIZED FOR ISSUANCE
UNDER EQUITY COMPENSATION PLANS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">The following table shows information
regarding our equity compensation plans as of December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Plan Category</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Number
    of<br/> securities<br/> to be<br/> issued upon<br/> exercise of<br/> outstanding<br/> options,<br/> warrants<br/> and<br/> rights (a)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Weighted<br/>
    average<br/> exercise<br/> price of<br/> outstanding<br/> options,<br/> warrants<br/> and<br/> rights (b)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Number
    of<br/> securities<br/> remaining<br/> available for<br/> future<br/> issuance<br/> under<br/> equity<br/> compensation<br/> plans<br/> (excluding<br/>
    securities<br/> reflected<br/> in<br/> column (c)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Equity compensation plans approved by security holders (1)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">22,850</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">9.19</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">447,150</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">Equity compensation plans not approved by security holders</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Total</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">22,850</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">9.19</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">447,150</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amended
                                            and Restated 2020 Omnibus Equity Incentive Plan</b>. On January 18, 2021, the board of directors
                                            of the Company approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020
                                            Plan&#8221;) to incentivize employees, officers, directors and consultants of the Company
                                            and its affiliates. The number of shares of common stock that are reserved and available
                                            for issuance under the 2020 Plan shall be equal to 170,000 shares provided that with respect
                                            to exempt awards as defined in the 2020 Plan, shall not count against such share limit. The
                                            2020 Plan provides for the grant, from time to time, at the discretion of the Board or a
                                            committee thereof, of cash, stock options, including incentive stock options and nonqualified
                                            stock options, restricted stock, dividend equivalents, restricted stock units, stock appreciation
                                            units and other stock or cash-based awards. The Plan shall terminate on the tenth anniversary
                                            of the date of adoption by the Board of Directors. Subject to certain restrictions, the Board
                                            of Directors may amend or terminate the Plan at any time and for any reason. An amendment
                                            of the Plan shall be subject to the approval of the Company&#8217;s stockholders only to
                                            the extent required by applicable laws, rules or regulations. On March 10, 2021, the stockholders
                                            of the Company approved the Plan. On&#160;<span>September
                                            15</span>, 2023, our Board of Directors adopted the Silo Pharma, Inc. Amended and Restated
                                            2020 Omnibus Equity Incentive Plan, which was approved by the Company&#8217;s stockholders
                                            on December, 2023. The Amended and Restated 2020 Omnibus Equity Incentive Plan (i) increases
                                            the number of shares of common stock that may be issued under such Plan by 300,000 shares
                                            and (ii) includes clawback provisions to comply with recent developments of applicable law.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>ITEM 13. CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Except as set forth
below, there were no transactions during our fiscal years ended December 31, 2023 and 2022 to which we were a party, including transactions
in which the amount involved in the transaction exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end&#160;for
the last two completed fiscal years, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of
more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or
indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are
described elsewhere in this registration statement. We are not otherwise a party to a current related party transaction, and no transaction
is currently proposed, in which the amount of the transaction exceeds the lesser of $120,000 or 1% of the average of our total assets
at year-end&#160;for the last two completed fiscal years and in which a related person had or will have a direct or indirect material
interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Director Independence</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our board of directors
has determined that a majority of the board consists of members who are currently &#8220;independent&#8221; as that term is defined under
Nasdaq Listing Rule 5605(a)(2). The Board considers Wayne D. Linsley, Jeff Pavell and Dr. Kevin Mu&#241;oz to be &#8220;independent.&#8221;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.55pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The board of directors
as a whole carries out the function of a nominating and corporate governance committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Except as may be
provided in our bylaws, we do not currently have specified procedures in place pursuant to which whereby security holders may recommend
nominees to the board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>ITEM 14. PRINCIPAL
ACCOUNTING FEES AND SERVICES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The following table
shows the fees for services provided by Salberg &amp; Company, P.A. for the years ended December 31, 2023 and 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Audit Fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">64,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,100</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Audit Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">All Other Fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">64,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">81,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Audit Fees:</b>&#160;Audit
fees consist of fees billed for professional services performed by Salberg &amp; Company, P.A. for the audit of our annual consolidated
financial statements, and the review of interim consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Audit-Related
Fees:</b>&#160;Audit-related fees may consist of fees billed by our independent registered public accounting firm for audit-related consulting
services related to registration statements. There were no such fees incurred by the Company in the fiscal year ended December 31, 2023
and 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Tax Fees:</b>&#160;Tax
fees may consist of fees for professional services, including tax compliance. There were no such fees incurred by the Company in the
fiscal years ended December 31, 2023 and 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>All Other Fees:
</b>There were no such fees incurred by the Company in the fiscal years ended December 31, 2023 and 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Pre-Approval
Policies and Procedures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">In accordance with
Sarbanes-Oxley, our audit committee charter requires the audit committee to pre-approve all audit and permitted non-audit services provided
by our independent registered public accounting firm, including the review and approval in advance of our independent registered public
accounting firm&#8217;s annual engagement letter and the proposed fees contained therein. The audit committee has the ability to delegate
the authority to pre-approve non-audit services to one or more designated members of the audit committee. If such authority is delegated,
such delegated members of the audit committee must report to the full audit committee at the next audit committee meeting all items pre-approved
by such delegated members. In the fiscal years ended December 31, 2023 and 2022 all of the services performed by our independent registered
public accounting firm were pre-approved by the audit committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>PART IV</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>ITEM 15. EXHIBITS, FINANCIAL STATEMENT
SCHEDULES</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements
    and Report of Independent Registered Public Accounting Firm are listed in the &#8220;Index to Financial Statements and Schedules&#8221;
    on page F-1 and included on pages F-2 thereon.</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statement Schedules</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All schedules for which
    provision is made in the applicable accounting regulations of the Securities and Exchange Commission (the &#8220;Commission&#8221;)
    are either not required under the related instructions, are not applicable (and therefore have been omitted), or the required disclosures
    are contained in the financial statements included herein.</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits (including those
    incorporated by reference).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390023097364/ea190371ex2-1_silopharma.htm">Plan of Conversion dated December 19, 2023, filed as Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 20, 2023 and incorporated herein by reference</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1514183/000121390023097364/ea190371ex3-3_silopharma.htm">Articles of Incorporation of Silo Pharma, Inc., a Nevada corporation, filed as an Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 20, 2023 and incorporated herein by reference</a>.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1514183/000121390023097364/ea190371ex3-4_silopharma.htm">Bylaws of Silo Pharma, Inc., a Nevada corporation, filed as an Exhibit 3.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 20, 2023 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1514183/000121390023097364/ea190371ex3-1_silopharma.htm">Articles of Conversion filed with the Nevada Secretary of State on December 19, 2023, filed as an Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 20, 2023 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1514183/000121390023097364/ea190371ex3-2_silopharma.htm">Certificate of Conversion filed with the Delaware Secretary of State on December 19, 2023, filed as an Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 20, 2023 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="ea020195701ex4-1_silophar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of the Registrant&#8217;s Securities.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000149315213000764/ex10-2.htm">Stock Purchase Agreement dated April 24, 2013 between Point Capital, Inc. and Alpha Capital Anstalt, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on April 30, 2013 and incorporated herein by reference</a>.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390018017594/f8k121318ex10-1_pointcapital.htm">Corrected Asset Purchase Agreement with Blind Faith Concepts Holdings, Inc. dated September 28, 2018, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on December 20, 2018 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390018017594/f8k121318ex10-2_pointcapital.htm">Form of Return to Treasury Agreement, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on December 20, 2018 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390019023011/f10q0919ex10-1_uppercut.htm">Form of Securities Purchase Agreement, dated October 2019, between Uppercut Brands, Inc., and Investors, filed as an exhibit to the Annual Report on Form 10-K filed with the Commission on March 20, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390019023011/f10q0919ex10-2_uppercut.htm">Form of convertible note agreement with Investors dated October 2019, filed as an exhibit to the Annual Report on Form 10-K filed with the Commission on March 20, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390019023011/f10q0919ex10-3_uppercut.htm">Form of Warrant, dated October 2019, filed as an exhibit to the Quarterly Report on Form 10-Q filed with the Commission on November 13, 2019 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020007000/f10k2019ex10-7_uppercut.htm">Form of Securities Purchase Agreement for the purchase of Series B preferred shares, dated November 2019, between Uppercut Brands, Inc., and Investors, filed as an exhibit to the Annual Report on Form 10-K filed with the Commission on March 20, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020007000/f10k2019ex10-8_uppercut.htm">Form of Warrant related to Series B preferred shares, dated November 2019, between Uppercut Brands, Inc., and Investors, filed as an exhibit to the Annual Report on Form 10-K, filed with the Commission on March 20, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020007000/f10k2019ex10-9_uppercut.htm">Form of registration rights agreement related to Series B preferred shares, dated November 2019, between Uppercut Brands, Inc., and Investors, filed as an exhibit to the Annual Report on Form 10-K filed with the Commission on March 20, 2020 and incorporated herein by reference.</a></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="text-align: justify; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-1_uppercut.htm">Form of Exchange Agreement for Convertible Notes, dated as of April 15, 2020, filed as an exhibit to the Current Report on Form 8-K/A, filed with the Commission on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-2_uppercut.htm">Form of Exchange Agreement for Series B Preferred Stock, dated as of April 15, 2020, filed as an exhibit to the Current Report on Form 8-K/A, filed with the Commission on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-3_uppercut.htm">Form of Subscription Agreement, dated as of April 17, 2020, filed as an exhibit to the Current Report on Form 8-K/A, filed with the Commission on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-4_uppercut.htm">Form of Consulting Agreement, dated as of April 17, 2020, filed as an exhibit to the Current Report on Form 8-K/A, filed with the Commission on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-5_uppercut.htm">Form of Advisory Agreement, dated as of April 17, 2020, filed as an exhibit to the Current Report on Form 8-K/A, filed with the Commission on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15+</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-6_uppercut.htm">Employment Agreement by and between the Company and Eric Weisblum, dated as of April 17, 2020, filed as an exhibit to the Current Report on Form 8-K/A, filed with the Commission on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020010355/ea121172ex10-1_uppercut.htm">Form of Securities Purchase Agreement, dated as of April 28, 2020, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on April 28, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020010355/ea121172ex10-2_uppercut.htm">Form of Registration Rights Agreement, dated as of April 28, 2020, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on April 28, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020010355/ea121172ex10-3_uppercut.htm">Form of Lock-Up Agreement, dated as of April 28, 2020, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on April 28, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021001330/ea132847ex10-1_silo.htm">Patent License Agreement by and among the Company and Silo Pharma, Inc., a Florida corporation and their affiliates and subsidiaries and AIkido Pharma Inc., filed as an exhibit to the Current Report on Form 8-K filed with the Commission on January 11, 2021 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021001462/ea133115ex10-1_silopharma.htm">Sponsored Research Agreement by and between the Company and the University of Maryland, Baltimore, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on January 11, 2021 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21+</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021004937/ea134100ex10-1_silopharma.htm">Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on January 28, 2021 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22+</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021004937/ea134100ex10-2_silopharma.htm">First Amendment to Employment Agreement, dated January 18, 2021, by and between the Company and Eric Weisblum, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on January 28, 2021 and incorporated herein by reference.</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021007944/ea135066ex10-1_silopharma.htm">Form of Securities Purchase Agreement, dated as of February 9, 2021, between Silo Pharma, Inc. and the signatories thereto (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021007944/ea135066ex10-2_silopharma.htm">Form of Warrant (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021007944/ea135066ex10-3_silopharma.htm">Form of Registration Rights Agreement, dated as of February 9, 2021, between Silo Pharma, Inc. and the signatories thereto (Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021007944/ea135066ex10-4_silopharma.htm">Form of Lock-Up Agreement, dated as of February 9, 2021 (Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021009075/ea135511ex10-5_silopharma.htm">Form of Placement Agent Warrant (Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K/A filed on February 12, 2021)</a></span></td></tr>
  </table><div>
</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28#</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021009265/ea135663ex10-1_silopharma.htm">Master License Agreement, dated February 12, 2021, by and between the Company and the University of Maryland, Baltimore (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 16, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29#</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021009265/ea135663ex10-2_silopharma.htm">Letter of Intent, dated February 12, 2021, by and between the Company and Aikido Pharma, Inc. (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on February 16, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021001330/ea132847ex10-1_silo.htm">Patent License Agreement by and among the Company and Silo Pharma, Inc., a Florida corporation and their affiliates and subsidiaries and Aikido Pharma Inc. (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 11, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021001462/ea133115ex10-1_silopharma.htm">Sponsored Research Agreement by and between the Company and the University of Maryland, Baltimore (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 11, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/ea166467ex1-1_silopharma.htm">Underwriting Agreement by and between the Company and Laidlaw &amp; Company (UK) Ltd., as representative of the several underwriters named therein, dated September 26, 2022. (Incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed on September 30, 2022.)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/ea166467ex4-1_silopharma.htm">Representative&#8217;s Warrant, dated as of September 29, 2022. (Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on September 30, 2022.)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/ea166467ex10-1_silopharma.htm">Ryweck Employment Agreement, dated September 28, 2022. (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on September 30, 2022.)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022064735/ea167262ex10-1_silopharma.htm">Form of First Amendment to Sponsored Research Agreement by and between the Company and Columbia University. (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report om Form 8-K filed with the SEC on October 18, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022064735/ea167262ex10-2_silopharma.htm">Employment Agreement by and between the Company and Eric Weisblum, dated October 12, 2022. (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 18, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022064735/ea167262ex10-2_silopharma.htm">First Amendment to Employment Agreement by and between the Company and Daniel Ryweck, dated October 12, 2022. (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 18, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1514183/000101376223005850/ea187109-def14a_silopharma.htm">Silo Pharma, Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan, filed as Appendix A to the Company Definitive Proxy Statement on Schedule 14A filed with the SEC on October 23, 2023 and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020195701ex21-1_silophar.htm">Subsidiaries</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020195701ex23-1_silophar.htm">Consent on Independent Registered Accounting Firm</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020195701ex31-1_silophar.htm">Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020195701ex31-2_silophar.htm">Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020195701ex32-1_silophar.htm">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020195701ex97-1_silophar.htm">Silo Pharma, Inc. Clawback Policy</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline
    XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">*</td>
    <td style="text-align: justify">Filed herewith.</td></tr>
  <tr style="vertical-align: top">
    <td>+</td>
    <td style="text-align: justify">Indicates a management contract or any compensatory plan, contract or arrangement.</td></tr>
  <tr style="vertical-align: top">
    <td>#</td>
    <td style="text-align: justify">Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation&#160;S-K Item&#160;601(b)(10)(iv). </td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>ITEM 16. FORM
10-K SUMMARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Not applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the
requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SILO PHARMA, INC</b>.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 4%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 36%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 25, 2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Eric
    Weisblum</i></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Weisblum</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, Chief Executive Officer\</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer\)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the
requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 30%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 45%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 23%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Eric
    Weisblum</i></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, Chief Executive Officer,</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Weisblum</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, and Director&#160;(Principal Executive Officer)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Daniel
    Ryweck</i></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer,</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Ryweck</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Accounting and Financial Officer)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Wayne
    D. Linsley</i></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne D. Linsley</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Dr.
    Kevin Mu&#241;oz</i></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Kevin Mu&#241;oz</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Jeff
    Pavell</i></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff Pavell</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span>

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 90%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm (Firm ID No. <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-14831">106</ix:nonNumeric>)</span></a></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Financial Statements:</span></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022</span></a></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2023 and 2022</span></a></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><a href="#f_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 63; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Report of Independent Registered Public Accounting
Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Shareholders and the Board of Directors
of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Silo Pharma, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Opinion on the Financial Statements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of SILO Pharma, Inc. (the &#8220;Company&#8221;) as of December 31, 2023, and 2022, the related consolidated statements
of operations, changes in stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2023, and
the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2023,
and 2022, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December 31,
2023, in conformity with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis for Opinion</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Critical Audit Matters</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The critical audit matters are matters arising
from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit
committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved
our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;<span style="font-family: Times New Roman, Times, Serif">/s/
Salberg&#160;&amp; Company, P.A.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-14832">SALBERG&#160;&amp; COMPANY, P.A.</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor
since 2019<i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-14833">Boca Raton, Florida</ix:nonNumeric></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">March 25, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-14834">3,524,308</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-14835">11,367,034</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd" id="ixv-14836">4,140,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Equity investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" unitRef="usd" id="ixv-14837">3,118</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-14838">15,970</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-14839">135,894</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify; padding-bottom: 1.5pt">Note receivable, including interest receivable of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" unitRef="usd" id="ixv-14840">9,600</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" unitRef="usd" id="ixv-14841">6,010</ix:nonFraction> at December 31, 2023 and 2022, respectively</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-14842">66,010</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-14843">7,681,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-14844">11,572,056</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and other assets - non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd" id="ixv-14845">64,983</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd" id="ixv-14846">70,821</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14847">7,746,141</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14848">11,642,877</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14849">703,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14850">364,216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Deferred revenue - current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd" id="ixv-14851">72,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd" id="ixv-14852">72,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14853">775,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14854">436,318</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">LONG TERM LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Deferred revenue - long-term portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="0" unitRef="usd" id="ixv-14855">793,680</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="0" unitRef="usd" id="ixv-14856">865,782</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total Long Term Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-14857">793,680</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-14858">865,782</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-14859">1,569,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-14860">1,302,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitment and Contingencies (see Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">STOCKHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Preferred stock, $<ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14861"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14862">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14863"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14864">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized: <span style="-sec-ix-hidden: hidden-fact-5"><span style="-sec-ix-hidden: hidden-fact-6">none</span></span> designated as of December 31, 2023 Common stock, $<ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14865"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14866">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14867"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14868">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-14869">3,159,096</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-14870">3,158,797</ix:nonFraction> shares issued and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14871">2,906,241</ix:nonFraction> and&#160;&#160;<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14872">3,158,797</ix:nonFraction> shares outstanding at December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-14873">316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-14874">316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalPreferredStock" scale="0" unitRef="usd" id="ixv-14875">17,525,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalPreferredStock" scale="0" unitRef="usd" id="ixv-14876">17,511,589</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Treasury stock, at cost (<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-14877">252,855</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-14878">0</ix:nonFraction> shares on December 31, 2023 and
2022, respectively)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockPreferredValue" scale="0" unitRef="usd" id="ixv-14879">471,121</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-14880">6,227</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-14881">10,871,811</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-14882">7,171,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14883">6,176,871</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14884">10,340,777</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-14885">7,746,141</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-14886">11,642,877</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">LICENSE FEE REVENUE</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-14887">72,102</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-14888">72,102</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">COST OF REVENUES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-14889">5,838</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-14890">5,838</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">GROSS PROFIT</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14891">66,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14892">66,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">OPERATING EXPENSES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-14893">871,625</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-14894">577,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-14895">1,726,061</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-14896">1,496,687</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14897">845,092</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14898">1,286,434</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="0" unitRef="usd" id="ixv-14899">89,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="0" unitRef="usd" id="ixv-14900">125,889</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-14901">20,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Selling, general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14902">390,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14903">227,259</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14904">3,921,856</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14905">3,693,920</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">LOSS FROM CONTINUING OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14906">3,855,592</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14907">3,627,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">OTHER INCOME (EXPENSE):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Interest and dividend income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="0" unitRef="usd" id="ixv-14908">398,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="0" unitRef="usd" id="ixv-14909">72,637</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Other income from equity shares earned for lock up agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-14910">85,733</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-14911">4,869</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-14912">2,199</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Net realized loss on equity investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" sign="-" unitRef="usd" id="ixv-14913">104,700</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Penalty from early termination of CD</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:PenaltyFromEarlyTerminationOfCD" scale="0" unitRef="usd" id="ixv-14914">166,034</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net unrealized loss on equity investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-14915">3,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-14916">331,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total other income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-14917">224,509</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-14918">279,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-14919">3,631,083</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-14920">3,907,388</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">LOSS FROM CONTINUING OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" sign="-" unitRef="usd" id="ixv-14921">3,631,083</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" sign="-" unitRef="usd" id="ixv-14922">3,907,388</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">DISCONTINUED OPERATIONS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from discontinued operations, net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="0" sign="-" unitRef="usd" id="ixv-14923">69,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="0" sign="-" unitRef="usd" id="ixv-14924">1,163</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">LOSS FROM DISCONTINUED OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" sign="-" unitRef="usd" id="ixv-14925">69,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" sign="-" unitRef="usd" id="ixv-14926">1,163</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">NET LOSS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14927">3,700,683</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14928">3,908,551</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">COMPREHENSIVE LOSS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14929">3,700,683</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14930">3,908,551</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Other comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Unrealized loss on short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-14931">6,227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-14932">3,706,910</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-14933">3,908,551</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>NET LOSS PER COMMON SHARE:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-16; -sec-ix-hidden: hidden-fact-15">Continuing operations - basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-14934">1.18</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-14935">1.71</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-18; -sec-ix-hidden: hidden-fact-17">Discontinued operations - basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-14936">0.02</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" unitRef="usdPershares" id="ixv-14937">0.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-20; -sec-ix-hidden: hidden-fact-19">Basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14938">3,079,874</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14939">2,284,240</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center">See accompanying notes to consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF CHANGES
IN STOCKHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>FOR THE YEARS ENDED DECEMBER 31, 2023
AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center"><b>Series C</b></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated<br/> Other</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid In</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Treasury Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Comprehensive</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gain</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 25%; font-weight: bold">Balance, December 31, 2021</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-14940">227</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-14941">1,972,739</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14942">197</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14943">12,324,646</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14944">3,262,577</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14945">9,062,266</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sales of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-14946">1,150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-14947">115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-14948">4,940,833</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-14949">4,940,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accretion of stock options expense to stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-14950">111,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-14951">111,014</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common shares issued for professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-14952">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-14953">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-14954">135,098</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-14955">135,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock issued for conversion of Series C preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-14956">227</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" sign="-" unitRef="shares" id="ixv-14957">15,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="0" unitRef="usd" id="ixv-14958">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="0" sign="-" unitRef="usd" id="ixv-14959">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Rounding of share due to reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-14960">891</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14961">3,908,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14962">3,908,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Balance, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-14963">3,158,797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14964">316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14965">17,511,589</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14966">7,171,128</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14967">10,340,777</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accretion of stock options expense to stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-14968">14,125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-14969">14,125</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Purchase of treasury stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" unitRef="shares" id="ixv-14970">252,855</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" unitRef="usd" id="ixv-14971">471,121</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" unitRef="usd" id="ixv-14972">471,121</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accumulated other comprehensive loss - short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-14973">6,227</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-14974">6,227</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Rounding of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-14975">299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14976">3,700,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14977">3,700,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c32" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-14978">3,159,096</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14979">316</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14980">17,525,714</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-14981">252,855</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14982">471,121</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14983">6,227</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14984">10,871,811</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14985">6,176,871</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center">See accompanying notes to consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14986">3,700,683</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14987">3,908,551</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Adjustments&#160;to&#160;reconcile&#160;net&#160;loss to&#160;net&#160;cash used in operating&#160;activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Bad debt expense - discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:ProvisionForDoubtfulAccountsDiscontinuedOperations" scale="0" unitRef="usd" id="ixv-14988">69,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-14989">20,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Stock-based compensation and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd" id="ixv-14990">14,125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd" id="ixv-14991">156,047</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Amortization of prepaid stock-based professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:AmortizationOfPrepaidStockbasedExpense" scale="0" unitRef="usd" id="ixv-14992">90,067</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Net realized loss on equity investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" sign="-" unitRef="usd" id="ixv-14993">104,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Net unrealized loss on equity investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-14994">3,118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-14995">331,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Equity shares earned for lock up agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="silo:EquitySharesEarnedForServices" scale="0" sign="-" unitRef="usd" id="ixv-14996">85,733</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd" id="ixv-14997">35,695</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd" id="ixv-14998">55,335</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-align: left">Interest receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" unitRef="usd" id="ixv-14999">3,590</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" unitRef="usd" id="ixv-15000">4,800</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-15001">339,272</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-15002">53,721</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-align: left">Insurance payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Deferred revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="0" sign="-" unitRef="usd" id="ixv-15003">72,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="0" sign="-" unitRef="usd" id="ixv-15004">72,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">NET&#160;CASH&#160;USED IN OPERATING&#160;ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-15005">3,224,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-15006">3,497,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Purchase of short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" scale="0" unitRef="usd" id="ixv-15007">4,147,107</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" scale="0" sign="-" unitRef="usd" id="ixv-15008">66,707</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Collection on note receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="0" unitRef="usd" id="ixv-15009">20,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">NET&#160;CASH&#160;(USED IN) PROVIDED BY INVESTING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-15010">4,147,107</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" unitRef="usd" id="ixv-15011">86,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Net proceeds from sale of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-15012">4,940,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Purchase of treasury stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfOtherEquity" scale="0" unitRef="usd" id="ixv-15013">471,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">NET&#160;CASH&#160;(USED IN) PROVIDED BY&#160;&#160;FINANCING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" sign="-" unitRef="usd" id="ixv-15014">471,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-15015">4,940,948</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NET&#160;(DECREASE) INCREASE&#160;&#160;IN CASH AND CASH EQUIVALENTS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-15016">7,842,726</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-15017">1,530,033</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH AND CASH EQUIVALENTS - beginning of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-15018">11,367,034</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-15019">9,837,001</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">CASH AND CASH EQUIVALENTS - end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-15020">3,524,308</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-15021">11,367,034</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">SUPPLEMENTAL&#160;DISCLOSURE&#160;OF&#160;CASH&#160;FLOW&#160;INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash&#160;paid&#160;during&#160;the&#160;period&#160;for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; padding-bottom: 4pt">Interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-15022">4,869</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-15023">2,199</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Income&#160;taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd" id="ixv-15024">25,159</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Change in accumulated other comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" scale="0" unitRef="usd" id="ixv-15025">6,227</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Common stock issued for future services</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd" id="ixv-15026">135,100</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center">See accompanying notes to consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:NatureOfOperations" id="ixv-12752"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">N<b>OTE 1 &#8211; <span style="text-decoration:underline">ORGANIZATION AND BUSINESS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Silo Pharma, Inc. (the &#8220;Company&#8221;)
was incorporated in the State of New York on July 13, 2010, under the name Gold Swap, Inc. On January 24, 2013, the Company changed its
state of incorporation from New York to Delaware. On December 19, 2023, the Company changed its state of incorporation from the State
of Delaware to the State of Nevada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research.&#160;The Company seeks to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications
such as depression, post-traumatic stress disorder (&#8220;PTSD&#8221;), Alzheimer&#8217;s, Parkinson&#8217;s, and other rare neurological
disorders. The Company&#8217;s mission is to identify assets to license and fund the research which the Company believes will be transformative
to the well-being of patients and the health care industry.&#160;The Company was previously engaged in the development of a streetwear
apparel brand, NFID (see below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2019, the Company filed an amendment
to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter,
on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name
from Uppercut Brands, Inc. to Silo Pharma, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2020, the Company incorporated a new
wholly-owned subsidiary, Silo Pharma Inc.,&#160;in the State of Florida. The Company has also secured the domain name www.silopharma.com.
The Company had been exploring opportunities to expand the Company&#8217;s business by seeking to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. In July 2020, through the Company&#8217;s newly formed subsidiary, the Company entered into a commercial evaluation license
and option agreement with University of Maryland, Baltimore (&#8220;UMB&#8221;) (see Note 8) pursuant to which, among other things, UMB
granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to certain technology.
The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master License Agreement with
UMB (see Note 8). The Company plans to actively pursue the acquisition and/or development of intellectual property or technology rights
to treat rare diseases, and to ultimately expand the Company&#8217;s business to focus on this new line of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered into
and closed on an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company (the
&#8220;Buyer&#8221;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the Company&#8217;s
NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd" id="ixv-15027">60,000</ix:nonFraction> in the form of a promissory note
amounting to $<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfNotesReceivable" scale="0" unitRef="usd" id="ixv-15028">60,000</ix:nonFraction>. The promissory note bore <ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-15029">8</ix:nonFraction>% interest per annum and matured on <ix:nonNumeric contextRef="c39" format="ixt:date-monthname-day-year-en" name="us-gaap:LongTermDebtMaturityDate" id="ixv-15030">October 1, 2023</ix:nonNumeric>. On November 8, 2023 and effective
on October 1, 2023, the Company and the Buyer entered into a First Amendment Promissory Note which increased the interest rate to <ix:nonFraction contextRef="c40" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-15031">9</ix:nonFraction>% per
annum and extended the maturity date to <ix:nonNumeric contextRef="c40" format="ixt:date-monthname-day-year-en" name="us-gaap:LongTermDebtMaturityDate" id="ixv-15032">December 30, 2023</ix:nonNumeric> for no consideration. Accordingly, the results of operations of this component,
for all periods presented, are separately reported as &#8220;discontinued operations&#8221; on the accompanying consolidated statements
of operations and comprehensive loss (see Note 4). On December 30, 2023, the buyer defaulted on the promissory note (See Note 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 14, 2022, the Company filed a Certificate
of Amendment to the Amended and Restated Articles of Incorporation (the &#8220;Certificate of Amendment&#8221;) with the Secretary of
State of the State of Delaware to effect a 1-for-50 reverse stock split (the &#8220;Reverse Stock Split&#8221;) with respect to the outstanding
shares of the Company&#8217;s common stock. The Certificate of Amendment became effective on September 14, 2022. The Reverse Stock Split
was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split was deemed effective
at the open of business on September 15, 2022. All share and per share data in the consolidated financial statements have been retroactively
adjusted to reflect the effect of the reverse stock split.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-12771"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-12777"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation and Principles of Consolidation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;), the instructions to Form 10-K, and the rules and regulations of the United States Securities and Exchange Commission (the
&#8220;SEC&#8221;) for financial information. The Company&#8217;s consolidated financial statements include financial statements for Silo
Pharma, Inc. and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc. All intercompany transactions
and balances have been eliminated in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with, Accounting Standard Codification
(&#8220;ASC&#8221;) 205-20 &#8220;Discontinued Operations&#8221; establishes that the disposal or abandonment of a component of an entity
or a group of components of an entity should be reported in discontinued operations if the disposal represents a strategic shift that
has (or will have) a major effect on an entity&#8217;s operations and financial results. As a result, the NFID, LLC component&#8217;s
results of operations have been classified as discontinued operations on a retrospective basis for all periods presented. Accordingly,
the results of operations of this component, for all periods, are separately reported as &#8220;discontinued operations&#8221; on the
consolidated statements of operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="silo_LiquidityPolicyTextBlock-c0_cont_1" escape="true" name="silo:LiquidityPolicyTextBlock" id="ixv-12814"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="silo_LiquidityPolicyTextBlock-c0_cont_2" id="silo_LiquidityPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying consolidated
financial statements, the Company generated a net loss of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15033">3,700,683</ix:nonFraction> and used cash in operations of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-15034">3,224,498</ix:nonFraction> during the year ended December
31, 2023. Additionally, the Company has an accumulated deficit of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-15035">10,871,811</ix:nonFraction> on December 31, 2023. As of December 31, 2023, the Company
had working capital of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="silo:WorkingCapital" scale="0" unitRef="usd" id="ixv-15036">6,905,568</ix:nonFraction>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="silo_LiquidityPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The positive working capital serves to mitigate
the conditions that historically raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company
believes that the Company has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months
from the date of this filing.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-12824"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible
that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements,
which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the
actual results could differ significantly from estimates. Significant estimates during the years ended December 31, 2023 and 2022 include
the collectability of notes receivable, the percentage of completion of research and development projects, valuation of equity investments,
valuation allowances for deferred tax assets, the fair value of warrants issued with debt, and the fair value of shares and stock options
issued for services.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-12832"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments with a maturity
of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial institutions.
The Company&#8217;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to
$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd" id="ixv-15037">250,000</ix:nonFraction> or by the Securities Investor Protection Corporation up to $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="silo:CashSPICInsuredAmount" scale="0" unitRef="usd" id="ixv-15038">250,000</ix:nonFraction>. To reduce its risk associated with the failure of such financial
institutions, the Company evaluates at least annually the rating of the financial institutions in which it holds deposits. On December
31, 2023 and 2022, the Company had cash in excess of FDIC limits of approximately $<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd" id="ixv-15039">2,805,000</ix:nonFraction> and $<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd" id="ixv-15040">10,868,000</ix:nonFraction>, respectively. During the
year ended December 31, 2023, the Company transferred funds to other high quality financial institutions to mitigate its risk to ensure
that its exposure is limited or reduced to the FDIC protection limits. In connection with the early termination of a certificate of deposit,
in 2023, the Company paid a penalty of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:PenaltyFromEarlyTerminationOfCD" scale="0" unitRef="usd" id="ixv-15041">166,034</ix:nonFraction>, which is reflected on the accompanying consolidated statement of operations and comprehensive
loss during the year ended December 2023. Any material loss that we may experience in the future could have an adverse effect on our ability
to pay our operational expenses or make other payments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock" id="ixv-12840"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Short-Term Investments</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_2" id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s portfolio of short-term investments
consists of marketable debt securities which are comprised solely of  highly rated U.S. government securities with maturities
of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate
such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending
upon changing liquidity requirements. These debt securities are classified as current assets in the consolidated balance sheet and recorded
at fair value, with unrealized gains or losses included in accumulated other comprehensive income and as a component of the consolidated
statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification
method and are reported in other income (expense), net in the consolidated statements of operations and comprehensive loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_3" id="_InvestmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An impairment loss may be recognized when the
decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary
declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis
of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and
the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security,
such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required
to sell the security before recovery of its amortized cost basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-15042">6,227</ix:nonFraction> of unrealized loss
on short-term investments as a component of other comprehensive loss for the year ended December 31, 2023, respectively. The Company did
not recognize any unrealized gains or losses on short-term investments during the year ended December 31, 2022.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="silo_EquityInvestmentsAtFairValuePolicyTextBlock-c0_cont_1" escape="true" name="silo:EquityInvestmentsAtFairValuePolicyTextBlock" id="ixv-12880"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Fair Value</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="silo_EquityInvestmentsAtFairValuePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Realized gain or loss is recognized when an investment
is disposed of and is computed as the difference between the Company&#8217;s carrying value and the net proceeds received from such disposition.
Realized gains and losses on investment transactions are determined by specific identification. Net unrealized appreciation or depreciation
is computed as the difference between the fair value of the investment and the cost basis of such investment. Net unrealized gains or
losses for equity investments are recognized in operations as the difference between the carrying value at the beginning of the period
and the fair value at the end of the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="ixv-12888"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note Receivable</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recorded as part of general
and administrative expenses. As of December 31, 2023, the Company recognized an allowance for loss on the note receivable and accrued interest
receivable in an amount equal to the estimated probable losses, and accordingly, the Company recorded bad debt expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:BadDebtExpense" scale="0" unitRef="usd" id="ixv-15043">69,600</ix:nonFraction>, which
represents the note receivable principal balance of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivableWithImputedInterestFaceAmount" scale="0" unitRef="usd" id="ixv-15044">60,000</ix:nonFraction> and accrued interest receivable of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" unitRef="usd" id="ixv-15045">9,600</ix:nonFraction>, which is recorded in loss from
discontinued operations on the accompanying consolidated statement of operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="silo_PrepaidExpensesPolicyTextBlock-c0_cont_1" escape="true" name="silo:PrepaidExpensesPolicyTextBlock" id="ixv-12895"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid Expenses</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="silo_PrepaidExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-15046">15,970</ix:nonFraction>
and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-15047">135,894</ix:nonFraction> on December 31, 2023 and 2022, respectively, consist primarily of costs paid for future services which will occur within
a year. On December 31, 2023 and 2022, prepaid expenses and other assets &#8211; non-current amounted to $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-15048">64,983</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-15049">70,821</ix:nonFraction>, respectively,
and consist primarily of costs paid for future services which will occur after a year. Prepaid expenses may include prepayments in cash
and equity instruments for consulting, research and development, license fees, public relations and business advisory services, and legal
fees which are being amortized over the terms of their respective agreements, which may exceed a year of service.<b>&#160;</b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-12904"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies ASC Topic 606, Revenue from
Contracts with Customers (&#8220;ASC 606&#8221;). ASC 606 establishes a single comprehensive model for entities to use in accounting for
revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records interest and dividend income
on an accrual basis to the extent that the Company expects to collect such amounts.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the license and royalty income, revenue is
recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the licensee
that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related license
agreement (see Note 8).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product sales were recognized when the NFID products
were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately reported
as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="silo_CostOfRevenuesPolicyTextBlock-c0_cont_1" escape="true" name="silo:CostOfRevenuesPolicyTextBlock" id="ixv-12920"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of Revenues</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="silo_CostOfRevenuesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues on
license fees includes the cost of the license fees. Payments made to the licensor that are related to future periods are recorded as prepaid
expense to be amortized over the term of the related license agreement (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationForfeituresPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock" id="ixv-12953"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ShareBasedCompensationForfeituresPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation is accounted for based
on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211; Stock Compensation&#8221;, which requires recognition in the financial
statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the
period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting
period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award
based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under Accounting
Standards Update (&#8220;ASU&#8221;) 2016-09 Improvements to Employee Share-Based Payment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-12960"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities arise
from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates,
which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current,
depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to
an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected
to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provisions of Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, &#8220;Uncertainty in Income Taxes&#8221;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#8220;more-likely-than-not&#8221; threshold. The Company does not believe it has any uncertain tax positions as
of December 31, 2023 and 2022 that would require either recognition or disclosure in the accompanying consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-12970"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 730-10, <i>&#8220;Research
and Development-Overall,&#8221;</i> research and development costs are expensed when incurred. During the years ended December 31, 2023
and 2022, research and development costs were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15050">845,092</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15051">1,286,434</ix:nonFraction>, respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-12978"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Leases</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases are accounted for using ASU 2016-02, &#8220;<i>Leases
(Topic 842)&#8221;</i>. ASU 2016-02 sets out the principles for the recognition, measurement, presentation and disclosure of leases for
both parties to a contract (i.e., lessees and lessors). The standard requires lessees to apply a dual approach, classifying leases as
either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee.
This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis
over the term of the lease. A lessee is also required to recognize a right-of-use asset and a lease liability for all leases with a term
of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to
existing guidance for operating leases today. As of December 31, 2023 and 2022, the Company has no leases. The Company will analyze any
lease to determine if it would be required to record a lease liability and a right of use asset on its consolidated balance sheets at
fair value upon adoption of ASU 2016-02. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term
leases that have a term of 12 months or less.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-12986"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Loss per Common Share</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted
loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock,
common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially
dilutive securities which include stock options and stock warrants are excluded from the computation of diluted shares outstanding if
they would have an anti-dilutive impact on the Company&#8217;s net losses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-15052">The following potentially dilutive shares have
been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the years ended December 31,
2023 and 2022:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c43" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15053">28,849</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c44" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15054">28,849</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15055">404,580</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c46" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15056">404,580</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15057">433,429</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15058">433,429</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-13074"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Accounting Pronouncements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any recently
issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#8217;s consolidated
financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-13083"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; <span style="text-decoration:underline">FAIR VALUE OF FINANCIAL INSTRUMENTS
AND FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value Measurements and Fair Value of Financial
Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820 - Fair Value Measurements and Disclosures,
defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether
or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent
information available to the Company on December 31, 2023 and 2022. Accordingly, the estimates presented in these financial statements
are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies
a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable
inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest
priority to unobservable inputs (Level 3 measurement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="width: 0.6in; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 -</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 -</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 -</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unobservable inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying value of certain financial instruments,
including cash and cash equivalents, prepaid expenses and other current assets, notes receivable, and accounts payable and accrued expenses
are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under the Financial Accounting Standard Board&#8217;s (the &#8220;FASB&#8221;) accounting
standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest
level of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="ixv-15059">The following table represents the Company&#8217;s
fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and 2022.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Short-term investments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd" id="ixv-15060">4,140,880</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Equity investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-15061">3,118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term investments and
equity investments are level 1 measurements and are based on redemption value at each date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Short-Term Investments &#8211; Debt Securities,
at Fair Value</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock-c0_cont_1" escape="true" name="silo:ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock" id="ixv-15062">The following table summarizes activity in the
Company&#8217;s short-term investments, at fair value for the periods presented:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock-c0_cont_2" id="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Balance, beginning of year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%">Additions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="silo:AdditionsOfShortTermInvestments" scale="0" unitRef="usd" id="ixv-15063">4,147,107</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unrealized losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-15064">6,227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Balance, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd" id="ixv-15065">4,140,880</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Equity Investments, at Fair Value</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation continuedAt="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock-c0_cont_3" id="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock-c0_cont_2">The following table summarizes activity in the
Company&#8217;s equity investments, at fair value for the periods presented:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance, beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" unitRef="usd" id="ixv-15067">3,118</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" unitRef="usd" id="ixv-15068">419,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="silo:AdditionsofEquitySecurities" scale="0" unitRef="usd" id="ixv-15069">85,733</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales at original cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="silo:EquitySecuritiesSalesAtOriginalCost" scale="0" unitRef="usd" id="ixv-15070">171,407</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Unrealized loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-15071">3,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-15072">331,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" unitRef="usd" id="ixv-15073">3,118</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 31, 2023 and 2022, equity instruments,
at fair value consisted of <ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-15074"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-15075">1,559</ix:nonFraction></ix:nonFraction> shares of common equity securities of one entity, Home Bistro, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
received <ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-15076">1,559</ix:nonFraction> shares of Home Bistro, Inc. common stock with grant date fair value of $<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue" scale="0" unitRef="usd" id="ixv-15077">85,733</ix:nonFraction>, or $<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15078">54.99</ix:nonFraction> per share, in exchange for entering
into a lock up and leak out agreement which was recorded as other income from equity shares earned for services in the accompanying consolidated
statement of operations and comprehensive loss. The Company measures equity securities received for services at fair value on the date
of receipt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
sold its equity investments in Aikido Pharma, Inc. with cost of $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-15079">171,407</ix:nonFraction> for gross proceeds of $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-15080">66,707</ix:nonFraction> and the Company recorded a net
realized loss on equity investments amounting to $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" sign="-" unitRef="usd" id="ixv-15081">104,700</ix:nonFraction> as reflected in the accompanying consolidated statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments are carried at fair value with
unrealized gains or losses which are recorded as net unrealized gain (loss) on equity investments in the accompanying consolidated statement
of operations and comprehensive loss.&#160;Realized gains and losses are determined on a specific identification basis which is recorded
as net realized gain (loss) on equity investments in the consolidated statement of operations and comprehensive loss. The Company reviews
equity investments, at fair value, for impairment whenever circumstances and situations change such that there is an indication that the
carrying amounts may not be recovered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 825-10 &#8220;Financial Instruments&#8221;
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="ixv-13432"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span style="text-decoration:underline">DISPOSAL OF THE DISCONTINUED
OPERATIONS OF THE NFID BUSINESS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered into
and closed on an Asset Purchase Agreement (see Note 1) with NFID, LLC, an unrelated party, a Florida limited liability company, whereby
the Company sold certain assets, properties, and rights in connection with its NFID trademark name, logos, domain, and apparel clothing
and accessories for a purchase price of $<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd" id="ixv-15082">60,000</ix:nonFraction> in the form of a promissory note amounting to $<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-15083">60,000</ix:nonFraction>. The promissory note bore <ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-15084">8</ix:nonFraction>% interest
per annum and matured on <ix:nonNumeric contextRef="c69" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15085">October 1, 2023</ix:nonNumeric>. On November 8, 2023 and effective on October 1, 2023, the Company and the Buyer entered into
a First Amendment Promissory Note which increased the interest rate to <ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-15086">9</ix:nonFraction>% per annum and extended the maturity date to <ix:nonNumeric contextRef="c71" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15087">December 30, 2023</ix:nonNumeric>
for no consideration. As of December 31, 2023, the Company recognized an allowance for loss on the note receivable and accrued interest
receivable in an amount equal to the estimated probable losses, and accordingly, the Company recorded bad debt expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:ProvisionForDoubtfulAccountsDiscontinuedOperations" scale="0" unitRef="usd" id="ixv-15088">69,600</ix:nonFraction>, which
represents the note receivable principal balance of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="0" unitRef="usd" id="ixv-15089">60,000</ix:nonFraction> and accrued interest receivable of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" unitRef="usd" id="ixv-15090">9,600</ix:nonFraction>, which is recorded in loss from
discontinued operations on the accompanying consolidated statement of operations. As of December 31, 2022, the note receivable had a principal
balance of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="0" unitRef="usd" id="ixv-15091">60,000</ix:nonFraction> and accrued interest receivable of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" unitRef="usd" id="ixv-15092">6,010</ix:nonFraction> for a total outstanding receivable balance of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-15093">66,010</ix:nonFraction> (see Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 205-20 &#8220;Discontinued Operations&#8221;
establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should be reported in discontinued
operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s operations and financial
results. As a result, the component&#8217;s results of operations have been classified as discontinued operations on a retrospective basis
for all periods presented. Accordingly, the results of operations of this component, for all periods, are separately reported as &#8220;discontinued
operations&#8221; on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="ixv-15094">The summarized operating result of discontinued
operations of the NFID Business included in the Company&#8217;s consolidated statements of operations for the years ended December 31,
2023 and 2022 is as follows:</ix:nonNumeric>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Product sales, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt">Cost of sales</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" unitRef="usd" id="ixv-15095">1,079</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-15096">1,079</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating and other non-operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="0" unitRef="usd" id="ixv-15097">69,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="0" unitRef="usd" id="ixv-15098">84</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15099">69,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15100">1,163</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="ixv-13520"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5 &#8211; <span style="text-decoration:underline">NOTE RECEIVABLE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="ixv-15101">On December 31, 2023 and 2022, note receivable consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amount of note receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="0" unitRef="usd" id="ixv-15102">60,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="0" unitRef="usd" id="ixv-15103">60,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" unitRef="usd" id="ixv-15104">9,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" unitRef="usd" id="ixv-15105">6,010</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableGross" scale="0" unitRef="usd" id="ixv-15106">69,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableGross" scale="0" unitRef="usd" id="ixv-15107">66,010</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" scale="0" unitRef="usd" id="ixv-15108">69,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Note receivable &#8211; current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-15109">66,010</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company executed a
note receivable agreement with NFID, LLC in connection with an Asset Purchase Agreement (see Note 4). The promissory note bore <ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-15110">8</ix:nonFraction>% interest
per annum and matured on <ix:nonNumeric contextRef="c72" format="ixt:date-monthname-day-year-en" name="us-gaap:LongTermDebtMaturityDate" id="ixv-15111">October 1, 2023</ix:nonNumeric>. On November 8, 2023 and effective on October 1, 2023, the Company and the Buyer entered into
a First Amendment Promissory Note which increased the interest rate to <ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-15112">9</ix:nonFraction>% per annum and extended the maturity date to <ix:nonNumeric contextRef="c73" format="ixt:date-monthname-day-year-en" name="us-gaap:LongTermDebtMaturityDate" id="ixv-15113">December 30, 2023</ix:nonNumeric>
for no consideration. The outstanding principal and accrued interest shall be due and payable on maturity. As of December 31, 2023, the
Company recognized an allowance for loss on the note receivable and accrued interest receivable in an amount equal to the estimated probable
losses, and accordingly, the Company recorded bad debt expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:ProvisionForDoubtfulAccountsDiscontinuedOperations" scale="0" unitRef="usd" id="ixv-15114">69,600</ix:nonFraction>, which represents the note receivable principal balance of $<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-15115">60,000</ix:nonFraction>
and accrued interest receivable of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" unitRef="usd" id="ixv-15116">9,600</ix:nonFraction>, which is recorded in loss from discontinued operations on the accompanying consolidated statement
of operations. As of December 31, 2022, this note receivable had outstanding principal receivable of $<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-15117">60,000</ix:nonFraction> and accrued interest receivable
of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" unitRef="usd" id="ixv-15118">6,010</ix:nonFraction> for a total receivable balance of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-15119">66,010</ix:nonFraction> which is reflected in the accompanying consolidated balance sheet as note receivable
&#8211; current.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-13628"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shares Authorized</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 4, 2023, stockholders of the Company
approved a decrease to the number of authorized shares of the Company&#8217;s common stock from <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15120">500,000,000</ix:nonFraction> shares to <ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15121">100,000,000</ix:nonFraction> shares.
On December 4, 2023, the Company filed a Certificate of Amendment (the &#8220;Amendment&#8221;) to its Certificate of Incorporation with
the Delaware Secretary of State to decrease its authorized shares of common stock from <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15122">500,000,000</ix:nonFraction> shares to <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15123">100,000,000</ix:nonFraction> shares. On December
19, 2023, the Company reincorporated as a Nevada corporation and filed Articles of Incorporation with the Nevada Secretary of State on
such date. The Company has <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-15124">105,000,000</ix:nonFraction> shares authorized which consist of <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-15125">100,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-15126">5,000,000</ix:nonFraction> shares of
preferred stock.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Convertible Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2021, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &#8220;Certificate of Designations&#8221;)
with the Delaware Secretary of State, designating <ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="silo:PreferredStockShareDesignated" scale="0" unitRef="shares" id="ixv-15127">4,280</ix:nonFraction> shares of preferred stock as Series C Convertible preferred stock. The Company
had designated <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="silo:PreferredStockShareDesignated" scale="0" unitRef="shares" id="ixv-15128">4,280</ix:nonFraction> shares of preferred stock as Series C Convertible preferred stock. Each share of Series C Convertible Preferred Stock
had a par value of $<ix:nonFraction contextRef="c83" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15129">0.0001</ix:nonFraction> per share and a stated value of $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-15130">1,000</ix:nonFraction> (the &#8220;Series C Stated Value&#8221;). Each <ix:nonNumeric contextRef="c84" name="us-gaap:ConvertiblePreferredStockTermsOfConversion" id="ixv-15131">share of Series C Convertible
preferred stock was convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number
of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price.</ix:nonNumeric> &#8220;Series C Conversion
Price&#8221; means $<ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-15132">15.00</ix:nonFraction>, subject to adjustment in the event of stock split, stock dividends, subsequent right offerings and similar
recapitalization transactions. Notwithstanding anything herein to the contrary, after the date that the Company&#8217;s stockholder approval
is obtained and deemed effective, the Company may deliver a written notice to all holders (the &#8220;Forced Conversion Notice Date&#8221;)
to cause each holder to convert all or part of such holder&#8217;s Series C Convertible preferred stock pursuant to Section 6 (&#8220;Forced
Conversion&#8221;), it being agreed that the &#8220;Conversion Date&#8221; shall be deemed to occur no later than the earlier of (i) two
(2) trading days and (ii) the number of trading days comprising the standard settlement period following the Forced Conversion Notice
Date; provided, however, a holder shall only be required to convert pursuant to a Forced Conversion to the extent that such conversion
would not cause a holder to exceed its beneficial ownership limitation. On March 31, 2022, the Company notified holders of the remaining
<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-15133">227</ix:nonFraction> shares of its Series C Convertible preferred stock of its election to force the conversion to its Series C Convertible preferred stock
into shares of the Company&#8217;s common stock (see below). As of December 31, 2022, there were <span style="-sec-ix-hidden: hidden-fact-126"><span style="-sec-ix-hidden: hidden-fact-127">no</span></span> shares of the Series preferred stock
issued and outstanding. On December 19, 2023, the Company changed its state of incorporation from the State of Delaware to the State of
Nevada and since there were no shares of Series C Convertible Stock outstanding at the time or the reincorporation the Company did not
designate Series C Convertible Stock in Nevada and it was deemed cancelled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conversion of Series C Convertible Preferred
Stock into Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2022, the Company notified holders
of the remaining <ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-15134">227</ix:nonFraction> shares of its Series C Convertible preferred stock of its election to force the conversion to its Series C Convertible
preferred stock into shares of the Company&#8217;s common stock pursuant to the Certificate of Designations unless such conversion would
cause the holder to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On March 31, 2022, the Company
converted the remaining <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-15135">227</ix:nonFraction> Series C Convertible preferred stock into <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15136">15,167</ix:nonFraction> shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sale of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2022, the Company entered into
an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Laidlaw &amp; Company (UK) Ltd., as representative of the several
underwriters identified therein (the &#8220;Underwriters&#8221;), relating to the public offering (the &#8220;Offering&#8221;) of <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-15137">1,000,000</ix:nonFraction>
shares of the Company&#8217;s common stock (the &#8220;Firm Shares&#8221;), at public offering price of $<ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-15138">5.00</ix:nonFraction> per share. Under the terms
of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 45 days following the closing of the Offering,
to purchase up to an additional <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-15139">150,000</ix:nonFraction> shares of common stock at the public offering price to cover over-allotments, if any. On September
28, 2022, the Underwriters fully exercised their over-allotment option and purchased an additional <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-15140">150,000</ix:nonFraction> shares (the &#8220;Option Shares,&#8221;
together with the Firm Shares, the &#8220;Shares&#8221;). On September 29, 2022 the Company closed the Offering and issued the Shares
for aggregate net proceeds of $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-15141">4,940,948</ix:nonFraction>, after deducting underwriting discounts and commissions and offering expenses. The Company intends
to use the net proceeds from the offering for research and development activities, sales and marketing, general working capital purposes,
potential acquisitions of other companies, products or technologies, and to repay certain indebtedness. Concurrently with the closing
of the Offering, the Company also issued warrants to purchase an aggregate of up to <ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-15142">57,500</ix:nonFraction> shares of its common stock to the representative
of the Underwriters or its designees, at an exercise price of $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-15143">6.25</ix:nonFraction> per share (the &#8220;Representative&#8217;s Warrants&#8221;). The
Representative&#8217;s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and
conditions of the Representative&#8217;s Warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock Issued for Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 29, 2022, the Company entered into a
one-year consulting agreement with an entity for investor relations services. In connection with this consulting agreement, the Company
issued <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-15144">20,000</ix:nonFraction> restricted common shares of the Company to the consultant. These shares vest immediately. These shares were valued at $<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd" id="ixv-15145">135,100</ix:nonFraction>,
or $<ix:nonFraction contextRef="c98" decimals="3" format="ixt:num-dot-decimal" name="silo:RestrictedCommonSharePrice" scale="0" unitRef="usdPershares" id="ixv-15146">6.755</ix:nonFraction> per common share, based on contemporaneous common share sales by the Company. In connection with this consulting agreement,
during the years ended December 31, 2023 and 2022, the Company recorded stock-based professional fees of $<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-15147">90,067</ix:nonFraction> and $<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-15148">45,033</ix:nonFraction>, respectively.
which was amortized into stock-based professional fees over the term of the agreement.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Repurchase Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 26, 2023, the Company&#8217;s Board
of Directors authorized a stock repurchase plan to repurchase up to $<ix:nonFraction contextRef="c99" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" unitRef="usd" id="ixv-15149">1.0</ix:nonFraction>&#160;million of the Company&#8217;s issued and outstanding common
stock, from time to time, with such plan to be in place until December 31, 2023. On January 9, 2024, the Board of Directors of the Company
approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $<ix:nonFraction contextRef="c100" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" unitRef="usd" id="ixv-15150">1</ix:nonFraction> million of the Company&#8217;s
common stock until March 31, 2024. Through December 31, 2023, the Company purchased <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" unitRef="shares" id="ixv-15151">252,855</ix:nonFraction> shares of common stock for a cost of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockPurchaseCost" scale="0" unitRef="usd" id="ixv-15152">471,121</ix:nonFraction>,
which is reflected in treasury stock on the accompanying consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 18, 2021, the Company&#8217;s board
of directors (&#8220;Board&#8221;) approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;) to
incentivize employees, officers, directors and consultants of the Company and its affiliates. <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-15153">170,000</ix:nonFraction> shares of common stock are reserved
and available for issuance under the 2020 Plan, provided that certain exempt awards (as defined in the 2020 Plan), shall not count against
such share limit. The 2020 Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of cash,
stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock
units, stock appreciation units and other stock or cash-based awards.&#160;The 2020 Plan shall terminate on the tenth anniversary of the
date of adoption by the Board. Subject to certain restrictions, the Board may amend or terminate the Plan at any time and for any reason.
An amendment of the 2020 Plan shall be subject to the approval of the Company&#8217;s stockholders only to the extent required by applicable
laws, rules or regulations. On March 10, 2021, the 2020 Plan was approved by the stockholders. On&#160;September 15, 2023, our Board of
Directors adopted the Silo Pharma, Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan which was approved by the Company&#8217;s
stockholders on December 4, 2023. The Amended and Restated Omnibus Equity Incentive Plan (i) increases the number of shares of common
stock that may be issued under such plan by <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="0" unitRef="shares" id="ixv-15154">300,000</ix:nonFraction> shares to <ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="0" unitRef="shares" id="ixv-15155">470,000</ix:nonFraction> shares and (ii) includes clawback provisions to comply with recent
developments of applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 29, 2021 and effective January 1,
2022, the Board granted an aggregate of <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateOfIncentiveStockOptions" scale="0" unitRef="shares" id="ixv-15156">6,849</ix:nonFraction> incentive stock options under the 2020 Plan, to two non-employee board members, exercisable
at $<ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-15157">7.30</ix:nonFraction> per share which expire on December 26, 2026 and vest on the first anniversary date of the grant date. These options were valued
at $<ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="silo:StockOptionValue" scale="0" unitRef="usd" id="ixv-15158">30,224</ix:nonFraction> on the grant date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of
<ix:nonFraction contextRef="c104" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-15159">0.75</ix:nonFraction>%, expected dividend yield of <ix:nonFraction contextRef="c104" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-15160">0</ix:nonFraction>%, expected term of <ix:nonNumeric contextRef="c104" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15161">2</ix:nonNumeric> years using the simplified method and expected volatility of <ix:nonFraction contextRef="c104" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-15162">115</ix:nonFraction>% based on historical
volatility. The Company recorded the fair value of the unvested stock options, in the amount of $<ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationEquity" scale="0" unitRef="usd" id="ixv-15163">30,224</ix:nonFraction>, as deferred compensation which
is being amortized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2022, pursuant to an Employment
Agreement (see Note 8), an aggregate of <ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="0" unitRef="shares" id="ixv-15164">16,000</ix:nonFraction> incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $<ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-15165">10.00</ix:nonFraction>
per share and expires on January 31, 2032. The stock options vest as follows: (i) <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-15166">6,000</ix:nonFraction> stock options upon issuance; (ii) <ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-15167">5,000</ix:nonFraction> vests
on October 31, 2022 and; (iii) <ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-15168">5,000</ix:nonFraction> vests on October 31, 2023. The <ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-15169">16,000</ix:nonFraction> stock options had a fair value of $<ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" unitRef="usd" id="ixv-15170">94,915</ix:nonFraction> which were valued
at the grant date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of <ix:nonFraction contextRef="c110" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-15171">1.18</ix:nonFraction>%, expected
dividend yield of <ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-15172">0</ix:nonFraction>%, expected term of <ix:nonNumeric contextRef="c110" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15173">2</ix:nonNumeric> years using the simplified method and expected volatility of <ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-15174">117</ix:nonFraction>% based on historical volatility.
The Company recorded the fair value of the stock options, in the amount of $<ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" unitRef="usd" id="ixv-15175">94,915</ix:nonFraction>, as deferred compensation which is being amortized
over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022,
the Company amortized $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationEquity" scale="0" unitRef="usd" id="ixv-15176">14,125</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationEquity" scale="0" unitRef="usd" id="ixv-15177">111,014</ix:nonFraction> of the deferred compensation which was recorded as compensation expenses in the accompanying
consolidated statement of operations and comprehensive loss. As of December 31, 2023, there was no remaining deferred compensation related
to these issuances. As of December 31, 2022, the deferred compensation related to these issuances had a balance of $<ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" scale="0" unitRef="usd" id="ixv-15178">14,125</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-15179">Stock option activities for the years ended December
31, 2023 and 2022 are summarized as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual Term<br/> (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance Outstanding, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c113" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-15180">12,849</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15181">3.89</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c114" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15182">2.54</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd" id="ixv-15183">42,870</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c115" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-15184">16,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c115" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15185">10.0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-15186">28,849</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15187">7.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c115" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15188">6.31</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd" id="ixv-15189">20,130</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance Outstanding, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-15190">28,849</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15191">7.28</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c117" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15192">5.31</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd" id="ixv-15193">8,610</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-15194">28,849</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15195">7.28</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c117" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-15196">5.31</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd" id="ixv-15197">8,610</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2022, concurrently with the closing
of the Offering as discussed above, the Company also issued warrants to purchase an aggregate of up to <ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-15198">57,500</ix:nonFraction> shares of its common stock
to the representative of the Underwriters or its designees, at an exercise price of $<ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-15199">6.25</ix:nonFraction> per share (the &#8220;Representative&#8217;s
Warrants&#8221;). The Representative&#8217;s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant
to the terms and conditions of the Representative&#8217;s Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-15200">Warrant activities for the years ended December
31, 2023 and 2022 are summarized as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual Term<br/> (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance Outstanding, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-15201">347,080</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c119" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15202">15.5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c120" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-15203">4.1</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c121" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-15204">57,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15205">6.25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c121" format="ixt-sec:duryear" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" id="ixv-15206">5.0</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-15207">404,580</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15208">14.05</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c121" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-15209">3.3</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance Outstanding, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c124" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-15210">404,580</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c124" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15211">14.05</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c123" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-15212">2.3</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c123" decimals="INF" format="ixt:num-dot-decimal" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable" scale="0" unitRef="shares" id="ixv-15213">404,580</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c123" decimals="2" format="ixt:num-dot-decimal" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable" scale="0" unitRef="shares" id="ixv-15214">14.05</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c123" format="ixt-sec:duryear" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable" id="ixv-15215">2.3</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-14034"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8211; <span style="text-decoration:underline">CONCENTRATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Customer concentration</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023 and 2022,
one licensee accounted for <ix:nonFraction contextRef="c125" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-15216"><ix:nonFraction contextRef="c126" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-15217">100</ix:nonFraction></ix:nonFraction>% total revenues from customer license fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Vendor concentrations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023 and 2022,
one licensor accounted for <ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-15218"><ix:nonFraction contextRef="c128" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-15219">100</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s vendor license agreements (see below) related to the Company&#8217;s biopharmaceutical
operations.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-14074"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8211; <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Employment Agreements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Eric Weisblum</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2020, the Company entered into an
employment agreement (&#8220;Employment Agreement&#8221;) with Eric Weisblum to serve as Chief Executive Officer and Chief Financial Officer
of the Company. The term of the Employment Agreement continued for a period of one year from the date of execution date thereof and automatically
renewed for successive one-year periods at the end of each term until either party delivers written notice of their intent not to renew
at least six months prior to the expiration of the then effective term. The Employment Agreement provided for a base salary of $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="0" unitRef="usd" id="ixv-15220">120,000</ix:nonFraction>
and <ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" scale="0" unitRef="shares" id="ixv-15221">152,619</ix:nonFraction> vested shares of the Company&#8217;s common stock in April 2020. On January 18, 2021, the Company and Mr. Weisblum entered
into the first amendment (the &#8220;Amendment&#8221;) to the Employment Agreement, effective as of January 1, 2021. Pursuant to the Amendment
Mr. Weisblum&#8217;s base salary was increased from $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="0" unitRef="usd" id="ixv-15222">120,000</ix:nonFraction> per year to $<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="0" unitRef="usd" id="ixv-15223">180,000</ix:nonFraction> per year and all the terms and provisions of the Employment
Agreement remained in full force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2022, the Company entered into
a new employment agreement with Eric Weisblum (the &#8220;2022 Weisblum Employment Agreement&#8221;) pursuant to which Mr. Weisblum&#8217;s
(i) base salary will be $<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="0" unitRef="usd" id="ixv-15224">350,000</ix:nonFraction> per year, (ii) Mr. Weisblum was paid a one-time signing bonus of $<ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" scale="0" unitRef="usd" id="ixv-15225">100,000</ix:nonFraction>, and (iii) Mr. Weisblum shall
be entitled to receive an annual bonus of up to $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15226">350,000</ix:nonFraction>, subject to the sole discretion of the Compensation Committee of the Board of
Directors of the Company (the &#8220;Compensation Committee&#8221;), and upon the achievement of additional criteria established by the
Compensation Committee from time to time (the &#8220;Annual Bonus&#8221;). In addition, pursuant to the 2022 Weisblum Employment Agreement,
upon termination of Mr. Weisblum&#8217;s employment for death or Total Disability (as defined in the 2022 Weisblum Employment Agreement),
in addition to any accrued but unpaid compensation and vacation pay through the date of his termination and any other benefits accrued
to him under any Benefit Plans (as defined in the 2022 Weisblum Employment Agreement) outstanding at such time and the reimbursement of
documented, unreimbursed expenses incurred prior to such termination date (collectively, the &#8220;Weisblum Payments&#8221;), Mr. Weisblum
shall also be entitled to the following severance benefits: (i) 24 months of his then base salary; (ii) if Mr. Weisblum elects continuation
coverage for group health coverage pursuant to COBRA Rights (as defined in the 2022 Weisblum Employment Agreement), then for a period
of 24 months following Mr. Weisblum&#8217;s termination he will be obligated to pay only the portion of the full COBRA Rights cost of
the coverage equal to an active employee&#8217;s share of premiums (if any) for coverage for the respective plan year; and (iii) payment
on a pro-rated basis of any Annual Bonus or other payments earned in connection with any bonus plan to which Mr. Weisblum was a participant
as of the date of his termination (together with the Weisblum Payments, the &#8220;Weisblum Severance&#8221;). Furthermore, pursuant to
the 2022 Weisblum Employment Agreement, upon Mr. Weisblum&#8217;s termination (i) at his option (A) upon 90 days prior written notice
to the Company or (B) for Good Reason (as defined in the 2022 Weisblum Employment Agreement), (ii) termination by the Company without
Cause (as defined in the 2022 Weisblum Employment Agreement) or (iii) termination of Mr. Weisblum&#8217;s employment within 40 days of
the consummation of a Change in Control Transaction (as defined in the Weisblum Employment Agreement), Mr. Weisblum shall receive the
Weisblum Severance; provided, however, Mr. Weisblum shall be entitled to a pro-rated Annual Bonus of at least $<ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15227">200,000</ix:nonFraction>. In addition, any
equity grants issued to Mr. Weisblum shall immediately vest upon termination of Mr. Weisblum&#8217;s employment by him for Good Reason
or by the Company at its option upon 90 days prior written notice to Mr. Weisblum, without Cause. In September 2023 and October 2022,
the Company paid a bonus of $<ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToEmployees" scale="0" unitRef="usd" id="ixv-15228">200,000</ix:nonFraction> and $<ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToEmployees" scale="0" unitRef="usd" id="ixv-15229">100,000</ix:nonFraction> to Mr. Weisblum, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Daniel Ryweck</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 27, 2022, the Board appointed Daniel
Ryweck as Chief Financial Officer of the Company. On September 28, 2022, the Company entered into an employment agreement (the &#8220;Ryweck
Employment Agreement&#8221;) with Mr. Ryweck. Pursuant to the terms of the Ryweck Employment Agreement, which was amended on October
12, 2022, Mr. Ryweck will (i) receive a base salary at an annual rate of $<ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="0" unitRef="usd" id="ixv-15230">60,000</ix:nonFraction> (the &#8220;Base Compensation&#8221;) payable in equal
monthly installments, and (ii) be eligible to receive an annual discretionary bonus. The term of Mr. Ryweck&#8217;s engagement under
the Ryweck Employment Agreement commenced on September 28, 2022 and continues until September 28, 2023, unless earlier terminated in
accordance with the terms of the Ryweck Employment Agreement. The term of Mr. Ryweck&#8217;s Employment Agreement is automatically renewed
for successive one-year periods until terminated by Mr. Ryweck or the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dr. James Kuo</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2022, the Company and Dr. James
Kuo entered into an employment agreement (&#8220;Kuo Employment Agreement&#8221;) for Dr. Kuo to serve as the Vice President of Research
&amp; Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for a
period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days prior to the applicable renewal date.
Dr. Kuo shall be paid an annual base salary of $<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="0" unitRef="usd" id="ixv-15231">30,000</ix:nonFraction>. For each twelve-month period of his employment, Dr. Kuo shall be entitled to a
bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#8220;Board&#8221;) and shall
be payable at the Company&#8217;s sole option in stock or in cash. In addition, an aggregate of <ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" unitRef="shares" id="ixv-15232">16,000</ix:nonFraction> incentive stock options were granted
under the 2020 Plan to Dr. Kou, exercisable at $<ix:nonFraction contextRef="c141" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15233">10.00</ix:nonFraction> per share and expires on <ix:nonNumeric contextRef="c140" format="ixt:date-monthname-day-year-en" name="us-gaap:LeaseExpirationDate1" id="ixv-15234">January 31, 2032</ix:nonNumeric>. The stock options vest as follows: (i)
<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-15235">6,000</ix:nonFraction> stock options upon issuance; (ii) <ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-15236">5,000</ix:nonFraction> vests on October 31, 2022 and; (iii) <ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-15237">5,000</ix:nonFraction> vests on October 31, 2023. The <ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares" id="ixv-15238">16,000</ix:nonFraction> stock options
had a fair value of $<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" unitRef="usd" id="ixv-15239">94,915</ix:nonFraction> which valued at grant date using Binomial Lattice option pricing model with the following assumptions: risk-free
interest rate of <ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-15240">1.18</ix:nonFraction>%, expected dividend yield of <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-15241">0</ix:nonFraction>%, expected term of <ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-15242">2</ix:nonFraction> years using the simplified method and expected volatility of
<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-15243">117</ix:nonFraction>% based on calculated volatility. The Company recorded the fair value of the stock options, in the amount of $<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" unitRef="usd" id="ixv-15244">94,915</ix:nonFraction>, as deferred compensation
which is being amortized over the vesting period. During the years ended December 31, 2023 and 2022, the Company amortized $<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCostsNet" scale="0" unitRef="usd" id="ixv-15245">14,125</ix:nonFraction> and
$<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCostsNet" scale="0" unitRef="usd" id="ixv-15246">80,790</ix:nonFraction> of the deferred compensation which was recorded as compensation expenses in the consolidated statement of operations and comprehensive
loss, respectively. As of December 31, 2023 and 2022, the deferred compensation had a balance of $<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-15247">0</ix:nonFraction> and $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-15248">14,125</ix:nonFraction>, respectively (see Note
6).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">License Agreements between the Company and
Vendors</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore - License
Agreement for Development and Use of Central Nervous System-Homing Peptides</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option Agreement
with the University of Maryland, Baltimore</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of July 15, 2020, the Company, through
its wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1) and University of Maryland, Baltimore (&#8220;UMB&#8221;) (collectively as
&#8220;Parties&#8221;), entered into a commercial evaluation license and option agreement (&#8220;License Agreement&#8221;), granting
the Company an exclusive, non-sublicensable, non-transferable license to with respect to the exploration of the potential use of central
nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory
pathology. The License Agreement also granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing
license (&#8220;Exclusive Option&#8221;) with respect to the subject technology. The License Agreement had a term of six months from the
effective date however if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation
period (as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company exercised
its Exclusive Option on January 13, 2021 and entered into a Master License Agreement on February 12, 2021. Both parties may terminate
this agreement within thirty days by giving written notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore - License
Agreement for Development and Use of Joint-Homing Peptides</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option Agreement
with the University of Maryland, Baltimore</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#8220;UMB&#8221;) (collectively as &#8220;Parties&#8221;),
entered into a commercial evaluation license and option agreement (&#8220;License Agreement&#8221;), which granted the Company an exclusive,
non-sublicensable, non-transferable license with respect to the exploration of the potential use of joint-homing peptides for use in the
investigation and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate
and obtain an exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive Option&#8221;) with respect to the subject technology.
On July 6, 2021, the Company entered into a First Amendment Agreement (&#8220;First Amendment&#8221;) with UMB to extend the term of the
original License Agreement by an additional six months such that the First Amendment was effective until February 25, 2022. On January
28, 2022, the Parties entered into a second amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Second
Amendment&#8221;) to extend the term of the original license agreement until December 31, 2022. On June 22, 2022, the Parties entered
into a third amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Third Amendment&#8221;). The
Third Amendment expanded the scope of the license granted in the License Agreement to add additional patent rights with respect to an
invention generally known as <i>Peptide-Targeted Liposomal Delivery for Treatment Diagnosis, and Imaging of Diseases and Disorders</i>.
In consideration of the licenses granted under this Third Amendment, the Company agreed to pay a one-time, non-refundable fee of $<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15249">2,500</ix:nonFraction>
which was recorded as research and development expense in the consolidated statement of operations and comprehensive loss during the year
ended December 31, 2022. On December 16, 2022, the Company and UMB entered into a fourth amendment to License Agreement (the &#8220;Fourth
Amendment&#8221;) to extend the term of the License Agreement until March 31, 2023. In addition, the parties agreed in the Fourth Amendment
to allow the Company to extend the term of the License Agreement to June 30, 2023 by paying UMB a fee of $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15250">1,000</ix:nonFraction> on or before February
28, 2023. This fee was paid and the term of the License Agreement was extended to June 30, 2023. In February 2023, upon payment of the
extension fee of $<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15251">1,000</ix:nonFraction>, the Company recorded license fees of $<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15252">1,000</ix:nonFraction> which are included in research and development expenses on the accompanying
consolidated statement of operations and comprehensive loss. On June 28, 2023, the Company and UMB entered into a fifth amendment to License
Agreement (the &#8220;Fifth Amendment&#8221;) to extend the term of the License Agreement until September 30, 2023. The Company may at
its option extend this Agreement until December 31, 2023, by providing written notice to University on or before August 31, 2023, and
by paying an additional license fee of $<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15253">2,500</ix:nonFraction>. This fee was paid and the term of the License Agreement was extended to December 31, 2023.
In August 2023, upon payment of the extension fee of $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="silo:ExtensionFee" scale="0" unitRef="usd" id="ixv-15254">2,500</ix:nonFraction>, the Company recorded license fees of $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15255">2,500</ix:nonFraction> which are included in research
and development expense on the accompanying consolidated statement of operations and comprehensive loss. As of December 31, 2023, the
Company decided not to extend this License Agreement and will not continue to pursue this license.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Master License Agreement with the University
of Maryland, Baltimore</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed above, effective as of February 12,
2021, the Company and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into the Master License Agreement (&#8220;Master
License Agreement&#8221;) which grants the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual
property: (i) to make, have made, use, sell, offer to sell, and import certain licensed products and: (ii) to use the invention titled,
&#8220;Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other
neuroinflammatory pathology&#8221; and UMB&#8217;s confidential information to develop and perform certain licensed processes for the
therapeutic treatment of neuroinflammatory disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Master License Agreement will remain in effect
on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under the
Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity,
or other legally enforceable market exclusivity, if applicable, or (c) <ix:nonNumeric contextRef="c159" format="ixt-sec:duryear" name="silo:CommercialSaleTerm" id="ixv-15256">10</ix:nonNumeric> years after the first commercial sale of a Licensed Product
in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the Master License
Agreement shall expire <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="silo:LicenseAgreementExpire" id="ixv-15257">15</ix:nonNumeric> years after the Master License Agreement Effective Date in which (a) there were never any patent rights, (b)
there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable
market exclusivity or (c) there was never a first commercial sale of a Licensed Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may assign, sublicense, grant, or
otherwise convey any rights or obligations under the Master License Agreement to a Company affiliate, without obtaining prior written
consent from UMB provided that it meets the terms defined in the Master License Agreement. The Company may grant sublicenses of some or
all of the rights granted by the Master License Agreement, provided that there is no uncured default or breach of any material term or
condition under the Master License Agreement, by Company, at the time of the grant, and that the grant complies with the terms and conditions
of the Master License Agreement. The Company shall be and shall remain responsible for the performance by each of the Company&#8217;s
sublicensee. Any sublicense shall be consistent with and subject to the terms and conditions of the Master License Agreement and shall
incorporate terms and conditions sufficient to enable Company to comply with the Master License Agreement. The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="silo:SublicenseIncomeReceivablePercentage" scale="-2" unitRef="pure" id="ixv-15258">25</ix:nonFraction>% of the Company&#8217;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) <ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="silo:SublicenseIncomeReceivablePercentage" scale="-2" unitRef="pure" id="ixv-15259">15</ix:nonFraction>% of the Company&#8217;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Master License Agreement, the
Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments
depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company paid to UMB a
license fee of $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15260">75,000</ix:nonFraction>, payable as follows: (a) $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="silo:DueToRelatedPartieCurrent" scale="0" unitRef="usd" id="ixv-15261">25,000</ix:nonFraction> was due and paid within 30 days following the effective date; and (b) $<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FeesPaidOnAcceptancesResold" scale="0" unitRef="usd" id="ixv-15262">50,000</ix:nonFraction>
on or before the first anniversary of the effective date, which was paid in February 2022. The license fee is non-refundable and is not
creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection
with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid
$<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15263">25,000</ix:nonFraction> license fee on February 17, 2021 and $<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15264">50,000</ix:nonFraction> in February 2022 which was recorded as prepaid expense and is being amortized over
the <ix:nonNumeric contextRef="c163" format="ixt-sec:duryear" name="us-gaap:LongTermDebtTerm" id="ixv-15265">15</ix:nonNumeric>-year term. During the years ended December 31, 2023 and 2022, the Company recognized license fees of $<ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15266">5,000</ix:nonFraction> and $<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15267">5,000</ix:nonFraction>, respectively,
from the amortization of prepaid license fees, which is included in costs of revenues on the accompanying consolidated statements of operations.
On December 31, 2023, prepaid expense and other current assets &#8211; current amounted to $<ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-15268">5,000</ix:nonFraction> and prepaid expense &#8211; non-current
amounted to $<ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="0" unitRef="usd" id="ixv-15269">55,625</ix:nonFraction>. <ix:nonNumeric contextRef="c0" continuedAt="silo_ScheduleOfMilestonePaymentsTableTextBlock-c0_cont_1" escape="true" name="silo:ScheduleOfMilestonePaymentsTableTextBlock" id="ixv-15270">On December 31, 2022, prepaid expense and other current assets &#8211; current amounted to $<ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-15271">5,000</ix:nonFraction> and prepaid expense
&#8211; non-current amounted to $<ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="0" unitRef="usd" id="ixv-15272">60,625</ix:nonFraction> as reflected in the consolidated balance sheets.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><ix:continuation id="silo_ScheduleOfMilestonePaymentsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><ix:nonNumeric contextRef="c225" name="silo:MilestoneBalanceDescription" id="ixv-15273">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd" id="ixv-15274">50,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonNumeric contextRef="c226" name="silo:MilestoneBalanceDescription" id="ixv-15275">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd" id="ixv-15276">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonNumeric contextRef="c227" name="silo:MilestoneBalanceDescription" id="ixv-15277">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd" id="ixv-15278">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonNumeric contextRef="c228" name="silo:MilestoneBalanceDescription" id="ixv-15279">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c228" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd" id="ixv-15280">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonNumeric contextRef="c229" name="silo:MilestoneBalanceDescription" id="ixv-15281">Achievement of First Commercial Sale of Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd" id="ixv-15282">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Royalty Payments Terms</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="silo:SalesOfLicensedProductsPercentage" scale="-2" unitRef="pure" id="ixv-15283">3</ix:nonFraction>%
on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalesCommissionsAndFees" scale="0" unitRef="usd" id="ixv-15284">50,000,000</ix:nonFraction>;
and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="silo:SalesOfLicensedProductsPercentage" scale="-2" unitRef="pure" id="ixv-15285">5</ix:nonFraction>%
on sales of licensed products during the applicable calendar year for sales greater than $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalesCommissionsAndFees" scale="0" unitRef="usd" id="ixv-15286">50,000,000</ix:nonFraction>; and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock-c0_cont_1" escape="true" name="silo:ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock" id="ixv-14284"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">minimum
annual royalty payments, as follows:</span></ix:nonNumeric></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minimum<br/>
 Annual<br/>
 Royalty</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonNumeric contextRef="c225" name="silo:MinimumAnnualRoyaltyPaymentsDescription" id="ixv-15287">Prior to First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonNumeric contextRef="c226" name="silo:MinimumAnnualRoyaltyPaymentsDescription" id="ixv-15288">Year of First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><ix:nonNumeric contextRef="c227" name="silo:MinimumAnnualRoyaltyPaymentsDescription" id="ixv-15289">First calendar year following the First Commercial Sale</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="0" unitRef="usd" id="ixv-15290">25,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonNumeric contextRef="c228" name="silo:MinimumAnnualRoyaltyPaymentsDescription" id="ixv-15291">Second calendar year following the First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c228" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="0" unitRef="usd" id="ixv-15292">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonNumeric contextRef="c229" name="silo:MinimumAnnualRoyaltyPaymentsDescription" id="ixv-15293">Third calendar year following the First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="0" unitRef="usd" id="ixv-15294">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 10, 2023, the Company entered into
a Third Amendment to Master License Agreement (the &#8220;Third Amendment&#8221;) with UMB, pursuant to which the parties agreed to an
amended and restated schedule of diligence milestones for the Master License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2021, in connection with the Company&#8217;s
Sublicense Agreement with Aikido Pharma Inc. (see below - <i>Patent License Agreement with Aikido Pharma Inc.</i>), the Company paid <ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="silo:SublicenseIncomePercentage" scale="-2" unitRef="pure" id="ixv-15295">25</ix:nonFraction>%
of its sublicense income to UMB, pursuant to the Master License Agreement, which amounted to $<ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="silo:SublicenseAgreementAmountPaid" scale="0" unitRef="usd" id="ixv-15296">12,500</ix:nonFraction>. During the years ended December
31, 2023 and 2022, the Company recognized license fees of $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="0" unitRef="usd" id="ixv-15297">838</ix:nonFraction> and $<ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="0" unitRef="usd" id="ixv-15298">838</ix:nonFraction>, respectively, from the amortization of the sublicense fee. On
December 31, 2023, prepaid expense and other current assets &#8211; current amounted to $<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-15299">838</ix:nonFraction> and prepaid expenses &#8211; non-current
amounted to $<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="0" unitRef="usd" id="ixv-15300">9,358</ix:nonFraction>. On December 31, 2022, prepaid expense and other current assets &#8211; current amounted to $<ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-15301">838</ix:nonFraction> and prepaid expenses
&#8211; non-current amounted to $<ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="0" unitRef="usd" id="ixv-15302">10,196</ix:nonFraction> as reflected in the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">License Agreements between the Company and
Customer</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Patent License Agreement with Aikido
Pharma Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company and its subsidiary
Silo Pharma, Inc., entered into a patent license agreement (&#8220;License Agreement&#8221;) (collectively, the &#8220;Licensor&#8221;)
with Aikido Pharma Inc. (&#8220;Aikido&#8221; or the &#8220;Customer&#8221;), as amended on April 12, 2021, pursuant to which the Licensor
granted Aikido an exclusive, worldwide (&#8220;Territory&#8221;), sublicensable, royalty-bearing license to certain intellectual property:
(i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise certain licensed
products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused by cancer (&#8220;Field
of Use&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement also provided that, if the
Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective as
of July 15, 2020, it would grant Aikido a non-exclusive sublicense (&#8220;Right&#8221;) to certain UMB patent rights in the field of
neuroinflammatory diseases occurring in patients diagnosed with cancer (&#8220;Field&#8221;). Pursuant to the License Agreement, Aikido
agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $<ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="silo:NonrefundableCashPayment" scale="0" unitRef="usd" id="ixv-15303">500,000</ix:nonFraction> and (ii) royalty payments equal
to <ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="silo:NetSalePercentage" scale="-2" unitRef="pure" id="ixv-15304">2</ix:nonFraction>% of net sales (as defined in the License Agreement) in the Field of Use in the Territory. In addition, Aikido agreed to issue the
Licensor <ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="silo:LicensorShare" scale="0" unitRef="shares" id="ixv-15305">500</ix:nonFraction> shares of Aikido&#8217;s newly designated Series M Convertible Preferred Stock which were to be converted into an aggregate
of <ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateOfConvertedShares" scale="0" unitRef="shares" id="ixv-15306">625,000</ix:nonFraction> shares of Aikido&#8217;s common stock. On April 12, 2021, the Company entered into an amendment to the License Agreement (&#8220;Amended
License Agreement&#8221;) with Aikido dated January 5, 2021 whereby Aikido issued an aggregate of <ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateOfConvertedShares" scale="0" unitRef="shares" id="ixv-15307">625,000</ix:nonFraction> restricted shares of Aikido&#8217;s
common stock instead of the <ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="silo:LicensorShare" scale="0" unitRef="shares" id="ixv-15308">500</ix:nonFraction> shares of the Series M Convertible Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the License Agreement, the Company
is required to prepare, file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the
licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed
patents. The Company may terminate the License Agreement upon 30 day written notice if Aikido fails to pay any amounts due and payable
to the Company or if Aikido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal
or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (&#8220;Patent Challenge&#8221;)
against the Company (except as required under a court order or subpoena). Aikido may terminate the Agreement at any time without cause,
and without incurring any additional penalty, (i) by providing at least 30 days&#8217; prior written notice and paying the Company all
amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed
to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $<ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="silo:NonrefundableCashPayment" scale="0" unitRef="usd" id="ixv-15309">500,000</ix:nonFraction> on January
5, 2021 which was recorded as deferred revenue to be recognized as revenues over <ix:nonNumeric contextRef="c173" format="ixt-sec:duryear" name="silo:RevenueTerm" id="ixv-15310">15</ix:nonNumeric> years, the estimated term of the UMB Master License
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the April 12, 2021, issuance of the common
stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-15311">500</ix:nonFraction> Series M Convertible Preferred
stock which was equivalent into Aikido&#8217;s <ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares" id="ixv-15312">625,000</ix:nonFraction> shares of common stock at a fair value of $<ix:nonFraction contextRef="c175" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" unitRef="usdPershares" id="ixv-15313">0.85</ix:nonFraction> per common share or $<ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="silo:TradingPrice" scale="0" unitRef="usd" id="ixv-15314">531,250</ix:nonFraction> based
quoted trading price of Aikido&#8217;s common stock on the date of grant. The Company recorded an equity investment of $<ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-15315">531,250</ix:nonFraction> (see Note
3) and deferred revenue of $<ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="0" unitRef="usd" id="ixv-15316">531,250</ix:nonFraction> to be recognized as revenues over the estimated term of the UMB Master License. Accordingly, the Company
recorded a total deferred revenue of $<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="0" unitRef="usd" id="ixv-15317">1,031,250</ix:nonFraction> ($<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-15318">500,000</ix:nonFraction> cash received and $<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="silo:SecuritiesReceived" scale="0" unitRef="usd" id="ixv-15319">531,250</ix:nonFraction> value of equity securities received) to be recognized
as revenues over the <ix:nonNumeric contextRef="c172" format="ixt-sec:duryear" name="silo:RevenueTerm" id="ixv-15320">15</ix:nonNumeric>-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022,
the Company recognized license fee revenues of $<ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd" id="ixv-15321">68,750</ix:nonFraction> and $<ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd" id="ixv-15322">68,750</ix:nonFraction>, respectively. On December 31, 2023, deferred revenue &#8211; current
portion amounted to $<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd" id="ixv-15323">68,750</ix:nonFraction> and deferred revenue &#8211; long-term portion amounted to $<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="0" unitRef="usd" id="ixv-15324">756,250</ix:nonFraction>. On December 31, 2022, deferred revenue
&#8211; current portion amounted to $<ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd" id="ixv-15325">68,750</ix:nonFraction> and deferred revenue &#8211; long-term portion amounted to $<ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="0" unitRef="usd" id="ixv-15326">825,000</ix:nonFraction> as reflected in the consolidated
balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Right shall be, to the full extent permitted
by and on terms and conditions required by UMB, for a term consistent with the term of patent and technology licenses that UMB normally
grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after
the execution of such UMB license, for consideration to be agreed upon and paid by Aikido, which consideration shall in no event exceed
<ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="silo:ConsiderationFeePayablePercentage" scale="-2" unitRef="pure" id="ixv-15327">110</ix:nonFraction>% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant Aikido a nonexclusive
sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including
any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly,
on April 6, 2021, the Company entered into the Sublicense Agreement with Aikido pursuant to which it granted Aikido a worldwide exclusive
sublicense to its licensed patents under the Master License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Sublicense&#160;Agreement with
Aikido Pharma Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2021 (the &#8220;Sublicense Agreement
Effective Date&#8221;), the Company entered into the Sublicense Agreement with Aikido pursuant to which the Company granted Aikido an
exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and
(ii) in connection therewith to (A) use an invention known as &#8220;Central nervous system-homing peptides in vivo and their use for
the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#8221; which was sublicensed to the Company
pursuant to the Master License Agreement&#160;and (B) practice certain patent rights (&#8220;Patent Rights&#8221;) for the therapeutic
treatment of neuroinflammatory disease in cancer patients. &#8220;Licensed Products&#8221; means any product, service, or process, the
development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent
Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent
Rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Sublicense Agreement, Aikido agreed
to pay the Company (i) an upfront license fee of $<ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="silo:UpfrontLicenseFees" scale="0" unitRef="usd" id="ixv-15328">50,000</ix:nonFraction>, (ii)&#160;the same sales-based royalty payments that the Company is subject
to under the Master License Agreement and (iii) total milestone payments of up to $<ix:nonFraction contextRef="c180" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="6" unitRef="usd" id="ixv-15329">1.9</ix:nonFraction> million. The Sublicense Agreement shall continue
on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the last to expire
claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new chemical entity,
orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii) <ix:nonNumeric contextRef="c180" format="ixt-sec:duryear" name="silo:FirstCommercialSale" id="ixv-15330">10</ix:nonNumeric> years after
the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the Sublicense Agreement.
Furthermore, the Sublicense Agreement shall expire <ix:nonNumeric contextRef="c180" format="ixt-sec:duryear" name="silo:AgreementShallExpire" id="ixv-15331">15</ix:nonNumeric> years after the Sublicense Agreement Effective Date with respect to any country
in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity, orphan drug exclusivity,
regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and (ii) there was never a commercial
sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The Company collected the upfront license
fee of $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15332">50,000</ix:nonFraction> in April 2021. During the years ended December 31, 2023 and 2022, the Company recognized revenue of $<ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd" id="ixv-15333">3,352</ix:nonFraction> and $<ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd" id="ixv-15334">3,352</ix:nonFraction>,
respectively. On December 31, 2023, deferred revenue &#8211; current portion amounted to $<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd" id="ixv-15335">3,352</ix:nonFraction> and deferred revenue &#8211; long-term
portion amounted to $<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="0" unitRef="usd" id="ixv-15336">37,430</ix:nonFraction>, and on December 31, 2022, deferred revenue &#8211; current portion amounted to $<ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd" id="ixv-15337">3,352</ix:nonFraction> and deferred revenue
&#8211; long-term portion amounted to $<ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="0" unitRef="usd" id="ixv-15338">40,782</ix:nonFraction> as reflected in the consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Sponsored Study and Research Agreements
between the Company and Vendors</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investigator-Sponsored Study Agreement with
University of Maryland, Baltimore</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company entered into an
investigator-sponsored study agreement (&#8220;Sponsored Study Agreement&#8221;) with the University of Maryland, Baltimore. The research
project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (&#8220;MS&#8221;).
More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the
CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and
progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March
1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. The total cost
under the Sponsored Study Agreement shall not exceed $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd" id="ixv-15339">81,474</ix:nonFraction> which is payable in two equal installments of $<ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd" id="ixv-15340">40,737</ix:nonFraction> upon execution of the
Sponsored Study Agreement and $<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="silo:SponsoredStudyAgreement" scale="0" unitRef="usd" id="ixv-15341">40,737</ix:nonFraction> upon completion of the project with an estimated project timeline of nine months. In 2021, the Company
paid $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" unitRef="usd" id="ixv-15342">40,737</ix:nonFraction> and recorded research and development expense of $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15343">40,737</ix:nonFraction>. This project has been postponed until further notice and the second
payment is not due.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with The Regents
of the University of California</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021 (the &#8220;Effective Date&#8221;),
the Company entered into a sponsored research agreement (the &#8220;Sponsored Research Agreement&#8221;) with The Regents of the University
of California, on behalf of its San Francisco Campus (&#8220;UCSF&#8221;) pursuant to which UCSF shall conduct a study to examine psilocybin&#8217;s
effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson&#8217;s Disease, chronic
pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a total fee of $<ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15344">342,850</ix:nonFraction> to conduct the research over
the two-year period. The Agreement was effective for a period of two years from the Effective Date, subject to renewal or earlier termination
as set forth in the Sponsored Research Agreement. During the years ended December 31, 2022 and 2021, pursuant to the Sponsored Research
Agreement, the Company paid to UCSF $<ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-15345">181,710</ix:nonFraction> and $<ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-15346">100,570</ix:nonFraction>, respectively, which were recorded to prepaid expense and other current assets
&#8211; current to be amortized over the two-year period. During the year ended December 31, 2023, the Company paid the remaining amount
due of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="0" unitRef="usd" id="ixv-15347">60,570</ix:nonFraction>. During the years ended December 31, 2023 and 2022, the Company recorded research and development expenses of $<ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15348">71,427</ix:nonFraction> and
$<ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15349">178,568</ix:nonFraction>, respectively, from the amortization of the prepaid research and development fees. On December 31, 2023 and 2022, prepaid research
and development fees amounted to $<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-15350">0</ix:nonFraction> and $<ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-15351">10,857</ix:nonFraction>, respectively which is reflected in prepaid expenses and other current assets &#8211;
current on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with University
of Maryland, Baltimore</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company and University of
Maryland, Baltimore (&#8220;UMB&#8221;) entered into a sponsored research agreement (&#8220;July 2021 Sponsored Research Agreement&#8221;)
pursuant to which UMB shall&#160;evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome. The research
pursuant to the July 2021 Sponsored Research Agreement shall commence on September 1, 2021 and will continue until the substantial completion
thereof, subject to renewal upon written consent of the parties. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#8217; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, the Company shall relinquish any and all rights it may have in the Results (as
defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated
early, the Company, among other things, will pay all costs incurred and accrued by UMB as of the date of termination. On June 7, 2022,
the Company and UMB amended the July 2021 Sponsored Research Agreement whereby both parties agreed to make changes to the original project
work and budget. The amendment had no effect on the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the July 2021 Sponsored
Research Agreement, UMB granted the Company an option (the &#8220;Option&#8221;) to negotiate and obtain an exclusive license to any UMB
Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#8217;s rights in any Joint Arising IP (as defined in the
July 2021 Sponsored Research Agreement) (collectively, the &#8220;UMB IP&#8221;). The Company may exercise the Option by giving UMB written
notice within 60 days after it receives notice from UMB of the UMB IP. <ix:nonNumeric contextRef="c0" continuedAt="silo_ScheduleOfShallPayUMBFeesTableTextBlock-c0_cont_1" escape="true" name="silo:ScheduleOfShallPayUMBFeesTableTextBlock" id="ixv-15352">Pursuant to the July 2021 Sponsored Research Agreement, the Company
shall pay UMB the fees below:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="silo_ScheduleOfShallPayUMBFeesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 7%; text-align: center">1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15353">92,095</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 80%; text-align: justify"><ix:nonNumeric contextRef="c230" name="silo:PaymentDescription" id="ixv-15354">Paid upon execution of the July 2021 Sponsored Research Agreement</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">2</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15355">92,095</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c231" name="silo:PaymentDescription" id="ixv-15356">Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15357">92,095</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c232" name="silo:PaymentDescription" id="ixv-15358">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</ix:nonNumeric></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid the first payment of $<ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" unitRef="usd" id="ixv-15359">92,095</ix:nonFraction>
on September 1, 2021 and on August 31, 2022, the Company paid the second payment of $<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" unitRef="usd" id="ixv-15360">92,095</ix:nonFraction>. These payments were recorded to prepaid expense
and other current assets &#8211; current to be amortized into research and development expense during the years ended December 31, 2022
and 2021. During the years ended December 31, 2023 and 2022, the Company recorded research and development expenses of $<ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15361">0</ix:nonFraction> and $<ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15362">187,090</ix:nonFraction>,
respectively, from the amortization of these prepaid research and development fees and other expenses. On December 31, 2023 and 2022,
the Company owed UMB $<ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-15363"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-15364">92,095</ix:nonFraction></ix:nonFraction> which was included in accounts payable on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with Columbia
University</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into a
sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets
currently under development, including assets related to the potential treatment of patients suffering from Alzheimer&#8217;s disease.
The term of the option will commence on the effective date of this agreement and will expire upon the earlier of (i) 90 days after the
date of the Company&#8217;s receipt of a final research report for each specific research proposal as defined in the agreement or (ii)
termination of the research. If the Company elects to exercise the option, both parties will commence negotiation of a license agreement
and will execute a license agreement no later than 3 months after the date of the exercise of the option. Columbia University and the
Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer&#8217;s disease to post-traumatic stress
disorder. During a one-year period from the date of this agreement, <ix:nonNumeric contextRef="c191" name="silo:SponsoredResearchAgreementDescription" id="ixv-15365">the Company shall pay a total of $1,436,082 to Columbia University
for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after
the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project.</ix:nonNumeric> The Company
paid the first payment of $<ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" unitRef="usd" id="ixv-15366">430,825</ix:nonFraction> in November 2021 and the second payment of $<ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" unitRef="usd" id="ixv-15367">430,825</ix:nonFraction> in July 2022, which were recorded to prepaid expense
and other current assets &#8211; current to be amortized over the estimated project timeline of twelve months. On October 13, 2022, the
Company entered into an amendment to the Columbia Agreement (the &#8220;Columbia Amendment&#8221;), pursuant to which the parties agreed
to extend the payment schedule, whereby the third payment of $<ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" unitRef="usd" id="ixv-15368">430,825</ix:nonFraction> was due in March 2023. In August 2023, the Company paid $<ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" unitRef="usd" id="ixv-15369">100,000</ix:nonFraction>
of this balance and $<ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" unitRef="usd" id="ixv-15370">330,825</ix:nonFraction> of such payment remains unpaid as of December 31, 2023, which is included in accounts payable on the accompanying
consolidated balance sheet. The remaining payment of $<ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-15371">143,607</ix:nonFraction> is due upon completion. As of December 31, 2022, accrued expenses related
to this sponsored research agreement was $<ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15372">143,607</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022,
the Company recorded research and development expense of $<ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15373">287,218</ix:nonFraction> and $<ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15374">646,236</ix:nonFraction>, respectively, from the amortization of the prepaid research
and development fees. As of December 31, 2023, the Company estimates that this research project is approximately <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="silo:ResearchProjectEstimatePercentage" scale="-2" unitRef="pure" id="ixv-15375">90</ix:nonFraction>% complete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research Agreement with Reprocell</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 25, 2022, (the &#8220;Effective Date&#8221;),
the Company entered into a research agreement (the &#8220;Reprocell Research Agreement&#8221;) with Reprocell Europe Ltd. (&#8220;Reprocell&#8221;)
pursuant to which Reprocell shall conduct a study to assess the binding of a peptide on healthy and rheumatoid arthritis synovial tissue.
Pursuant to the Reprocell Research Agreement, the Company shall pay Reprocell a total fee of $<ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15376">41,306</ix:nonFraction> to conduct the research over a three-month
period. During the year ended December 31, 2022, pursuant to the Reprocell Research Agreement, the Company paid to Reprocell $<ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-15377">21,172</ix:nonFraction> which
was recorded as prepaid expense and other current assets &#8211; current to be amortized over the three-month period. During the year
ended December 31, 2023 and 2022, the Company recorded research and development expense of $<ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15378">19,835</ix:nonFraction> and $<ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15379">33,252</ix:nonFraction> from the amortization of
the prepaid research and development fees and the payment pf other fees. As of December 31, 2023 and 2022, accounts payable and accrued
expenses related to this research agreement were $<ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-15380">5,891</ix:nonFraction> and $<ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-15381">20,134</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research Agreements with Upperton Pharma Solutions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 16, 2023, (the &#8220;Effective Date&#8221;),
the Company entered into research agreements (the &#8220;Upperton Research Agreements&#8221;) with Upperton Pharma Solutions (&#8220;Upperton&#8221;)
pursuant to which Upperton shall conduct a study to support the development and feasibility of Prucalopride nasal solutions. Pursuant
to the Upperton Research Agreements, the Company shall pay Upperton an aggregate total fee of <ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromFeesReceived" scale="0" unitRef="gbp" id="ixv-15382">242,932</ix:nonFraction> British Pound (GBP) (approximately
$<ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromFeesReceived" scale="0" unitRef="usd" id="ixv-15383">261,462</ix:nonFraction>) to conduct the research, which will expensed over the research period. During the year ended December 31, 2023, pursuant to
the Upperton Research Agreements, the Company paid Upperton $<ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromFeesReceived" scale="0" unitRef="usd" id="ixv-15384">177,903</ix:nonFraction>. During the year ended December 31, 2023, the Company recorded research
and development expense of $<ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15385">212,428</ix:nonFraction> from the amortization of the prepaid research and development fees. As of December 31, 2023, accounts
payable and accrued expenses related to this research agreement were $<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-15386">34,525</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research Agreement with AmplifyBio</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 16, 2023, (the &#8220;Effective Date&#8221;),
the Company entered into a research agreement (the &#8220;AmplifyBio Research Agreement&#8221;) with AmplifyBio, LLC. (&#8220;AmplifyBio&#8221;)
pursuant to which AmplifyBio shall conduct a study in rates to investigate intranasal administration of a novel drug product. Pursuant
to the AmplifyBio Research Agreement, the Company shall pay AmplifyBio a total fee of $<ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15387">229,000</ix:nonFraction> to conduct the research. During the year
ended December 31, 2023, pursuant to the AmplifyBio Research Agreement, the Company paid AmplifyBio $<ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-15388">182,980</ix:nonFraction> which was recorded as prepaid
expense and other current assets &#8211; current to be amortized over the research period. During the year ended December 31, 2023, the
Company recorded research and development expense of $<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15389">182,980</ix:nonFraction> from the amortization of the prepaid research and development fees. As of
December 31, 2023, accounts payable and accrued expenses related to this research agreement were $<ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15390">0</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022,
the Company entered into other research and development agreements. In connection with such agreements, the Company recorded research
and development expenses of $<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15391">71,204</ix:nonFraction> and $<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15392">241,288</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-15393">On December 31, 2023, future amounts due under
sponsored study and research agreements between the Company and vendors is as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">2024</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-15394">725,244</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-15395">725,244</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Joint Venture Agreement with Zyl&#246; Therapeutics,
Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021 (&#8220;Effective Date&#8221;),
the Company entered into a Joint Venture Agreement (&#8220;JV Agreement&#8221;) with Zyl&#246; Therapeutics, Inc. (&#8220;ZTI&#8221;)
pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (&#8220;Joint Venture&#8221;),
to, among other things, focus on the clinical development of ketamine using ZTI&#8217;s Z-pod&#8482; technology (&#8220;Venture&#8221;).
Pursuant to the JV Agreement, the Company shall act as the manager (&#8220;Manager&#8221;) of the Joint Venture. The Joint Venture shall
terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days
of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Joint
Venture at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the JV Agreement, (A)
the Company shall contribute (1) $<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-15396">225,000</ix:nonFraction> and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute
(1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets
with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4)
reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, <ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="silo:JointVentureInterestRate" scale="-2" unitRef="pure" id="ixv-15397">51</ix:nonFraction>% of the interest in
the Joint Venture shall initially be owned by the Company and <ix:nonFraction contextRef="c221" decimals="2" format="ixt:num-dot-decimal" name="silo:JointVentureInterestRate" scale="-2" unitRef="pure" id="ixv-15398">49</ix:nonFraction>% of the interest in the Joint Venture shall initially be owned by ZTI,
subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either
party own more than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="silo:JointVentureInterestRate" scale="-2" unitRef="pure" id="ixv-15399">60</ix:nonFraction>% of the interest in the Joint Venture. As of December 31, 2023 and 2022 and as of the current date of this report,
the joint venture entity has not been formed yet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the terms of the JV Agreement,
ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#8220;License Agreement&#8221;) with Albert Einstein
College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating that the patented
technology (the &#8220;Patented Technology&#8221;) licensed to ZTI pursuant to the License Agreement is needed to advance the development
of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant to the JV Agreement,
ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development of psilocybin using ZTI&#8217;s
Z-pod&#8482; technology on the same terms and conditions set forth in the JV Agreement, which option expired <ix:nonNumeric contextRef="c220" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-15400">24</ix:nonNumeric> months after the JV Effective
Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amended Service Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2021 (&#8220;Effective Date&#8221;),
the Company entered into an Amendment Agreement (&#8220;Amended Service Agreement&#8221;) to a certain service agreement dated on September
8, 2020 with the University of Texas (&#8220;University&#8221;) at Austin whereby the University will provide advisory service and assist
the Company on identifying license and sponsored research opportunities for the Company. The Company shall pay the University $<ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForDepositsWithOtherInstitutions" scale="0" unitRef="usd" id="ixv-15401">5,000</ix:nonFraction> per
quarter starting on the Effective Date. Any cost incurred will be reimbursed only after prior written consent by the Company. The term
of the Amended Service Agreement is for 36 months unless earlier terminated by either party upon giving a written notice as defined in
the agreement. During the years ended December 31, 2023 and 2022, the Company paid $<ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-15402">25,000</ix:nonFraction> and $<ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-15403">25,000</ix:nonFraction>, respectively, related to this
agreement which in included in professional fees on the accompanying consolidated statements of operations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-14626"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 &#8211; <span style="text-decoration:underline">INCOME
TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains deferred tax assets and
liabilities that reflect the net tax effects of temporary differences between the carrying amounts of the assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. The deferred tax assets on December 31, 2023 and 2022 consist of net
operating loss carry-forwards. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of
the attainment of future taxable income. As of December 31, 2023 and 2022, the Company had not recorded a liability for any unrecognized
tax positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-15404">The items accounting for the difference between
income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2023 and 2022 was as
follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Income tax benefit at U.S. statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-15405">777,143</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-15406">820,796</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Income tax benefit &#8211; state</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd" id="ixv-15407">240,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd" id="ixv-15408">254,056</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" unitRef="usd" id="ixv-15409">29,510</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" unitRef="usd" id="ixv-15410">133,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-15411">988,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-15412">940,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-15413">The Company&#8217;s approximate net deferred tax
asset as of December 31, 2023 and 2022 was as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="text-decoration:underline">Deferred Tax Asset:</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Net operating loss carryforward</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-15414">2,538,565</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-15415">1,550,388</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Total deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-15416">2,538,565</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-15417">1,550,388</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" unitRef="usd" id="ixv-15418">2,538,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" unitRef="usd" id="ixv-15419">1,550,388</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net operating loss carryforward was approximately
$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-15420">9,231,000</ix:nonFraction> on December 31, 2023. Future utilization of the net operating loss carryforward to offset future taxable income is subject
to an annual limitation as a result of ownership changes that may occur in the future. The net operating loss carry forwards may be available
to reduce future years&#8217; taxable income. Net loss carryforwards in the amount of $<ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-15421">9,231,000</ix:nonFraction> from 2018 onwards can be carried over
indefinitely, subject to annual usage limits. Management believes that it appears more likely than not that the Company will not realize
these tax benefits due to the Company&#8217;s continuing losses for income taxes purposes. Accordingly, the Company has provided a <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="srt:FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent" scale="-2" unitRef="pure" id="ixv-15422">100</ix:nonFraction>%
valuation allowance on the deferred tax asset benefit related to the U.S. net operating loss carry forwards to reduce the asset to <ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" unitRef="usd" id="ixv-15423">zero</ix:nonFraction>.
Management will review this valuation allowance periodically and will make adjustments as necessary. In 2023, the valuation allowance
increased by $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-15424">988,177</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-14779"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 &#8211; <span style="text-decoration:underline">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Repurchase Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2024, the Board of Directors of the
Company approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $<ix:nonFraction contextRef="c234" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" unitRef="usd" id="ixv-15425">1</ix:nonFraction> million of the
Company&#8217;s common stock until March 31, 2024. From January 1, 2024 to March 23, 2024, the Company purchased <ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares" id="ixv-15426">62,607</ix:nonFraction> shares of common
stock for a cost of $<ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" unitRef="usd" id="ixv-15427">95,682</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-25</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c4" id="hidden-fact-0" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:EquitySecuritiesFvNi" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:ReceivablesNetCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="silo:PreferredStockDesignated" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="silo:PreferredStockDesignated" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:TreasuryStockPreferredValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-9" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-10" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-11" name="silo:PenaltyFromEarlyTerminationOfCD" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-12" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-13" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-14" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-15" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" sign="-" unitRef="usdPershares">1.18</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-16" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" sign="-" unitRef="usdPershares">1.71</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-17" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" unitRef="usdPershares">0.00</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-18" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" sign="-" unitRef="usdPershares">0.02</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="0" id="hidden-fact-19" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">2284240</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-20" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">3079874</ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-21" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-22" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-23" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-27" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-28" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-29" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-33" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-34" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-35" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-36" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-37" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-38" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-39" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-40" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-41" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-43" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-44" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-45" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-46" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-47" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-48" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-49" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-50" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-51" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-52" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-53" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-54" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-55" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-56" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-57" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-58" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-59" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-60" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-61" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-62" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-63" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-64" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-65" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-66" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-67" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-68" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-69" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-70" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-71" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-72" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-73" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-74" name="silo:ProvisionForDoubtfulAccountsDiscontinuedOperations" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-75" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-76" name="silo:AmortizationOfPrepaidStockbasedExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-77" name="us-gaap:RealizedInvestmentGainsLosses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-78" name="silo:EquitySharesEarnedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-79" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-80" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-81" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-82" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-83" name="us-gaap:PaymentsForRepurchaseOfOtherEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-84" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-85" name="silo:ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-86" name="us-gaap:StockIssued1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-87" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-88" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-89" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-90" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-91" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c51" id="hidden-fact-92" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-93" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-94" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-95" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-96" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-97" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-98" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-99" name="silo:AdditionsOfShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-100" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-101" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c64" id="hidden-fact-102" name="silo:AdditionsofEquitySecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c64" id="hidden-fact-103" name="silo:EquitySecuritiesSalesAtOriginalCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c66" id="hidden-fact-104" name="us-gaap:EquitySecuritiesFvNi" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-105" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-106" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-107" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-108" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-109" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-110" name="us-gaap:ReceivablesNetCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c115" id="hidden-fact-111" name="silo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xsi:nil="true"/>
<ix:nonFraction contextRef="c115" id="hidden-fact-112" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c117" id="hidden-fact-113" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c117" id="hidden-fact-114" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c117" id="hidden-fact-115" name="silo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xsi:nil="true"/>
<ix:nonFraction contextRef="c117" id="hidden-fact-116" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-117" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c122" id="hidden-fact-118" name="silo:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c122" id="hidden-fact-119" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c123" id="hidden-fact-120" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c123" id="hidden-fact-121" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c123" id="hidden-fact-122" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" xsi:nil="true"/>
<ix:nonFraction contextRef="c124" id="hidden-fact-123" name="silo:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c124" id="hidden-fact-124" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c123" id="hidden-fact-125" name="silo:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c87" id="hidden-fact-126" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c88" id="hidden-fact-127" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c225" id="hidden-fact-128" name="us-gaap:RoyaltyExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c226" id="hidden-fact-129" name="us-gaap:RoyaltyExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-130" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-131" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-132" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-133" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-15564">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-15565">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-15566">0001514183</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="silo-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-30</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">silo:HomeBistroIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">silo:HomeBistroIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">silo:HomeBistroIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">silo:AikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-30</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:NoteReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:NoteReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:AmendmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:AmendmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConversionPriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-26</xbrli:startDate>
    <xbrli:endDate>2022-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-26</xbrli:startDate>
    <xbrli:endDate>2022-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-28</xbrli:startDate>
    <xbrli:endDate>2022-09-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-29</xbrli:startDate>
    <xbrli:endDate>2022-09-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-29</xbrli:startDate>
    <xbrli:endDate>2022-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-26</xbrli:startDate>
    <xbrli:endDate>2022-01-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-29</xbrli:startDate>
    <xbrli:endDate>2021-12-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-27</xbrli:startDate>
    <xbrli:endDate>2022-01-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-31</xbrli:startDate>
    <xbrli:endDate>2022-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:IncentiveStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-31</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4i1C0FowDB+JJ6vZGU2Zb4gNMIwDsAMZiEWauoJ3WqFTBJuAnXEEK8HERTRlnFgqdFP3tTsASEsgw90kSc27NBp9xZy8aFids2zNA0ooYt/rCwJKM1RAKPAP57tvAAHxLwWFZJ9rV72hQ==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-31</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:CustomerConcentrationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:CustomerConcentrationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">silo:VendorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">silo:VendorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2022-10-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MrWeisblumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MrWeisblumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MrWeisblumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2022-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DanielRyweckMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-27</xbrli:startDate>
    <xbrli:endDate>2022-01-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-01-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">silo:ThirdAmendmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-30</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">silo:ExtensionFeeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-01</xbrli:startDate>
    <xbrli:endDate>2023-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-01</xbrli:startDate>
    <xbrli:endDate>2023-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-31</xbrli:startDate>
    <xbrli:endDate>2023-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-01</xbrli:startDate>
    <xbrli:endDate>2023-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-01</xbrli:startDate>
    <xbrli:endDate>2023-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-01</xbrli:startDate>
    <xbrli:endDate>2022-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-01-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesMConvertiblePreferredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-31</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silo:FirstPaymentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-01</xbrli:startDate>
    <xbrli:endDate>2021-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silo:SecondPaymentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2022-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-13</xbrli:startDate>
    <xbrli:endDate>2022-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-01</xbrli:startDate>
    <xbrli:endDate>2023-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithReprocellMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2022-10-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithReprocellMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithReprocellMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithReprocellMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithReprocellMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementsWithUppertonPharmaSolutionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UppertonResearchAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementsWithUppertonPharmaSolutionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UppertonResearchAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AmplifyBioResearchAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AmplifyBioResearchAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithAmplifyBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithAmplifyBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithAmplifyBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">silo:JVAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ZylTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AmendedServiceAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-10</xbrli:startDate>
    <xbrli:endDate>2021-09-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AmendedServiceAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AmendedServiceAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="gbp">
  <xbrli:measure>iso4217:GBP</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea020195701ex4-1_silophar.htm
<DESCRIPTION>DESCRIPTION OF THE REGISTRANT'S SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
PURSUANT TO SECTION 12 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, Silo Pharma, Inc. (&ldquo;the Company&rdquo;) had one class of security registered under Section&nbsp;12(b) of
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), its common stock, par value $0.0001 per share (the
&ldquo;Common Stock&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of the common stock, par value $0.0001 per share (&ldquo;Common Stock&rdquo;) of Silo Pharma, Inc., a Nevada corporation
(the &ldquo;Company&rdquo;) is a summary and does not purport to be complete. It is<B>&nbsp;</B>subject to and qualified in its entirety
by reference to the Company&rsquo;s Articles of Incorporation, as amended (the &ldquo;Articles of Incorporation&rdquo;), and the Company&rsquo;s
Bylaws the &ldquo;Bylaws&rdquo;), each of which was filed as an exhibit to our Current Report on Form 8-K filed with the U.S. Securities
and Exchange Commission on December 20, 2023 and incorporated herein by reference. The Company encourages you to<B>&nbsp;</B>read its
Articles of Incorporation, Bylaws, and the applicable provisions of the&nbsp;Nevada Revised Statutes for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Authorized
Capital Shares</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s authorized capital shares consist of 100,000,000 shares of Common Stock, and 5,000,000 shares of preferred stock, $0.0001
par value per share (&ldquo;Preferred Stock&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in these Articles of Incorporation or required by applicable law, the holders of Common Stock shall be entitled
to vote on each matter on which the stockholders of the corporation shall be entitled to vote, and each holder of Common Stock shall
be entitled to one vote for each share of such stock held by him. Notwithstanding the foregoing, except as otherwise required by law,
holders of Common Stock shall not be entitled to vote on any amendment to these Articles of Incorporation (including any resolution relating
to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders
of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to
vote thereon pursuant to these Articles of Incorporation (including any resolution adopted relating to any series of Preferred Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors (the &ldquo;Board of Directors&rdquo; or &ldquo;Board&rdquo;) of the corporation may cause dividends to be paid to
the holders of shares of Common Stock out of funds legally available for the payment of dividends by declaring an amount per share as
a dividend. When and as dividends are declared on the Common Stock, whether payable in cash, in property or in shares of stock or other
securities of the corporation, the holders of Common Stock shall be entitled to share ratably according to the number of shares of Common
Stock held by them, in such dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of any resolution or resolutions adopted by the Board of Directors pursuant to the rights of any holders of preferred stock,
in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the corporation, the holders of
Common Stock shall be entitled to share ratably, according to the number of shares of Common Stock held by them, in all remaining assets
of the corporation available for distribution to its stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 25, 2024, we have options to purchase up to 28,849 shares of our common stock issued and outstanding at a weighted average exercise
price of $7.28 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 25, 2024, we have warrants to purchase up to 404,580 shares of our common stock issued and outstanding at an exercise price
between $6.25 to $17.50 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Provisions of our Certificate of Incorporation and our Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a summary of the provisions of the Company&rsquo;s Articles of Incorporation and Bylaws that could have the effect of
delaying or preventing a change in control of the Company. The following description is only a summary, and it is qualified by reference
to the Articles of Incorporation, Bylaws and relevant provisions of the Nevada Revised Statutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
of Directors Vacancies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws authorize only its board of directors to fill vacant directorships. In addition, the number of directors constituting the Company&rsquo;s
board of directors may be set only by resolution of the majority of the incumbent directors.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Special
Meeting of Stockholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws provide that special meeting of our stockholders may be called by our President or our board of directors and Chairman of the
Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
but Unissued Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized but unissued shares of Common Stock and Preferred Stock are available for future issuance without shareholder approval and
may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions
and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and Preferred Stock could render more
difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indemnification</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
78.7502(1) of the Nevada Revised Statutes provides that a corporation may indemnify any person who was or is a party, or is threatened
to be made a party, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(except in an action brought by or on behalf of the corporation) if that person is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation
or enterprise, against expenses, including attorneys&rsquo; fees, judgments, fines and amounts paid in settlement actually and reasonably
incurred by that person in connection with such action, suit or proceeding, if that person acted in good faith and in a manner which
that person reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal
action or proceedings, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding
by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, alone, does not create a presumption
that the person did not act in good faith and in a manner which the person reasonably believed to be in, or not opposed to, the best
interests of the corporation, and that, with respect to any criminal action or proceeding, the person had reasonable cause to believe
his action was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
78.7502(2) of the Nevada Revised Statutes provides that a corporation may indemnify any person who was or is a party or is threatened
to be made a party to any threatened, pending or completed action or suit brought by or on behalf of the corporation to procure a judgment
in its favor because the person acted in any of the capacities set forth above, against expenses, including amounts paid in settlement
and attorneys&rsquo; fees, actually and reasonably incurred by that person in connection with the defense or settlement of such action
or suit, if the person acted in accordance with the standard set forth above, except that no indemnification may be made in respect of
any claim, issue or matter as to which such person shall have been adjudged by a court of competent jurisdiction after exhaustion of
all appeals therefrom to be liable to the corporation or for amounts paid in settlement to the corporation unless and only to the extent
that the court in which such action or suit was brought or other court of competent jurisdiction determines that, in view of all the
circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
78.7502(3) of the Nevada Revised Statutes further provides that, to the extent a director or officer of a corporation has been successful
on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections 1 and 2 thereof, or in the defense
of any claim, issue or matter therein, that person shall be indemnified by the corporation against expenses (including attorneys&rsquo;
fees) actually and reasonably incurred by that person in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
78.751 of the Nevada Revised Statutes provides that unless indemnification is ordered by a court, the determination to provide indemnification
must be made by the shareholders, by a majority vote of a quorum of the board of directors who were not parties to the action, suit or
proceeding, or in specified circumstances by independent legal counsel in a written opinion. In addition, the articles of incorporation,
bylaws or an agreement made by the corporation may provide for the payment of the expenses of a director or officer of the expenses of
defending an action as incurred upon receipt of an undertaking to repay the amount if it is ultimately determined by a court of competent
jurisdiction that the person is not entitled to indemnification. Section 78.751 of the Nevada Revised Statutes further provides that
the indemnification provided for therein shall not be deemed exclusive of any other rights to which the indemnified party may be entitled
and that the scope of indemnification shall continue as to directors, officers, employees or agents who have ceased to hold such positions,
and to their heirs, executors and administrators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
78.752 of the Nevada Revised Statutes provides that a corporation may purchase and maintain insurance on behalf of a director, officer,
employee or agent of the corporation against any liability asserted against him or incurred by him in any such capacity or arising out
of his status as such whether or not the corporation would have the authority to indemnify him against such liabilities and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles of Incorporation and Bylaws provide that the Company shall, to the fullest extent permitted by the provisions of the Nevada
Revised Statutes, indemnify any and all persons whom it shall have the power to indemnify under the Nevada Revised Statutes.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
Agent and Registrar</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
transfer agent and registrar is&nbsp;West Coast Stock Transfer, Inc. whose address is&nbsp;721 N. Vulcan Avenue, Suite 106, Encinitas,
CA 92024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is quoted the Nasdaq Capital Market under the symbol &ldquo;SILO.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ea020195701ex21-1_silophar.htm
<DESCRIPTION>SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Subsidiaries of Silo Pharma, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding: 0pt; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0pt; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction&nbsp;of&nbsp;Incorporation/Formation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Silo Pharma, Inc.</FONT></TD>
    <TD STYLE="padding: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Florida</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ea020195701ex23-1_silophar.htm
<DESCRIPTION>CONSENT ON INDEPENDENT REGISTERED ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in this Registration Statement on Form S-3 (File No. 333-276658) of our report dated
March 25, 2024, relating to the consolidated financial statements of Silo Pharma, Inc. as of and for the years ended December 31, 2023
and 2022, and to the reference to our firm under the heading &ldquo;Experts&rdquo; in the prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Salberg &amp; Company, P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SALBERG
&amp; COMPANY, P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boca
Raton, Florida</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2024</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ea020195701ex31-1_silophar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>Certification of Chief Executive Officer
of Silo Pharma, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Eric Weisblum, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this Annual Report on Form 10-K of Silo Pharma, Inc.;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures, and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 25, 2024</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eric Weisblum</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Weisblum</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President and Chairman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ea020195701ex31-2_silophar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Certification of Chief Financial Officer of
Silo Pharma, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Daniel Ryweck, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this Annual Report on Form 10-K of Silo Pharma, Inc.;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures, and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left">a.</TD>
    <TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 25, 2024</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Daniel Ryweck</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Ryweck</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ea020195701ex32-1_silophar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statement
of Chief Executive Officer and Chief Financial Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 1350 of Title 18 of the United States Code</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned,
Eric Weisblum, the Chief Executive Officer and Principal Executive Officer and Daniel Ryweck, the Chief Financial Officer and Principal
Financial and Accounting Officer, of Silo Pharma, Inc. (the &ldquo;Company&rdquo;), each hereby certifies that based on the undersigned&rsquo;s
knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company&rsquo;s Annual Report on Form 10-K for the period ended December 31, 2023 (the &ldquo;Report&rdquo;)
                                            fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
                                            Act of 1934; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in the Report fairly presents, in all material respects, the financial
                                            condition and results of operations of the Company.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 25, 2024</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/<I>s/
    Eric Weisblum</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Weisblum</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer<BR>
    (<I>Principal Executive Officer</I>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 25, 2024</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Daniel
    Ryweck Daniel Ryweck</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer <BR>
    (<I>Principal Financial and Accounting Officer</I>)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>ea020195701ex97-1_silophar.htm
<DESCRIPTION>SILO PHARMA, INC. CLAWBACK POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
97.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SILO
PHARMA, INC.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CLAWBACK
POLICY</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Purpose
                                            and Scope</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of Silo Pharma, Inc. (the &ldquo;<B>Company</B>&rdquo;) believes that it is in the
best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and
that reinforces the Company&rsquo;s pay-for-performance compensation philosophy. The Board has therefore adopted this Clawback Policy
(this &ldquo;<B>Policy</B>&rdquo;), which provides for the recovery of erroneously awarded Compensation in the event of a Triggering
Event (as defined below). Unless otherwise defined herein, the capitalized terms have the meanings set forth under &ldquo;XIII. Definitions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>II.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Administration</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 of the
Exchange Act, Nasdaq Listing Rule 5608 and other regulations, rules and guidance of the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;)
thereunder, and related securities regulations and regulations of the stock exchange or association on which Company&rsquo;s common shares
are listed (collectively, the &ldquo;<B>Listing Standards</B>&rdquo;). This Policy shall be administered by the Compensation Committee
of the Board (the &ldquo;<B>Committee</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
determinations made by the Committee shall be final and binding. In addition, the Company shall file all disclosures with respect to
this Policy in accordance with the Listing Standards. The Committee hereby has the power and authority to enforce the terms and conditions
of this Policy and to use any and all of the Company&rsquo;s resources it deems appropriate to recoup any excess Compensation subject
to this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>III.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Covered
                                            Executives</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to the Company&rsquo;s current and former Covered Executives, as determined by the Committee in accordance with the Listing
Standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Events
                                            That Trigger Recoupment Under This Policy</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board or Committee will be required to recoup any excess Compensation received by any Covered Executive during the three (3) completed
fiscal years (together with any interim stub fiscal year period(s) of less than nine (9) months resulting from the Company&rsquo;s transition
to different fiscal year measurement dates) immediately preceding the date the Company is deemed (as determined pursuant to the immediately
following sentence) to be required to prepare a Covered Accounting Restatement (the &ldquo;<B>Three-Year Recovery Period</B>&rdquo;)
irrespective of any fault, misconduct or responsibility of such Covered Executive for the Covered Accounting Restatement. For purposes
of the immediately preceding sentence, the Company is deemed to be required to prepare a Covered Accounting Restatement on the earlier
of (A) the date upon which the Board or applicable committee of the Board, or the officer or officers of the Company authorized to take
such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare
a Covered Accounting Restatement; or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare
a Covered Accounting Restatement (each a &ldquo;<B>Triggering Event</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Excess
                                            Compensation: Amount Subject to Recovery</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of Compensation to be recovered shall be the excess of the Compensation received by the Covered Executive over the amount of Compensation
which would have been received by the Covered Executive had the amount of such Compensation been calculated based on the restated amounts,
as determined by the Committee. For purposes of this Policy, Compensation shall be deemed &ldquo;received&rdquo;, either wholly or in
part, in the fiscal year during which any applicable Financial Reporting Measure is attained, even if the payment, vesting or grant of
such Compensation occurs after the end of such fiscal year. Amounts required to be recouped under this Policy shall be calculated on
a pre-tax basis. The date of receipt of the Compensation depends upon the terms of the award of such Compensation. For example:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the <I>grant</I> of an award of Compensation is based, either wholly or in part, on the satisfaction
                                            of a Financial Reporting Measure performance goal, then the award would be deemed received
                                            in the fiscal period when that measure was <I>satisfied</I>;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the <I>vesting</I> of an equity award of Compensation occurs <I>only </I>upon the satisfaction
                                            of a Financial Reporting Measure performance condition, then the award would be deemed received
                                            in the fiscal period when it <I>vests</I>;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the <I>earning</I> of a non-equity incentive plan award of Compensation is based on the satisfaction
                                            of the relevant Financial Reporting Measure performance goal, then the non-equity incentive
                                            plan award will be deemed received in the fiscal year in which that performance goal is <I>satisfied</I>;
                                            and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the <I>earning</I> of a cash award of Compensation is based on the satisfaction of a Financial
                                            Reporting Measure performance goal, then the cash award will be deemed received in the fiscal
                                            period when that measure is <I>satisfied</I>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is specifically understood that, to the extent that the impact of the Covered Accounting Restatement on the amount of Compensation received
cannot be calculated directly from the information in the Covered Accounting Restatement (e.g., if such restatement&rsquo;s impact on
the Company&rsquo;s share price is not clear), then such excess amount of Compensation shall be determined based on the Committee&rsquo;s
reasonable estimate of the effect of the Covered Accounting Restatement on the share price or total shareholder return upon which the
Compensation was received. The Company shall maintain documentation for the determination of such excess amount and provide such documentation
to the Nasdaq Stock Market (&ldquo;<B>Nasdaq</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VI.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Method
                                            of Recovery</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee shall determine, in its sole discretion, the methods for recovering excess Compensation hereunder, which methods may include,
without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
                                            reimbursement of cash Compensation previously paid;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
                                            recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other
                                            disposition of any equity-based awards;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">offsetting
                                            the recouped amount from any compensation otherwise owed by the Company to the Covered Executive;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancelling
                                            outstanding vested or unvested equity awards; and/or</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">taking
                                            any other remedial and recovery action permitted by law, as determined by the Committee.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything in this Section VI, and subject to applicable law, the Committee may cause recoupment under this Policy from any amount of Compensation
approved, awarded, granted, paid, or payable to any Covered Executive prior to, on, or following the Effective Date (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VII.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Impracticability</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee shall recover any excess Compensation in accordance with this Policy unless such recovery would be impracticable, as determined
by the Committee in accordance with the Listing Standards. It is specifically understood that recovery shall only be deemed impractical
if (A) the direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered (before concluding
that it would be impracticable to recover any amount of erroneously awarded Compensation based on the expense of enforcement, the Committee
shall make a reasonable attempt to recover such erroneously awarded Compensation, document such reasonable attempt(s) to recover, and
provide that documentation to Nasdaq); (B) recovery would violate home country law where that law was adopted prior to the November 28,
2022 (before concluding that it would be impracticable to recover any amount of erroneously awarded Compensation based on violation of
home country law, the Committee shall obtain an opinion of home country counsel, acceptable to the applicable national securities exchange
or association on which Company&rsquo;s common shares are trading, that recovery would result in such a violation, and must provide such
opinion to the exchange or association); or (C) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits
are broadly available to employees of the registrant, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a), and
the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VIII.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Other
                                            Recoupment Rights; Acknowledgement</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee may require that any employment agreement, equity award agreement, or similar agreement entered into on or after the Effective
Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this
Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that
may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar
agreement and any other legal remedies available to the Company. The Company shall provide notice and seek written acknowledgement of
this Policy from each Covered Executive; <I>provided</I>, that the failure to provide such notice or obtain such acknowledgement shall
have no impact on the applicability or enforceability of this Policy to, or against, any Covered Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IX.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>No
                                            Indemnification of Covered Executives</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
any right to indemnification under any plan, policy or agreement of the Company or any of its affiliates, the Company shall not indemnify
any Covered Executives against the loss of any excess Compensation. In addition, the Company shall be prohibited from paying or reimbursing
a Covered Executive for premiums of any third-party insurance purchased to fund any potential recovery obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Indemnification</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent allowable pursuant to applicable law, each member of the Board or the Committee and any officer or other employee to whom
authority to administer any component of this Policy is designated shall be indemnified and held harmless by the Company from any loss,
cost, liability, or expense that may be imposed upon or reasonably incurred by such member in connection with or resulting from any claim,
action, suit, or proceeding to which he or she may be a party or in which he or she may be a party or in which he or she may be involved
by reason of any action or failure to act pursuant to this Policy and against and from any and all amounts paid by him or her in satisfaction
of judgment in such action, suit, or proceeding against him or her; <I>provided</I>, <I>however</I>, that he or she gives the Company
an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own
behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such individuals
may be entitled pursuant to the Company&rsquo;s Articles of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that
the Company may have to indemnify them or hold them harmless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XI.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Effective
                                            Date</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be effective as of the date the Policy is adopted by the Board (the &ldquo;<B>Board Adoption Date</B>&rdquo;). This Policy
shall apply to any Compensation that is received by Covered Executives on or after the October 2, 2023 (the &ldquo;<B>Effective Date</B>&rdquo;),
even if such Compensation was approved, awarded, granted, or paid to Covered Executives prior to the Effective Date or the Board Adoption
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XII.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amendment
                                            and Termination; Interpretation</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend this Policy from time to time in its sole discretion and shall amend this Policy as it deems necessary to reflect and
comply with further regulations, rules and guidance of the SEC and Listing Standards. The Board may terminate this Policy at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for
the administration of this Policy. This Policy is designed and intended to be interpreted in a manner that is consistent with the requirements
of the Listing Standards. To the extent there is any inconsistency between this Policy and such regulations, rules and guidance, such
regulations, rules and guidance shall control, and this Policy shall be deemed amended to incorporate such regulations, rules and guidance
until or unless the Board or the Committee expressly determine otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be applicable, binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators
or other legal representatives to the fullest extent of the law. For the avoidance of doubt, this Policy shall be in addition to (and
not in substitution of) any other clawback policy of the Company in effect from time to time or applicable to any Covered Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XIII.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Definitions</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Board</B>&rdquo;
                                            means the Board of Directors of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company</B>&rdquo;
                                            means Silo Pharma, Inc., a Delaware corporation, and its subsidiaries and their successors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Compensation</B>&rdquo;
                                            means any compensation which was approved, awarded or granted to, or earned by a Covered
                                            Executive (A) while the Company had a class of securities listed on a national securities
                                            exchange or a national securities association, and (B) following on or after the Effective
                                            Date (including any award under any short-term or long-term incentive compensation plan of
                                            the Company, including any other short-term or long-term cash or equity incentive award or
                                            any other payment) that, in each case, is granted, earned, or vested based wholly or in part
                                            upon the attainment of any Financial Reporting Measure (i.e., any measures that are determined
                                            and presented in accordance with the accounting principles used in preparing the Company&rsquo;s
                                            financial statements, and any measure that is derived wholly or in part from such measures,
                                            including share price and total shareholder return). Compensation may include (but is not
                                            limited to) any of the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
                                            bonuses and other short- and long-term cash incentives;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
                                            options;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
                                            appreciation rights;</FONT></TD>
</TR></TABLE>

<P STYLE="text-indent: 0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
                                            shares;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
                                            share units;</FONT></TD>
</TR></TABLE>

<P STYLE="text-indent: 0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
                                            shares; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
                                            units.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Covered
                                            Accounting Restatement</B>&rdquo; means any accounting restatement of the Company&rsquo;s
                                            financial statements due to the Company&rsquo;s material noncompliance with any financial
                                            reporting requirement under U.S. securities laws. A Covered Accounting Restatement includes
                                            any required accounting restatement to correct an error in previously issued financial statements
                                            that is material to the previously issued financial statements (commonly referred to as &ldquo;Big
                                            R&rdquo; restatements) or that would result in a material misstatement if the error were
                                            corrected in the current period or left uncorrected in the current period (commonly referred
                                            to as &ldquo;little r&rdquo; restatements). A Covered Accounting Restatement does not include
                                            (A) an out-of-period adjustment when the error is immaterial to the previously issued financial
                                            statements, and the correction of the error is also immaterial to the current period; (B)
                                            a retrospective application of a change in accounting principle; (C) a retrospective revision
                                            to reportable segment information due to a change in the structure of an issuer&rsquo;s internal
                                            organization; (D) retrospective reclassification due to a discontinued operation; (E) a retrospective
                                            application of a change in reporting entity, such as from a reorganization of entities under
                                            common control; or (F) a retrospective revision for stock splits, reverse stock splits, stock
                                            dividends or other changes in capital structure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Covered
                                            Executive</B>&rdquo; means any person who:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
                                            received applicable Compensation:</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the Three-Year Recovery Period; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
                                            beginning service as an Executive Officer; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
                                            served as an Executive Officer at any time during the performance period for such Compensation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exchange
                                            Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Executive
                                            Officer(s)</B>&rdquo; means an &ldquo;executive officer&rdquo; as defined in Exchange Act
                                            Rule 10D-1(d) and the Listing Standards and includes any person who is the Company&rsquo;s
                                            president, principal financial officer, principal accounting officer (or if there is no such
                                            accounting officer, the controller), any vice president of the issuer in charge of a principal
                                            business unit, division, or function (such as sales, administration, or finance), any other
                                            officer who performs a policy-making function, or any other person who performs similar policy-making
                                            functions for the Company (with any executive officers of the Company&rsquo;s parent(s) or
                                            subsidiaries being deemed Covered Executives of the Company if they perform such policy making
                                            functions for the Company), and such other senior executives or employees who may from time
                                            to time be deemed subject to the Policy by the Board in its sole discretion. All executive
                                            officers of the Company identified by the Board pursuant to 17 CFR 229.401(b) shall be deemed
                                            &ldquo;Executive Officers.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Financial
                                            Reporting Measure(s)</B>&rdquo; means any measures that are determined and presented in accordance
                                            with the accounting principles used in preparing the Company&rsquo;s financial statements,
                                            and any measure that is derived wholly or in part from such measures, including share price
                                            and total shareholder return, including, but not limited to, financial reporting measures
                                            including &ldquo;non-GAAP financial measures&rdquo; for purposes of Exchange Act Regulation
                                            G and 17 CFR 229.10, as well other measures, metrics and ratios that are not non-GAAP measures,
                                            like same store sales. Financial Reporting Measures may or may not be included in a filing
                                            with the SEC and may be presented outside the Company&rsquo;s financial statements, such
                                            as in Management&rsquo;s Discussion and Analysis of Financial Conditions and Results of Operations
                                            or the performance graph. Financial Reporting Measures include, without limitation, any of
                                            the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
share price;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
shareholder return;</FONT></TD>
</TR></TABLE>

<P STYLE="text-indent: 0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues;</FONT></TD>
</TR></TABLE>

<P STYLE="text-indent: 0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
income;</FONT></TD>
</TR></TABLE>

<P STYLE="text-indent: 0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
before interest, taxes, depreciation, and amortization (EBITDA);</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funds
from operations;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-left: 0.25in; text-indent: 0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
measures such as working capital or operating cash flow;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
measures such as return on invested capital or return on assets; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
measures such as earnings per share.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #K G # 2(  A$! Q$!_\0
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M-_\ F<=#W#_AIO\ :5_Z.+^.G_AVO'W_ ,O:/^&F_P!I7_HXOXZ?^':\??\
MR]KP^C!_S^7\Z7]@9!_T(LB_\,F3?_.O^NX_]9N)/^BBXA_\2#/?_GP>X?\
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MJ_D/_0AR/_PR9/\ _.H/]9N)/^BCXA_\2#/?_GP>Y?\ #3?[2O\ T<7\=/\
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MQ=/B//<10S''T<IQ4\RQU)SSB4'0K9A6K0P\80C25'!4IPC>;G+;'[3?[2Q
MS^T5\=1CL?BWX]/89Z:Z>"1GK2_\--_M*_\ 1Q?QT_\ #M>/O_E[7ARC@?0?
MJ*6OJ_\ 5_(?^A#D>O\ U),GUOZY7U=SXY<3<26_Y*+B'1+_ )J#/=%\LX^7
MG;N>X?\ #3?[2O\ T<7\=/\ P[7C[_Y>T?\ #3?[2O\ T<7\=/\ P[7C[_Y>
MUX?02 ,D@<@<D#D\ ?B>!ZGBC_5_(?\ H0Y'_P"&3)__ )U>3^X/]9N)/^BB
MXA_\2#/?_GQ_7D>X?\--_M*_]'%_'3_P[7C[_P"7M'_#3?[2O_1Q?QT_\.UX
M^_\ E[7ARLKC*,KC)7*D,,J<$94D9!X(['BD#H69 ZEU +(&!90>A9<Y /8D
M<]J/]7\A_P"A#D??_D29/_\ .H/]9N)-/^,CXAUV_P",@SW7?;_A9UV>W9]F
M>Y?\--_M*_\ 1Q?QT_\ #M>/O_E[2']IO]I;M^T5\=#_ -U:\>\>_.N\_P">
M17B% YR!R5."!R01C@CL>1QUYH609!?_ )$.1>?_  B9-Y_]2KR!\3<26LN(
MN(K[_P#)09[Z_P#0XZZ?>?9/Q(_:,_:'LO"/P'N+3X^_&JTN-4^%.H7VJ36O
MQ1\;V\NIWR?%GXFZ>E[J$L6MJUY>+865I9)<W!DF6SL[6V#B"WA1?)O^&F_V
ME3S_ ,-%?'4?7XM^/2?S&NU4^*)_XHS]GC_LCVI?I\9/BM7C5>7D^0Y%/ 4Y
M2R/))2>)S)-RR;*9.T<VS6,5>662TC&,8K71*,4E&,8Q];.^).(H9C4C'B'/
MXQ^J92^6.?9W&*<LDRB<G:.;I7E*4I2=M92E)WE*4I>X?\--_M*_]'%_'3_P
M[7C[_P"7M'_#3?[2O_1Q?QT_\.UX^_\ E[7A_J>PZGT[\^G'- Y&000>A!R/
MS'%>I_J_D/\ T(<C_P##)D__ ,ZCR?\ 6;B3_HHN(?\ Q(,]]/\ H<=SW#_A
MIO\ :5_Z.+^.G_AVO'W_ ,O:/^&F_P!I7_HXOXZ?^':\??\ R]KP\<]._P"'
M\Z*/]7\A_P"A#D?7_F29,]G9[96^N@?ZS<2?]%%Q#_XD&>__ #X/</\ AIO]
MI7_HXOXZ?^':\??_ "]H_P"&F_VE?^CBOCI_X=KQ]_\ +VO#Z*/[ R!;Y#D?
M_ADR=?\ O*#_ %FXD_Z*/B'_ ,2#/?\ Y\'V'\0/VC?VB+3PE\&;BT^/WQKM
MKC4? -[=ZC/;_%+QO!+?W2^*=8@6ZO9(M;5[JY6".. 33L\@A1(PVQ54>6?\
M--_M*_\ 1Q7QT_\ #M>/O_E[6;\2/^1,^!A['X<WV/\ PK];_P :\AKRLER'
M(YY="4LCR63^M9FKRR;*9NRS?-81C>>62=HQC&$%?W8QC"*2C%+U\]XDXBAF
M4U'B'/XKZIE+Y8Y]G4$G+)<GG)VAFT5><YRE)M7E*4I2<IRE*7N'_#3?[2O_
M $<7\=/_  [7C[_Y>T?\--_M*_\ 1Q?QT_\ #M>/O_E[7AP(.<$'!P<<X/H<
M=#[4M>K_ &!D/_0BR+_PR9-\O^95UZ=^ESR?]9N)-O\ 6+B*][?\E!GN_;_D
M<'N'_#3?[2O_ $<7\=/_  [7C[_Y>T?\--_M*_\ 1Q?QT_\ #M>/O_E[7A__
M .O_ #_AU/:BC_5_(?\ H0Y'_P"&3)__ )U"_P!9N)/^BCXA_P#$@SWM?_H<
M]M3VFZ_:<_:66VN&'[1GQU!$$I!7XM^/@P(C8@@C7<@@\@]C7MG[0?[1?[0F
MD_%[Q-I^D_'KXT:780:/\.)(;'3OBCXVLK.&2\^%?@>_NY([6VUJ.&.2[O;J
MXO+ED0-/=W$]S*7FFD=OB*[_ ./2Z_Z]YO\ T6U>]?M)_P#):_%?_8%^&'_J
MH? ->3B,AR)9WE<?[#R51EE^=.4%D^4QC*4:F3<LI166*,G'FERMIN*E))Q4
MI*7K4.(^(I9'FDGQ#Q!S+,LEC&3SW.G)1E2SIRBI2S9RBI.$.91E%2<8\RER
MQY6_\--_M*]_VB_CI_X=OQZ?_<[1_P --_M*_P#1Q?QT_P##M>/O_E[7AQ('
M)(  )R2 ,#KUI1SC'.>GOFO6_P!7\AM?^P<CMW_L/)[?^JH\G_6;B3_HHN(=
M%_T4&>[+37_A8T_ ]P_X:;_:5_Z.+^.G_AVO'W_R]H_X:;_:5_Z.+^.G_AVO
M'W_R]KP_!]#_ )&?Y<_2BC^P,@_Z$61?^&3)O_G5OY;KJD/_ %FXD_Z*+B+_
M ,2#/?\ Y\>3/</^&F_VE?\ HXOXZ?\ AVO'W_R]J&?]IS]I<0S$?M%?'4$1
MR88?%KQ[D84D$?\ $^!S^H_"O%:BG_U$W_7*3_T T?ZOY"T_^$+(]GJLER?3
M1OIE?X/\P7$W$C:_XR/B'=.W^L&>.Z5GK?.-M#[+^.?[1O[0^E_%WQM8:9\?
M?C7IMA;W&@BVL;'XI>-[.TMQ)X2\/SR""VM];CAB$D\LL\@1%W2R22-EY&8^
M4_\ #3?[2O\ T<7\=/\ P[7C[_Y>U1_:"_Y+/X\_Z^O#_P#ZAOARO':\S)<A
MR*6391*61Y+*4LLP,I2GDV43E*4L+1<I2E+*W)MMMMMMMW;DVVSUL_XCXBIY
M[G<(<0Y_&$,VS",8QS[.X1C&.*JI*,8YO&,8I62BE&,4K)):+W#_ (:;_:5_
MZ.+^.G_AVO'W_P O:/\ AIO]I7_HXOXZ?^':\??_ "]KP_\ S_G\J*]/_5_(
M?^A%D7_ADR;_ .=?FOO7='D?ZS<2?]%%Q#_XD&>^G_0X\T>X?\--_M*_]'%_
M'3_P[7C[_P"7M'_#3?[2O_1Q?QT_\.UX^_\ E[7AYX_+/K_*D!!Y!!'J""/S
M'Z^E'^K^0_\ 0AR/_P ,F3^G_0J#_6;B3_HH^(?_ !(,]]/^AQW_ *VO[C_P
MTW^TK_T<7\=/_#M>/O\ Y>T?\--_M*_]'%_'3_P[7C[_ .7M>'T=,^WY_EUH
M_P!7\A_Z$61_^&3)O7_H5=M?37;4/]9N)%OQ%Q"O7B#/?_GP>X?\--_M*CD?
MM%?'7\/BUX^S_P"GT5]U?\$U_CM\<?&/[9OPD\/>+_C3\6?%?A^__P"$J^W:
M#XE^(OB[7=&O?(\+ZI/!]KTO4]7NK*X\F>-)8C+ _ER(KKAE!'Y2U^@O_!+3
M_D^;X,_3QA_ZB>JU\GQYD>24N".+JE+)<FI5:?#><SIU:64952JTYPP%:4)T
MZE/+85*<XR2E&<)PG%I.,HM)K[?PSXAX@K^(W E&MG^>UJ%7B[A^G5HUL\SF
MM1JTYYGAXSIU:5;-:E*I"<6XSA4ISA*+:E"2;3\C^*.E:?KW[<7Q'T+5K=;S
M2]:_:M\7Z3J=HY*K=:?J'Q7U"TO+9BI#!9K>62(E2& ;((/-?;_Q/_9^^&?B
M74_VH/#-U^S?:? /P_\ !;QEX;T+X8?%KPY+XNTF/QG>:QX\TOPPOA34[;Q?
M>WNB^)M0UK2-0GO],ET*&-K.:T:Y>.6V9E7\[_VE;JYL_P!J#]H*\L[B:UN[
M3X^?%6YM;FWD:*>VN8/'^N20SP2H0\4T4JJ\<B$,CJ&!!%<'XH^*GQ/\;-IK
M>,OB/XZ\5?V//'=Z0GB#Q3K&JQ:9=0N)(;JR@N[J2""YBD :.X2(31G/ENN3
MGEJ\.9SG&$X1QN69U_9=+"<+Y-0ERULUA6HXE4\BQRQF&P^#Q5'+L55J86A5
MRRI#-:&)H0PV)KU(4Y58T5'HI<49#D>/XWP&;9#_ &Q5QO%^>XB*E0R>5&OA
M?;<29>\!BL5CL'7S/"4:6+Q-'-Z57)L1A,1+%8*A3G44)U&?>/C?]B[X;RZQ
M\;O#OP5U7XS>.=9^"/QF^%/PFURRU+1O#MQ>WL/C3Q%J.C^*O$UOIN@:?)>Q
M:-H<-O;IIVHW26L;7:W4VHVT=LT4:^U>'?\ @FS\+KWXD1>!KGQ#\=/%MAK7
MQ^^)'PCA\0_#S3/!5]IOPMT?X?R6\5KJ7QCO-0LG-CJWBY9GO]$.G6-G:-ID
M;3I:W4ZF%_R7T_XA>/\ 2-:UGQ'I'CKQAI.O^(Q./$&MZ7XCU;3M5US[2_F7
M!U:]L[J&>_,SY=S<O(Q8E@02<^Y?#']KKXK_  GM=4D\.VW@_4O%FIZWJGB1
M?B1XET%M9\?V.OZM9QV,^L1:Y->(E_J%O"@;3[G5[74)+"7#VIC(&/.S;AGQ
M+IX)T\IXQEBZT</AZ5-UJWU3$U,34PV%IXO%8C&U,#.G'#X;&T:^-PU##8?Z
MQ6HXEX/$*5.#<_4R;BWPGJY@JV=\"1P5"6-Q&(J_5X/'86G@J6,QE;"8+"Y?
M3Q].K+$XK UZ&7XO$XO%_5Z-;"PQ^&:JS<(=;^S#^S=X5^,?C'XE:?XR?X@0
M^#/ 6O:3X<EUSP1<>&$U&SO_ !!XSF\*Z,=3L];L=1N=0:[2%YHK;1=-D#7$
M;B[N--M=LX^EM&_8'^#EMXD\+_#;QCX_^*A\??$/XY?'+X*>#=3\-Z3X7'A6
MRG^%%E)?Z9XA\26&IVLVL&+4XUB@U'2]-OFGCFD+V]S!%$3)^87A_P ;>-/"
M5]J&J>%/&'BCPOJ>K1W,6JZAX>US4='N]2CNYC<7,=[-87%N]RD]PS3.LS./
M,9G7!-6V^(WQ":^T_5&\=>+&U/2=6U'7]+U$Z[J!O=.UW6$,>KZQ9W!F,MOJ
M>J(=FH7L;">Z7Y9789!]G-.&^-,;F.*KX+C.>6Y?5PF#AA\'0HU54HXO#8&M
M3J5G4>'JQY,3F$Z>(Q5.G:->A!T)1HN3D_G\GXIX"R_+,-A\?P'#-<QI8S'U
M,1C<1B:2IU\%C,?0J4\/&E3Q-"HJF%RZG6PV$J56Y87%55B(RQ%./)']3/A+
M^R5\,O"7P]\<>(=>T+X@?$7Q1K7["_Q4^,EEXNN/#FD7'P$\/ZO>:;,-'TS0
M]<1&U<?$;PE+88EDFNVA@OWOK?[%'Y*RM\[? _P#X;TO]FB7XSZ7\ [#]ICX
MBZC\8H?ASJ_AC6%\3ZOH_P ._#']C6U_IE]-X:\(7=GJ<FK>,[Z>:VTW7KQW
MLK!+62-%\_:5^/=/^)'Q%TK0)O"FF>/O&>G^%;B/4H;CPS9^)=7@\/S0ZS$8
M=6ADT>.[%@T.I1,R7D7D>7,'D++ND<M6\)>.O&_@&\N=0\"^,?%'@R^O+5K&
M\NO"^NZEH<UW:-UMKIM/N(!<0]=J3!]FYC&4+,3E#A'B9T,W6,XF688G'YKE
M6-IQJU,XPF&JX'+:>94JN68B6 KX3%8##8R.-PE1T\FJ4X0J97256MB:>(JQ
MATU>-^$OK.2/ \)RRS#9;DV=8"JZ5/(\;BJ>8YK/*JM#-\,LRPV-P68XK SR
M_&QA//*-2<XYO7E2HX2IAJ,I_HCX3_8G\.^/_AEX^^(7B7P_\2?@IXN32OB[
MXX\+^#89]'UCPGIFC_"^_0:KX5FM-4@OO&EG=Q0B[T^'4/$6J6$L>II&L6FZ
MA80M*_IGBO\ 8D^!OBKXM>(T\*V_Q4\$_#?P?^SQ\,_BK/I.GKI&I:O\0=1\
M5:)X::>7X>ZE>:5>6DMKI3ZN+WQ[=&WUH66L2M:Z?9V%C<1>1^5]G\3OB7I^
MEW^B6/Q%\=6NC:K<WUYJFE1>*];&GZE=ZI;O:ZE<W]HUZT-W/J%O))%>R7"2
M-<AW,Q=F+4VQ^)7Q(TN?PU=:;\0O&]A<^#;>>S\(W%GXIUJWF\,6=RZR7-EH
M3Q7BG3;.Y=4:XM+;9;S>7$)(V6*,)QU^$./*E?$UZ/';PL6\7#+\/1AF,J&"
MH8G#8&E&FO;JM5Q$J<L%*-*KBZF*K8=8JOBZ566,E*-3LP_&_AS2PV$P]?P[
M6,FOJ-3,L76J97#$X_$83%X^LZG^S/#T,-3K0QT95:.#IX.C7^IX;!5J,<$E
M4I?IEX._X)^_"O7=?NK&U\9?&7XCZ1J'QTM?A'9W7PT\*Z#:W_PSTQ_#^C:_
M=>)/C)I_B>!;K3/*FU:X\/1-96EC83:AI-Y?6TUS"\=B<>T_8%\!S:0MJ?%?
MQ1N-<\0:)\=O$_A[QYI>AZ!>?!SP58_!G7M9TB#P]\4-::*._@\1ZY%H_FWD
MFGW&FQ:;)J-CY.G7B.%;Y$^$7[5/Q(^##ZI?^'M-\&>(?$NI:Z/$R>,_'&AS
M>)O%MEKRP^5#J":Q<WR2:E]EE"7EI::VFIV=O>*9HX%,DN[QR?XB?$"YL?$>
ME3>./%ITCQAJ\^O^*M&B\0:G;Z+X@UJZGDN;C4=3TFWN8M/N;B:>5Y)2]N4E
M8CS5<(@7GH\->)D\;BX5>-)4,)3^I+#8J2I5IXV4/9NO66!P^"IQP2I<L_W%
M2HZ>9S:AC_80G4JKJK<6>$U/+L%.CP%'$9A5>8/%X2#JT*>!IS57ZO1>/Q6/
MJ2QSQ#G"]>G34\GA%SRUXJI3HTI?H;KW[$_P@U/Q[J/P"^%WC/XH:M^T$?@O
MX3^*/AK3?%<7@^Q\$^)-<U:QT37]9\&Z;<6UG!J]S=6OA>_U#5-/F=[1IIK$
MV^RY1)9J^.O&WA/P=X!_:/7P-X"UW4/%'AOP=\4?"7AF/Q'J?V19M9U;1]>T
M:R\1WMM'906\,6E_\)!%J,&E*4>8V$$$D\LTCLYC^&?[1/Q%^%GB/5O&VBOH
MFN^/KW0XM"T7QYXSTP>)O%7@B&'3+W14O?!>IWTQ?1;]='OY],655FC6S\N%
M(U6-:\P\%%F\<^!V=GD=O'/A!W>1V>1W;Q+IC/)(['<\CDEG=B6=B68DDU[^
M491Q1E]3-7G6>XC-<OIY#.G0]O4H5)XK-:V$S">9XMQAA</5PV HTZ6$P^7X
M*M*<Z5:>-Q"G5I5*"A\WG6=\(YG2R=9%P[ALGS:KQ%"IB?J]+$4Z6"R7#XG+
M(95@E.KC,31Q>8XBM/'8C,\?0C3A6P\<!0=.G7I5Y3W_ (Q?\EB^,'_96?B9
M_P"IQKU>=5Z+\8O^2Q?&#_LK/Q,_]3C7J\ZK['+?^1;EO_8NR[_U7X ^%S7_
M )&V;?\ 8VS7_P!6>8FIH=O#=Z[H=G<1B6WO-:TBTN(CD>9!<ZC;0S1Y7YOW
MD;LAVD'#'!K]:?&W['7[."?%/Q59:Y?_ !-\$:=XC_:KTW]G+X?>&_AW:^'+
MK1M$FUCP=H>KV6KZJ_B2WNK][>WU34LWEM;7+2W%K,ZP>1)$';\A$=XW26)W
MBEB=)8I8V*R1RQL'CD1QRCHP#*PY5@",'FNLN?B!X]O+F*\N_&OBFZO(=?B\
M5Q75QK5[-/%XH@BBMX?$<<KRETUR&W@A@CU(-]I2**) ^$6OGN),BSO-L5@:
M^4<0XC(X8?"XNAB5AI5E4KSK556H3C:%:@G2J4L/&4IX>55T%7I4ZM.-::E]
M1PKQ'P_DN#S'#YUPOAN(:F*Q>"Q.%GBE1=/#1P]&="O3:E4H5Y>VIUL1*,:>
M)IT8UGAZU6G5EAX<OZN?!7]C'X;>$)-'U3QEIGQ ^*&O>(/A7^T?XD74+'PQ
MI5U\#O#4GP['BWPE9Z3XGU)UDUJT\9)?:5#KUHR7L,=A<2Z? UC.9//6CXY_
M9)\%>(GM?'GBN;XI>+;?2OAC^RGX;M? G[/?@'P2/'8OOB5\.I-=/BW6=%BL
M;?39_#.G-;G1GU>2T76O$.NR)'JFM+)ONA^76G_$WXEZ38ZAI>E?$3QQINEZ
MM?WFJZKIEEXHUBVT_4M3U&&XMM1O[ZRBNUM;FYOX+JYBO99(6:Z6>0SF1CNI
MMG\2OB/IVIOK6F_$#QKINLR:%:^%Y-5T[Q/K%C?R^&K"V-G8:!+=6MW%-+I-
MC:DV]C9.QALXR5MUCR<_)/@CC:68ULSEQM&6)E!TH35+'4OW$FG4H4E"$Z66
M0JK]W*>7X>O4C&E"JJE2IB:\:'VW_$0?#V.5TLHI^'TX815%6FI8C+JLE7CS
M>SKU9SE"MF\J4^6NJ>9XK#4*DZDZ;HTZ6'P[K_?VE_L3> $^"5_\3O%%Y\7/
M#^O>'/#NE?$V_P!)U2'P:NE>(OAW+\14\(75O;VME#?7?A7Q%<6C%XH-:UV\
MDMKR"\6XTP6J032?0/C+]D;X<WOBC]I+X3?#J+6?A1X0NOBI^R9X4L-3^(?A
M[PYJMI;)X_\ $>NVMQX@\'>*[RPM]?T_PWY4$<%O'IVKQIKVN//9:M<7-E';
M00_CX/B+\0AX<?P=_P )[XS/A&2*\MY/"[^)=7D\/R0:A/%=7T4FDR7;V3I=
MW4,=S,K0D-.@EXD+LYJ/Q$^(.L:>^DZQX\\8ZKI<EIHMB]AJ/B/5;VV:S\-S
MRW?AVV,=S<R?N="NYY[O2$!'V"YFDGMC'(Q8U6X*XVQ.)J5Z_''M$L55JX2D
MZ&,GA\%2^N8''86<<)*-.ABZ^%JX24*<<6Y4Z<*DHTZTJ<YT#+#\?>'^#PU'
M#X;P\4;86A3QE7ZS@:>)QU7ZEF> QE/ZY3=6M@L/BZ&/@ZLL#3C5JSH4I5*,
M:E*GB'^F.G_L&?"74=4TW5KS6OCYX&\&Q:?^T7'KGA;X@:#X2T7XKW=Y\ _#
M<'B,^+/"UFME_9-YX&\0H\VE*]U;"X@UE([1-4>-C<#XJ_:+^$G@_P"&5S\*
M=>^'FL>*=5\"_&'X5:'\3/#T/C>#2H?%FC"_O+[3-0TC5Y-#2+2+P07MA)+9
M7EE#"LMM*J2Q++&S/Y1>?$OXD:EJ2:UJ7Q!\;:EK$>A77A>/5-1\3ZO?W\?A
MJ_MA9W^@QW5W=2S1Z3?VH%O>V2,(;N(*LZR%0:YS4-;UC5H=+MM4U74-1M="
MT]-)T2WOKN:YAT?2HY9)H]-TU)69;.Q26221+:$+$LCNX7+&O?R+(.+<!F-#
M%YMQ;4S7"4Z=6E5R]PJNA*%2A74&I5L-2JU<12QDJ-=8ZM*G5EAXSPLJ#2IS
M/G.(N)N"\RRS$8+)>":.38RI4IU:69QK4_K,:M/%8:4OW='%5:%'"5<#3Q&&
ME@:,:M*.(J4L5&NG[6G',HHHK[H_.CUWQY_R3?X ?]B=\0/_ %:OBNO(J]=\
M>?\ )-_@!_V)WQ _]6KXKKR*O+R;_</^Y[-__5UFI[&>_P#(Q_[I^2?^J+)P
MP#U&<$'GV_S]?2OO7]B/P)X,\6^'_P!J?7_%?ASX.ZYJ7P\^%/@SQ!X-U#X[
MM<Q?#7PUK&J>/[?1K[4-=NK6:*6UCN],FELXW!9FN_LJ 8)S\%=:][^%'P$^
M*GQ1\-^)O$_AK4O#WA'P#9WUAX9\0>*_'/CW3_A[X0U?6[S-YIGA07>IW=M;
M^(]2:18[L:8L-Y%INZ*_N?LRXF'F\8TZ.(R#&8?$9S2R&&(K9?!YG4E5BZ?)
MF6#KRH4X8>M1Q%:KC*.&K82%&C-3J*M)3YJ4:JCZW M6OAN)L#BL-D,^)*F&
MH9G4_LF$:,HU7+*<PPU/$5IXJAB,-1HX"MC*&.G7K4^6DZ$91<:TJ#?V-\3/
M@E^R'XC\+_%WXN^"/$>K:/I'AWQ5\%_A1I%M\-IHF^$%O\8?B%X1U"\\4ZE:
MWGC&SF\0K\*=%UVR2YM;BVE6^DTV.:&WC,DZW$/I%Y_P3>^&EWXGA\+V_C+X
MK?#]-"^+6C?#2_\ $_Q-TOPI::+\9[:^\'ZCXIFU7X$BRB@^U7U])IAT_0[/
M4KG6+&;^UM*DN;]9R\4_YE7WPG^+VG6?CRT@\*^+-:\+^ -9GM/'>J^$DU#Q
M/\/=.U;20\#WMYK.@F\\,ZC]BB:0PZM')<"WM)&E$\-O*S-)XB\#_'C3?"^D
M^+O%GAOXO6W@W2ETF7P_XDU^'Q<_AK2(]6@BNM$GT+5+V673]+2\MS;R:?-I
MTENC V\<3K(8HZ^)_L+.81PM#*?%2I2I.M*AA_KF(P>.Q#A4R[!?4*,:%2O!
M8C%N,JU>I0Q//+V.*PV+H1EBL)1^L??/B3(:U3%8K-_!ZG5J>PAB,7'+\-F&
M7X1UJ6:8]YC7EB*="I+"8-2CAL-3Q.%Y5"ME^*P->I3P>/Q#H?JK\+OV:_@1
M\'[+Q3\:->\'_%<W-G^SA\:_B)HGPC^-6@^![SQUX%U'X<>(=&\-R^,-:\-7
M&F_V%J=AXBAUJ"7P2VKZ=]A26UULWJ7A2R:+Y)_9G_9B\&_''P?K?Q#\20?%
MSQ/<:A\:-!^&-KX.^!VD^&[O6O!]IXLMY]5D^)/C>WU>UNH+'P38M,+"%-/M
MK: 7-I=0&YAA2)8_F75/ G[0,FH>'FUOPO\ &JXU?XD:;_9_AF35['QM=:EX
MWT>0^<VEZ?+>"2ZUK2V"BYFTMVFM!&%NYK81A9:L>&?A=^T-'KGB3P_X*\#?
M&.Q\2:)-9Z1XNT?PKIGBW3-8TV:_BN9M/T_Q#9Z2;6Z2*\AM[N:S2^5K6:.*
M62)BA9BZ.1YAA\%G%9^(V$><9DLH<,SJ9C"=# Y;E5?,*5;!PE/'>VIT:F+Q
M5.A4S"G3IXJKB,(Z&,E*K7JQA.)XARS%X_(</'PNQD<DREYRJF5TLJG'$YAF
MF<X;+:^'Q]:-/+O85*U'!X*I7I995K3P-'#XWZS@80HTJ$I_9?[4W@3X3_ _
M]F'X6_#CP;:6_B#Q9XB^*GQFM/$'Q2BT?PQ=1^-#\)_&\'AA[[3_ !$MM+KV
MGZ*Z2VZZ+I6D7Z:?/;&Y.LB\N%MY%_,^O:-2^!GQQL_A);_%_5O!?BV'X4:7
MXJU?P:FJZE]M6UT#7[9P=9BDT.[<3Z':2ZBALKO4C:6MM>:W ]E+))>Q%1XO
M7V/!^"I9?EN+PT<]AQ%BO[8S.OF.91Q$:\GCL16HU)X>K&%>O#"SP]#ZO'ZI
M3E"C1C.*H0C1<$?$<<YA5S/-L%BGPY/A;!?V%E&'RK*I86IAX++\+1Q-&GBJ
M,ZM##U<92Q-;V\EC*T)8BO*E4>)J3K\\@KU3X0_\C!XH_P"R3_%__P!5SXBK
MRNO5/A#_ ,C!XH_[)/\ %_\ ]5SXBKUL[_Y%.._Z\P_]2L >%D/_ ".,O_Z_
M3_\ 43,3V7]A?X?>#OBE^TKX.\&^/M!TCQ+X6N?#'Q'U:\T?7KBXL]$N+OP]
MX!UW6]*FU:ZLY8+FWTVTU*QMKF^GBF1H[6.63(VU]277P0_9+^*;:/<OKGA3
MP=XB\#_!3XH_%/XV6/[)^NW'Q \!V]GX6UG1E\$V^B7OC:2\MY->U?2;O41K
M-K:W_DPSBRFEGAC012_EMHNNZWX<OH]5\/:OJ6A:I';W5K'J.DW<UC>I;7]K
M)97]NMS R2B"]LYIK6YB#;)K>62)PR,06Z7K.KZ&M^FBZI?Z0NJZ;/HVIKIM
MU+9KJ.D713[3I=Z(67[187 C3S[63=%(54LO  ^9SWA3-\TSBKFV!XGS#)^7
M+\%A,)A<'.K&G&M3K8GZ]7KJ=6KAVL1A<0XTE#+ZM3ZS1PU6K7IPP\:=7Z_A
MSC/(\FR*ADV8\'Y9GKGFF-QV.Q>/C2E5GAZE#"?4</AG&A2Q,98?%852J2J9
MG2HO"U\70I8:4\5*K2_2>_\ V'OA*OP<\(^.(OBMXNT3Q%\0/!'ACXB>&-<U
M_1[&X^%^FZ=XP\50Z'IO@_Q9J&C:;/=Z5X@TBRG5]>UU]5BTJ#5X9K,:;! R
M2IZ!H?[*'PL^'7Q)^*?A9_!WQGUYO!OP8_:;TN^\0_%SP9X?L?AOXF\3>"_A
MH-8T/QI\+]3TQXKJ0PW['5M&AO$U)AI$]CJ:ZH)G: ?E4GC/QE'X7F\$1^+_
M !2G@JXN#=W'A!=?U4>&)[@\F670Q=#3G);]XRM;F-Y<2LAD&ZM.;XF?$FY2
MPCNOB%XXNX]+T6_\-Z;'>>*=:NX[#P]JL!M=3T2SCN;R5+?3=1M6-M>VJ )<
MV^()=T0"#R*O"'&]>&+H8CCJIB<-B<1C_9TY4*^%E0PU>MAJF#O5P5&E5JSH
M4J'L)8:=:GAHROC:&(=:M6PQ[5#C?@##U,%B,/X=T<-BL+A\M52I"OAL5"OB
M</1Q=/'VIX^M6IT(8JOB5B88J%"MC)0C' 8B@J-"AB3]3_B)^RS\&=1U35?&
MGQ4\2?$:UBM_%7[*GP=T>T^%GAKX<^'(Y;GXK_"K3]7CU?5-*;1H--WZ5<1O
M]JOK=!?:M&J&]6:\NGOHDG_8OT6\\#>&/ WB;Q3K%_IGPG\9?MF7U]9^ ?!/
MA=/B7X^L?@_JOA*WL]#\+7T]G_:6N>(]<M]72\%AX@N-7TW0H;'4&TFRCC+E
MORHNOB!X]OHC!?>-?%%Y"VH:+JS17.M7TR-JGANU-CX=U$J\I4WNA61-II-Q
MCS;&V_<V[(F09'^(_P 1)+S3=1;Q[XQ_M#1M8U+Q#I-^OB+4XKW3-?UEHVUC
M6K&ZBN(Y[;4M6:*(ZE=1.)+T1JMR9%&*YH<#\9TJ.$I4N-N6.#E[2A!X:K.E
MAYT:-6AAOJ<72]IAG*EBL;3Q%253%3E+$PQ%*"K86A&75/Q"X%JU\75J^'T9
M/&TH4<34CC*,*^+53$T<1BWCIJHJ>*BZF$R^IAJ2IX.$8X2IAJ]5T<=B*B_2
M?X5?L#^!/B7JOB.VOX/VA_A[I.J:VWASX;7_ (YT;P1I6L6NKI\/8_&DEMXU
M\+6T5_JUW;1S.JIJUG'X6L[O29[2XB"7\SV,7S3^UKX*\.^"M$_9'30-$TS1
M[OQ%^RAX)\0^*KC3;7[,?$/BB7Q7XSTZ_P#$%\<EKB^O8K"W22=_G:.*)3@*
M!7S[9_%KXKZ?=:O>V/Q/^(-G>>(+VWU'7KJW\8:_'<:U?VN1;7>J2?;R;V>!
M3Y<<DVXK$!#S$JH.5U77]=UU=,77-9U36%T73HM'TA=3O9[P:7I$$TUQ#I>G
MB9F^R6$4]S<31VL.V))9YG"AG8GV<HX:XKPV?8?,LVXGAF.6X55_899&.-O"
M=?*8Y=*3K5XTG67M81Q,GB(U.>LGB(4\-7J31X.<\5<&XGAS%95DW",LKS3%
MN@J^;RG@$IPH9R\SBHX?#NNJ%J/-A8?5ZE*4*,_JU2IBL/2A*7IWQ1_Y$S]G
MC_LCVI_^KD^*M>->GNRCMW8#O[$_X5[+\4?^1,_9X_[(]J7_ *N3XJUXU7UF
M2ZY;36U\1FB^_-\X5_QN?&9X_P#A3F_^H3)G;TR/)7;\+?,_;/XN?!W]D[P1
M>-X1UGPM\$_"^M'P[\!-0^&5AX0\6^)=0^./B+QYXJG\,W6OV7Q \'7%U=:%
M;^"-0TZ[U.:YN9X+/]Q+!);227!B0\7\4_V,_A!\1/BCXVO?@W%\3+4Z-^UE
M/\#_ !I\/[>V\#Z3806U]X,UGQW+J'PPGNG@M-+T[0M.T&^MVM?$]Q>RW"J)
MX5#E+:3\F=1\1^(=8U6'7=6UW5M3URW2Q2#6+Z_N+G4X4TM(XM-6*\E=IT6P
MBABBM KCR(XT6/:%7&JOQ \>I-<W,?C?Q9'<WGB.W\87=S%KVI0W%SXLM(7M
MK7Q--/%<)+)KMO;RRV\6IE_M20R21"38[*?SK">'_$V70P];!<<Y@\?#!U:5
M>>*EC*V"G7KUKU>3#5*^,J3HRI1A-3JUZ6*ACO\ :J?L*:E@ZWZCC/$KA+-)
M8JAC_#S*XY?4QE"KAXX*.!P^8PH8;#RA24L93PN!HQK1K3J0Y*>'JX2>7U'A
M*_UJK;&4OU$MOV /@I+XYT'3#\0?BK<:!XY^$WA'X@>!- 33M"L/$M]K/B'Q
MIKG@^]\/ZKXTOO#O_"'Z<8#H;W^BG4](T5]<-Y':1W%N;::X;A?%'["O@/P7
M\%;_ ,;>*O'7CC2?'$WA+QQXTTY8-*TG7O ?AY_"/B.\T./X>>,[[0[2^ND\
M7$69AUK6+'5+?1]+U2[LXUL[JR9KBOA%?C/\8DU*764^+'Q(36)]/GTF?54\
M:^(5U"?2KF>XNI].GNUOQ/-9O=7=U<""1V2*:YGDB"-,Y/-P>-O&UKX?U'PE
M;>,_%MOX5UBZ^VZOX;A\1ZNFA:I>%VD>YU#2Q>?8[N::1C)<//%(US*3).9'
M.:VH<)^(<)X5UO$)RIT:N6RQ$(X*4IUZ6$JUWB:<9U,-&$7B*$Z$*CG2J2Q5
M6FY8BKAZ?) QQ'&?AA.GBU0\,N2I5H9I##2>80A3P];%T,)'"U94:>*<I_5\
M12Q,Z<:=:C# T:JAA:>*JISE]":A\/\ PC#^PWX-^*\>A01^/]4_:E\6^ ;[
MQ'OF-U-X1T_X7Z7K]GH;+YAMO(@U>>:]5DB$WF,P,A3BOE6M1M;UI]$A\-/J
M^I/X<M]5FUVWT!KR8Z/!K=Q:I8SZO#IY;[-'J,UDB6DEVB"9[95B9R@ K+K]
M!RO!8G!1S%8G%O%O%YQF688=R=5_5<)C*F$GA\#'VLI-1PJH58J-/EH)5?W,
M()SO^9YOF&%S#^ROJN"C@OJ.1Y7EF)Y517US'8&GC(8K,9*C"%YXQXBC*4JW
M/B'["/M:DK04?7OB/_R)?P*_[)S??^I=K5?H]\)?A3^S#I_[-_[//C+XR>'/
M@?I.C?$32OBQ<?$OQIXU\8^*- ^+T\7AR_OK309/A+I&CW9M]:U2WF2UM3#)
MI]PAG>..78KLX_.'XC_\B5\"O^R<WW_J7:U7FMWK>M:AINDZ/?ZMJ-]I&@+=
M)H>EW=W-/I^CI?2^?>IIMK(S16:7<_[ZY6!4$TN'?<W-?)X[A_&<19-E>%PN
M<XS)88;.LUQ6+Q&!G5IXNM0^M\18>%&C*GB,/3C4IXFM0Q5.>(=:C3G0C4^K
M8BI&-.7V.6<38+A?/\YQF+R+!9_/%Y!D^"P>&S&%"I@Z&)^I<,8J6(KPJX7%
MSG2GAL/B,)4IX>-"O5I8FI2CB\+&<ZT/T_\ '_[.?P)\:^!?!MMX0E\9^&/B
MUHW[%FF?&ZTAL-*T&+P-XM31-8N('B\3,\8UP^+_ !-I\R33:S:W$.E6=PD$
M4]M/AT&KK7_!/OX6Z-%\.;[6?&7Q8\(P77Q+G^&?Q3TS5='T'Q/J>D:JGPXN
M/'<=QX>O/"FF3Z=:1?:;1M'U*>Y7Q'I^B0W*:C=7TBVUQ!7Y>?\ "9^+_E/_
M  E/B %?#K>#UQJMV-OA-\[_  RI$F5T-P>=-!^R]?W?-;S_ !=^+4IT@R?%
M+XB2'P_+:3Z"S^,O$#2:+-8VLEC9RZ9(;\O9/;V4TUG&;<Q@VLLD$@>-RM>3
M_J=QSA84L/EW'E:CAJ=;%UI+$4\1B:]L7#,U*E3JU*%5>RIU<7A,10A451X>
MOAZM2C4E2J4\+3]O_7KP\Q=2KB<T\.*-;%3P^"P\7A*^&P>&O@I9/R5ZE"CB
M*3]M4I8#&T,3.C.BL70Q=.G6IQJTYXNI^FNF?\$[/APM[XNU3Q1XF^*VD>$[
M;7_ /AWPGI^@MX+\9^+(+'QOX<.MV_Q$\2R:%I=Q:W/A&ZD$L.@:99Z5HVL:
MC';SK=3V%W&(&^0O@_\ "WP3JV@_MGIJ\5CXSE^$?PPBU+P)XFBBO;6"/58/
MBOX?\,_\)+8VCM'-#_:.CW-S']FO49H8KHHZ>8I(^?;7XH?$VRUO6O$ME\1_
M'EIXC\202V_B+7K;Q=KL&KZ[!,ICDBU6_COEN;V/RV,<:32,MNA*6XB4D5S=
MCKNMZ9#J]OIVL:I8V_B"T6PU^&UOKB%-;L%NH[Y;/5@CC[=;B]BBN_+N-X^T
MQI/_ *Q0U>A@>&.,887,Z&:\9RS"6+IY-'!2IX:MAE@IX#&X'$XZ2G!4\1)X
M[#X6OA9S]NY8CZW*KB84N7V;\[,.+N!9XS*,1E' D<LIX*KGT\?3JXJABWF$
M,QP&8X7+X.,N?#1C@<3C,/C(0>&7U=X*G3PM>KS.<?HW]NOX>^$/A3^U)\</
MA[X!T2#PWX/\,ZEHMMH6AVSS/!IUO>^!?#>J7$4;7$DLQ$M]?75R?,=F#3L
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MI.J:/J>G6D+6MW]HCOM*N4+P0SQR.H_KK_X57\&O^B*_";_P@_#W_P @TO\
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M0I.ZU46M&TU_"V)8@ /,3H.C TOFQ?WU_.O[E_\ A5?P:_Z(K\)O_"#\/?\
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M_P###F7_ ,W'\-'FQ?WU_.CSHLX\Q,^FX?6O[E_^%5_!K_HBOPF_\(/P]_\
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M  _K_P"=I^$'D7'_ #[7/_@/-_\ &Z/(N/\ GVN?_ >;_P"-U^[_ /9VF_\
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MKUE@G96N[DJRPRE2#,Y!!"8(((((JI]GN?\ GWN/^_$O_P 15C4&<7]Z \@
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M!)]FN?\ GVN/^_$O_P 11]FN?^?:X_[\2_\ Q%1[W_YZ2?\ ?Q__ (JC>_\
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M"7_XBKE];W!N9"+><@I ,B&0C(MH00"%(.",'T.0>16>7DP?WDG0_P#+1_\
MXJKE\[_:I )) -EOP'<#FVA)X!QR>3ZGF@"#[-<_\^UQ_P!^)?\ XBC[-<_\
M^UQ_WXE_^(J/>_\ STD_[^/_ /%4;W_YZ2?]_'_^*H D^S7/_/M<?]^)?_B*
M/LUS_P ^UQ_WXE_^(J/>_P#STD_[^/\ _%4;W_YZ2?\ ?Q__ (J@"3[-<_\
M/M<?]^)?_B*0VUS@_P"C7'0_\L)?_B*9O?\ YZ2?]_'_ /BJ0O)@_O).A_Y:
M/_\ %4 7KRWN/M,I^SSG.P\0RD?ZI!P0N#TZCOQVJM]FN?\ GVN/^_$O_P 1
M4MX[_:91YDF 4 'F. !Y4?0;OQ^O-5M[_P#/23_OX_\ \50!)]FN?^?:X_[\
M2_\ Q%'V:Y_Y]KC_ +\2_P#Q%1[W_P">DG_?Q_\ XJC>_P#STD_[^/\ _%4
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M=3$X>EZI1117YV?K84444 %%%% !4D/^NA_Z[1?^C%J.I(?]=#_UVB_]&+0
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M)_\ A(O$'_0>UK_P:W__ ,D4?\)%X@_Z#VM?^#6__P#DBC_BI?D?_1H<Z_\
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MX3_\)%X@_P"@]K7_ (-;_P#^2*/^$B\0?]![6O\ P:W_ /\ )%'_ !4OR/\
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M&J;=#]#_ "JY??\ 'U)_N6__ *2PT 5**** "BBB@ I&Z'Z'^5+2-T/T/\J
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M+:Z46]Y>P7">7.I3+Q+O(W)E3NKQ;_AE_P"./_0EQ'_N8?#W_P M!7Z]S?\
M'M9?[MQ_Z4255K^*>+OH(>#O&G%/$7%V:YSQ[2S/B;.LQSW,*6"SG*J6#IXS
M,\3+$XB&%I5<BK5*="-235*$ZU64864IR:N?O62?2)XYR')LJR/!X+AR>#RC
M 8;+L++$8#%SKRH86FJ5.5:<,QIQG5<4N><804GJHQU/R._X9?\ CC_T)47_
M (4/A[_Y:4?\,O\ QQ_Z$J+_ ,*'P]_\M*_7&BOG?^*=7@=_T//$?_P^Y/\
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M]_\ +2G+^RY\<G)"^"HB0K,?^*B\.CY44LQYU3L >!R>0.2,?K?4]O\ ??\
MZX7'_HB2G_Q3J\#O^AYXC_\ A]R?_P"AT/\ B9_Q"_Z%_"W_ (;L=_\ /0_(
M?_AE_P"./_0E1?\ A0^'O_EI1_PR_P#''_H2HO\ PH?#W_RTK]<:*7_%.KP.
M_P"AYXC_ /A]R?\ ^AT/^)G_ !"_Z%_"W_ANQW_ST/R._P"&7_CC_P!"5%_X
M4/A[_P"6E'_#+_QQ_P"A*B_\*'P]_P#+2OUQHH_XIU>!W_0\\1__  ^Y/_\
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M,]QD\9C\7-N3?NT:%)75'"X2BFX8?"X>%J=&A3M&*4IS=2K4JU9V[G_4V/\
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MC[))_P ]+;_P(3_"JU% %G[))_STMO\ P(3_  H^R2?\]+;_ ,"$_P *K44
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M2>'Q_P!QK3?_ ))H_P"$J\+_ /0R^'__  =:;_\ )-?A9CZ_]]'_ !HP/?\
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M+F*[@>R2^35?B9XGD\2:=>MK.GB&2V>WK]@/-DY'F/AOO#>WS< <\\\ #GL
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M3/S7_P"&)_'?_0U^%O\ OF__ /C5'_#$_CO_ *&OPM_WS?\ _P :K](:*/\
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M(?%>FVFC^(TLV614?^V-,L+.SNWNH[A_+@1H6BE+R-T=%'Z._P T[_F']/\
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MW_?3_P#Q%'D1_P#/W;?]]/\ _$56HH L^1'_ ,_=M_WT_P#\11Y$?_/W;?\
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MEE_X]K/_ ';C_P!*)*JT 6?(C_Y^[;_OI_\ XBCR(_\ G[MO^^G_ /B*K44
M6?(C_P"?NV_[Z?\ ^(H\B/\ Y^[;_OI__B*K44 6?(C_ .?NV_[Z?_XBCR(_
M^?NV_P"^G_\ B*K44 6?(C_Y^[;_ +Z?_P"(H\B/_G[MO^^G_P#B*K44 6?(
MC_Y^[;_OI_\ XBIX((]SXNK=CY%QP&?_ )X2<_<' ZGT S@UGU/;\.^/^>%Q
M_P"B)* '>1'_ ,_=M_WT_P#\11Y$?_/W;?\ ?3__ !%5J* +/D1_\_=M_P!]
M/_\ $4>1'_S]VW_?3_\ Q%5J* +/D1_\_=M_WT__ ,11Y$?_ #]VW_?3_P#Q
M%5J* +/D1_\ /W;?]]/_ /$4>1'_ ,_=M_WT_P#\15:B@#3GAC,5I_I-N MN
MPR6;#9N9SE1LS@$[<^H/&,$U?(C_ .?NV_[Z?_XBG7'^ILO^O9O_ $JN:J4
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M#C=7U;$")X0>")X@1Z$2+7YO>&O^">^B>%/BA+XELO$WA/6?AO<?$G4/B?\
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M+I>UC2J5(8A4YS@M)2II0D]4EL?N'@^A_(T8/H?R-?AY_P + \=_]#KXL_\
M"BU?_P"3*/\ A8'CO_H=?%G_ (46K_\ R97RO_%2[A3_ *-+Q/\ ^)5P]_\
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M_HLLH_\ #3FG_P TH_</:?0_D:,'T/Y&OP['C_QV/^9U\6GZ^(]7/_MY2_\
M"P/'?_0Z^+/_  HM7_\ DRC_ (J7<*?]&EXG_P#$JX>_^=H?\2HYS_T664?^
M&G-/_FD_</:?0_E2E2,D@@ XY'?G\/KSW[U^'?\ PL#QW_T.OBS_ ,*+5_\
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MKS26$VOQ):3<5+_P4 \7ZSXV^&'B[3O"^J>)]0TOX8_M'7WB7X)_!KQT-?\
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M-NYXU9K, !:W_AI^S_X2^&'Q)^)WQ+T6ZN9=0^(FC_#[PEINAK96&G:!\/?
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MKK17SO\ Q3F\$O\ HH_$G_P\9#_]#AZO_$T7'_\ T*^%O_"/,O\ YYGY%?\
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M'_%.;P2_Z*/Q)_\ #QD/_P!#@?\ $T7'_P#T*^%O_"/,O_GF?D5_PS#\<_\
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M_/E'_P!]2_\ QR@#RVBO4O["TG_GRC_[ZE_^.4?V%I/_ #Y1_P#?4O\ \<H
M\WN/]5:?]<3_ .C'JK7J9T;3'PK6D9$8"H-TGR@Y)'#^I)YS2?V%I/\ SY1_
M]]2__'* /+:*]2_L+2?^?*/_ +ZE_P#CE']A:3_SY1_]]2__ !R@#RVBO4O[
M"TG_ )\H_P#OJ7_XY1_86D_\^4?_ 'U+_P#'* /+&Z'Z'^57+[_CZD_W+?\
M])H:]'_L+2?^?*/_ +ZE_P#CE/?1M+D8N]G&S$*"2TF2%4(O1QT50!["@#RJ
MBO4O["TG_GRC_P"^I?\ XY1_86D_\^4?_?4O_P <H \MHKU+^PM)_P"?*/\
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%=Z /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #K G # 2(  A$! Q$!_\0
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M-_\ F<=#W#_AIO\ :5_Z.+^.G_AVO'W_ ,O:/^&F_P!I7_HXOXZ?^':\??\
MR]KP^C!_S^7\Z7]@9!_T(LB_\,F3?_.O^NX_]9N)/^BBXA_\2#/?_GP>X?\
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MJ_D/_0AR/_PR9/\ _.H/]9N)/^BCXA_\2#/?_GP>Y?\ #3?[2O\ T<7\=/\
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MQ=/B//<10S''T<IQ4\RQU)SSB4'0K9A6K0P\80C25'!4IPC>;G+;'[3?[2Q
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MA[X!T2#PWX/\,ZEHMMH6AVSS/!IUO>^!?#>J7$4;7$DLQ$M]?75R?,=F#3L
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MI.J:/J>G6D+6MW]HCOM*N4+P0SQR.H_KK_X57\&O^B*_";_P@_#W_P @TO\
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M0I.ZU46M&TU_"V)8@ /,3H.C TOFQ?WU_.O[E_\ A5?P:_Z(K\)O_"#\/?\
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M_P###F7_ ,W'\-'FQ?WU_.CSHLX\Q,^FX?6O[E_^%5_!K_HBOPF_\(/P]_\
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M  _K_P"=I^$'D7'_ #[7/_@/-_\ &Z/(N/\ GVN?_ >;_P"-U^[_ /9VF_\
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MKUE@G96N[DJRPRE2#,Y!!"8(((((JI]GN?\ GWN/^_$O_P 15C4&<7]Z \@
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M!)]FN?\ GVN/^_$O_P 11]FN?^?:X_[\2_\ Q%1[W_YZ2?\ ?Q__ (JC>_\
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M"7_XBKE];W!N9"+><@I ,B&0C(MH00"%(.",'T.0>16>7DP?WDG0_P#+1_\
MXJKE\[_:I )) -EOP'<#FVA)X!QR>3ZGF@"#[-<_\^UQ_P!^)?\ XBC[-<_\
M^UQ_WXE_^(J/>_\ STD_[^/_ /%4;W_YZ2?]_'_^*H D^S7/_/M<?]^)?_B*
M/LUS_P ^UQ_WXE_^(J/>_P#STD_[^/\ _%4;W_YZ2?\ ?Q__ (J@"3[-<_\
M/M<?]^)?_B*0VUS@_P"C7'0_\L)?_B*9O?\ YZ2?]_'_ /BJ0O)@_O).A_Y:
M/_\ %4 7KRWN/M,I^SSG.P\0RD?ZI!P0N#TZCOQVJM]FN?\ GVN/^_$O_P 1
M4MX[_:91YDF 4 'F. !Y4?0;OQ^O-5M[_P#/23_OX_\ \50!)]FN?^?:X_[\
M2_\ Q%'V:Y_Y]KC_ +\2_P#Q%1[W_P">DG_?Q_\ XJC>_P#STD_[^/\ _%4
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M=3$X>EZI1117YV?K84444 %%%% !4D/^NA_Z[1?^C%J.I(?]=#_UVB_]&+0
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M)_\ A(O$'_0>UK_P:W__ ,D4?\)%X@_Z#VM?^#6__P#DBC_BI?D?_1H<Z_\
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MX3_\)%X@_P"@]K7_ (-;_P#^2*/^$B\0?]![6O\ P:W_ /\ )%'_ !4OR/\
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M&J;=#]#_ "JY??\ 'U)_N6__ *2PT 5**** "BBB@ I&Z'Z'^5+2-T/T/\J
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M+:Z46]Y>P7">7.I3+Q+O(W)E3NKQ;_AE_P"./_0EQ'_N8?#W_P M!7Z]S?\
M'M9?[MQ_Z4255K^*>+OH(>#O&G%/$7%V:YSQ[2S/B;.LQSW,*6"SG*J6#IXS
M,\3+$XB&%I5<BK5*="-235*$ZU64864IR:N?O62?2)XYR')LJR/!X+AR>#RC
M 8;+L++$8#%SKRH86FJ5.5:<,QIQG5<4N><804GJHQU/R._X9?\ CC_T)47_
M (4/A[_Y:4?\,O\ QQ_Z$J+_ ,*'P]_\M*_7&BOG?^*=7@=_T//$?_P^Y/\
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M]_\ +2G+^RY\<G)"^"HB0K,?^*B\.CY44LQYU3L >!R>0.2,?K?4]O\ ??\
MZX7'_HB2G_Q3J\#O^AYXC_\ A]R?_P"AT/\ B9_Q"_Z%_"W_ (;L=_\ /0_(
M?_AE_P"./_0E1?\ A0^'O_EI1_PR_P#''_H2HO\ PH?#W_RTK]<:*7_%.KP.
M_P"AYXC_ /A]R?\ ^AT/^)G_ !"_Z%_"W_ANQW_ST/R._P"&7_CC_P!"5%_X
M4/A[_P"6E'_#+_QQ_P"A*B_\*'P]_P#+2OUQHH_XIU>!W_0\\1__  ^Y/_\
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M,]QD\9C\7-N3?NT:%)75'"X2BFX8?"X>%J=&A3M&*4IS=2K4JU9V[G_4V/\
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MC[))_P ]+;_P(3_"JU% %G[))_STMO\ P(3_  H^R2?\]+;_ ,"$_P *K44
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M2>'Q_P!QK3?_ ))H_P"$J\+_ /0R^'__  =:;_\ )-?A9CZ_]]'_ !HP/?\
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M+F*[@>R2^35?B9XGD\2:=>MK.GB&2V>WK]@/-DY'F/AOO#>WS< <\\\ #GL
M*0NY4*68J/NJ6)5?H,X'&1T[FFG:5TE;WO=>J]ZW3Y7?=ZZ=4U=6N]DD^NC?
M7T:7RZGX9?%'QC\3O^$I_P""@_AGX<>%?$_B?]H'XS?M-?#/]G'P?%X7O8;?
M7]"^!.G?"WP[KT^O6NLZA=:?I7@^W30KWQF-$U?4+^PT^/Q)JEO))-+(&SX=
MXDU3QCI_PT_9D_9__:/\ ?&C1?!_[.?[;>GZ)X_L]3D\2^+M?UW]EOQ+\,/'
MFN?#Z[\4^)/A->:M)XJ.DI<67AO7I= U+494U'2K.:]*7=R8E_H2TSP-X.T7
MQ?XI\?Z3X<TS3O&OCBPT#2_&/B6T2:+4O$NG^%8KF#PW:ZL1,;>Y718+RY@L
M9?LZ7"0RF)YI$2-4ZU9)%QMD=< @;788!.2!@C )Y([GK2BW%):OW8*6VO)>
MUO.[E)OK*<NFU-WOII>37?WDDWTZ**2Z<D?-O^>O4%U[1;6T\9?"FS^*$7P9
M\/?M]?LF0_L<)\5F\66_B6&T\6VM]X6_:,M_!,/CO9XZ7X<W&GW,Z:?I^MJ;
M>".SO$L8A:PLJ_T+W*HEQ.L>/+6614QTVAB%Q[8Q7'>)? O@[QEJ_@S7_%?A
MS3?$.L_#O7Y?%7@74-32:>;PMXEFTZYTB37-+03) NH_V;>75G'/<Q7'D13R
M- L<I\P=71LDM='>^EVE&,5?O)N+OV7+ONU;WF_[MK=GS2D^NWO*V[>OHBBB
MB@#XP^,_[,7BSXD^/]0\9Z9XAT"PL-3L=,@BM;Y+PW*/IELME,9/*C>,J\B$
MQD'[K#/.:\M_X8G\=_\ 0U^%O^^=0_\ C5?I7-_QZV7^[<?^E$E5:_D_B;Z%
M?@)Q=Q%GG%.=9)Q%5SCB+-<=G6:5J'%N:X:A5Q^8UWB,54I8:GAW3P].563<
M*-.4H4X^[%V/V/*/'GQ(R3*\OR?+\RRRG@<KP>'P&#A4R3 5JD,-AH>SHQG5
MG/GJS4-)5))2E971^;W_  Q/X[_Z&OPM_P!\W_\ \:H_X8G\=_\ 0U^%O^^;
M_P#^-5^D-%>'_P 2$_1Q_P"A!Q/_ .)GG'_S.>C_ ,3&^*G_ $-,I_\ $?R[
M_P"3/S>_X8G\=_\ 0U^%O^^;_P#^-4?\,3^._P#H:_"W_?-__P#&J_2&BC_B
M0GZ./_0@XG_\3/./_F</^)C?%3_H:93_ .(_EW_R9^;W_#$_CO\ Z&OPM_WS
M?_\ QJC_ (8G\=_]#7X6_P"^;_\ ^-5^D-%'_$A/T<?^A!Q/_P")GG'_ ,SA
M_P 3&^*G_0TRG_Q'\N_^3/S='[%'CL]/%?A;_OG4/_C5+_PQ/X[_ .AK\+?]
M\W__ ,:K](:*/^)"?HX_]"#B?_Q,\X_^9P_XF-\5/^AIE/\ XC^7?_)GYO?\
M,3^._P#H:_"W_?-__P#&J5?V)?'C$@>*_"W"2.3MU \1H7/2$]54X]Z_2"I[
M?[[_ /7"X_\ 1$E'_$A/T<?^A!Q/_P")GG'_ ,SA_P 3&^*G_0TRG_Q'\N_^
M3/S7_P"&)_'?_0U^%O\ OF__ /C5'_#$_CO_ *&OPM_WS?\ _P :K](:*/\
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M(?%>FVFC^(TLV614?^V-,L+.SNWNH[A_+@1H6BE+R-T=%'Z._P T[_F']/\
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MW_?3_P#Q%'D1_P#/W;?]]/\ _$56HH L^1'_ ,_=M_WT_P#\11Y$?_/W;?\
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MEE_X]K/_ ';C_P!*)*JT 6?(C_Y^[;_OI_\ XBCR(_\ G[MO^^G_ /B*K44
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MPR6;#9N9SE1LS@$[<^H/&,$U?(C_ .?NV_[Z?_XBG7'^ILO^O9O_ $JN:J4
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M#C=7U;$")X0>")X@1Z$2+7YO>&O^">^B>%/BA+XELO$WA/6?AO<?$G4/B?\
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M+I>UC2J5(8A4YS@M)2II0D]4EL?N'@^A_(T8/H?R-?AY_P + \=_]#KXL_\
M"BU?_P"3*/\ A8'CO_H=?%G_ (46K_\ R97RO_%2[A3_ *-+Q/\ ^)5P]_\
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M_HLLH_\ #3FG_P TH_</:?0_D:,'T/Y&OP['C_QV/^9U\6GZ^(]7/_MY2_\
M"P/'?_0Z^+/_  HM7_\ DRC_ (J7<*?]&EXG_P#$JX>_^=H?\2HYS_T664?^
M&G-/_FD_</:?0_E2E2,D@@ XY'?G\/KSW[U^'?\ PL#QW_T.OBS_ ,*+5_\
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MKS26$VOQ):3<5+_P4 \7ZSXV^&'B[3O"^J>)]0TOX8_M'7WB7X)_!KQT-?\
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M-NYXU9K, !:W_AI^S_X2^&'Q)^)WQ+T6ZN9=0^(FC_#[PEINAK96&G:!\/?
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MKK17SO\ Q3F\$O\ HH_$G_P\9#_]#AZO_$T7'_\ T*^%O_"/,O\ YYGY%?\
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M'_%.;P2_Z*/Q)_\ #QD/_P!#@?\ $T7'_P#T*^%O_"/,O_GF?D5_PS#\<_\
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M_/E'_P!]2_\ QR@#RVBO4O["TG_GRC_[ZE_^.4?V%I/_ #Y1_P#?4O\ \<H
M\WN/]5:?]<3_ .C'JK7J9T;3'PK6D9$8"H-TGR@Y)'#^I)YS2?V%I/\ SY1_
M]]2__'* /+:*]2_L+2?^?*/_ +ZE_P#CE']A:3_SY1_]]2__ !R@#RVBO4O[
M"TG_ )\H_P#OJ7_XY1_86D_\^4?_ 'U+_P#'* /+&Z'Z'^57+[_CZD_W+?\
M])H:]'_L+2?^?*/_ +ZE_P#CE/?1M+D8N]G&S$*"2TF2%4(O1QT50!["@#RJ
MBO4O["TG_GRC_P"^I?\ XY1_86D_\^4?_?4O_P <H \MHKU+^PM)_P"?*/\
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%=Z /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>silo-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 20:01:03 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://www.silopharma.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:silo="http://www.silopharma.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="silo-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="silo-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="silo-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="silo-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.silopharma.com/role/ConsolidatedBalanceSheet" id="silo_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="silo_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ConsolidatedIncomeStatement" id="silo_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ConsolidatedIncomeStatementAlt0" id="silo_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" id="silo_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>995304 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ShareholdersEquityType2or3" id="silo_r_ShareholdersEquityType2or3">
        <link:definition>995305 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ConsolidatedCashFlow" id="silo_r_ConsolidatedCashFlow">
        <link:definition>995306 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/OrganizationandBusiness" id="silo_r_OrganizationandBusiness">
        <link:definition>995307 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/SummaryofSignificantAccountingPolicies" id="silo_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995308 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements" id="silo_r_FairValueofFinancialInstrumentsandFairValueMeasurements">
        <link:definition>995309 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness" id="silo_r_DisposaloftheDiscontinuedOperationsoftheNFIDBusiness">
        <link:definition>995310 - Disclosure - Disposal of the Discontinued Operations of the NFID Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/NoteReceivable" id="silo_r_NoteReceivable">
        <link:definition>995311 - Disclosure - Note Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/StockholdersEquity" id="silo_r_StockholdersEquity">
        <link:definition>995312 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/Concentrations" id="silo_r_Concentrations">
        <link:definition>995313 - Disclosure - Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/CommitmentsandContingencies" id="silo_r_CommitmentsandContingencies">
        <link:definition>995314 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/IncomeTaxes" id="silo_r_IncomeTaxes">
        <link:definition>995315 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/SubsequentEvents" id="silo_r_SubsequentEvents">
        <link:definition>995316 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/AccountingPoliciesByPolicy" id="silo_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesTables" id="silo_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables" id="silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsTables">
        <link:definition>996002 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables" id="silo_r_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables">
        <link:definition>996003 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/NoteReceivableTables" id="silo_r_NoteReceivableTables">
        <link:definition>996004 - Disclosure - Note Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/StockholdersEquityTables" id="silo_r_StockholdersEquityTables">
        <link:definition>996005 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/CommitmentsandContingenciesTables" id="silo_r_CommitmentsandContingenciesTables">
        <link:definition>996006 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/IncomeTaxesTables" id="silo_r_IncomeTaxesTables">
        <link:definition>996007 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/OrganizationandBusinessDetails" id="silo_r_OrganizationandBusinessDetails">
        <link:definition>996008 - Disclosure - Organization and Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" id="silo_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996009 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable" id="silo_r_ScheduleofPotentiallyDilutiveSharesTable">
        <link:definition>996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Potentially Dilutive Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" id="silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsDetails">
        <link:definition>996011 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" id="silo_r_ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable">
        <link:definition>996012 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" id="silo_r_ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable">
        <link:definition>996013 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Summarizes Activity in the Company&#8217;s Short Term Investments and Equity Investments at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails" id="silo_r_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails">
        <link:definition>996014 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable" id="silo_r_ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable">
        <link:definition>996015 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of Operating Result of Discontinued Operations of the NFID Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/NoteReceivableDetails" id="silo_r_NoteReceivableDetails">
        <link:definition>996016 - Disclosure - Note Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofNoteReceivableTable" id="silo_r_ScheduleofNoteReceivableTable">
        <link:definition>996017 - Disclosure - Note Receivable (Details) - Schedule of Note Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/StockholdersEquityDetails" id="silo_r_StockholdersEquityDetails">
        <link:definition>996018 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable" id="silo_r_ScheduleofStockOptionActivitiesTable">
        <link:definition>996019 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of Stock Option Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable" id="silo_r_ScheduleofWarrantActivitiesTable">
        <link:definition>996020 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of Warrant Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ConcentrationsDetails" id="silo_r_ConcentrationsDetails">
        <link:definition>996021 - Disclosure - Concentrations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4i1C0FowDB+JJ6vZGU2Zb4gNMIwDsAMZiEWauoJ3WqFTBJuAnXEEK8HERTRlnFgqdFP3tTsASEsgw90kSc27NBp9xZy8aFids2zNA0ooYt/rIyM5RbAtUsrR+CCvvOHHRpObwWaCc38Zw==] CSR-->
      <link:roleType roleURI="http://www.silopharma.com/role/CommitmentsandContingenciesDetails" id="silo_r_CommitmentsandContingenciesDetails">
        <link:definition>996022 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable" id="silo_r_ScheduleofMilestonePaymentsTable">
        <link:definition>996023 - Disclosure - Commitments and Contingencies (Details) - Schedule of Milestone Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable" id="silo_r_ScheduleofMinimumAnnualRoyaltyPaymentsTable">
        <link:definition>996024 - Disclosure - Commitments and Contingencies (Details) - Schedule of Minimum Annual Royalty Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable" id="silo_r_ScheduleofShallPayUMBFeesTable">
        <link:definition>996025 - Disclosure - Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable" id="silo_r_ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable">
        <link:definition>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Amounts Due Under Sponsored Study and Research Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/IncomeTaxesDetails" id="silo_r_IncomeTaxesDetails">
        <link:definition>996027 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable" id="silo_r_ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable">
        <link:definition>996028 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable" id="silo_r_ScheduleofNetDeferredTaxAssetTable">
        <link:definition>996029 - Disclosure - Income Taxes (Details) - Schedule of Net Deferred Tax Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/SubsequentEventsDetails" id="silo_r_SubsequentEventsDetails">
        <link:definition>996030 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.silopharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd"/>
  <xs:element name="ScheduleOfPotentiallyDilutiveSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfPotentiallyDilutiveSharesAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfStockOptionActivitiesAbstract"/>
  <xs:element name="ScheduleOfWarrantActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfWarrantActivitiesAbstract"/>
  <xs:element name="ScheduleOfMilestonePaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfMilestonePaymentsAbstract"/>
  <xs:element name="ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract"/>
  <xs:element name="ScheduleOfShallPayUmbFeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfShallPayUmbFeesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract38"/>
  <xs:element name="CashPaidDuringThePeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CashPaidDuringThePeriodForAbstract"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract39"/>
  <xs:element name="PreferredStockDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="silo_PreferredStockDesignated"/>
  <xs:element name="PenaltyFromEarlyTerminationOfCD" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_PenaltyFromEarlyTerminationOfCD"/>
  <xs:element name="ProvisionForDoubtfulAccountsDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations"/>
  <xs:element name="AmortizationOfPrepaidStockbasedExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AmortizationOfPrepaidStockbasedExpense"/>
  <xs:element name="EquitySharesEarnedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_EquitySharesEarnedForServices"/>
  <xs:element name="ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments"/>
  <xs:element name="LiquidityPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_LiquidityPolicyTextBlock"/>
  <xs:element name="EquityInvestmentsAtFairValuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_EquityInvestmentsAtFairValuePolicyTextBlock"/>
  <xs:element name="PrepaidExpensesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PrepaidExpensesPolicyTextBlock"/>
  <xs:element name="CostOfRevenuesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CostOfRevenuesPolicyTextBlock"/>
  <xs:element name="ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock"/>
  <xs:element name="ScheduleOfMilestonePaymentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfMilestonePaymentsTableTextBlock"/>
  <xs:element name="ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock"/>
  <xs:element name="ScheduleOfShallPayUMBFeesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfShallPayUMBFeesTableTextBlock"/>
  <xs:element name="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"/>
  <xs:element name="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems"/>
  <xs:element name="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"/>
  <xs:element name="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems"/>
  <xs:element name="AdditionsOfShortTermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AdditionsOfShortTermInvestments"/>
  <xs:element name="AdditionsofEquitySecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AdditionsofEquitySecurities"/>
  <xs:element name="EquitySecuritiesSalesAtOriginalCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_EquitySecuritiesSalesAtOriginalCost"/>
  <xs:element name="StockholdersEquityDetailsScheduleofStockOptionActivitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems"/>
  <xs:element name="MilestoneBalanceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_MilestoneBalanceDescription"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_MilestonePayment"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable"/>
  <xs:element name="MinimumAnnualRoyaltyPaymentsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_MinimumAnnualRoyaltyPaymentsDescription"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems"/>
  <xs:element name="PaymentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentDescription"/>
  <xs:element name="OrganizationandBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_OrganizationandBusinessDetailsTable"/>
  <xs:element name="OrganizationandBusinessDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_OrganizationandBusinessDetailsLineItems"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_WorkingCapital"/>
  <xs:element name="CashSPICInsuredAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_CashSPICInsuredAmount"/>
  <xs:element name="BadDebtExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_BadDebtExpense"/>
  <xs:element name="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue"/>
  <xs:element name="DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable"/>
  <xs:element name="NoteReceivableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_NoteReceivableDetailsTable"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_StockholdersEquityDetailsTable"/>
  <xs:element name="PreferredStockShareDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="silo_PreferredStockShareDesignated"/>
  <xs:element name="RestrictedCommonSharePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_RestrictedCommonSharePrice"/>
  <xs:element name="CommonStockPurchaseCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockPurchaseCost"/>
  <xs:element name="AggregateOfIncentiveStockOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AggregateOfIncentiveStockOptions"/>
  <xs:element name="StockOptionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_StockOptionValue"/>
  <xs:element name="ConcentrationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_ConcentrationsDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="ExtensionFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_ExtensionFee"/>
  <xs:element name="CommercialSaleTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommercialSaleTerm"/>
  <xs:element name="LicenseAgreementExpire" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_LicenseAgreementExpire"/>
  <xs:element name="SublicenseIncomeReceivablePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SublicenseIncomeReceivablePercentage"/>
  <xs:element name="DueToRelatedPartieCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_DueToRelatedPartieCurrent"/>
  <xs:element name="SalesOfLicensedProductsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SalesOfLicensedProductsPercentage"/>
  <xs:element name="SublicenseIncomePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SublicenseIncomePercentage"/>
  <xs:element name="SublicenseAgreementAmountPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_SublicenseAgreementAmountPaid"/>
  <xs:element name="NonrefundableCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_NonrefundableCashPayment"/>
  <xs:element name="NetSalePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_NetSalePercentage"/>
  <xs:element name="LicensorShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_LicensorShare"/>
  <xs:element name="AggregateOfConvertedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AggregateOfConvertedShares"/>
  <xs:element name="RevenueTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_RevenueTerm"/>
  <xs:element name="TradingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_TradingPrice"/>
  <xs:element name="SecuritiesReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_SecuritiesReceived"/>
  <xs:element name="ConsiderationFeePayablePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ConsiderationFeePayablePercentage"/>
  <xs:element name="UpfrontLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UpfrontLicenseFees"/>
  <xs:element name="FirstCommercialSale" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_FirstCommercialSale"/>
  <xs:element name="AgreementShallExpire" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AgreementShallExpire"/>
  <xs:element name="SponsoredStudyAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_SponsoredStudyAgreement"/>
  <xs:element name="SponsoredResearchAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SponsoredResearchAgreementDescription"/>
  <xs:element name="ResearchProjectEstimatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ResearchProjectEstimatePercentage"/>
  <xs:element name="JointVentureInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_JointVentureInterestRate"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_SubsequentEventsDetailsTable"/>
  <xs:element name="AikidoPharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AikidoPharmaIncMember"/>
  <xs:element name="AmendedServiceAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AmendedServiceAgreementMember"/>
  <xs:element name="AmendmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AmendmentMember"/>
  <xs:element name="AmplifyBioResearchAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AmplifyBioResearchAgreementMember"/>
  <xs:element name="ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember"/>
  <xs:element name="CustomerConcentrationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CustomerConcentrationMember"/>
  <xs:element name="CustomerPatentLicenseAgreementWithAikidoPharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember"/>
  <xs:element name="CustomerSublicenseAgreementWithAikidoPharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember"/>
  <xs:element name="DanielRyweckMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_DanielRyweckMember"/>
  <xs:element name="DrJamesKuoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_DrJamesKuoMember"/>
  <xs:element name="EricWeisblumMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_EricWeisblumMember"/>
  <xs:element name="ExtensionFeeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ExtensionFeeMember"/>
  <xs:element name="FirstPaymentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_FirstPaymentMember"/>
  <xs:element name="HomeBistroIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_HomeBistroIncMember"/>
  <xs:element name="IncentiveStockOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_IncentiveStockOptionMember"/>
  <xs:element name="InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember"/>
  <xs:element name="JVAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_JVAgreementMember"/>
  <xs:element name="MasterLincenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_MasterLincenseAgreementMember"/>
  <xs:element name="MrWeisblumMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_MrWeisblumMember"/>
  <xs:element name="NoteReceivableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_NoteReceivableMember"/>
  <xs:element name="OmnibusEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_OmnibusEquityIncentivePlanMember"/>
  <xs:element name="PaymentFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentFiveMember"/>
  <xs:element name="PaymentFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentFourMember"/>
  <xs:element name="PaymentOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentOneMember"/>
  <xs:element name="PaymentThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentThreeMember"/>
  <xs:element name="PaymentTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentTwoMember"/>
  <xs:element name="PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PromissoryNoteMember"/>
  <xs:element name="ResearchAgreementWithAmplifyBioMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ResearchAgreementWithAmplifyBioMember"/>
  <xs:element name="ResearchAgreementWithReprocellMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ResearchAgreementWithReprocellMember"/>
  <xs:element name="ResearchAgreementsWithUppertonPharmaSolutionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ResearchAgreementsWithUppertonPharmaSolutionsMember"/>
  <xs:element name="SecondPaymentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SecondPaymentMember"/>
  <xs:element name="SeriesCConversionPriceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SeriesCConversionPriceMember"/>
  <xs:element name="SeriesCConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SeriesCConvertiblePreferredStockMember"/>
  <xs:element name="SeriesMConvertiblePreferredMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SeriesMConvertiblePreferredMember"/>
  <xs:element name="SponsoredResearchAgreementWithColumbiaUniversityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SponsoredResearchAgreementWithColumbiaUniversityMember"/>
  <xs:element name="SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember"/>
  <xs:element name="SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember"/>
  <xs:element name="StockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_StockOptionsMember"/>
  <xs:element name="SublicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SublicenseAgreementMember"/>
  <xs:element name="ThirdAmendmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ThirdAmendmentMember"/>
  <xs:element name="UniversityOfMarylandBaltimoreMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UniversityOfMarylandBaltimoreMember"/>
  <xs:element name="UppertonResearchAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UppertonResearchAgreementsMember"/>
  <xs:element name="VendorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_VendorMember"/>
  <xs:element name="ZylTherapeuticsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ZylTherapeuticsIncMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>silo-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 20:01:03 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedBalanceSheet" roleURI="http://www.silopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedIncomeStatement" roleURI="http://www.silopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedCashFlow" roleURI="http://www.silopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable" roleURI="http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofNoteReceivableTable" roleURI="http://www.silopharma.com/role/ScheduleofNoteReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable" roleURI="http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable" roleURI="http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_EquitySecuritiesFvNi" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalPreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalPreferredStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockPreferredValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockPreferredValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockPreferredValue" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ProfessionalFees" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralInsuranceExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="silo_PenaltyFromEarlyTerminationOfCD" xlink:href="silo-20231231.xsd#silo_PenaltyFromEarlyTerminationOfCD"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="silo_PenaltyFromEarlyTerminationOfCD" order="6" weight="-1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4i1C0FowDB+JJ6vZGU2Zb4gNMIwDsAMZiEWauoJ3WqFTBJuAnXEEK8HERTRlnFgqdFP3tTsASEsgw90kSc27NBp9xZy8aFids2zNA0ooYt/rKwajCU4Sfu/8AVM14SvTvBf2CinBusCNw==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:href="silo-20231231.xsd#silo_ProvisionForDoubtfulAccountsDiscontinuedOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense" xlink:href="silo-20231231.xsd#silo_AmortizationOfPrepaidStockbasedExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_EquitySharesEarnedForServices" xlink:href="silo-20231231.xsd#silo_EquitySharesEarnedForServices"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="silo_EquitySharesEarnedForServices" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInsuranceLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfOtherEquity" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofNoteReceivableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_NotesReceivableGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>silo-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 20:01:03 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedBalanceSheet" roleURI="http://www.silopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedIncomeStatement" roleURI="http://www.silopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ShareholdersEquityType2or3" roleURI="http://www.silopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedCashFlow" roleURI="http://www.silopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_OrganizationandBusiness" roleURI="http://www.silopharma.com/role/OrganizationandBusiness"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.silopharma.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurements" roleURI="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNFIDBusiness" roleURI="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_NoteReceivable" roleURI="http://www.silopharma.com/role/NoteReceivable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_StockholdersEquity" roleURI="http://www.silopharma.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_Concentrations" roleURI="http://www.silopharma.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_CommitmentsandContingencies" roleURI="http://www.silopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_IncomeTaxes" roleURI="http://www.silopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_SubsequentEvents" roleURI="http://www.silopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_AccountingPoliciesByPolicy" roleURI="http://www.silopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsTables" roleURI="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables" roleURI="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_NoteReceivableTables" roleURI="http://www.silopharma.com/role/NoteReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_StockholdersEquityTables" roleURI="http://www.silopharma.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_CommitmentsandContingenciesTables" roleURI="http://www.silopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_IncomeTaxesTables" roleURI="http://www.silopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofPotentiallyDilutiveSharesTable" roleURI="http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" roleURI="http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" roleURI="http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable" roleURI="http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofNoteReceivableTable" roleURI="http://www.silopharma.com/role/ScheduleofNoteReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofStockOptionActivitiesTable" roleURI="http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofWarrantActivitiesTable" roleURI="http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofMilestonePaymentsTable" roleURI="http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofMinimumAnnualRoyaltyPaymentsTable" roleURI="http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofShallPayUMBFeesTable" roleURI="http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable" roleURI="http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable" roleURI="http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofNetDeferredTaxAssetTable" roleURI="http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_OrganizationandBusinessDetails" roleURI="http://www.silopharma.com/role/OrganizationandBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" roleURI="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails" roleURI="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_NoteReceivableDetails" roleURI="http://www.silopharma.com/role/NoteReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_StockholdersEquityDetails" roleURI="http://www.silopharma.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConcentrationsDetails" roleURI="http://www.silopharma.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_CommitmentsandContingenciesDetails" roleURI="http://www.silopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_IncomeTaxesDetails" roleURI="http://www.silopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_SubsequentEventsDetails" roleURI="http://www.silopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#DocumentAndEntityInformation" roleURI="http://www.silopharma.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_EquitySecuritiesFvNi" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalPreferredStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockPreferredValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockPreferredValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockPreferredValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockDesignated" xlink:href="silo-20231231.xsd#silo_PreferredStockDesignated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="silo_PreferredStockDesignated" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralInsuranceExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PenaltyFromEarlyTerminationOfCD" xlink:href="silo-20231231.xsd#silo_PenaltyFromEarlyTerminationOfCD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="silo_PenaltyFromEarlyTerminationOfCD" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashIncludingDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashIncludingDiscontinuedOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CashIncludingDiscontinuedOperationsAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashIncludingDiscontinuedOperationsAbstract" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OciNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciNetOfTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OciNetOfTaxAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AociAttributableToNoncontrollingInterestMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:href="silo-20231231.xsd#silo_ProvisionForDoubtfulAccountsDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense" xlink:href="silo-20231231.xsd#silo_AmortizationOfPrepaidStockbasedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EquitySharesEarnedForServices" xlink:href="silo-20231231.xsd#silo_EquitySharesEarnedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="silo_EquitySharesEarnedForServices" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInsuranceLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfOtherEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CashPaidDuringThePeriodForAbstract" xlink:href="silo-20231231.xsd#silo_CashPaidDuringThePeriodForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="silo_CashPaidDuringThePeriodForAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" xlink:href="silo-20231231.xsd#silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/OrganizationandBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/NoteReceivable">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesReceivableNetAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/Concentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LiquidityPolicyTextBlock" xlink:href="silo-20231231.xsd#silo_LiquidityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_LiquidityPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtFairValuePolicyTextBlock" xlink:href="silo-20231231.xsd#silo_EquityInvestmentsAtFairValuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_EquityInvestmentsAtFairValuePolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PrepaidExpensesPolicyTextBlock" xlink:href="silo-20231231.xsd#silo_PrepaidExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_PrepaidExpensesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CostOfRevenuesPolicyTextBlock" xlink:href="silo-20231231.xsd#silo_CostOfRevenuesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_CostOfRevenuesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/NoteReceivableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesReceivableNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfMilestonePaymentsTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfMilestonePaymentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="silo_ScheduleOfMilestonePaymentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfShallPayUMBFeesTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfShallPayUMBFeesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="silo_ScheduleOfShallPayUMBFeesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable">
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable">
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquityMethodInvestmentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AdditionsOfShortTermInvestments" xlink:href="silo-20231231.xsd#silo_AdditionsOfShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="silo_AdditionsOfShortTermInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AdditionsofEquitySecurities" xlink:href="silo-20231231.xsd#silo_AdditionsofEquitySecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="silo_AdditionsofEquitySecurities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EquitySecuritiesSalesAtOriginalCost" xlink:href="silo-20231231.xsd#silo_EquitySecuritiesSalesAtOriginalCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="silo_EquitySecuritiesSalesAtOriginalCost" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofNoteReceivableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_NotesReceivableNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_NotesReceivableGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable" xlink:href="silo-20231231.xsd#silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_StockOptionsMember" xlink:href="silo-20231231.xsd#silo_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="silo_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:href="silo-20231231.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:href="silo-20231231.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:href="silo-20231231.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable">
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOneMember" xlink:href="silo-20231231.xsd#silo_PaymentOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentTwoMember" xlink:href="silo-20231231.xsd#silo_PaymentTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentThreeMember" xlink:href="silo-20231231.xsd#silo_PaymentThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFourMember" xlink:href="silo-20231231.xsd#silo_PaymentFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFiveMember" xlink:href="silo-20231231.xsd#silo_PaymentFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_MilestoneBalanceDescription" xlink:href="silo-20231231.xsd#silo_MilestoneBalanceDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" xlink:to="silo_MilestoneBalanceDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_MilestonePayment" xlink:href="silo-20231231.xsd#silo_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" xlink:to="silo_MilestonePayment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOneMember" xlink:href="silo-20231231.xsd#silo_PaymentOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentTwoMember" xlink:href="silo-20231231.xsd#silo_PaymentTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentThreeMember" xlink:href="silo-20231231.xsd#silo_PaymentThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFourMember" xlink:href="silo-20231231.xsd#silo_PaymentFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFiveMember" xlink:href="silo-20231231.xsd#silo_PaymentFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_MinimumAnnualRoyaltyPaymentsDescription" xlink:href="silo-20231231.xsd#silo_MinimumAnnualRoyaltyPaymentsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silo_MinimumAnnualRoyaltyPaymentsDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RoyaltyExpense" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable">
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOneMember" xlink:href="silo-20231231.xsd#silo_PaymentOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentTwoMember" xlink:href="silo-20231231.xsd#silo_PaymentTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentThreeMember" xlink:href="silo-20231231.xsd#silo_PaymentThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" xlink:to="us-gaap_PaymentsForFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentDescription" xlink:href="silo-20231231.xsd#silo_PaymentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" xlink:to="silo_PaymentDescription" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4i1C0FowDB+JJ6vZGU2Zb4gNMIwDsAMZiEWauoJ3WqFTBJuAnXEEK8HERTRlnFgqdFP3tTsASEsgw90kSc27NBp9xZy8aFids2zNA0ooYt/rIZScvPyfBB+DeGShfFwrqo81w06gJ7Nuw==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/OrganizationandBusinessDetails">
    <loc xlink:type="locator" xlink:label="silo_OrganizationandBusinessDetailsLineItems" xlink:href="silo-20231231.xsd#silo_OrganizationandBusinessDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_OrganizationandBusinessDetailsTable" xlink:href="silo-20231231.xsd#silo_OrganizationandBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_OrganizationandBusinessDetailsLineItems" xlink:to="silo_OrganizationandBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_OrganizationandBusinessDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_OrganizationandBusinessDetailsLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_OrganizationandBusinessDetailsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_OrganizationandBusinessDetailsLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_OrganizationandBusinessDetailsLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="silo-20231231.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="silo_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_BankTimeDepositsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_WorkingCapital" xlink:href="silo-20231231.xsd#silo_WorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="silo_WorkingCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CashSPICInsuredAmount" xlink:href="silo-20231231.xsd#silo_CashSPICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="silo_CashSPICInsuredAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PenaltyFromEarlyTerminationOfCD" xlink:href="silo-20231231.xsd#silo_PenaltyFromEarlyTerminationOfCD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="silo_PenaltyFromEarlyTerminationOfCD" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_BadDebtExpense" xlink:href="silo-20231231.xsd#silo_BadDebtExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="silo_BadDebtExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ReceivableWithImputedInterestFaceAmount" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_HomeBistroIncMember" xlink:href="silo-20231231.xsd#silo_HomeBistroIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="silo_HomeBistroIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AikidoPharmaIncMember" xlink:href="silo-20231231.xsd#silo_AikidoPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="silo_AikidoPharmaIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" xlink:href="silo-20231231.xsd#silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNoteMember" xlink:href="silo-20231231.xsd#silo_PromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PromissoryNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:href="silo-20231231.xsd#silo_ProvisionForDoubtfulAccountsDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_NotesReceivableNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/NoteReceivableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_NoteReceivableDetailsTable" xlink:href="silo-20231231.xsd#silo_NoteReceivableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="silo_NoteReceivableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_NoteReceivableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNoteMember" xlink:href="silo-20231231.xsd#silo_PromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PromissoryNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NoteReceivableMember" xlink:href="silo-20231231.xsd#silo_NoteReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_NoteReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:href="silo-20231231.xsd#silo_ProvisionForDoubtfulAccountsDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsTable" xlink:href="silo-20231231.xsd#silo_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="silo_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesCConvertiblePreferredStockMember" xlink:href="silo-20231231.xsd#silo_SeriesCConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="silo_SeriesCConvertiblePreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesCConversionPriceMember" xlink:href="silo-20231231.xsd#silo_SeriesCConversionPriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="silo_SeriesCConversionPriceMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember" xlink:href="silo-20231231.xsd#silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AmendmentMember" xlink:href="silo-20231231.xsd#silo_AmendmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silo_AmendmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_OmnibusEquityIncentivePlanMember" xlink:href="silo-20231231.xsd#silo_OmnibusEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silo_OmnibusEquityIncentivePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_IncentiveStockOptionMember" xlink:href="silo-20231231.xsd#silo_IncentiveStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silo_IncentiveStockOptionMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockShareDesignated" xlink:href="silo-20231231.xsd#silo_PreferredStockShareDesignated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="silo_PreferredStockShareDesignated" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_RestrictedCommonSharePrice" xlink:href="silo-20231231.xsd#silo_RestrictedCommonSharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="silo_RestrictedCommonSharePrice" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProfessionalFees" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockPurchaseCost" xlink:href="silo-20231231.xsd#silo_CommonStockPurchaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="silo_CommonStockPurchaseCost" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateOfIncentiveStockOptions" xlink:href="silo-20231231.xsd#silo_AggregateOfIncentiveStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="silo_AggregateOfIncentiveStockOptions" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_StockOptionValue" xlink:href="silo-20231231.xsd#silo_StockOptionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="silo_StockOptionValue" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredCompensationEquity" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="39" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_ConcentrationsDetailsTable" xlink:href="silo-20231231.xsd#silo_ConcentrationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="silo_ConcentrationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_ConcentrationsDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_VendorMember" xlink:href="silo-20231231.xsd#silo_VendorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="silo_VendorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CustomerConcentrationMember" xlink:href="silo-20231231.xsd#silo_CustomerConcentrationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="silo_CustomerConcentrationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseAgreementMember" xlink:href="silo-20231231.xsd#silo_SublicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="silo_SublicenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_JVAgreementMember" xlink:href="silo-20231231.xsd#silo_JVAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="silo_JVAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ExtensionFeeMember" xlink:href="silo-20231231.xsd#silo_ExtensionFeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="silo_ExtensionFeeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_FirstPaymentMember" xlink:href="silo-20231231.xsd#silo_FirstPaymentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="silo_FirstPaymentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SecondPaymentMember" xlink:href="silo-20231231.xsd#silo_SecondPaymentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="silo_SecondPaymentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ThirdAmendmentMember" xlink:href="silo-20231231.xsd#silo_ThirdAmendmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="silo_ThirdAmendmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesMConvertiblePreferredMember" xlink:href="silo-20231231.xsd#silo_SeriesMConvertiblePreferredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="silo_SeriesMConvertiblePreferredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EricWeisblumMember" xlink:href="silo-20231231.xsd#silo_EricWeisblumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_EricWeisblumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_MrWeisblumMember" xlink:href="silo-20231231.xsd#silo_MrWeisblumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_MrWeisblumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DanielRyweckMember" xlink:href="silo-20231231.xsd#silo_DanielRyweckMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_DanielRyweckMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DrJamesKuoMember" xlink:href="silo-20231231.xsd#silo_DrJamesKuoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_DrJamesKuoMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_UniversityOfMarylandBaltimoreMember" xlink:href="silo-20231231.xsd#silo_UniversityOfMarylandBaltimoreMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_UniversityOfMarylandBaltimoreMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_MasterLincenseAgreementMember" xlink:href="silo-20231231.xsd#silo_MasterLincenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_MasterLincenseAgreementMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember" xlink:href="silo-20231231.xsd#silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember" xlink:href="silo-20231231.xsd#silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember" xlink:href="silo-20231231.xsd#silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredResearchAgreementWithColumbiaUniversityMember" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementWithColumbiaUniversityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_SponsoredResearchAgreementWithColumbiaUniversityMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ResearchAgreementWithReprocellMember" xlink:href="silo-20231231.xsd#silo_ResearchAgreementWithReprocellMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_ResearchAgreementWithReprocellMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ResearchAgreementsWithUppertonPharmaSolutionsMember" xlink:href="silo-20231231.xsd#silo_ResearchAgreementsWithUppertonPharmaSolutionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_ResearchAgreementsWithUppertonPharmaSolutionsMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_UppertonResearchAgreementsMember" xlink:href="silo-20231231.xsd#silo_UppertonResearchAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_UppertonResearchAgreementsMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AmplifyBioResearchAgreementMember" xlink:href="silo-20231231.xsd#silo_AmplifyBioResearchAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_AmplifyBioResearchAgreementMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ResearchAgreementWithAmplifyBioMember" xlink:href="silo-20231231.xsd#silo_ResearchAgreementWithAmplifyBioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_ResearchAgreementWithAmplifyBioMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ZylTherapeuticsIncMember" xlink:href="silo-20231231.xsd#silo_ZylTherapeuticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_ZylTherapeuticsIncMember" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AmendedServiceAgreementMember" xlink:href="silo-20231231.xsd#silo_AmendedServiceAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_AmendedServiceAgreementMember" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OfficersCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToEmployees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsToEmployees" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDeferredCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherDeferredCostsNet" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForFees" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ExtensionFee" xlink:href="silo-20231231.xsd#silo_ExtensionFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_ExtensionFee" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommercialSaleTerm" xlink:href="silo-20231231.xsd#silo_CommercialSaleTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_CommercialSaleTerm" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseAgreementExpire" xlink:href="silo-20231231.xsd#silo_LicenseAgreementExpire"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_LicenseAgreementExpire" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseIncomeReceivablePercentage" xlink:href="silo-20231231.xsd#silo_SublicenseIncomeReceivablePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_SublicenseIncomeReceivablePercentage" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DueToRelatedPartieCurrent" xlink:href="silo-20231231.xsd#silo_DueToRelatedPartieCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_DueToRelatedPartieCurrent" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeesPaidOnAcceptancesResold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FeesPaidOnAcceptancesResold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_FeesPaidOnAcceptancesResold" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LongTermDebtTerm" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SalesOfLicensedProductsPercentage" xlink:href="silo-20231231.xsd#silo_SalesOfLicensedProductsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_SalesOfLicensedProductsPercentage" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesCommissionsAndFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SalesCommissionsAndFees" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseIncomePercentage" xlink:href="silo-20231231.xsd#silo_SublicenseIncomePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_SublicenseIncomePercentage" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseAgreementAmountPaid" xlink:href="silo-20231231.xsd#silo_SublicenseAgreementAmountPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_SublicenseAgreementAmountPaid" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NonrefundableCashPayment" xlink:href="silo-20231231.xsd#silo_NonrefundableCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_NonrefundableCashPayment" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NetSalePercentage" xlink:href="silo-20231231.xsd#silo_NetSalePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_NetSalePercentage" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LicensorShare" xlink:href="silo-20231231.xsd#silo_LicensorShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_LicensorShare" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateOfConvertedShares" xlink:href="silo-20231231.xsd#silo_AggregateOfConvertedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_AggregateOfConvertedShares" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_RevenueTerm" xlink:href="silo-20231231.xsd#silo_RevenueTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_RevenueTerm" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TradingPrice" xlink:href="silo-20231231.xsd#silo_TradingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_TradingPrice" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredRevenue" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_Cash" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SecuritiesReceived" xlink:href="silo-20231231.xsd#silo_SecuritiesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_SecuritiesReceived" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ConsiderationFeePayablePercentage" xlink:href="silo-20231231.xsd#silo_ConsiderationFeePayablePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_ConsiderationFeePayablePercentage" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_UpfrontLicenseFees" xlink:href="silo-20231231.xsd#silo_UpfrontLicenseFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_UpfrontLicenseFees" order="50" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_FirstCommercialSale" xlink:href="silo-20231231.xsd#silo_FirstCommercialSale"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_FirstCommercialSale" order="51" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AgreementShallExpire" xlink:href="silo-20231231.xsd#silo_AgreementShallExpire"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_AgreementShallExpire" order="52" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherNotesPayable" order="53" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredStudyAgreement" xlink:href="silo-20231231.xsd#silo_SponsoredStudyAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_SponsoredStudyAgreement" order="54" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RepaymentsOfOtherDebt" order="55" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="56" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="57" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" order="58" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="59" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredResearchAgreementDescription" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_SponsoredResearchAgreementDescription" order="60" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="61" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="62" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ResearchProjectEstimatePercentage" xlink:href="silo-20231231.xsd#silo_ResearchProjectEstimatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_ResearchProjectEstimatePercentage" order="63" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="64" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="65" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="66" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_JointVentureInterestRate" xlink:href="silo-20231231.xsd#silo_JointVentureInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="silo_JointVentureInterestRate" order="67" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="68" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForDepositsWithOtherInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDepositsWithOtherInstitutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForDepositsWithOtherInstitutions" order="69" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProfessionalFees" order="70" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_SubsequentEventsDetailsTable" xlink:href="silo-20231231.xsd#silo_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silo_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>silo-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 20:01:03 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long Term Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">GROSS PROFIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM CONTINUING OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">LOSS FROM CONTINUING OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xml:lang="en-US">LOSS FROM DISCONTINUED OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash in operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS - beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">CASH AND CASH EQUIVALENTS - end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Balance, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Balance, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl1" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US">Balance, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl0" xml:lang="en-US">Balance, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl1" xml:lang="en-US">Equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Disposal of the Discontinued Operations of the NFID Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract_lbl" xml:lang="en-US">Schedule of Operating Result of Discontinued Operations of the NFID Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableNetAbstract_lbl" xml:lang="en-US">Note Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNetAbstract" xlink:to="us-gaap_NotesReceivableNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Schedule of Note Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Note receivable &#8211; current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl0" xml:lang="en-US">Note receivable, including interest receivable of $9,600 and $6,010 at December 31, 2023 and 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl1" xml:lang="en-US">Outstanding receivable balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl2" xml:lang="en-US">Total receivable balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Options, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Equity instruments at fair value of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Ending (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Concentrations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xml:lang="en-US">Debt Conversion Description [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAbstract_lbl" xml:lang="en-US">Schedule of Future Amounts Due Under Sponsored Study and Research Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl" xml:lang="en-US">Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total provision for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Total deferred tax asset before valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expense and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US">Interest receivable current (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestReceivableCurrent_lbl0" xml:lang="en-US">Accrued interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses and other assets - non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract" xlink:to="silo_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue - current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred revenue current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract0" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract0" xlink:to="silo_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue - long-term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl0" xml:lang="en-US">Deferred revenue long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract1" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract1" xlink:to="silo_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract2" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract2" xlink:to="silo_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract3" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract3" xlink:to="silo_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitment and Contingencies (see Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract4" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract4" xlink:to="silo_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value, 5,000,000 shares authorized: none designated as of December 31, 2023 Common stock, $0.0001 par value, 100,000,000 shares authorized; 3,159,096 and 3,158,797 shares issued and 2,906,241 and 3,158,797 shares outstanding at December 31, 2023 and 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockDesignated" xlink:href="silo-20231231.xsd#silo_PreferredStockDesignated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PreferredStockDesignated_lbl" xml:lang="en-US">Preferred stock, designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockDesignated" xlink:to="silo_PreferredStockDesignated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:to="us-gaap_AdditionalPaidInCapitalPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract5" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract5" xlink:to="silo_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">LICENSE FEE REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract6" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract6" xlink:to="silo_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract7" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract7" xlink:to="silo_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Stock-based professional fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xml:lang="en-US">Insurance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Bad debt recovery</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract8" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract8" xlink:to="silo_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract9" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract9" xlink:to="silo_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US">Interest and dividend income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income from equity shares earned for lock up agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xml:lang="en-US">Net realized loss on equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl0" xml:lang="en-US">Net realized loss on equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Net unrealized loss on equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Net unrealized loss on equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1" xml:lang="en-US">Unrealized loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl2" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl2"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract10" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract10" xlink:to="silo_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract11" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract11" xlink:to="silo_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract12" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract12" xlink:to="silo_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract13" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract13" xlink:to="silo_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashIncludingDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashIncludingDiscontinuedOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashIncludingDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">DISCONTINUED OPERATIONS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashIncludingDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashIncludingDiscontinuedOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract14" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract14" xlink:to="silo_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract15" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract15" xlink:to="silo_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract16" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract16" xlink:to="silo_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">COMPREHENSIVE LOSS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract17" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract17" xlink:to="silo_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OciNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciNetOfTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OciNetOfTaxAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_OciNetOfTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Unrealized loss on short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl0" xml:lang="en-US">Unrealized losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract18" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract18" xlink:to="silo_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract19" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract19" xlink:to="silo_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Continuing operations - basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Continuing operations - diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Discontinued operations - basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Discontinued operations - diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract20" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract20" xlink:to="silo_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract21" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract21" xlink:to="silo_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sales of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sales of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract22" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract22" xlink:to="silo_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Accretion of stock options expense to stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract23" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract23" xlink:to="silo_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common shares issued for professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common shares issued for professional fees (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract24" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract24" xlink:to="silo_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Common stock issued for conversion of Series C preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract25" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract25" xlink:to="silo_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Rounding of share due to reverse stock split (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract26" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract26" xlink:to="silo_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract27" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract27" xlink:to="silo_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract28" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract28" xlink:to="silo_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract29" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract29" xlink:to="silo_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US">Purchase of treasury stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract30" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract30" xlink:to="silo_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss - short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract31" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract31" xlink:to="silo_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract32" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract32" xlink:to="silo_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:href="silo-20231231.xsd#silo_ProvisionForDoubtfulAccountsDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations_lbl" xml:lang="en-US">Bad debt expense - discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:to="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations_lbl0" xml:lang="en-US">Bad debt expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:to="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation and professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense" xlink:href="silo-20231231.xsd#silo_AmortizationOfPrepaidStockbasedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense_lbl" xml:lang="en-US">Amortization of prepaid stock-based professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmortizationOfPrepaidStockbasedExpense" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EquitySharesEarnedForServices" xlink:href="silo-20231231.xsd#silo_EquitySharesEarnedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EquitySharesEarnedForServices_lbl" xml:lang="en-US">Equity shares earned for lock up agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquitySharesEarnedForServices" xlink:to="silo_EquitySharesEarnedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInInsuranceLiabilities_lbl" xml:lang="en-US">Insurance payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:to="us-gaap_IncreaseDecreaseInInsuranceLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract33" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract33" xlink:to="silo_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable_lbl" xml:lang="en-US">Collection on note receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract34" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract34" xlink:to="silo_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Aggregate net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract35" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract35" xlink:to="silo_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract36" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract36" xlink:to="silo_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract37" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract37" xlink:to="silo_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract38" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract38" xlink:to="silo_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CashPaidDuringThePeriodForAbstract" xlink:href="silo-20231231.xsd#silo_CashPaidDuringThePeriodForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CashPaidDuringThePeriodForAbstract_lbl" xml:lang="en-US">Cash paid during the period for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashPaidDuringThePeriodForAbstract" xlink:to="silo_CashPaidDuringThePeriodForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract39" xlink:href="silo-20231231.xsd#silo_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract39" xlink:to="silo_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" xlink:href="silo-20231231.xsd#silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments_lbl" xml:lang="en-US">Change in accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" xlink:to="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Common stock issued for future services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockPreferredValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockPreferredValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockPreferredValue_lbl" xml:lang="en-US">Treasury stock, at cost (252,855 and 0 shares on December 31, 2023 and 2022, respectively)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockPreferredValue" xlink:to="us-gaap_TreasuryStockPreferredValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PenaltyFromEarlyTerminationOfCD" xlink:href="silo-20231231.xsd#silo_PenaltyFromEarlyTerminationOfCD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="silo_PenaltyFromEarlyTerminationOfCD_lbl" xml:lang="en-US">Penalty from early termination of CD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PenaltyFromEarlyTerminationOfCD" xlink:to="silo_PenaltyFromEarlyTerminationOfCD_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PenaltyFromEarlyTerminationOfCD_lbl0" xml:lang="en-US">Penalty paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PenaltyFromEarlyTerminationOfCD" xlink:to="silo_PenaltyFromEarlyTerminationOfCD_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Common stock issued for conversion of Series C preferred stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Convertible common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xml:lang="en-US">Purchase of treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl0" xml:lang="en-US">Repurchase of shares (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl" xml:lang="en-US">Purchase of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity_lbl" xml:lang="en-US">Purchase of treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:to="us-gaap_PaymentsForRepurchaseOfOtherEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AociAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AociAttributableToNoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">ORGANIZATION AND BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl0" xml:lang="en-US">Equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Summarizes Activity in the Company&#8217;s Short Term Investments and Equity Investments at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock" xlink:to="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AdditionsOfShortTermInvestments" xlink:href="silo-20231231.xsd#silo_AdditionsOfShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AdditionsOfShortTermInvestments_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionsOfShortTermInvestments" xlink:to="silo_AdditionsOfShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AdditionsofEquitySecurities" xlink:href="silo-20231231.xsd#silo_AdditionsofEquitySecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AdditionsofEquitySecurities_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionsofEquitySecurities" xlink:to="silo_AdditionsofEquitySecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">DISPOSAL OF THE DISCONTINUED OPERATIONS OF THE NFID BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of Operating Result of Discontinued Operations of the NFID Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Product sales, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Gross loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl" xml:lang="en-US">Loss from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">NOTE RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of Note Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesReceivableNet_lbl" xml:lang="en-US">Principal amount of note receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesReceivableNet_lbl0" xml:lang="en-US">Note receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesReceivableGross_lbl" xml:lang="en-US">Subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_NotesReceivableGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years). Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:href="silo-20231231.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercisable per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years). Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Fair value per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:href="silo-20231231.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable_lbl" xml:lang="en-US">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:href="silo-20231231.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfMilestonePaymentsTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfMilestonePaymentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ScheduleOfMilestonePaymentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMilestonePaymentsTableTextBlock" xlink:to="silo_ScheduleOfMilestonePaymentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_MilestoneBalanceDescription" xlink:href="silo-20231231.xsd#silo_MilestoneBalanceDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_MilestoneBalanceDescription_lbl" xml:lang="en-US">Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MilestoneBalanceDescription" xlink:to="silo_MilestoneBalanceDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_MilestonePayment" xlink:href="silo-20231231.xsd#silo_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_MilestonePayment_lbl" xml:lang="en-US">Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MilestonePayment" xlink:to="silo_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Minimum Annual Royalty Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock" xlink:to="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_MinimumAnnualRoyaltyPaymentsDescription" xlink:href="silo-20231231.xsd#silo_MinimumAnnualRoyaltyPaymentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_MinimumAnnualRoyaltyPaymentsDescription_lbl" xml:lang="en-US">Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MinimumAnnualRoyaltyPaymentsDescription" xlink:to="silo_MinimumAnnualRoyaltyPaymentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Minimum Annual Royalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfShallPayUMBFeesTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfShallPayUMBFeesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ScheduleOfShallPayUMBFeesTableTextBlock_lbl" xml:lang="en-US">Schedule of Shall Pay UMB Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfShallPayUMBFeesTableTextBlock" xlink:to="silo_ScheduleOfShallPayUMBFeesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentDescription" xlink:href="silo-20231231.xsd#silo_PaymentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentDescription_lbl" xml:lang="en-US">Payment description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentDescription" xlink:to="silo_PaymentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Amounts Due Under Sponsored Study and Research Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax benefit at U.S. statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Income tax benefit &#8211; state</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Valuation allowance increased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred Tax Asset:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EquitySecuritiesSalesAtOriginalCost" xlink:href="silo-20231231.xsd#silo_EquitySecuritiesSalesAtOriginalCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="silo_EquitySecuritiesSalesAtOriginalCost_lbl" xml:lang="en-US">Sales at original cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquitySecuritiesSalesAtOriginalCost" xlink:to="silo_EquitySecuritiesSalesAtOriginalCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xml:lang="en-US">Total operating and other non-operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xml:lang="en-US">Less: allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US">Short-Term Investments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsMember_lbl" xml:lang="en-US">Equity Investments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsMember" xlink:to="us-gaap_EquityMethodInvestmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_StockOptionsMember" xlink:href="silo-20231231.xsd#silo_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockOptionsMember" xlink:to="silo_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOneMember" xlink:href="silo-20231231.xsd#silo_PaymentOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentOneMember_lbl" xml:lang="en-US">Payment One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentOneMember" xlink:to="silo_PaymentOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentTwoMember" xlink:href="silo-20231231.xsd#silo_PaymentTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentTwoMember_lbl" xml:lang="en-US">Payment Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentTwoMember" xlink:to="silo_PaymentTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentThreeMember" xlink:href="silo-20231231.xsd#silo_PaymentThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentThreeMember_lbl" xml:lang="en-US">Payment Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentThreeMember" xlink:to="silo_PaymentThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFourMember" xlink:href="silo-20231231.xsd#silo_PaymentFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentFourMember_lbl" xml:lang="en-US">Payment Four [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentFourMember" xlink:to="silo_PaymentFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFiveMember" xlink:href="silo-20231231.xsd#silo_PaymentFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentFiveMember_lbl" xml:lang="en-US">Payment Five [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentFiveMember" xlink:to="silo_PaymentFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl" xml:lang="en-US">Promissory note amounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xml:lang="en-US">Promissory note bears interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_WorkingCapital" xlink:href="silo-20231231.xsd#silo_WorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_WorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WorkingCapital" xlink:to="silo_WorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal deposit insurance corporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CashSPICInsuredAmount" xlink:href="silo-20231231.xsd#silo_CashSPICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CashSPICInsuredAmount_lbl" xml:lang="en-US">Securities investor protection corporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashSPICInsuredAmount" xlink:to="silo_CashSPICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_BadDebtExpense" xlink:href="silo-20231231.xsd#silo_BadDebtExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_BadDebtExpense_lbl" xml:lang="en-US">Bad debt expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_BadDebtExpense" xlink:to="silo_BadDebtExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivableWithImputedInterestFaceAmount_lbl" xml:lang="en-US">Note receivable principal balance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:to="us-gaap_ReceivableWithImputedInterestFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Prepaid expenses and other assets &#8211; non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue_lbl" xml:lang="en-US">Grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl" xml:lang="en-US">sale of equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Promissory note amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Bears interest per annum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xml:lang="en-US">Shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockShareDesignated" xlink:href="silo-20231231.xsd#silo_PreferredStockShareDesignated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PreferredStockShareDesignated_lbl" xml:lang="en-US">Designated shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockShareDesignated" xlink:to="silo_PreferredStockShareDesignated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Stated value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Convertible preferred stock, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Series C convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Share issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Purchase additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Public offering price per shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Issued warrants to purchase an aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted common value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_RestrictedCommonSharePrice" xlink:href="silo-20231231.xsd#silo_RestrictedCommonSharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_RestrictedCommonSharePrice_lbl" xml:lang="en-US">Restricted common share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RestrictedCommonSharePrice" xlink:to="silo_RestrictedCommonSharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xml:lang="en-US">Stock repurchase program (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl0" xml:lang="en-US">Stock repurchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Common stock purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockPurchaseCost" xlink:href="silo-20231231.xsd#silo_CommonStockPurchaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockPurchaseCost_lbl" xml:lang="en-US">Common stock purchase cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockPurchaseCost" xlink:to="silo_CommonStockPurchaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">of common stock reserved and avail for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Common stock issued under the plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateOfIncentiveStockOptions" xlink:href="silo-20231231.xsd#silo_AggregateOfIncentiveStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AggregateOfIncentiveStockOptions_lbl" xml:lang="en-US">Aggregate of incentive stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfIncentiveStockOptions" xlink:to="silo_AggregateOfIncentiveStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_StockOptionValue" xlink:href="silo-20231231.xsd#silo_StockOptionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_StockOptionValue_lbl" xml:lang="en-US">Stock option value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockOptionValue" xlink:to="silo_StockOptionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationEquity_lbl" xml:lang="en-US">Deferred compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationEquity" xlink:to="us-gaap_DeferredCompensationEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock options vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Fair value of unvested stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair value of stock option (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0" xml:lang="en-US">Fair value of stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Fair value of the unvested stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl0" xml:lang="en-US">Fair value of the unvested stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US">Issuance of deferred compensation balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Purchase aggregate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Base salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xml:lang="en-US">Vested common stock shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl" xml:lang="en-US">Signing bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xml:lang="en-US">Annual bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToEmployees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToEmployees_lbl" xml:lang="en-US">Paid bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToEmployees" xlink:to="us-gaap_PaymentsToEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Share granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Expire date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vests (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Stock option (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDeferredCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDeferredCostsNet_lbl" xml:lang="en-US">Amortized deferred compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCostsNet" xlink:to="us-gaap_OtherDeferredCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Deferred compensation balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ExtensionFee" xlink:href="silo-20231231.xsd#silo_ExtensionFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ExtensionFee_lbl" xml:lang="en-US">Extension Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ExtensionFee" xlink:to="silo_ExtensionFee_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommercialSaleTerm" xlink:href="silo-20231231.xsd#silo_CommercialSaleTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommercialSaleTerm_lbl" xml:lang="en-US">Commercial sale term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommercialSaleTerm" xlink:to="silo_CommercialSaleTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseAgreementExpire" xlink:href="silo-20231231.xsd#silo_LicenseAgreementExpire"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LicenseAgreementExpire_lbl" xml:lang="en-US">License agreement expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseAgreementExpire" xlink:to="silo_LicenseAgreementExpire_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseIncomeReceivablePercentage" xlink:href="silo-20231231.xsd#silo_SublicenseIncomeReceivablePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SublicenseIncomeReceivablePercentage_lbl" xml:lang="en-US">percentage of sublicense income receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomeReceivablePercentage" xlink:to="silo_SublicenseIncomeReceivablePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DueToRelatedPartieCurrent" xlink:href="silo-20231231.xsd#silo_DueToRelatedPartieCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DueToRelatedPartieCurrent_lbl" xml:lang="en-US">Due amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DueToRelatedPartieCurrent" xlink:to="silo_DueToRelatedPartieCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeesPaidOnAcceptancesResold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FeesPaidOnAcceptancesResold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FeesPaidOnAcceptancesResold_lbl" xml:lang="en-US">Paid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeesPaidOnAcceptancesResold" xlink:to="us-gaap_FeesPaidOnAcceptancesResold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US">Term year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xml:lang="en-US">Prepaid expenses non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SalesOfLicensedProductsPercentage" xlink:href="silo-20231231.xsd#silo_SalesOfLicensedProductsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SalesOfLicensedProductsPercentage_lbl" xml:lang="en-US">Sales of licensed products percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SalesOfLicensedProductsPercentage" xlink:to="silo_SalesOfLicensedProductsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesCommissionsAndFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesCommissionsAndFees_lbl" xml:lang="en-US">Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseIncomePercentage" xlink:href="silo-20231231.xsd#silo_SublicenseIncomePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SublicenseIncomePercentage_lbl" xml:lang="en-US">Sublicense income, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomePercentage" xlink:to="silo_SublicenseIncomePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseAgreementAmountPaid" xlink:href="silo-20231231.xsd#silo_SublicenseAgreementAmountPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SublicenseAgreementAmountPaid_lbl" xml:lang="en-US">Sublicense agreement amount paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAgreementAmountPaid" xlink:to="silo_SublicenseAgreementAmountPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US">License fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NonrefundableCashPayment" xlink:href="silo-20231231.xsd#silo_NonrefundableCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NonrefundableCashPayment_lbl" xml:lang="en-US">Non-refundable cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NonrefundableCashPayment" xlink:to="silo_NonrefundableCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NetSalePercentage" xlink:href="silo-20231231.xsd#silo_NetSalePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NetSalePercentage_lbl" xml:lang="en-US">Net sale percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetSalePercentage" xlink:to="silo_NetSalePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LicensorShare" xlink:href="silo-20231231.xsd#silo_LicensorShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LicensorShare_lbl" xml:lang="en-US">Licensor share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicensorShare" xlink:to="silo_LicensorShare_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateOfConvertedShares" xlink:href="silo-20231231.xsd#silo_AggregateOfConvertedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AggregateOfConvertedShares_lbl" xml:lang="en-US">Aggregate of converted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfConvertedShares" xlink:to="silo_AggregateOfConvertedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_RevenueTerm" xlink:href="silo-20231231.xsd#silo_RevenueTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_RevenueTerm_lbl" xml:lang="en-US">Revenue term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RevenueTerm" xlink:to="silo_RevenueTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Convertible preferred stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US">Common stock shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xml:lang="en-US">Per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_TradingPrice" xlink:href="silo-20231231.xsd#silo_TradingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_TradingPrice_lbl" xml:lang="en-US">Trading price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TradingPrice" xlink:to="silo_TradingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SecuritiesReceived" xlink:href="silo-20231231.xsd#silo_SecuritiesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SecuritiesReceived_lbl" xml:lang="en-US">Securities received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SecuritiesReceived" xlink:to="silo_SecuritiesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xml:lang="en-US">Recognized revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConsiderationFeePayablePercentage" xlink:href="silo-20231231.xsd#silo_ConsiderationFeePayablePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ConsiderationFeePayablePercentage_lbl" xml:lang="en-US">Consideration fee payable percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConsiderationFeePayablePercentage" xlink:to="silo_ConsiderationFeePayablePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UpfrontLicenseFees" xlink:href="silo-20231231.xsd#silo_UpfrontLicenseFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UpfrontLicenseFees_lbl" xml:lang="en-US">Upfront license fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UpfrontLicenseFees" xlink:to="silo_UpfrontLicenseFees_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FirstCommercialSale" xlink:href="silo-20231231.xsd#silo_FirstCommercialSale"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_FirstCommercialSale_lbl" xml:lang="en-US">First commercial sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FirstCommercialSale" xlink:to="silo_FirstCommercialSale_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AgreementShallExpire" xlink:href="silo-20231231.xsd#silo_AgreementShallExpire"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AgreementShallExpire_lbl" xml:lang="en-US">Agreement shall expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AgreementShallExpire" xlink:to="silo_AgreementShallExpire_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Installments payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredStudyAgreement" xlink:href="silo-20231231.xsd#silo_SponsoredStudyAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SponsoredStudyAgreement_lbl" xml:lang="en-US">Sponsored study agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredStudyAgreement" xlink:to="silo_SponsoredStudyAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfOtherDebt_lbl" xml:lang="en-US">Cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherDebt" xlink:to="us-gaap_RepaymentsOfOtherDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Remaining amount due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Amortization of the prepaid research and development fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredResearchAgreementDescription" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SponsoredResearchAgreementDescription_lbl" xml:lang="en-US">Sponsored research agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementDescription" xlink:to="silo_SponsoredResearchAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ResearchProjectEstimatePercentage" xlink:href="silo-20231231.xsd#silo_ResearchProjectEstimatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ResearchProjectEstimatePercentage_lbl" xml:lang="en-US">Percentage of estimate research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ResearchProjectEstimatePercentage" xlink:to="silo_ResearchProjectEstimatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Aggregate total fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Contribution cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_JointVentureInterestRate" xlink:href="silo-20231231.xsd#silo_JointVentureInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_JointVentureInterestRate_lbl" xml:lang="en-US">Joint venture interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_JointVentureInterestRate" xlink:to="silo_JointVentureInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Option expired term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForDepositsWithOtherInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDepositsWithOtherInstitutions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForDepositsWithOtherInstitutions_lbl" xml:lang="en-US">Payments to the university</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForDepositsWithOtherInstitutions" xlink:to="us-gaap_PaymentsForDepositsWithOtherInstitutions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent_lbl" xml:lang="en-US">Valuation allowance percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent" xlink:to="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Net operating loss carry forwards to reduce the asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Share purchased (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Share purchased cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LiquidityPolicyTextBlock" xlink:href="silo-20231231.xsd#silo_LiquidityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LiquidityPolicyTextBlock" xlink:to="silo_LiquidityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtFairValuePolicyTextBlock" xlink:href="silo-20231231.xsd#silo_EquityInvestmentsAtFairValuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EquityInvestmentsAtFairValuePolicyTextBlock_lbl" xml:lang="en-US">Equity Investments, at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtFairValuePolicyTextBlock" xlink:to="silo_EquityInvestmentsAtFairValuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Note Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PrepaidExpensesPolicyTextBlock" xlink:href="silo-20231231.xsd#silo_PrepaidExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PrepaidExpensesPolicyTextBlock_lbl" xml:lang="en-US">Prepaid Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PrepaidExpensesPolicyTextBlock" xlink:to="silo_PrepaidExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CostOfRevenuesPolicyTextBlock" xlink:href="silo-20231231.xsd#silo_CostOfRevenuesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CostOfRevenuesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CostOfRevenuesPolicyTextBlock" xlink:to="silo_CostOfRevenuesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4i1C0FowDB+JJ6vZGU2Zb4gNMIwDsAMZiEWauoJ3WqFTBJuAnXEEK8HERTRlnFgqdFP3tTsASEsgw90kSc27NBp9xZy8aFids2zNA0ooYt/rIZScvPyfBB+3NfaOEBXYKb74ImUjhER0g==] CSR-->
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BankTimeDepositsMember_lbl" xml:lang="en-US">Bank Time Deposits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankTimeDepositsMember" xlink:to="us-gaap_BankTimeDepositsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_HomeBistroIncMember" xlink:href="silo-20231231.xsd#silo_HomeBistroIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_HomeBistroIncMember_lbl" xml:lang="en-US">Home Bistro, Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_HomeBistroIncMember" xlink:to="silo_HomeBistroIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silo_HomeBistroIncMember_lbl0" xml:lang="en-US">Home Bistro, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_HomeBistroIncMember" xlink:to="silo_HomeBistroIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_AikidoPharmaIncMember" xlink:href="silo-20231231.xsd#silo_AikidoPharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AikidoPharmaIncMember_lbl" xml:lang="en-US">Aikido Pharma, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AikidoPharmaIncMember" xlink:to="silo_AikidoPharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNoteMember" xlink:href="silo-20231231.xsd#silo_PromissoryNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNoteMember" xlink:to="silo_PromissoryNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NoteReceivableMember" xlink:href="silo-20231231.xsd#silo_NoteReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NoteReceivableMember_lbl" xml:lang="en-US">Note Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NoteReceivableMember" xlink:to="silo_NoteReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AmendmentMember" xlink:href="silo-20231231.xsd#silo_AmendmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AmendmentMember_lbl" xml:lang="en-US">Amendment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmendmentMember" xlink:to="silo_AmendmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesCConvertiblePreferredStockMember" xlink:href="silo-20231231.xsd#silo_SeriesCConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesCConvertiblePreferredStockMember" xlink:to="silo_SeriesCConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesCConversionPriceMember" xlink:href="silo-20231231.xsd#silo_SeriesCConversionPriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SeriesCConversionPriceMember_lbl" xml:lang="en-US">Series C Conversion Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesCConversionPriceMember" xlink:to="silo_SeriesCConversionPriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredClassBMember_lbl" xml:lang="en-US">Preferred Class B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember" xlink:href="silo-20231231.xsd#silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember_lbl" xml:lang="en-US">Conversion of Series C Convertible Preferred Stock into Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember" xlink:to="silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_OmnibusEquityIncentivePlanMember" xlink:href="silo-20231231.xsd#silo_OmnibusEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">Omnibus Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OmnibusEquityIncentivePlanMember" xlink:to="silo_OmnibusEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board Granted [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl1" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="silo_IncentiveStockOptionMember" xlink:href="silo-20231231.xsd#silo_IncentiveStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IncentiveStockOptionMember_lbl" xml:lang="en-US">Incentive Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncentiveStockOptionMember" xlink:to="silo_IncentiveStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CustomerConcentrationMember" xlink:href="silo-20231231.xsd#silo_CustomerConcentrationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CustomerConcentrationMember_lbl" xml:lang="en-US">Customer Concentration [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CustomerConcentrationMember" xlink:to="silo_CustomerConcentrationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Vendor Concentraion Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_VendorMember" xlink:href="silo-20231231.xsd#silo_VendorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_VendorMember_lbl" xml:lang="en-US">Vendor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_VendorMember" xlink:to="silo_VendorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EricWeisblumMember" xlink:href="silo-20231231.xsd#silo_EricWeisblumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EricWeisblumMember_lbl" xml:lang="en-US">Eric Weisblum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EricWeisblumMember" xlink:to="silo_EricWeisblumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_MrWeisblumMember" xlink:href="silo-20231231.xsd#silo_MrWeisblumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_MrWeisblumMember_lbl" xml:lang="en-US">Mr. Weisblum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MrWeisblumMember" xlink:to="silo_MrWeisblumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DanielRyweckMember" xlink:href="silo-20231231.xsd#silo_DanielRyweckMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DanielRyweckMember_lbl" xml:lang="en-US">Daniel Ryweck [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DanielRyweckMember" xlink:to="silo_DanielRyweckMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DrJamesKuoMember" xlink:href="silo-20231231.xsd#silo_DrJamesKuoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DrJamesKuoMember_lbl" xml:lang="en-US">Dr. James Kuo [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DrJamesKuoMember" xlink:to="silo_DrJamesKuoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk-Free interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Dividend Yield [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Expected Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ThirdAmendmentMember" xlink:href="silo-20231231.xsd#silo_ThirdAmendmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ThirdAmendmentMember_lbl" xml:lang="en-US">Third Amendment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ThirdAmendmentMember" xlink:to="silo_ThirdAmendmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UniversityOfMarylandBaltimoreMember" xlink:href="silo-20231231.xsd#silo_UniversityOfMarylandBaltimoreMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UniversityOfMarylandBaltimoreMember_lbl" xml:lang="en-US">University of Maryland Baltimore [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UniversityOfMarylandBaltimoreMember" xlink:to="silo_UniversityOfMarylandBaltimoreMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ExtensionFeeMember" xlink:href="silo-20231231.xsd#silo_ExtensionFeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ExtensionFeeMember_lbl" xml:lang="en-US">Extension fee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ExtensionFeeMember" xlink:to="silo_ExtensionFeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseMember_lbl0" xml:lang="en-US">License [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_MasterLincenseAgreementMember" xlink:href="silo-20231231.xsd#silo_MasterLincenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_MasterLincenseAgreementMember_lbl" xml:lang="en-US">Master Lincense Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MasterLincenseAgreementMember" xlink:to="silo_MasterLincenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseAgreementMember" xlink:href="silo-20231231.xsd#silo_SublicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SublicenseAgreementMember_lbl" xml:lang="en-US">Sublicense Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAgreementMember" xlink:to="silo_SublicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember" xlink:href="silo-20231231.xsd#silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember_lbl" xml:lang="en-US">Customer Patent License Agreement with Aikido Pharma Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember" xlink:to="silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesMConvertiblePreferredMember" xlink:href="silo-20231231.xsd#silo_SeriesMConvertiblePreferredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SeriesMConvertiblePreferredMember_lbl" xml:lang="en-US">Series M Convertible Preferred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesMConvertiblePreferredMember" xlink:to="silo_SeriesMConvertiblePreferredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember" xlink:href="silo-20231231.xsd#silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember_lbl" xml:lang="en-US">Customer Sublicense Agreement with Aikido Pharma Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember" xlink:to="silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember" xlink:href="silo-20231231.xsd#silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember_lbl" xml:lang="en-US">Investigator-Sponsored Study Agreement with University of Maryland, Baltimore [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember" xlink:to="silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember_lbl" xml:lang="en-US">Sponsored Research Agreement with The Regents of the University of California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:to="silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredResearchAgreementWithColumbiaUniversityMember" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementWithColumbiaUniversityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SponsoredResearchAgreementWithColumbiaUniversityMember_lbl" xml:lang="en-US">Sponsored Research Agreement with Columbia University [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementWithColumbiaUniversityMember" xlink:to="silo_SponsoredResearchAgreementWithColumbiaUniversityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember_lbl" xml:lang="en-US">Sponsored Research Agreement with University of Maryland, Baltimore [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember" xlink:to="silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FirstPaymentMember" xlink:href="silo-20231231.xsd#silo_FirstPaymentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_FirstPaymentMember_lbl" xml:lang="en-US">First Payment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FirstPaymentMember" xlink:to="silo_FirstPaymentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SecondPaymentMember" xlink:href="silo-20231231.xsd#silo_SecondPaymentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SecondPaymentMember_lbl" xml:lang="en-US">Second Payment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SecondPaymentMember" xlink:to="silo_SecondPaymentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ResearchAgreementWithReprocellMember" xlink:href="silo-20231231.xsd#silo_ResearchAgreementWithReprocellMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ResearchAgreementWithReprocellMember_lbl" xml:lang="en-US">Research Agreement with Reprocell [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ResearchAgreementWithReprocellMember" xlink:to="silo_ResearchAgreementWithReprocellMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ResearchAgreementsWithUppertonPharmaSolutionsMember" xlink:href="silo-20231231.xsd#silo_ResearchAgreementsWithUppertonPharmaSolutionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ResearchAgreementsWithUppertonPharmaSolutionsMember_lbl" xml:lang="en-US">Research Agreements with Upperton Pharma Solutions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ResearchAgreementsWithUppertonPharmaSolutionsMember" xlink:to="silo_ResearchAgreementsWithUppertonPharmaSolutionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UppertonResearchAgreementsMember" xlink:href="silo-20231231.xsd#silo_UppertonResearchAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UppertonResearchAgreementsMember_lbl" xml:lang="en-US">Upperton Research Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UppertonResearchAgreementsMember" xlink:to="silo_UppertonResearchAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AmplifyBioResearchAgreementMember" xlink:href="silo-20231231.xsd#silo_AmplifyBioResearchAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AmplifyBioResearchAgreementMember_lbl" xml:lang="en-US">AmplifyBio Research Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmplifyBioResearchAgreementMember" xlink:to="silo_AmplifyBioResearchAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ResearchAgreementWithAmplifyBioMember" xlink:href="silo-20231231.xsd#silo_ResearchAgreementWithAmplifyBioMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ResearchAgreementWithAmplifyBioMember_lbl" xml:lang="en-US">Research Agreement with AmplifyBio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ResearchAgreementWithAmplifyBioMember" xlink:to="silo_ResearchAgreementWithAmplifyBioMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_JVAgreementMember" xlink:href="silo-20231231.xsd#silo_JVAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_JVAgreementMember_lbl" xml:lang="en-US">JV Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_JVAgreementMember" xlink:to="silo_JVAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ZylTherapeuticsIncMember" xlink:href="silo-20231231.xsd#silo_ZylTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ZylTherapeuticsIncMember_lbl" xml:lang="en-US">Zyl&#246; Therapeutics, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ZylTherapeuticsIncMember" xlink:to="silo_ZylTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AmendedServiceAgreementMember" xlink:href="silo-20231231.xsd#silo_AmendedServiceAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AmendedServiceAgreementMember_lbl" xml:lang="en-US">Amended Service Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmendedServiceAgreementMember" xlink:to="silo_AmendedServiceAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Shares [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US">Investments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Summarizes Activity in the Company&#8217;s Short Term Investments and Equity Investments at Fair Value [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems_lbl" xml:lang="en-US">Schedule of Summarizes Activity in the Company&#8217;s Short Term Investments and Equity Investments at Fair Value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable" xlink:href="silo-20231231.xsd#silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of Stock Option Activities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable" xlink:to="silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Schedule of Stock Option Activities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Warrant Activities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of Milestone Payments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems_lbl" xml:lang="en-US">Schedule of Milestone Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of Minimum Annual Royalty Payments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0" xml:lang="en-US">Schedule of Minimum Annual Royalty Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xml:lang="en-US">Debt Conversion, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems_lbl" xml:lang="en-US">Schedule of Shall Pay UMB Fees [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_OrganizationandBusinessDetailsTable" xlink:href="silo-20231231.xsd#silo_OrganizationandBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_OrganizationandBusinessDetailsTable_lbl" xml:lang="en-US">Organization and Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OrganizationandBusinessDetailsTable" xlink:to="silo_OrganizationandBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_OrganizationandBusinessDetailsLineItems" xlink:href="silo-20231231.xsd#silo_OrganizationandBusinessDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_OrganizationandBusinessDetailsLineItems_lbl" xml:lang="en-US">Organization and Business [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OrganizationandBusinessDetailsLineItems" xlink:to="silo_OrganizationandBusinessDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="silo-20231231.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="silo_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" xlink:href="silo-20231231.xsd#silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable_lbl" xml:lang="en-US">Disposal of the Discontinued Operations of the NFID Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" xlink:to="silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Disposal of the Discontinued Operations of the NFID Business [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NoteReceivableDetailsTable" xlink:href="silo-20231231.xsd#silo_NoteReceivableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NoteReceivableDetailsTable_lbl" xml:lang="en-US">Note Receivable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NoteReceivableDetailsTable" xlink:to="silo_NoteReceivableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Note Receivable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsTable" xlink:href="silo-20231231.xsd#silo_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="silo_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConcentrationsDetailsTable" xlink:href="silo-20231231.xsd#silo_ConcentrationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConcentrationsDetailsTable_lbl" xml:lang="en-US">Concentrations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConcentrationsDetailsTable" xlink:to="silo_ConcentrationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentrations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US">Other Commitments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="silo_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SubsequentEventsDetailsTable" xlink:href="silo-20231231.xsd#silo_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SubsequentEventsDetailsTable" xlink:to="silo_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AdditionsOfShortTermInvestments_lbl0" xml:lang="en-US">Represent the amount of additions of short term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionsOfShortTermInvestments" xlink:to="silo_AdditionsOfShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AdditionsofEquitySecurities_lbl0" xml:lang="en-US">Additions for equity securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionsofEquitySecurities" xlink:to="silo_AdditionsofEquitySecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AggregateOfConvertedShares_lbl0" xml:lang="en-US">This value for aggregate of converted shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfConvertedShares" xlink:to="silo_AggregateOfConvertedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AggregateOfIncentiveStockOptions_lbl0" xml:lang="en-US">Aggregate of incentive stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfIncentiveStockOptions" xlink:to="silo_AggregateOfIncentiveStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AgreementShallExpire_lbl0" xml:lang="en-US">Agreement shall expire.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AgreementShallExpire" xlink:to="silo_AgreementShallExpire_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense_lbl0" xml:lang="en-US">This value for amortization of prepaid stock-based expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmortizationOfPrepaidStockbasedExpense" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CashSPICInsuredAmount_lbl0" xml:lang="en-US">The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Securities Investor Protection Corporation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashSPICInsuredAmount" xlink:to="silo_CashSPICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments_lbl0" xml:lang="en-US">Change in accumulated other comprehensive loss and short-term investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" xlink:to="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CommercialSaleTerm_lbl0" xml:lang="en-US">This term used for commercial sale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommercialSaleTerm" xlink:to="silo_CommercialSaleTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CommonStockPurchaseCost_lbl0" xml:lang="en-US">Amount of common stock purchase cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockPurchaseCost" xlink:to="silo_CommonStockPurchaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ConsiderationFeePayablePercentage_lbl0" xml:lang="en-US">This percentage used for consideration fee payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConsiderationFeePayablePercentage" xlink:to="silo_ConsiderationFeePayablePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CostOfRevenuesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for cost of revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CostOfRevenuesPolicyTextBlock" xlink:to="silo_CostOfRevenuesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_DueToRelatedPartieCurrent_lbl0" xml:lang="en-US">The amount of due to related partie current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DueToRelatedPartieCurrent" xlink:to="silo_DueToRelatedPartieCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_EquityInvestmentsAtFairValuePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for equity investments, at fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtFairValuePolicyTextBlock" xlink:to="silo_EquityInvestmentsAtFairValuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_EquitySecuritiesSalesAtOriginalCost_lbl0" xml:lang="en-US">The amount of equity securities, sales at original cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquitySecuritiesSalesAtOriginalCost" xlink:to="silo_EquitySecuritiesSalesAtOriginalCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_EquitySharesEarnedForServices_lbl0" xml:lang="en-US">Equity shares earned for services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquitySharesEarnedForServices" xlink:to="silo_EquitySharesEarnedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ExtensionFee_lbl0" xml:lang="en-US">Amount of extension fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ExtensionFee" xlink:to="silo_ExtensionFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_FirstCommercialSale_lbl0" xml:lang="en-US">First commercial sale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FirstCommercialSale" xlink:to="silo_FirstCommercialSale_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_JointVentureInterestRate_lbl0" xml:lang="en-US">Joint venture interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_JointVentureInterestRate" xlink:to="silo_JointVentureInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_LicenseAgreementExpire_lbl0" xml:lang="en-US">License agreement expire.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseAgreementExpire" xlink:to="silo_LicenseAgreementExpire_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_LicensorShare_lbl0" xml:lang="en-US">Licensor share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicensorShare" xlink:to="silo_LicensorShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_LiquidityPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for liquidity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LiquidityPolicyTextBlock" xlink:to="silo_LiquidityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_MilestoneBalanceDescription_lbl0" xml:lang="en-US">Milestone balance description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MilestoneBalanceDescription" xlink:to="silo_MilestoneBalanceDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_MilestonePayment_lbl0" xml:lang="en-US">This amount used for milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MilestonePayment" xlink:to="silo_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_MinimumAnnualRoyaltyPaymentsDescription_lbl0" xml:lang="en-US">Minimum annual royalty payment description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MinimumAnnualRoyaltyPaymentsDescription" xlink:to="silo_MinimumAnnualRoyaltyPaymentsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_NetSalePercentage_lbl0" xml:lang="en-US">This percentage for net sale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetSalePercentage" xlink:to="silo_NetSalePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_NonrefundableCashPayment_lbl0" xml:lang="en-US">Non-refundable cash payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NonrefundableCashPayment" xlink:to="silo_NonrefundableCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PaymentDescription_lbl0" xml:lang="en-US">Description on payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentDescription" xlink:to="silo_PaymentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PenaltyFromEarlyTerminationOfCD_lbl1" xml:lang="en-US">Amount of Penalty from early termination of CD.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PenaltyFromEarlyTerminationOfCD" xlink:to="silo_PenaltyFromEarlyTerminationOfCD_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PreferredStockDesignated_lbl0" xml:lang="en-US">Preferred stock designated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockDesignated" xlink:to="silo_PreferredStockDesignated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PreferredStockShareDesignated_lbl0" xml:lang="en-US">Preferred stock share designated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockShareDesignated" xlink:to="silo_PreferredStockShareDesignated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PrepaidExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for prepaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PrepaidExpensesPolicyTextBlock" xlink:to="silo_PrepaidExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations_lbl1" xml:lang="en-US">Bad debt expense discontinued operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:to="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ResearchProjectEstimatePercentage_lbl0" xml:lang="en-US">Percentage of research project estimate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ResearchProjectEstimatePercentage" xlink:to="silo_ResearchProjectEstimatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_RestrictedCommonSharePrice_lbl0" xml:lang="en-US">Restricted common share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RestrictedCommonSharePrice" xlink:to="silo_RestrictedCommonSharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_RevenueTerm_lbl0" xml:lang="en-US">This term for revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RevenueTerm" xlink:to="silo_RevenueTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SalesOfLicensedProductsPercentage_lbl0" xml:lang="en-US">Sales of licensed products percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SalesOfLicensedProductsPercentage" xlink:to="silo_SalesOfLicensedProductsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ScheduleOfMilestonePaymentsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMilestonePaymentsTableTextBlock" xlink:to="silo_ScheduleOfMilestonePaymentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of minimum annual royalty payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock" xlink:to="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ScheduleOfShallPayUMBFeesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of shall pay fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfShallPayUMBFeesTableTextBlock" xlink:to="silo_ScheduleOfShallPayUMBFeesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of company&apos;s short term investments and equity investments at fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock" xlink:to="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SecuritiesReceived_lbl0" xml:lang="en-US">Amount of securities received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SecuritiesReceived" xlink:to="silo_SecuritiesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue_lbl0" xml:lang="en-US">Represent the Amount of share based compensation arrangement by share based payment award equity instruments other than options grants in period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable_lbl0" xml:lang="en-US">he number of exercisable made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable_lbl0" xml:lang="en-US">Per share or unit weighted-average fair value of exercisable award under share-based payment arrangement. Excludes share and unit options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable_lbl0" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted_lbl0" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted_lbl0" xml:lang="en-US">Aggregate intrinsic value granted amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl0" xml:lang="en-US">Intrinsic value of exercisable award under share-based payment arrangement. Excludes share and unit options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl0" xml:lang="en-US">Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently granted, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SponsoredResearchAgreementDescription_lbl0" xml:lang="en-US">Description on sponsored research agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementDescription" xlink:to="silo_SponsoredResearchAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SponsoredStudyAgreement_lbl0" xml:lang="en-US">Sponsored study agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredStudyAgreement" xlink:to="silo_SponsoredStudyAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_StockOptionValue_lbl0" xml:lang="en-US">Stock option value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockOptionValue" xlink:to="silo_StockOptionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SublicenseAgreementAmountPaid_lbl0" xml:lang="en-US">Amount of sublicense agreement amount paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAgreementAmountPaid" xlink:to="silo_SublicenseAgreementAmountPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SublicenseIncomePercentage_lbl0" xml:lang="en-US">Percentage sublicense income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomePercentage" xlink:to="silo_SublicenseIncomePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SublicenseIncomeReceivablePercentage_lbl0" xml:lang="en-US">Sublicense income receivable percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomeReceivablePercentage" xlink:to="silo_SublicenseIncomeReceivablePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_TradingPrice_lbl0" xml:lang="en-US">The amount of trading price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TradingPrice" xlink:to="silo_TradingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_UpfrontLicenseFees_lbl0" xml:lang="en-US">Upfront license fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UpfrontLicenseFees" xlink:to="silo_UpfrontLicenseFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_WorkingCapital_lbl0" xml:lang="en-US">Amount of working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WorkingCapital" xlink:to="silo_WorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AmendmentMember_lbl0" xml:lang="en-US">Amendment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmendmentMember" xlink:to="silo_AmendmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_MrWeisblumMember_lbl0" xml:lang="en-US">Mr Weisblum Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MrWeisblumMember" xlink:to="silo_MrWeisblumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Term Years Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl1" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_WorkingCapital_lbl1" xml:lang="en-US">Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WorkingCapital" xlink:to="silo_WorkingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl0" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTerm_lbl0" xml:lang="en-US">Long-Term Debt, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract38" xlink:to="silo_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract39" xlink:to="silo_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl0" xml:lang="en-US">Derivative Liability, Measurement Input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LiquidityPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LiquidityPolicyTextBlock" xlink:to="silo_LiquidityPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LicensorShare_lbl1" xml:lang="en-US">Licensor Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicensorShare" xlink:to="silo_LicensorShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl0" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_BadDebtExpense_lbl0" xml:lang="en-US">Bad Debt Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_BadDebtExpense" xlink:to="silo_BadDebtExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NetSalePercentage_lbl1" xml:lang="en-US">Net Sale Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetSalePercentage" xlink:to="silo_NetSalePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Options Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl2" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract18" xlink:to="silo_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract19" xlink:to="silo_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract16" xlink:to="silo_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract17" xlink:to="silo_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl0" xml:lang="en-US">Treasury Stock, Common [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent_lbl0" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss, to Total, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent" xlink:to="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SublicenseIncomeReceivablePercentage_lbl1" xml:lang="en-US">Sublicense Income Receivable Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomeReceivablePercentage" xlink:to="silo_SublicenseIncomeReceivablePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ResearchAgreementsWithUppertonPharmaSolutionsMember_lbl0" xml:lang="en-US">Research Agreements With Upperton Pharma Solutions Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ResearchAgreementsWithUppertonPharmaSolutionsMember" xlink:to="silo_ResearchAgreementsWithUppertonPharmaSolutionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl0" xml:lang="en-US">Proceeds from License Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SponsoredResearchAgreementDescription_lbl1" xml:lang="en-US">Sponsored Research Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementDescription" xlink:to="silo_SponsoredResearchAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract21" xlink:to="silo_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract22" xlink:to="silo_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract20" xlink:to="silo_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract25" xlink:to="silo_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract26" xlink:to="silo_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract23" xlink:to="silo_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract24" xlink:to="silo_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract29" xlink:to="silo_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract27" xlink:to="silo_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract28" xlink:to="silo_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity_lbl0" xml:lang="en-US">Payments for Repurchase of Other Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:to="us-gaap_PaymentsForRepurchaseOfOtherEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ZylTherapeuticsIncMember_lbl0" xml:lang="en-US">Zyl Therapeutics Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ZylTherapeuticsIncMember" xlink:to="silo_ZylTherapeuticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl1" xml:lang="en-US">Realized Investment Gains (Losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SecondPaymentMember_lbl0" xml:lang="en-US">Second Payment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SecondPaymentMember" xlink:to="silo_SecondPaymentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentOneMember_lbl0" xml:lang="en-US">Payment One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentOneMember" xlink:to="silo_PaymentOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_MasterLincenseAgreementMember_lbl0" xml:lang="en-US">Master Lincense Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MasterLincenseAgreementMember" xlink:to="silo_MasterLincenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract32" xlink:to="silo_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract33" xlink:to="silo_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract30" xlink:to="silo_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract31" xlink:to="silo_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract36" xlink:to="silo_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract37" xlink:to="silo_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract34" xlink:to="silo_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract35" xlink:to="silo_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherDebt_lbl0" xml:lang="en-US">Repayments of Other Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherDebt" xlink:to="us-gaap_RepaymentsOfOtherDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationEquity_lbl0" xml:lang="en-US">Deferred Compensation Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationEquity" xlink:to="us-gaap_DeferredCompensationEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConsiderationFeePayablePercentage_lbl1" xml:lang="en-US">Consideration Fee Payable Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConsiderationFeePayablePercentage" xlink:to="silo_ConsiderationFeePayablePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SeriesCConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series CConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesCConvertiblePreferredStockMember" xlink:to="silo_SeriesCConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfMilestonePaymentsAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfMilestonePaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfMilestonePaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Milestone Payments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMilestonePaymentsAbstract" xlink:to="silo_ScheduleOfMilestonePaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AggregateOfIncentiveStockOptions_lbl1" xml:lang="en-US">Aggregate Of Incentive Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfIncentiveStockOptions" xlink:to="silo_AggregateOfIncentiveStockOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl1" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract10" xlink:to="silo_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FirstCommercialSale_lbl1" xml:lang="en-US">First Commercial Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FirstCommercialSale" xlink:to="silo_FirstCommercialSale_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract11" xlink:to="silo_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense Other, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SublicenseAgreementAmountPaid_lbl1" xml:lang="en-US">Sublicense Agreement Amount Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAgreementAmountPaid" xlink:to="silo_SublicenseAgreementAmountPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract14" xlink:to="silo_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract15" xlink:to="silo_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract12" xlink:to="silo_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract13" xlink:to="silo_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsMember_lbl0" xml:lang="en-US">Equity Method Investments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsMember" xlink:to="us-gaap_EquityMethodInvestmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ExtensionFee_lbl1" xml:lang="en-US">Extension Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ExtensionFee" xlink:to="silo_ExtensionFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableNet_lbl1" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CashPaidDuringThePeriodForAbstract_lbl0" xml:lang="en-US">Cash Paid During The Period For Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashPaidDuringThePeriodForAbstract" xlink:to="silo_CashPaidDuringThePeriodForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EquitySecuritiesSalesAtOriginalCost_lbl1" xml:lang="en-US">Equity Securities Sales At Original Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquitySecuritiesSalesAtOriginalCost" xlink:to="silo_EquitySecuritiesSalesAtOriginalCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ThirdAmendmentMember_lbl0" xml:lang="en-US">Third Amendment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ThirdAmendmentMember" xlink:to="silo_ThirdAmendmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesCommissionsAndFees_lbl0" xml:lang="en-US">Sales Commissions and Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract2" xlink:to="silo_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract1" xlink:to="silo_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract4" xlink:to="silo_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_JointVentureInterestRate_lbl1" xml:lang="en-US">Joint Venture Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_JointVentureInterestRate" xlink:to="silo_JointVentureInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract3" xlink:to="silo_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl0" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract0" xlink:to="silo_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract9" xlink:to="silo_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract6" xlink:to="silo_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract5" xlink:to="silo_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract8" xlink:to="silo_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract7" xlink:to="silo_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SecuritiesReceived_lbl1" xml:lang="en-US">Securities Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SecuritiesReceived" xlink:to="silo_SecuritiesReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl1" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl1" xml:lang="en-US">License [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CostOfRevenuesPolicyTextBlock_lbl1" xml:lang="en-US">Cost Of Revenues Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CostOfRevenuesPolicyTextBlock" xlink:to="silo_CostOfRevenuesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ResearchAgreementWithAmplifyBioMember_lbl0" xml:lang="en-US">Research Agreement With Amplify Bio Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ResearchAgreementWithAmplifyBioMember" xlink:to="silo_ResearchAgreementWithAmplifyBioMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfPotentiallyDilutiveSharesAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfPotentiallyDilutiveSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfPotentiallyDilutiveSharesAbstract_lbl" xml:lang="en-US">Schedule Of Potentially Dilutive Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfPotentiallyDilutiveSharesAbstract" xlink:to="silo_ScheduleOfPotentiallyDilutiveSharesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UniversityOfMarylandBaltimoreMember_lbl0" xml:lang="en-US">University Of Maryland Baltimore Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UniversityOfMarylandBaltimoreMember" xlink:to="silo_UniversityOfMarylandBaltimoreMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl1" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl1" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ResearchAgreementWithReprocellMember_lbl0" xml:lang="en-US">Research Agreement With Reprocell Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ResearchAgreementWithReprocellMember" xlink:to="silo_ResearchAgreementWithReprocellMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommercialSaleTerm_lbl1" xml:lang="en-US">Commercial Sale Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommercialSaleTerm" xlink:to="silo_CommercialSaleTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract" xlink:to="silo_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PromissoryNoteMember_lbl0" xml:lang="en-US">Promissory Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNoteMember" xlink:to="silo_PromissoryNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AmplifyBioResearchAgreementMember_lbl0" xml:lang="en-US">Amplify Bio Research Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmplifyBioResearchAgreementMember" xlink:to="silo_AmplifyBioResearchAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl0" xml:lang="en-US">Accounts Payable, Interest-Bearing, Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl0" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentFiveMember_lbl0" xml:lang="en-US">Payment Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentFiveMember" xlink:to="silo_PaymentFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_HomeBistroIncMember_lbl1" xml:lang="en-US">Home Bistro Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_HomeBistroIncMember" xlink:to="silo_HomeBistroIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfStockOptionActivitiesAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfStockOptionActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfStockOptionActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Stock Option Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfStockOptionActivitiesAbstract" xlink:to="silo_ScheduleOfStockOptionActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToEmployees_lbl0" xml:lang="en-US">Payments to Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToEmployees" xlink:to="us-gaap_PaymentsToEmployees_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfShallPayUmbFeesAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfShallPayUmbFeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfShallPayUmbFeesAbstract_lbl" xml:lang="en-US">Schedule Of Shall Pay Umb Fees Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfShallPayUmbFeesAbstract" xlink:to="silo_ScheduleOfShallPayUmbFeesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_MinimumAnnualRoyaltyPaymentsDescription_lbl1" xml:lang="en-US">Minimum Annual Royalty Payments Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MinimumAnnualRoyaltyPaymentsDescription" xlink:to="silo_MinimumAnnualRoyaltyPaymentsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl2" xml:lang="en-US">Equity Securities, FV-NI, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EquityInvestmentsAtFairValuePolicyTextBlock_lbl1" xml:lang="en-US">Equity Investments At Fair Value Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtFairValuePolicyTextBlock" xlink:to="silo_EquityInvestmentsAtFairValuePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl0" xml:lang="en-US">Proceeds from Sale of Notes Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AikidoPharmaIncMember_lbl0" xml:lang="en-US">Aikido Pharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AikidoPharmaIncMember" xlink:to="silo_AikidoPharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_TradingPrice_lbl1" xml:lang="en-US">Trading Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TradingPrice" xlink:to="silo_TradingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LicenseAgreementExpire_lbl1" xml:lang="en-US">License Agreement Expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseAgreementExpire" xlink:to="silo_LicenseAgreementExpire_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl0" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl0" xml:lang="en-US">Short-Term Investments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember_lbl0" xml:lang="en-US">Customer Sublicense Agreement With Aikido Pharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember" xlink:to="silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl0" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:to="us-gaap_AdditionalPaidInCapitalPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SublicenseAgreementMember_lbl0" xml:lang="en-US">Sublicense Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAgreementMember" xlink:to="silo_SublicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Minimum Annual Royalty Payments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract" xlink:to="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember_lbl0" xml:lang="en-US">Sponsored Research Agreement With University Of Maryland Baltimore Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember" xlink:to="silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl2" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember_lbl0" xml:lang="en-US">Sponsored Research Agreement With The Regents Of The University Of California Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:to="silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl1" xml:lang="en-US">Interest Receivable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NonrefundableCashPayment_lbl1" xml:lang="en-US">Nonrefundable Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NonrefundableCashPayment" xlink:to="silo_NonrefundableCashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember_lbl0" xml:lang="en-US">Conversion Of Series CConvertible Preferred Stock Into Common Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember" xlink:to="silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl0" xml:lang="en-US">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_OmnibusEquityIncentivePlanMember_lbl0" xml:lang="en-US">Omnibus Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OmnibusEquityIncentivePlanMember" xlink:to="silo_OmnibusEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl0" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_MilestonePayment_lbl1" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MilestonePayment" xlink:to="silo_MilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassBMember_lbl0" xml:lang="en-US">Preferred Class B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PrepaidExpensesPolicyTextBlock_lbl1" xml:lang="en-US">Prepaid Expenses Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PrepaidExpensesPolicyTextBlock" xlink:to="silo_PrepaidExpensesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl1" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfShallPayUMBFeesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Shall Pay UMBFees Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfShallPayUMBFeesTableTextBlock" xlink:to="silo_ScheduleOfShallPayUMBFeesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentDescription_lbl1" xml:lang="en-US">Payment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentDescription" xlink:to="silo_PaymentDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense_lbl1" xml:lang="en-US">Amortization Of Prepaid Stockbased Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmortizationOfPrepaidStockbasedExpense" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EquitySharesEarnedForServices_lbl1" xml:lang="en-US">Equity Shares Earned For Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquitySharesEarnedForServices" xlink:to="silo_EquitySharesEarnedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentFourMember_lbl0" xml:lang="en-US">Payment Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentFourMember" xlink:to="silo_PaymentFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AmendedServiceAgreementMember_lbl0" xml:lang="en-US">Amended Service Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmendedServiceAgreementMember" xlink:to="silo_AmendedServiceAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NoteReceivableMember_lbl0" xml:lang="en-US">Note Receivable Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NoteReceivableMember" xlink:to="silo_NoteReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember_lbl0" xml:lang="en-US">Customer Patent License Agreement With Aikido Pharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember" xlink:to="silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AdditionsofEquitySecurities_lbl1" xml:lang="en-US">Additionsof Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionsofEquitySecurities" xlink:to="silo_AdditionsofEquitySecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SeriesCConversionPriceMember_lbl0" xml:lang="en-US">Series CConversion Price Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesCConversionPriceMember" xlink:to="silo_SeriesCConversionPriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SponsoredStudyAgreement_lbl1" xml:lang="en-US">Sponsored Study Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredStudyAgreement" xlink:to="silo_SponsoredStudyAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Term Years Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_lbl0" xml:lang="en-US">Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl1" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Summarizes Activity In The Companys Short Term Investments And Equity Investments At Fair Value Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock" xlink:to="silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl0" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableWithImputedInterestFaceAmount_lbl0" xml:lang="en-US">Receivable with Imputed Interest, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:to="us-gaap_ReceivableWithImputedInterestFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl1" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashIncludingDiscontinuedOperationsAbstract_lbl0" xml:lang="en-US">Cash, Including Discontinued Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashIncludingDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashIncludingDiscontinuedOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_RestrictedCommonSharePrice_lbl1" xml:lang="en-US">Restricted Common Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RestrictedCommonSharePrice" xlink:to="silo_RestrictedCommonSharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Forfeiture [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl3" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_VendorMember_lbl0" xml:lang="en-US">Vendor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_VendorMember" xlink:to="silo_VendorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockPreferredValue_lbl0" xml:lang="en-US">Treasury Stock, Preferred, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockPreferredValue" xlink:to="us-gaap_TreasuryStockPreferredValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract_lbl" xml:lang="en-US">Schedule Of Summarizes Activity In The Company SShort Term Investments And Equity Investments At Fair Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract" xlink:to="silo_ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl0" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EricWeisblumMember_lbl0" xml:lang="en-US">Eric Weisblum Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EricWeisblumMember" xlink:to="silo_EricWeisblumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfWarrantActivitiesAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfWarrantActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfWarrantActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Warrant Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfWarrantActivitiesAbstract" xlink:to="silo_ScheduleOfWarrantActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DanielRyweckMember_lbl0" xml:lang="en-US">Daniel Ryweck Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DanielRyweckMember" xlink:to="silo_DanielRyweckMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SponsoredResearchAgreementWithColumbiaUniversityMember_lbl0" xml:lang="en-US">Sponsored Research Agreement With Columbia University Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementWithColumbiaUniversityMember" xlink:to="silo_SponsoredResearchAgreementWithColumbiaUniversityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OciNetOfTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Alternative [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_OciNetOfTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentThreeMember_lbl0" xml:lang="en-US">Payment Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentThreeMember" xlink:to="silo_PaymentThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments_lbl1" xml:lang="en-US">Change In Accumulated Other Comprehensive Loss And Shortterm Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" xlink:to="silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl0" xml:lang="en-US">Treasury Stock, Common, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Financial Assets And Liabilities Measured At Fair Value On ARecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="silo_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl0" xml:lang="en-US">Other Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PenaltyFromEarlyTerminationOfCD_lbl2" xml:lang="en-US">Penalty From Early Termination Of CD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PenaltyFromEarlyTerminationOfCD" xlink:to="silo_PenaltyFromEarlyTerminationOfCD_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfMilestonePaymentsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Milestone Payments Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMilestonePaymentsTableTextBlock" xlink:to="silo_ScheduleOfMilestonePaymentsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_StockOptionValue_lbl1" xml:lang="en-US">Stock Option Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockOptionValue" xlink:to="silo_StockOptionValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl0" xml:lang="en-US">Stock Repurchased During Period, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UppertonResearchAgreementsMember_lbl0" xml:lang="en-US">Upperton Research Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UppertonResearchAgreementsMember" xlink:to="silo_UppertonResearchAgreementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BankTimeDepositsMember_lbl0" xml:lang="en-US">Bank Time Deposits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankTimeDepositsMember" xlink:to="us-gaap_BankTimeDepositsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AociAttributableToNoncontrollingInterestMember_lbl0" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AociAttributableToNoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AgreementShallExpire_lbl1" xml:lang="en-US">Agreement Shall Expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AgreementShallExpire" xlink:to="silo_AgreementShallExpire_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsShares_lbl0" xml:lang="en-US">Common Stock Dividends, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_JVAgreementMember_lbl0" xml:lang="en-US">JVAgreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_JVAgreementMember" xlink:to="silo_JVAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AggregateOfConvertedShares_lbl1" xml:lang="en-US">Aggregate Of Converted Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfConvertedShares" xlink:to="silo_AggregateOfConvertedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl1" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_RevenueTerm_lbl1" xml:lang="en-US">Revenue Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RevenueTerm" xlink:to="silo_RevenueTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IncentiveStockOptionMember_lbl0" xml:lang="en-US">Incentive Stock Option Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncentiveStockOptionMember" xlink:to="silo_IncentiveStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_StockOptionsMember_lbl0" xml:lang="en-US">Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockOptionsMember" xlink:to="silo_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SublicenseIncomePercentage_lbl1" xml:lang="en-US">Sublicense Income Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomePercentage" xlink:to="silo_SublicenseIncomePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl0" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ExtensionFeeMember_lbl0" xml:lang="en-US">Extension Fee Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ExtensionFeeMember" xlink:to="silo_ExtensionFeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SeriesMConvertiblePreferredMember_lbl0" xml:lang="en-US">Series MConvertible Preferred Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesMConvertiblePreferredMember" xlink:to="silo_SeriesMConvertiblePreferredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember_lbl0" xml:lang="en-US">Investigator Sponsored Study Agreement With University Of Maryland Baltimore Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember" xlink:to="silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations_lbl2" xml:lang="en-US">Provision For Doubtful Accounts Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:to="silo_ProvisionForDoubtfulAccountsDiscontinuedOperations_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable_lbl0" xml:lang="en-US">Proceeds from Collection of Notes Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl0" xml:lang="en-US">Proceeds from Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeesPaidOnAcceptancesResold_lbl0" xml:lang="en-US">Fees Paid on Acceptances Resold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeesPaidOnAcceptancesResold" xlink:to="us-gaap_FeesPaidOnAcceptancesResold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl1" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ResearchProjectEstimatePercentage_lbl1" xml:lang="en-US">Research Project Estimate Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ResearchProjectEstimatePercentage" xlink:to="silo_ResearchProjectEstimatePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AdditionsOfShortTermInvestments_lbl1" xml:lang="en-US">Additions Of Short Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionsOfShortTermInvestments" xlink:to="silo_AdditionsOfShortTermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl0" xml:lang="en-US">Long-Term Debt, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl2" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl0" xml:lang="en-US">Payments for (Proceeds from) Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl3" xml:lang="en-US">Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralInsuranceExpense_lbl0" xml:lang="en-US">General Insurance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl1" xml:lang="en-US">Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SalesOfLicensedProductsPercentage_lbl1" xml:lang="en-US">Sales Of Licensed Products Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SalesOfLicensedProductsPercentage" xlink:to="silo_SalesOfLicensedProductsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDeferredCostsNet_lbl0" xml:lang="en-US">Other Deferred Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCostsNet" xlink:to="us-gaap_OtherDeferredCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DueToRelatedPartieCurrent_lbl1" xml:lang="en-US">Due To Related Partie Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DueToRelatedPartieCurrent" xlink:to="silo_DueToRelatedPartieCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CustomerConcentrationMember_lbl0" xml:lang="en-US">Customer Concentration Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CustomerConcentrationMember" xlink:to="silo_CustomerConcentrationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl0" xml:lang="en-US">Investment Income, Interest and Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FirstPaymentMember_lbl0" xml:lang="en-US">First Payment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FirstPaymentMember" xlink:to="silo_FirstPaymentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_MilestoneBalanceDescription_lbl1" xml:lang="en-US">Milestone Balance Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MilestoneBalanceDescription" xlink:to="silo_MilestoneBalanceDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Minimum Annual Royalty Payments Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock" xlink:to="silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockPurchaseCost_lbl1" xml:lang="en-US">Common Stock Purchase Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockPurchaseCost" xlink:to="silo_CommonStockPurchaseCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UpfrontLicenseFees_lbl1" xml:lang="en-US">Upfront License Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UpfrontLicenseFees" xlink:to="silo_UpfrontLicenseFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DrJamesKuoMember_lbl0" xml:lang="en-US">Dr James Kuo Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DrJamesKuoMember" xlink:to="silo_DrJamesKuoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentTwoMember_lbl0" xml:lang="en-US">Payment Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentTwoMember" xlink:to="silo_PaymentTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PreferredStockDesignated_lbl1" xml:lang="en-US">Preferred Stock Designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockDesignated" xlink:to="silo_PreferredStockDesignated_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl0" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInsuranceLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Insurance Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:to="us-gaap_IncreaseDecreaseInInsuranceLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CashSPICInsuredAmount_lbl1" xml:lang="en-US">Cash SPICInsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashSPICInsuredAmount" xlink:to="silo_CashSPICInsuredAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl0" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForDepositsWithOtherInstitutions_lbl0" xml:lang="en-US">Payments for Deposits with Other Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForDepositsWithOtherInstitutions" xlink:to="us-gaap_PaymentsForDepositsWithOtherInstitutions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl0" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PreferredStockShareDesignated_lbl1" xml:lang="en-US">Preferred Stock Share Designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockShareDesignated" xlink:to="silo_PreferredStockShareDesignated_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl0" xml:lang="en-US">Treasury Stock, Shares, Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableGross_lbl0" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_NotesReceivableGross_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>silo-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 20:01:03 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedBalanceSheet" roleURI="http://www.silopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedIncomeStatement" roleURI="http://www.silopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ShareholdersEquityType2or3" roleURI="http://www.silopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConsolidatedCashFlow" roleURI="http://www.silopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_OrganizationandBusiness" roleURI="http://www.silopharma.com/role/OrganizationandBusiness"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.silopharma.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurements" roleURI="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNFIDBusiness" roleURI="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_NoteReceivable" roleURI="http://www.silopharma.com/role/NoteReceivable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_StockholdersEquity" roleURI="http://www.silopharma.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_Concentrations" roleURI="http://www.silopharma.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_CommitmentsandContingencies" roleURI="http://www.silopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_IncomeTaxes" roleURI="http://www.silopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_SubsequentEvents" roleURI="http://www.silopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_AccountingPoliciesByPolicy" roleURI="http://www.silopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsTables" roleURI="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables" roleURI="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_NoteReceivableTables" roleURI="http://www.silopharma.com/role/NoteReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_StockholdersEquityTables" roleURI="http://www.silopharma.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_CommitmentsandContingenciesTables" roleURI="http://www.silopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_IncomeTaxesTables" roleURI="http://www.silopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofPotentiallyDilutiveSharesTable" roleURI="http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" roleURI="http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" roleURI="http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable" roleURI="http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofNoteReceivableTable" roleURI="http://www.silopharma.com/role/ScheduleofNoteReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofStockOptionActivitiesTable" roleURI="http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofWarrantActivitiesTable" roleURI="http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofMilestonePaymentsTable" roleURI="http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofMinimumAnnualRoyaltyPaymentsTable" roleURI="http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofShallPayUMBFeesTable" roleURI="http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable" roleURI="http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable" roleURI="http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ScheduleofNetDeferredTaxAssetTable" roleURI="http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_OrganizationandBusinessDetails" roleURI="http://www.silopharma.com/role/OrganizationandBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" roleURI="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails" roleURI="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_NoteReceivableDetails" roleURI="http://www.silopharma.com/role/NoteReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_StockholdersEquityDetails" roleURI="http://www.silopharma.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_ConcentrationsDetails" roleURI="http://www.silopharma.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_CommitmentsandContingenciesDetails" roleURI="http://www.silopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_IncomeTaxesDetails" roleURI="http://www.silopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20231231.xsd#silo_r_SubsequentEventsDetails" roleURI="http://www.silopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_EquitySecuritiesFvNi" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalPreferredStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockPreferredValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockPreferredValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockPreferredValue" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockDesignated" xlink:href="silo-20231231.xsd#silo_PreferredStockDesignated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="PreferredStockDesignated" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralInsuranceExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PenaltyFromEarlyTerminationOfCD" xlink:href="silo-20231231.xsd#silo_PenaltyFromEarlyTerminationOfCD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="PenaltyFromEarlyTerminationOfCD" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashIncludingDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashIncludingDiscontinuedOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CashIncludingDiscontinuedOperationsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashIncludingDiscontinuedOperationsAbstract" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OciNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciNetOfTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OciNetOfTaxAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockCommonMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AociAttributableToNoncontrollingInterestMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="6.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:href="silo-20231231.xsd#silo_ProvisionForDoubtfulAccountsDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ProvisionForDoubtfulAccountsDiscontinuedOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfPrepaidStockbasedExpense" xlink:href="silo-20231231.xsd#silo_AmortizationOfPrepaidStockbasedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfPrepaidStockbasedExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="EquitySharesEarnedForServices" xlink:href="silo-20231231.xsd#silo_EquitySharesEarnedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="EquitySharesEarnedForServices" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInsuranceLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfOtherEquity" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidDuringThePeriodForAbstract" xlink:href="silo-20231231.xsd#silo_CashPaidDuringThePeriodForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="CashPaidDuringThePeriodForAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" xlink:href="silo-20231231.xsd#silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/OrganizationandBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/NoteReceivable">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesReceivableNetAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/Concentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityPolicyTextBlock" xlink:href="silo-20231231.xsd#silo_LiquidityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityInvestmentsAtFairValuePolicyTextBlock" xlink:href="silo-20231231.xsd#silo_EquityInvestmentsAtFairValuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="EquityInvestmentsAtFairValuePolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesPolicyTextBlock" xlink:href="silo-20231231.xsd#silo_PrepaidExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PrepaidExpensesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CostOfRevenuesPolicyTextBlock" xlink:href="silo-20231231.xsd#silo_CostOfRevenuesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CostOfRevenuesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/NoteReceivableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesReceivableNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMilestonePaymentsTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfMilestonePaymentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfMilestonePaymentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfShallPayUMBFeesTableTextBlock" xlink:href="silo-20231231.xsd#silo_ScheduleOfShallPayUMBFeesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfShallPayUMBFeesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentiallyDilutiveSharesAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfPotentiallyDilutiveSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentiallyDilutiveSharesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_EquityMethodInvestmentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="us-gaap_ShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionsOfShortTermInvestments" xlink:href="silo-20231231.xsd#silo_AdditionsOfShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="AdditionsOfShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="us-gaap_ShortTermInvestments_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionsofEquitySecurities" xlink:href="silo-20231231.xsd#silo_AdditionsofEquitySecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="AdditionsofEquitySecurities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitySecuritiesSalesAtOriginalCost" xlink:href="silo-20231231.xsd#silo_EquitySecuritiesSalesAtOriginalCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="EquitySecuritiesSalesAtOriginalCost" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofNoteReceivableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_NotesReceivableNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_NotesReceivableGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofStockOptionActivitiesTable" xlink:href="silo-20231231.xsd#silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="StockholdersEquityDetailsScheduleofStockOptionActivitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofStockOptionActivitiesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="silo-20231231.xsd#silo_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="StockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofStockOptionActivitiesTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:href="silo-20231231.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivitiesAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfWarrantActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivitiesAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:href="silo-20231231.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:href="silo-20231231.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMilestonePaymentsAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfMilestonePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMilestonePaymentsAbstract" xlink:to="CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentOneMember" xlink:href="silo-20231231.xsd#silo_PaymentOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentTwoMember" xlink:href="silo-20231231.xsd#silo_PaymentTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentThreeMember" xlink:href="silo-20231231.xsd#silo_PaymentThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFourMember" xlink:href="silo-20231231.xsd#silo_PaymentFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFiveMember" xlink:href="silo-20231231.xsd#silo_PaymentFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable" xlink:to="CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MilestoneBalanceDescription" xlink:href="silo-20231231.xsd#silo_MilestoneBalanceDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" xlink:to="MilestoneBalanceDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="silo-20231231.xsd#silo_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems" xlink:to="MilestonePayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract" xlink:to="CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4i1C0FowDB+JJ6vZGU2Zb4gNMIwDsAMZiEWauoJ3WqFTBJuAnXEEK8HERTRlnFgqdFP3tTsASEsgw90kSc27NBp9xZy8aFids2zNA0ooYt/rIZScvPyfBB+tMOuiSJeEirwfHswvjIHgg==] CSR-->
    <loc xlink:type="locator" xlink:label="PaymentOneMember" xlink:href="silo-20231231.xsd#silo_PaymentOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentTwoMember" xlink:href="silo-20231231.xsd#silo_PaymentTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentThreeMember" xlink:href="silo-20231231.xsd#silo_PaymentThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFourMember" xlink:href="silo-20231231.xsd#silo_PaymentFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFiveMember" xlink:href="silo-20231231.xsd#silo_PaymentFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumAnnualRoyaltyPaymentsDescription" xlink:href="silo-20231231.xsd#silo_MinimumAnnualRoyaltyPaymentsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="MinimumAnnualRoyaltyPaymentsDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RoyaltyExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShallPayUmbFeesAbstract" xlink:href="silo-20231231.xsd#silo_ScheduleOfShallPayUmbFeesAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShallPayUmbFeesAbstract" xlink:to="CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentOneMember" xlink:href="silo-20231231.xsd#silo_PaymentOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentTwoMember" xlink:href="silo-20231231.xsd#silo_PaymentTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentThreeMember" xlink:href="silo-20231231.xsd#silo_PaymentThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable" xlink:to="CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" xlink:to="us-gaap_PaymentsForFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentDescription" xlink:href="silo-20231231.xsd#silo_PaymentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems" xlink:to="PaymentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/OrganizationandBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandBusinessDetailsTable" xlink:href="silo-20231231.xsd#silo_OrganizationandBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandBusinessDetailsLineItems" xlink:href="silo-20231231.xsd#silo_OrganizationandBusinessDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandBusinessDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDetailsTable" xlink:to="OrganizationandBusinessDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDetailsLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDetailsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDetailsLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDetailsLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="silo-20231231.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_BankTimeDepositsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapital" xlink:href="silo-20231231.xsd#silo_WorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="WorkingCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashSPICInsuredAmount" xlink:href="silo-20231231.xsd#silo_CashSPICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="CashSPICInsuredAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PenaltyFromEarlyTerminationOfCD" xlink:href="silo-20231231.xsd#silo_PenaltyFromEarlyTerminationOfCD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="PenaltyFromEarlyTerminationOfCD" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BadDebtExpense" xlink:href="silo-20231231.xsd#silo_BadDebtExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="BadDebtExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ReceivableWithImputedInterestFaceAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:href="silo-20231231.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HomeBistroIncMember" xlink:href="silo-20231231.xsd#silo_HomeBistroIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="HomeBistroIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AikidoPharmaIncMember" xlink:href="silo-20231231.xsd#silo_AikidoPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AikidoPharmaIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue" xlink:href="silo-20231231.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" xlink:href="silo-20231231.xsd#silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteMember" xlink:href="silo-20231231.xsd#silo_PromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:href="silo-20231231.xsd#silo_ProvisionForDoubtfulAccountsDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ProvisionForDoubtfulAccountsDiscontinuedOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_NotesReceivableNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/NoteReceivableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="NoteReceivableDetailsTable" xlink:href="silo-20231231.xsd#silo_NoteReceivableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesReceivableNetAbstract" xlink:to="NoteReceivableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteReceivableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteMember" xlink:href="silo-20231231.xsd#silo_PromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoteReceivableMember" xlink:href="silo-20231231.xsd#silo_NoteReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="NoteReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteReceivableDetailsTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProvisionForDoubtfulAccountsDiscontinuedOperations" xlink:href="silo-20231231.xsd#silo_ProvisionForDoubtfulAccountsDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ProvisionForDoubtfulAccountsDiscontinuedOperations" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="silo-20231231.xsd#silo_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AmendmentMember" xlink:href="silo-20231231.xsd#silo_AmendmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="AmendmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OmnibusEquityIncentivePlanMember" xlink:href="silo-20231231.xsd#silo_OmnibusEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="OmnibusEquityIncentivePlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncentiveStockOptionMember" xlink:href="silo-20231231.xsd#silo_IncentiveStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="IncentiveStockOptionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesCConvertiblePreferredStockMember" xlink:href="silo-20231231.xsd#silo_SeriesCConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesCConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesCConversionPriceMember" xlink:href="silo-20231231.xsd#silo_SeriesCConversionPriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesCConversionPriceMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_PreferredClassBMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember" xlink:href="silo-20231231.xsd#silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockShareDesignated" xlink:href="silo-20231231.xsd#silo_PreferredStockShareDesignated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PreferredStockShareDesignated" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedCommonSharePrice" xlink:href="silo-20231231.xsd#silo_RestrictedCommonSharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="RestrictedCommonSharePrice" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProfessionalFees" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockPurchaseCost" xlink:href="silo-20231231.xsd#silo_CommonStockPurchaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="CommonStockPurchaseCost" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateOfIncentiveStockOptions" xlink:href="silo-20231231.xsd#silo_AggregateOfIncentiveStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="AggregateOfIncentiveStockOptions" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionValue" xlink:href="silo-20231231.xsd#silo_StockOptionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="StockOptionValue" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredCompensationEquity" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/ConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsTable" xlink:href="silo-20231231.xsd#silo_ConcentrationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="ConcentrationsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="VendorMember" xlink:href="silo-20231231.xsd#silo_VendorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="VendorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CustomerConcentrationMember" xlink:href="silo-20231231.xsd#silo_CustomerConcentrationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerConcentrationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="silo-20231231.xsd#silo_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EricWeisblumMember" xlink:href="silo-20231231.xsd#silo_EricWeisblumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EricWeisblumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrWeisblumMember" xlink:href="silo-20231231.xsd#silo_MrWeisblumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrWeisblumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DanielRyweckMember" xlink:href="silo-20231231.xsd#silo_DanielRyweckMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DanielRyweckMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DrJamesKuoMember" xlink:href="silo-20231231.xsd#silo_DrJamesKuoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DrJamesKuoMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniversityOfMarylandBaltimoreMember" xlink:href="silo-20231231.xsd#silo_UniversityOfMarylandBaltimoreMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniversityOfMarylandBaltimoreMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MasterLincenseAgreementMember" xlink:href="silo-20231231.xsd#silo_MasterLincenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MasterLincenseAgreementMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerPatentLicenseAgreementWithAikidoPharmaIncMember" xlink:href="silo-20231231.xsd#silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CustomerPatentLicenseAgreementWithAikidoPharmaIncMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerSublicenseAgreementWithAikidoPharmaIncMember" xlink:href="silo-20231231.xsd#silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CustomerSublicenseAgreementWithAikidoPharmaIncMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember" xlink:href="silo-20231231.xsd#silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SponsoredResearchAgreementWithColumbiaUniversityMember" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementWithColumbiaUniversityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SponsoredResearchAgreementWithColumbiaUniversityMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAgreementWithReprocellMember" xlink:href="silo-20231231.xsd#silo_ResearchAgreementWithReprocellMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ResearchAgreementWithReprocellMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAgreementsWithUppertonPharmaSolutionsMember" xlink:href="silo-20231231.xsd#silo_ResearchAgreementsWithUppertonPharmaSolutionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ResearchAgreementsWithUppertonPharmaSolutionsMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UppertonResearchAgreementsMember" xlink:href="silo-20231231.xsd#silo_UppertonResearchAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UppertonResearchAgreementsMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmplifyBioResearchAgreementMember" xlink:href="silo-20231231.xsd#silo_AmplifyBioResearchAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AmplifyBioResearchAgreementMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAgreementWithAmplifyBioMember" xlink:href="silo-20231231.xsd#silo_ResearchAgreementWithAmplifyBioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ResearchAgreementWithAmplifyBioMember" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZylTherapeuticsIncMember" xlink:href="silo-20231231.xsd#silo_ZylTherapeuticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ZylTherapeuticsIncMember" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmendedServiceAgreementMember" xlink:href="silo-20231231.xsd#silo_AmendedServiceAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AmendedServiceAgreementMember" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SublicenseAgreementMember" xlink:href="silo-20231231.xsd#silo_SublicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SublicenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JVAgreementMember" xlink:href="silo-20231231.xsd#silo_JVAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="JVAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstPaymentMember" xlink:href="silo-20231231.xsd#silo_FirstPaymentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="FirstPaymentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondPaymentMember" xlink:href="silo-20231231.xsd#silo_SecondPaymentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="SecondPaymentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesMConvertiblePreferredMember" xlink:href="silo-20231231.xsd#silo_SeriesMConvertiblePreferredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesMConvertiblePreferredMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExtensionFeeMember" xlink:href="silo-20231231.xsd#silo_ExtensionFeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ExtensionFeeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LicenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ThirdAmendmentMember" xlink:href="silo-20231231.xsd#silo_ThirdAmendmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="ThirdAmendmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OfficersCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToEmployees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsToEmployees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDeferredCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherDeferredCostsNet" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForFees" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExtensionFee" xlink:href="silo-20231231.xsd#silo_ExtensionFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ExtensionFee" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommercialSaleTerm" xlink:href="silo-20231231.xsd#silo_CommercialSaleTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="CommercialSaleTerm" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseAgreementExpire" xlink:href="silo-20231231.xsd#silo_LicenseAgreementExpire"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="LicenseAgreementExpire" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SublicenseIncomeReceivablePercentage" xlink:href="silo-20231231.xsd#silo_SublicenseIncomeReceivablePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="SublicenseIncomeReceivablePercentage" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToRelatedPartieCurrent" xlink:href="silo-20231231.xsd#silo_DueToRelatedPartieCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="DueToRelatedPartieCurrent" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeesPaidOnAcceptancesResold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FeesPaidOnAcceptancesResold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_FeesPaidOnAcceptancesResold" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LongTermDebtTerm" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesOfLicensedProductsPercentage" xlink:href="silo-20231231.xsd#silo_SalesOfLicensedProductsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="SalesOfLicensedProductsPercentage" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesCommissionsAndFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SalesCommissionsAndFees" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SublicenseIncomePercentage" xlink:href="silo-20231231.xsd#silo_SublicenseIncomePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="SublicenseIncomePercentage" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SublicenseAgreementAmountPaid" xlink:href="silo-20231231.xsd#silo_SublicenseAgreementAmountPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="SublicenseAgreementAmountPaid" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonrefundableCashPayment" xlink:href="silo-20231231.xsd#silo_NonrefundableCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="NonrefundableCashPayment" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetSalePercentage" xlink:href="silo-20231231.xsd#silo_NetSalePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="NetSalePercentage" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicensorShare" xlink:href="silo-20231231.xsd#silo_LicensorShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="LicensorShare" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateOfConvertedShares" xlink:href="silo-20231231.xsd#silo_AggregateOfConvertedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="AggregateOfConvertedShares" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueTerm" xlink:href="silo-20231231.xsd#silo_RevenueTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="RevenueTerm" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradingPrice" xlink:href="silo-20231231.xsd#silo_TradingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="TradingPrice" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredRevenue" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_Cash" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecuritiesReceived" xlink:href="silo-20231231.xsd#silo_SecuritiesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="SecuritiesReceived" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="45.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="46.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="47.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsiderationFeePayablePercentage" xlink:href="silo-20231231.xsd#silo_ConsiderationFeePayablePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ConsiderationFeePayablePercentage" order="48.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontLicenseFees" xlink:href="silo-20231231.xsd#silo_UpfrontLicenseFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="UpfrontLicenseFees" order="49.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstCommercialSale" xlink:href="silo-20231231.xsd#silo_FirstCommercialSale"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="FirstCommercialSale" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementShallExpire" xlink:href="silo-20231231.xsd#silo_AgreementShallExpire"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="AgreementShallExpire" order="51.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherNotesPayable" order="52.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SponsoredStudyAgreement" xlink:href="silo-20231231.xsd#silo_SponsoredStudyAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="SponsoredStudyAgreement" order="53.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RepaymentsOfOtherDebt" order="54.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="55.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="56.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" order="57.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="58.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SponsoredResearchAgreementDescription" xlink:href="silo-20231231.xsd#silo_SponsoredResearchAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="SponsoredResearchAgreementDescription" order="59.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="61.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchProjectEstimatePercentage" xlink:href="silo-20231231.xsd#silo_ResearchProjectEstimatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ResearchProjectEstimatePercentage" order="62.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="63.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="64.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="65.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JointVentureInterestRate" xlink:href="silo-20231231.xsd#silo_JointVentureInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="JointVentureInterestRate" order="66.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="67.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForDepositsWithOtherInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDepositsWithOtherInstitutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForDepositsWithOtherInstitutions" order="68.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProfessionalFees" order="69.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.silopharma.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="silo-20231231.xsd#silo_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/dei/role/document/Cover"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227775564784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 23, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SILO PHARMA, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001514183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3046338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,962,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">677 N. Washington Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sarasota<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-9031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SILO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,843,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227682329440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">SALBERG&#160;& COMPANY, P.A.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boca Raton, Florida<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679324848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,524,308<span></span>
</td>
<td class="nump">$ 11,367,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">4,140,880<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">15,970<span></span>
</td>
<td class="nump">135,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Note receivable, including interest receivable of $9,600 and $6,010 at December 31, 2023 and 2022, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">66,010<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">7,681,158<span></span>
</td>
<td class="nump">11,572,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses and other assets - non-current</a></td>
<td class="nump">64,983<span></span>
</td>
<td class="nump">70,821<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">7,746,141<span></span>
</td>
<td class="nump">11,642,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">703,488<span></span>
</td>
<td class="nump">364,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue - current portion</a></td>
<td class="nump">72,102<span></span>
</td>
<td class="nump">72,102<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">775,590<span></span>
</td>
<td class="nump">436,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue - long-term portion</a></td>
<td class="nump">793,680<span></span>
</td>
<td class="nump">865,782<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long Term Liabilities</a></td>
<td class="nump">793,680<span></span>
</td>
<td class="nump">865,782<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,569,270<span></span>
</td>
<td class="nump">1,302,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitment and Contingencies (see Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Preferred stock, $0.0001 par value, 5,000,000 shares authorized: none designated as of December 31, 2023 Common stock, $0.0001 par value, 100,000,000 shares authorized; 3,159,096 and 3,158,797 shares issued and 2,906,241 and 3,158,797 shares outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalPreferredStock', window );">Additional paid-in capital</a></td>
<td class="nump">17,525,714<span></span>
</td>
<td class="nump">17,511,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockPreferredValue', window );">Treasury stock, at cost (252,855 and 0 shares on December 31, 2023 and 2022, respectively)</a></td>
<td class="num">(471,121)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,227)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(10,871,811)<span></span>
</td>
<td class="num">(7,171,128)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">6,176,871<span></span>
</td>
<td class="nump">10,340,777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 7,746,141<span></span>
</td>
<td class="nump">$ 11,642,877<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholder in nonredeemable preferred stock-related transaction in excess of par value, value contributed to entity and value received from other stock-related transaction. Includes, but is not limited to, preferred stock redeemable solely at option of issuer. Excludes common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockPreferredValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued preferred shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockPreferredValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227676188672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable current (in Dollars)</a></td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="nump">$ 6,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PreferredStockDesignated', window );">Preferred stock, designated</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,159,096<span></span>
</td>
<td class="nump">3,158,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,906,241<span></span>
</td>
<td class="nump">3,158,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares</a></td>
<td class="nump">252,855<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PreferredStockDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PreferredStockDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679760096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">LICENSE FEE REVENUE</a></td>
<td class="nump">$ 72,102<span></span>
</td>
<td class="nump">$ 72,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
<td class="nump">5,838<span></span>
</td>
<td class="nump">5,838<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">66,264<span></span>
</td>
<td class="nump">66,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expense</a></td>
<td class="nump">871,625<span></span>
</td>
<td class="nump">577,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">1,726,061<span></span>
</td>
<td class="nump">1,496,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">845,092<span></span>
</td>
<td class="nump">1,286,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance expense</a></td>
<td class="nump">89,007<span></span>
</td>
<td class="nump">125,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt recovery</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">390,071<span></span>
</td>
<td class="nump">227,259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,921,856<span></span>
</td>
<td class="nump">3,693,920<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM CONTINUING OPERATIONS</a></td>
<td class="num">(3,855,592)<span></span>
</td>
<td class="num">(3,627,656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest and dividend income, net</a></td>
<td class="nump">398,530<span></span>
</td>
<td class="nump">72,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income from equity shares earned for lock up agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">85,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,869)<span></span>
</td>
<td class="num">(2,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Net realized loss on equity investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(104,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PenaltyFromEarlyTerminationOfCD', window );">Penalty from early termination of CD</a></td>
<td class="num">(166,034)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Net unrealized loss on equity investments</a></td>
<td class="num">(3,118)<span></span>
</td>
<td class="num">(331,203)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">224,509<span></span>
</td>
<td class="num">(279,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES</a></td>
<td class="num">(3,631,083)<span></span>
</td>
<td class="num">(3,907,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">LOSS FROM CONTINUING OPERATIONS</a></td>
<td class="num">(3,631,083)<span></span>
</td>
<td class="num">(3,907,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashIncludingDiscontinuedOperationsAbstract', window );"><strong>DISCONTINUED OPERATIONS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="num">(69,600)<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">LOSS FROM DISCONTINUED OPERATIONS</a></td>
<td class="num">(69,600)<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(3,700,683)<span></span>
</td>
<td class="num">(3,908,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>COMPREHENSIVE LOSS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,700,683)<span></span>
</td>
<td class="num">(3,908,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciNetOfTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on short-term investments</a></td>
<td class="num">(6,227)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (3,706,910)<span></span>
</td>
<td class="num">$ (3,908,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations - basic (in Dollars per share)</a></td>
<td class="num">$ (1.18)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations - basic (in Dollars per share)</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">3,079,874<span></span>
</td>
<td class="nump">2,284,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PenaltyFromEarlyTerminationOfCD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Penalty from early termination of CD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PenaltyFromEarlyTerminationOfCD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashIncludingDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashIncludingDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227676021808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations - diluted</a></td>
<td class="num">$ (1.18)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations - diluted</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in Shares)</a></td>
<td class="nump">3,079,874<span></span>
</td>
<td class="nump">2,284,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227683021104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Series C </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 12,324,646<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,262,577)<span></span>
</td>
<td class="nump">$ 9,062,266<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">1,972,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sales of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">4,940,833<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,940,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sales of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Accretion of stock options expense to stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">111,014<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">111,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common shares issued for professional fees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">135,098<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">135,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common shares issued for professional fees (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Common stock issued for conversion of Series C preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Common stock issued for conversion of Series C preferred stock (in Shares)</a></td>
<td class="num">(227)<span></span>
</td>
<td class="nump">15,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Rounding of share due to reverse stock split (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,908,551)<span></span>
</td>
<td class="num">(3,908,551)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">17,511,589<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,171,128)<span></span>
</td>
<td class="nump">10,340,777<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,158,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Accretion of stock options expense to stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,125<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (471,121)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(471,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss - short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,227)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Rounding of share due to reverse stock split (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,700,683)<span></span>
</td>
<td class="num">(3,700,683)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 17,525,714<span></span>
</td>
<td class="num">$ (471,121)<span></span>
</td>
<td class="num">$ (6,227)<span></span>
</td>
<td class="num">$ (10,871,811)<span></span>
</td>
<td class="nump">$ 6,176,871<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,159,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227676450560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,700,683)<span></span>
</td>
<td class="num">$ (3,908,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ProvisionForDoubtfulAccountsDiscontinuedOperations', window );">Bad debt expense - discontinued operations</a></td>
<td class="nump">69,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt recovery</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation and professional fees</a></td>
<td class="nump">14,125<span></span>
</td>
<td class="nump">156,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AmortizationOfPrepaidStockbasedExpense', window );">Amortization of prepaid stock-based professional fees</a></td>
<td class="nump">90,067<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Net realized loss on equity investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">104,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Net unrealized loss on equity investments</a></td>
<td class="nump">3,118<span></span>
</td>
<td class="nump">331,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquitySharesEarnedForServices', window );">Equity shares earned for lock up agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(85,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">35,695<span></span>
</td>
<td class="nump">55,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Interest receivable</a></td>
<td class="num">(3,590)<span></span>
</td>
<td class="num">(4,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">339,272<span></span>
</td>
<td class="num">(53,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities', window );">Insurance payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(72,102)<span></span>
</td>
<td class="num">(72,102)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(3,224,498)<span></span>
</td>
<td class="num">(3,497,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(4,147,107)<span></span>
</td>
<td class="nump">66,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Collection on note receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</a></td>
<td class="num">(4,147,107)<span></span>
</td>
<td class="nump">86,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,940,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfOtherEquity', window );">Purchase of treasury stock</a></td>
<td class="num">(471,121)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="num">(471,121)<span></span>
</td>
<td class="nump">4,940,948<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS:</a></td>
<td class="num">(7,842,726)<span></span>
</td>
<td class="nump">1,530,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS - beginning of the year</a></td>
<td class="nump">11,367,034<span></span>
</td>
<td class="nump">9,837,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS - end of the year</a></td>
<td class="nump">3,524,308<span></span>
</td>
<td class="nump">11,367,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CashPaidDuringThePeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">4,869<span></span>
</td>
<td class="nump">2,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments', window );">Change in accumulated other comprehensive loss</a></td>
<td class="nump">6,227<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for future services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 135,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AmortizationOfPrepaidStockbasedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This value for amortization of prepaid stock-based expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AmortizationOfPrepaidStockbasedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CashPaidDuringThePeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CashPaidDuringThePeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in accumulated other comprehensive loss and short-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EquitySharesEarnedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity shares earned for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EquitySharesEarnedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ProvisionForDoubtfulAccountsDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bad debt expense discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ProvisionForDoubtfulAccountsDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to reacquire equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227797319040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">N<b>OTE 1 &#8211; <span style="text-decoration:underline">ORGANIZATION AND BUSINESS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Silo Pharma, Inc. (the &#8220;Company&#8221;)
was incorporated in the State of New York on July 13, 2010, under the name Gold Swap, Inc. On January 24, 2013, the Company changed its
state of incorporation from New York to Delaware. On December 19, 2023, the Company changed its state of incorporation from the State
of Delaware to the State of Nevada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research.&#160;The Company seeks to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications
such as depression, post-traumatic stress disorder (&#8220;PTSD&#8221;), Alzheimer&#8217;s, Parkinson&#8217;s, and other rare neurological
disorders. The Company&#8217;s mission is to identify assets to license and fund the research which the Company believes will be transformative
to the well-being of patients and the health care industry.&#160;The Company was previously engaged in the development of a streetwear
apparel brand, NFID (see below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2019, the Company filed an amendment
to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter,
on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name
from Uppercut Brands, Inc. to Silo Pharma, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2020, the Company incorporated a new
wholly-owned subsidiary, Silo Pharma Inc.,&#160;in the State of Florida. The Company has also secured the domain name www.silopharma.com.
The Company had been exploring opportunities to expand the Company&#8217;s business by seeking to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. In July 2020, through the Company&#8217;s newly formed subsidiary, the Company entered into a commercial evaluation license
and option agreement with University of Maryland, Baltimore (&#8220;UMB&#8221;) (see Note 8) pursuant to which, among other things, UMB
granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to certain technology.
The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master License Agreement with
UMB (see Note 8). The Company plans to actively pursue the acquisition and/or development of intellectual property or technology rights
to treat rare diseases, and to ultimately expand the Company&#8217;s business to focus on this new line of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered into
and closed on an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company (the
&#8220;Buyer&#8221;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the Company&#8217;s
NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form of a promissory note
amounting to $60,000. The promissory note bore 8% interest per annum and matured on October 1, 2023. On November 8, 2023 and effective
on October 1, 2023, the Company and the Buyer entered into a First Amendment Promissory Note which increased the interest rate to 9% per
annum and extended the maturity date to December 30, 2023 for no consideration. Accordingly, the results of operations of this component,
for all periods presented, are separately reported as &#8220;discontinued operations&#8221; on the accompanying consolidated statements
of operations and comprehensive loss (see Note 4). On December 30, 2023, the buyer defaulted on the promissory note (See Note 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 14, 2022, the Company filed a Certificate
of Amendment to the Amended and Restated Articles of Incorporation (the &#8220;Certificate of Amendment&#8221;) with the Secretary of
State of the State of Delaware to effect a 1-for-50 reverse stock split (the &#8220;Reverse Stock Split&#8221;) with respect to the outstanding
shares of the Company&#8217;s common stock. The Certificate of Amendment became effective on September 14, 2022. The Reverse Stock Split
was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split was deemed effective
at the open of business on September 15, 2022. All share and per share data in the consolidated financial statements have been retroactively
adjusted to reflect the effect of the reverse stock split.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227676704928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation and Principles of Consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;), the instructions to Form 10-K, and the rules and regulations of the United States Securities and Exchange Commission (the
&#8220;SEC&#8221;) for financial information. The Company&#8217;s consolidated financial statements include financial statements for Silo
Pharma, Inc. and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc. All intercompany transactions
and balances have been eliminated in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with, Accounting Standard Codification
(&#8220;ASC&#8221;) 205-20 &#8220;Discontinued Operations&#8221; establishes that the disposal or abandonment of a component of an entity
or a group of components of an entity should be reported in discontinued operations if the disposal represents a strategic shift that
has (or will have) a major effect on an entity&#8217;s operations and financial results. As a result, the NFID, LLC component&#8217;s
results of operations have been classified as discontinued operations on a retrospective basis for all periods presented. Accordingly,
the results of operations of this component, for all periods, are separately reported as &#8220;discontinued operations&#8221; on the
consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying consolidated
financial statements, the Company generated a net loss of $3,700,683 and used cash in operations of $3,224,498 during the year ended December
31, 2023. Additionally, the Company has an accumulated deficit of $10,871,811 on December 31, 2023. As of December 31, 2023, the Company
had working capital of $6,905,568.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The positive working capital serves to mitigate
the conditions that historically raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company
believes that the Company has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months
from the date of this filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible
that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements,
which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the
actual results could differ significantly from estimates. Significant estimates during the years ended December 31, 2023 and 2022 include
the collectability of notes receivable, the percentage of completion of research and development projects, valuation of equity investments,
valuation allowances for deferred tax assets, the fair value of warrants issued with debt, and the fair value of shares and stock options
issued for services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments with a maturity
of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial institutions.
The Company&#8217;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to
$250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of such financial
institutions, the Company evaluates at least annually the rating of the financial institutions in which it holds deposits. On December
31, 2023 and 2022, the Company had cash in excess of FDIC limits of approximately $2,805,000 and $10,868,000, respectively. During the
year ended December 31, 2023, the Company transferred funds to other high quality financial institutions to mitigate its risk to ensure
that its exposure is limited or reduced to the FDIC protection limits. In connection with the early termination of a certificate of deposit,
in 2023, the Company paid a penalty of $166,034, which is reflected on the accompanying consolidated statement of operations and comprehensive
loss during the year ended December 2023. Any material loss that we may experience in the future could have an adverse effect on our ability
to pay our operational expenses or make other payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Short-Term Investments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s portfolio of short-term investments
consists of marketable debt securities which are comprised solely of  highly rated U.S. government securities with maturities
of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate
such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending
upon changing liquidity requirements. These debt securities are classified as current assets in the consolidated balance sheet and recorded
at fair value, with unrealized gains or losses included in accumulated other comprehensive income and as a component of the consolidated
statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification
method and are reported in other income (expense), net in the consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An impairment loss may be recognized when the
decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary
declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis
of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and
the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security,
such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required
to sell the security before recovery of its amortized cost basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded $6,227 of unrealized loss
on short-term investments as a component of other comprehensive loss for the year ended December 31, 2023, respectively. The Company did
not recognize any unrealized gains or losses on short-term investments during the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Fair Value</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Realized gain or loss is recognized when an investment
is disposed of and is computed as the difference between the Company&#8217;s carrying value and the net proceeds received from such disposition.
Realized gains and losses on investment transactions are determined by specific identification. Net unrealized appreciation or depreciation
is computed as the difference between the fair value of the investment and the cost basis of such investment. Net unrealized gains or
losses for equity investments are recognized in operations as the difference between the carrying value at the beginning of the period
and the fair value at the end of the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note Receivable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recorded as part of general
and administrative expenses. As of December 31, 2023, the Company recognized an allowance for loss on the note receivable and accrued interest
receivable in an amount equal to the estimated probable losses, and accordingly, the Company recorded bad debt expense of $69,600, which
represents the note receivable principal balance of $60,000 and accrued interest receivable of $9,600, which is recorded in loss from
discontinued operations on the accompanying consolidated statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid Expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets of $15,970
and $135,894 on December 31, 2023 and 2022, respectively, consist primarily of costs paid for future services which will occur within
a year. On December 31, 2023 and 2022, prepaid expenses and other assets &#8211; non-current amounted to $64,983 and $70,821, respectively,
and consist primarily of costs paid for future services which will occur after a year. Prepaid expenses may include prepayments in cash
and equity instruments for consulting, research and development, license fees, public relations and business advisory services, and legal
fees which are being amortized over the terms of their respective agreements, which may exceed a year of service.<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies ASC Topic 606, Revenue from
Contracts with Customers (&#8220;ASC 606&#8221;). ASC 606 establishes a single comprehensive model for entities to use in accounting for
revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records interest and dividend income
on an accrual basis to the extent that the Company expects to collect such amounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the license and royalty income, revenue is
recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the licensee
that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related license
agreement (see Note 8).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product sales were recognized when the NFID products
were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately reported
as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of Revenues</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues on
license fees includes the cost of the license fees. Payments made to the licensor that are related to future periods are recorded as prepaid
expense to be amortized over the term of the related license agreement (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation is accounted for based
on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211; Stock Compensation&#8221;, which requires recognition in the financial
statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the
period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting
period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award
based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under Accounting
Standards Update (&#8220;ASU&#8221;) 2016-09 Improvements to Employee Share-Based Payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities arise
from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates,
which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current,
depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to
an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected
to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provisions of Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, &#8220;Uncertainty in Income Taxes&#8221;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#8220;more-likely-than-not&#8221; threshold. The Company does not believe it has any uncertain tax positions as
of December 31, 2023 and 2022 that would require either recognition or disclosure in the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 730-10, <i>&#8220;Research
and Development-Overall,&#8221;</i> research and development costs are expensed when incurred. During the years ended December 31, 2023
and 2022, research and development costs were $845,092 and $1,286,434, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases are accounted for using ASU 2016-02, &#8220;<i>Leases
(Topic 842)&#8221;</i>. ASU 2016-02 sets out the principles for the recognition, measurement, presentation and disclosure of leases for
both parties to a contract (i.e., lessees and lessors). The standard requires lessees to apply a dual approach, classifying leases as
either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee.
This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis
over the term of the lease. A lessee is also required to recognize a right-of-use asset and a lease liability for all leases with a term
of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to
existing guidance for operating leases today. As of December 31, 2023 and 2022, the Company has no leases. The Company will analyze any
lease to determine if it would be required to record a lease liability and a right of use asset on its consolidated balance sheets at
fair value upon adoption of ASU 2016-02. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term
leases that have a term of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Loss per Common Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted
loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock,
common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially
dilutive securities which include stock options and stock warrants are excluded from the computation of diluted shares outstanding if
they would have an anti-dilutive impact on the Company&#8217;s net losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potentially dilutive shares have
been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the years ended December 31,
2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,849</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,849</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">404,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">404,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">433,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">433,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any recently
issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#8217;s consolidated
financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227673797056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; <span style="text-decoration:underline">FAIR VALUE OF FINANCIAL INSTRUMENTS
AND FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value Measurements and Fair Value of Financial
Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820 - Fair Value Measurements and Disclosures,
defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether
or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent
information available to the Company on December 31, 2023 and 2022. Accordingly, the estimates presented in these financial statements
are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies
a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable
inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest
priority to unobservable inputs (Level 3 measurement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="width: 0.6in; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 -</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 -</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 -</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unobservable inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying value of certain financial instruments,
including cash and cash equivalents, prepaid expenses and other current assets, notes receivable, and accounts payable and accrued expenses
are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under the Financial Accounting Standard Board&#8217;s (the &#8220;FASB&#8221;) accounting
standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest
level of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table represents the Company&#8217;s
fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Short-term investments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,140,880</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Equity investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term investments and
equity investments are level 1 measurements and are based on redemption value at each date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Short-Term Investments &#8211; Debt Securities,
at Fair Value</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes activity in the
Company&#8217;s short-term investments, at fair value for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Balance, beginning of year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%">Additions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,147,107</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unrealized losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,227</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Balance, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,140,880</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Equity Investments, at Fair Value</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes activity in the
Company&#8217;s equity investments, at fair value for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance, beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,118</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">419,995</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,733</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales at original cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(171,407</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Unrealized loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(331,203</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,118</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 31, 2023 and 2022, equity instruments,
at fair value consisted of 1,559 shares of common equity securities of one entity, Home Bistro, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
received 1,559 shares of Home Bistro, Inc. common stock with grant date fair value of $85,733, or $54.99 per share, in exchange for entering
into a lock up and leak out agreement which was recorded as other income from equity shares earned for services in the accompanying consolidated
statement of operations and comprehensive loss. The Company measures equity securities received for services at fair value on the date
of receipt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
sold its equity investments in Aikido Pharma, Inc. with cost of $171,407 for gross proceeds of $66,707 and the Company recorded a net
realized loss on equity investments amounting to $104,700 as reflected in the accompanying consolidated statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments are carried at fair value with
unrealized gains or losses which are recorded as net unrealized gain (loss) on equity investments in the accompanying consolidated statement
of operations and comprehensive loss.&#160;Realized gains and losses are determined on a specific identification basis which is recorded
as net realized gain (loss) on equity investments in the consolidated statement of operations and comprehensive loss. The Company reviews
equity investments, at fair value, for impairment whenever circumstances and situations change such that there is an indication that the
carrying amounts may not be recovered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 825-10 &#8220;Financial Instruments&#8221;
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227779407568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the NFID Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Disposal of the Discontinued Operations of the NFID Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISPOSAL OF THE DISCONTINUED OPERATIONS OF THE NFID BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span style="text-decoration:underline">DISPOSAL OF THE DISCONTINUED
OPERATIONS OF THE NFID BUSINESS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered into
and closed on an Asset Purchase Agreement (see Note 1) with NFID, LLC, an unrelated party, a Florida limited liability company, whereby
the Company sold certain assets, properties, and rights in connection with its NFID trademark name, logos, domain, and apparel clothing
and accessories for a purchase price of $60,000 in the form of a promissory note amounting to $60,000. The promissory note bore 8% interest
per annum and matured on October 1, 2023. On November 8, 2023 and effective on October 1, 2023, the Company and the Buyer entered into
a First Amendment Promissory Note which increased the interest rate to 9% per annum and extended the maturity date to December 30, 2023
for no consideration. As of December 31, 2023, the Company recognized an allowance for loss on the note receivable and accrued interest
receivable in an amount equal to the estimated probable losses, and accordingly, the Company recorded bad debt expense of $69,600, which
represents the note receivable principal balance of $60,000 and accrued interest receivable of $9,600, which is recorded in loss from
discontinued operations on the accompanying consolidated statement of operations. As of December 31, 2022, the note receivable had a principal
balance of $60,000 and accrued interest receivable of $6,010 for a total outstanding receivable balance of $66,010 (see Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 205-20 &#8220;Discontinued Operations&#8221;
establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should be reported in discontinued
operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s operations and financial
results. As a result, the component&#8217;s results of operations have been classified as discontinued operations on a retrospective basis
for all periods presented. Accordingly, the results of operations of this component, for all periods, are separately reported as &#8220;discontinued
operations&#8221; on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summarized operating result of discontinued
operations of the NFID Business included in the Company&#8217;s consolidated statements of operations for the years ended December 31,
2023 and 2022 is as follows:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Product sales, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt">Cost of sales</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1,079</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,079</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating and other non-operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(84</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(69,600</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,163</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679218656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNetAbstract', window );"><strong>Note Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">NOTE RECEIVABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5 &#8211; <span style="text-decoration:underline">NOTE RECEIVABLE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 31, 2023 and 2022, note receivable consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amount of note receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,010</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,010</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Note receivable &#8211; current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">66,010</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company executed a
note receivable agreement with NFID, LLC in connection with an Asset Purchase Agreement (see Note 4). The promissory note bore 8% interest
per annum and matured on October 1, 2023. On November 8, 2023 and effective on October 1, 2023, the Company and the Buyer entered into
a First Amendment Promissory Note which increased the interest rate to 9% per annum and extended the maturity date to December 30, 2023
for no consideration. The outstanding principal and accrued interest shall be due and payable on maturity. As of December 31, 2023, the
Company recognized an allowance for loss on the note receivable and accrued interest receivable in an amount equal to the estimated probable
losses, and accordingly, the Company recorded bad debt expense of $69,600, which represents the note receivable principal balance of $60,000
and accrued interest receivable of $9,600, which is recorded in loss from discontinued operations on the accompanying consolidated statement
of operations. As of December 31, 2022, this note receivable had outstanding principal receivable of $60,000 and accrued interest receivable
of $6,010 for a total receivable balance of $66,010 which is reflected in the accompanying consolidated balance sheet as note receivable
&#8211; current.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227673606000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shares Authorized</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 4, 2023, stockholders of the Company
approved a decrease to the number of authorized shares of the Company&#8217;s common stock from 500,000,000 shares to 100,000,000 shares.
On December 4, 2023, the Company filed a Certificate of Amendment (the &#8220;Amendment&#8221;) to its Certificate of Incorporation with
the Delaware Secretary of State to decrease its authorized shares of common stock from 500,000,000 shares to 100,000,000 shares. On December
19, 2023, the Company reincorporated as a Nevada corporation and filed Articles of Incorporation with the Nevada Secretary of State on
such date. The Company has 105,000,000 shares authorized which consist of 100,000,000 shares of common stock and 5,000,000 shares of
preferred stock.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Convertible Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2021, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &#8220;Certificate of Designations&#8221;)
with the Delaware Secretary of State, designating 4,280 shares of preferred stock as Series C Convertible preferred stock. The Company
had designated 4,280 shares of preferred stock as Series C Convertible preferred stock. Each share of Series C Convertible Preferred Stock
had a par value of $0.0001 per share and a stated value of $1,000 (the &#8220;Series C Stated Value&#8221;). Each share of Series C Convertible
preferred stock was convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number
of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price. &#8220;Series C Conversion
Price&#8221; means $15.00, subject to adjustment in the event of stock split, stock dividends, subsequent right offerings and similar
recapitalization transactions. Notwithstanding anything herein to the contrary, after the date that the Company&#8217;s stockholder approval
is obtained and deemed effective, the Company may deliver a written notice to all holders (the &#8220;Forced Conversion Notice Date&#8221;)
to cause each holder to convert all or part of such holder&#8217;s Series C Convertible preferred stock pursuant to Section 6 (&#8220;Forced
Conversion&#8221;), it being agreed that the &#8220;Conversion Date&#8221; shall be deemed to occur no later than the earlier of (i) two
(2) trading days and (ii) the number of trading days comprising the standard settlement period following the Forced Conversion Notice
Date; provided, however, a holder shall only be required to convert pursuant to a Forced Conversion to the extent that such conversion
would not cause a holder to exceed its beneficial ownership limitation. On March 31, 2022, the Company notified holders of the remaining
227 shares of its Series C Convertible preferred stock of its election to force the conversion to its Series C Convertible preferred stock
into shares of the Company&#8217;s common stock (see below). As of December 31, 2022, there were <span style="-sec-ix-hidden: hidden-fact-126"><span style="-sec-ix-hidden: hidden-fact-127">no</span></span> shares of the Series preferred stock
issued and outstanding. On December 19, 2023, the Company changed its state of incorporation from the State of Delaware to the State of
Nevada and since there were no shares of Series C Convertible Stock outstanding at the time or the reincorporation the Company did not
designate Series C Convertible Stock in Nevada and it was deemed cancelled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conversion of Series C Convertible Preferred
Stock into Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2022, the Company notified holders
of the remaining 227 shares of its Series C Convertible preferred stock of its election to force the conversion to its Series C Convertible
preferred stock into shares of the Company&#8217;s common stock pursuant to the Certificate of Designations unless such conversion would
cause the holder to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On March 31, 2022, the Company
converted the remaining 227 Series C Convertible preferred stock into 15,167 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sale of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2022, the Company entered into
an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Laidlaw &amp; Company (UK) Ltd., as representative of the several
underwriters identified therein (the &#8220;Underwriters&#8221;), relating to the public offering (the &#8220;Offering&#8221;) of 1,000,000
shares of the Company&#8217;s common stock (the &#8220;Firm Shares&#8221;), at public offering price of $5.00 per share. Under the terms
of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 45 days following the closing of the Offering,
to purchase up to an additional 150,000 shares of common stock at the public offering price to cover over-allotments, if any. On September
28, 2022, the Underwriters fully exercised their over-allotment option and purchased an additional 150,000 shares (the &#8220;Option Shares,&#8221;
together with the Firm Shares, the &#8220;Shares&#8221;). On September 29, 2022 the Company closed the Offering and issued the Shares
for aggregate net proceeds of $4,940,948, after deducting underwriting discounts and commissions and offering expenses. The Company intends
to use the net proceeds from the offering for research and development activities, sales and marketing, general working capital purposes,
potential acquisitions of other companies, products or technologies, and to repay certain indebtedness. Concurrently with the closing
of the Offering, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock to the representative
of the Underwriters or its designees, at an exercise price of $6.25 per share (the &#8220;Representative&#8217;s Warrants&#8221;). The
Representative&#8217;s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and
conditions of the Representative&#8217;s Warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock Issued for Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 29, 2022, the Company entered into a
one-year consulting agreement with an entity for investor relations services. In connection with this consulting agreement, the Company
issued 20,000 restricted common shares of the Company to the consultant. These shares vest immediately. These shares were valued at $135,100,
or $6.755 per common share, based on contemporaneous common share sales by the Company. In connection with this consulting agreement,
during the years ended December 31, 2023 and 2022, the Company recorded stock-based professional fees of $90,067 and $45,033, respectively.
which was amortized into stock-based professional fees over the term of the agreement.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Repurchase Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 26, 2023, the Company&#8217;s Board
of Directors authorized a stock repurchase plan to repurchase up to $1.0&#160;million of the Company&#8217;s issued and outstanding common
stock, from time to time, with such plan to be in place until December 31, 2023. On January 9, 2024, the Board of Directors of the Company
approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the Company&#8217;s
common stock until March 31, 2024. Through December 31, 2023, the Company purchased 252,855 shares of common stock for a cost of $471,121,
which is reflected in treasury stock on the accompanying consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 18, 2021, the Company&#8217;s board
of directors (&#8220;Board&#8221;) approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;) to
incentivize employees, officers, directors and consultants of the Company and its affiliates. 170,000 shares of common stock are reserved
and available for issuance under the 2020 Plan, provided that certain exempt awards (as defined in the 2020 Plan), shall not count against
such share limit. The 2020 Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of cash,
stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock
units, stock appreciation units and other stock or cash-based awards.&#160;The 2020 Plan shall terminate on the tenth anniversary of the
date of adoption by the Board. Subject to certain restrictions, the Board may amend or terminate the Plan at any time and for any reason.
An amendment of the 2020 Plan shall be subject to the approval of the Company&#8217;s stockholders only to the extent required by applicable
laws, rules or regulations. On March 10, 2021, the 2020 Plan was approved by the stockholders. On&#160;September 15, 2023, our Board of
Directors adopted the Silo Pharma, Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan which was approved by the Company&#8217;s
stockholders on December 4, 2023. The Amended and Restated Omnibus Equity Incentive Plan (i) increases the number of shares of common
stock that may be issued under such plan by 300,000 shares to 470,000 shares and (ii) includes clawback provisions to comply with recent
developments of applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 29, 2021 and effective January 1,
2022, the Board granted an aggregate of 6,849 incentive stock options under the 2020 Plan, to two non-employee board members, exercisable
at $7.30 per share which expire on December 26, 2026 and vest on the first anniversary date of the grant date. These options were valued
at $30,224 on the grant date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of
0.75%, expected dividend yield of 0%, expected term of 2 years using the simplified method and expected volatility of 115% based on historical
volatility. The Company recorded the fair value of the unvested stock options, in the amount of $30,224, as deferred compensation which
is being amortized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2022, pursuant to an Employment
Agreement (see Note 8), an aggregate of 16,000 incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $10.00
per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests
on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023. The 16,000 stock options had a fair value of $94,915 which were valued
at the grant date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of 1.18%, expected
dividend yield of 0%, expected term of 2 years using the simplified method and expected volatility of 117% based on historical volatility.
The Company recorded the fair value of the stock options, in the amount of $94,915, as deferred compensation which is being amortized
over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022,
the Company amortized $14,125 and $111,014 of the deferred compensation which was recorded as compensation expenses in the accompanying
consolidated statement of operations and comprehensive loss. As of December 31, 2023, there was no remaining deferred compensation related
to these issuances. As of December 31, 2022, the deferred compensation related to these issuances had a balance of $14,125.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock option activities for the years ended December
31, 2023 and 2022 are summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual Term<br/> (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance Outstanding, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12,849</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.89</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">42,870</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,849</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,130</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance Outstanding, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">28,849</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.31</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,610</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">28,849</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.31</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,610</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2022, concurrently with the closing
of the Offering as discussed above, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock
to the representative of the Underwriters or its designees, at an exercise price of $6.25 per share (the &#8220;Representative&#8217;s
Warrants&#8221;). The Representative&#8217;s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant
to the terms and conditions of the Representative&#8217;s Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant activities for the years ended December
31, 2023 and 2022 are summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual Term<br/> (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance Outstanding, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">347,080</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15.5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">57,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">404,580</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance Outstanding, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">404,580</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14.05</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">404,580</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14.05</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227682928208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentrations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8211; <span style="text-decoration:underline">CONCENTRATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Customer concentration</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023 and 2022,
one licensee accounted for 100% total revenues from customer license fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Vendor concentrations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023 and 2022,
one licensor accounted for 100% of the Company&#8217;s vendor license agreements (see below) related to the Company&#8217;s biopharmaceutical
operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679110992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8211; <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Employment Agreements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Eric Weisblum</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2020, the Company entered into an
employment agreement (&#8220;Employment Agreement&#8221;) with Eric Weisblum to serve as Chief Executive Officer and Chief Financial Officer
of the Company. The term of the Employment Agreement continued for a period of one year from the date of execution date thereof and automatically
renewed for successive one-year periods at the end of each term until either party delivers written notice of their intent not to renew
at least six months prior to the expiration of the then effective term. The Employment Agreement provided for a base salary of $120,000
and 152,619 vested shares of the Company&#8217;s common stock in April 2020. On January 18, 2021, the Company and Mr. Weisblum entered
into the first amendment (the &#8220;Amendment&#8221;) to the Employment Agreement, effective as of January 1, 2021. Pursuant to the Amendment
Mr. Weisblum&#8217;s base salary was increased from $120,000 per year to $180,000 per year and all the terms and provisions of the Employment
Agreement remained in full force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2022, the Company entered into
a new employment agreement with Eric Weisblum (the &#8220;2022 Weisblum Employment Agreement&#8221;) pursuant to which Mr. Weisblum&#8217;s
(i) base salary will be $350,000 per year, (ii) Mr. Weisblum was paid a one-time signing bonus of $100,000, and (iii) Mr. Weisblum shall
be entitled to receive an annual bonus of up to $350,000, subject to the sole discretion of the Compensation Committee of the Board of
Directors of the Company (the &#8220;Compensation Committee&#8221;), and upon the achievement of additional criteria established by the
Compensation Committee from time to time (the &#8220;Annual Bonus&#8221;). In addition, pursuant to the 2022 Weisblum Employment Agreement,
upon termination of Mr. Weisblum&#8217;s employment for death or Total Disability (as defined in the 2022 Weisblum Employment Agreement),
in addition to any accrued but unpaid compensation and vacation pay through the date of his termination and any other benefits accrued
to him under any Benefit Plans (as defined in the 2022 Weisblum Employment Agreement) outstanding at such time and the reimbursement of
documented, unreimbursed expenses incurred prior to such termination date (collectively, the &#8220;Weisblum Payments&#8221;), Mr. Weisblum
shall also be entitled to the following severance benefits: (i) 24 months of his then base salary; (ii) if Mr. Weisblum elects continuation
coverage for group health coverage pursuant to COBRA Rights (as defined in the 2022 Weisblum Employment Agreement), then for a period
of 24 months following Mr. Weisblum&#8217;s termination he will be obligated to pay only the portion of the full COBRA Rights cost of
the coverage equal to an active employee&#8217;s share of premiums (if any) for coverage for the respective plan year; and (iii) payment
on a pro-rated basis of any Annual Bonus or other payments earned in connection with any bonus plan to which Mr. Weisblum was a participant
as of the date of his termination (together with the Weisblum Payments, the &#8220;Weisblum Severance&#8221;). Furthermore, pursuant to
the 2022 Weisblum Employment Agreement, upon Mr. Weisblum&#8217;s termination (i) at his option (A) upon 90 days prior written notice
to the Company or (B) for Good Reason (as defined in the 2022 Weisblum Employment Agreement), (ii) termination by the Company without
Cause (as defined in the 2022 Weisblum Employment Agreement) or (iii) termination of Mr. Weisblum&#8217;s employment within 40 days of
the consummation of a Change in Control Transaction (as defined in the Weisblum Employment Agreement), Mr. Weisblum shall receive the
Weisblum Severance; provided, however, Mr. Weisblum shall be entitled to a pro-rated Annual Bonus of at least $200,000. In addition, any
equity grants issued to Mr. Weisblum shall immediately vest upon termination of Mr. Weisblum&#8217;s employment by him for Good Reason
or by the Company at its option upon 90 days prior written notice to Mr. Weisblum, without Cause. In September 2023 and October 2022,
the Company paid a bonus of $200,000 and $100,000 to Mr. Weisblum, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Daniel Ryweck</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 27, 2022, the Board appointed Daniel
Ryweck as Chief Financial Officer of the Company. On September 28, 2022, the Company entered into an employment agreement (the &#8220;Ryweck
Employment Agreement&#8221;) with Mr. Ryweck. Pursuant to the terms of the Ryweck Employment Agreement, which was amended on October
12, 2022, Mr. Ryweck will (i) receive a base salary at an annual rate of $60,000 (the &#8220;Base Compensation&#8221;) payable in equal
monthly installments, and (ii) be eligible to receive an annual discretionary bonus. The term of Mr. Ryweck&#8217;s engagement under
the Ryweck Employment Agreement commenced on September 28, 2022 and continues until September 28, 2023, unless earlier terminated in
accordance with the terms of the Ryweck Employment Agreement. The term of Mr. Ryweck&#8217;s Employment Agreement is automatically renewed
for successive one-year periods until terminated by Mr. Ryweck or the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dr. James Kuo</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2022, the Company and Dr. James
Kuo entered into an employment agreement (&#8220;Kuo Employment Agreement&#8221;) for Dr. Kuo to serve as the Vice President of Research
&amp; Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for a
period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days prior to the applicable renewal date.
Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled to a
bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#8220;Board&#8221;) and shall
be payable at the Company&#8217;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options were granted
under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i)
6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023. The 16,000 stock options
had a fair value of $94,915 which valued at grant date using Binomial Lattice option pricing model with the following assumptions: risk-free
interest rate of 1.18%, expected dividend yield of 0%, expected term of 2 years using the simplified method and expected volatility of
117% based on calculated volatility. The Company recorded the fair value of the stock options, in the amount of $94,915, as deferred compensation
which is being amortized over the vesting period. During the years ended December 31, 2023 and 2022, the Company amortized $14,125 and
$80,790 of the deferred compensation which was recorded as compensation expenses in the consolidated statement of operations and comprehensive
loss, respectively. As of December 31, 2023 and 2022, the deferred compensation had a balance of $0 and $14,125, respectively (see Note
6).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">License Agreements between the Company and
Vendors</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore - License
Agreement for Development and Use of Central Nervous System-Homing Peptides</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option Agreement
with the University of Maryland, Baltimore</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of July 15, 2020, the Company, through
its wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1) and University of Maryland, Baltimore (&#8220;UMB&#8221;) (collectively as
&#8220;Parties&#8221;), entered into a commercial evaluation license and option agreement (&#8220;License Agreement&#8221;), granting
the Company an exclusive, non-sublicensable, non-transferable license to with respect to the exploration of the potential use of central
nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory
pathology. The License Agreement also granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing
license (&#8220;Exclusive Option&#8221;) with respect to the subject technology. The License Agreement had a term of six months from the
effective date however if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation
period (as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company exercised
its Exclusive Option on January 13, 2021 and entered into a Master License Agreement on February 12, 2021. Both parties may terminate
this agreement within thirty days by giving written notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore - License
Agreement for Development and Use of Joint-Homing Peptides</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option Agreement
with the University of Maryland, Baltimore</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#8220;UMB&#8221;) (collectively as &#8220;Parties&#8221;),
entered into a commercial evaluation license and option agreement (&#8220;License Agreement&#8221;), which granted the Company an exclusive,
non-sublicensable, non-transferable license with respect to the exploration of the potential use of joint-homing peptides for use in the
investigation and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate
and obtain an exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive Option&#8221;) with respect to the subject technology.
On July 6, 2021, the Company entered into a First Amendment Agreement (&#8220;First Amendment&#8221;) with UMB to extend the term of the
original License Agreement by an additional six months such that the First Amendment was effective until February 25, 2022. On January
28, 2022, the Parties entered into a second amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Second
Amendment&#8221;) to extend the term of the original license agreement until December 31, 2022. On June 22, 2022, the Parties entered
into a third amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Third Amendment&#8221;). The
Third Amendment expanded the scope of the license granted in the License Agreement to add additional patent rights with respect to an
invention generally known as <i>Peptide-Targeted Liposomal Delivery for Treatment Diagnosis, and Imaging of Diseases and Disorders</i>.
In consideration of the licenses granted under this Third Amendment, the Company agreed to pay a one-time, non-refundable fee of $2,500
which was recorded as research and development expense in the consolidated statement of operations and comprehensive loss during the year
ended December 31, 2022. On December 16, 2022, the Company and UMB entered into a fourth amendment to License Agreement (the &#8220;Fourth
Amendment&#8221;) to extend the term of the License Agreement until March 31, 2023. In addition, the parties agreed in the Fourth Amendment
to allow the Company to extend the term of the License Agreement to June 30, 2023 by paying UMB a fee of $1,000 on or before February
28, 2023. This fee was paid and the term of the License Agreement was extended to June 30, 2023. In February 2023, upon payment of the
extension fee of $1,000, the Company recorded license fees of $1,000 which are included in research and development expenses on the accompanying
consolidated statement of operations and comprehensive loss. On June 28, 2023, the Company and UMB entered into a fifth amendment to License
Agreement (the &#8220;Fifth Amendment&#8221;) to extend the term of the License Agreement until September 30, 2023. The Company may at
its option extend this Agreement until December 31, 2023, by providing written notice to University on or before August 31, 2023, and
by paying an additional license fee of $2,500. This fee was paid and the term of the License Agreement was extended to December 31, 2023.
In August 2023, upon payment of the extension fee of $2,500, the Company recorded license fees of $2,500 which are included in research
and development expense on the accompanying consolidated statement of operations and comprehensive loss. As of December 31, 2023, the
Company decided not to extend this License Agreement and will not continue to pursue this license.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Master License Agreement with the University
of Maryland, Baltimore</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed above, effective as of February 12,
2021, the Company and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into the Master License Agreement (&#8220;Master
License Agreement&#8221;) which grants the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual
property: (i) to make, have made, use, sell, offer to sell, and import certain licensed products and: (ii) to use the invention titled,
&#8220;Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other
neuroinflammatory pathology&#8221; and UMB&#8217;s confidential information to develop and perform certain licensed processes for the
therapeutic treatment of neuroinflammatory disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Master License Agreement will remain in effect
on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under the
Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity,
or other legally enforceable market exclusivity, if applicable, or (c) 10 years after the first commercial sale of a Licensed Product
in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the Master License
Agreement shall expire 15 years after the Master License Agreement Effective Date in which (a) there were never any patent rights, (b)
there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable
market exclusivity or (c) there was never a first commercial sale of a Licensed Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may assign, sublicense, grant, or
otherwise convey any rights or obligations under the Master License Agreement to a Company affiliate, without obtaining prior written
consent from UMB provided that it meets the terms defined in the Master License Agreement. The Company may grant sublicenses of some or
all of the rights granted by the Master License Agreement, provided that there is no uncured default or breach of any material term or
condition under the Master License Agreement, by Company, at the time of the grant, and that the grant complies with the terms and conditions
of the Master License Agreement. The Company shall be and shall remain responsible for the performance by each of the Company&#8217;s
sublicensee. Any sublicense shall be consistent with and subject to the terms and conditions of the Master License Agreement and shall
incorporate terms and conditions sufficient to enable Company to comply with the Master License Agreement. The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#8217;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#8217;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Master License Agreement, the
Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments
depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company paid to UMB a
license fee of $75,000, payable as follows: (a) $25,000 was due and paid within 30 days following the effective date; and (b) $50,000
on or before the first anniversary of the effective date, which was paid in February 2022. The license fee is non-refundable and is not
creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection
with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid
$25,000 license fee on February 17, 2021 and $50,000 in February 2022 which was recorded as prepaid expense and is being amortized over
the 15-year term. During the years ended December 31, 2023 and 2022, the Company recognized license fees of $5,000 and $5,000, respectively,
from the amortization of prepaid license fees, which is included in costs of revenues on the accompanying consolidated statements of operations.
On December 31, 2023, prepaid expense and other current assets &#8211; current amounted to $5,000 and prepaid expense &#8211; non-current
amounted to $55,625. On December 31, 2022, prepaid expense and other current assets &#8211; current amounted to $5,000 and prepaid expense
&#8211; non-current amounted to $60,625 as reflected in the consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Achievement of First Commercial Sale of Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Royalty Payments Terms</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3%
on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000;
and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5%
on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">minimum
annual royalty payments, as follows:</span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minimum<br/>
 Annual<br/>
 Royalty</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prior to First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Year of First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">First calendar year following the First Commercial Sale</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Second calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Third calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 10, 2023, the Company entered into
a Third Amendment to Master License Agreement (the &#8220;Third Amendment&#8221;) with UMB, pursuant to which the parties agreed to an
amended and restated schedule of diligence milestones for the Master License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2021, in connection with the Company&#8217;s
Sublicense Agreement with Aikido Pharma Inc. (see below - <i>Patent License Agreement with Aikido Pharma Inc.</i>), the Company paid 25%
of its sublicense income to UMB, pursuant to the Master License Agreement, which amounted to $12,500. During the years ended December
31, 2023 and 2022, the Company recognized license fees of $838 and $838, respectively, from the amortization of the sublicense fee. On
December 31, 2023, prepaid expense and other current assets &#8211; current amounted to $838 and prepaid expenses &#8211; non-current
amounted to $9,358. On December 31, 2022, prepaid expense and other current assets &#8211; current amounted to $838 and prepaid expenses
&#8211; non-current amounted to $10,196 as reflected in the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">License Agreements between the Company and
Customer</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Patent License Agreement with Aikido
Pharma Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company and its subsidiary
Silo Pharma, Inc., entered into a patent license agreement (&#8220;License Agreement&#8221;) (collectively, the &#8220;Licensor&#8221;)
with Aikido Pharma Inc. (&#8220;Aikido&#8221; or the &#8220;Customer&#8221;), as amended on April 12, 2021, pursuant to which the Licensor
granted Aikido an exclusive, worldwide (&#8220;Territory&#8221;), sublicensable, royalty-bearing license to certain intellectual property:
(i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise certain licensed
products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused by cancer (&#8220;Field
of Use&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement also provided that, if the
Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective as
of July 15, 2020, it would grant Aikido a non-exclusive sublicense (&#8220;Right&#8221;) to certain UMB patent rights in the field of
neuroinflammatory diseases occurring in patients diagnosed with cancer (&#8220;Field&#8221;). Pursuant to the License Agreement, Aikido
agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $500,000 and (ii) royalty payments equal
to 2% of net sales (as defined in the License Agreement) in the Field of Use in the Territory. In addition, Aikido agreed to issue the
Licensor 500 shares of Aikido&#8217;s newly designated Series M Convertible Preferred Stock which were to be converted into an aggregate
of 625,000 shares of Aikido&#8217;s common stock. On April 12, 2021, the Company entered into an amendment to the License Agreement (&#8220;Amended
License Agreement&#8221;) with Aikido dated January 5, 2021 whereby Aikido issued an aggregate of 625,000 restricted shares of Aikido&#8217;s
common stock instead of the 500 shares of the Series M Convertible Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the License Agreement, the Company
is required to prepare, file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the
licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed
patents. The Company may terminate the License Agreement upon 30 day written notice if Aikido fails to pay any amounts due and payable
to the Company or if Aikido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal
or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (&#8220;Patent Challenge&#8221;)
against the Company (except as required under a court order or subpoena). Aikido may terminate the Agreement at any time without cause,
and without incurring any additional penalty, (i) by providing at least 30 days&#8217; prior written notice and paying the Company all
amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed
to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $500,000 on January
5, 2021 which was recorded as deferred revenue to be recognized as revenues over 15 years, the estimated term of the UMB Master License
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the April 12, 2021, issuance of the common
stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible Preferred
stock which was equivalent into Aikido&#8217;s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based
quoted trading price of Aikido&#8217;s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note
3) and deferred revenue of $531,250 to be recognized as revenues over the estimated term of the UMB Master License. Accordingly, the Company
recorded a total deferred revenue of $1,031,250 ($500,000 cash received and $531,250 value of equity securities received) to be recognized
as revenues over the 15-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022,
the Company recognized license fee revenues of $68,750 and $68,750, respectively. On December 31, 2023, deferred revenue &#8211; current
portion amounted to $68,750 and deferred revenue &#8211; long-term portion amounted to $756,250. On December 31, 2022, deferred revenue
&#8211; current portion amounted to $68,750 and deferred revenue &#8211; long-term portion amounted to $825,000 as reflected in the consolidated
balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Right shall be, to the full extent permitted
by and on terms and conditions required by UMB, for a term consistent with the term of patent and technology licenses that UMB normally
grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after
the execution of such UMB license, for consideration to be agreed upon and paid by Aikido, which consideration shall in no event exceed
110% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant Aikido a nonexclusive
sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including
any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly,
on April 6, 2021, the Company entered into the Sublicense Agreement with Aikido pursuant to which it granted Aikido a worldwide exclusive
sublicense to its licensed patents under the Master License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Sublicense&#160;Agreement with
Aikido Pharma Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2021 (the &#8220;Sublicense Agreement
Effective Date&#8221;), the Company entered into the Sublicense Agreement with Aikido pursuant to which the Company granted Aikido an
exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and
(ii) in connection therewith to (A) use an invention known as &#8220;Central nervous system-homing peptides in vivo and their use for
the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#8221; which was sublicensed to the Company
pursuant to the Master License Agreement&#160;and (B) practice certain patent rights (&#8220;Patent Rights&#8221;) for the therapeutic
treatment of neuroinflammatory disease in cancer patients. &#8220;Licensed Products&#8221; means any product, service, or process, the
development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent
Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent
Rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Sublicense Agreement, Aikido agreed
to pay the Company (i) an upfront license fee of $50,000, (ii)&#160;the same sales-based royalty payments that the Company is subject
to under the Master License Agreement and (iii) total milestone payments of up to $1.9 million. The Sublicense Agreement shall continue
on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the last to expire
claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new chemical entity,
orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii) 10 years after
the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the Sublicense Agreement.
Furthermore, the Sublicense Agreement shall expire 15 years after the Sublicense Agreement Effective Date with respect to any country
in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity, orphan drug exclusivity,
regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and (ii) there was never a commercial
sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The Company collected the upfront license
fee of $50,000 in April 2021. During the years ended December 31, 2023 and 2022, the Company recognized revenue of $3,352 and $3,352,
respectively. On December 31, 2023, deferred revenue &#8211; current portion amounted to $3,352 and deferred revenue &#8211; long-term
portion amounted to $37,430, and on December 31, 2022, deferred revenue &#8211; current portion amounted to $3,352 and deferred revenue
&#8211; long-term portion amounted to $40,782 as reflected in the consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Sponsored Study and Research Agreements
between the Company and Vendors</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investigator-Sponsored Study Agreement with
University of Maryland, Baltimore</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company entered into an
investigator-sponsored study agreement (&#8220;Sponsored Study Agreement&#8221;) with the University of Maryland, Baltimore. The research
project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (&#8220;MS&#8221;).
More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the
CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and
progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March
1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of the
Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. In 2021, the Company
paid $40,737 and recorded research and development expense of $40,737. This project has been postponed until further notice and the second
payment is not due.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with The Regents
of the University of California</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021 (the &#8220;Effective Date&#8221;),
the Company entered into a sponsored research agreement (the &#8220;Sponsored Research Agreement&#8221;) with The Regents of the University
of California, on behalf of its San Francisco Campus (&#8220;UCSF&#8221;) pursuant to which UCSF shall conduct a study to examine psilocybin&#8217;s
effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson&#8217;s Disease, chronic
pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a total fee of $342,850 to conduct the research over
the two-year period. The Agreement was effective for a period of two years from the Effective Date, subject to renewal or earlier termination
as set forth in the Sponsored Research Agreement. During the years ended December 31, 2022 and 2021, pursuant to the Sponsored Research
Agreement, the Company paid to UCSF $181,710 and $100,570, respectively, which were recorded to prepaid expense and other current assets
&#8211; current to be amortized over the two-year period. During the year ended December 31, 2023, the Company paid the remaining amount
due of $60,570. During the years ended December 31, 2023 and 2022, the Company recorded research and development expenses of $71,427 and
$178,568, respectively, from the amortization of the prepaid research and development fees. On December 31, 2023 and 2022, prepaid research
and development fees amounted to $0 and $10,857, respectively which is reflected in prepaid expenses and other current assets &#8211;
current on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with University
of Maryland, Baltimore</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company and University of
Maryland, Baltimore (&#8220;UMB&#8221;) entered into a sponsored research agreement (&#8220;July 2021 Sponsored Research Agreement&#8221;)
pursuant to which UMB shall&#160;evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome. The research
pursuant to the July 2021 Sponsored Research Agreement shall commence on September 1, 2021 and will continue until the substantial completion
thereof, subject to renewal upon written consent of the parties. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#8217; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, the Company shall relinquish any and all rights it may have in the Results (as
defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated
early, the Company, among other things, will pay all costs incurred and accrued by UMB as of the date of termination. On June 7, 2022,
the Company and UMB amended the July 2021 Sponsored Research Agreement whereby both parties agreed to make changes to the original project
work and budget. The amendment had no effect on the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the July 2021 Sponsored
Research Agreement, UMB granted the Company an option (the &#8220;Option&#8221;) to negotiate and obtain an exclusive license to any UMB
Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#8217;s rights in any Joint Arising IP (as defined in the
July 2021 Sponsored Research Agreement) (collectively, the &#8220;UMB IP&#8221;). The Company may exercise the Option by giving UMB written
notice within 60 days after it receives notice from UMB of the UMB IP. Pursuant to the July 2021 Sponsored Research Agreement, the Company
shall pay UMB the fees below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 7%; text-align: center">1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,095</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 80%; text-align: justify">Paid upon execution of the July 2021 Sponsored Research Agreement</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">2</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">92,095</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">92,095</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid the first payment of $92,095
on September 1, 2021 and on August 31, 2022, the Company paid the second payment of $92,095. These payments were recorded to prepaid expense
and other current assets &#8211; current to be amortized into research and development expense during the years ended December 31, 2022
and 2021. During the years ended December 31, 2023 and 2022, the Company recorded research and development expenses of $0 and $187,090,
respectively, from the amortization of these prepaid research and development fees and other expenses. On December 31, 2023 and 2022,
the Company owed UMB $92,095 which was included in accounts payable on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with Columbia
University</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into a
sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets
currently under development, including assets related to the potential treatment of patients suffering from Alzheimer&#8217;s disease.
The term of the option will commence on the effective date of this agreement and will expire upon the earlier of (i) 90 days after the
date of the Company&#8217;s receipt of a final research report for each specific research proposal as defined in the agreement or (ii)
termination of the research. If the Company elects to exercise the option, both parties will commence negotiation of a license agreement
and will execute a license agreement no later than 3 months after the date of the exercise of the option. Columbia University and the
Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer&#8217;s disease to post-traumatic stress
disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University
for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after
the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project. The Company
paid the first payment of $430,825 in November 2021 and the second payment of $430,825 in July 2022, which were recorded to prepaid expense
and other current assets &#8211; current to be amortized over the estimated project timeline of twelve months. On October 13, 2022, the
Company entered into an amendment to the Columbia Agreement (the &#8220;Columbia Amendment&#8221;), pursuant to which the parties agreed
to extend the payment schedule, whereby the third payment of $430,825 was due in March 2023. In August 2023, the Company paid $100,000
of this balance and $330,825 of such payment remains unpaid as of December 31, 2023, which is included in accounts payable on the accompanying
consolidated balance sheet. The remaining payment of $143,607 is due upon completion. As of December 31, 2022, accrued expenses related
to this sponsored research agreement was $143,607.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022,
the Company recorded research and development expense of $287,218 and $646,236, respectively, from the amortization of the prepaid research
and development fees. As of December 31, 2023, the Company estimates that this research project is approximately 90% complete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research Agreement with Reprocell</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 25, 2022, (the &#8220;Effective Date&#8221;),
the Company entered into a research agreement (the &#8220;Reprocell Research Agreement&#8221;) with Reprocell Europe Ltd. (&#8220;Reprocell&#8221;)
pursuant to which Reprocell shall conduct a study to assess the binding of a peptide on healthy and rheumatoid arthritis synovial tissue.
Pursuant to the Reprocell Research Agreement, the Company shall pay Reprocell a total fee of $41,306 to conduct the research over a three-month
period. During the year ended December 31, 2022, pursuant to the Reprocell Research Agreement, the Company paid to Reprocell $21,172 which
was recorded as prepaid expense and other current assets &#8211; current to be amortized over the three-month period. During the year
ended December 31, 2023 and 2022, the Company recorded research and development expense of $19,835 and $33,252 from the amortization of
the prepaid research and development fees and the payment pf other fees. As of December 31, 2023 and 2022, accounts payable and accrued
expenses related to this research agreement were $5,891 and $20,134, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research Agreements with Upperton Pharma Solutions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 16, 2023, (the &#8220;Effective Date&#8221;),
the Company entered into research agreements (the &#8220;Upperton Research Agreements&#8221;) with Upperton Pharma Solutions (&#8220;Upperton&#8221;)
pursuant to which Upperton shall conduct a study to support the development and feasibility of Prucalopride nasal solutions. Pursuant
to the Upperton Research Agreements, the Company shall pay Upperton an aggregate total fee of 242,932 British Pound (GBP) (approximately
$261,462) to conduct the research, which will expensed over the research period. During the year ended December 31, 2023, pursuant to
the Upperton Research Agreements, the Company paid Upperton $177,903. During the year ended December 31, 2023, the Company recorded research
and development expense of $212,428 from the amortization of the prepaid research and development fees. As of December 31, 2023, accounts
payable and accrued expenses related to this research agreement were $34,525.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research Agreement with AmplifyBio</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 16, 2023, (the &#8220;Effective Date&#8221;),
the Company entered into a research agreement (the &#8220;AmplifyBio Research Agreement&#8221;) with AmplifyBio, LLC. (&#8220;AmplifyBio&#8221;)
pursuant to which AmplifyBio shall conduct a study in rates to investigate intranasal administration of a novel drug product. Pursuant
to the AmplifyBio Research Agreement, the Company shall pay AmplifyBio a total fee of $229,000 to conduct the research. During the year
ended December 31, 2023, pursuant to the AmplifyBio Research Agreement, the Company paid AmplifyBio $182,980 which was recorded as prepaid
expense and other current assets &#8211; current to be amortized over the research period. During the year ended December 31, 2023, the
Company recorded research and development expense of $182,980 from the amortization of the prepaid research and development fees. As of
December 31, 2023, accounts payable and accrued expenses related to this research agreement were $0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022,
the Company entered into other research and development agreements. In connection with such agreements, the Company recorded research
and development expenses of $71,204 and $241,288, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 31, 2023, future amounts due under
sponsored study and research agreements between the Company and vendors is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">2024</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">725,244</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">725,244</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Joint Venture Agreement with Zyl&#246; Therapeutics,
Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021 (&#8220;Effective Date&#8221;),
the Company entered into a Joint Venture Agreement (&#8220;JV Agreement&#8221;) with Zyl&#246; Therapeutics, Inc. (&#8220;ZTI&#8221;)
pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (&#8220;Joint Venture&#8221;),
to, among other things, focus on the clinical development of ketamine using ZTI&#8217;s Z-pod&#8482; technology (&#8220;Venture&#8221;).
Pursuant to the JV Agreement, the Company shall act as the manager (&#8220;Manager&#8221;) of the Joint Venture. The Joint Venture shall
terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days
of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Joint
Venture at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the JV Agreement, (A)
the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute
(1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets
with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4)
reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in
the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI,
subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either
party own more than 60% of the interest in the Joint Venture. As of December 31, 2023 and 2022 and as of the current date of this report,
the joint venture entity has not been formed yet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the terms of the JV Agreement,
ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#8220;License Agreement&#8221;) with Albert Einstein
College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating that the patented
technology (the &#8220;Patented Technology&#8221;) licensed to ZTI pursuant to the License Agreement is needed to advance the development
of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant to the JV Agreement,
ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development of psilocybin using ZTI&#8217;s
Z-pod&#8482; technology on the same terms and conditions set forth in the JV Agreement, which option expired 24 months after the JV Effective
Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amended Service Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2021 (&#8220;Effective Date&#8221;),
the Company entered into an Amendment Agreement (&#8220;Amended Service Agreement&#8221;) to a certain service agreement dated on September
8, 2020 with the University of Texas (&#8220;University&#8221;) at Austin whereby the University will provide advisory service and assist
the Company on identifying license and sponsored research opportunities for the Company. The Company shall pay the University $5,000 per
quarter starting on the Effective Date. Any cost incurred will be reimbursed only after prior written consent by the Company. The term
of the Amended Service Agreement is for 36 months unless earlier terminated by either party upon giving a written notice as defined in
the agreement. During the years ended December 31, 2023 and 2022, the Company paid $25,000 and $25,000, respectively, related to this
agreement which in included in professional fees on the accompanying consolidated statements of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227676381680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 &#8211; <span style="text-decoration:underline">INCOME
TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains deferred tax assets and
liabilities that reflect the net tax effects of temporary differences between the carrying amounts of the assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. The deferred tax assets on December 31, 2023 and 2022 consist of net
operating loss carry-forwards. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of
the attainment of future taxable income. As of December 31, 2023 and 2022, the Company had not recorded a liability for any unrecognized
tax positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The items accounting for the difference between
income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2023 and 2022 was as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Income tax benefit at U.S. statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(777,143</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(820,796</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Income tax benefit &#8211; state</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(240,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(254,056</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,510</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,994</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">988,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">940,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s approximate net deferred tax
asset as of December 31, 2023 and 2022 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="text-decoration:underline">Deferred Tax Asset:</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Net operating loss carryforward</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,538,565</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1,550,388</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Total deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,538,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,550,388</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,538,565</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,550,388</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net operating loss carryforward was approximately
$9,231,000 on December 31, 2023. Future utilization of the net operating loss carryforward to offset future taxable income is subject
to an annual limitation as a result of ownership changes that may occur in the future. The net operating loss carry forwards may be available
to reduce future years&#8217; taxable income. Net loss carryforwards in the amount of $9,231,000 from 2018 onwards can be carried over
indefinitely, subject to annual usage limits. Management believes that it appears more likely than not that the Company will not realize
these tax benefits due to the Company&#8217;s continuing losses for income taxes purposes. Accordingly, the Company has provided a 100%
valuation allowance on the deferred tax asset benefit related to the U.S. net operating loss carry forwards to reduce the asset to zero.
Management will review this valuation allowance periodically and will make adjustments as necessary. In 2023, the valuation allowance
increased by $988,177.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227673826992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 &#8211; <span style="text-decoration:underline">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Repurchase Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2024, the Board of Directors of the
Company approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the
Company&#8217;s common stock until March 31, 2024. From January 1, 2024 to March 23, 2024, the Company purchased 62,607 shares of common
stock for a cost of $95,682.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227673601360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,700,683)<span></span>
</td>
<td class="num">$ (3,908,551)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679031744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679330976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation and Principles of Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;), the instructions to Form 10-K, and the rules and regulations of the United States Securities and Exchange Commission (the
&#8220;SEC&#8221;) for financial information. The Company&#8217;s consolidated financial statements include financial statements for Silo
Pharma, Inc. and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc. All intercompany transactions
and balances have been eliminated in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with, Accounting Standard Codification
(&#8220;ASC&#8221;) 205-20 &#8220;Discontinued Operations&#8221; establishes that the disposal or abandonment of a component of an entity
or a group of components of an entity should be reported in discontinued operations if the disposal represents a strategic shift that
has (or will have) a major effect on an entity&#8217;s operations and financial results. As a result, the NFID, LLC component&#8217;s
results of operations have been classified as discontinued operations on a retrospective basis for all periods presented. Accordingly,
the results of operations of this component, for all periods, are separately reported as &#8220;discontinued operations&#8221; on the
consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying consolidated
financial statements, the Company generated a net loss of $3,700,683 and used cash in operations of $3,224,498 during the year ended December
31, 2023. Additionally, the Company has an accumulated deficit of $10,871,811 on December 31, 2023. As of December 31, 2023, the Company
had working capital of $6,905,568.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The positive working capital serves to mitigate
the conditions that historically raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company
believes that the Company has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months
from the date of this filing.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible
that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements,
which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the
actual results could differ significantly from estimates. Significant estimates during the years ended December 31, 2023 and 2022 include
the collectability of notes receivable, the percentage of completion of research and development projects, valuation of equity investments,
valuation allowances for deferred tax assets, the fair value of warrants issued with debt, and the fair value of shares and stock options
issued for services.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments with a maturity
of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial institutions.
The Company&#8217;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to
$250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of such financial
institutions, the Company evaluates at least annually the rating of the financial institutions in which it holds deposits. On December
31, 2023 and 2022, the Company had cash in excess of FDIC limits of approximately $2,805,000 and $10,868,000, respectively. During the
year ended December 31, 2023, the Company transferred funds to other high quality financial institutions to mitigate its risk to ensure
that its exposure is limited or reduced to the FDIC protection limits. In connection with the early termination of a certificate of deposit,
in 2023, the Company paid a penalty of $166,034, which is reflected on the accompanying consolidated statement of operations and comprehensive
loss during the year ended December 2023. Any material loss that we may experience in the future could have an adverse effect on our ability
to pay our operational expenses or make other payments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Short-Term Investments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s portfolio of short-term investments
consists of marketable debt securities which are comprised solely of  highly rated U.S. government securities with maturities
of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate
such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending
upon changing liquidity requirements. These debt securities are classified as current assets in the consolidated balance sheet and recorded
at fair value, with unrealized gains or losses included in accumulated other comprehensive income and as a component of the consolidated
statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification
method and are reported in other income (expense), net in the consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An impairment loss may be recognized when the
decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary
declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis
of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and
the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security,
such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required
to sell the security before recovery of its amortized cost basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded $6,227 of unrealized loss
on short-term investments as a component of other comprehensive loss for the year ended December 31, 2023, respectively. The Company did
not recognize any unrealized gains or losses on short-term investments during the year ended December 31, 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsAtFairValuePolicyTextBlock', window );">Equity Investments, at Fair Value</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Fair Value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Realized gain or loss is recognized when an investment
is disposed of and is computed as the difference between the Company&#8217;s carrying value and the net proceeds received from such disposition.
Realized gains and losses on investment transactions are determined by specific identification. Net unrealized appreciation or depreciation
is computed as the difference between the fair value of the investment and the cost basis of such investment. Net unrealized gains or
losses for equity investments are recognized in operations as the difference between the carrying value at the beginning of the period
and the fair value at the end of the period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Note Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recorded as part of general
and administrative expenses. As of December 31, 2023, the Company recognized an allowance for loss on the note receivable and accrued interest
receivable in an amount equal to the estimated probable losses, and accordingly, the Company recorded bad debt expense of $69,600, which
represents the note receivable principal balance of $60,000 and accrued interest receivable of $9,600, which is recorded in loss from
discontinued operations on the accompanying consolidated statement of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PrepaidExpensesPolicyTextBlock', window );">Prepaid Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid Expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets of $15,970
and $135,894 on December 31, 2023 and 2022, respectively, consist primarily of costs paid for future services which will occur within
a year. On December 31, 2023 and 2022, prepaid expenses and other assets &#8211; non-current amounted to $64,983 and $70,821, respectively,
and consist primarily of costs paid for future services which will occur after a year. Prepaid expenses may include prepayments in cash
and equity instruments for consulting, research and development, license fees, public relations and business advisory services, and legal
fees which are being amortized over the terms of their respective agreements, which may exceed a year of service.<b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies ASC Topic 606, Revenue from
Contracts with Customers (&#8220;ASC 606&#8221;). ASC 606 establishes a single comprehensive model for entities to use in accounting for
revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records interest and dividend income
on an accrual basis to the extent that the Company expects to collect such amounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the license and royalty income, revenue is
recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the licensee
that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related license
agreement (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product sales were recognized when the NFID products
were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately reported
as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CostOfRevenuesPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of Revenues</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues on
license fees includes the cost of the license fees. Payments made to the licensor that are related to future periods are recorded as prepaid
expense to be amortized over the term of the related license agreement (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation is accounted for based
on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211; Stock Compensation&#8221;, which requires recognition in the financial
statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the
period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting
period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award
based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under Accounting
Standards Update (&#8220;ASU&#8221;) 2016-09 Improvements to Employee Share-Based Payment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities arise
from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates,
which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current,
depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to
an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected
to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provisions of Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, &#8220;Uncertainty in Income Taxes&#8221;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#8220;more-likely-than-not&#8221; threshold. The Company does not believe it has any uncertain tax positions as
of December 31, 2023 and 2022 that would require either recognition or disclosure in the accompanying consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 730-10, <i>&#8220;Research
and Development-Overall,&#8221;</i> research and development costs are expensed when incurred. During the years ended December 31, 2023
and 2022, research and development costs were $845,092 and $1,286,434, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases are accounted for using ASU 2016-02, &#8220;<i>Leases
(Topic 842)&#8221;</i>. ASU 2016-02 sets out the principles for the recognition, measurement, presentation and disclosure of leases for
both parties to a contract (i.e., lessees and lessors). The standard requires lessees to apply a dual approach, classifying leases as
either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee.
This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis
over the term of the lease. A lessee is also required to recognize a right-of-use asset and a lease liability for all leases with a term
of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to
existing guidance for operating leases today. As of December 31, 2023 and 2022, the Company has no leases. The Company will analyze any
lease to determine if it would be required to record a lease liability and a right of use asset on its consolidated balance sheets at
fair value upon adoption of ASU 2016-02. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term
leases that have a term of 12 months or less.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Loss per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted
loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock,
common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially
dilutive securities which include stock options and stock warrants are excluded from the computation of diluted shares outstanding if
they would have an anti-dilutive impact on the Company&#8217;s net losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potentially dilutive shares have
been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the years ended December 31,
2023 and 2022:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,849</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,849</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">404,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">404,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">433,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">433,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any recently
issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#8217;s consolidated
financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CostOfRevenuesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CostOfRevenuesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EquityInvestmentsAtFairValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity investments, at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EquityInvestmentsAtFairValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PrepaidExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PrepaidExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227775570224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Shares</a></td>
<td class="text">The following potentially dilutive shares have
been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the years ended December 31,
2023 and 2022:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,849</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,849</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">404,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">404,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">433,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">433,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679701136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">The following table represents the Company&#8217;s
fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and 2022.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Short-term investments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,140,880</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Equity investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock', window );">Schedule of Summarizes Activity in the Company&#8217;s Short Term Investments and Equity Investments at Fair Value</a></td>
<td class="text">The following table summarizes activity in the
Company&#8217;s short-term investments, at fair value for the periods presented:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Balance, beginning of year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%">Additions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,147,107</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unrealized losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,227</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Balance, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,140,880</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>The following table summarizes activity in the
Company&#8217;s equity investments, at fair value for the periods presented:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance, beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,118</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">419,995</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,733</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales at original cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(171,407</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Unrealized loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(331,203</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,118</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of company's short term investments and equity investments at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679477920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the NFID Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Disposal of the Discontinued Operations of the NFID Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Operating Result of Discontinued Operations of the NFID Business</a></td>
<td class="text">The summarized operating result of discontinued
operations of the NFID Business included in the Company&#8217;s consolidated statements of operations for the years ended December 31,
2023 and 2022 is as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Product sales, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt">Cost of sales</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1,079</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,079</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating and other non-operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(84</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(69,600</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,163</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679754224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNetAbstract', window );"><strong>Note Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Note Receivable</a></td>
<td class="text">On December 31, 2023 and 2022, note receivable consisted of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amount of note receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,010</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,010</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Note receivable &#8211; current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">66,010</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227673601360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activities</a></td>
<td class="text">Stock option activities for the years ended December
31, 2023 and 2022 are summarized as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual Term<br/> (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance Outstanding, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12,849</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.89</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">42,870</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,849</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,130</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance Outstanding, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">28,849</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.31</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,610</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">28,849</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.31</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,610</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activities</a></td>
<td class="text">Warrant activities for the years ended December
31, 2023 and 2022 are summarized as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual Term<br/> (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance Outstanding, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">347,080</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15.5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">57,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">404,580</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance Outstanding, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">404,580</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14.05</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">404,580</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14.05</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679802496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfMilestonePaymentsTableTextBlock', window );">Schedule of Milestone Payments</a></td>
<td class="text">On December 31, 2022, prepaid expense and other current assets &#8211; current amounted to $5,000 and prepaid expense
&#8211; non-current amounted to $60,625 as reflected in the consolidated balance sheets.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Achievement of First Commercial Sale of Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock', window );">Schedule of Minimum Annual Royalty Payments</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">minimum
annual royalty payments, as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minimum<br/>
 Annual<br/>
 Royalty</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prior to First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Year of First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">First calendar year following the First Commercial Sale</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Second calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Third calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfShallPayUMBFeesTableTextBlock', window );">Schedule of Shall Pay UMB Fees</a></td>
<td class="text">Pursuant to the July 2021 Sponsored Research Agreement, the Company
shall pay UMB the fees below:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 7%; text-align: center">1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,095</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 80%; text-align: justify">Paid upon execution of the July 2021 Sponsored Research Agreement</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">2</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">92,095</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">92,095</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Amounts Due Under Sponsored Study and Research Agreements</a></td>
<td class="text">On December 31, 2023, future amounts due under
sponsored study and research agreements between the Company and vendors is as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">2024</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">725,244</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">725,244</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfMilestonePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfMilestonePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of minimum annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfShallPayUMBFeesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of shall pay fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfShallPayUMBFeesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227775716352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes</a></td>
<td class="text">The items accounting for the difference between
income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2023 and 2022 was as
follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Income tax benefit at U.S. statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(777,143</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(820,796</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Income tax benefit &#8211; state</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(240,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(254,056</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,510</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,994</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">988,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">940,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Asset</a></td>
<td class="text">The Company&#8217;s approximate net deferred tax
asset as of December 31, 2023 and 2022 was as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="text-decoration:underline">Deferred Tax Asset:</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Net operating loss carryforward</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,538,565</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1,550,388</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Total deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,538,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,550,388</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,538,565</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,550,388</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679414496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Business (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_OrganizationandBusinessDetailsLineItems', window );"><strong>Organization and Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Purchase price</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfNotesReceivable', window );">Promissory note amounting</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_OrganizationandBusinessDetailsLineItems', window );"><strong>Organization and Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Promissory note bears interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_OrganizationandBusinessDetailsLineItems', window );"><strong>Organization and Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Promissory note bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 30,  2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_OrganizationandBusinessDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_OrganizationandBusinessDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableInterestBearingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 25<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482981/835-30-25-12<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 25<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482981/835-30-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableInterestBearingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of long-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227676532000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,700,683)<span></span>
</td>
<td class="num">$ (3,908,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash in operations</a></td>
<td class="num">(3,224,498)<span></span>
</td>
<td class="num">(3,497,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(10,871,811)<span></span>
</td>
<td class="num">(7,171,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_WorkingCapital', window );">Working capital</a></td>
<td class="nump">6,905,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance corporation</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CashSPICInsuredAmount', window );">Securities investor protection corporation</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PenaltyFromEarlyTerminationOfCD', window );">Penalty paid</a></td>
<td class="nump">166,034<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on short-term investments</a></td>
<td class="num">(6,227)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_BadDebtExpense', window );">Bad debt expense</a></td>
<td class="nump">69,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestFaceAmount', window );">Note receivable principal balance amount</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="nump">6,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">15,970<span></span>
</td>
<td class="nump">135,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other assets &#8211; non-current</a></td>
<td class="nump">64,983<span></span>
</td>
<td class="nump">70,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development cost</a></td>
<td class="nump">845,092<span></span>
</td>
<td class="nump">1,286,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Bank Time Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance corporation</a></td>
<td class="nump">$ 2,805,000<span></span>
</td>
<td class="nump">$ 10,868,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_BadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_BadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CashSPICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Securities Investor Protection Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CashSPICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PenaltyFromEarlyTerminationOfCD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Penalty from early termination of CD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PenaltyFromEarlyTerminationOfCD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The principal amount of the receivable or note before consideration of the discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227778949472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Potentially Dilutive Shares - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Potentially Dilutive Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">433,429<span></span>
</td>
<td class="nump">433,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Potentially Dilutive Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">28,849<span></span>
</td>
<td class="nump">28,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Potentially Dilutive Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">404,580<span></span>
</td>
<td class="nump">404,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679232752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gross proceeds</a></td>
<td class="num">$ (3,118)<span></span>
</td>
<td class="num">$ (331,203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Net realized loss on equity investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (104,700)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=silo_HomeBistroIncMember', window );">Home Bistro, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Equity instruments at fair value of shares (in Shares)</a></td>
<td class="nump">1,559<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=silo_AikidoPharmaIncMember', window );">Aikido Pharma, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">sale of equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Net realized loss on equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (104,700)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the Amount of share based compensation arrangement by share based payment award equity instruments other than options grants in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=silo_HomeBistroIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=silo_HomeBistroIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=silo_AikidoPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=silo_AikidoPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679326816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Fair Value, Recurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems', window );"><strong>Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 4,140,880<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems', window );"><strong>Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems', window );"><strong>Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227795884496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Summarizes Activity in the Company&#8217;s Short Term Investments and Equity Investments at Fair Value - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems', window );"><strong>Schedule of Summarizes Activity in the Company&#8217;s Short Term Investments and Equity Investments at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Balance, beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AdditionsOfShortTermInvestments', window );">Additions</a></td>
<td class="nump">4,147,107<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized losses</a></td>
<td class="num">(6,227)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Balance, end of year</a></td>
<td class="nump">4,140,880<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquityMethodInvestmentsMember', window );">Equity Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems', window );"><strong>Schedule of Summarizes Activity in the Company&#8217;s Short Term Investments and Equity Investments at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Balance, beginning of year</a></td>
<td class="nump">3,118<span></span>
</td>
<td class="nump">419,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AdditionsofEquitySecurities', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">85,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquitySecuritiesSalesAtOriginalCost', window );">Sales at original cost</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(171,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Unrealized loss</a></td>
<td class="num">(3,118)<span></span>
</td>
<td class="num">(331,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Balance, end of year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AdditionsOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of additions of short term investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AdditionsOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AdditionsofEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions for equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AdditionsofEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EquitySecuritiesSalesAtOriginalCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity securities, sales at original cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EquitySecuritiesSalesAtOriginalCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227775515504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the NFID Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of the Discontinued Operations of the NFID Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ProvisionForDoubtfulAccountsDiscontinuedOperations', window );">Bad debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="nump">6,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Outstanding receivable balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 66,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of the Discontinued Operations of the NFID Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Promissory note amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PromissoryNoteMember', window );">Promissory Note [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of the Discontinued Operations of the NFID Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Bears interest per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PromissoryNoteMember', window );">Promissory Note [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of the Discontinued Operations of the NFID Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Bears interest per annum</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Dec. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ProvisionForDoubtfulAccountsDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bad debt expense discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ProvisionForDoubtfulAccountsDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227672761408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of Operating Result of Discontinued Operations of the NFID Business - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract', window );"><strong>Schedule of Operating Result of Discontinued Operations of the NFID Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Product sales, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Total operating and other non-operating expenses</a></td>
<td class="num">(69,600)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Loss from discontinued operations</a></td>
<td class="num">$ (69,600)<span></span>
</td>
<td class="num">$ (1,163)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679501440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 01, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Note Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ProvisionForDoubtfulAccountsDiscontinuedOperations', window );">Bad debt expense</a></td>
<td class="nump">$ 69,600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="nump">6,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivable balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">66,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Note Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Promissory note bears interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_NoteReceivableMember', window );">Note Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Note Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ProvisionForDoubtfulAccountsDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bad debt expense discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ProvisionForDoubtfulAccountsDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableInterestBearingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 25<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482981/835-30-25-12<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 25<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482981/835-30-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableInterestBearingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of long-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_NoteReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_NoteReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227676697632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note Receivable (Details) - Schedule of Note Receivable - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Schedule of Note Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Principal amount of note receivable</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="nump">6,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Subtotal</a></td>
<td class="nump">69,600<span></span>
</td>
<td class="nump">66,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(69,600)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Note receivable &#8211; current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 66,010<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (3)<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (c)<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 80<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479294/326-20-55-80<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 79<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479294/326-20-55-79<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br> -Publisher SEC<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-7A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227662029776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Sep. 29, 2022</div></th>
<th class="th"><div>Sep. 28, 2022</div></th>
<th class="th"><div>Sep. 26, 2022</div></th>
<th class="th"><div>Aug. 29, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 27, 2022</div></th>
<th class="th"><div>Jan. 26, 2022</div></th>
<th class="th"><div>Dec. 29, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 09, 2024</div></th>
<th class="th"><div>Dec. 04, 2023</div></th>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Jan. 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PreferredStockShareDesignated', window );">Designated shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Series C convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price per shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,940,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Issued warrants to purchase an aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted common value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RestrictedCommonSharePrice', window );">Restricted common share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Stock-based professional fees (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,726,061<span></span>
</td>
<td class="nump">1,496,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of shares (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 471,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Common stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockPurchaseCost', window );">Common stock purchase cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 471,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Deferred compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,125<span></span>
</td>
<td class="nump">$ 111,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Stock options vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Fair value of unvested stock option</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,940,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Stock-based professional fees (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,067<span></span>
</td>
<td class="nump">$ 45,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of shares (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Purchase aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=silo_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PreferredStockShareDesignated', window );">Designated shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Stated value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible preferred stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">share of Series C Convertible
preferred stock was convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number
of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=silo_SeriesCConversionPriceMember', window );">Series C Conversion Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Preferred Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember', window );">Conversion of Series C Convertible Preferred Stock into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Series C convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Series C convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board Granted [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price per shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateOfIncentiveStockOptions', window );">Aggregate of incentive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockOptionValue', window );">Stock option value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Deferred compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent', window );">Issuance of deferred compensation balance (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board Granted [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Common stock issued under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board Granted [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Common stock issued under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silo_AmendmentMember', window );">Amendment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silo_AmendmentMember', window );">Amendment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silo_OmnibusEquityIncentivePlanMember', window );">Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">of common stock reserved and avail for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silo_IncentiveStockOptionMember', window );">Incentive Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Fair value of unvested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock option (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Fair value of the unvested stock options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AggregateOfIncentiveStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate of incentive stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AggregateOfIncentiveStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockPurchaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock purchase cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockPurchaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock share designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_RestrictedCommonSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted common share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_RestrictedCommonSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_StockOptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_StockOptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480637/718-40-25-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=silo_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=silo_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=silo_SeriesCConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=silo_SeriesCConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silo_AmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silo_AmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silo_OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silo_OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silo_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silo_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227795947200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of Stock Option Activities - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Stock Option Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Balance</a></td>
<td class="nump">12,849<span></span>
</td>
<td class="nump">28,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years). Balance</a></td>
<td class="text">2 years 6 months 14 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">6 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Balance</a></td>
<td class="nump">$ 42,870<span></span>
</td>
<td class="nump">$ 20,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,849<span></span>
</td>
<td class="nump">28,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="nump">$ 7.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Balance</a></td>
<td class="text">2 years 6 months 14 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">6 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,610<span></span>
</td>
<td class="nump">$ 20,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate intrinsic value granted amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=silo_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=silo_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679325568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of Warrant Activities - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Warrant Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Options, Ending</a></td>
<td class="nump">347,080<span></span>
</td>
<td class="nump">404,580<span></span>
</td>
<td class="nump">404,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Ending (in Dollars per share)</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="nump">$ 14.05<span></span>
</td>
<td class="nump">$ 14.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term (Years). Ending</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Ending (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable', window );">Number of Options, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable', window );">Aggregate Intrinsic Value, Exercisable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">57,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted', window );">Weighted Average Remaining Contractual Term (Years), Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted', window );">Aggregate Intrinsic Value, Granted (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>he number of exercisable made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of exercisable award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of exercisable award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227775629680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations (Details) - Revenue Benchmark [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer Concentration Risk [Member] | Customer Concentration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=silo_VendorMember', window );">Vendor [Member] | Vendor Concentraion Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=silo_CustomerConcentrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=silo_CustomerConcentrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=silo_VendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=silo_VendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227582658992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="14">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 13, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 27, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 10, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 12, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 05, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 16, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 16, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 25, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 27, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 17, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 845,092<span></span>
</td>
<td class="nump">$ 1,286,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LicenseAgreementExpire', window );">License agreement expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SublicenseIncomeReceivablePercentage', window );">percentage of sublicense income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,970<span></span>
</td>
<td class="nump">135,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SalesOfLicensedProductsPercentage', window );">Sales of licensed products percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,102<span></span>
</td>
<td class="nump">72,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">793,680<span></span>
</td>
<td class="nump">865,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Installments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ResearchProjectEstimatePercentage', window );">Percentage of estimate research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_JointVentureInterestRate', window );">Joint venture interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,726,061<span></span>
</td>
<td class="nump">1,496,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=silo_SeriesMConvertiblePreferredMember', window );">Series M Convertible Preferred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible preferred stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=silo_SublicenseAgreementMember', window );">Sublicense Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Prepaid expenses non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SublicenseIncomePercentage', window );">Sublicense income, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SublicenseAgreementAmountPaid', window );">Sublicense agreement amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=silo_JVAgreementMember', window );">JV Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_JointVentureInterestRate', window );">Joint venture interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expired term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_EricWeisblumMember', window );">Eric Weisblum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Vested common stock shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses', window );">Signing bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_EricWeisblumMember', window );">Eric Weisblum [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_EricWeisblumMember', window );">Eric Weisblum [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_EricWeisblumMember', window );">Eric Weisblum [Member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrentAndNoncurrent', window );">Annual bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_MrWeisblumMember', window );">Mr. Weisblum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrentAndNoncurrent', window );">Annual bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToEmployees', window );">Paid bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DanielRyweckMember', window );">Daniel Ryweck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DrJamesKuoMember', window );">Dr. James Kuo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share granted (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Stock options (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vests (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Stock option (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Fair value of the unvested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCostsNet', window );">Amortized deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,125<span></span>
</td>
<td class="nump">80,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Deferred compensation balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">14,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DrJamesKuoMember', window );">Dr. James Kuo [Member] | Risk-Free interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DrJamesKuoMember', window );">Dr. James Kuo [Member] | Dividend Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DrJamesKuoMember', window );">Dr. James Kuo [Member] | Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_UniversityOfMarylandBaltimoreMember', window );">University of Maryland Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fee</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ExtensionFee', window );">Extension Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_UniversityOfMarylandBaltimoreMember', window );">University of Maryland Baltimore [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_UniversityOfMarylandBaltimoreMember', window );">University of Maryland Baltimore [Member] | Extension fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_UniversityOfMarylandBaltimoreMember', window );">University of Maryland Baltimore [Member] | License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_MasterLincenseAgreementMember', window );">Master Lincense Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommercialSaleTerm', window );">Commercial sale term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SublicenseIncomeReceivablePercentage', window );">percentage of sublicense income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DueToRelatedPartieCurrent', window );">Due amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeesPaidOnAcceptancesResold', window );">Paid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Prepaid expenses non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,625<span></span>
</td>
<td class="nump">60,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SalesOfLicensedProductsPercentage', window );">Sales of licensed products percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_MasterLincenseAgreementMember', window );">Master Lincense Agreement [Member] | License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_MasterLincenseAgreementMember', window );">Master Lincense Agreement [Member] | Sublicense Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Prepaid expenses non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember', window );">Customer Patent License Agreement with Aikido Pharma Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NonrefundableCashPayment', window );">Non-refundable cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NetSalePercentage', window );">Net sale percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LicensorShare', window );">Licensor share (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateOfConvertedShares', window );">Aggregate of converted shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RevenueTerm', window );">Revenue term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Common stock shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TradingPrice', window );">Trading price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 531,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">531,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 531,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SecuritiesReceived', window );">Securities received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">531,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756,250<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConsiderationFeePayablePercentage', window );">Consideration fee payable percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember', window );">Customer Sublicense Agreement with Aikido Pharma Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,352<span></span>
</td>
<td class="nump">3,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,352<span></span>
</td>
<td class="nump">3,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,430<span></span>
</td>
<td class="nump">40,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FirstCommercialSale', window );">First commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AgreementShallExpire', window );">Agreement shall expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember', window );">Investigator-Sponsored Study Agreement with University of Maryland, Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Installments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredStudyAgreement', window );">Sponsored study agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember', window );">Sponsored Research Agreement with The Regents of the University of California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,710<span></span>
</td>
<td class="nump">$ 100,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithColumbiaUniversityMember', window );">Sponsored Research Agreement with Columbia University [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,218<span></span>
</td>
<td class="nump">646,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Amortization of the prepaid research and development fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,427<span></span>
</td>
<td class="nump">178,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredResearchAgreementDescription', window );">Sponsored research agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company shall pay a total of $1,436,082 to Columbia University
for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after
the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithColumbiaUniversityMember', window );">Sponsored Research Agreement with Columbia University [Member] | First Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithColumbiaUniversityMember', window );">Sponsored Research Agreement with Columbia University [Member] | Second Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember', window );">Sponsored Research Agreement with University of Maryland, Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">187,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,095<span></span>
</td>
<td class="nump">92,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ResearchAgreementWithReprocellMember', window );">Research Agreement with Reprocell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,835<span></span>
</td>
<td class="nump">33,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,891<span></span>
</td>
<td class="nump">20,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ResearchAgreementsWithUppertonPharmaSolutionsMember', window );">Research Agreements with Upperton Pharma Solutions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Aggregate total fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,462<span></span>
</td>
<td class="nump">&#163; 242,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_UppertonResearchAgreementsMember', window );">Upperton Research Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Aggregate total fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AmplifyBioResearchAgreementMember', window );">AmplifyBio Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ResearchAgreementWithAmplifyBioMember', window );">Research Agreement with AmplifyBio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,204<span></span>
</td>
<td class="nump">241,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Amortization of the prepaid research and development fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ZylTherapeuticsIncMember', window );">Zyl&#246; Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_JointVentureInterestRate', window );">Joint venture interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AmendedServiceAgreementMember', window );">Amended Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDepositsWithOtherInstitutions', window );">Payments to the university</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AggregateOfConvertedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This value for aggregate of converted shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AggregateOfConvertedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AgreementShallExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement shall expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AgreementShallExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommercialSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This term used for commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommercialSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ConsiderationFeePayablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This percentage used for consideration fee payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ConsiderationFeePayablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DueToRelatedPartieCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of due to related partie current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DueToRelatedPartieCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ExtensionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of extension fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ExtensionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_FirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_FirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_JointVentureInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint venture interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_JointVentureInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LicenseAgreementExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LicenseAgreementExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LicensorShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensor share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LicensorShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NetSalePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This percentage for net sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NetSalePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NonrefundableCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NonrefundableCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ResearchProjectEstimatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of research project estimate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ResearchProjectEstimatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_RevenueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This term for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_RevenueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SalesOfLicensedProductsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales of licensed products percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SalesOfLicensedProductsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SecuritiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of securities received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SecuritiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SponsoredResearchAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description on sponsored research agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SponsoredResearchAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SponsoredStudyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sponsored study agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SponsoredStudyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SublicenseAgreementAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublicense agreement amount paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SublicenseAgreementAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SublicenseIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage sublicense income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SublicenseIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SublicenseIncomeReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicense income receivable percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SublicenseIncomeReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TradingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trading price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TradingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_UpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_UpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeesPaidOnAcceptancesResold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amortization to expense from discounts on short-term negotiable time drafts drawn on and accepted by an institution (also known as Banker's Acceptances) which have been resold in the secondary market.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph 14<br> -SubTopic 210<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeesPaidOnAcceptancesResold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDepositsWithOtherInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid to make deposits at other institutions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDepositsWithOtherInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to employees, including wages and salaries, during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=silo_SeriesMConvertiblePreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=silo_SeriesMConvertiblePreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=silo_SublicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=silo_SublicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=silo_JVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=silo_JVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_EricWeisblumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_EricWeisblumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_MrWeisblumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_MrWeisblumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DanielRyweckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DanielRyweckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DrJamesKuoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DrJamesKuoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_UniversityOfMarylandBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_UniversityOfMarylandBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=silo_ThirdAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=silo_ThirdAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=silo_ExtensionFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=silo_ExtensionFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_MasterLincenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_MasterLincenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithColumbiaUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithColumbiaUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=silo_FirstPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=silo_FirstPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=silo_SecondPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=silo_SecondPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ResearchAgreementWithReprocellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ResearchAgreementWithReprocellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ResearchAgreementsWithUppertonPharmaSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ResearchAgreementsWithUppertonPharmaSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_UppertonResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_UppertonResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AmplifyBioResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AmplifyBioResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ResearchAgreementWithAmplifyBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ResearchAgreementWithAmplifyBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ZylTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ZylTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AmendedServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AmendedServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679412288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Milestone Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember', window );">Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems', window );"><strong>Schedule of Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestoneBalanceDescription', window );">Milestone</a></td>
<td class="text">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember', window );">Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems', window );"><strong>Schedule of Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestoneBalanceDescription', window );">Milestone</a></td>
<td class="text">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember', window );">Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems', window );"><strong>Schedule of Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestoneBalanceDescription', window );">Milestone</a></td>
<td class="text">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember', window );">Payment Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems', window );"><strong>Schedule of Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestoneBalanceDescription', window );">Milestone</a></td>
<td class="text">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember', window );">Payment Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems', window );"><strong>Schedule of Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestoneBalanceDescription', window );">Milestone</a></td>
<td class="text">Achievement of First Commercial Sale of Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_MilestoneBalanceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone balance description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_MilestoneBalanceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This amount used for milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227676043616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Minimum Annual Royalty Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember', window );">Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Minimum Annual Royalty Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MinimumAnnualRoyaltyPaymentsDescription', window );">Years</a></td>
<td class="text">Prior to First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Minimum Annual Royalty</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember', window );">Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Minimum Annual Royalty Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MinimumAnnualRoyaltyPaymentsDescription', window );">Years</a></td>
<td class="text">Year of First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Minimum Annual Royalty</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember', window );">Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Minimum Annual Royalty Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MinimumAnnualRoyaltyPaymentsDescription', window );">Years</a></td>
<td class="text">First calendar year following the First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Minimum Annual Royalty</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember', window );">Payment Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Minimum Annual Royalty Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MinimumAnnualRoyaltyPaymentsDescription', window );">Years</a></td>
<td class="text">Second calendar year following the First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Minimum Annual Royalty</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember', window );">Payment Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Minimum Annual Royalty Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MinimumAnnualRoyaltyPaymentsDescription', window );">Years</a></td>
<td class="text">Third calendar year following the First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Minimum Annual Royalty</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_MinimumAnnualRoyaltyPaymentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum annual royalty payment description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_MinimumAnnualRoyaltyPaymentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679763664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentOneMember', window );">Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems', window );"><strong>Schedule of Shall Pay UMB Fees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment</a></td>
<td class="nump">$ 92,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Paid upon execution of the July 2021 Sponsored Research Agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentTwoMember', window );">Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems', window );"><strong>Schedule of Shall Pay UMB Fees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment</a></td>
<td class="nump">$ 92,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentThreeMember', window );">Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems', window );"><strong>Schedule of Shall Pay UMB Fees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment</a></td>
<td class="nump">$ 92,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description on payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679150320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Future Amounts Due Under Sponsored Study and Research Agreements<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Schedule of Future Amounts Due Under Sponsored Study and Research Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 725,244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 725,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227673504416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 9,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,231,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent', window );">Valuation allowance percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net operating loss carry forwards to reduce the asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance increased</a></td>
<td class="nump">$ 988,177<span></span>
</td>
<td class="nump">$ 940,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage, before allowance for credit loss, of financing receivable to total financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (c)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227676267504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract', window );"><strong>Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at U.S. statutory rate</a></td>
<td class="num">$ (777,143)<span></span>
</td>
<td class="num">$ (820,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">Income tax benefit &#8211; state</a></td>
<td class="num">(240,544)<span></span>
</td>
<td class="num">(254,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Permanent differences</a></td>
<td class="nump">29,510<span></span>
</td>
<td class="nump">133,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">988,177<span></span>
</td>
<td class="nump">940,858<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227679785424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Net Deferred Tax Asset - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred Tax Asset:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 2,538,565<span></span>
</td>
<td class="nump">$ 1,550,388<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Total deferred tax asset before valuation allowance</a></td>
<td class="nump">2,538,565<span></span>
</td>
<td class="nump">1,550,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Valuation allowance</a></td>
<td class="num">(2,538,565)<span></span>
</td>
<td class="num">(1,550,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227676339440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2024</div></th>
<th class="th"><div>Jan. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Share purchased (in Shares)</a></td>
<td class="nump">62,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Share purchased cost</a></td>
<td class="nump">$ 95,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M@,:\^!<][7][X@Y0D'%!DS(8[B")TOU?_%R">!4 #54'.&6 \Y\ VVL(<,L
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M ;\R@.=S#N*CNE''WO7/'./_ %!+ P04    " #;BGE8D72]>CT#   %"P
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M54WAEC ^ /B\\5,AUVO^P/*3)F5WL=&WVVB$2,HF>LJ>,JA_P)(BV((D^H'
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M##H#RIJJ:W(],+)R96TN#15)U\WI&4-E ^C_0DJS'=@%VH<Q^0M02P,$%
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M3XX=*,S1IMKS=M4:W!=]D<"VV/9-0QN[H17V"O6"C,/' 4U:[?DH:-88E)9
MT7;2&1_=#:#N/_DCK1[RDJ."+B7>>J=NV*AVMW3LG@BVJ6\0^,J$8.OZX8JF
M"UJI ?+])6/B^8FZYV!_8\WD%U!+ P04    " #;BGE8]&KT+4H'  !-(
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M\B#$5WTS"R\ZCM:(QSQ06@2#KPV?\#C6DD"/?RNAG>T[]<3=ZQ?IUP5X //
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MIH??=,)WA75ZOP/DX)0LO(4(I[53D8J9I9$ZYF6]7A^1Q,5V<(0V<)3L&LC
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M VYC*$MIQNUJ6-A#:8I&#@!.]M[(('4.&I&)1I'!16IL#L:I$$Q;A[]8UXQ
M#!(C/0UM>_X\>"K/#QDUE+[ZH(]RF"J,XKV.M^?1\]:C&:J2P\BP2 ;C%4I'
MMHJ[4TU+;:3AB6];5W&$Y>D?9'&V'1D2F?V"]U?%?=RI9<%YS-M MXX>H,C1
MH:^6H]XG9OJ.P1_2*<]0_?BUN;O;?:N?Q4_4V^7Q0S]&SI6&!!1JB:WCHY?/
M!['MM1?!5OS!>F%#L"7_Q-"-]- "/%]:5'1S00=T_X-Q\1]02P,$%     @
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M$4[T+XR>@V%ILL8_?*A>F\!)Q449.4-?)>FY_HVTN;8B!3T!-T.@=:R5DZK
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M[6AF\I<E#:EH.(#>SS0)Z&YX@7[LG?P/4$L#!!0    ( -N*>5C]+%%.R!
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MB:@[SB90 $$^3D \0-OYS,(M9B&E6Z42;8UMOZAQ4MH(U9G!,A<SW(C$L?M
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MU:#WS.5L@V^)D>4R#T8XXV[Q9XM6&5)O$5)V-<?R8^XFC5IH@6_NQJA(\%:
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MY3I!8QU]-ZKZZ=Q;_"#WEC^;>PMT(Z&F,X3971;S@?)V7 9-  B[G,X3[=4
M&H^[-$11ZJ7&-(4^F&<$T""3(1 G'%]>&1[?72%J\U[.L+_-4S,K=],PITFT
M?=2&JKJ J!3Z>8(,)@/@82+#L^Z)!LE&0X^U.%#>TAQB,!]JQ"OD0-B?C;?>
M-2_,UIM<R>ETR[Z%V3?*@'_QMK_2%+U=$P6*SDUD"W%N[=<J :/+@L).;(ES
M3*23SVD^#Y$+=#9*P^*X=I>.XIQX"#OI@$T \T+7XO<<# !DQT9$'7V-RZ7"
MF7_5ZZ(J,DQ(X1S"#?&DKX[MO-/Q,D=-DL7"QRQ>(J63NZK"W#-6,>$/-$I!
MA1B5] ,B3HR(%C WT4\&EBB:N;,"64_7P1IJ#6(XS^^'9%C',,$Q1[=D7^<'
MQ*@H"B51-2Z(,,L]G=_# >W-:6&%B2J)4Z.;AX0O1EQ .(#J6&\XG02>RN+O
M,,PJ!OAE,4X 8@=F@3<B ,Y"<3H,_8F@TQGF5+BQS724)3AO$LZO?F&BV06)
M,&N>,.ZQSS2RQI^UH?]3QH_H&3_2&3_FD!AC& ],FFF^H  !<@YXE0H%C*B<
MLSK(B9.JQ'N#L&(!;7> 1F@9KQ7HYDE[[?WES9FZ6+9OH2D*E6=\_H9&.+GD
M5[N,&SZRH]GFJ'O-Y)VP#PB8<+G!I\ROYJ8) R'7BFN*H<*YQX_-%9!GAB-1
M*@P,[?S!8G35QMT;R4>SQP.9QL"$*5!?<VY+1 FB6+&"@1+VQX/>6I3K%5#/
MO&R6CH3H1JF6Z%A$((;7A<ND2=62N*+**7>5U+LL+K^KNCT0)OJX<$1$617)
M8SDY,:Z_>%$;+R%G# =RIHI3Q;97%^*"6'U<6WAO#Q?*H7!A/U%W#-#];/?V
MDV+$))V<];8X>I;>&GF'=K*VGDJ#(C :10MRLC(Y52 08(0"PCP'?-T_]J]!
M KD-"40?">RA]U;XD#-OV]-HS<85)@8'3%X93Q4N4- "[X'^D07=J0W!PPA\
M7#^GP7& PP5?1@^(5",G;A8+G6H7(\2,#];SB0V'F2("O<=D_:)'!)5CE\Y/
M^*MKF2EEI!D'OSH.BNU8&8*#(R >&(38H)6@SB@0+PWV&AA8K<GDP(S-$W56
MS&<('"T'@869H!CYX!HO!.NLI#"AR<'+8DI&3@WUE,*%3O> >81+<^Y8H_Q3
M\JK9B#EK%G/F/@,!/><IZK:=[(!V]%;L1?@6Q"XHZ2//1F2@Y@C#4>*%E;)&
MG'%2ZD9:H P$&84_,9!3ESB3N^ G13S25>TT0%I$.TE]:(N[>%L0#=4Y,,EU
M0=&MP:&J!O-_M*$&E1/'M]!!#0J!OO$@WP^L *\>654F\Y=2JPLB&\J 1><O
MIHDB=F%R&*PX4S;1Q51OH'\F@&@WP D&X2]C%3$!W'EH']KB.6C'?6.A=6),
MUI7Q'B)]J07JR"SA4J/U [?]].Y2/H+=XUU@8YCC S.DY(*T6$3L47351I,)
M"U)_\H#-R)^P&1%*ZQ_92T\%[B=MC;.#VM0P>&I$! 'L>,EIJDZ=7RAE<D2M
M-JE0HS[BL&FF056H,2/$)0-3T&:&];>T7'.=R8#333'1BXT']Y:8J[7BU'K,
MY5!8U0/38%K3CO$X9>L.EPP6.*72MY"[=W9MDJ&<#4L7(M@TA07/S[B$Q:4V
MA 0 ZL3AE /R*(;G#;,S&M'X@$]-QJ,/B/=S8SP&'G+%#"K+R/U#7*?ZKSVR
M;%Q(EE:A T\V>R^^!J8^;I)D3WY4J@7($-XBFEIXM18)0%/7?'498Z9<4'1!
M>&&/T9_+")_OLG5[BH;[& TL#!?[3'+V1*]+M29#,S+D0L*TLF$%7#8*$!C'
M!G5YT(H71^,;W9E9<*DPQH]'PK32T@+[2"+L6;=P) P5G >Q!G.4O1,8"9K3
MYK2K"[&',)0$0&'#R1DGQG&YXQ], <"%+'.:(-@;)\V>^9190PIA:#P2KN;4
M+-)93'9'X8B19YM BFDSMS4#E,VR\"3O*K,27B+N;CAUH&KG#I![MK?O:!"^
MC,94?H.H 59Q7;D*97>9<C<XU2H 1G<\^QK2DGE5M%\]BYY-S\A[V/,I_LN7
M)P:6UW[UV0DN3Q)6+E).E1E*V; I$]0! *!][=B_J;D0'T)1]C%TCU"^PKU\
MAX81RC=$O3$9U[=8Y*$TW/%=49D9F"T"W9(>A;8I1HT ?A-Y!:L@L^PKJ<R#
M1A ,:=+ ]QESNN^84[/.+Z@9K(G%N7U?>@;D/'4@[WVP:D3N ^,"PR%.MP&'
M9[UL5S.R?S^(_MT:FW (&$3@B$-?#%NWA33R*PI;JD4]_07%$UJ61'I]+]Q
M7'A,"WD,,M-QKB#-,L%=SV-3&TQ)P30?>25JM*X->\5_+S$T)#B/;M?:'C;=
M$MUAI*%U9I1F1I@R Y3(FDS8Y/2.6A.%&H/X;V+.U^:5&YMD.GQ&A_+3DTMZ
M9?P<^1F^U]U%J'",O<T237#DY(^,P'&&'QG %F( 8_P$XHT8X^3$\NVQV)J(
M93>T@94<HTYQ'&=[O,1%W**!RFQ6#SC"0Y&9N8ELV ('9+J8S\C"*5FI><-D
M-@=VB-T^E->4G>]UBU'W,6@A,(F&"NN&C-];K^IV8AR7^KN>VYAZD%O%:O41
M$#KI/B,1DH&W'Y %=T5M96"?[I=]9A/A;$'J_ME8!P5CJYHD C&00]")21I]
MKQ]QVQG&WU*-R^\4I7U4C(+?EH33+>OP-XAA0Q0&8$'A>JNFQG1 F5J0#".N
M79*P3BJSFI$XCP\LJA(C^^7&3__'(D#218#$U@B0\9%%)N)#:;_T$Q/UX?)<
M5W6I9TW=B199SAVU8B'Q')3FFER7G6B(""-'+G#T8W&4=NPD026)NUI4FVP-
MAUC!M:9B#Z&YZU, 5$K%R-\JU8K>CN5/M'R(D<G_$O:8?784A[@YE\+E7!3H
M)@T11=?5C^2Z>'891D%%/P\4IKLOFG1NO(D6^4@7]2D?@95NX4)UTF$0WYX"
M>7Y;,6>C9RQ,KOA :&UN(\.454;8JG.KYF%HET+*B@WWP1/R1]-UL@QX5PP/
M\[*"&QMX8HQ0_T:-D[1\]!4L,?) GA?7JJ-CF6.51&@X'YX%%8V/AKPJIM8-
MYI_^PC&]VN@V^V7OF3L?; [^-Y<7)!UWZ-1MV/-U.Z>2U#:&GF%Q@NNGXSD@
M^=IR=9]B^R ,1Y XO54ERMUKK.PE4D98W)0VL?N6<NZ-68WN]+HP/EY\."C>
M<N4DB*3/C#$_NHRPH\]QT&YJNCOM)^\G?(S'Z2^9G6\+U <2A*VPCBQTM3_F
M(5,$W*V@L5M&/:742;NI47OWHM//"-24V.6"MD\/K^QS0GN130!30;Y5,(%*
M0T#D_E'D_%'>]:,B[_F)#6IZ+LT.($RR' EH1KV4H$"&(<YVQ^+PMJVY#"+1
M8;P8./\,5E7DH8O+G(H=!U>-6YD/^J9<"JD*I)7=33=6Y;8S@FJ4@,N>R&[1
MM;8GC\4L:64YE2D,:8@U.K<FN4 'FA'X08Q5;VKS? A"SI#C5E[I2M OJ+!B
MWSH6@S$C"D:23PBY([%W&H"<81PFQ=!Y/$?K"QOHD?3Q8YHE@B0#91!#K)3I
M1)%6%UNU-4 4OERO"\X:VG30P)^7I5>CNU[9R9RB-[ 1^0@$G%K7[%<QN&R:
MTF"TO<0H'_Y%9:^S=:'R&.2+ 6;_:%M5BQ0H0BEAHZ:D8$24*&DO<7<9 AN>
M:)"R!3.E"!EJ+V6K+$UC&ZZ'-*YKPQ*&:_8-7E@;SZGC:2I"]&&EPR;]]AK<
MM)W8Q_)]6/^Y#0JH>[FH* =+*>T=>VR@3HDXS=V 4"!0=-40UC/CE^<0#,=P
MAK*S0U(S.K_1J_:5S3X977AV/>0"=I5*Q@MJY%C@G*47K(<40_XV*8*Y&'K:
MLCBLCJ/,-E"6QE(L@">'A:Y="6>K%.U0+!2$:W('O+1YB B@7>HJ::H@AR[$
M&U. :(7,]C'-.CPPO;^,Y7!'H/<E?DO((45UJR-/CB_.J"S4/LF==THXW=-)
M-#T[X=I!\5M3$-C+>&Z2%AAH6U0*Z^*V]=BD'(_4&L;L"ZPW)MW,XYA9A2]0
M.^4RJ1XNA4_OQJN'8!.P*TH(@HU;4]A*<+\!F!,;C TN:Q*=V&TXHB%J<J%H
MCCZ8A]SI&)"@%@!$BXAB7WC<VZ(8W.(?#:*T"KB&@RC!K-BQXB(Z/S/1%/Z]
M6]0X'+WHP:T3!A"VV53;I^]G&QT@!1ODB YX<(CSLV<(]+&P17=8T5G7\* _
M85T7AI9WQ2M$)UY!]$5VI8M,1JX#6D/99B3=URAP:AJ G4NF3TXOC<-)]=F&
MC6'VS]/*NUDFH:9I=3ZJTK>U!19QC A#6LLQ[04[M'*>+ME:1)UW9%RLVJ7V
M0>U7T'J'ZY])6:Z"N'Y886!)NY_)'?1>(EDI6-<-BKE(G./++FV,NY#EV,JB
M=.FI,V5M0E)'7:#<F2TV.-A^TW0N0HEL-HTJ%1S,9'+RB\V,0D*S$?I.%R(3
MV7>]T.CLJ<M>D)<QL/FA,';?@>'\%Z*59<!#YIJLUYH4X%$@AR9VKU6F:\."
MBPA@[-P()E6.:LTQH(KUBL2-;%P^2,Q#:/I<GKY&2MDJR2IXB(%@T(A$K',M
M#=38M26!</[)W84RI$#L\EWWG9NZEEV79N#&'#P;X^_J:?>[$^B.O?MZ=*EB
MP,_[N0.&5BQB:"313E_USM>?#;YPO)YK6'C7G =I&Y!H.NR=PA]F\ =6J@L_
MMCU2%)9X+%U@KQW_0.M ,4LMN(,>.2F#5']77/*3<OV)Z_W40N=^KK]79#V8
M77M.JU)UN\-N347$)H%K["Z/ZJAUGK:Y3\>JY=:4K89%Q(9\C8#8KT: F[J0
M$]7Z6(_;(9+@Z"T$,A7G;(0;QWQ$/9+@<3+=C<^=4]?FOO@U0BRD?"!"OFXL
M@/]GU(O91\F#&8,7MD&@YXQ&7;FJ@=F&.AVAC8EY6$D::]\3BP$F&& O37O#
MQ^088GY,#2Q0%,.RL)/(/Q4S:9L66M$R-.)\Z1,N<>B/#HV-.R70$'P)DI$;
MK77T?6Q#;*'CHQ6!=]KY+= /C4W[8%%!B,QFQ=G&SAPR69F>3N18-FF!/4=T
M3U71E15VN( ]DL9]PU(V)@8R#PO7>WIR_!P?2 &*+,0&^2.+=>O,>T"-R@.K
M4[C@:14VYN^VL:>R%2I4Q'('0<C6QC7?-Q;0DQKUHK#N+0T[*S6D1IEB#G=(
M/U#1(AY8S+"UEF%W04MPQNV2%E&O'E32(L=*6H)2%NL,[K+45NN[(;0Y%JUV
ML:/2=U?]RN!+G=J5H91BLR?AZUKT2%U+"W$\)OSDPA;Q<W"AO]?^L?HX;:_X
MQ>.%&,<+AP=$(CZ8J0>+G;I14L*,;3[!#K\4;7[9^B[$Y&=F;8;NE-/H](P;
M0_*O>#Q_W,,P;(;[N78;\L,^BM/SZ.FI^?) L9>/X8^N3.SI8GAZ$IU?3!^<
M$2EO,<VY8)]G,V?O@6WE&&3+B)%L&6E[1OG4R:(\Z@[:,3MV%Q7O2J#I!#"#
MK@\P>^5FKWA+O2#FZ/K:04QC%F]?*Q-8:;M? ELBBQC5:=#!3 8F+X3D90SD
MJL@<!P2WNOS1LJ$,"6)6<UM&3EF46#PTF+0QH,"[8NI;%_T7UPA/I"B]X"Z9
M#$E>$>ES&+EF+#+)%$H^FF#!-?<KO[X]FAR!(K=..7*2<KV[PA21(!B2NF_H
MP$_8);R,G99=9/+JTRWSP^D^0Z/CNFJH=0_99/ $>?#-_8@S2YS=A$WZ"'B4
M>Z;SE9[IVG(K3)Q?FRI[/!\X[*HR:@5F')?X&354T;"9J,XR[): *7 @/M(B
MV\"F:CVDJXXA461F-41DM39NC8MLXYHP91*DWP]%:3$YK(ZY=IK*JQ0+N\#G
M8OM[DHLJ:RAIR8:$;/&A[:;"Z8"FGI4T4LQC#WI/CA,M[P ;EK(S2QY>3**G
MYT]]>GS0KKB^+\QG <)6Q<3KD4>=G@\T6$+\&)^>A$/XKH>&VYVA.E,>%T0#
M[!T,/>)7OL@,Q)_<7H0\E#W^(LC59^?D9$D3&W#'RLS:MS2RN?!^HPAKA(U9
M 9"#G"$+!1RN81ODR<*#7K!Z%@8IB4*Y/X@-TG&-"\8G0Z;=9]4, W(<JR6Q
M;AL+:7&RJSC5P%9R';L.(9,!C\^(<T>,,V/IV:^'U6!FZ[9=M!EQL!O9VXUH
M[29" ILIP-B%C>O? D)\P)[W8(P6\&BV;CRK_'9U^V'+-X[PMK>[6*GK<_-U
MI=,BV<QT[C)2F"]*ZAT;^!OH(QD<&I.K)D,' @(M252JJ/J2F@0C>A-/8CE/
MB0BN&Y(7 B@6;D Q!4(KW,RVJ0B8]"O0[G2"R)RSRC(#_IG&)9KE%,@?^'K6
M8')+6'&' +$!,JLPGCZ=1A<<JK-0:K% 5P<$S"'LD,W<*$#=5C>?[H?CD+.P
MYNE\#VWT'.2-U+RXK2MCC1;ZK12!$/#+*$K;$')O_7=J]=])_^-(_0G$",!=
MF1^"^W "_/9\$GP*X.R\6]D49I3YKJ_%WJ4ZO5B8B8'T&[KVSK #F#&[8&B#
MA"29*9YG?5;,&]<O'[;Y4^R.O3@WRZASD&Q3XOGB<')^$9T]N^A">K2&C"41
MPWMT-BPL&S9K@@UT1Q%#H[0- (<=0(GGG8ZP0?5O8!MT4*,:Q0UKPPA[>6>]
MV[B5,2:P=G<TVMK(K->K2.S;;^]!TLN\3^L@6;F/#!,#8N7ZK?6W6)6;D(<"
M,4D!'!W4FX0PLJU,&Q6;S]PTL],)MJ6NY)V.G8;<M4HZC&B_#0RHKOYK#;O4
M5U)A!E58;E92+,95V7UTV#VW@/E8,]7Y!@-W[!><L16D&V[/'C.PL]^2*NMN
M+K%>M+\%D-!G]JIV-PS?)(.^:$?-,RHQY#@SGKURH*7#GINGI$V;* F,5LU-
MS+3?M(.#YP*$S R;DZ/3*<@XZT#"<<  %I$[(M<[U#S=3XG;;_D#7]4J?8TB
M[</,8(+H[9-IMYEU"Z@> D",I;$0H4]6V>QW^F:"ZX#2/5J;6]%7H$HT07YK
M=,4?&J-R#[QL0NN,K12=-!H)+ G1 X.-HI/^OM\.'IN,@CZF/@ *.G1$"]2F
MVIE3P\4!Q!0H.S=-3<VT^WH@[=Q^:)%3!0:^^>'5-=_&T'X)1?2X/XYA:HT>
ML#>;BSX+V^7Z:@ ,&&.F;K[T21&N"Z.Q[ 1^69WUZV:^5"8MSN?48Z=D3 =Q
M%D'/*;=PGUGRA>([OF@TL#W1WUY$8!EI8&J_Z1:89)T>H_4>_:C##'23]B$N
M2TWUR1]OA@HW]L7<;C<YGX&"\U#?8+EU)K'O3./U<0B^CS?M,J<PE]UFF- [
MIB6Q;YZ,;W>^ S.8T*MKFPQ8M5@LOA]D,GZ\Z2/%?EML>S=:_5,XF0S52<IB
M>"%L9?Q$'LKGT^CD^1D8F7H^[+;9EY5/.X,%#5Y]A F0OZRY&8-QYQ!A5?@E
MT_3A&"1._:3?=OB-_M!$ PU:7/POS+'FM8A1-0I3D)IE@\GL+IXP:#.9]K3]
ML0E!JR#$O,L>%'NW;NC:@Z0O[_2&S?<TFH4UFO_=]IXUFR[. 7XG[>C3=E.O
MVM/8"\PJ._,N^Z\EW K\TCT2JCGC(/,F[$J"QAA5,%A?[+_ 2+LJTB:;Z3B,
MX'P./E6^.U0CMMI7K4E">VY[-ICSK%I!YX4;/&_ED\TH,OX.@]= W^P";V7H
MN.Q$2PW4?,?G-PUYXSA-ENLSL5T:9ST0!EVF_UPI;2JC29;9WJ3BZZK3XMED
M+^J.X87W.A]4H#=:G?R=+6:B^.Z;X=8#9G([GK>D#TK*\#MKW6YB@=(=DZJ2
M^K,# L 4N87]1)@--/DGL(BZJ#"ZTE,$8.&OGM1O7CW1%?R7P+^RN(?_"2'?
MQ77\YA7 ;*FN5)I6G$?P^F!R$%Q%A\;K@\O)B\OIP1-XTS_^YM4Z7JKKN 15
M#3MQ+.#5D^/SLP-6(^P?=;'&(5']JXN,?EVI&/ !'X#[BP).VOR!$Z"@H.6]
M^7]02P,$%     @ VXIY6/XA)F3?!0  2@X  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&ULC5??<]LV#'[77\%SNUYZI]JR;,=VFO@NOWK+0])<DW;;
M[?9 2;#-1B(UDK+C_O4#2,EV6B79@Q.2 D#@ _"1/%XK_6"6 )8]%KDT)YVE
MM>51KV?2)13<=%4)$K_,E2ZXQ:E>]$RI@6=.J<A[<10=]@HN9&=V[-9N]>Q8
M5387$FXU,U51<+TY@URM3SK]3K/P12R6EA9ZL^.2+^ .[-?R5N.LM[62B0*D
M$4HR#?.3SFG_Z&Q(\D[@FX"UV1LSBB11ZH$F5]E))R*'((?4D@6._U9P#GE.
MAM"-?VN;G>V6I+@_;JQ_<K%C+ DW<*[R/T1FER>=28=E,.=5;K^H]>]0QS,B
M>ZG*C?O+UEXV'G986AFKBEH9/2B$]/_Y8XW#GL(D>D8AKA5BY[??R'EYP2V?
M'6NU9IJDT1H-7*A.&YT3DI)R9S5^%:AG9U<R506P>_X(YKAGT2*M]]):^\QK
MQ\]H]V-VK:1=&G8I,\B>&NBA*UM_XL:?L_A%BQ>0=MF@'[(XB@<OV!MLXQLX
M>X/_$1_[^S0Q5F,A_-,6JC<T;#=$S7%D2I["20>KWX!>06?V[DW_,/KX@IO#
MK9O#EZS/KF[./U]?LOO3/R_OVGQ[6?OF\_TEF[)W;R9QO_^1>6.!,\;NE\#.
M55%RN6'4I!9_ANH6M(:,6?[(N#%@#>,R"W+!$Y$+*Q MN^26^HX:""? )'($
MR<-\CDN&J3FS4)1*8S>S3."J!IFB9@)V#2"=4LJUW@BY8+Q0E:RU<'VW*=O?
M%&F&S87D,A4\#S2@=4O:9:5+9< K./W:7&4P"M(2/M/D8"/<==&WQ8I\@)4&
M10)Z6VW.- YBEBHD'6/)58PY0 ;4W'F1*V-\1!]PRS776;T'0?/K/FS)"0Q$
M8E[E^0;MS6DUV3#.5CRON">F')D1 P8433G&TT!4X9JF?%E2#5S4EN9(BLZY
M>64K[4+F20XU EUVZD!^/K[066^*8LDS)A5E.E4:FQA]:Q*R<<"24"7I\T**
M'Y %#F)E!'E?QR^P$# W:4I)(:1(D7;9E453%<$N491.7UJ^I)"?F;'<5E9A
M12'FL$UWJ=5*N)/@::[KDB&1#7!M&! 1O93<->:$FV"N"'9S%/R%:IZ^V&X8
M/#&P/PFN=G66@(2YL!3$U^Y=]V??W[*#\7@<]H<#]IXFDS@*Q]-#]K[-1M.\
M9 /803R,PM%PB(H'\6@81B-2NP4\AR0E?[_;XFDXZD>L/QB$T^DP.%]RN:!B
M:"VQZ602]L=C-D7[D]$DN%>6Y\^BBUY_<+\]%G&.CC\BB"6J/8J"_/VY_@-?
M__R52JR3P;;)>![VB\8Z4CE6.%H_"FYPB[;FK'L3/8_#T6 2C@Y'..Z'HU$4
M#B9-T"W]F@"J0BMP.TL[.]]:Y YV@IB[K2QF[Z:=(_8AEJ\$Y.#:P9YO@K?3
M,$9XHBAJY;0N^^0YHK+8T#^\LS6]O+:950UAM?(,$P:O<LEW[-L 13F"(&6%
MN.:B$+:&!=U%8C%X1:)=U5J"-DM1LM05:7W&%!SY+4TKJCSGF=^O^R(DK"%@
MIYX@4ZRXR,D_\@8AKM+&D&>&NFY_84M*RR_!F\85?\R0\WM(S[4J$-[^!#'W
MTBF&G_C#3F!VU0HT\AQF6TA!>0H;J)B#RN%4&;SU>K201:^YQ*EC]@1R :L&
M'>*7LG3<5E!QYN(!#=(WZ7C;">T3^EKD><WH'',.='"8)V2#YW\%Y(EM:6L\
M_!#JJD&[)M@GC+L[7T]3.C10ED)\>JH8SRK^1.E'T6]!6ULI#W-K+WIBU)!C
MJ6>-NXYH7R^*70UL+QNT]@.TZ@9[6#NP-*SH_6"76-)M3N).0F4BY72($W<Y
MK8(_H.7L.U[2R90C,HD-: S>A[KL2KH.]+"T6*5S$#-$UQ>\$+RMB;G;=IGL
M[=WO"] +]XJA3&%I^JO^=G7[4#KU[X.=N']E77.]H M@#G-4C;KC48=I_W+Q
M$ZM*]UI(E,6WAQLN\;$'F@3P^UPIVTQH@^WS<?8?4$L#!!0    ( -N*>5@'
M*.NGUP(  ",&   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;(V5WT_;
M,!#'W_DK3@'Q5#4_6DJ!-A*%HFT2T%%@#],>W.3:1#AVL)T6]M?OG%]T6JGV
MDMB^N\]]+_5=1QNI7G2":. MXT*/G<28_-QU=91@QG17YBC(LI0J8X:V:N7J
M7"&+RZ",NX'G#=R,I<()1^793(4C61B>"IPIT$66,?4^02XW8\=WFH.'=)48
M>^"&HYRM<([F*9\IVKDM)4XS%#J5 A0NQ\ZE?S[I6__2X3G%C=Y:@ZUD(>6+
MW7R-QXYG!2''R%@"H]<:KY!S"R(9KS73:5/:P.UU0[\I:Z=:%DSCE>0_TM@D
M8V?H0(Q+5G#S(#=?L*[GQ/(BR77YA$WE&YPY$!7:R*P.)@59*JHW>ZN_PU;
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M<R]S:&5E=#(P+GAM;)V56V^;,!2 _XK%I#VUX9;+E@%2TFY:'CI%:;<].W
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M9>1 L@;3<U5WT.EYJ/ENEK+&*<2._C DB ,XR<</_MS[,J(\'92G8_1DUU!
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MK=+3()PI\53NFAJ^-?!<\_HF3:NV;$RY5)^JW*1&VUC-M_S+5CUU'SY[>=K
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M W@WJN%Q^HNCS<JDJW!W:%TFTS4#.=H0L5[0"CJ;ES8E1B(,5Q"_1'0E7\T
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MP0 3M'N 3MS",<3P8PN1">%PW0)#2:Q01;11*@+!@@*:$<%LII&#"1,!FI7
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M<=;W']A;LFA0,-G:WNE@=N-ZJ&AC6]=71=5;DL/'7VPBZS(Z%*_-&T+<0U=
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M[PU^<-R;HSFX2%*E'MWB6[X((B<(!6;6(3 :GO :A7! ).-WAQGTE,[Q>'Y
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M8']4"XU6V%$R7H(T7$FB(9\&LW@\'SI_[_"3P\9L[8FK9*74G3.^9-,@<H)
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MS.B[!@U?H/.EUFZ[8 7ME]+D;U!+ P04    " #;BGE80@0OMID#  #>"
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M/+,!,RE>"GMDZ,2>0)R3>I',>:G/5*306!&E-!5KK@N^M+5,]:P@?A)YBK!
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M-YW_"Y/+@BLH,:=4O]<G%\BFFS83+6K;P19"4S^TPQ5]@* T ?0\%T+O)Z9
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M,T _GW/]DY8=4TQ7+T_Q/U!+ P04    " #;BGE8V:@)J,0$  "7$@  &0
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M=P;\OL5C=X]W@*] H[=O$A_C#X@+?E7SL1)I-_<(1I73D<HB%GO@X R/_02
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M:&5E=#,T+GAM;-5846_:.A3^*U8V39NT-G$"!#I *G35*JU2-6YW'Z8]&'(
M:X[-; ?6_?K93AH"#5G9T)7N2XD=G\_?=WQR?$[[&R&_J26 1C]2QM7 6VJ]
MNO!]-5M"2M2Y6 $W;^9"ID2;H5SX:B6!),XH97X8!!T_)91[P[Z;NY/#OL@T
MHQSN)%)9FA+Y, (F-@,/>X\3G^ABJ>V$/^ROR (FH.]7=]*,_!(EH2EP105'
M$N8#[Q)?C'';&K@5GREL5.4962E3(;[9P4TR\ ++"!C,M(4@YF<-8V#,(AD>
MWPM0K]S3&E:?']&OG7@C9DH4C 7[ER9Z.?"Z'DI@3C*F/XG-!R@$.8(SP93[
MBS;%VL!#LTQID1;&AD%*>?Y+?A2.J!C@S@&#L# (]PU:!PRBPB!R0G-F3M85
MT638EV*#I%UMT.R#\XVS-FHHM\<XT=*\I<9.#Z\)E>@S81D@,4?7E!,^HX2A
M&ZZTS,QY:84(3U!EW2T0E4G(W[V^ DTH4V_0&9J8&$LRYI F+BSH3U#HTIX4
MU0^(<J27@,8B71'^\.I%-\3Q.X4F2R$U^@=D:G9=@]+;7=]_SZSASK2N<CE#
M]Y,K]/KEF[ZOC3>L)G]6*!_ERL,#RG&(;@772X7>\P2270#?N+'T9?CHRU'8
MB'@%LW,4X;<H#,*HAM#X^>9A YVH/-K(X;4.X#F_GCWQZY=;2*<@O]9YK!'0
M9I0+M2(S&'@F92B0:_"&KU[@3O"N3NV)P':TMTKM+8<>'=+^WX?BEX^& [K1
MD*I:W[9.Z=L3@>WXMEWZMMT85R/"3)* MV@*"\HYY0OKY0<@LDYV(U8]4U2G
M^.]Q=L1V2K&=1K&724+M?:/JM.6F'6=J[\OUL(5;,0[BOK^N<F_<XGCN<<D]
M;N1^S\W%SDS@)X@)I:!60_Q$PUDG#/<5-&YTO()NJ:#[O% #\P4V!%FW[B""
M;C?8D]&XV_$R>J6,7J.,FMS1E(4;P8[-%"<"V]&-@VUU$?S?\G#!^$3N/17:
MKG\KU1L^82XNP*K?281Q=^\CJ5G5PKU>KUVNVR4;;LF&?YY+FVV/N"@*H"K]
M;CN.H@/LM]44_DTY11BX6!.2&E^;&GDFE*Z5\@>53[V4Z&ERQK');/$!,=OR
M"#=6"/M70ZV*UM/-ZZ*E;EF$P^"0P[=E!GYFG?&;Y-\,<XR[<Z#VH<\CU^%7
MFJT4Y,+UH,H$0\9UWBN4LV6?>^FZN[WYD>U_71.WA<F;YULB380IQ&!N((/S
MV%"2>3^:#[18N99N*K1I$-WCTO3P(.T"\WXNA'X<V W*_PH,?P%02P,$%
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M:3M:-D(U ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+:XU:9'FUZ;M:).(TN2
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M7+_4V^[I5G ID^W97U.^4%!1!',EZ?1&JD">;8-G)Y*MTHWA>R8EB]/#)=
MN!Z@[L\9DR\G>H+BSXCI?U!+ P04    " #;BGE8LIC6=#D$  " %   &0
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MAVH^J@6H%J):A&HQJB6HEJ):AFHYJA6H5J*:6$_Y5GH9G%UN;S=FQ[A@Y[C
M!GD["VTJF@>=O8:?PFIU :GQ](LT>I@]31?2[=/^+(36,:.:C&H*JJFHIJ&:
MCFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%:CFH%JI6H)M93
MOKG;Y^+D?/<M6NQAV3DNL$'>SD*;$N;5I?8ZLI#?JNJIYHOQPVBQ:NAY*6?>
M&XLZQ:-C$:G)J*:@FHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%
MJ):@6HIJ&:KEJ%:@6HEJ8CWPV^_PNMX)1>A!V2DNL#'>#D6;#N=!=^FC.1M/
M%]+792YZJE>EA8MJ>92%5"^3T=Y A!8YHYJ,:@JJJ:BFH9J.:@:JF:AFH9J-
M:@ZJN:CFH9J/:@&JA:@6H5J,:@FJI:B6H5J.:@6JE:@FUL.^'8@N=@(16^;,
M<M@8;P>B39_SH+O0V:]G=]5\/IY-1Q/IKMK_%OANX^@8A#8WHYJ":BJJ::BF
MHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ9:B6HUJ!:B6JB?6(
M;S4:7@XO3BX&.U'H8F>3T>#L^N+BZG)GCS3;V$QQ[92SZ6P>=)<V*W\\5C>+
MZE:*J_I!^K=3/7RNZKW7:>^&CHXZ:$DSJBFHIJ*:AFHZJAFH9J*:A6HVJCFH
MYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYJA6H5J*:Z)GSQW+LM!?LN!?8O&^'
MIDT;]."E;_'TG=#TZ^SA8;QX>5_9ZBH7O\ZFB_'T2S6]&5=SZ=_V\NZ2L:@>
MYON#%%H*C6HRJBFHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQ
MJB6HEJ):AFHYJA6H5J*:$"S'3GO!CGN!S?MVD-HT2P^ZJZ7%?/[T\+@8SZ;[
M5]?0AFE4DU%-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M
M0;44U3)4RU&M0+42U<1ZN#?7S'9K%MG2:9;#AG@K_@PWM=/#[MII^_42\5W+
M;MW$L1D(U6144U!-134-U714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)4
M2U M1;4,U7)4*U"M1#71,^&//EO$<NRX%]B\;\>E37GU</"!RVY#M,P:U614
M4U!-134-U714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42U M1;4,U7)4
M*U"M1#4A6(Z=]H(=]P*;]^T@-=P$J>YB;'_T[25%W<WJU5O;]L8EM!0;U614
M4U!-134-U714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42U M1;4,U7)4
M*U"M1#6QGO#;EWW=7GX;[G9G[[D;.YX%-I_;\6;3=3WL[KJ.JGIU0LA9G2#Z
M6M6+\>=))?GU^M)GG:MM:/TUJLFHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>
MJOFH%J!:B&H1JL6HEJ!:BFH9JN6H5J!:B6JB9_ ??Y*(;<EF.6S>MU/4IB5[
M>?,#5]O.T"!%:C*J*:BFHIJ&:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$
M:C&J):B6HEJ&:CFJ%:A6HIH0+,=.>\&.>X'-^W:0VC1K#[N;M9MGH1[?SD+-
M%[.;WZ2_CJ=2=#]:'O9OTI_2_/G6WCB%UFVCFHQJ"JJIJ*:AFHYJ!JJ9J&:]
M:EMGH=LGH6WTD ZJN:CFH9J/:@&JA:@6H5J,:@FJI:B6H5J.:@6JE:@F>@;[
M\2F)K=MF.6R,MU/2IFY[V%VW'3U]GKR^'4Y\J:MJ=>*I>ZD.K=Y&-1G5%%13
M44U#-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E1+42U#M1S5"E0K
M44WTC/OCLQ/*L>->8/.^G9TV)=[#RX]<JD.+O5%-1C4%U514TU!-1S4#U4Q4
MLU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[4"U4I4$X+EV&DOV'$O
ML'G?#E*;8N]A9]_E)[^N'D?C6ZGZX_'Y3-0J3,T6]U4MW3S5]>J,U&@^KQ;[
ME^C06F]4DU%-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M
M0;44U3)4RU&M0+42U43/Y#\^1EWM;&FX.KW:>5\=V]9-<>UTM&GK'G:W=6^E
MH[DTG4W__AJ,]B8BM+X;U6144U!-134-U714,U#-1#4+U6Q4<U#-134/U7Q4
M"U M1+4(U6)42U M1;4,U7)4*U"M1#71,^V/3T2[;>"#D\'UQ4XF8BN\*:Z5
MB4XW%=ZGW17>C6U+X^G-[*'Z47JLZN4'%J,O>WN5NKUC0Q&JR:BFH)J*:AJJ
MZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJY:_:=6.TG_PT
M/&]/]@(]9HEJHF>,'QUV6(X=XP*;X^U,M.GI/NVLKVQFHM';5N[1P^QI^9_5
M":2]L0AMYT8U&=445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U
M&-425$M1+4.U_%5K=C .ACMO;"W0@Y:H)GI&^?&YB*W=9CELD+=ST7"3B[IK
MM\WTP+>V=3M'AR&T>QO5%%1344U#-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+
M42U"M1C5$E1+42U#M1S5"E0K44WTC/GC,Q/*L>->8/.^G9DV7=ZG+RV7'_/6
MME.TSAO59%134$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+
M4"U%M0S5<E0K4*U$-2%8CIWV@AWW IOW[2"UJ?->WNPZ^;0*3O7X\]-B/)M*
M-[/YWAW;W<;1>8G49%134$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$
MM0C58E1+4"U%M0S5<E0K4*U$-;$>\<T%Q^%PWV7?V..R@UQ@D[R=A#9]W*?=
M?=SF;#Q=2%^KZ>*I7NW:7E3+HRRD>K38OV$;K=Y&-1G5%%1344U#-1W5#%0S
M4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E1+42U#M1S5"E0K44VLAWU[;_KY
M8"<1L=W;+(?-\78BVG1OGW9W;WN/SV>%JC\>QZM+DRP#T</>)(0V;J.:C&H*
MJJFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%:CFH%
MJI6H)OJ&_/!,>IA-%_?[R@L%.]L%.]P%-MW;^6C3KWW:63OY2:G'-U)6C>>?
M)T\/W3NWT2YM5)-134$U%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B
M5(M1+4&U%-4R5,M1K4"U$M5$SYP_?L,1VZ7-<MB\;X>F39?VZ4L;Y0?MW$;;
MM%%-1C4%U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4
MRU M1[4"U4I4$X+EV&DOV'$OL'G?#E*;VNW3[MKM7T;S2IJ/)J/ZV]ZDA+9L
MHYJ,:LJKUMS^=KK:_;:U_4U%CZJAFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%
MJ!:A6HQJ":JEJ):A6HYJ!:J5>^;'8+@[/T3/0#X^W: <.Z(%-J-;Z>9L4Z!]
MUEV@G5;S174KW<P>'F93:;Z8W?PFS>]'RT-)?QU/I>CYYM^D/U\_N"\!=1_A
MV 2$:C*J*:BFHIJ&:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):B6
MHEJ&:CFJ%:A6OFJM*WF<#R\&U]LY"3VL8.>X8 >YP"9Y.R=M2K7/>DJUQU^F
MX^D7Z?-L^K0_!:$-VJ@FHYKRJK6O-+/G/!!Z5 W5=%0S4,U$-0O5;%1S4,U%
M-0_5?%0+4"U$M0C58E1+4"U%M0S5<E0K4*U$-=$SN(]/06R%-LMAD[R=@H:;
M%-1=H;U_)[;TI^2,I^.'GLW9W?;1"0FMU48U!=545--034<U ]5,5+-0S48U
M!]5<5/-0S4>U -5"5(M0+4:U!-525,M0+4>U M5*5!,]H__X',76:K,<-N_;
M.6I3JWWVD;7:9VBM-JK)J*:@FHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@
M6HAJ$:K%J):@6HIJ&:KEJ%:@6HEJ0K <.^T%.^X%-N_;06I3J[V\V75"JF=S
M=O>CCTY*I":CFH)J*JIIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!:C
M6H)J*:IEJ):C6H%J):J)]7#OW1'.SG'!#G*!3?)V!MH4:I]U%VJ_OR@W^J-_
M40ZMUT8U&=445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-42
M5$M1+4.U'-4*5"M13?2,_N//);$UW"R'S?MVCMK4<)]=?.2B'-K.C6HRJBFH
MIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYJA6H
M5J*:$"S'3GO!CGN!S?MVD-KT=9]U]W7W+<JA)=VH)J.:@FHJJFFHIJ.:@6HF
MJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHIJF6HEJ-:@6HEJHGU<&^]O?MJ
M[Z(<6[_-<M@D;V>@3?WV66<KY?N+<K_,1O6M-+N3Y'%=W2QF];Q[?0XMXD8U
M&=445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.U
M'-4*5"M13?2D@.-/*[%%W"R'S?MVI-H4<9]=?^3Z'-K3C6HRJBFHIJ*:AFHZ
MJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYJA6H5J*:$"S'
M3GO!CGN!S?M6D#K?='Z?=W=^B^GT:31YO\JR^^''1B54DU%-.=^M6MU[21/T
MJ!JJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJY:A6H%J)
M:J)G;A\=@EB.'>0"F^3M$+0I]#[O+O1VZI]VU^?VIB&TV!O59%134$U%-0W5
M=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+4"U%M0S5<E0K4*U$-=$S
MYH_/3&S]-\MA\[Z=F8:;S#3\P!6X<[3_&]5D5%-0344U#=5T5#-0S40U"]5L
M5'-0S44U#]5\5 M0+42U"-5B5$M0+46U#-5R5"M0K40U(5B.G?:"'?<"F_?M
M(+7I_S[OK,7L7X%#&[Y1348UY55K5H -]UU,#CVJAFHZJAFH9J*:A6HVJCFH
MYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYJA6H5J*:Z)G;QX<@MKN;Y;!)W@Y!
MF^[NY<VN$.2/QK<=$:CSP4='(%*344U!-175-%334<U -1/5+%2S4<U!-1?5
MO%>M[Y\#/GK4 -7"/9_#ONMC1^A18U1+4"U%M0S5<E0K4*U$-=$SCX\/-RC'
MCFB!S>AVN-F4<I]WEW++H^FXFDCAM]^KF]^Z]Q>A#=RH)J.:@FHJJFFHIJ.:
M@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHIJF6HEJ-:@6HEJHF>.7]\
M:&(;N%D.F_?MT+1IX#[_R ;N<[2!&]5D5%-0344U#=5T5#-0S40U"]5L5'-0
MS44U#]5\5 M0+42U"-5B5$M0+46U#-5R5"M0K40U(5B.G?:"'?<"F_?M(+5I
MX#[_CQJXNQ]]=%)"&[A134$U%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U
M$-4B5(M1+4&U%-4R5,M1K4"U$M7$>K@W%Y O]A5PLX=EY[C !GD[ FT*N,^[
M"[CE^B?)'#U4<\EZFG4OP*$5VZ@FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ
M>:CFHUJ :B&J1:@6HUJ":BFJ9:B6HUJ!:B6JB9XY?_QY([9BF^6P>=\.39N*
M[?./K-@^1RNV44U&-0755%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+
M4"U&M0354E3+4"U'M0+52E03@N78:2_8<2^P>=\*4A>;BNV+[HKMG@6X[D<?
MFY10348U!=545-->M>9YUM/=\ZPZ>E #U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4
MBU M1K4$U5)4RU M1[4"U4I4$SU3^^@(Q'+L'!?8(&]'H$W!]D5WP79T/ZHK
MZ4L]FBZJ6^FOXZGT_)'YWZ0_I?GSK;W)"&W;1C49U1144U%-0S4=U0Q4,U'-
M0C4;U1Q4<U'-0S4?U0)4"U$M0K48U1)42U^UUE7I+W;^K9:A!\U1K4"U$M5$
MSS _/AFQ-=HLAPWR=C(:;I)19[OD)^6/JKX9ST>?)Y7T6-4O:>@Y(<FSR614
MSS<?786EOT@_=P4FM%4;U6144U!-137M56MWOFR?1T*[LE'-1#4+U6Q4<U#-
M134/U7Q4"U M1+4(U6)42U M/>#W3(8>,4>U M5*5!,]8_OX#,0V8+,<-IO;
M&6C3@'W1W8"M_/$X7H:>V]&BVIMJT )L5)-134$U%=4T5--1S4 U$]4L5+-1
MS4$U%]4\5/-1+4"U$-4B5(M1+4&UM&>JF*/I3]+IX$=)&IZ<#O<NG:'-V*A6
MH%J):J)GGA\?CMAF;);#1GP['&V:L9<W.Y?.%K.;WZ39XV(\F\X/7SKK1(_.
M3*0FHYJ":BJJ::]:\T3U[GEJ'3VF@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H
M%J-:@FKI0;]I,O28.:H5J%:BFNB9T<<''I1CQ[/ YG,[\&S:LB^ZV[+3:KXX
M(NB@C=FH)J.:@FHJJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&KAJ]8<[.>[
MEP]!CQFC6H)J*:IEJ):C6H%J):J)GAE^?"!BF[!93N[[&6P'G4W#]45G\6/K
MS,[A>0<MMD8U&=445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U
M&-425$M1+4.U'-4*5"M13:Q'?L_6=,&.<<'.<8$-\G8PVC167W0W5JNC<2U]
M'4V>*FEV)\T;,6EO(D(+K%%-1C4%U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-
M1[4 U4)4BU M1K4$U5)4RU M1[4"U4I4$^M9W]RE?GUV/3C?241L@37+88.\
MG8@V!=87W076[42TN*^DI^G7:KYZ,WUO/$(;K5%-1C4%U514TU!-1S4#U4Q4
MLU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[4"U4I4$^O!?]$;C]BJ
M:I;#!GD['FVJJB\Z&QP_B8=9O1C_]S(-W59W55TO;]S,'AZKZ7ST;BQ"^ZE1
M348U!=545--034<U ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+4:U!-525,M0
M+4>U M5*5!/K@=]:1SL;#'=CT>[]KDXNK[?7V]@!+; )W<H[EYM&Z<ON1FEY
M7\J1/H\FH^G-WK?0=WO'IAU4DU%-0345U314TU'-0#43U2Q4LU'-0347U3Q4
M\U$M0+40U2)4BU$M0;44U3)4RU&M0+42U<1ZW#?7R'9V#+W>IR\1L<-98-.Y
MG70VQ=&7W<71^Z_<*OTIA>/Y;W]7ZZJ2QM-%M3ST0@I'BZKSXJ[=QSHZ!:%]
MTJBFH)J*:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJ
MY:A6H%J):J(G"AS+L=->L.->8/.^G:N&FUSU4NGX,1=WO41[IE%-1C4%U514
MTU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[4"U4I4
M$X+EV&DOV'$OL'G?#E*;[NK+[I91,9\_/;R4,^Y-2FAW-:K)J*:@FHIJ&JKI
MJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6HIJ&:KEJ%:@6HEJ8CW<
M!Z?-5;6?!E<[BV]L0S7+88.\'8$V#=7+F]^U1B>/OXYOJ^FM5(RKR6WWTESG
M(8[.2:0FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ"
M:BFJ9:B6HUJ!:B6JB9X$</P9)91CQ[W YGT[3FWZKR_//W)I#NW#1C49U114
M4U%-0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K48U1)42U$M0[4<U0I4
M*U%-")9CI[U@Q[W YGT[2&WZM2^[^[7[EN;0)FU4DU%-0345U314TU'-0#43
MU2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M0;44U3)4RU&M0+42U<1ZN#??[[;[
MGCBV19OEL"'>CC^;%NW+[A;M=Y?EE#\>JYM5=60ZFXP6X\EX\:U[;0XMV$8U
M&=445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.U
M'-4*5"M13?3$@.-/*;$]W"R'S?MVIMKT<%]>?>3:'%K%C6HRJBFHIJ*:AFHZ
MJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYJA6H5J*:$"S'
M3GO!CGN!S?MVD-HT=E_V-';WK,VA[=RH)J.:@FHJJFFHIJ.:@6HFJEFH9J.:
M@VHNJGFHYJ-:@&HAJD6H%J-:@FHIJF6HEJ-:@6HEJHGU<&]U40XN=U;GT(.R
M4UQ@8[P5@*XV%=Y7W17>R73\M:KGJ[6WV9WDC.IOD]4)I5]&D\7X859W%UEV
MV\?&(U2344U!-175-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42U!
MM135,E3+4:U M1+51,_H/_I$$LNQXUY@\[Z=HS8%X5>##UR1NT(;P5%-1C4%
MU514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[4"
MU4I4$X+EV&DOV'$OL'G?#E+#39#J+,K\Y(^^O:2HNUDMW55[+R/W2C2O4S,\
M/]G:EO_KGGL-3K;O)7<_G:/C#=K3C6H:JNFH9J":B6H6JMFHYJ":BVH>JOFH
M%J!:B&H1JL6HEJ!:BFH9JN6H5J!:B6JB9R(?'V_8GFZ6P^9].]YL>KJONGNZ
ME3\6U72^NDRN^DZV09NZ44U&-0755%334$U'-0/53%2S4,U&-0?57%3S4,U_
MU;K_?12@QPQ1+4*U&-425$M1+4.U'-4*5"M13?2,[>,S$%O4S7+8'&]GH$U1
M]_(FLN=(^E.*[\?UK20>JNGMZK10]W:DSL,>'9U(348U!=545--034<U ]5,
M5+-0S48U!]5<5/-0S4>U -5"5(M0+4:U!-525,M0+4>U M5*5!,]J>#XB(5R
M[+@7V+QO1ZQ->??51Y9W7Z'EW:@FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ
M>:CFHUJ :B&J1:@6HUJ":BFJ9:B6HUJ!:B6J"<%R[+07[+@7V+QO!ZE->?=5
M=WEWN#1']<W]<XJZK;Y6D]GC\XFHZH_':CJO]M8&=)M'YR>TTAO5%%1344U#
M-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E1+42U#M1S5"E0K44WT
MC/SC\]-N0_CN:KM@Q[C YG@[%VU:O:^Z6[V/6</;['FZJWH*!="*;U2344U!
M-175-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42U!M135,E3+4:U
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M?%0+4"U$M0C58E1+4"U%M0S5<E0K4*U$-=$WY0<GTK=J5.^[5(=@1[M@9[O
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MF2QGL9S-<@[+N2SGL9S/<@'+A2P7L5S,<@G+I2R7L5S.<@7+E2PG!.S!.4#
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M\%YFF/T7('::6F'T2=@E#2)>8WH"/?(KT(3VX//L&M[\\C: VVLGK%?AGN[
M;33"'Q+ARQT6#ZC_V:8WB.+OM7.S9"F.(W<S&=2/&$U>OR*#Y/< Q].6XVF%
MWMO!\8"E@B\?73'<6BS,5AVG/T%'O]71#\[UW\CT5C.%RZ::*PU6P0W7QH*W
M..J4._4S)C# :]#R&@0'V#ZGVX@&<;;/'@0(GK4$SW[(I)]6*FC2(,J1BSML
M.0Y?S*3#GZ#C7:OCW7$FW5_FI1_J49)T3_;DF5P:!CK<IF0C?<B/&377&'Z>
MAH&.7&-".Z+TQ=S:#/7,4KH (^$$VVG8/76U4U-G3YDY[ZZ]@>=*N/<Z]\(
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M%8JRNR@GBB_-?3OC"F]O,TRP(0.A _#]G'.UF>@-ZA8O^ -02P,$%     @
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ VXIY6%BZ+,8M!   %B(
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M!?'2_4H8[6:C2GEMRZ:6)G1Q=%)'0.-W:N\S9D0MY]G"'J2+UP,GN*VZ:PL
ME43*72IH<+=5BT>'<M54*K!;T^T,K0E6CF#EM%@+*%NM*CA[Q?X66IA2LO;.
M^@2P0 "+P0#9Q5(DD!R!Y+\1<A4AX@Z>V0V[V_>>P"D".1T0\C%/(&<(Y&PP
MR,5.I)WF+0+Y=CA(X7<)Y#L$\ATMY)W;"J->V@8F#'2>QBLC?=JOWR-X[VGQ
M5DU="W>,,5NIK5&PFS"!796E;4Q0:=(>8UE[3(MY(Y1C#T(W,I+>* /Y1PD-
MB=P'U]0I)BH78KM<*[^W'K@ ,NPD@W()LE>F@2?T;I]B8K*9$-OF"XQGV%=9
M2G40[9E_8&&*F1 [9A5L^;2SNI+./[)/WQH83*5LF%DF]&HI80O7M:14F$HF
MY"ZI:Q6ZK!=SRZ)]V+82.H?L06(JF1"[Y-:4MI;L7GSO,V'FF!"K8]6LO?S6
MP$;LTR&&+P7#;#$AUL52'-G!LZ5T[>YQE!63B+:^<;V.BCEC0BP-R+H*.BF[
M=Z*"QXU=.2?@J:M?!3+'C)$3&^-D,,!;PB A=H@_V/K8%8XLQ<2,D1,; _5O
M;S28H],38F.@_NUC8@;)B0V"^K>/B<DD)Y;)*_^RB_OXX]^D?)A6<F*MG!/Q
M64A,*SGY% 5Q'[M(,3'3Y,2F2>UW-H:8;?*A)B?LXEJ&=%:?8[[)AYRD/!;I
M"@FFG()8.3@F3S$QY13$RL%S>2^:F'**0973BR:Z+D:L'!QSFF)BRBF(E8.;
ML7?3,?,4Q.;!,7LW'7-/0>R>GP0>LZ72O<1>8-8IB*WSOX#L3[8JTZ6Q O-/
M0>R?\P.-<\'$]%-0ZP>E3*<2'-,/I]8/AMD;_'),/YQ8/_V5E+-WFV/>X>2O
M8I!Q93^,F'<X^0L9##--Z!Q](T.^;H9AI@F=8][A0RZD]2S.,>_P(><\C[,4
M$[,/_ZUSGG,='),.)Y;.>;I.C+)J4DS,.IQ\D0W![.6A*6:=*?FDY]5*ZMD;
M/L6,,^T^23A]AU#)#<Q!JR]P> _UI=#ETK'XT[TXX=.X^+EIM%Y W9WY;$5U
M^JSA]$G&Q_\ 4$L#!!0    ( -N*>5BAE^J4R0$  * >   :    >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'/-V;ENPD 4A>%707X AKN8+()4:=)&O(!%
MAD4LMCP3!=X^" IRK!1IHCF5-;9\_<O%)VL\>X_[)F_;8]ILNS0Z'?;'-*\V
M.7?/(:3E)AZ:-&Z[>+Q<6;7]H<F79;\.7;/<->L8=#*9AO[GC.IE]G/F:''N
MXE\FMJO5=AE?V^7G(1[S+X/#5]OOTB;&7(T63;^.>5Z%T_Y^.H7K0<:7R=7H
M[6->]6\?4H7200I!6C[((,C*!SD$>?F@&H+J\D%3")J6#WJ H(?R08\0]%@^
MZ F"GLH'R01EG! D#; FT%J0:R'P6A!L(1!;D&PA,%L0;2%06Y!M(7!;$&XA
MD%N0;B&P6Q!O(=!;46\ET%M1;R706P<?VP1Z*^JM!'HKZJT$>BOJK01Z*^JM
M!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'K;8+.$0&]#O8U ;T.]
MC4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=0&]'O9U ;Q]L
M=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z%VCWC6!WC7J7?^GWBF?]S'=
M>VYK?/Y_4ITO]\;[XZ_+V\G!2[CB'."'],LW4$L#!!0    ( -N*>5@HM&@3
MPP$  (D>   3    6T-O;G1E;G1?5'EP97-=+GAM;,W9R6[",!0%T%]!V5;$
M>( . C9MMRV+_H";/" BB2W;4/C[.F&06M&HB$J]FT2)[7=?;.EL,G[;6?*]
M;576?I(L0[ /C/EL297VJ;%4QY&Y<94.\=$MF-792B^(B<%@Q#)3!ZI#/S0U
MDNGXB>9Z78;>\S:^]H6I)XFCTB>]Q_W$)FN2:&O+(M,ACK--G7]+Z1\2TKBR
MG>.7A?4W<4+"SB8T(S\''-:];LBY(J?>3+OPHJLXBVU+YL.N))]VESC3HYG/
MBXQRDZVKN"3UUI'._9(H5&6Z+WK3G1SB#M/^RJ_.;\MT!<:9,V>LCR?FZ/*X
MXY$TJ_LV%B(7BNY//"7&TE=_'S6GG5/^R^RXO1_&K=KS\*R]7;_'7\_X5/_"
M/@1('Q*D#P72QQ"DCQ%('[<@?=R!]'$/T@<?H#2"(BI'(96CF,I14.4HJG(4
M5CF*JQP%5HXBJT"15:#(*E!D%2BR"A19!8JL D56@2*K0)%5H,@J4625*+)*
M%%DEBJP215:)(JM$D56BR"I19)4HLBH4616*K I%5H4BJT*15:'(JE!D52BR
M*A19%8JL0Q19A_\IZ[LQJ[_^.=K<TTH7]3&?M7^@IY]02P$"% ,4    " #;
MBGE8!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P
M+GAM;%!+ 0(4 Q0    ( -N*>5C*.X>U[0   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -N*>5B97)PC$ 8
M )PG   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ VXIY6!N9 >?=!P  ]30  !@              ("!# @  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -N*>5AX*JO20 (
M +H%   8              " @1\0  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " #;BGE8U-F_VSX&  #R&   &               @(&5
M$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ VXIY6)%T
MO7H] P  !0L  !@              ("!"1D  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( -N*>5@MQR\OB@<  +8A   8
M  " @7P<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #;
MBGE82_:J)+H"   D!P  &               @($\)   >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ VXIY6"^.EJ+L!@  9#,  !@
M         ("!+"<  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( -N*>5CT:O0M2@<  $T@   8              " @4XN  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #;BGE8T\7DGY0)  #-&
M&               @('.-0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ VXIY6)&.!B+#%0  '3X  !D              ("!F#\  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #;BGE8:D7&#V,*
M   *'0  &0              @(&250  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( -N*>5@';4@X4P8  $H/   9              "
M@2Q@  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ VXIY
M6$B4","2!    @L  !D              ("!MF8  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " #;BGE8_2Q13L@0  #*-   &0
M        @(%_:P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( -N*>5C2KE@;J0(  !,&   9              " @7Y\  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ VXIY6">0VZ#6)0  &H@
M !D              ("!7G\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " #;BGE8_B$F9-\%  !*#@  &0              @(%KI0
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( -N*>5@'*.NG
MUP(  ",&   9              " @8&K  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ VXIY6/JN$:=  @  F04  !D
M ("!CZX  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #;
MBGE89#JB:T,"  "*!@  &0              @($&L0  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( -N*>5@YQNDIFA8  $!&   9
M          " @8"S  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#
M%     @ VXIY6&L=\7W$ @  (P8  !D              ("!4<H  'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #;BGE81A45(;(#  "Z
M"0  &0              @(%,S0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;%!+ 0(4 Q0    ( -N*>5CVI@.  @,  .4&   9              " @371
M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ VXIY6&=5
M!'*@ @  \ 4  !D              ("!;M0  'AL+W=O<FMS:&5E=',O<VAE
M970R-2YX;6Q02P$"% ,4    " #;BGE83H)_!3 #  #!"   &0
M    @(%%UP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M -N*>5C29&H&R 0  #4-   9              " @:S:  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ VXIY6$($+[:9 P  W@@  !D
M             ("!J]\  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " #;BGE8JX*.]?X"  !(#0  &0              @(%[XP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -N*>5C9J FHQ 0
M )<2   9              " @;#F  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ VXIY6-)+JR[O @  5 L  !D              ("!
MJ^L  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #;BGE8
M8+7HCM<#  #?$   &0              @('1[@  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( -N*>5C>69,X+P,  ,$/   9
M      " @=_R  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ VXIY6,=W+:K- P  (1   !D              ("!1?8  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #;BGE8HV#=]HX$  #1'@
M&0              @(%)^@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( -N*>5A('+AD_P(  '$)   9              " @0[_  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ VXIY6*U@VFCF
M P  &Q8  !D              ("!1 (! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " #;BGE8.,A<@+ "   )"   &0
M@(%A!@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -N*
M>5C=AQME$1T  +PJ @ 9              " @4@) 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ VXIY6*F<9LAW!   F!@  !D
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M=#0T+GAM;%!+ 0(4 Q0    ( -N*>5B4G";<AP,  /(0   9
M  " @9N' 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
MVXIY6$7\/1XI P  N L  !D              ("!68L! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " #;BGE8AQI )3<"  #_!   &0
M            @(&YC@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( -N*>5BL:_%QY (  .X)   9              " @2>1 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ VXIY6+-N;Q(> P
M1@D  !D              ("!0I0! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    " #;BGE8#88L*(H"  !K!P  &0              @(&7
MEP$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -N*>5C]
MJP77N@(  $4)   9              " @5B: 0!X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ VXIY6%4'#O-? P  [!4   T
M     ( !29T! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #;BGE8EXJ[',
M   3 @  "P              @ '3H $ 7W)E;',O+G)E;'-02P$"% ,4
M" #;BGE86+HLQBT$   6(@  #P              @ &\H0$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ VXIY6*&7ZI3) 0  H!X  !H
M ( !%J8! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
MVXIY6"BT:!/# 0  B1X  !,              ( !%Z@! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     #L .P 4$   "ZH!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>236</ContextCount>
  <ElementCount>345</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>82</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Disposal of the Discontinued Operations of the NFID Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness</Role>
      <ShortName>Disposal of the Discontinued Operations of the NFID Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/NoteReceivable</Role>
      <ShortName>Note Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/Concentrations</Role>
      <ShortName>Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables</Role>
      <ShortName>Disposal of the Discontinued Operations of the NFID Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Note Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/NoteReceivableTables</Role>
      <ShortName>Note Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/NoteReceivable</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Organization and Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/OrganizationandBusinessDetails</Role>
      <ShortName>Organization and Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/OrganizationandBusiness</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Potentially Dilutive Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Potentially Dilutive Shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Summarizes Activity in the Company???s Short Term Investments and Equity Investments at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Summarizes Activity in the Company???s Short Term Investments and Equity Investments at Fair Value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails</Role>
      <ShortName>Disposal of the Discontinued Operations of the NFID Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of Operating Result of Discontinued Operations of the NFID Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable</Role>
      <ShortName>Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of Operating Result of Discontinued Operations of the NFID Business</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Note Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/NoteReceivableDetails</Role>
      <ShortName>Note Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/NoteReceivableTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Note Receivable (Details) - Schedule of Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofNoteReceivableTable</Role>
      <ShortName>Note Receivable (Details) - Schedule of Note Receivable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/NoteReceivableTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Stockholders??? Equity (Details) - Schedule of Stock Option Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of Stock Option Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Stockholders??? Equity (Details) - Schedule of Warrant Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of Warrant Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Concentrations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ConcentrationsDetails</Role>
      <ShortName>Concentrations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/Concentrations</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Commitments and Contingencies (Details) - Schedule of Milestone Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Milestone Payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Commitments and Contingencies (Details) - Schedule of Minimum Annual Royalty Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Minimum Annual Royalty Payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Amounts Due Under Sponsored Study and Research Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Future Amounts Due Under Sponsored Study and Research Agreements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Income Taxes (Details) - Schedule of Net Deferred Tax Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Net Deferred Tax Asset</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0201957-10k_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.silopharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.silopharma.com/role/SubsequentEvents</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare, us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  ea0201957-10k_silopharma.htm 11372, 11373, 11374, 11375, 11376, 11377</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0201957-10k_silopharma.htm">ea0201957-10k_silopharma.htm</File>
    <File>silo-20231231.xsd</File>
    <File>silo-20231231_cal.xml</File>
    <File>silo-20231231_def.xml</File>
    <File>silo-20231231_lab.xml</File>
    <File>silo-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="653">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0201957-10k_silopharma.htm": {
   "nsprefix": "silo",
   "nsuri": "http://www.silopharma.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ea0201957-10k_silopharma.htm"
     ]
    },
    "schema": {
     "local": [
      "silo-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_def.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_pre.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "silo-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "silo-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "silo-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "silo-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 284,
   "keyCustom": 61,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 44,
   "hidden": {
    "total": 137,
    "http://fasb.org/us-gaap/2023": 116,
    "http://www.silopharma.com/20231231": 18,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 236,
   "entityCount": 1,
   "segmentCount": 82,
   "elementCount": 754,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 653,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.silopharma.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.silopharma.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "995304 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.silopharma.com/role/ShareholdersEquityType2or3",
     "longName": "995305 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.silopharma.com/role/ConsolidatedCashFlow",
     "longName": "995306 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.silopharma.com/role/OrganizationandBusiness",
     "longName": "995307 - Disclosure - Organization and Business",
     "shortName": "Organization and Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.silopharma.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "995308 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements",
     "longName": "995309 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness",
     "longName": "995310 - Disclosure - Disposal of the Discontinued Operations of the NFID Business",
     "shortName": "Disposal of the Discontinued Operations of the NFID Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.silopharma.com/role/NoteReceivable",
     "longName": "995311 - Disclosure - Note Receivable",
     "shortName": "Note Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.silopharma.com/role/StockholdersEquity",
     "longName": "995312 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.silopharma.com/role/Concentrations",
     "longName": "995313 - Disclosure - Concentrations",
     "shortName": "Concentrations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.silopharma.com/role/CommitmentsandContingencies",
     "longName": "995314 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.silopharma.com/role/IncomeTaxes",
     "longName": "995315 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.silopharma.com/role/SubsequentEvents",
     "longName": "995316 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c37",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c37",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.silopharma.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables",
     "longName": "996002 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Tables)",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables",
     "longName": "996003 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Tables)",
     "shortName": "Disposal of the Discontinued Operations of the NFID Business (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.silopharma.com/role/NoteReceivableTables",
     "longName": "996004 - Disclosure - Note Receivable (Tables)",
     "shortName": "Note Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.silopharma.com/role/StockholdersEquityTables",
     "longName": "996005 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.silopharma.com/role/CommitmentsandContingenciesTables",
     "longName": "996006 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "silo:ScheduleOfMilestonePaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "silo:ScheduleOfMilestonePaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.silopharma.com/role/IncomeTaxesTables",
     "longName": "996007 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.silopharma.com/role/OrganizationandBusinessDetails",
     "longName": "996008 - Disclosure - Organization and Business (Details)",
     "shortName": "Organization and Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c38",
      "name": "us-gaap:ProceedsFromNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c38",
      "name": "us-gaap:ProceedsFromSaleOfNotesReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996009 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "silo:WorkingCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable",
     "longName": "996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Potentially Dilutive Shares",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Potentially Dilutive Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails",
     "longName": "996011 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details)",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable",
     "longName": "996012 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c51",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c51",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable",
     "longName": "996013 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Summarizes Activity in the Company\u2019s Short Term Investments and Equity Investments at Fair Value",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Summarizes Activity in the Company\u2019s Short Term Investments and Equity Investments at Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c59",
      "name": "silo:AdditionsOfShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c59",
      "name": "silo:AdditionsOfShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
     "longName": "996014 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details)",
     "shortName": "Disposal of the Discontinued Operations of the NFID Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c38",
      "name": "us-gaap:ProceedsFromNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c68",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable",
     "longName": "996015 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of Operating Result of Discontinued Operations of the NFID Business",
     "shortName": "Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of Operating Result of Discontinued Operations of the NFID Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.silopharma.com/role/NoteReceivableDetails",
     "longName": "996016 - Disclosure - Note Receivable (Details)",
     "shortName": "Note Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "silo:ProvisionForDoubtfulAccountsDiscontinuedOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c72",
      "name": "us-gaap:AccountsPayableInterestBearingInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.silopharma.com/role/ScheduleofNoteReceivableTable",
     "longName": "996017 - Disclosure - Note Receivable (Details) - Schedule of Note Receivable",
     "shortName": "Note Receivable (Details) - Schedule of Note Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:NotesReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:NotesReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.silopharma.com/role/StockholdersEquityDetails",
     "longName": "996018 - Disclosure - Stockholders\u2019 Equity (Details)",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockSplits",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable",
     "longName": "996019 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of Stock Option Activities",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of Stock Option Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c113",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c113",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable",
     "longName": "996020 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of Warrant Activities",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of Warrant Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c119",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c119",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.silopharma.com/role/ConcentrationsDetails",
     "longName": "996021 - Disclosure - Concentrations (Details)",
     "shortName": "Concentrations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c125",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c125",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
     "longName": "996022 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "silo:LicenseAgreementExpire",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable",
     "longName": "996023 - Disclosure - Commitments and Contingencies (Details) - Schedule of Milestone Payments",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Milestone Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c225",
      "name": "silo:MilestoneBalanceDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c225",
      "name": "silo:MilestoneBalanceDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable",
     "longName": "996024 - Disclosure - Commitments and Contingencies (Details) - Schedule of Minimum Annual Royalty Payments",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Minimum Annual Royalty Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c225",
      "name": "silo:MinimumAnnualRoyaltyPaymentsDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c225",
      "name": "silo:MinimumAnnualRoyaltyPaymentsDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable",
     "longName": "996025 - Disclosure - Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c230",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c230",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable",
     "longName": "996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Amounts Due Under Sponsored Study and Research Agreements",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Future Amounts Due Under Sponsored Study and Research Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.silopharma.com/role/IncomeTaxesDetails",
     "longName": "996027 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable",
     "longName": "996028 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes",
     "shortName": "Income Taxes (Details) - Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable",
     "longName": "996029 - Disclosure - Income Taxes (Details) - Schedule of Net Deferred Tax Asset",
     "shortName": "Income Taxes (Details) - Schedule of Net Deferred Tax Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.silopharma.com/role/SubsequentEventsDetails",
     "longName": "996030 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c234",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c234",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201957-10k_silopharma.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.silopharma.com/role/NoteReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r631"
     ]
    },
    "us-gaap_AccountsPayableInterestBearingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableInterestBearingInterestRate",
     "presentation": [
      "http://www.silopharma.com/role/NoteReceivableDetails",
      "http://www.silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note bears interest rate",
        "label": "Accounts Payable, Interest-Bearing, Interest Rate",
        "documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r81"
     ]
    },
    "us-gaap_AccruedBonusesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual bonus",
        "label": "Accrued Bonuses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r118",
      "r197",
      "r457",
      "r480",
      "r481"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r494",
      "r782",
      "r783",
      "r784",
      "r806",
      "r833"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalPreferredStock",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Preferred Stock",
        "documentation": "Value received from shareholder in nonredeemable preferred stock-related transaction in excess of par value, value contributed to entity and value received from other stock-related transaction. Includes, but is not limited to, preferred stock redeemable solely at option of issuer. Excludes common stock."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "silo_AdditionsOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "AdditionsOfShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "documentation": "Represent the amount of additions of short term investments",
        "label": "Additions Of Short Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "silo_AdditionsofEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "AdditionsofEquitySecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "documentation": "Additions for equity securities.",
        "label": "Additionsof Equity Securities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of stock options expense to stock based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_AggregateOfConvertedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "AggregateOfConvertedShares",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate of converted shares (in Shares)",
        "documentation": "This value for aggregate of converted shares.",
        "label": "Aggregate Of Converted Shares"
       }
      }
     },
     "auth_ref": []
    },
    "silo_AggregateOfIncentiveStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "AggregateOfIncentiveStockOptions",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate of incentive stock options",
        "documentation": "Aggregate of incentive stock options.",
        "label": "Aggregate Of Incentive Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r677",
      "r693",
      "r721"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r680",
      "r696",
      "r724"
     ]
    },
    "silo_AgreementShallExpire": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "AgreementShallExpire",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement shall expire",
        "documentation": "Agreement shall expire.",
        "label": "Agreement Shall Expire"
       }
      }
     },
     "auth_ref": []
    },
    "silo_AikidoPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "AikidoPharmaIncMember",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aikido Pharma, Inc. [Member]",
        "label": "Aikido Pharma Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r681",
      "r697",
      "r716",
      "r725",
      "r729",
      "r737"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "silo_AmendedServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "AmendedServiceAgreementMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Service Agreement [Member]",
        "label": "Amended Service Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "silo_AmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "AmendmentMember",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment [Member]",
        "label": "Amendment Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_AmortizationOfPrepaidStockbasedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "AmortizationOfPrepaidStockbasedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of prepaid stock-based professional fees",
        "documentation": "This value for amortization of prepaid stock-based expense.",
        "label": "Amortization Of Prepaid Stockbased Expense"
       }
      }
     },
     "auth_ref": []
    },
    "silo_AmplifyBioResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "AmplifyBioResearchAgreementMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AmplifyBio Research Agreement [Member]",
        "label": "Amplify Bio Research Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive shares",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially Dilutive Shares [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_AociAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AociAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Gain",
        "label": "AOCI Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r35",
      "r771",
      "r772",
      "r773"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r191",
      "r222",
      "r249",
      "r258",
      "r262",
      "r272",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r390",
      "r392",
      "r411",
      "r452",
      "r537",
      "r631",
      "r644",
      "r795",
      "r796",
      "r813"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r200",
      "r222",
      "r272",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r390",
      "r392",
      "r411",
      "r631",
      "r795",
      "r796",
      "r813"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r660",
      "r673"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r660",
      "r673"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r660",
      "r673"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "silo_BadDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "BadDebtExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense",
        "label": "Bad Debt Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BankTimeDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BankTimeDepositsMember",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank Time Deposits [Member]",
        "label": "Bank Time Deposits [Member]",
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors Chairman [Member]",
        "verboseLabel": "Board Granted [Member]",
        "netLabel": "Board of Directors [Member]",
        "label": "Board of Directors Chairman [Member]",
        "documentation": "Leader of board of directors."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r673"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r454",
      "r505",
      "r531",
      "r631",
      "r644",
      "r760"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r190",
      "r608"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH AND CASH EQUIVALENTS - beginning of the year",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS - end of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r131",
      "r220"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS:",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r131"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal deposit insurance corporation",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashIncludingDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashIncludingDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DISCONTINUED OPERATIONS:",
        "label": "Cash, Including Discontinued Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_CashPaidDuringThePeriodForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CashPaidDuringThePeriodForAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid during the period for:",
        "label": "Cash Paid During The Period For Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "silo_CashSPICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CashSPICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities investor protection corporation",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Securities Investor Protection Corporation.",
        "label": "Cash SPICInsured Amount"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accumulated other comprehensive loss",
        "documentation": "Change in accumulated other comprehensive loss and short-term investments.",
        "label": "Change In Accumulated Other Comprehensive Loss And Shortterm Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/ShareholdersEquityType2or3",
      "http://www.silopharma.com/role/StockholdersEquityDetails",
      "http://www.silopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r193",
      "r194",
      "r195",
      "r222",
      "r239",
      "r240",
      "r242",
      "r244",
      "r247",
      "r248",
      "r272",
      "r289",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r314",
      "r315",
      "r318",
      "r319",
      "r322",
      "r411",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r523",
      "r546",
      "r565",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r755",
      "r779",
      "r785"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r247",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r488",
      "r489",
      "r490",
      "r491",
      "r623",
      "r755",
      "r779"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued warrants to purchase an aggregate amount",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase aggregate",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "silo_CommercialSaleTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CommercialSaleTerm",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial sale term",
        "documentation": "This term used for commercial sale.",
        "label": "Commercial Sale Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment and Contingencies (see Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r85",
      "r453",
      "r522"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r283",
      "r284",
      "r601",
      "r792"
     ]
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsLineItems",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Milestone Payments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CommitmentsandContingenciesDetailsScheduleofMilestonePaymentsTable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of Milestone Payments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CommitmentsandContingenciesDetailsScheduleofMinimumAnnualRoyaltyPaymentsTable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of Minimum Annual Royalty Payments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesLineItems",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Shall Pay UMB Fees [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CommitmentsandContingenciesDetailsScheduleofShallPayUMBFeesTable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of common stock reserved and avail for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share (in Dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_CommonStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsShares",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares (in Shares)",
        "label": "Common Stock Dividends, Shares",
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3",
      "http://www.silopharma.com/role/StockholdersEquityDetails",
      "http://www.silopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r635",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r782",
      "r783",
      "r806",
      "r829",
      "r833"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "silo_CommonStockPurchaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CommonStockPurchaseCost",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchase cost (in Dollars)",
        "documentation": "Amount of common stock purchase cost.",
        "label": "Common Stock Purchase Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r523"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r112",
      "r523",
      "r543",
      "r833",
      "r834"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value, 5,000,000 shares authorized: none designated as of December 31, 2023 Common stock, $0.0001 par value, 100,000,000 shares authorized; 3,159,096 and 3,158,797 shares issued and 2,906,241 and 3,158,797 shares outstanding at December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r456",
      "r631"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Asset:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r203",
      "r205",
      "r213",
      "r449",
      "r464"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMPREHENSIVE LOSS:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r54",
      "r76",
      "r77",
      "r266",
      "r482",
      "r600"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r54",
      "r76",
      "r77",
      "r266",
      "r600",
      "r757"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/Concentrations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONCENTRATIONS",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r54",
      "r76",
      "r77",
      "r266"
     ]
    },
    "silo_ConcentrationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ConcentrationsDetailsTable",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ConsiderationFeePayablePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ConsiderationFeePayablePercentage",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration fee payable percentage",
        "documentation": "This percentage used for consideration fee payable.",
        "label": "Consideration Fee Payable Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "silo_ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series C Convertible Preferred Stock into Common Stock [Member]",
        "label": "Conversion Of Series CConvertible Preferred Stock Into Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for conversion of Series C preferred stock",
        "label": "Conversion of Stock, Amount Converted",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common stock issued for conversion of Series C preferred stock (in Shares)",
        "terseLabel": "Convertible common stock",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C convertible preferred stock",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r58",
      "r111",
      "r142",
      "r320"
     ]
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, description",
        "label": "Preferred Stock, Convertible, Terms",
        "documentation": "Description of conversion terms for preferred stock."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r58",
      "r59",
      "r111",
      "r141",
      "r143"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COST OF REVENUES",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r222",
      "r272",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r411",
      "r795"
     ]
    },
    "silo_CostOfRevenuesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CostOfRevenuesPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenues",
        "documentation": "Disclosure of accounting policy for cost of revenues.",
        "label": "Cost Of Revenues Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "silo_CustomerConcentrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CustomerConcentrationMember",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration [Member]",
        "label": "Customer Concentration Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r266"
     ]
    },
    "silo_CustomerPatentLicenseAgreementWithAikidoPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CustomerPatentLicenseAgreementWithAikidoPharmaIncMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Patent License Agreement with Aikido Pharma Inc [Member]",
        "label": "Customer Patent License Agreement With Aikido Pharma Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_CustomerSublicenseAgreementWithAikidoPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "CustomerSublicenseAgreementWithAikidoPharmaIncMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Sublicense Agreement with Aikido Pharma Inc [Member]",
        "label": "Customer Sublicense Agreement With Aikido Pharma Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_DanielRyweckMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "DanielRyweckMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Daniel Ryweck [Member]",
        "label": "Daniel Ryweck Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion Description [Axis]",
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r49"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/NoteReceivableDetails",
      "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable",
      "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r108",
      "r109",
      "r154",
      "r155",
      "r224",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r421",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r780"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/NoteReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note amount",
        "verboseLabel": "Principal balance",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r82",
      "r298",
      "r421",
      "r619",
      "r620"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bears interest per annum",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r299"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r618",
      "r808"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/NoteReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r224",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r421",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r780"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation balance",
        "label": "Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense",
        "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of the unvested stock options (in Dollars)",
        "verboseLabel": "Fair value of the unvested stock option",
        "label": "Deferred Compensation Arrangement with Individual, Compensation Expense",
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r145"
     ]
    },
    "us-gaap_DeferredCompensationEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation (in Dollars)",
        "label": "Deferred Compensation Equity",
        "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r62"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue - current portion",
        "verboseLabel": "Deferred revenue current",
        "label": "Deferred Revenue, Current",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue - long-term portion",
        "verboseLabel": "Deferred revenue long term",
        "label": "Deferred Revenue, Noncurrent",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueRevenueRecognized1",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized revenues",
        "label": "Deferred Revenue, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Deferred Tax Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r805"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Signing bonus",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r805"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofNetDeferredTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax asset before valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution cost",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r700"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r75",
      "r511",
      "r514",
      "r528",
      "r529",
      "r530",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r560",
      "r561",
      "r562",
      "r580",
      "r581",
      "r582",
      "r583",
      "r611",
      "r634",
      "r636"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumptions",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from discontinued operations, net of tax",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r99",
      "r122",
      "r825"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal of the Discontinued Operations of the NFID Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r187"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross loss",
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r187"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total operating and other non-operating expenses",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r22",
      "r100"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofOperatingResultofDiscontinuedOperationsoftheNFIDBusinessTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales, net",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r187"
     ]
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Result of Discontinued Operations of the NFID Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DISPOSAL OF THE DISCONTINUED OPERATIONS OF THE NFID BUSINESS",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r137"
     ]
    },
    "silo_DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetailsTable",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal of the Discontinued Operations of the NFID Business (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r700"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r660",
      "r673"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r660",
      "r673",
      "r717"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r660",
      "r673",
      "r717"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "silo_DrJamesKuoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "DrJamesKuoMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dr. James Kuo [Member]",
        "label": "Dr James Kuo Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_DueToRelatedPartieCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "DueToRelatedPartieCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due amount",
        "documentation": "The amount of due to related partie current.",
        "label": "Due To Related Partie Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER COMMON SHARE:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation and professional fees",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'.  This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r186",
      "r207",
      "r208",
      "r209",
      "r225",
      "r226",
      "r227",
      "r229",
      "r234",
      "r236",
      "r246",
      "r273",
      "r274",
      "r324",
      "r364",
      "r365",
      "r366",
      "r382",
      "r383",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r424",
      "r476",
      "r477",
      "r478",
      "r494",
      "r565"
     ]
    },
    "silo_EquityInvestmentsAtFairValuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "EquityInvestmentsAtFairValuePolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Investments, at Fair Value",
        "documentation": "Disclosure of accounting policy for equity investments, at fair value.",
        "label": "Equity Investments At Fair Value Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investments",
        "verboseLabel": "Equity investment",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r271",
      "r761",
      "r788"
     ]
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Investments [Member]",
        "label": "Equity Method Investments [Member]",
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of year",
        "periodEndLabel": "Balance, end of year",
        "terseLabel": "Equity investments",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r410",
      "r609"
     ]
    },
    "silo_EquitySecuritiesSalesAtOriginalCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "EquitySecuritiesSalesAtOriginalCost",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sales at original cost",
        "documentation": "The amount of equity securities, sales at original cost.",
        "label": "Equity Securities Sales At Original Cost"
       }
      }
     },
     "auth_ref": []
    },
    "silo_EquitySharesEarnedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "EquitySharesEarnedForServices",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity shares earned for lock up agreement",
        "documentation": "Equity shares earned for services.",
        "label": "Equity Shares Earned For Services"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "silo_EricWeisblumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "EricWeisblumMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eric Weisblum [Member]",
        "label": "Eric Weisblum Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r677",
      "r693",
      "r721"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r674",
      "r690",
      "r718"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "silo_ExtensionFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ExtensionFee",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension Fee",
        "documentation": "Amount of extension fee.",
        "label": "Extension Fee"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ExtensionFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ExtensionFeeMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension fee [Member]",
        "label": "Extension Fee Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Fair Value Measurements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r408"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r404",
      "r430",
      "r431",
      "r432",
      "r619",
      "r620",
      "r626",
      "r627",
      "r628"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r406",
      "r407",
      "r409"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r326",
      "r331",
      "r404",
      "r430",
      "r626",
      "r627",
      "r628"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r326",
      "r331",
      "r404",
      "r431",
      "r619",
      "r620",
      "r626",
      "r627",
      "r628"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r404",
      "r432",
      "r619",
      "r620",
      "r626",
      "r627",
      "r628"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r409"
     ]
    },
    "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisLineItems",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueLineItems",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Summarizes Activity in the Company\u2019s Short Term Investments and Equity Investments at Fair Value [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Summarizes Activity in the Company\u2019s Short Term Investments and Equity Investments at Fair Value [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FeesPaidOnAcceptancesResold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FeesPaidOnAcceptancesResold",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid amount",
        "label": "Fees Paid on Acceptances Resold",
        "documentation": "Represents the amortization to expense from discounts on short-term negotiable time drafts drawn on and accepted by an institution (also known as Banker's Acceptances) which have been resold in the secondary market."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofNoteReceivableTable": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofNoteReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: allowance for doubtful accounts",
        "label": "Financing Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r182",
      "r184",
      "r185",
      "r198",
      "r275",
      "r276",
      "r278",
      "r822"
     ]
    },
    "srt_FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent",
     "presentation": [
      "http://www.silopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance percentage",
        "label": "Financing Receivable, before Allowance for Credit Loss, to Total, Percent",
        "documentation": "Percentage, before allowance for credit loss, of financing receivable to total financing receivable."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "silo_FirstCommercialSale": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "FirstCommercialSale",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First commercial sale",
        "documentation": "First commercial sale.",
        "label": "First Commercial Sale"
       }
      }
     },
     "auth_ref": []
    },
    "silo_FirstPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "FirstPaymentMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Payment [Member]",
        "label": "First Payment Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r681",
      "r697",
      "r725"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r681",
      "r697",
      "r725"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r681",
      "r697",
      "r725"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r681",
      "r697",
      "r725"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r681",
      "r697",
      "r725"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r684"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance expense",
        "label": "General Insurance Expense",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "GROSS PROFIT",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r222",
      "r249",
      "r257",
      "r261",
      "r263",
      "r272",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r411",
      "r614",
      "r795"
     ]
    },
    "silo_HomeBistroIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "HomeBistroIncMember",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Home Bistro, Inc [Member]",
        "verboseLabel": "Home Bistro, Inc. [Member]",
        "label": "Home Bistro Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r660",
      "r673"
     ]
    },
    "silo_IncentiveStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "IncentiveStockOptionMember",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Stock Option [Member]",
        "label": "Incentive Stock Option Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM CONTINUING OPERATIONS",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r125",
      "r133",
      "r230",
      "r231",
      "r232",
      "r233",
      "r241",
      "r244"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r120",
      "r161",
      "r249",
      "r257",
      "r261",
      "r263",
      "r451",
      "r461",
      "r614"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations - basic (in Dollars per share)",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r159",
      "r162",
      "r214",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r239",
      "r242",
      "r243",
      "r401",
      "r450",
      "r826"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations - diluted",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r214",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r239",
      "r242",
      "r243",
      "r244",
      "r401",
      "r450",
      "r826"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM DISCONTINUED OPERATIONS",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r99",
      "r102",
      "r150"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations - basic (in Dollars per share)",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r214",
      "r240",
      "r242",
      "r243",
      "r823",
      "r826"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations - diluted",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r240",
      "r242",
      "r243"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow",
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails",
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized loss on equity investments",
        "negatedLabel": "Net unrealized loss on equity investments",
        "verboseLabel": "Unrealized loss",
        "netLabel": "Gross proceeds",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r121",
      "r160",
      "r253",
      "r271",
      "r460"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal of the Discontinued Operations of the NFID Business [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r369",
      "r374",
      "r375",
      "r380",
      "r384",
      "r386",
      "r387",
      "r388",
      "r493"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total provision for income tax",
        "negatedLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r178",
      "r235",
      "r236",
      "r254",
      "r372",
      "r385",
      "r468"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r370",
      "r371",
      "r375",
      "r376",
      "r379",
      "r381",
      "r487"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/IncomeTaxesDetails",
      "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "verboseLabel": "Valuation allowance increased",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit at U.S. statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofIncomeTaxesattheEffectiveStatutoryRateandtheProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit \u2013 state",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_IncreaseDecreaseInInsuranceLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInsuranceLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance payable",
        "label": "Increase (Decrease) in Insurance Liabilities",
        "documentation": "The increase (decrease) in insurance liability balances during the period."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest receivable",
        "label": "Increase (Decrease) in Receivables",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r681",
      "r697",
      "r716",
      "r725",
      "r729",
      "r737"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r741"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r741"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r741"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r164",
      "r210",
      "r252",
      "r420",
      "r550",
      "r642",
      "r830"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r219"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/NoteReceivableDetails",
      "http://www.silopharma.com/role/ScheduleofNoteReceivableTable",
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivable current (in Dollars)",
        "verboseLabel": "Accrued interest receivable",
        "label": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "silo_InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investigator-Sponsored Study Agreement with University of Maryland, Baltimore [Member]",
        "label": "Investigator Sponsored Study Agreement With University Of Maryland Baltimore Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r687",
      "r688",
      "r689"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and dividend income, net",
        "label": "Investment Income, Interest and Dividend",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r483",
      "r484",
      "r485",
      "r486",
      "r572",
      "r573"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r569",
      "r571",
      "r575",
      "r578",
      "r579",
      "r584",
      "r585",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r636"
     ]
    },
    "silo_JVAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "JVAgreementMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JV Agreement [Member]",
        "label": "JVAgreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_JointVentureInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "JointVentureInterestRate",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint venture interest rate",
        "documentation": "Joint venture interest rate.",
        "label": "Joint Venture Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expire date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Amounts Due Under Sponsored Study and Research Agreements",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofFutureAmountsDueUnderSponsoredStudyandResearchAgreementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r222",
      "r272",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r391",
      "r392",
      "r393",
      "r411",
      "r521",
      "r613",
      "r644",
      "r795",
      "r813",
      "r814"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r156",
      "r459",
      "r631",
      "r781",
      "r789",
      "r809"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r189",
      "r222",
      "r272",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r391",
      "r392",
      "r393",
      "r411",
      "r631",
      "r795",
      "r813",
      "r814"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Long Term Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r105",
      "r106",
      "r107",
      "r110",
      "r222",
      "r272",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r391",
      "r392",
      "r393",
      "r411",
      "r795",
      "r813",
      "r814"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LONG TERM LIABILITIES:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_LicenseAgreementExpire": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "LicenseAgreementExpire",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement expire",
        "documentation": "License agreement expire.",
        "label": "License Agreement Expire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fees [Member]",
        "verboseLabel": "License [Member]",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "silo_LicensorShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "LicensorShare",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensor share (in Shares)",
        "documentation": "Licensor share.",
        "label": "Licensor Share"
       }
      }
     },
     "auth_ref": []
    },
    "silo_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity",
        "documentation": "Disclosure of accounting policy for liquidity.",
        "label": "Liquidity Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/NoteReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOTE RECEIVABLE",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturityDate",
     "presentation": [
      "http://www.silopharma.com/role/NoteReceivableDetails",
      "http://www.silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Long-Term Debt, Maturity Date",
        "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_LongTermDebtTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTerm",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term year",
        "label": "Long-Term Debt, Term",
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r625",
      "r799",
      "r827",
      "r828"
     ]
    },
    "silo_MasterLincenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "MasterLincenseAgreementMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Lincense Agreement [Member]",
        "label": "Master Lincense Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/OrganizationandBusinessDetails",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r334",
      "r434",
      "r475",
      "r513",
      "r514",
      "r570",
      "r574",
      "r576",
      "r577",
      "r586",
      "r602",
      "r603",
      "r615",
      "r623",
      "r629",
      "r633",
      "r797",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend Yield [Member]",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Term [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-Free interest Rate [Member]",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "silo_MilestoneBalanceDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "MilestoneBalanceDescription",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone",
        "documentation": "Milestone balance description.",
        "label": "Milestone Balance Description"
       }
      }
     },
     "auth_ref": []
    },
    "silo_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment",
        "documentation": "This amount used for milestone payment.",
        "label": "Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "silo_MinimumAnnualRoyaltyPaymentsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "MinimumAnnualRoyaltyPaymentsDescription",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Years",
        "documentation": "Minimum annual royalty payment description.",
        "label": "Minimum Annual Royalty Payments Description"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/OrganizationandBusinessDetails",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r334",
      "r434",
      "r475",
      "r513",
      "r514",
      "r570",
      "r574",
      "r576",
      "r577",
      "r586",
      "r602",
      "r603",
      "r615",
      "r623",
      "r629",
      "r633",
      "r797",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "silo_MrWeisblumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "MrWeisblumMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Weisblum [Member]",
        "label": "Mr Weisblum Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them.  The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r625",
      "r799",
      "r827",
      "r828"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.silopharma.com/role/OrganizationandBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND BUSINESS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r180"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow",
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "terseLabel": "Cash in operations",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow",
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.silopharma.com/role/ShareholdersEquityType2or3",
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r133",
      "r163",
      "r187",
      "r201",
      "r204",
      "r209",
      "r222",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r241",
      "r249",
      "r257",
      "r261",
      "r263",
      "r272",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r401",
      "r411",
      "r462",
      "r545",
      "r563",
      "r564",
      "r614",
      "r642",
      "r795"
     ]
    },
    "silo_NetSalePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "NetSalePercentage",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sale percentage",
        "documentation": "This percentage for net sale.",
        "label": "Net Sale Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r687",
      "r688",
      "r689"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r681",
      "r697",
      "r716",
      "r725"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME (EXPENSE):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_NonrefundableCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "NonrefundableCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable cash payment",
        "documentation": "Non-refundable cash payment.",
        "label": "Nonrefundable Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "silo_NoteReceivableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "NoteReceivableDetailsTable",
     "presentation": [
      "http://www.silopharma.com/role/NoteReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Receivable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_NoteReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "NoteReceivableMember",
     "presentation": [
      "http://www.silopharma.com/role/NoteReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Receivable [Member]",
        "label": "Note Receivable Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesReceivableGross",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ScheduleofNoteReceivableTable": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofNoteReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subtotal",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r182",
      "r183",
      "r196",
      "r279",
      "r280",
      "r616",
      "r617",
      "r759",
      "r790"
     ]
    },
    "us-gaap_NotesReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/ScheduleofNoteReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of note receivable",
        "verboseLabel": "Note receivable",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r280",
      "r532"
     ]
    },
    "us-gaap_NotesReceivableNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesReceivableNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OciNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OciNetOfTaxAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Alternative [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base salary",
        "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "silo_OmnibusEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "OmnibusEquityIncentivePlanMember",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omnibus Equity Incentive Plan [Member]",
        "label": "Omnibus Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING EXPENSES:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM CONTINUING OPERATIONS",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r257",
      "r261",
      "r263",
      "r614"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_OrganizationandBusinessDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "OrganizationandBusinessDetailsLineItems",
     "presentation": [
      "http://www.silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_OrganizationandBusinessDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "OrganizationandBusinessDetailsTable",
     "presentation": [
      "http://www.silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Amounts Due Under Sponsored Study and Research Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss - short-term investments",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r15",
      "r202",
      "r205",
      "r212",
      "r412",
      "r413",
      "r418",
      "r448",
      "r463",
      "r771",
      "r772"
     ]
    },
    "us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of deferred compensation balance (in Dollars)",
        "label": "Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent",
        "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDeferredCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherDeferredCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized deferred compensation",
        "label": "Other Deferred Costs, Net",
        "documentation": "Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income from equity shares earned for lock up agreement",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r547",
      "r587",
      "r588",
      "r589"
     ]
    },
    "us-gaap_OtherNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installments payable",
        "label": "Other Notes Payable",
        "documentation": "Amount of long-term notes payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r155",
      "r824"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of the prepaid research and development fees",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r679",
      "r695",
      "r723"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r682",
      "r698",
      "r726"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r682",
      "r698",
      "r726"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option [Member]",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "silo_PaymentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PaymentDescription",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment description",
        "documentation": "Description on payment.",
        "label": "Payment Description"
       }
      }
     },
     "auth_ref": []
    },
    "silo_PaymentFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PaymentFiveMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable",
      "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Five [Member]",
        "label": "Payment Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_PaymentFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PaymentFourMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable",
      "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Four [Member]",
        "label": "Payment Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_PaymentOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PaymentOneMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable",
      "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable",
      "http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment One [Member]",
        "label": "Payment One Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_PaymentThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PaymentThreeMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable",
      "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable",
      "http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Three [Member]",
        "label": "Payment Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_PaymentTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PaymentTwoMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMilestonePaymentsTable",
      "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable",
      "http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Two [Member]",
        "label": "Payment Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForDepositsWithOtherInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForDepositsWithOtherInstitutions",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to the university",
        "label": "Payments for Deposits with Other Institutions",
        "documentation": "Cash paid to make deposits at other institutions during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/ScheduleofShallPayUMBFeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment",
        "verboseLabel": "Payments for fee",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForProceedsFromShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of short-term investments",
        "label": "Payments for (Proceeds from) Short-Term Investments",
        "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r778"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfOtherEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury stock",
        "label": "Payments for Repurchase of Other Equity",
        "documentation": "Amount of cash outflow to reacquire equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_PaymentsToEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToEmployees",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid bonus",
        "label": "Payments to Employees",
        "documentation": "Payments of cash to employees, including wages and salaries, during the current period."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "silo_PenaltyFromEarlyTerminationOfCD": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PenaltyFromEarlyTerminationOfCD",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Penalty from early termination of CD",
        "terseLabel": "Penalty paid",
        "documentation": "Amount of Penalty from early termination of CD.",
        "label": "Penalty From Early Termination Of CD"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_PreferredClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredClassBMember",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Class B [Member]",
        "label": "Preferred Class B [Member]",
        "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share (in Dollars per share)",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock (in Shares)",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "silo_PreferredStockDesignated": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PreferredStockDesignated",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, designated",
        "documentation": "Preferred stock designated.",
        "label": "Preferred Stock Designated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "verboseLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641",
      "r829",
      "r833"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r314"
     ]
    },
    "silo_PreferredStockShareDesignated": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PreferredStockShareDesignated",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated shares",
        "documentation": "Preferred stock share designated.",
        "label": "Preferred Stock Share Designated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r523"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r314"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r523",
      "r543",
      "r833",
      "r834"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated value (in Dollars)",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r455",
      "r631"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expense and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets \u2013 non-current",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r763"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expense",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r281",
      "r282",
      "r610"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets - non-current",
        "label": "Prepaid Expense, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_PrepaidExpenseOtherNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseOtherNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses non-current",
        "label": "Prepaid Expense Other, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "silo_PrepaidExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PrepaidExpensesPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses",
        "documentation": "Disclosure of accounting policy for prepaid expenses.",
        "label": "Prepaid Expenses Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collection on note receivable",
        "label": "Proceeds from Collection of Notes Receivable",
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate total fee",
        "label": "Proceeds from Fees Received",
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sale of common stock",
        "verboseLabel": "Aggregate net proceeds (in Dollars)",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLicenseFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fees",
        "label": "Proceeds from License Fees Received",
        "documentation": "Cash received from licensees for license fees during the current period."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "sale of equity investments",
        "label": "Proceeds from Sale of Equity Method Investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ProceedsFromSaleOfNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfNotesReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note amounting",
        "label": "Proceeds from Sale of Notes Receivable",
        "documentation": "The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r435",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r606",
      "r624",
      "r632",
      "r758",
      "r793",
      "r794",
      "r799",
      "r827"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r435",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r606",
      "r624",
      "r632",
      "r758",
      "r793",
      "r794",
      "r799",
      "r827"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "verboseLabel": "Stock-based professional fees (in Dollars)",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r831",
      "r832"
     ]
    },
    "silo_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/NoteReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Note [Member]",
        "label": "Promissory Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow",
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt recovery",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r277"
     ]
    },
    "silo_ProvisionForDoubtfulAccountsDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ProvisionForDoubtfulAccountsDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow",
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/NoteReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense - discontinued operations",
        "verboseLabel": "Bad debt expense",
        "documentation": "Bad debt expense discontinued operations.",
        "label": "Provision For Doubtful Accounts Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/OrganizationandBusinessDetails",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r325",
      "r334",
      "r359",
      "r360",
      "r361",
      "r433",
      "r434",
      "r475",
      "r513",
      "r514",
      "r570",
      "r574",
      "r576",
      "r577",
      "r586",
      "r602",
      "r603",
      "r615",
      "r623",
      "r629",
      "r633",
      "r636",
      "r791",
      "r797",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/OrganizationandBusinessDetails",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r325",
      "r334",
      "r359",
      "r360",
      "r361",
      "r433",
      "r434",
      "r475",
      "r513",
      "r514",
      "r570",
      "r574",
      "r576",
      "r577",
      "r586",
      "r602",
      "r603",
      "r615",
      "r623",
      "r629",
      "r633",
      "r636",
      "r791",
      "r797",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.silopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow",
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net realized loss on equity investments",
        "negatedLabel": "Net realized loss on equity investments",
        "label": "Realized Investment Gains (Losses)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_ReceivableWithImputedInterestFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableWithImputedInterestFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable principal balance amount",
        "label": "Receivable with Imputed Interest, Face Amount",
        "documentation": "The principal amount of the receivable or note before consideration of the discount or premium."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r421"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Note Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.silopharma.com/role/ScheduleofNoteReceivableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails",
      "http://www.silopharma.com/role/NoteReceivableDetails",
      "http://www.silopharma.com/role/ScheduleofNoteReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Note receivable \u2013 current",
        "terseLabel": "Note receivable, including interest receivable of $9,600 and $6,010 at December 31, 2023 and 2022, respectively",
        "verboseLabel": "Outstanding receivable balance",
        "netLabel": "Total receivable balance",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r674",
      "r690",
      "r718"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r425",
      "r426",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r542",
      "r544",
      "r568"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r812"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r425",
      "r426",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r542",
      "r544",
      "r568",
      "r812"
     ]
    },
    "us-gaap_RepaymentsOfOtherDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfOtherDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments",
        "label": "Repayments of Other Debt",
        "documentation": "Amount of cash outflow for the payment of debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "silo_ResearchAgreementWithAmplifyBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ResearchAgreementWithAmplifyBioMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Agreement with AmplifyBio [Member]",
        "label": "Research Agreement With Amplify Bio Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ResearchAgreementWithReprocellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ResearchAgreementWithReprocellMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Agreement with Reprocell [Member]",
        "label": "Research Agreement With Reprocell Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ResearchAgreementsWithUppertonPharmaSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ResearchAgreementsWithUppertonPharmaSolutionsMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Agreements with Upperton Pharma Solutions [Member]",
        "label": "Research Agreements With Upperton Pharma Solutions Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development cost",
        "netLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r368",
      "r821"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "silo_ResearchProjectEstimatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ResearchProjectEstimatePercentage",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of estimate research",
        "documentation": "Percentage of research project estimate.",
        "label": "Research Project Estimate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r675",
      "r691",
      "r719"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r664",
      "r676",
      "r692",
      "r720"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r683",
      "r699",
      "r727"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "silo_RestrictedCommonSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "RestrictedCommonSharePrice",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted common share price (in Dollars per share)",
        "documentation": "Restricted common share price.",
        "label": "Restricted Common Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r144",
      "r458",
      "r479",
      "r481",
      "r492",
      "r524",
      "r631"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r225",
      "r226",
      "r227",
      "r229",
      "r234",
      "r236",
      "r273",
      "r274",
      "r364",
      "r365",
      "r366",
      "r382",
      "r383",
      "r394",
      "r396",
      "r397",
      "r399",
      "r400",
      "r476",
      "r478",
      "r494",
      "r833"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r605",
      "r612"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining amount due",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "silo_RevenueTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "RevenueTerm",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue term",
        "documentation": "This term for revenue.",
        "label": "Revenue Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LICENSE FEE REVENUE",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r222",
      "r250",
      "r251",
      "r256",
      "r259",
      "r260",
      "r264",
      "r265",
      "r266",
      "r272",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r411",
      "r451",
      "r795"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum Annual Royalty",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of common stock (in Shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesCommissionsAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesCommissionsAndFees",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales",
        "label": "Sales Commissions and Fees",
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller)."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "silo_SalesOfLicensedProductsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SalesOfLicensedProductsPercentage",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of licensed products percentage",
        "documentation": "Sales of licensed products percentage.",
        "label": "Sales Of Licensed Products Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r756"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/NoteReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Note Receivable",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Shares",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Deferred Tax Asset",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Result of Discontinued Operations of the NFID Business",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r14",
      "r21",
      "r88",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r101",
      "r103",
      "r104",
      "r138"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Taxes at the Effective Statutory Rate and the Provision for Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404"
     ]
    },
    "silo_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Assets And Liabilities Measured At Fair Value On ARecurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ScheduleOfMilestonePaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfMilestonePaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Milestone Payments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ScheduleOfMilestonePaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfMilestonePaymentsTableTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Milestone Payments",
        "documentation": "Tabular disclosure of milestone payment.",
        "label": "Schedule Of Milestone Payments Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfMinimumAnnualRoyaltyPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Minimum Annual Royalty Payments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Minimum Annual Royalty Payments",
        "documentation": "Tabular disclosure of minimum annual royalty payment.",
        "label": "Schedule Of Minimum Annual Royalty Payments Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ScheduleOfPotentiallyDilutiveSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfPotentiallyDilutiveSharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Potentially Dilutive Shares Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ScheduleOfShallPayUMBFeesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfShallPayUMBFeesTableTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shall Pay UMB Fees",
        "documentation": "Tabular disclosure of shall pay fees.",
        "label": "Schedule Of Shall Pay UMBFees Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ScheduleOfShallPayUmbFeesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfShallPayUmbFeesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Shall Pay Umb Fees Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activities",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r66"
     ]
    },
    "silo_ScheduleOfStockOptionActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfStockOptionActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Option Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrant Activities",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "silo_ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfSummarizesActivityInTheCompanySShortTermInvestmentsAndEquityInvestmentsAtFairValueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Summarizes Activity In The Company SShort Term Investments And Equity Investments At Fair Value Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Summarizes Activity in the Company\u2019s Short Term Investments and Equity Investments at Fair Value",
        "documentation": "Tabular disclosure of company's short term investments and equity investments at fair value.",
        "label": "Schedule Of Summarizes Activity In The Companys Short Term Investments And Equity Investments At Fair Value Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ScheduleOfWarrantActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ScheduleOfWarrantActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrant Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SecondPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SecondPaymentMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Payment [Member]",
        "label": "Second Payment Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SecuritiesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SecuritiesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities received",
        "documentation": "Amount of securities received.",
        "label": "Securities Received"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r767",
      "r798"
     ]
    },
    "silo_SeriesCConversionPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SeriesCConversionPriceMember",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Conversion Price [Member]",
        "label": "Series CConversion Price Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SeriesCConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SeriesCConvertiblePreferredStockMember",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Convertible Preferred Stock [Member]",
        "label": "Series CConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C",
        "verboseLabel": "Series C Preferred Stock [Member]",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r767",
      "r798"
     ]
    },
    "silo_SeriesMConvertiblePreferredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SeriesMConvertiblePreferredMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series M Convertible Preferred [Member]",
        "label": "Series MConvertible Preferred Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails",
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Granted",
        "verboseLabel": "Shares of common stock (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value",
        "documentation": "Represent the Amount of share based compensation arrangement by share based payment award equity instruments other than options grants in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails",
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted (in Dollars per share)",
        "verboseLabel": "Fair value per share (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails",
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Ending",
        "terseLabel": "Equity instruments at fair value of shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Ending (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349"
     ]
    },
    "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Exercisable",
        "documentation": "he number of exercisable made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (Years). Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "documentation": "Per share or unit weighted-average fair value of exercisable award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Term Years Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Granted",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Term Years Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofMinimumAnnualRoyaltyPaymentsTable",
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activities [Line Items]",
        "terseLabel": "Schedule of Minimum Annual Royalty Payments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share granted (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Granted",
        "documentation": "Aggregate intrinsic value granted amount.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "verboseLabel": "Exercisable per share (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Balance",
        "periodEndLabel": "Number of Options, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vests (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement, Forfeiture [Policy Text Block]",
        "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options (in Shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested common stock shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number",
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable (in Dollars)",
        "documentation": "Intrinsic value of exercisable award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Granted (in Dollars)",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Ending (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option expired term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Granted",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (Years). Balance",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years), Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of stock option (in Dollars)",
        "verboseLabel": "Fair value of stock option",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of unvested stock option",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r146"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering price per shares (in Dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.silopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable",
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of year",
        "periodEndLabel": "Balance, end of year",
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r769"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Investments [Member]",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r594",
      "r607"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r221"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "silo_SponsoredResearchAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SponsoredResearchAgreementDescription",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsored research agreement, description",
        "documentation": "Description on sponsored research agreement.",
        "label": "Sponsored Research Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SponsoredResearchAgreementWithColumbiaUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SponsoredResearchAgreementWithColumbiaUniversityMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsored Research Agreement with Columbia University [Member]",
        "label": "Sponsored Research Agreement With Columbia University Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsored Research Agreement with The Regents of the University of California [Member]",
        "label": "Sponsored Research Agreement With The Regents Of The University Of California Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsored Research Agreement with University of Maryland, Baltimore [Member]",
        "label": "Sponsored Research Agreement With University Of Maryland Baltimore Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SponsoredStudyAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SponsoredStudyAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsored study agreement",
        "documentation": "Sponsored study agreement.",
        "label": "Sponsored Study Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/ShareholdersEquityType2or3",
      "http://www.silopharma.com/role/StockholdersEquityDetails",
      "http://www.silopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r193",
      "r194",
      "r195",
      "r222",
      "r239",
      "r240",
      "r242",
      "r244",
      "r247",
      "r248",
      "r272",
      "r289",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r314",
      "r315",
      "r318",
      "r319",
      "r322",
      "r411",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r523",
      "r546",
      "r565",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r755",
      "r779",
      "r785"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r31",
      "r186",
      "r207",
      "r208",
      "r209",
      "r225",
      "r226",
      "r227",
      "r229",
      "r234",
      "r236",
      "r246",
      "r273",
      "r274",
      "r324",
      "r364",
      "r365",
      "r366",
      "r382",
      "r383",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r424",
      "r476",
      "r477",
      "r478",
      "r494",
      "r565"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r246",
      "r435",
      "r483",
      "r506",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r523",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r565",
      "r637"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r246",
      "r435",
      "r483",
      "r506",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r523",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r565",
      "r637"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r666",
      "r678",
      "r694",
      "r722"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for future services",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued under the plan",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options vest",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r111",
      "r112",
      "r144"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares issued for professional fees (in Shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase additional shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r111",
      "r112",
      "r144",
      "r488",
      "r565",
      "r596"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchase",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted common shares",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r144"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rounding of share due to reverse stock split (in Shares)",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockSplits",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized",
        "label": "Stock Issued During Period, Shares, Stock Splits",
        "documentation": "Number of shares issued during the period as a result of a stock split."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r111",
      "r112",
      "r144"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares issued for professional fees",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r111",
      "r112",
      "r144",
      "r494",
      "r565",
      "r596",
      "r643"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted common value (in Dollars)",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r111",
      "r112",
      "r144"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "silo_StockOptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "StockOptionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option value (in Dollars)",
        "documentation": "Stock option value.",
        "label": "Stock Option Value"
       }
      }
     },
     "auth_ref": []
    },
    "silo_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "label": "Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails",
      "http://www.silopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program (in Dollars)",
        "verboseLabel": "Stock repurchase",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.silopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share purchased (in Shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r111",
      "r112",
      "r144",
      "r491",
      "r565",
      "r598"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share purchased cost",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r111",
      "r112",
      "r144",
      "r494",
      "r565",
      "r598",
      "r643"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r115",
      "r116",
      "r136",
      "r525",
      "r543",
      "r566",
      "r567",
      "r631",
      "r644",
      "r781",
      "r789",
      "r809",
      "r833"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_StockholdersEquityDetailsScheduleofStockOptionActivitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "StockholdersEquityDetailsScheduleofStockOptionActivitiesTable",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of Stock Option Activities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_StockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "StockholdersEquityDetailsTable",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SublicenseAgreementAmountPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SublicenseAgreementAmountPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicense agreement amount paid",
        "documentation": "Amount of sublicense agreement amount paid.",
        "label": "Sublicense Agreement Amount Paid"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SublicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SublicenseAgreementMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicense Agreement [Member]",
        "label": "Sublicense Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SublicenseIncomePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SublicenseIncomePercentage",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicense income, percentage",
        "documentation": "Percentage sublicense income.",
        "label": "Sublicense Income Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SublicenseIncomeReceivablePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SublicenseIncomeReceivablePercentage",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "percentage of sublicense income receivable",
        "documentation": "Sublicense income receivable percentage.",
        "label": "Sublicense Income Receivable Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.silopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r428"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.silopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r428"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.silopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r428"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.silopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.silopharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r429"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "silo_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor Concentraion Risk [Member]",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "silo_ThirdAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ThirdAmendmentMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Amendment [Member]",
        "label": "Third Amendment Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r811"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r268",
      "r269",
      "r270"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "silo_TradingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "TradingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading price",
        "documentation": "The amount of trading price.",
        "label": "Trading Price"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_TreasuryStockPreferredValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockPreferredValue",
     "crdr": "debit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost (252,855 and 0 shares on December 31, 2023 and 2022, respectively)",
        "label": "Treasury Stock, Preferred, Value",
        "documentation": "Amount allocated to previously issued preferred shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of treasury stock (in Shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r112",
      "r144"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.silopharma.com/role/ShareholdersEquityType2or3",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury stock",
        "terseLabel": "Repurchase of shares (in Dollars)",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r144"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "silo_UniversityOfMarylandBaltimoreMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "UniversityOfMarylandBaltimoreMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "University of Maryland Baltimore [Member]",
        "label": "University Of Maryland Baltimore Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.silopharma.com/role/ScheduleofSummarizesActivityintheCompanysShortTermInvestmentsandEquityInvestmentsatFairValueTable",
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on short-term investments",
        "verboseLabel": "Unrealized losses",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "silo_UpfrontLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "UpfrontLicenseFees",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront license fees",
        "documentation": "Upfront license fees.",
        "label": "Upfront License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "silo_UppertonResearchAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "UppertonResearchAgreementsMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upperton Research Agreements [Member]",
        "label": "Upperton Research Agreements Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r172",
      "r173",
      "r174",
      "r175"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry forwards to reduce the asset",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "silo_VendorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "VendorMember",
     "presentation": [
      "http://www.silopharma.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor [Member]",
        "label": "Vendor Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.silopharma.com/role/ScheduleofPotentiallyDilutiveSharesTable",
      "http://www.silopharma.com/role/ScheduleofWarrantActivitiesTable",
      "http://www.silopharma.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants\t[Member]",
        "verboseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r244"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r244"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "silo_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "documentation": "Amount of working capital.",
        "label": "Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "silo_ZylTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.silopharma.com/20231231",
     "localname": "ZylTherapeuticsIncMember",
     "presentation": [
      "http://www.silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zyl\u00f6 Therapeutics, Inc. [Member]",
        "label": "Zyl Therapeutics Inc Member"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(c)(1)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "14",
   "SubTopic": "210",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-6"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-7"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480637/718-40-25-10"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482981/835-30-25-12"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482981/835-30-25-13"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "b.",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(a)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(a)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(a)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(c)",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "79",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "80",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation",
   "URI": "www.leiroc.org",
   "URIDate": "2013-08-21"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001213900-24-025615-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-025615-xbrl.zip
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M?*K)1=W<N>#IX)F:PJG"[8I5F*9VS_S-'&FY ,9L[E]CW[SS9]@D[B7^C#
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M,-47&[%@-;H*M:,B*;^P?5K#,2"G".+ -]1NZM?5[:E<"G_2\?6+_,+LJKQ
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MT[6W9TW/-\^$O: A$Z=Q+?94FI?T;Q/AP.[(<)Y4%)2D5KH"U7 \&@?*M):
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M 0M),!G)U6M<$RX(_<Y?<9D);K'"\'N26J/<YKK@5&<(Z"=A-9O5&1IY(=8
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MSL,RR$=B2;6IV\P8$R$35/-1Z,7LQ+5H18_&R\5L7N6HME-?/.!V<(C@D%)
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MDS34UNW75QLTN&A0H)V>\^^CPH^G8299P42-9R;&X>P 2V?$^& 8G53<K+S
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M-&AIR;8>2X_:?^;L!B08(;43PVZ3HJ)9Z(O)9;!R!50WNTZ4U^#!:U<O- <
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M\W*S9ZP.T@1([)(FBM)YG,#$Z-9S"TI%]&@#DHH4$S )/'Y!=C4T!K'%P)1
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MB!>FC<0\B]U>V/8^",_")+6(.S+B'W7OPH^D%X_]]&5+)4 (S:^""\C#J'Y
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M49)');O2S?R*O&6(M7==DOCAM F5L9$X!NL\=&/:Z<MTE E,02@TA5T\46E
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M<QDRYTCO&0D>28OL,'2[MFE(%XN2%VJ_910,^HM*0AU5.\$?H'S-AB)"SO+
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M(U!I5>Z*_5;"&C=7E=D3S,I_Z38&MA($?1=G3 (7*64.0<F)#)3&5J^S?^P
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M:80%ZVG%&:$\=C'5 FJ2UF(ZCJB_M2B-+V1R[X-,3D9Z'+M.G3,72)  =;?
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M;8=[KQD..SP;;=9Q^WRV)&<566<E![N>'*FIS0V=',3C(IT8NTLZ/TEKBG^
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M)UHFG$RR7^!AC568>1S5KH>[G'_/IB<M70%;42:OM1E(G>PZBQ-_HQF?LT]
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M5.!SWD8,&V$G](C39UZD_&*WS9:ESQD,'.:4^;WQ.G/VS;[&J0.JXG;C67*
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MAJEB]"&D2H%A:8HSH\9!I0BG5+.RAEV-">Z<6=)H[6C58'4J"R+1[O)&0:2
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MIU!IS%5@^<*:$8:'X%A?5<" 1.J@FLG[N;*B)4KE*UOBU@(%NC7O6A6CWCU
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M/I>)N4LK)5\CBT<0S5P:&8D")0=A23B2K5LJ2C$!>)X).6VP@%G+N81] </
MQCP,TK4?2#9OZ:&&_$,5CR-L:0!;;\Q=:YLF(VZX$0,==2,?1W\!P\Y5MGK!
M#:5%98B>1DUUJ-V%!<(8(Z,)DEA0,@I4@8FP)NA=S7O1<P+Q,<*I]MC@!H4
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M<ZO+0,>OY@G$R2'V,S0'9MAH39A/7/_&#R/ZGL+\I#Y0:*1=1,+8Z7K2%K^
M"<0<I>3D5=(<%Y[L82+?I3>7R7VQJ@9, \-0T%/<94U6HGUF+-+>'X-1-DMA
M)YW3AG7?_\$-5$%5<(](V/&\T-RT,4O&V!DO0VY61)#QCTT8C$+'Q!/)G;GF
MH#.&UWX<9E-*<JJ#57J,Z,&@V8GC-9J-6HJ.:XPF*)4&X^8S=DWA_(Q4IX$<
M9KQG!T'I>'+,\21$8NJ$TG@+-9FLJ7B7H_CE9!,$FR>GA]3I3_5.I*140@+Y
M_1U_Y)RA$_V2G;.36,ST^HX;4P-9GQ.\&:6]'#&E?>LP,-D0-)FYQUO0%'ZH
M1A]L(%H)&7IL_T'6A_J9Z2B#I2/<AI-[YK%1%\>RT7)!CRA7A!E31W/KD=,"
MPPPP6S C/AWB$L^&G4&(BX]P01$EV>< =AB&R'U.R8*R"&+-<1B"TS& XR4*
M@AD5K81##&/@C<<P09,"+-8IXC0L:+%T@X4S8RI!D6DPQ:.'35L%/2.6V])D
M^ (? 7L%CM%MS1P)#B&6"F'W(:S.H6Z/?$WW1V4JT%?N+)F)6GFQ^[;)$M/R
MJ*K'+&/,>3!C#.RKI>TJN%_=9'*J)I/['":3L]AD<I_69'+N,YG<[]=D4K'#
M[9=\/*T6.W2^+"NN<7_RG?9IZM$,_?,,\9DZ0(95"JI@,7?4EK)"@A9H;J5H
M.VJ;0$6@3N(;[/ [P3VW:<)^E_"XN0G<8:0SOPT"M@<UIS%L[S_P9$NSS<W-
M%6*&UCRI(?,#8;AV/OZ@FH\_HQ#.(3E^^,NKNP$!!&,TP5$=&=/M12C(-=*@
M;NYPGY5A$TL$?)L@#4L$?"W#8:4%5,GREZN&5LIK[[SFM5?/:W=>\]KKO0=$
M(Y"KPJ$OJJYCB!)9FW ^*%9YQRY'\; ;]FVSP2I:IL%B?8CPH?,P%FLMR+>J
MQ>H\<I!O28O5>:H@WUI;K$]HS6VI)&?)G/M+H5RO03"L_.0*AMT2>4LV%_&^
M)HY'T'E5Q:4V-!=^+7G"8PJ PW.J9(J8,BCMJ$9BE[*:P7P'<32$B+QP1^4X
M&*34;J335:Y*/8'_T4?XO?-!+%!C=;]%F1%#_]/']V[M"I.Y61I^K#T;N&&3
M4^.P4X./4W9RD94B[)Y)JF)]V( M9U2$GILF<WC0'"P*IKNQ$KC*L&Z&F"*B
M"2Z:@O;G C-GZN/]"ZP!R> ''G:!#U(^>O!/PAI/B3M%W5J>-M(8=@$D\;W1
MU\(IT@#E"L_+06,IO]1[.U+O35OS)KQ)K&0AWEA9_J'VQQ2\OJ0I&HJ\3:$7
ME;2%\3CRIU-S(G&V09;*H90];IR2%U@3#.WPN0L=/OY'7:96D"7RX1#.]1O7
MQ)_S'-WGG=4Q'W?+ADF5-FX"QZ#V'P_I(:^V>:5RWA]",'! ,V"?(4X .<>V
M1^N!N^I/8EQBEM63J3^1FE<I>1<'=P'>8W=GQ]MN;S'>XZ6J2,$)6E:RXE40
MF@6J8$54313-T4WG[0'SCV+G8Z<A\/:I(0+&%ZGF"@UFGOJ@LJ6$:4$5@$EL
M7ZVH3N0A)(O,5FT29+,P)A:)=-1RKFB;U]"*8;8 L,@T#H13T$K$U%?DH"X,
MDN2H?^1.$U0HTP3&0^TK"YA;]^,EIA)1L*F0/KM.;IV&*7*;I^CE0R85>/C0
M HN=A[, 2PI>LHU1;C+%+9BXRU3X?[&\TP(06Z$K9R93\RCMMNZ=@J:@RZI/
MNR\\$T[!>XKR?[QYXV;I\!]O0E"_P?^VV]W6OV>3-W]_Q$:"3V]*+W_\.WSJ
M?P? ^E_"=ZM8.,X":[G9PGG)!'RO7LLWX;5XWX+;HKP66R1.U(N4&2AX7:6Y
M93QF$IHRT:D="B6X1)#B=XT3.<12_LPD9"Q0:NG-ZH/7H9NK"AZ^+NDJX3>=
M4O!=.EVB$!X9.#?"NZBB564'\S N FG:R<P+: /B4TB<0&G/00XSX[$HA!@#
M_0\TS)G(MMVWA'4?A[&Q(B^5>%N#W:B\QL@5DPE;=E(H=HB\I (X8>FSGAW\
M-0M57^6Q(8R@ZH$9DE<-(S_44R7NU057BC:,L%$O;#A#I*,@FQ8'5!VI6QDI
M05JH6HGN61XBQ61!$'*.<WLN%I@.KY$& SE78/9SNL$,V[Y3:%ZI"OS"L<+"
M]N?X1);Z*)B0P1TP80H97ARW+?\ FTTS,HI4C3"ZHEQA9A09!/PT"C$,:"66
M52E&ICK,ZL FN*Z5ZQJGDA0V_8C\(>S@C->A@)GJ]7% 2_O#;L]KM]L>+[K:
M3 3+%MJ^:0B#1A8B1QIJ9Y[,NVA.UWS.C;"E@"T.D(( [E0$]).;#1?9)J;%
MM.&7)'<W&T0A2 <-[&^T#GUFAM$Z&Q$@L.=DAS:^/@-.4G#JF8:&T99N><\A
M%/(G$,X-(\X2*R QQ"/DGL #BSZ^V>#A1=!=5@2=%440-\W05C1,OF*0G*:0
MPLU0PQ!#3_64XIW,M,VT&1T1;27/EHB'#(U+1T2[I$]]#2+4W98;I[FNB9O7
MG!2LK(G;Z=5>K@*Y#6/!;X@$I!(XBK%<P"5V*I8&KG?7BXS7@4(SES4ML_/P
MRWR/IM'+6AZAXZ^RJ"\VSK0:(F'W%9&P.B*A^XI(6.\]T,_J_#;5@EC;QV,*
M70,O6R+ABHK90KCY9?ZW.9N+# ^KQ'LW)P41AI%^U)%82G_[PVNG$5CU47DE
ME\]0&U[;;+R!=FV1,V+_1!$/RS<XPA[";(JHHQ(-K#.N#C4VC%XWG.)_@BN4
M/V>L8PVGU;AR/MDI.CC2W6E GWJ.*B_ RJ);<(.C^2923H:CT$>7!9FLI0;)
M<T_B88L-WR^*@'C5F(PYY)W K+_-WBK5P6;?OEV40C0/83-)Q57*$44[P!(G
M\68YLN+@1\P""_XW&BY6:*4*F!$#.DK*?J8A+A.P[+]12"LTW$*MFP7*P2P%
M-)Q:0,-/89E";/)"E2<J7L"F9MVT]*,LN7<"K#+T.)@D,&3Q_),!(TICQYJL
M)4-0:GF.]%-X!^O@R8*)A-O_F_[4!6NE=W/Z5D$:9DF5>6WS)JKX0]EP;KGO
M$V0)A"E$I IW;>$B:F/Q-\=+<*#<]@2#9R-_GF&9S"2\81JTVQ391&-L<@(_
M_:YU^5GL_K, F[])Q33R/SB:_\&.Q(KPT'>4L[XS$HNGP&(ZB 3\(,J"UM=U
M0!O!I/H=2XHH8$..(MYDX4@8<:@%C3UUHVJY_+/K7B>WZ-603UL&B3$% I=D
MZLWB\&;Q[HS?B<<H(\17ES=6NQ@W]0S6+ADUA;+J82R7Z$@35 W!D.@@'?*V
MIA0QKQ,QB(8EAS(9#@N,_>&:EBD+9GXX:@C>=-H8O,%UP^4+K=*]3C6D5(_5
M*]U.DT\ 2PPL9R$:[O;T\B;'#DM8B49]*6A))1J7X5%'EPR(G1##)Z3MV6P+
M.2@ YR#&<AP,+!7IZ_[V8Y;MO2;48]DF6)2=JM+D!(AR='VM"N0PJ$L^\]'6
M3!FM,2[Y3EJI*$7!Z(?JMR6,YCTQ<][9U7[<W198G=_3UO[>A;\ %]"0&M4D
M'U29R+8CLHU&PU>)-@=S39Z0H^.>I#!4-7PV3&:!3G'(S<7R<T0L#HX^],F]
M'8UL?%LYZ5$URL29YA2>87#^C#S"Z%FL@#,K5TZM"C/3Q5.P#'H;=G:66 JE
M9I"6+K]V2FMQ=QKXF'Y15R<+%VNQ&5*/PK-&*1%+;55*P,B/$(-5LB*REM61
MT5(AG*8T$:L,!ZXEZ=YJ"[AQ0$D.7!,2.W-RT\&-CD[J<KS+FH@]]1Y7>'SB
M3_",9AN AE%D2XR%SW7#$ET:&('3HR#G$UK)NJA,&#1U;<$D%(ZQJK"WOFL-
M]DOXCD,E?[ M4\66_,\\^MM_=;=W?BYU-?(<]/?)*/J?S5DR@EVPO=>%:[2/
M]KW'6C0RN-M=HK+W2Y: 0B[:S/F?JY,["GL;M ;1%L..\SD*X8HMZZ@L#S.P
MQ 2_U)6PI7%Z[H</!QYU*/7!19I(D@<=XPGR0QA2Y,!$3RLLS:KADG1LD;<@
M)LZ28-G.?S5MO&#RRA/.5I0/)YB0W3"U?*HT3NDF[*[('P[_5(<$E%5GOXGT
M;7-'"4PP.A=(,Z,3T!K6:OCT=1X:FS6 M4OL=-19[:Y7<B3LL-6FD(,:.R4!
ME[U'RSU-<KP/]H;1;;)09T\2;']#?WZ4R9EB#1DFGD&!9DG$C6;3@$G<S8SD
M9K;00J5S!G;,=ZU8JU(JYT^#M)D(EL=#?=O?:)!=JXOPV\Z&^T.W2V '!AMT
M-VB-T/.%72X14@E#RB?(B8[+B,T8AD&U$P,B*M^^W\ =V/P\)<R&,UU3TO.-
M-=^41;#>*-M_V'L41^[;L53T[M&4W+P&RX6CG?X(Q1OEKFZ,XI,7: H-F<)>
MC:KX4K5SM'0/#&)KPV@B5GR(OR?SU/1FY$)03)]O8V6JGR5<2UJ8R1W[PS R
M;3"XK9"@X'I-2Z3>]!ZM9HF(V^MHTIN03I$L;][RO(R"[X^HJH [?7"'EI)M
MO+V_W$V=NVX*LN.9<"UZ%;@;IE(L2M)XHZ+6QMG0<D;*$6X3A'2.X'DUOT];
MH2,3)W)?\92MG^/8N"M&CI"%G?9R;]ER^[15:[Z]- ]7-Q%*!5+ C&^J=LUF
M=5HZ805'04E*/"JH=D)ZI<R#[]N?/N9"4FXNT@@CTQK4UB*.T5KDX#9L!M]"
M797NC'NR3K1GNWSWQ)K[$4A([AXA%VX0QLX!=E]CH-='Z;XHSJ'F .SNHCAU
M=KWROM"Q9;4SJ=T3APM8G!&>BP5&BKU.%>W0OI ?*SWL6)K0?IUSI:>-L:Y?
M2*-H8&)P3JM+4/>-PXS*X"5+/KKQ5<#5KM%H.O5<HBR4+H%Y@&UB<%#4-90M
M"]65R\ P2X/65$Q@F(Q:[IVB4Y>6%5)@9*N;P"2L!-H\Y3VMCII%=J[5]FII
M2U?9SAG8X"+\PJ"F6J;=<[:R[2\O4@HC=K=54D.#RASX;1GK2U[U*"$E91@<
M%.Q7^R:)Z?A4]FKLW*R-=Z[V!J+)&R49 E;0#"'*!.N<UMX''<=V3V5\L,T@
M]SVK3G#D36:U(;$E532*/-0QY*$5^LQ7S[V)K+56-1); ?R[0X::K_6>@Z2!
MU_5MY19WN/AZ81=6C2""(0UN$@'/ZB(2#6"N9NQQO]E/II*&Y2EFG8HIKKE
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MX!=[5)S%;K^8P%]N9\>S]LU)/(Y8NBZ"4<%RTQ_F>("28_L6+\+EZ;9_/KG
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MNQAM5W0,\/&%6H#7,W^9,564H/. BIF.J6R&=;\( L*D8)!AL6Z875-=,=Q
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MR!*8PV'VQ'[]FHK12C"KWBO,:F68U7;[%6;U$C;*?;&N#VALL=.+>/JC:H!
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M3ZB&_^AC?922+II4+HJ:J=Q1G1%9,)E$7D3Q(]41PR)4Q:XQF4##*Z% Y3.
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MJ@1U]2+X+?Z&@/*-=-H6Z.5G<\1]V*HPJA$ P*3CNIB/DPE7@*P9./_Q1X.
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MO9Q:[,+)*'?AM+I+I,S%D+',BZ$77?88)2Y[<N(V0X7BBR.%?G$#%H-HIP7
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MW6<C<^T)CGZ4L/=DUC93UM;?;2F6,XGE7L]57H^O5P**3+NM5P5F$X-C^8O
M19TWW1:7]X!3_312-QG29.[7C?2J>RS32%<;VK4C&1.H(!+_*>/AP;E*':I
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M>4@,D_RE)K*"4LU)&AJEZP#4(.ZZ'.F3S U&TF5H.B_9,GI8;@U?A9P4QD%
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M3\VTL'NE\<2"@%$O4%@D!D9B"'@BZK)BCNP@,+/@6Q0*@>V$9&K@]H%J1W6
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M[;])=XZEUY%V@7\T48%(W2Y7%LTIGW7O1'^3 ::O>$#K/>YXC[[[J/7N2A\
MH\[FO">:B6/ZO="JOS2:0C.")9>FXLO$&I5_'V'8&S!!C7]!W>*6#F!'@FS8
M@YL69> \1D]2$7(T#W046+)%HLJ:]9X+6NX6U%%APU1 #OX0F_ZZO/< WN)8
M80%F;Q<V3F4C!Z%/W!Q\\9 KJP(!=X9#WL/@@2E$-FEJ 5Y$.99@XOK4M51V
MA1PP\@V>L",[-8)D<@_8!A0[2=*_A[!B@ "JQN:6]+@(0IF)F?IAV>;RRN^@
M/VQXX %[5&+8) I\5WN,4I<>J!MZ:*49R088*G;@=+'GL!MRT362N,()T61W
MP&D2-YQDR>'CHDF\[,*9=L:4?$A]TY-!"*J_N?PJ93-+NLKZ9P8VCQ,/NJ*?
MI1]BN\LB#I8X7P'C&D6,:Y9@W!S?IGN7752G,(,YQ@R&8H;M:H2WAF3P9%+)
M)8A*G)6 !LRK:B4 2J%EA5 L/)2D()P\H(!?TA-:!#GA=7_XE*T@#XD:_>"%
MCAPQ(N2AZ'F,$B ]K3(\["0TB6305\REP* =#2Q) XWD?1E7+.RQ?YM?X0TH
M.6]C<'D.C^J'>VQ_K[DO/,K/*1P4KLBWS;%,K5*<3N%Y4#-5!Y'_^E.SW?CH
M_T=V/QX'M"8A?0WC0G[H$""P:+MV.'^*YD9PVGWQQ075,P.[X!T8J"#LJ>V+
M3LYF/_9L%;]EH J$'I,MDFT_&/D!ZMH''V2U1S'S)%3[MH3B"\U2$?0PDKL#
M1PP;ZC[+1M'<[/DBO)^<9M&U&B>58! ;5;'-P6+E6#*"J4XV]=?&FXQ(,TC1
M=BC*T$0 @!^ >'#@#"(T3^?8%$RAV2Q,SN?WM3?([VO7S)O;RZNSRYO.5Z-S
M=G;]_>K^\NJOYI>+"^'[W5W<_O/R[&*UY5&+[N%7)T&]\VGS("R<>$)E523<
MN+S,PEM#FI64G#\X(G?,!3WZ8/X7&XX^JHBL9=[4.K7D!JR</[A=9V55,.U&
MU5=1\UJ%T$5K/;3GUU+&@<RY>#7#%NZVN9S=OF93UT[<<R+S"TBL*0GJ1:@M
MD\G]RWP9Y4=MT2ELCESQ8J99/^B'QU;C!: O-X-=T/16AB!TVDY#1UGD%NR>
M[A,;4W]9M.**H&FVK9-Q6BR+ ,MI?G;/?KX]PBP$S3*/QD3=@>VYKBE46B0)
MYU X6:MB2O_ZLFB<;Z7IB)Z@G<J"\J;1L%H!D0>I/=)X%8$!Q:/5%DS?3WL1
MJL!#9L^/P7(NI0WG6F.J>B_<^J(LN:E;/VE8ITO9^D;---_X"#AF="?V[0>$
M3T!*'QKDILL(-\:@Z.^NX[I<Y.N!T][G(:;NX-5@XLKS !NGE/?E&4$@+YN8
MYV%V+[X5Q1:E?_4=C' Z=/\HK]GD12C-8>2/#F (GJ=;(6>8>=@L>KB*"Y3F
MC -I)1M%')),:";.P$CF!&Z1,[6U>P5Y?<HQ,W($8L&Q:<AF3,/8@6C!4*2$
M9EXC\]UQ-F/";NJ[R)]P(RLR<+54 \II(^@<CZ*Z^>P_=?&OW5]."C495:AI
M'I925KW&2/"1,9%])DJ93$('+$J7S@[>@RQ*;6.N3).*W*4D2,9K^& @U5]^
M%K>..IMM -P$_* C$^*-&]";-LWV!53>)#=;&PGXIN+T<FQ>M'''@B[S>'AP
M_9.NY,G2(;,G+;"Q!RP ?:@*!D+--M*J<'SLDG@@T]:IA:+X"=)KA"D+$2I#
MS_<.Q.=C-RS&(KHX(VY3FXNJO50M!8[)[CW2GJ4M-_451NX52<J]M "Y]\!$
M1A98^1$B1AE\*O?)5/8I5K"(@H* .YY(B\@C;L D0L$B<40B5H^[_ &,!$,@
M.AJ(_(X<B@M0B8ET'LWCIERY'@^!/<@(42D@*I$J"T3-O)23J-.W4<Z'@*-G
M&6),M?I[QG+F$/@1$#OR@Z2RI1\G')'^3A:%><#*XVMP+M(*X#D'#*90WSPQ
M2S%,-$%\;L&L>GY2.4NAPS"9;XP)9B*I$AUHI4'RV-\L*?&Z FRN6H*3JI9@
M_EJ"5E5+\(J))H<K3#0I-SH5+:O.[;UY^<\M2+_,8>]HJ=@KG9%S6#,O_N>W
MR\^7]W>6^>7RJG-U=MGY:M[==^#KBZM[X^[LMXOS[U]%2LXK)]N^3F>+3,K%
MS"[UDVYTF^W1S]*'<.$V%6QJ<_K"-AL:?,L$I5&;!LF*\? E"4#>)2&I"4V8
M5M.#O@3F7[[HBI%(^60%D5Q#%9?>"C,8;,M+S7J\3;V.&V$]=E+K\0M:CZ)!
M0QBEY3XR!QJ7^8EF=1']Z)5W]@"\8Y>',D5:-&#U2$F;7PX:LN2!ZEU[ZHL0
MOFG*9@K>I $'N\\'I?N2;10J%N7>YH;)GY1UMP'K&R6(,*09*NQ1?)KRN\4P
M,E7)CE[]D/6X$BE:Q;KFO6H]'Y1/?)>T2";A<?%3%JV=H1-+,?!,OZ'T8]5$
M2,A#D&G<H;@K9JXG'2C2KCKJT@1;U02Q:ONARM8T</=DT"4@!T2DOG<Y]TQ?
M1)KV+=-72\JW8.\9UP]CU2* 2F&2($T2SAV7Y:FLE(&<-\N<;TLZMEY3.E[\
M'#A=[.6SIT<X_5#T:H+/5*D-A97@& !K@A^_O[ZQ-*]?=+B9SLU4[IR1U](=
M3X]*TE>7W#%/,5C&_YZ6;/OR\UI^L_4_EPUMO  #YU1$35VI\D@HD35&?N$+
MN\\N;K<U2H[0VB@;Y5=F#D!2_>7=((I&']Z_?WIZJH7<KCWXC^\[@3UP'GGX
MGO<>6/"^QR+VOG'8:#=.6N_K]7JCV6B=UNO-5OWTN'74?L]9X[3>.F[PG\V#
MQO^&CNN/J%M3;1 -Y=@<,%W.? ];EZ%Y(I)NDAN QJGJ!M5W,!&$A:8\$"8@
M5]U:Y+LNG<D">>74>>87'WRUDX._JW6H/Y!\5%E&6LLE>*=V\Y"1XL*VR AS
M$>N:GRM7PG.M'>"Y<%E,USIHC3%=!RGABB96EPEE9:GL6$,QL&IA%X^LQTSM
MIQH[POX51[9JK0WBR 6F'[X\^7X%G-&J-5=N$N\(L[?'F/TSU2$O@;/;&\+9
MM9<+V[7Q;:OBVW)\.VX9Z$):LPYR#"79]XYCLUIL]8Q\'LG6J--LB QK;XH9
ML3!K;Z30;E?,7X[YFV/,?X9$[@.914O>R?Q_SEUL$LQ?>@*:VWX"UL[?[5KC
MOS>$P15;<E9OUANGA\=U8*NV)E,%4RUO[YH_KN+.MS)S7C0F(M9)0]&I(<JV
M7JXUZL7NU<X(MCGE6ONTU3@$X0;_/D:Y]K-1/V@*AKNC7G\W:IYWYR'@XO)(
MN/B=4>"X9K.-XJ'1,KL\>L)[@1O?@9^<B7Z!LJ<SBHZ."ZRL/C<[7@C_$V7E
M&9?R3,FR1667@*Q5EY"MU-]Z#0;>;7=J(<7<.*DWC@]/V^_[)S_PH\8)<7+C
M?T?(CK)[I53.?A#0U%&S@QT-BQB<^.JSZP#C?&'X;]#@V"\J-'_S70QWAY*Q
MQ4E(VJ6;39I4@O-*5L'7.9W<.'ES5BDP_V[[9,MD_F8!\Q.G@<Z_Y5$<>,B1
M]]A2/@;#,V'_G6#>UV#-W?:8%F/-4_29&HWW_4;]W_73QJD4R_%HQ ,[CK)<
MJ64_C$ME2TK;:SOR!1^A5Z3,CN]R0?,S&+&],(F0 8]=@O<5BL;(4QB[(ZI.
M<GP-P/Y].E^+01W22ZJ_18E\6+%].;9O3F![F^(#D8-WZIX/KC_+6B() Q>>
M@"WGZ=?@V*.*8\MQ;&L"Q_Y._=(GB.0I#/F/F$H<W><"GOS'=)Z\\A]E+*Q%
M]L/I6Q2UQQ7CCH5D,7(!_Q\9]P?R!3'N\2(61M*09*2^HB>H+?-GK# $IL($
M1S'^2#%_PIAOT"!YC3-P4IV!<F?@9+KPUANG;""3SW G*[/[M#H'Y<[!Z81S
MD.D61&W(0LWRWNS3L:[#L8D)S=,JU4^K2O7Y*]7;;Z!2/5EX6=GT^H);EQ__
MHC[9R\V0QPO9^IQ:)\7$$I+EIZU_6E]N-<!2--SI\7$=$U":]=/FT=1X:E(^
MEG5QSK1XTY4?I7J,4;J6N#YM' KML>!MP/M.J4O:9G.];LJ2&;=*)2C)H9-"
MGQ,X-+&X;A*+ZTX.>=]I1GVE,A=DY2JIH"0K3XJ)WL7=-*UJ[-8JP[''N\.Q
M*^/'ZIZ_)#^V)_#C6=(K]^UPXRO*S^KROR2_'D[@UT[OT0G];"+*;G/KRGCQ
M\/]6S%B.&8]RS'@Q'+G^,]FAJ47:%0.F55A/;TY,33H"QS9_YT[8=>/AKO/L
M*TK8ZM:^B*D;]=;A(3%UHW'<?'EZE<ZX(IUU8<8MQ[8G6RUJJQOYDDPY*0)P
MJ]_"W(I;F#?"E*\H2ZM+]))L.\G;_^K;/PZ^C]X*JZZ,$:M;['%&;, _6RVR
M5%O-D_:Q5.I8#BC;K@!]@6.^.C;W,@E,TE)E0U_VZ=?MU,(& E] [CC9#@*J
MS[X3F*P/'.C VT0[NC#NAD[/88'J3]>Y_.'TU*)RS858?3JG_XUY,=;&-D0[
M^<:NBN7FO!=A;^4TM(^:=!I:C<:A=AKTFNN[$0[]PIN"6QYR2H H[<'AW]\]
MAXJT(RK!_@;LYL)7EOF9N9&#8QYV@+-7QK>-*N!0R+CMT]8Q,6X;_IC$N'FQ
M+-3Y]=!SNG%H7OP[1IZ$+X"_X*TF]MQ:*2]*BV)WI6RSXM:2W#K>VN*+$X21
MV0&IVB/)"CQ7%#-3UG BWR1/67,&T[:!S=?=+A59>.KM6.%Y6TMC6#7A=RO8
M_?BT38U<6H?UHZ,)PGF!T-D7W@V(P4X3EI>\/B[IE?$AYD?Y9%=3LV7@\;W+
M2;UGZ=#)PX ^U/S-7^0)P4\4M V1+=K8WT*!7MV]E63P GF>*PHHS74+M!Q:
M!=>MC*>JJM:2/#7>H'.!T.[:A>8"C3YW3&A6UVDE&7R\*6?)('">J<MSYP+-
M.K=*N%:W9H6\=UH_/A2\=]AHR&292;QWXS*;2Z<+_SNW C^<G\?>=XJXK#F+
MRZ;6$"VK,&-*51 \5E4%S5T5=/@&JH(6+&!;9!SD6B>T)R!5E4DO4U0G?UK3
MR(Y) SDV5U<UCZ2N.CIJ38B>?&,X>V_\GE*926,Z9&9XL-1-S=I#)T=+L[/6
M9*X@:Y].9>TW;(2-,?9XU.2K&$A/ RBB%S%TQ]%NT*6#N^X8S$O9=S/[([2J
MR_2M3BUQ\JDEZQ#KR9W1W<59T?W\_E:URFE5]:F;FT^RW>R\H3*_JF(=9_AF
M_:C>KA\APQ\=M8]0YA?P^W><#?N$=YQZP> L3O_*G)[+GLS_8D-@"O7-WO>_
M[YM?HQZJ@1#8>A3 $?(B1ODK<N) R(&OF"MFTN)[X;"8'AMR.6[6\:SQ]MK"
M4FF65@4O,_#3%XM>\O#BK3+Q6U4-;9G3T"XX#;<9GDVX)M?W4H3Y-?X\G8\_
MVYO#GQLJSZN;_5+RO,B N7U^XO:/J=E9^<$%<TC6%\9.MEZT5ND!A8S9/FY1
M\.3HN'G4G)%359!*^!*C^\QWXV'789KEO0IN'LZRL54S9)GRV-PY&[M*'"C)
M^N-QPZ65ER=,UIQ;;B\>-%P=I[\*'U=)" OS<<DL\%FL?<X\A[NFL%1VE+4W
M5(CO=@'PO-,]ZXW6\5&SV:K7#T\.*3I^<MRHGQ[T>+_19B5*=N@HH$?HD>D2
M$:?.5<?3&8U@">>GV<DQL7G.^X[GB&<"_^>SF ]*YPLM:7O >['+S4:[,X.9
MFZV='.79;&S.+,_ELW-F*FBS,386]$Z[.-DA&=5LO1VBML:(BKW;Y/F^!+F"
MDD&H+TRHYN@?=6P;Z$7!6E#&PZTYK*VW<UA;XX<U'0PM9^^>#1R.75"Y'9.
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M/_;>M3EQ9%D7_JY?H>.S9T=WA.P!<>^>XPC:EQ[.[C;>MGO6F??+"AD5MO:
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M;QWX6N71D>6U"4JUF-W:D3>.?4IS4RQ9PTR@/6.9+E?#P2F5Z5A"TS%K]"U
M<C1&H_ET/L$QM!+XSYG.7/;,;,_ZR1+'5[T)(;PIB#HG'>$22<)12=]%E&P(
M:4L0^H[K^QOT4NJM3:>6OTUMFM7J2)]X<DS6XD6D,ERU/&\N('_'<W_N,M43
M(+-O_C33D?G?!]<79$-2??N V*J>31K!0=0;8#YNT.Y8S7XOQ^SW?&.9]ST,
MOEL-@T\8!M^NAL%O/@R^O=-A\"4; 9^ZG)OAP]6]^C!48Q/@1>5__UMT%OR>
M5W9Y=7'U_<O5'0[H5G'P-!&*SV0N8B'IC,(UV,U\"M\:+3D%#!3B#'T[%^'D
M%HK)#33 AN/H',9 3^J=EKZ96%E!0!R$:HU?P3$'$L+9@GS\S__=U>OUS^IO
M.!0YYHF"OG?XNCZ!*\G<B66SD_/AW=?^S>#_HZP<T?S+C_O!S=7]_6^_XA/.
M)?F!/@6M/3R(XMYQ#[Z9>OML@!4$]] >G:D?L'X$B:77/E]P+4P_U3]_5%X,
M#YQ?H-8,"<8GQ.+'[U$%8^T)KN5/Q_T+,4G^[WSRJM8;R+7UFJ82:>G3R!SJ
M5V=BJO<OQDR\=@A?,.RYX;ZJ>I.^ ]_$3XLUJ+Q*%E[I>XHGWQ<N!BT]ZA,-
ME@ 6PR6;&"^&R^CQP:C[>H_?I-3GJZN>'^Q7@;_+%^#+%@CQTS"-L^-GD(<(
MB2Q/-<!\_LDFS@P-+FY\@;IZM)P9\="(S<G34X3]!O;UB$8) _5 ;CRA/>>[
MAFGY?"0<1@! ;."7//7%\I_5F?<Z>F8FFX",<9G'#'?T?,8W&EV*Q]A?9!0:
MHW_-+9<PLG\%7T^L#@[.9X15,H?%S%P<O.&_JO !GXV>;6?B/+UR?T%T%T^8
M@?8W&O/@K7H4J:,0GEP#_)(.&6P#7W7QR$W+PT)N("=P":_E)AZ8\W[/Z$9,
M=_[D:8HW'SVK<(5F&!$9O3Y:<"+X#OS6#*Q<VT=[]E',$L1?O\(9O:K/QD\*
M.HU@$P;^+[X60XW.Y">^U60SET_9TU1Q+L_,F  UR0OF&['9W,5]T_' VLD>
M],[4A0/>R8&1VSUCSFP";O=\/&:84>>$MFP35D!*(*!'=/TSQ_-/X8US<,O@
MB9Z/?U'E>M4/0C+=/MQ?2K&DJ?W)OY\9L+9+0K[S&<[DUG#_LL!?L,-?A4,Z
MZ/PR$$1^5YU:M#PD$#"!9>)1C5_E%!?X%>R>YBM3U'<NSC0@Q\NS!?^-2IM'
MH!>P*M)P@D>.1+8][HT"!RI"GKP $X,E*HJS9_ W]',"IA&G/,+M &'ASKJO
M"9<%Q390^*?ES#V0R<Q^,IY"X1VYT/@2@VC._!=8NF+,9O!L6""LSM34F^O!
MI?H![AZNWWGY^ ;D&RB&[W#%=+*N4#-$3VEL38!.8"Z QK)-I! >#-[-"PQI
MC9&3Z;(/8GJ"[D5,'43UQ$@$D>$II GI6MPZ(+'4"V-FP>T5*A$^^V,&@FLT
M]]4O> ">^ .<+8BA,9B(F@*ONV<SGVLVKCGUVKI=J#O?A4*[2%XN?'K)S'@3
MC-.?N=9$[2;1/&8E&2!K7I279V<R>3UU7G 4F3=_]"S3 G-'BQ*':*/QY2_:
M5M<3Q[7 IHA)[&>XVL;$<T ACN8(94XW&O8$WR;N>GEY.4-UP_7S&>CE,R7^
M !,N,[-QL 2^ "7-#!;N8UC+XH$7^).4.(N"\7'N@;4,$OJ1ZV32%Y56WEHK
M#X3]+#G+=>9/SXDG *PU>:4XY@);1=F1_$D2^7@XA*$"%Q7W!7;J9,XOO-!A
M"NG)&9]Y+:?D<6GP0Y[#*]+R.[QF0GKA"VS+FCI ?JF??WS_(M4S5Q@(%Z=V
M/ZJSN8NP(22"2"T"L:<.<AUI9O\92 >'!]]7GD"(^"S&=RC%&';.8;9(DZN$
M1]GLR8%S\KD&=A[I1.(?!MKP'6*X5%-=YQ56_0K:U2"NEQH<99LXT9 K^9T1
MKT-U"A(!9"F)59S)@L045I/T8KCGH]?)][AFCR[_K<Y_N_)XOAL>_*Q^$ROJ
MQPY! =+$2!H7"#,X$6$8HR$!K$$49_0^NI:>)<>91ZZFU/[1&ZJNO*%*VKVC
MN^.H<V0).! T.#+(#_@&F9Y(0F "XFL5/7%<E?S4VU ;H;YNU-9Q UW&T<01
MS 4<3=/ U !9)F2.J..>]J&/_!ZC':>IW[Y=P&E)O0+$GEIXW>0\PE=5.G'X
M9$4\^<O\E9O9W/)^05,$9#^^F_ZD2L@6,W27 Q=;W"MN-FN2ORS)-4+T6Y2S
ML06Z:6"&++".0L8H^B8,Z/X7:3M-!09UX&E< _*G2AL6J$C218Y3 GZ"C3./
MG!4C6#>L"NX=<MU_K.Y$Z>X&1HEP-,64GFQII<[)>3L91%.:]+@4;LL#B=%W
M<4#T8!Y% 5D[MWVAI?>SP7O8T69PH7HW=:=<Z"WL3GU$%;1Z4[WHIO1<FUH8
MJ23+-+]P!2)_Q#[N8'>G>F1[P&$LOK_>R?ERG] O)(1I'![<#N!66!;Q[)3"
MJ"0'5@5C<8O176&^[!14K/^,VSDUC==3; \[9?;B!K^!'D;HY4OVZ'_'EX$0
MN*3M1!;=J($0&_D.1=)X($UN02SGG%3>C?.3"[FNB%N3IJ0&=W1P81,+3]$6
M%+T9$2H+"O+:<H$Z_<"=N0WY@)0B][<MT7+/'Q00%6URY/[5K4FU$O%)HWYR
MOER!^ NRAQ*R1V"2X&ZGXOA4,[[;1(YIUHKE&!U'+8UB*F^)9T@*VSS):YDB
M3W"F(BU=-.(GPJ(%TH%EX:%T<X)T F][!*,!-99C TMH"DGUR43EG1L4 /&0
MC<!<-:@:!+0"-T]<AOX.VG*>U)]@S2"%+!MK2,+W"+W';92%-'4T.QW)22OQ
MA9(Z7ZH4B]ASS8_Q8+6D%]_](]T&DXT-( (7!7Z"'/QP'WG<&[.9ZCS&H2?&
M.*(1#:1\/QKQP,_3+X39COV!=%I]+$^:,&\Y!A)+AL2#)<&C S\G#)@@QH>/
MYKXS5@+_/364PH4B++Y^"DQ[VJK1/#(73!%>RN3-P!J++>5._)U*4M1[_'M\
M%<#K,WRFV+4S]V&K-MXC18Q$%PM:M,>CZ)K"L4C9-GC$(PPP!")==9*.B3\D
M8<'*0E02S#075(:I"FL2+A-Z%2X\'&^R+>7:_SBN\#]ID<_.!#WFA?VDOI6<
M-Q.-X:@R B>&R#1C=M3=6-A12^ZH#V*%R$C+0B7-?X*[;T@3+"8.DHI5>/R
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M(RP09G.H?%0184,,+U#8Q+.".C-9!+<(\1'A$A&PXSD+T<K_-DZUF?M4"RQ
MN!8I]>BX6#&(3IRC%H@1"P'YE@I/PPG(0!9/%K5C6H9L7@J5!;@K8429HR[P
M>L7@Y=)> KM1VH7QY%UDJ:)!BR>C^'-P9!LW3R6BGTQ5R5!MT"L?$8WQ>EK#
M"]$B8B9>..<@MF@EG$@8FX%7*E;-R6\%VE2WKF/.\5H;" ;^PA)*W7T!"HG*
M"3_K*?0Q[]F:S<)V.ZF;>*H3M0E-THBV!%*[!(MR@,AY\%H03T3S.5ZC1%0(
M#?X$S$8E[T"><F(V;A5 O "K93@6S+11_'#E$V+6O5YL(<B%,,#D4DIFV@?A
MPZPD+QAZ"(,"KPN(M"-!PE!FVDK4 Y>^OK030XLW^JF(O)\:)I-WG'^$-%1N
M22^"5(I,1W%!G^*^I\AV=95LKVK.,]2<UZN:\X2:\UY5<U[5G%<UY\=3<][<
MK.:\<9)SXA@B;GU!#PE]*AP,CDL'%VW,+%1VF\)4Y7UNS 9K%>A]XGU#:+%3
M6IP:75T);;%MSJ<P$G+Z<;=Z%%D5P0YR'A58;?09)7"]PYYL&O-T?P':NAMD
M[N2(R>@3Y=_X],+HGX37([,<09 N&L24B!D!BE#<'8J:AVPZFSBOC&G!N$6>
ME\%THOQ;&!L,(@2+P42,/KU@G#2*J!>FE*0%J(A.>0I,);R9QL!&7FP%6)!D
MAXI A^A@%&M:CFLRL98/6&9$6)H\?XM_P=):;*#G"_G("]3P1.(ASRDS,+@I
M*U *I)@2"],\(6[@*2$0+!<=T^?C;1;8P\H$BDLL'CT.;XJH$WZ524,/Z3BU
M?/P.#1N,C.Q0Y,@.3_TQHV6$8?X?D6D=]?9IK:<.IC2V,T#_O9+;I]LK)(UP
M-X[&\_XGAY)_,/[>&$TE^?LQ4=\NUMWF:U!A$:5SM7,2.X1.67LJA1'T4H8R
M!5I#B/ZY#*&+P"<"TEIVYD<J]+UX7T$JN"Z\(&@E2'X3E>X*,14 "3*<@B?@
M23&>%D#-HLL>E %S_QP%$D=-DJ% C\56*J;,GJF7RZBG"?M. Q41,EW\J"D!
MB(E*("8D6L471X9$YR)QYQ'BKAM[3S3A]2J""-E6R+O19$Q#$=7.L1>\9MY&
M",42C.$6P9$ 48\'/))8('H8"DEM0>@_DG!GZ=-!*E4$;FV&('OX8#] &$P
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M6RIW##Z+#YK-<(J]:F*-&8%Y&Z-G3;I+9!")98 !)NPI;A21S>C(V77R4['
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MV"/+/5>WKF/.P6+UL*M:P_JOPZ, UVO'.-"J7MMVHM5VD,2IE^%"U#;3$:\
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M"AQI,;)0.-S<B]>H$(//^>1>.DKZ%',H,C;U$><D_K1,.7@ZD=+XJ=@?0^K
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MS%=:P[%;E*;OF&-[J&]R)L#]Q#O,V8\"*QB(P_^<8E\5Q2Q!6%HX9/"53)9
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M,(/Q4?>YV<WM(IR)C)_/'(-9D6T?5;[HH+IF?/6(1N-].[X#BQM+VL$>@!O
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MQ5P'>TF(<)0EM-G"=4S[SM*QB-]QE\I<![?.<NZ%BY,A(V]<$BD)-8^" 5^
M%C:[=WPL&^>OO?5U[$U+4#M%:==9@C0MCV_!R$<V!80.(4#"MW MD"S,3+$A
M['EDDZF]<F/<L M\]ABH10#5H22SLD%S 39:)6I.1>2;IZ;3B^7G,OMVGL#C
MJ8D4= ?^9T!%])Q$#E'22Y%Y+/5[4#0\@A>A-HV9#I(F0>L3):FT+V<R68"7
M1?@)28<WV*)!^B2]1?2:0V2$+H=&X'&"Y.G^Q->0I07\_@.[=?D#.@&VPIF#
M^5.N,6#]RZAH$ XR2G6BK9PH$N6D;Y?J/5B.<*J2?0-[6E5>NZ7R"Q9K'PR3
M@V%2QC )#W-G((%PP;X;WF@<,TY6FB6M&DT1-<<449[$%.%AD'6W:4O9Q!XI
M:XS\FXYXVO9 G8!?X#>,LL;8 ").0;\Z]\PV)UA]A'7?S*O=EE!*VA)JW;:$
M@G5Q:'?+)#M]X7T@)*(0$RA&B& YJ6\D5P-BG%^CI3BN"0<3DTT9,M\206-X
M"C'CAG>Y3X7%D5XA!N@BJX?7ZD>GF;L:G3A*DY+LPQ&G*DT(CV'A6@R321!8
M?LB0UQE#1>5QP(QJ"4EY3>]0I A/.65N(0FS;^-;SXSWYEM?V$SM=%;L6Q'[
M1HMDR]N^H5=D=DTG4$E]B&I!MX/$A3=QYF'.(GAQ<#CS#$PJ3C.,N'"!!X$?
MN+R[/GV.=)MT"*\Z!#4!R@MK);_9X(ZB.@;C19@7QS=PU3!\^4=S[GAP&2$#
M"*AN26KI)M0\%Z9^;Z-KPV^&RYE^CX>=2ML\K,7A/@_\@]H?R'!YHUQ2\!)K
M1I.:4>S="S<?%%Z!D9FB8"K#@%0)$0@B]!VNK%UV!P\B57W'BD2.^Q5J4H+Z
MUU/;B%ET&T5%QT<GG59?AF0G#]Z[XI5$:B-F1HI ?K4XOHIQ?-5(IH 4>0:(
M'\OPK]H@KUX9-6I*-=TY"$&0/*-9J8]WJ'V@7VRD:+(/Y/KE$]$OJC1)U$K2
MI2WTBI T05&^@AC8'.X$:PD2&]YD.?!=TFK=MLB,W&)']!)ICS33BTIPA5JA
MH,/X@^-^*-I=W,=B WD)"QYO!*C!9IY0?0:W%17UP.G&747H684H13<DD96?
M_ 39B(.1KN:->W,.KQ,(/046\ &(+5>4KA5R2J7HJN71-7FF0G40G\M19#\5
M<!-*[:>3*R=<MV&IJ&F#:6CP4[9.MU&E&&7U)Q-."PQ<5=!T,<,B;/DLHKW,
MNQSEI>0H+_I!';HK:E*-I#\>,\*(C>XK,5"'\ 5P\M)/R^1F6Z2"J)TA&\7!
MY<;=P?A9/UW<@U\:>P[FJ")UEC2,8W);1&QK 'W82&R[>5=R??HK0WBRDP01
M<S68NK$&*U'T1./SW@<O JH5(UHOCV@UZ:X*=4REA*"?MY\UNDO)L\LDJJN*
MD99;7M$*\?J0WD@27&&Z\PC$6!(H@(\(^0"_';01DJ&-T N,_TPP[BF;Q%=,
MX=NY-O%1^] F+FL3'QW:Q ^38@Z-X5N?%%-_*WBW6BMX9XNMX 7S2;DI4$G6
M2-GSK!%8#0;G%L:3;AV,YJ>;L.-I844^#*!46BA5>8+/S&5-\'/^!24WNQ-/
M[GCYN1WUT7$MXQ%LH<+)"UCAA+F4_,"6$,IG(0 2N$=@G/E+CA,+WYKIW^ Q
M4QWH-]/Q!0L/WP*_: %Q[AC'N:5_(NG,&8*EAL\6KR/H>V.!V+'PI7<"IM*A
MK%!0?\+#N;Q?N154]P35;<]5W:)DJEO4L+I%,"GPHV.S*.P[ A' 8#S\E&QY
MD7T2MC.?!L!<_$Q**Y[S"G: 54:N/J=YALFU9Y=G\&CU'I26WJPZ063)\T$)
MA-Y%AYS#WGX,Z'C%9>[X=GF<_IM Q.7>QP)D;(G?$O\I/A2P4AC-UWW"C@/!
MU5^+OX K*[(4!-(;"_$S)7?5HFVXI;ZZ?1TD56/S;<!5(@A1GZ/NMFCJP63*
M9H@&P9OYEW#JW/D4CK_A+NY#'4 ?N.P>NTQ0"N)_5T*,7XO=4Z:$V311@O((
MP(EOS$\^""&(0\R%%N&]3EZO;G3NCXN-KH^J'Z[!3<59\DG/=( -V.DV9M&K
MH=_YHJV#SV.)Y;P\W6*\*BG-:84"W+H?\'DU[)DJ@SW+CNW(8W!VME/RF[$(
M6J)8:\T4O"*$%6\(7T"MX\E.I3Y.3.ZO)6ZN]$8U&=B-CM3BUY,X%+ /PAJP
MJ?*+ Z#&TG@D](KX'ES%T=>V(_;J*K%7LF(?B'EFA9M(VYZHW43 U</!'S'#
M@HGR5Z2P0A1^A#L'A?:!+8FA(F^+#."8ZKRC/L2>R)4P"D"')L[=G6F9(78-
M O'R<@VZ^N, OA0EI^HS++/$F'8X]XN.ONFK,\:$!<7!3E)5CZL/=)P<O$,W
M(@;I!,^98>I?P2,M#KZ@09#_%=#$>>]II5;,A1 N(1N,) 1OQ@Y7=J>#J4)Q
M:9=@802@^TRGR1:64#RN$D+Z%* Y!<7#&F]1PT&3$,1&!*^Y:24^YT3 N)V%
MJ<040&0254@II#,#$H<@-!$BDKCEL0  4^V4_!:6G3"A^(2#I1H0)68HAV-[
M(HZQ-^HIOBG\0_12RN5[?N@]T2*2$T]D6UQW+<30;TP;[I>Y0]W7TD=Y"X02
M,L5I8#9=TK'\*Q%]&9&\&%F!7IECY8DQ$C2GPQ%)V7DX]IND"S&[8<4S%F"=
MBK%BF(*)432-)[*Z7;F]>4\Y77'7X0LO:4U?:4E(H&A8><%9Y7W$O<[V:N5.
M)H\)"Z='U'OJAJN0%*HDQ(SK(D_44:-2X.DE;M%8HMP$[KC/%Z?J*V 9?@JZ
M%[%IX0T6%6,'HD^7DI+VK\0LB-MU"!S]\0[P8!PW1TKP0*V!!TK<J"S#@HR+
MNP<F0!J,.O_NB&=C(FT"JN1'/B CG@D3TRD"=Y>ARW_,>^1G)ICD/L+:A6-(
MJ&WHEF$%"M([R!62SN2#+A# FD<WPE\I!ILS/M0' >D8SM*#UR ,\IKG<8CG
M!URR;Y([E]2$&>%+ZE?*E@9*5(EMND#V;U"A[;I,]@_>=S*40]:T(FBVN$('
M^WY=!K-$OSOIDXL%NW&^,@)'X!6/YQM,JAAHJ,9SJC"PMV7!#0EBCVCIZ(H1
M$!%4"CGBB;Z<2(VNXUV%7F5DV!4L[(N-\U/G/EHQWE?F.98<<">S^<[12<Z<
M-B51OA#IJB(PD6%A'A'-3!8?=;C8QP6<C-1$:2+% ?&OOC*!DV3Z_*_W.J*J
MQT9]D4X(CG!T)G,,PK3]%ZL>X'K'3Q33).87\0Z*N<OF% 5M"5U/5K<7-#7A
MLM'2A.<$??G\H1Y?'#U?Q$6XK>:BW)($.:*T+N;O9A7$.OR%085BS5**H)M_
M>A(J+-Y+-8PU8VWQ<)3:3R_W0&3D. <]@D3$#&>Z!:(LPQ>AUL^5,3&@[[K0
M38CVY]CW& R[8+=^)B@VZ,OB-AP#G\^_K@AK@A2XMVEG&U:N#)ZXBG"0CTM7
M1""?N$9PD(L-EP2%:"GA*'<A8V%(.!#(.%]:D>$;+]+!(73$L]#F*5Z5XR7+
M<J@G15)\(SL>7)>+^5(8+<) "QGMVH_1GPFIB)>'K6-2E8HXOCY1HWYJ&P1+
MPR?(;F17C%:*69H,P6[Q'A0[5IYEQ[3=#:=]#< -Z_=; XD[_&9=8#J1@D=[
M[G^N)U-F+"SVY>Y38-.'<Y[0#)"AJ:L,ECG'++>[8$EOL^C3$CL:M@EK/%/2
M_T3R6V4D5DWR.]0VD5]%(K_/L^,R\COLT!0@F?SREI([BR/+R7I' @PF;XKQ
MX3>9J2V',D!I&:!V* .4E0&.#V6 AS+ 0QE@ \L >]7* ,&1SJP+GU?:)#KY
MB0=-)LRRYMA<8M_3+8C_]N;Z)/CWQI07ZA@1#/2Y!UHF^*\?U4?3\*?XE/8/
M1Z@D?O+=X/G@[M)$DH!)7/D<"57B&\65/:[T^)$ ^_$QEG%T$E+EI[>^<1)[
M6N:[/ZJ"%I'VPV='L@*_#Y<$&\.J1LINE%^>_)@(_J47+%V==,^Q!</_<0N1
M&Y@'Z\4)Z[:!#'3<=ZI[?_NJT^ZU.MU1J]/OO\ZR1'!U-/HAN16+W?E<:O/L
M^TZGGS#&0SZ=<:/I LQVUZ0^K*1!!J?A0SR7<AFOOR.HND?U LLX,,&"\8>\
M)$NVOB)KH"4Y$,CP#W*92']+1I+_E?/,<>K;%.4+*2@WC8F$I>+B:551S!3.
M#X#E$DI&@G+2F96]3>5M4$[>^D<G%XXGY(T'NN<@:^C%8$47XKZ KZ>IYR"3
M5%)T0]42T@*>/ %;)4X%9&ASP2D1$Z@@.(/\D<JKME)%7,HHLTT%:EA.H(:%
M!*K3+($JVRU93J"HON)I!:JZN(S*B<OXZ(3*(.:4C IOM],H5106_'^^.(U@
MI'+*"_0YUH*!/&UV!3ZY0)5H6BTO4*,V7FW[IZ'&I41N!!["Z61JLH>PIY;#
M+L7 Y:Y%D>K.RD_9DH%R\A/ -=0H06_)1Y.$[YI=_5.T\>RKR-P'SJR*B<L
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MSUW3$J.-$FVY$8I)&JTE@IE( UJ>FM],(YCE%9LPREO[CVGX"V_#S4'$S#X
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MCBA?I1A%DNP5W*DP)RW>>\71US&1]"5L@RC&'@0]E7.GELJ#0B9L$1=M7*%
M@T2W!D-V='0R!'>T(S?9E74[J%!34=<.L#)Q.&KU!Q7'- 5',I>S.&]+7MH0
M$Y;T4Q394S;) 8\KG*FDPMM$Q?7!ER^GH.N[9#9:KT93=D;]K!PGA2 *LB1R
MV)G!4^LF+RG!GP7H"QB/7$6@=MG_&3Y%W+BD<[#W.0"<&R%MED-12OBOBH06
MD2OTZ2STA#;RZ<3O:1WD01;Q[!2)L_7IC'L:G'!AG)UT)+6331QP=IAO3NB2
M2T;015R=JS8=;&8$)YFHX%5YZH.IAV'Q="HB90 7VX4D7GW-YKZ8V;HF9DW1
M%FG<6J$J4.<N/WY=)'!=< L(VGC+XN6AM^#,$ZRCPF$=8YBDJR$F!>VXVJ+?
MI@8RF'?BR0(P<D*)6MX:E *'%'"?!KO3%Q;8H;*"85%+[<;;P 4E"FZ>D%T#
M-%4P.9DANEC%>_'A8CV\!5O1VNKMP@/Q\[PX+&6*$N%%'Z-%*V314KWG$);B
MVUG<S&++1]]0[#?H.2 ,GKD?=H.+-XBVYB1G[I*MSL$"O$T(B(UTW"[%XQ?.
M8\$!!3;(.0?R3+,VZ-#/QA9<C$/_O3"]J1IH+OJS:';FTDJMB<(3AB6A>&"G
MH9*:(5)L!Z]%CW=64C>@@ADO_5?0BT\";<G'U9!2( A?BR>8/ $"*V"AX$IW
M%R&@@9IE=BQ,0'8AQ>^&+0G6#UT!^ PQOFN#O043*&YA\9*1S]@MBG"^]GW4
MINX OTR;C]RB_J1'Q_W&0T\+XYX)3+IHDL94-PA4( R692KZ@+$8N:/L,/R!
M@D&'NKZ<NK[>H:Y/5M?7.=3U'>KZ#G5]#:SK&U:KZQL\W9R$1'>?Y()5LA=L
MBR[F<,!@XM(.P%/B^;(O]*?X8#^;W8.5AS8!!0T(TB4Q7S,^*$% P2BGKNFA
M"7IY)9N_5M1V$G9%F'6*4&GP/;\X)B+>K'J34O1-^4-/D7R75]%\P7@;&YJ+
M >H,_893#TTJ88+CKX7QK@AC68H[#[:GP+?T$D8^_CX&O7IY]69E,V;[*'DD
M,&7X/]>3*3,6%OMR1YV75_H2'H6)KANL?<D*M':D,F^BS[&0U$78U'AQ2;%G
M)8-7G:PD%^-+LC(DEA]$,*LIX\%&0OYXEVX;?<*@2UHIX=9+$O[D)Y_/$&"6
M-4=WP;ZGP"#^VYOKD^#?&V]*6&(HY5B ]TX-_NM'D$?#G^)3VC\<H7WPD^\&
MSR=$\XEN!?OG=L>1L")\(U%OG+I- A+YQDGLF[CBXT>&YQ@?9X$)*/89&35H
M'R9^'[X.%HUEQX3S5=C$E+Q2MEZ1!$XO6+HZR4/S-KS![B3$S @</ORM[Q;B
M$W =B''O.@O;0,X[[CO5O;]]U6GW6IWNJ-7I]U]G>2G$8?B#G$Q:>H.!^/RP
M<E/AMY)/M=@=$.-_Y3QSG/HVJ?^CDY4!^DZW2@:U1"% OWMT,NZTVN,L2GPN
MJ61$D(O/1M0=M7_(\_!6W!E$L9B*%T2X@#O -><\+1G?;P_/BFG(:QX+*O:L
MMMY,L(NIH$Y S:+'+4<<-Y?!)VY-[_<+R^ ZP=M8,ZT6+6TCT1H(T?+,[Z)(
M-(;[X/FZ2Y''L.*4PCY@#R]\:W/KLJH(EM&M,B'M/IN05DANEQ+2X:X*:6<C
M(1T=G?RVIA1ZBX+YE@Q$2=BPV1G&N%<5%NEPS)SBH[3&%?K)RY>%]\>Y<JWD
M9NP0?W1QO\#A:B&<@+10B1=,;T*$"HT1Y8DP:.<2@5QF+X8"MJY:3%E7G)!;
M+4:)Y+75]T;! D8E*&#<L;*J"K-DJM<C#;2RE3/C9VUI&'2P,',($BHI:E2*
MUU%Y!2NI8A4V 6_7%5<E4FK.(^,YM754K5#WC(C(.)E1=$&%%:,\,?C1Y*,Q
M3;91]>B@N\;PT,852JBVL^3>"LM$WL6&%=H<U)I?[[I85]C;MHMU4[M4/77N
M6(O9K:G'6JGWJE[JR\1W8I?^JIYI967A4X):\4*KU?#,86-6$/J/POWP_2!B
M'Z#[BFIL<:^"E<I[41-HN2&&>W ;8S.O'P$.RYI'^  $PO%5O04B[.+O2;^>
M6O],&5#6#:/[ @/XC7(S30YB#C#>S50Q%'Z6G!C+?V%Z,?J%]5$"RY#"%O1+
MT0TAH#7'B7@\Y@ZB!X9DC3(142&,3N4#5L0[N!X0L_J..BZPZUAT?$?? $=A
M[GC8YIQ)C40+%]C 2GP^KEA-\*!,E0W#'(;'NX9B:0E.P%:RR"))SB#+(]X2
M38_0HW*@B)(T8T+V)2RTX(BE5*73S;KQ<:J&BTPP^HU4W$4'H1)LE59"GI;O
M/.JNX072RD=#^Q'V=*J9:6.!)!/5\?QCW]47<%'!$ST?&]>5J,5)&(@Z0C_'
M^Q0B6T(NGJW5V)IC3=[:&]I#P7/RO-5!_^A$WF,5M%>AP:FU>MU!JSWJX%8E
MQ%<"U -O,2?93LDA77,T6R%4!L)?\40*A) !',MR'CT.F-UM_X#C01'P@#"X
M"9Y2_/'.6;C$;VJPBTN0D@@$Q7SNEH!\%4^(M1G+(DAQ9YWJ5%^9#Z\U_M-<
MM_Y-!IDTYK0J99W63KM"O+J"OS8X.NEUVZU11S+<%%319^>!FZFAQUK&&>VT
M*P1"*VQNN'IS01RF4[1_J;Q'*AFG*6N+]Q^9]1 UQL?MAVXL/*#(#0@[5NP6
MHO^+0QR97?$L?_1Q\,-H:(3<KDB6YBETP\!];TA/>RLLZZ.JA:GI;B0T%0*3
M%81FM$)HT-S'#C%3((:0YT8UG2**D]-JMFZGE1K*2N]TS/O[9$BV2G!#!>Y)
M$<?^60[YL'UTTLWC5U"?' @=;_=#6'5B"Z]UE?0*AMTSF_IV2KYO%[0"! V'
M&QR$"O',E*.\B3L\Q&:C7K<U:$NZYDQ^$%)@(&_44RE)06T%9<9AA$NX#0II
M*IPRL-+[ 5:MHU*%@&=NW.#4-C:$%!UV\JFV!UU1-4R#K0L;I9J^J1I('':/
M3CJC8:NC91LR"VG+2K=;Y=7WCDX&O4&KTQW4VTXJ;03-4PNIJS*PC<(I)-2^
M&/G*(8H;@K!]IZ^" ;>2S FC>H.I@ &%K_A;WXN5;3P5<(@9>=E00*$S]P3O
M)B^Z!]<Z3EVRK+V+YW7ZP<56$<%F#6Y-2,&UN#71-]\O7&?.U(^^\2;LEPP_
M7=$2&3TA%X0&W1V/MV[=FG8P $L/0!/1))HRW?*G/%#C3AE&2ARTM423)(Y0
MLYT'B@^:GK=@;Y1T4>BJ/>=!Q42_V0@OIM.ND$4K4_TP1(=;:W7;6;V[$BZ&
M0EE @V/R#97-T"\Z6>B5XC0.H%>B7ZPC:84$7UW8)4-P_3M:2QM*@-U)V)5'
MPG<7UHCN%88J*>[JQ_B5AU:B;"E_7$3P*R0,:[ _P,O6QJU15^*TK3>>.NT*
MJ<,:%C]&E[/5D4U)R#.6%)FQE)\QCD=3YG="$%>:4C&1R3BJL39/)>U_J8'_
M)?.Z,!ZVAA5:A;CE5K*XH_;12;\U&FOE)*N"\MK.=L +[[1;6C>+I)HTU/?5
MDO0$S,8<=*@/_!*S?J\=BPJ.O;TS+;5!X!Q5,BVSY]E+/# DJ(3D2<LRE_01
MFH?XQBJ\C> AN;9ED%2B+%E,*1)Z M,]DXX/(6->N0LX.<[<19O3UC&%Z@6+
MBG &E6">^8J=YD(/!K_!J/H]?/V>0!/BEN4:O5BE]AL-+69X'^ R0<OR*V\)
M,Z0*X_YVGE08'5 8O4YKW)5<3V=D@D_5*RQ85E_]?';U6GV5\*?78&$]W;XR
MBA #+@.MU1MD]_4ZSW8.,SLB\\_'V84F6A1=V!1-+B;@RF8R1A9 ^/5UU*Y2
MG%V)VCW$&QNVQNWN>GBY8J![&>LU$RLJ;KUJE3(F50W 41^]BTZKUY'$_NI
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MYR?0/,M/N@_GS%]NAI46L*W$HY-,ZY)U+5'N=POX,1.3%D1-+O;LQ9H)O7#
MKRPEE#?@]X$/^*5ZNZAGYVGAU3*>9 [*6D76-11M;7V<+HV?(L4K^U-ND34'
ML>V49+\>P+8GP50;C23(7[GDA'/>6X$@MCFPW'K";X;25OAY97#<*N1Y5BJ%
MP%.]6+#/\+(;:KSZ1'U7Q:[1'M@ G7ZKT\L: 9MR:QT,7%UX:'(QZZ&XW&"
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MSJ3?T[&?S7D2ED92<E.4IO6(34D6S2O;0>&!)6N\45>*3E9:<N8!12-](JA
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M,]/)</3Y^O!VYF"_H*C>K@C"EH_V2X_.16P^V',O/:SW/+*PY0/^TB-T.W#
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M_<S.)"6NLR=&HNXRDPH?D*?,MWH%<5AIGL$?J?;LK%8/;W;&^P)02P,$%
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M#^4'47[/[R_2O%>V$<#S=3Q-H_*;OL9GKUX/_3=]?6Y1?'YE?1F5?<5%M:T
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M<+!%'U?(Y,]]7(Z"U4*%BR#-]+F* %)X*D$+FZB!L5T@!F66Z43JPL2PO!4
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M]G4V/P*XWA^L7 @EOMI]2*MNPO]@.T&++/>36O^6:Z&>3-6*+@.V*2O7*<V
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MZT"\V5^8,EBNR$&E[%-.9VJ L9;SLI9E:C75.NXX;O#PF']O*G\YKM\]VY^
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MOI(RV<"7386_4I*,;([S=0*'11R\-<]TS DQC9-";"$$R4*WN<ZE)&\$T7"
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M+4]??SC\@P[.KV?OWK[Z?U!+ P04    " #@BGE8ZG1-?LO>  !Y P$ #0
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MJ!J[,MNH%'%-"\.Y(63MYFQ:ZU_44.A]=V[^V27\0;.EK[QQP6MX02DLL9R
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MJ;>+MLKB#[;Q3"(DN[EC?.4HXRBI1Y7N5T Q+*!R$^B/@?1JAB>:--Y(RO1
MPNJ^'(HXAOI!9A"J"FY):CQQ\]W&O8!EC=[2P" =]^[(YF<6SE+&._0\X"<,
M>$03,G\K2ZTJI&R+K#,%.C$VR12"=IS,["J5\79373C"[_8DY84@%W<E_P5W
MXX]18>P/F[\]&G.@%F1UAZR*C948O>Q5IYDFJ#8JNPQ]WQS8^U99]B;2[T-0
M0S&L\P\WH_F ZQ"?3^JY2H-KW+QD7R,=IW%9YV0Y2-&:TV)HG:WN@$?MZKW%
MJ#R%YS[GG$X!UQV.<F5DZ9RTGAZIM4U4\ [/<UDH0J0UH2W==4BJ]1\Q1P?N
MC:F]"[8LN:709??=(%BAU*MH0J'.2(>@-,:5V>^C6\_YG7''P^![IMGXQ9XH
MF_+$FN1R>68* */+4;<Q3!'$/EDH%0FER:WBTG/,@1<4# >@+?(CUFL@V@=#
M[3TX7D=RQFM=4^WV]XT\?6X;AKY!$ZSQ4(HN,FGR[TI*5%;<\SW$O2?L0:\"
MT$;6I.+[B+!C#!TJZBN-.D&NW[,J[3*IK&-<GD':/T7XXPI(WRJC*MU=+ (K
M#1M4D3'A0;MEWO7F<UVQ)4F9@^ZF:['8P>W4Z+@"U%,GAC%MMB&S]OV*>T"1
MG;OBW!"VYN9&_G9@C=O*HM:F4:1A68CT(_>1N]E:KR(UA'R4+9N /)J4!9;@
MZ!(RJ"JVX 9H+\= 3[QW!G N'<4$P4B59K=W?C !<HGV^-JL*'EJR;M[V>W*
MM7>>&7(2<3R4T3R:UA?:T@"QV^T"XY*PSX6R^+)4PBU_DR+Z1IO;U9HQMO-3
M=>DU:7BT4RW09>^=D5MNVP(>8HI/$3S4=AGZ3B.-U3.OFR)JO>\.4FC"U]T-
M6VJ8KZD_U&8VC21$[,L3< GE\ W$'8$ ]7X9FX+U@H2^56S?J=T/<1M#\T-P
MD3BI=5'TL 4\\7XDG,M \<_%%8;&-(2PI]T7089E%*%25UWQ&J/%#IW4'Y;>
M_EX>VF45RW!7RS".8<_0+>@M^)$W%<HU-#A1+#-L4%1N.(0?B!DN<D?_Z8X4
MI]IC^DMBG*?.4'\2N?R?9C'!O)N/_)A!'XMBAXH%BV7+O3ZNSZ>07#_"$N%M
ML$%, K@6#L184GU3D!8U@>6#(Q2HN%\8HIC8[O*=L&94+=L4ALP.@'OGRJQ5
M5K47E93TD O+'US/_D8;89Y#_OZ\B2:9IY-EX!*.$0[8V60J3#ZE'<>%/ 42
M7+I*+8HS36VG@KYY3G\+EBUUS+:AK\EX&LS>31$JQ7 A"@V"50004W9JN<R*
M9PLU"O:XS-Q+Q8W.M^X""J']"FXM!T3SK%)?[3(,G:?$O*ZV0Q!A"5/IM\(<
M,>5];!^50"2=V7B+>X#3<MSXX0X5P-0HA0U>'-A=G[8=(0D9M)%K;<O-X65=
M/[_"J FVM&_E5 Y29 ;S?,!**R^@2H*F&8I.(QV%$KXB^<F680Y-DUH'OOU=
M0<2V)Z(];V8;D[9WN6QAA<N3546#2U^?7\T/ #:'EOFID7^@_':I.G^T?3 B
M2HI1(XF0DP@?*.\&ZK9S6XFKZ7QKH"KO\I*I-UNWNC^*^M"XNK]2WO3QPN5C
M.6.:6>->@._^588QX$R^Y#JTJ/BE:!O3&*[;JBPT7*HQS9[:;;^:XC&M&F[7
M0W7'Q:K'"AZ$Q_SZ0<QS\)N;&$N2LL\,?&UPVKD[;/7^_2B)[C 2>^2C=Q\C
M0_C6,[Y?^QIID&7F>U^F)-5'.L>=:9T;:@*WU8J:BTEY<V\OBG/]+7WWO%VI
MHA8^\;5<(?F]1Q)AEG#K_'1E(F$-4)AZLNY0JL.#<\@S/P71*?%%2A5.C<P9
M$SKO8+7K!F_4I.[U*!GK.2D5@%/'SN;=RMV@J&N&1F6=:Z4M9$Q KFB27,'B
M;.Q6)='V:X>^*P/^W:E7#?7.&2AD@6J&>MPCW--IZ4P+H2'POB*4'[JK.U\W
M7O?UWLHOP;4^NLI8WR[\#T,AK4-GUQ[$ GG=F6>!'*)2:\J6")$-7^Y'\J8&
M;6OASTV1I1Y]NAQ6O62D&04O_OGHQ=G%RP1QT0-_6L?7B'U=.2)4P#FPX-#"
M(7EQ" R];AKEJXI>%@,B TEC>+&KQ4[4^^BZ=P%[=4#V\L;!UM:NI85._MR\
MLC*Q?OQ9%-]5B;ZSO,LZ9IZ1:4XE,FE."_6/QL38LZZ&CNJI<=9?= !E2 ;6
M/P<>4);&'C>J, +)Q76O(H!N1X'9H;8831KBZ8FG'>C!T-'O!9;WQ!!GXR]=
MTUFT.?_T=\"XL91\/5W_39.3Z"]3'O(%70]J9Y=P7G*>MTWWIKU]M95V4L#)
MJ1H+L(@Y(LH^7"#:;F,ZT[\FUO04#0+^V&DP#"ZYVRN6$N#9A%"R$D14&D\3
M3,$FX8K3 ?;G'0O:<:Z\YX=*94N$YQ#1L_ZS^9+B?758-I07)'F9)\=TUL"[
M"OD[4-:(2"#!MR!DXQDEI'KE320W=0;+/9R.E/&M + V$3DNK;1LN/^-S;F,
M@F?#'J$JV*-.X[=WYC!9J-M8-D3J%C**_+Q7'M&^8@YX[<L#P?,OL2TK?R#Y
M#.ZK]LH@]7)N&BK/A3O5!_UXQ]# :3V?Q#IF3T8T\FPV2T=7M3:'=$$*7%"#
M*ZG1EEEEE>MP7H/0JO7HMH-/=;7K^>[GYY1;#RQL9SPZVV="MNN?OG!U+2X&
M5!H\>_*O.3?D1W%^,M&O:4?Q]4JM+Q9O'C(^6'2]ZW610&/2Q]GP;?Y-09WO
M0,# PKL%/[X/+A^(FEV6F37:=&VK(3'=$=<(C!Q4&I#*K'P\]WIM:#)?]D9X
MF9:%A,5//O^9,K,K_)7Y5VH/WA^>5ILS&?Y7:FMLJF2[_6([&%<A8*^\J5%Y
M(%;70\#8)< IHZL^#[$3H[?K>_%*>XB"[5I#S2=$O=:IG!J]X$P])Z1^XT]Z
MP3X_XHCA23C#BF;\F3@!WEP6IW[+HVFS0&:S9ZD!Z^[G@$C503MJTFQ/#SY7
M9SY.@"9 +!=*XPJ\V9V]^)V#V#G-5GM9$_L[,$8W <)BR)A%"Y(.H;H-FR3)
MTP74[,LB; BV )JTS1W0GC]"88%X-]L[),]0(].VE91W#Z"$.#O>_A#)DKJA
M(GKGSKN >2%MZZ7+8,HJD$X[@0AE'!J(D]L9$XFWT[XOPSCZ4B.B#*#2HHFT
MFW!CV1R9I7=Z-S\82;P>??MP^L^"5(Z6(LP@+$5OJ'3/JHDR(;S1Y99?I)R^
M$& H-1L25#1!"!N+)"UY2;QYC7W^MN%SZ?:UWTT75'RR8[S$,YQF@T]1[EC)
M5D8S0K?XB/9UB15?O.30_39[G]@EDI[<S<[4$^X"7#K-KCP)#;9;'Z@HMVJM
M&0_G?,:()3'!7*;@9"K-9,'E-"TOKN4!+G78?B_?]X\AV[TU'8=V#G!Z&2:A
M3HE+=[9.[W2E34: #2X%5:6'^BI"+;">U?S@LN,"_%H-.4[$,2=#-TL%@0=_
M A;&0&-DU*%MO8O( %H&Y@*]#W*B5D-XRM]4*GYPY4C1RLV:U#+-S'P)U-'3
M ;-5%BC9$7HJ8AM=-)P6 ?^-X0'8ES&N4W\8ZB28HXE%:GW=O=-:7%*..4;7
M6M/[V;82L]^Y.QN=&@M2J&A2:FJ!YKHC+8!'-0%F^  X#S*H)I#WBZ.[$,9N
MYE"FKJP,D^KV/7Q1?PY'1$8H3:[KT/]T77XG=2*8?*JE/NER0]B-N=U,%PF5
M);O9""Z3^2O3TV:3RML-GYZC3:?*\\W*I\-G\@KO?+5QEGZD7,;!]^H;Z=Y0
M#R/]#/G]<2\CH>+0H.OS)ZU*7.SO_3S5D%AFDQ1QO-*5RQSO9JQTNWK>:6,*
MY^"$F.!0X%((,PQ+Z2R.WU%JX8T?0<AF66;4V)2X.#\)M-U['3!-]*A4_3!)
MM"\S/>EX%,:;G'\\(V JZUREDET@;LM_^$+:^<8NJ-ZER&'L=TLF"+500CMZ
MR-R-:9NOZN:142R0],HJ^T'J"@]T-P!HZ$[K[BX^(# _MZ .;OK@FDI9H%?#
MS/5?<LSJYKLO+YG<O?QYB7$0J[@-7\"\+.6DA:!9H(!8%#%.'-!O"("##4\#
M&H.27#.&^FVOX5Q(K?J 4FC'9&,;U_V-.;_*MJSMZT6NNN\%?5[L*QR)#Z,Z
MNOSL2X(<,51 6E-74KMA)+P%89F7RE6RBTY&7B;WB?_E 6)(7'#7[C>?"DF7
M(VL^++D"&!M_0?VF*B6=1_XOGO8]W[] ]OA$R]33S4@000_Z:C8+>RIZ4Z-*
MS.S3<2.%MS9'DW0]-JT''>HRRI/QB4FB&K;5=6:PHMR ZKWW' Z]8JG/=.NU
MC0RE:Y++"F>8(XE^HUINS4\(7#!>%T2M<(:6J.ZIA5'A]7D\+#^G3,1XJ+5:
MAZXS.!$/;X:D,%1ID>3M> /3.K\]4S32G@HGF3P*HB[Z%9/8^H8@*>Z\,ZH&
MMC4NRXBA\1">QH$2H9O-%L6NZ?X.>Y;:%\LZ,D;TWANM"V&IEMO)!7%RZ $Z
M\P* IQYHJJ:[Z! L#L])AN440][_*<.WO9<:5TXN;(,_.#=ZWG V-E;V<?@!
M]X3-\SDE'^;<5,7S/N<Q(O23_<\!5/IB!!:C?(;:F*[5R $<=2Z='HYN3,RY
M08,2/N@[3!F]_-E1-!X?8J!1?9 F^Y!09RKSLJ/U424_(411PXRL>I2!F$:J
M5@ OB*5B0$_0Z@?Y\$(DE&P9!Q&")K>F[/J=ZYJ4>]MF\<Y[^D=K=X?V=_\=
M_RG7\J,AXE;-PN6-J<R!<0]Q94X<T3RW1F^J#+WW28H]:U#7;NP9_$:YJ(!B
MOZ=Z\ 6\>R4GS* G2Y$KO4S$\UEN7-//B=0+HK/J3O4K_1L1 3$G/-5#QZCO
MDN&)$34^CW\^GL\_5W(J>^#63'DRP7:0%&6GZ W4<T7G4A$,H[*].NH+>B#
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M/8I<3M<0*@9>.9VC-DX_,;XUT9FS%<\4!3$-,$FD(44;I3&$:*G/. QF,45
M+RH7F@=QS4FZ(8/# %'=A4-3#PBWD9I2/1\K=PXW43HO$"^7]%#?G:OLU^"*
M[T4%C2%/T5>S<UQ3=[V:P(G!7:'BZ;=K3V8[(3+M,B]^*GY<8!)_N,ND.=(\
M5?BLYJ*#C)='&=?U_1]U[2.;,#'5=1&5N3,$ ?S!F2"7Z%NA:#XWTMAQT@]/
M_]:B 4LQ#0<[[R&)WB=91M%/DI[PR=A:;Z_$</J,ZEDU$C$>G6UULNUVUV]R
M/'CUHM;/]<+3(V?"W<O?"B3O*K>_4]__#6NVOWBJJQK9_4A/-X-?U!CTB<S+
M/O,&:QGVX<R;DI5%R%PK"6N/B$F:ZB%^OX1]3BFP+HS'=EK68B.M!R$IW==\
M9'P^[C/(JM*6/O14<GQ1+6-E@X\%[&33=>)W4&V9'LG,"BI"A?A-PU\2:";F
MZU#O,)BY*'I&_C6I'_& !<AHB;* +VKL336#?[_(%$&WMHWS;BHA EB S3/?
M[^BAH/,M\\<W#;?/\#)4X;$N.^^COX:0WAV?X16==3[PO6EKA3&[F3^ %T?*
MU@R4F]094#@;YL]LS%K45=42ZFCGPOR#0_PU.A(<G<8<.V_TCC@YMG6K+YWO
M6&R;^V%R7(.][E[<.&F+#_Z0#)X&@UG 8X_U8>4-TYL@=XWJA_8P^H 4Y[8'
M];JQVO6&EQ%Z4B)[9X[4"OA82XEU&E90\[)&4N^B!][C/LWJ=/A>[#Z..7!3
M,/O9+;M'4/7<)]^MDHY,E( CGFYM'N)/<\VTRTW;% RKM(3:J&@>*4\X&=Z%
MT51=P$W"1PB,HX0P^+(A2@!-X:0L,$]G,X7@];B-PX0]!%H8;8T%'"1Y,TQ5
MV*Q\]A:,!?!J0YA7M6%4DU+"ANH[-./8=SACY%^8M(?=KIHDLX >,0P+('9Q
MLH!G!DR9FI,L(&M3GGUEWTT6T-E"Z_G=T5-+UY@;3/^M=A;04 AJL*'84K28
M^U%2+."K.(QBS1!GWZ9(2V.3 HP7O<@#H:N_]][B>\8"&'KCZ/6'__^ 6^V]
MTX2/WOW@OC^,[@!J\U7MZ(Y6[SJ^\"DDV'9UXA_SR=T#'4[FS*ZJ0."Y&0H1
M5WX<3%#(HJE&]EZY:6R1E:H@_/&$B< #&;-]7_UM+'<+Q:-S=SG9AP<IAI70
M_?-MLW*W2D/=5<KW]E].O2)1+F)MG-.'K##5+"J&3-U,MVB\.HO7;Y.=.RX:
MQ"@\W)&8D.T<[L*U%=3^W,*GQJS+>/@<6@@B^C4.>1ULT,IO:<)%9W-$G-/S
M*:8%SLZ3*K4U)J&_&T6HEB!'0':[U-5ES(Y/-K07%BRH?']?746#/M#H[&RL
M/-&JW]G8?</9(3;:[GO&+=EO2:.?DZ^YX_X:LH*&$/E%!E2$*S*%\_IW&NBH
M>:#5150FCP9ZZG.J9^SY8OKI[H4-!9D??;?I:(.+LP*Q351;J9O[K[QP5N5_
MN:C49L8E$--T[;+$QDQ-:.,1K5(?+]<>AGI@"3H$K:OWF8 GI*/OL@#::R8/
MND<(-&4!#R&1A/5=&- :O8LP%<.08P>;ETAFA#G]-9R3+"!:I8L%3.%;V1,0
MGZ.7?/ZEB8W^N@UYP82Y!6;L7"8+X-9)80%:$*)1FL@::2F[,W9S=IVTIOJ/
M2<'N2L)M:1[,*%R#-^,@0Y\%?%1'-_9^(RR?N\Y&L<1FQN_[_PV ,6S ,<QO
M[)[I'[?'SZ5XU[/^YV[L90/,:2=,Q;'U*&5R!POH.,0"^)W8G-H3PA99E$@U
MMA438#-]N01'1']A 9-F2 @=X'VV_Q181'T9%+!S?$/213)F$?(W!AA5[B:J
M/DP8<BLQI:$IGJNK)4Y&+MZJH>IBA]X],FF]E:IX?JCC#5_WG47'BT_"[>2?
M?/O-*5H=_8]0[_Z&2@Q$\?+.R=:#,YCA"45?I0G. \>OS#DKG^O>N1+:F*^9
MGC/^-<'RW7P'-%*G2TM@)8H^9F$:XK#-(.EKX-/R^F^@GD ZL[KLQ=MB-X?1
MN'Z'N[&)3'&]SRP 3WC&+%]Q(>+B8;N+47N-:)P3E>&,P-<(@S-@8C#=MAYU
M&'1Z#0:U-%9[1VG420V?I@L_>3/-E.?*F4F%8K'V9P8KT:Z/-B^\/T,ST+NK
MBYG%_0/-]?["6*K,_<Z_,Q91?</H:V#=WLO''0^\L-K JT2<Y(JJIPM+[(EM
MN'X,3_I\[<[GF, 0([,<Z:A&JP"LI4"N<XZ\F7'SI:DV:-2(><(UCVMWD,'$
M 6%%CNCVDF>.WEP3)562MSE%\[>N<\4V#'2X-1>)M?-$%+@.9&L/$'L*]I8\
M55;]KDI)F2^EU5 RPQG2.:[,[6#V#1; Z0U588-\3:O#8/Q\QF$B;FC!LLWV
MW?-,K<^YX2^&YE>CA3X9JRRG<3WL+\H*;9V(.,*=:(#>#+(;F8$>\LD"*RUI
MHPMS333?\8KP\7BT59^WWB&7">_PC4</"L80"2S@M,CB-#N],>YK]J8]47:G
M_!^K\IM$6=UN8F80*#9(<=B2(8J?G60<E#'RZH313R*RZV8HP!^R\ZR$BTAN
MG]/&/4V)==QAQ0<7<KBO5KU"WU?V^G)1D]_K]C0^^XC#M:\4OK7=*; 5.$V5
MM3.E"CF>4TP4N)".OFHT=WU</D:0]AEY@%>@RI<GHJ'AH8(%D88Z&J=SI\Q'
MVU//1?2[9?@%O[=5F:]?\^>]7<R.J ^^J.Q>A7YCR_2T6MT$?:_2W5D -3XR
M J_C7C@Q2>\G[*\]3NV.%M]7^A(!-9="W!XFKL73O"^FF2</]4X:;Y[@@6XZ
MA.AU9T5\*E86EA>YLZH+GW]""VY"\\!<\VMO4G&QXOO20N3G"!1TY)#1PY5,
M3@1LXG8-A1 QE!GCK7'RV<(REX0JS^@7-RWQAPK!/"MS:\D;DA7W"$,!& ]^
MVV5VC=Q;.DXR!RT)>]"T4-I"'Q/YDX7L:*[7F4J5#;?5,.!+AGYS$ MHQP11
M&A'I'S1"GN;3SJ$C<>>T]QYK-(JF^;]NX4JY5G#MB$5,46+UI03LF0P>VWBQ
MP4?"1T]<26VERDY=90C0H8G%A8CHAJK7HM'?_6>NNC3H)(F?:+KU3/SS1</
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MC?)^8@%'WX>P2YLE^KTW"\AY^XGCPA^3[CTWA8I<M^S5,EB&M=W77H@=@Y:
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MZI9H&;") S>J60 N#;,EN<*!@,\[T#$66YG0[<AK("EG*M4[6D,U4DJJ7\_
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M"&WI/$Q-:.:)$,Y)U>G^6;H[,ZPN^C/OF:Z>JKCC:AL:4,?_B3N"(;<K&3<
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M="8+Y/)=F0\BUJ,WI@5F+1X:RP=]6QCCK>-Y!WYF&F%_N4\^ %O;J!58+*+
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M7FE?-H(!!?NA&UUL\VFMC2G8MKA*4K%P&T?Z"L\Z4QUHC'RZ>+EBY.-&\X<
MM0W5P&/1=UX2XZ9&GT[];G,WDQAKQ+[UF?J)N8 (=)@T5 5,33NF>X\L+R&P
MI,C45C@8L6T[9WABG7\]!PAS+T4L*ZX< RK7G$OX[+&PAQ;R\1_'GKFVLD#Q
MF0L=6;V\B"KX*02.L RA8HDA67 >PS,((8+>S U$##$:1K34L'XVV>I?;XVO
MCZCYD:I"ZIJ%.+?&!+XH"XT(X;QW[4\%+43MZ5EYP)D I.62+L+X4\;N=:GT
MM51B!J5K2&HJ!>U#"J?56OVM,\[^T6B3$;JK#G&R29S%]4_7;953V/D]UAUJ
MK)[<[;P^K=NX&V5?5^!1*3\F4E@[!GX00=-];^PRJP!3)TS7-[]ZNU>?!RMN
M@Z>B6K^E4[WZ44)MT$4,);:/H001!<H)AD+4&J"$=FS%_0N3IZ4I*)#XW1W+
M6Z^^CEV<IWZ9"U7B_NEH?5.WT(&/"Y:$:HW<XH]M ++T5S LD)BJ%YJ$)KHN
M>'4!.$IZ"KFGB<K=$^D5)6J);ZZ<S9NQ=EMT.\.W]-XDY^KZ.45N"#T92"6%
MB&Y@N;O5J;^^P4DK _!D=TDJ-+ET8\KUI&I;3*/.8.FE><-A?<VYSTZT9'R<
MP.TQK;;,FF-EMFZ8 <@O80-K%N@VELP",>NPO(YSMB-4>\!7(./U/4X<.(TX
MQI^&2RXUSB%MWE*+"+NN>8\A8 Q33)R-UA4-]T[),XMQ=B Z9*R-";#1\L*^
M#H.)3DK<SH//EQ5/QN,2!NR)TV2#G[Q&ZL.3HZ&VKYMFGNRD7GZ+?^R YS3P
M.#%E=]<.=V(Y^-X2I'5E2^GWB2T!VHQ7$]!!F5[PK>I"2/OB5?].OXF7/_@!
MJ:YLK/NG->'Y&,T"S>3(S3&?PQW#* 7\H3)]'Y^2)?A8H**$2Y/(%DQ!R8O2
M_Q,]^O;:4>D'K\0?7C0X I2RUY#_BZ?"_N6I8-_ _]6SH-Q-_UVW-CI*.3]*
MD;E7H3;ZA#=/^K;DB:^("NZDPJ,U$:#FXVRYDDD%%T%TZ;#%?]UVA7FU$,H"
MZ24<ZD=+*$6*+'&?!<I(N#0?VT?RO5GZ >OSM^+W&LJ_;]&UXW!5W[) 'UQH
MVY*,S6X6J-08D73TR8,1VWAV:=ZL$U^CQ",^)3V\+<0"/>(V_LP"G2C4P1Z8
M=S^@Z?"YC*5TIAW.>N1RZ=ZAF*4T8*/HL$',H@8=W4S%O(Q)AV'Z1/$J6K D
MO21ZC58C$2*V-%:S(D?$IG9%NV_P$?%U[N[*27F5V6[O161=]?5=;Y$Y$-;(
M8J9H"#W/X'#%C9$1$'AZW"6Y'=$M.^ IBIQQ4 K]B@F XX9@:;,4^[6/O[B-
M#=@N6DB-R,BEOLZY-])<J&^J_<9+(,H[>TH]P[-M\CQ1YM#8[[;T2I//^VA)
M29Z=H$!JO57S+](CA7%*.>>?E)075T:9V^26M.56RAU^^+?M/Q/W;"-6?V=]
M6)/;Y/(QR41QS.M0=]S_*NQAA\*^?(0%<N[,8::I'%9K,.'27TV"X;!_WU'1
M)JQ8(/3.TW^5>YYYNU#CW;NMO-ZN_R;R[QYNP>*#2M07,E,/15JD';H(5;]_
MQ7K_%0LD?"G?/WK&]>-%"%/D0@0+U/WG_YREX3]GR0)][J=#!L&+.O245FI!
M?_%A+5=$MQJT(*#E#QL:2PP;6C??R@?5M(@4P0WZM;:VF+J\>-U5?JN),TE\
M:DL"=E&^_['E!/YSRSGW\4$_7@>$8R!HG046:*#/E042_2[ZO=D-+55Z\^1A
M%6\SVPKKQF1'?;ZV(.=X,S_GFRVJ9WBPH>ZK9YS+SK#9W5G^JXRVUF1QIN)&
MH<5:5FS)93FE KDG)67%QNYA3RIE9_]J_-Q[4BD?@_YW'9_XB8O][.SLXJM[
MXN&&,VT;+- _O=1?'0ADWR?[>5Q<@0'V$-&'1LFI,^UG!R-7Y-M!W\>[__XM
M("S0)@L$)<W0G_XWNKCR7Y=^"[4G3I^A%S<NAM'S70.3(:V^PS>N\CUT)*]@
M$GZ3\CPA=?/5F>]@+_=W^Y>9DZA6V1Q:S.!B7 YMDV)2X'$<0R5?NQ.^G6:H
MW=R2;#&1%,?>]R);WS4H0-<K^QM]@_Q][=%16&3HI=>5GXI,0U(:6"#*U":S
MY],ARP6Y[^Z;'<(YD 8_>! GC-HHHW)%Z6:@SSDO.T*^&N29.,>%K['EK*EG
M5(H6ZBA5"N2?'QDN<L-7D2NEG]A55&[>(!N>RS<M,J.!><*4QF0R;N^\7Q\Q
ML6O!G:^QT+Z7EI-X,==;0$YX1_[><%[?/UPL:E&5@F-*]$EB#\;_-_8?)"?]
MAYK>;J4X1?PSKC=P[B]J%X/OLTMUH+X:E*[LU?ZC/'\1KH30P6F1;V.6*)(7
M[.5/,'#(<8[,K'_<I!&"^D['_+=(-Y3]D  ?8=<FIM*@SRZ _]7,FNW+WZPU
M^@_TGOL/7 SG7"+\@Z!8H/)T8/T0G('#*XR>:M\#'-0_E',P;A(N<9EW)!DB
MV!WS*$F:EP7B7PW;PPQT.SS%'EQ=V1V%'8 FF8T?E:' E5?TZ/H"N6F3/6]4
M J,_5(=/N^\O_I[NV.LOU:_TQ>]DMAJ. 9_W39AO]^#$%3$G?RPD3FN]7?"G
MZ(GVIB:@DA*C;Q$JE]@--8CG"(P-UO7D@RFUO.(5"F\VD_+^Z&-H^W=K.@M9
MY&!:0#'0S4T""[27#-SKOM_]NN#LJ\H<;[Y\T^Q1FS&U"[FX'&_^W$HE9:%#
M/(V^+PYJ7PKJN/]QZ<YN"U.*K!#U+?*?_53MUU+"PX;C).$AW=J:\T,7N[V$
M*V\_S?4Z79_MHOJ_YR/F_\)'+-#$+T9U(^P _@KUQ?@1BI0C>[C6\*+]^?"H
M?S85C?_15.S%_M#=^;</T\^8,<.^T8<\4<=X-TY([4 :*R$;S,.27A$_E%.<
MA5#<P:F$_])7G6:B)5@@?..WO^FU_6W?14)CZQ?SYK_:H*C#G=.#^F*_!+>\
M/P.="Y9VI0GQ-+K_U06F_I,M%"Y"6AV'X03R/.;0\>$FX1&H?BVF/C*4AMDJ
MIN80EE6!:9HO,0[2QP(EUFTM@E/CS@$O;DXV(C$<&SG]]!Y5V]EO]0T&A10S
MSPLOF6XI#9W>Q^)LYK^H,OBFF;#BU8GI(<A>ZD;;=V34HX^YG5+IM38C]P+L
M_:G+87H1_MXB]@JMGSG9_*^$;]B.>=@\H4A7B@S<?>)B=2'=K+&#.I&"B.]+
M>7_2I!U5.E?FF-X95^*BU?+Z4YMHZ^="$N5P!(<W 38U)XF=XP+RXWSI 3>R
M@Z!20'FE_][/+2(-<F46/[=C,=<7L"*TKE=2GET7@=N ".QR6(SY*!BQ%2T[
MGY.Y=DOL3,*;V#X:E!X'^))OPNA_4M_,?UWQIX(/MP%;MS>IA^-0YC9R6Y"W
M9*$BRX&2!E,,M=[3,UO=\)B8IT#QC;G6S"LQ!Q=NGA)>' \T>8Y8:_>Q9VP?
M5 8WW&&! L"+I[Z/DP-=7\ P6('@H."@CWZX]N<)PWL?'TX<JS8B:MK4=M\[
MRYE5]N"8(SL9DX;E9]Q9#$2,D:%9W?8'&(/(Z"N(!*+>4)U@801'ZMFNYOAO
M&]?./$_[750_,<529")_,Z?4I?OBD\_"5KQ#:X7S])M*<AP?9V3&7+62 G3S
M8.>&E7S$P E$Z[$F^P //_LQ!2.MLM0R3FW9GFNV>4Z3UE\JB2+<IA@*\GC0
MH5:X8S]$BXM)2<OC++4+),5V\'EO'TDC>CV+V#&0$77JMA1?SG,KYDT<M!"(
M+[.*."UGC44 *W05($2EB?:"T,<6 <]8OC@7=X+A ]A2B]V:9UI#N-^[+Q,H
M,-X /6A:MV5(U1=19$&3WZ*X-GT=%Z!C%BAV$S^SF-EZ_\WIP"WWP_T>?X>A
MT@,\$GK0@#2B31/;1>>'MU,A)T@T,.&-1K_C8LC !PB)D4]SV8 +;VMQR&GK
M=:3G^_9-<I=X^?HMW@[2<_E@527$*)AFGD6P0-?FVK"\ZY)ZM.2<1B##RN R
M?CU.:K9UR]%MW^)7 ;M#3TM7<LR.QMK[]]T93OG'^,*^P3E1@8UI+-#)K0@S
M _V@U0,+8E%I1RWB49PTHN!RD.\P78^)]Y7(V!MT^3B?4K"7U'U>#/9\=BOB
MI)(,8?'Q*^&=EF 1FDKIR>E1Q)!3UR2!M&X;41=KRW_XY$K"I1,]U=O4-'#B
MAF)B)KTZ7$9<Z#UB@&Y!PJ"\;4+8[H5@96IIPZTZ7^1)<8&37J'":7V."<,>
M_JLU7NIYSQXKJ<!A$*OZ)MUZKFB1.%7^=.*!>^8=)77 I_;-@$3(5\*^#L*1
M LF(D_%G7D"E\  :+UWH.:21B(EC;@@/+3%]%H@',1YRZLNP;<O<UPBQDLL-
M4T)%BD%"E@^U!H-5OFDNW6S!5+:&+$!6USI2#52I2T.&4* :&4L#4PJ&5>-+
MN688.A6 &\)A%)4D: -?+SU+DTG&!6H_\YRA./TY$]ZC_0N7Y<^Q]+[_]-61
M7TF'5D8,,3W@N)A<0X()(\H']DKQ$J]=&LI(6V'6D]]VSW_[I".DOOS&(S3X
MI_PE@N9XBP9&O7#^V&P[D$D[V=AZ8-T=01Z:^5'B:CW_H^?J9M>#GNFV#QZ<
MT;U-OG=]+BQM1#^5*$KZ>D>N"Y[OZ/$P]LET,C M]IA<M]HY'A4,=SR9D QA
MOY)I;Y.ERO4 ;U7I:TW:&,[A?VQ5*B5@55+NGBAQTB0])^<7 YN&X% =4UM
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ME5]C2(MP*(KX_7>DIP.U.WC6'2)/'K-=@J$OU^%1_89,P2^3R(N]<TAOFM>
MVDVD!9:$)5[2L)_\ >'?B#:IQ7*K&$1*#*,;#>2K8#@78WJQR>2N_#?'P>BX
M5*[1 !W'*>6V08%?42S026PZT_;P#99R!,[=D3 OBE]8(NF,LT"<-7S>X3KL
M)9J0YMV#%:WN0W$?IVP>GB!'5$W)AH#'_ WC)RBJ/)I%2G/:S4[OQJJNA8R]
MN]23.^T\%/3ZUN*8-!][YNA\#A,7.BYX^MFO2$F'\F2<JY"+!2^,-[7QCIN&
MEH+=QDR9?8Q"1"CBNO$).WM)R5Y)O+F6C'FE@3(TY"":NB-DTR"G225GWK&C
M DH&[GR]8NS)O:><H3+1N>?)\M @F_RC8D;\>AI/F\+5P]?G<**MG]-K]@*K
M4/WZAN+*V^EML-.(8G+[(Y)^$.JEH02U%/MG1SS#E_Q*"1E"(N"7&%=I2D6"
M!:&!822QFF//OHAZE^:5!XIFW-_!S]"%0E/$/JHFL$ <2/XZ/VA[= #-"1B'
M)Z(XS\UTGR3[/>UIB[_D $YC0J@3#.EV[:S)-V!Z%B8L#/*NT;I(N"%-+RKM
MVB_Z/!D]N*0<XD)3+AA$2;H@,(,/+4+(RM%+Q,6OHKTOCHUZ92L[,/77GO=@
MQKS$_34SVK^8NZ;D/G+[D/4"O_YP@[YWOZG6:0F(G[RC!02%-)RU#.X/+N]U
MO>0DA>EP35]X^N+[-QU,ZU ."U1_8_;++817AD?2ZR\^W;Y* TY=49IW;7#)
M^&0G^57U3G$K/?.[=C0^Q%=#P5[!,/HW)PQ^M$'V]//8XIT6;I559\J%#!/K
MEX_&Y%=K/T\/3]>EE:5')6J('_=*&ENEJ" UO1X,4M2 5Y=)!;/+ITH,E*.[
MQT/W=.B;0 P)G 1MDQL&HWN/3)ZAKB0P-&K\VA<%T7=V#$0C>K8?('5JW8S%
MW,R4!BUB8R/N(8=]N/1!]Y..\E,J6W7Z6H.(F:,G#Y/K95_X<-7LM\# %32<
M2SGXUAWDDG='_K6E8.'CTCRA[B?)-\-<:<K+C8T(C.-,VT&(3>;:C%:LY_?
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M"L\8_#X7S0*E,8S+H8G><YHC=]P_A/L=BE;)KNY6983[AQLR43K$B84^TLK
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MD&(T3<J;J06O80%?AG[-9UAI&7ECEQL!5"UEIY4@NDF-O"4%8?3:LH"SIUF
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M>))>MUP@#9NC6F<&R.\#!MM1*7>=]I_\8C?[@UP*=V^=25_%5WS#5^JSZ^@
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M[G.OJ Q=:$9)?%*IE<^;";A7N::Y>&9,K"Z5NF30K_[UT<D#EFW?35G [8C
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MA*D#E?/A"GO+0A-S/,1E*;3NR,,/_!!^PXJCMF<'/J2Z%>,$VJY,(#L55X?
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M0M=')VA2,LY]EFKM5]#8/[[J.FKL[E*XZ+FRMC(?U!B.\"Z=OI(/3Z0+J?;
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M5F9WG!EL .I3B"'\\>+%P%S0VP.D1FO:S>1"-YU';7!-HWNE;Z/:3FR4'?F
M[,0SXKBA?- I1#1U,4L 4!.=IB_1.;/>__D1'[D&BVN,QFT)#-WK\]0NZ^I3
M<Z=C3.UAQ:QKJ<\# Y Q.4Z0Q\.8>PY6SOZ84#C8UN'JIX/]CW)LS>;<DS]^
M3U;"GNW0IU#5.W]H5V4+:34QV#+'[#L.29:<$HTA5.?)#CY=F^DZ96G_\&)J
M:N]: Q\D F=1U^5^)M5AZ7P0IP3VBW@"5,PS1.0;.!$$V%Q\Z6<BG)  ES-]
MGN)_')_B@UK:@&+!J^>*^*"]W'H^* 5F1/WGOUMP#\.2^* I))N\^4. V-M*
MEV+B8<R3N"38TCXFGGON1S+/!PP\IDO"IOP>"8C#TO'??297__EOS_F@&'4.
M?5,4)\4'-0I0/S"(N]]KP3T+[VWG12G !4@_6R#@>P8?)"[/+-H4U2=R+;XO
M\LYQ/T->6B1UPR4!-][:  P8U/M?DJC8:465PQ(3BN?J-)_],C\ WIMSJT]\
MT)XU3CVK&8X78-#E9A8?=-KRWQ%R^%^K!V&W\$P$*J]LIJ]V_5S(*%?9]S,!
M,V[G^L^<T<@X07,=^0!;>PIC7L':"UXL% #76)[ !'80,]M7U#GC8*[#7^2"
MP3Q#USKPG$.%J%<3!<XL/V"S7=W%\& 09J$M+W ;_G M.2WX[,01!>4/H3)Y
MVF^CFUE+^O'331';&I..:5^3EGEUQ;25HJL6H^H9^,DEDWGC&.%DF6;)L?=&
MU;DOC[E6[)*<LB(=&RK0Z'_TR-]VS6G]%% 4F^<:^>'FNB9)\U%#A;Q*YY27
MAN;]1XI6DKF3TXYW,X-F#EHV^^M;<<X$).9.>RCUS06YB[71S_75C 75OJRJ
MO6<A<JCM$&C7;SY7TA\Z?5:I.M*A7/U2W2I>:_V': SM\@L JP0&G]H9U7P^
M+Z:9<:/&C\'^>/VHTM.#/33&U(5H8WO?W@+;+$W[XOZH_;9[[WD]N@ 4N)*0
M@\6N#5:II8[%QB2DP],2AU+'_*<S]L7'W]UZ^NVXE>!'P^KBHP*US\WQ!\O?
M=_Z:PNA03UP^"EN>HZ\[W'(X^+=EAS^O+8._9''\.DGQ_RY@W/LS*='AY@;/
M+)\/NBD89Y:>):A_.>0#9/\WHOE_36/H_'6NQ_.MRNUF$NS59*@I,WD;IMY&
MKCV:XI8WC@EOR3A!&0CZ.FC@?O&]ZXQQ.-U/NE:NH"PT9('=J1.]7-#^:"%.
M7^N5F<:5#4U<=YU/E#);D4!K([,+&CXDWR[R([*?8JTR(G;-_E&=:=OGS:XE
M!;*.4TY,\$%5?L/BTVUZN_SKM(U"Q$BI2Z&.U+K*O%]R&171PS811S=(<Y#!
MAM"-]26S8.KF0ZJ/C84C^T,#C'9,AT3< =CQ]N"%9XSU[ID=P 2P+-B9_HGE
MGWQ[B+LQ-$OKYR11SS&[(3W#;?4#RV,3Z<:#*SDJ%R16POF@WS&"F$0H&NKT
MW#=$&J?"UC;;1V;'5.L?;^C9S_'(],L#$K5'KMKCYQ/UFS]\F%_(>X77W>;K
MJF']]K.B!$XP2 T6UPA+?)!=,^7*QA&N"(</2@BN5 3JW_@X<!!QVA330B#%
MCM#*,^O5X9H786R%,Q&[G6?7(02*4SXFW(W4-Z^GI]TG:F=9GS3S;B;<]$3
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MNUL\$&1:2NA>N&26Z=5H@=-Y*744%S'SA'GG#ML%[VD:RB W\4'W.&,S'GN
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MTH @BP0A#Q$AI $7EH"0M N$@(*"@ 8ALAD1,"J$(%N$ %$$$0))$X20(+M
MPAHAR\";>3.M;V9ZYIQY9V;^^,[YSCVY=7^I^]VZ5;=N5;&'V5-6?*XJ$JH1
M>]2O2%309!ER$QZ(.Y_42H=WAX!_B@ZO*LPHH%*K4M3;4F#VE(V+>O?3V]%
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M4"L6R[0VG01ME:J@ _F,6_7:0%SU2 YJ,.<[!$Z3D32/*H/1+4.)YH]BHX;
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M(6LP:K*+(6_PS+CQ7.,&8,,\,LSF6;-UUFP;]Z,N^V&^#*K\]/J1G!%K!N?
M@ Z<0Y=>LFY[< )\A[XY^.H#!TT0M \,1I?+RF)Z2%<+2-X<A)@F@(Q?>'C:
MB%\U6/OM X,"/(7T%LPA60 +QA4X$00YWF(&\!QP^*)"B_V+>G&0^V6C_.,8
M.Z(3L]EL-_CK,2 P!L5:J]+\8Z;]A[9HO75Z>MH0;Z.B/I&1&[T)J0U;)GG-
M,M"MQN\WUT,QT'%91I--X_))$H\:P<NHJ$UQ_G"P%PV.@H,P#YOMPP21K Q2
M#")R"06N!0_X-# ,/A& ZWH44#9S^6SZB<\H\7BQ0.[$>QL^8@_Y")U%7!C
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MJ6(/*7MH1K'GI'*B:Y9EW!,^DOT%[S\TIY$ZWJ:H4$:"9N.I)5B9=@%X%2/
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MX%$LO\W45SWPYV*2&J/]N8O&/HFRNT,9=,>6E1[4%.*3WOP1*+5+5EH/2K*
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M X1?$;$$=* )D*GX+>)(S+N(8RVC_OX5"T*%NQ_DBI,K2K6?\K6<JV4GPC^
M1]0T)-TD1+?@JTCJS0B^TB&BPL]DD/M:)2O?P2(1&VM B]X.D=)]S3Q_DZOL
MYH1O 1M@,[NM0?%DYIP^2>C!8J&H='5TYB6S&2H76]^S 64!&B4KH'(3[#U
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MC-G4GAI;(K0BC]Y*S(]W I[H"%1LLP0F-_(.( XT%D.G"%I6MY#S,GAZ*M8
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M$A]A<B&<1=K;X36)0CMPS,8FC"?"/GH[550D=5X4BH@]/\(R_@]02P,$%
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M]TG^PT_QW$MS)#OY>B7]"_Y?;ZH_>\-_].;]AS=?O__J*?%W++*_\=,=F?H
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M33P8!RG4(*/2PW$K$XF@U7LWK%O+TR&69BBZ @(K1' <)VQ9E73 K7]][,F
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M=$3VV);K9Q1B&2G"W3FYP^6.VWI05GKNBL%G:,&=R7I\B;V=TVH^ZYA,:.2
M[6>CQ,,+7",5>,P:^WQBWZ;S>@F (^J,1F+Q1)WP05X2H7#\$BG!4P:=].+Q
M.][&NNV"N6=YAG0B98V48T?YQA=!2)(TCD@Y7\M\XQQ?ANHZV/6&.\X[+"Q)
M- ](N]]<BVY+;,HU 43*/%FB/W7]^K4 9(9*.$:0_V[90J -4;;6,GOR/MT;
M#I1\Y!8!YS5JX=9',Y^R#25B>=HZL4MOC96>+"$S0*ZK,B]9IK5R@=0Q0LL;
M%Q-$2$-6B,5Q$G(?R6BE'1MOA^7*O8J(0;'9UD?N#DU=:WVW$[4G"FY_ZG3N
M'F-S0/<?30?0VD1Q"B)7=!B %CI:_\QUQKLAL/4)PY;QK),YBS-J#FOM*Z=M
MYPPQK4^V,\G.&M'@P4)1:U]-"M':9#O3N(P1W3F81U[(^P6=D&1.@_S<KH6M
MZGMG;=^1CEI*K*#?'30IELR9B:3Z:/BM;A I[##1:'/K+'X4!>ML/8NBS MO
MXJT7IMMV*.GE[7J/1DEF6M8E#OC 4Q=%-",YT+-W#"&\Q*/&&X_27$&]0U,O
M8:F7L-1+6.HE+/42EAHIH"]AJ9>PU&0P?0E+32TL)?<SS4-4>F,]F^1C,P31
M"NV41$^?^(2@\W</!G\VLI.!-]X8%YM<&+)Y?;XX.B/[BHRH@9P#FI*0%D#\
M1DK(UJGI01PG0B4D@K6<^F=&=4G>*B0E!KIW%,KVM'S,R[Q0?JP\VGZ.@M^S
M^DT#4E"JFR::<P(?I5(MG,,3MP;86)4#Z\11@U5",NZ#5=IZ+I>96?P*4DPH
MX2NIH)R'KT!EA=?;^SE$M51&X26JA0SH2U0+"UB\J%;%4G6\/8LIW_:![?/A
MZ$[>_Z#XRU+\-%: K?Z;!G$$G[G1?[P3BPB9\1[[S[(THV2VCC,>4,I(T==B
M$T=)3(E_FV;^ED%S0Q+"0%W-EFSU-]->;%9X_K*L!O[L/LG?0@(O=2D96\OT
MB20)(5?LG.-Q3?E$O(1\"KS[( QJ4;F,7#*AW#V2\(%<,)U:09LP:S;<[=]=
M$J_;+WN4D:Z^=1ER)&:W3UC[K@D;R6N7-7=A4<\C]D-RYSV1Q$N9VI\N%H0W
MNB&WJ9=F3,NV-UY*F%%EO[NF\4/ ':]%3&O?]6N'LQOHALQCMIF%01[*9C\X
M9B8]0#.W^G0M@VH2 KL?EU'V(Q(QX::S](PP)?'"'>[[[YD AIF\)6\N;Q"-
MU:>^@H%%A))>)N&1\T!FD?^)?1S6%N,PBB*E_MQ400XS:')4!Q>Y/S+S_Y4E
MA3\RC)!;5!W>=V+(MHVJWL$'2JK'*WY9>QZ=D 6A;!;L#V;,HT@37JBBN,\-
MP_B1/_H81N F#+ESSC%4P4@4:&7<)?L.EO /J+B-[,%(]1"X[@KDCMSN2Y(>
MZEKM:8[EG=&![C(:2+ZSDE2/!<!S6>*(V^*K18L&TEST:+I-DNL6;*,7I!Z*
M.N&''_[7FS>O_ON7BY__]C___5_S3?;TS^AOW_E_?/.P_.<V^GR2/7[\AG[W
MS3\^_.OSW38)OWF8__$N_"E]F]Z2G_[XYNLO3^_GG])WOYZ=?;C]Q]N'IZ/C
M?[Y[\&_I/V^.C[=Q=!$\+OW__!#^],\__#\^7SU\MSA_'[[]^?S=M^37M_^Z
M_':9_OPE?OC/RXN_W"V_W=[^_FGY]5]^.7Z__&OP_OC=6?QX<O27GW[Z^\.O
M'S]_^/7^K\O+B_/'DV1V\6MP^HN7Q3]]_<OO9W='/V6SZ+].3__Q[7^<WMS=
MA-'9\G?_[/KK]"Z9W9XFR\?OWGVYG7_XYO)H\]W3K]MOO;/ 3S[\<3E[%\?_
M3-_2\U]OYP_7V\71T5].R,?;U>+LD?X>?_O^\=W?ES]]<YD]_OCC_[PZOKUY
M\\8V\^) /OMP0IPDQQZE6W;8YHE;\/D7^I3=;@U&5J%Y$VP +MI#E*&=.TWO
M[3G(4^&=P6>6BLSP /OJ<Y%5CI;& 0M(.%4@-B!#R.F FKO#$9R\#@'4>< P
MG"=]19=>%/R1+WXO\H^R)(A(4MV#VF0"JT=L7: J[XUUQ[)Z2:,>7#]?5V<<
M/-LC3LHU%,+N%EL+$X 'WD;"HNEO-SRLH)L\RSZH&1_V7WO#TQP+R;SHI<0:
MJ%\NGB8*H"'RW=CZ;95U,!X@TTF9K2I4G :6!MEW/?#42S8U1-1!1JDNGO!/
MGMGXY8LH, UMCN<F'4R\["I$#V8,W=([)^$]P8+:&&^4H#9GC-5O^IK&<T+\
MY(SQ=!FG)+GVMFV'HG]6HXR,@QLF6[^C&S+@1$81P5LO)%>+G.P-F9/@ 5E8
M8GH.<R*!!"?!$2=C>#:?Y_F+I:*<,R>4DB0](AX-HF7UGPA9'P:$G571ZR%0
M$UQ!G^/O$L+B:,F[8_ L]0LOS6B0;D_@Q2@E,T'K*8=,KWGP@'=WV7KMT6V\
MN V64; (YEZ4EAK'M.LZ#H-:(K9A &(7O?&2U2SR^?_Q_A8/S"K)VS#TO_GJ
MH&;5+M$$)?U8A<6P X8N#,6W;WYB =; 00SUU!">!2L(.0U[V"MVXVI6 2/.
M2](;MN718)X27TQ;_%/]DY6!:'NQ,LA[5,73X>X%T"BDT0OU\6D"^+OCOKK@
M\&'R<)J \F*Y8NS(B[[<L1F?D$V<!$A+7D+$938-A$&L"UB&(UH;G$N2%OEN
M/(D!6%[-L1VG?>A[4Q)HNM>.)?Z<I_PQ##M$'&T_LS'/HUUNR8P_G\GO3>&%
MHTO8Y0*SDYLVI)TQ&;N]D?EM$?%//<J[72;,L\O66<@.HOX)PV\.GH2K0=!A
MMKV%"'40U$B<-CYP_A+3+[P_J;<)4B]L2DERF#SX9!HX"R>K$2.Q/^Z=G9P?
MGT=)1HE?/+A&..FU:3A,G3%7>@E,I5C^!B:6XOD_(W9[K92)K#*;\,M)(*V:
M>0GSWV&V]Z(: HEX 41^)< ,6;CEH<D@*EX++8Y/M-#N&F,ZN'>B44K@&U@'
MZW-$B1<&?Q#_(YL1=^6NHO/H@> \?NNB-@EQ:4-72NQ;6--TY/D\@"\LNBI9
M)0>?3&@3/IQL">EWX)OP_B;RER!=G:\W6<J]XN(:Z\R;$Y1M69?J-"1FC&5U
M9@3+5]F_42OO'W><'&>4$G#YR>FX320WEYD"L4I*\&&Q:THV7N"7JYMQ7+P2
MSE.B<02F0W%JHM-"L1(B_&L %?G+.)H/+L<:T<D%U73!K,0)=;RO!6R+:EX1
MVW<?2!AON"^#5.!=26MJ6YX2MTI<RN#!H!D69UY ^8LN7N>-'3.B><!+;E3-
M(7C-N]U?7!"/'P7+O@)5RH6=?NT&+1_)1'[MZ4M)R+^*V"[$-)T'(R.?J3VM
M_O/(2P*T% U8WNPB;/W$HI_C 4$'+>XMS?E T9[=60,$>R<EY6]('ON]]FBZ
MO:->E'ASI$+R*DJ.R\<#+IVF95=@BW;O**&*4C]>3<MM$7D-S=80%F[]>"51
MA&2.+FDYK20/*3"\(O+_$:_)4<!L0WP>S0UJ=(N^<^BH:EF)W?XFG#3TJS9.
M:!9\"?SX.O<XS? 5?^DN*FP&L&3>:%E%UGVI^*DFW=8VQ_R4>;?RHJN\*C4_
M:O(X-O$O,X1$I>'X=AK*0?-6'<A_@CK\D0V1)N?1-:%![$]&A0_8=KB[3%A_
M#V6O4PK%_/G%0.SG,M#:/H?EZ#FJI@O!HCR/&VH.OY!@N6(;Q>R!4&])\E_R
M-V4["4W4\';/RV7:Y[,QS1KJHU56%.!A=\'Y!4E7L8^7 :-/U]VI!UV[#,#O
M3.^SK_W+,W;R=*M!!*]'\UD;%4W885,-]T?Y(E=K3XIG;26<&_#' VI:S]%O
MTD2Y.X=QX&O0DR#9Q(D7Q@NV3;'_F.>-OC(&0O$<@C>[XK^Z/#L_:=>]LT]/
MX@LA;W>0[Z5>R,MIWJX(21GB,]_/9^B%G"$&$!-*<K2M6/U(XVS#-M!YF/E,
M)F*FL>Y(A^3<+OC80Z+ZUZ>]B6#9 .G5J0.5VYVG^HO$T4-\GGJZ=V61^G(?
M$$!,6=*[1X5:0(=M@@^!1*L!72>%VG1;2,;M?:E<8^7B,.NP#2H4E!;;4K$X
M;[%M+QF4<HG/L& JI/$25U,%O(E^J:CZ4E'UI:+JV(I_OE1410 5MZ)J\8"2
M,1(D24RWO+2D0=*)\$.GF0-=/NS^T:APSM Z*PK;_DD*UCH^/G<CCU6<N*F"
M: \@I63^O+*6(P^=Q2"F6*_=FH/@7S/'F_W"6\)W3](F[/)B9%0*H19/=]67
M_@J"6&U70<C==>BHQ&]8M]?&BRK:SI_%]"3.[M-%%E:UGL7,Z_I8IL,Z]<!<
MALMM1-!=!<>J^EJS1CM\;R\! ;=/=AVO=1'@W=?A+R42)B?H[G(+RCORGB5.
M>),Y'&F+:?QI]VX)Y)V%@0;-@>!&9\]H+;NA3[^-W)+Q_)+8BVH6K846<+>-
M3K*6P24A1OKY HK/D=:&-!' 5$ [MT0%P<O]_'!77-VJ"'#S_G+W_G+W_G+W
MCG7W_G)=@7E=(;"2!O */YP&O.(Y8]T0O'164XO-QM&RP1;M:>Z?L,,:A.PZ
MNZPI[F]>PK7#R:MOK%55>N_ESG7 !==Y80K\=/!/'CGM(ZKNL*>JCO]+T!-?
M0NJ(I>H28MB@Y6T:S[^LXI"QE10O"7MV PV])+E:Y,-B!2G%-*PZ?\IF;]#E
M4SV$BXZ>*A'LBS-T3-U1*#)__'['_A A"MD<VWD 4D_Y&L>9)CA8^8F=10L2
M6=6"/8.1?QUZ$5KH$H5%MV%/H>8;U9*P$@M2M!2#6?!(*YH6.8W2.E$DE%<3
M=T'*BUJ<1W[P$/B9%P(]LA*/.Z$-00&.1ABKMQAX.Y*\I",_R*^"S5U\RL[W
MC%UM4V\JH Z*;BQWIXI*1=4%8*=11A8AR)LO&R$Z>QF&(4?=NKM6^VN5BE/W
M]A%\9CD=/'%AN<\*S% :M-;)H'C! @+.GJMJ*V:C%Z4 (:Q339L6N#\ID8=#
M7["G-/0LF)7]RNZ3P \\NBT*EZ'9+RF="=HO.68XM2_W5+BC?[7 [J"@0=#M
M&;U3:QOBTH /+86LFSC\:5I/>F[M(:P -3V\'MO5+QX_EJ=7](87^$0PD'(Z
MTS.0"LQ 7W@IZ6%Z>D)*>,DY6C:Q4U$[)80<BE30Q/( Y7)R:OV@1/5210DC
MH->ND013K?>E/M)+?:0QUT=JG56+I<+O)N*(WT9@AK6$M+ D@![8$B.GDW1B
M);$#<BB>CY@&5E*068A+I:AU^4AP HWR*VF!^SE2J8PCVM5+,)AA^]*;TM^)
M#632'-OM^W^-DU%=#@>P8!T$XO4ZCG+SBB* ]O@NWTTHC7/#T6_#@F*9KAX(
MG85AG)>S+[J8H(A!3L=IOJ]^-+4N' 5HNEU872U^P;U77[6SK;='%H12XN,M
M?2$)I^JF)P0Q-/"O-&\)#4AR?,S[(=(T8'YLMU!D";=Z0XUB_Y.@;P0)Z-5T
MFS+WJJYI,#=YVZD<8%K MZ:/<Y.6DYP-8(A4E%QZ(WKF2(E3]RND?KM#SN(1
M[O;0H.'N98OAYM!$!K9&6KXD]VN1,=5A%\^C-.[PY"5FJS^5$>_H4#@BE4DK
MN1G, HHI3<4"2G#2*&GV4IC^I3"]"U"1"],S$D>Q1_VKQ4E R9S]17*\\@*Z
M]@QB"!TH=Q!P83MZ9-]7DNF"33>*8+";S]8D\O,BN_I[\^$W;D,UB _@=GMU
M"R64^CU7ZRBXSY*JG3 O<!T\$,Z:@7 Z!W&YKPXBK&X8X6,F.S*Y#R /F$J$
MIOC<W<%C$&&I@-.I_=_W<B&?0#++TE5,>1-7O&N&%J6Q.+B?5+41E% AI1;P
M T^29,0_R7CIIZ)K>D&]8&03!N"]JK7)CN9<J92;/HK0'3;*&D/U,U%.]80D
MP3+BS1NT3*)ZA)'<F A%H , 6CVE)MUKCU[1HF-&W@*;*4'."NJ-BI3H>*+-
MRJ6C"R%.I:4F]9PDJK0*"F->3TIDD$HH22-QO,H=XW8?O -W&+0)3\1_T >R
M,YS9?SW5V#FX4T)=9 JRTW G]%'4:>4 NB(+EZ9P=3YOXFCXI:G@8!S71G8K
M5 5L9S<'&/^ES@+J FT0FH#05#"5LOEN$-E<96F2>A'O%3* @.K4)BJE!F#5
M 1HV>:]QL[BG7"YTXK]',8PJ>A/Q_#6 JR0&_814>5Z_)(_YKP:->>R)3D1Z
MNA!6(E1%/*S+J)56.'>&D$[;<CK3\"45.%6BP8B+[+L)<]*\)18_?>RBF^"[
M5Q>]B:PJ#> JJ4%G>PD?)EQF?%(\96;.R\SS! PO#(E_M#WUYJOFWT+O<[WY
MF<8"!<"]4@E57 90*4Z?")T'"<G-R>Z72?G;!-SAL>)A(@O>$N!*XN#):*I=
M_88D*>,H+3WL_-[Q(XV301TE.1-3B*K:XEO)&SS0(V$HC_<ZEG<'#Q-9X)8
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M+^#>XN"O+O,3 M^[5L'F+CYE/)M8+U-!=5 <X*PER2]0JJI44ET @B<>&'(
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MP-5(2@?O7+MB7])Y=D_>L)\6!<J;,M16R48D0XY8IY=I*:0ZI9/<U@)+1T
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M'B5A_H>LBM6ZPH'M9T;#:*Z5LC<H-DV)[<\4 _3/K ?HGXT_0/],(D#_K&^
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MF_H$YA/2O>OY*8TW6>)U&K&PR>G'M9^ZV,WRX6YWY*S-O(*+7?,>1\SG;S
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MGP9(* *:.U6ZKCIBTN23."8[RL9+:$IN>]@^9L3&,X<ZNP"XV5='^=U'#FT
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M.;8>/--)YG47!OGYZ661P3O'<W.(3P(W*Q":I2 F TRC"&L'I211.[89&=;
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M2:Y5,[?.MU$8&]5T82:,O^VH\0DFO"R^1^MPNPT#JX^%>O @K1.+)ZO'$Q)
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M7-3*54O9BDK#<210:),F-WF"</"J^1SC9+[)*2AM/.(>S!J"A+R [K-Q0LT
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M@+$JUN0][&3S3=M). N2,'L>[ZH9]:=B6F?NS3&<=;<X L,-DE*N/-)]Z98
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M\B?R1ZB<E27+T7\9;G=A0( V""[X-#1O'B)8<!F HN^R(@SEQZ/ AE!*57C
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MY N'KI@)J]:E2LXK00<F<^.*&)&$QMA>.F2$4TE.U3)^31O,4"<52,:HIS;
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MD0H_T8I!/9L0PGPVIQ#FLX@0YK,YA#"?30AA/IM3"/-91 CS6=H09L<D?IK
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MT]/?BI8C^-VU'Z"N281;2@[(:[P80_ZA>&FZOZMD3QAZ0=3@8"\0PY/?'WA
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M$&+J^L NP_D \<&;<0IX&<1#W!$&9(MH+A<9'SBW>KT?.R9[) *,31:=D;H
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MVL0/0_6H>6C>/+]4S:L'>5LUA8>>;IPS/P69.QHSX2+Q0,7OJ:@J-O8OSX^
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MFUT 5NUGUK+O;J7Y.X2LMJ^KHHLU&HOI0(JI*I?[C0/J'8__\?:L$XH_:05
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M:,A>D-5!Y*5HLCE YX@F0W$=DOF=0*US02XP)H(QUB(E*>"-=R\^/-$/]).
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M"G,S EC/BCO)A)W+K[<M[ZYN+;F/!])5I6:CT4TC'9/\/LQ+?=%2/I.?V?.
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ME^@<1-EEH?Y!ALZY#]8@<;AK*8HC:<4T?KS=%^U=^[&'UQLW\J@:;]'&+38
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M5&;$E#UY.T[USI.QBE"(B<7-"65;E92\93TE->PG[#^/[!@%D?U_4$L#!!0
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M2#OG50VXRS0Z]?.K2%C'4VR/!^U:X;< R,0N61&I7/?..L+?RK.0#V-2!U-
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M6I>MLY YM=K-1UD:>%[=%Y,T[8I>BVY>4R!.A0+JA.47MC&Y'5_GM;YGT.T
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ME_0'SX,:/O'B&#TUHX?SO9M4L(D)1R<#X*;9J\C$,1YW7DB)D,X)7E*"AFP
ML91LR*SSK$%DA$2*(Z6P_%5!6#X4PA*AI9>BP-";5G0Y8M85*\<;)M= #N:S
M(E*XI2396$K;MP F,YC) VXSBXR>9UG2MWAJ-O-W@#:SD[R6?>?,6Y1D81HO
M5(8DZ0_?:TR/N8Y3+M3JC^P/Z#-&1_?=W #</43G%FT1_8'-G<LAX'Z*$8CH
MU$^Y#AO<!OX4,&:V53)?_!C'07(7'\@ZO 2U,'$:-'0L2&VV.'4-*V!._R1)
M;DB\P"DSLMS)TS$BKIO_.):H%E^@BKXLR]-E1,%1P^S\D4W%<7C#'2/RE<M3
MBR\:CF+0][D"[GN[]O 8="=7/&3<5IDZEBPN=_3=R&F<>N$HGE.<H8^Z ^@.
MR]AZ]? @Z)H/[1&%P,AR +A6SQT<JI\+'FE<-L*OU/H!I=.,L+V">S9%<!R_
M("7YUD$G?4N][3H$.6^YZ6?WQ!4@IL$Z/G6@NV,J5JVWYZ[.PC#^PB8A7\3D
ME.)2V.W'<4OSXG4%R!/1J4K$=&VVUO9$E;\=9<N'X3*U7I*3 N( &H/.2D8/
M39C+4 5&NG[SHWF@QZOJUFUVKJ4\P; UJ;0=O!&31 IS(PC:K0FX8WN+01)9
MNHI9,"KX1 6%U(#?A%Z4G#\BXN,$W1#LHULO6EJ;V6$)2;==%Z5$/1\0:"9Y
MSJJOSA"AJJ^8H55%0F]Q\IN%FKU.4,Y*1B$T1L,%T4E0$#YKZ,1RNC>O**M+
MT34_<VV8R<CJ_BP>[1BX9<B4)=36;>*L&1=_0S,VEF"9IW"<[ Y_4D[@G7WQ
M2%#*R#Q+D]2+F*OP.K-2> J-G].90E:-D7Y!->(K<(&48VG]C/!R11^'LRTB
MWA(UR#M>&>[$VO4=,TGI[I8#?9M#D!NO+?4/_;M]4-[M+6)#H>C/V>AF9I9G
M7LBR[][9. $#[\"QJW/@PS"T>+B>U0ZH 2[IWG"48#]/)QVO[C_"TVGRU215
M_3&C30OGS J?H#;X(YL@EEQ&-SE.-B))-C!\ME6,^&O@7P>(A?5N*5':TYA,
M<4#,'0_B&X^ 0TH#6$&BDAO0T,+*-XB.=R:RKM[*^1@'QNEINTT&Y[!&K22
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M&?6A2>)*+,Q=:1;LNUN4I!3SM'QXY"VR?B1Q,JB])T9B&FYS70I7DN',ZR9
M/'?\.Y:,'APFHS0T25R)AK$#3E$R#BB59A&388ZO71">[OA\U&Z8KFU7K#!V
MI6D'+.,%2I)\O.4% G^)MY8?-:/$1*G8I.$A ^I/=D^0EV1D=PB>SOS?,\S*
M^N,DO4+I*H;V8$N!G 1#Y8A7Y8@X3-2Z19N,^"N/F7SQDGCK6\024:EF/R24
M'?ZFF.,!;6@;(#*MBU.3V)68./.R=1F$-R6V\\4L2="P:7TMV%-YGBM2M!*
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M$^1_LXRWKP.$"\A![&?,E'Y]&F]+2^/[U^QCEM; 8/Y_4$L! A0#%     @
MX(IY6%#N'/P;I ( 1,(5 !P              ( !     &5A,#(P,3DU-RTQ
M,&M?<VEL;W!H87)M82YH=&U02P$"% ,4    " #@BGE8+2VV%>H!   B!P
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M87(N:'1M4$L! A0#%     @ X(IY6(=70+,2!   QQ<  !X
M ( !E+@" &5A,#(P,3DU-S Q97@S,BTQ7W-I;&]P:&%R+FAT;5!+ 0(4 Q0
M   ( ."*>5BQO5WY^1$   QK   =              "  >*\ @!E83 R,#$Y
M-3<P,65X-"TQ7W-I;&]P:&%R+FAT;5!+ 0(4 Q0    ( ."*>5C/KX6XS1X
M )8$ 0 >              "  1;/ @!E83 R,#$Y-3<P,65X.3<M,5]S:6QO
M<&AA<BYH=&U02P$"% ,4    " #@BGE8ZG1-?LO>  !Y P$ #0
M    @ $?[@( :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    ( ."*>5CJ=$U^R]X
M 'D# 0 -              "  17- P!I;6%G95\P,#(N:G!G4$L! A0#%
M  @ X8IY6*8L-L@X%@  V L! !$              ( !"ZP$ '-I;&\M,C R
M,S$R,S$N>'-D4$L! A0#%     @ X8IY6&[;T"G:#   G8\  !4
M     ( !<L($ '-I;&\M,C R,S$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( .&*
M>5C/E/425$X  !7G!  5              "  7_/! !S:6QO+3(P,C,Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    " #ABGE85'8%D5"V   ]- D %0
M    @ $&'@4 <VEL;RTR,#(S,3(S,5]L86(N>&UL4$L! A0#%     @ X8IY
M6#.PO^+(20  N]L$ !4              ( !B=0% '-I;&\M,C R,S$R,S%?
=<')E+GAM;%!+!08     #P / !X$  "$'@8    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>ea0201957-10k_silopharma_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:silo="http://www.silopharma.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="silo-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2024-03-23</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-01</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">silo:HomeBistroIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">silo:HomeBistroIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">silo:HomeBistroIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">silo:AikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-01</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-01</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-01</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:NoteReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:NoteReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-04</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-04</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:AmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-04</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:AmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-04</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-26</startDate>
            <endDate>2022-09-26</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2022-09-26</startDate>
            <endDate>2022-09-26</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-28</startDate>
            <endDate>2022-09-28</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-29</startDate>
            <endDate>2022-09-29</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2022-09-29</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2022-01-26</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2024-01-09</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-18</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-29</startDate>
            <endDate>2021-12-29</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-29</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2022-01-27</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2022-01-27</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-30</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:CustomerConcentrationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:CustomerConcentrationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">silo:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">silo:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-12</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:EricWeisblumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-12</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MrWeisblumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-12</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MrWeisblumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MrWeisblumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DanielRyweckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-27</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-27</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">silo:ThirdAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">silo:ExtensionFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-05</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesMConvertiblePreferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-12</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-12</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-01</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silo:FirstPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silo:SecondPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-13</startDate>
            <endDate>2022-10-13</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:SponsoredResearchAgreementWithColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithReprocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithReprocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithReprocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithReprocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithReprocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementsWithUppertonPharmaSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-16</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UppertonResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementsWithUppertonPharmaSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:UppertonResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AmplifyBioResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AmplifyBioResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithAmplifyBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithAmplifyBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ResearchAgreementWithAmplifyBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">silo:JVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ZylTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AmendedServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AmendedServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AmendedServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-09</instant>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-23</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-14802">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-14803">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-14804">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-14805">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-14806">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-14807">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-14808">001-41512</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-62">SILO PHARMA, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-76">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-81">27-3046338</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-99">677 N. Washington Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-14809">Sarasota</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-14810">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-108">34236</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-14811">(718)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-14812">400-9031</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-143">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-148">SILO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-14813">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-14814">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-14815">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-14816">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-14817">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-14818">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-14819">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-14820">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-14821">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-14822">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-14823">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" id="ixv-14824" unitRef="usd">5962382</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-14825"
      unitRef="shares">2843634</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c0" id="ixv-14826">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c37" id="ixv-14827">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c37" id="ixv-14828">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c37" id="ixv-14829">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c37" id="ixv-14830">false</ecd:Rule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="c0" id="ixv-14831">106</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0" id="ixv-14832">SALBERG &amp; COMPANY, P.A.</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-14833">Boca Raton, Florida</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-14834" unitRef="usd">3524308</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" id="ixv-14835" unitRef="usd">11367034</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c3" decimals="0" id="ixv-14836" unitRef="usd">4140880</us-gaap:ShortTermInvestments>
    <us-gaap:EquitySecuritiesFvNi contextRef="c4" decimals="0" id="ixv-14837" unitRef="usd">3118</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-14838" unitRef="usd">15970</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="0" id="ixv-14839" unitRef="usd">135894</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="c3" decimals="0" id="ixv-14840" unitRef="usd">9600</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="c4" decimals="0" id="ixv-14841" unitRef="usd">6010</us-gaap:InterestReceivableCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-14842" unitRef="usd">66010</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ixv-14843" unitRef="usd">7681158</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="0" id="ixv-14844" unitRef="usd">11572056</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c3" decimals="0" id="ixv-14845" unitRef="usd">64983</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c4" decimals="0" id="ixv-14846" unitRef="usd">70821</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-14847" unitRef="usd">7746141</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" id="ixv-14848" unitRef="usd">11642877</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-14849" unitRef="usd">703488</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-14850" unitRef="usd">364216</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c3" decimals="0" id="ixv-14851" unitRef="usd">72102</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c4" decimals="0" id="ixv-14852" unitRef="usd">72102</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-14853" unitRef="usd">775590</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-14854" unitRef="usd">436318</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c3" decimals="0" id="ixv-14855" unitRef="usd">793680</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c4" decimals="0" id="ixv-14856" unitRef="usd">865782</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="0" id="ixv-14857" unitRef="usd">793680</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c4" decimals="0" id="ixv-14858" unitRef="usd">865782</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-14859" unitRef="usd">1569270</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="0" id="ixv-14860" unitRef="usd">1302100</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-14861"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-14862"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ixv-14863"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c4"
      decimals="INF"
      id="ixv-14864"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="4"
      id="ixv-14865"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="4"
      id="ixv-14866"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ixv-14867"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="INF"
      id="ixv-14868"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-14869"
      unitRef="shares">3159096</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-14870"
      unitRef="shares">3158797</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-14871"
      unitRef="shares">2906241</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-14872"
      unitRef="shares">3158797</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ixv-14873" unitRef="usd">316</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="0" id="ixv-14874" unitRef="usd">316</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="c3" decimals="0" id="ixv-14875" unitRef="usd">17525714</us-gaap:AdditionalPaidInCapitalPreferredStock>
    <us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="c4" decimals="0" id="ixv-14876" unitRef="usd">17511589</us-gaap:AdditionalPaidInCapitalPreferredStock>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c3"
      decimals="INF"
      id="ixv-14877"
      unitRef="shares">252855</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c4"
      decimals="INF"
      id="ixv-14878"
      unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockPreferredValue contextRef="c3" decimals="0" id="ixv-14879" unitRef="usd">471121</us-gaap:TreasuryStockPreferredValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" id="ixv-14880" unitRef="usd">-6227</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-14881" unitRef="usd">-10871811</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" id="ixv-14882" unitRef="usd">-7171128</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-14883" unitRef="usd">6176871</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-14884" unitRef="usd">10340777</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-14885" unitRef="usd">7746141</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" id="ixv-14886" unitRef="usd">11642877</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-14887" unitRef="usd">72102</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" id="ixv-14888" unitRef="usd">72102</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" id="ixv-14889" unitRef="usd">5838</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c5" decimals="0" id="ixv-14890" unitRef="usd">5838</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-14891" unitRef="usd">66264</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" id="ixv-14892" unitRef="usd">66264</us-gaap:GrossProfit>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-14893" unitRef="usd">871625</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="0" id="ixv-14894" unitRef="usd">577651</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfessionalFees contextRef="c0" decimals="0" id="ixv-14895" unitRef="usd">1726061</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c5" decimals="0" id="ixv-14896" unitRef="usd">1496687</us-gaap:ProfessionalFees>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-14897" unitRef="usd">845092</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-14898" unitRef="usd">1286434</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralInsuranceExpense contextRef="c0" decimals="0" id="ixv-14899" unitRef="usd">89007</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense contextRef="c5" decimals="0" id="ixv-14900" unitRef="usd">125889</us-gaap:GeneralInsuranceExpense>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c5" decimals="0" id="ixv-14901" unitRef="usd">-20000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-14902" unitRef="usd">390071</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c5" decimals="0" id="ixv-14903" unitRef="usd">227259</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-14904" unitRef="usd">3921856</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" id="ixv-14905" unitRef="usd">3693920</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-14906" unitRef="usd">-3855592</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" id="ixv-14907" unitRef="usd">-3627656</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c0" decimals="0" id="ixv-14908" unitRef="usd">398530</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c5" decimals="0" id="ixv-14909" unitRef="usd">72637</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:OtherIncome contextRef="c5" decimals="0" id="ixv-14910" unitRef="usd">85733</us-gaap:OtherIncome>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" id="ixv-14911" unitRef="usd">4869</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c5" decimals="0" id="ixv-14912" unitRef="usd">2199</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c5" decimals="0" id="ixv-14913" unitRef="usd">-104700</us-gaap:RealizedInvestmentGainsLosses>
    <silo:PenaltyFromEarlyTerminationOfCD contextRef="c0" decimals="0" id="ixv-14914" unitRef="usd">166034</silo:PenaltyFromEarlyTerminationOfCD>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c0" decimals="0" id="ixv-14915" unitRef="usd">-3118</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c5" decimals="0" id="ixv-14916" unitRef="usd">-331203</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-14917" unitRef="usd">224509</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="0" id="ixv-14918" unitRef="usd">-279732</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-14919" unitRef="usd">-3631083</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" id="ixv-14920" unitRef="usd">-3907388</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c0" decimals="0" id="ixv-14921" unitRef="usd">-3631083</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c5" decimals="0" id="ixv-14922" unitRef="usd">-3907388</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c0" decimals="0" id="ixv-14923" unitRef="usd">-69600</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c5" decimals="0" id="ixv-14924" unitRef="usd">-1163</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c0" decimals="0" id="ixv-14925" unitRef="usd">-69600</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c5" decimals="0" id="ixv-14926" unitRef="usd">-1163</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-14927" unitRef="usd">-3700683</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-14928" unitRef="usd">-3908551</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-14929" unitRef="usd">-3700683</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-14930" unitRef="usd">-3908551</us-gaap:NetIncomeLoss>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c0" decimals="0" id="ixv-14931" unitRef="usd">-6227</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" id="ixv-14932" unitRef="usd">-3706910</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c5" decimals="0" id="ixv-14933" unitRef="usd">-3908551</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c0"
      decimals="2"
      id="ixv-14934"
      unitRef="usdPershares">-1.18</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c5"
      decimals="2"
      id="ixv-14935"
      unitRef="usdPershares">-1.71</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c0"
      decimals="2"
      id="ixv-14936"
      unitRef="usdPershares">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c5"
      decimals="2"
      id="ixv-14937"
      unitRef="usdPershares">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-14938"
      unitRef="shares">3079874</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-14939"
      unitRef="shares">2284240</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-14940"
      unitRef="shares">227</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-14941"
      unitRef="shares">1972739</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" id="ixv-14942" unitRef="usd">197</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" id="ixv-14943" unitRef="usd">12324646</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" id="ixv-14944" unitRef="usd">-3262577</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="0" id="ixv-14945" unitRef="usd">9062266</us-gaap:StockholdersEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c14"
      decimals="INF"
      id="ixv-14946"
      unitRef="shares">1150000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c14" decimals="0" id="ixv-14947" unitRef="usd">115</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c15" decimals="0" id="ixv-14948" unitRef="usd">4940833</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c5" decimals="0" id="ixv-14949" unitRef="usd">4940948</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c15" decimals="0" id="ixv-14950" unitRef="usd">111014</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c5" decimals="0" id="ixv-14951" unitRef="usd">111014</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c14"
      decimals="INF"
      id="ixv-14952"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c14" decimals="0" id="ixv-14953" unitRef="usd">2</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c15" decimals="0" id="ixv-14954" unitRef="usd">135098</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c5" decimals="0" id="ixv-14955" unitRef="usd">135100</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c13"
      decimals="INF"
      id="ixv-14956"
      unitRef="shares">227</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c14"
      decimals="INF"
      id="ixv-14957"
      unitRef="shares">-15167</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c14" decimals="0" id="ixv-14958" unitRef="usd">2</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c15" decimals="0" id="ixv-14959" unitRef="usd">-2</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c14"
      decimals="INF"
      id="ixv-14960"
      unitRef="shares">891</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:NetIncomeLoss contextRef="c18" decimals="0" id="ixv-14961" unitRef="usd">-3908551</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-14962" unitRef="usd">-3908551</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20"
      decimals="INF"
      id="ixv-14963"
      unitRef="shares">3158797</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" id="ixv-14964" unitRef="usd">316</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" id="ixv-14965" unitRef="usd">17511589</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="0" id="ixv-14966" unitRef="usd">-7171128</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-14967" unitRef="usd">10340777</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c27" decimals="0" id="ixv-14968" unitRef="usd">14125</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="0" id="ixv-14969" unitRef="usd">14125</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c28"
      decimals="INF"
      id="ixv-14970"
      unitRef="shares">252855</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c28" decimals="0" id="ixv-14971" unitRef="usd">471121</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c0" decimals="0" id="ixv-14972" unitRef="usd">471121</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c29" decimals="0" id="ixv-14973" unitRef="usd">-6227</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c0" decimals="0" id="ixv-14974" unitRef="usd">-6227</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c26"
      decimals="INF"
      id="ixv-14975"
      unitRef="shares">299</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:NetIncomeLoss contextRef="c30" decimals="0" id="ixv-14976" unitRef="usd">-3700683</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-14977" unitRef="usd">-3700683</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c32"
      decimals="INF"
      id="ixv-14978"
      unitRef="shares">3159096</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="0" id="ixv-14979" unitRef="usd">316</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="0" id="ixv-14980" unitRef="usd">17525714</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c34"
      decimals="INF"
      id="ixv-14981"
      unitRef="shares">252855</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="0" id="ixv-14982" unitRef="usd">-471121</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="0" id="ixv-14983" unitRef="usd">-6227</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c36" decimals="0" id="ixv-14984" unitRef="usd">-10871811</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-14985" unitRef="usd">6176871</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-14986" unitRef="usd">-3700683</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-14987" unitRef="usd">-3908551</us-gaap:NetIncomeLoss>
    <silo:ProvisionForDoubtfulAccountsDiscontinuedOperations contextRef="c0" decimals="0" id="ixv-14988" unitRef="usd">69600</silo:ProvisionForDoubtfulAccountsDiscontinuedOperations>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c5" decimals="0" id="ixv-14989" unitRef="usd">-20000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="0" id="ixv-14990" unitRef="usd">14125</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c5" decimals="0" id="ixv-14991" unitRef="usd">156047</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <silo:AmortizationOfPrepaidStockbasedExpense contextRef="c0" decimals="0" id="ixv-14992" unitRef="usd">90067</silo:AmortizationOfPrepaidStockbasedExpense>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c5" decimals="0" id="ixv-14993" unitRef="usd">-104700</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c0" decimals="0" id="ixv-14994" unitRef="usd">-3118</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c5" decimals="0" id="ixv-14995" unitRef="usd">-331203</us-gaap:IncomeLossFromEquityMethodInvestments>
    <silo:EquitySharesEarnedForServices contextRef="c5" decimals="0" id="ixv-14996" unitRef="usd">-85733</silo:EquitySharesEarnedForServices>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" id="ixv-14997" unitRef="usd">-35695</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="0" id="ixv-14998" unitRef="usd">-55335</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c0" decimals="0" id="ixv-14999" unitRef="usd">3590</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c5" decimals="0" id="ixv-15000" unitRef="usd">4800</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" id="ixv-15001" unitRef="usd">339272</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="0" id="ixv-15002" unitRef="usd">-53721</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="0" id="ixv-15003" unitRef="usd">-72102</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c5" decimals="0" id="ixv-15004" unitRef="usd">-72102</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-15005" unitRef="usd">-3224498</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" id="ixv-15006" unitRef="usd">-3497622</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments contextRef="c0" decimals="0" id="ixv-15007" unitRef="usd">4147107</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments contextRef="c5" decimals="0" id="ixv-15008" unitRef="usd">-66707</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable contextRef="c5" decimals="0" id="ixv-15009" unitRef="usd">20000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-15010" unitRef="usd">-4147107</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" id="ixv-15011" unitRef="usd">86707</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c5" decimals="0" id="ixv-15012" unitRef="usd">4940948</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity contextRef="c0" decimals="0" id="ixv-15013" unitRef="usd">471121</us-gaap:PaymentsForRepurchaseOfOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-15014" unitRef="usd">-471121</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" id="ixv-15015" unitRef="usd">4940948</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-15016" unitRef="usd">-7842726</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c5" decimals="0" id="ixv-15017" unitRef="usd">1530033</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-15018" unitRef="usd">11367034</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c12" decimals="0" id="ixv-15019" unitRef="usd">9837001</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-15020" unitRef="usd">3524308</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-15021" unitRef="usd">11367034</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-15022" unitRef="usd">4869</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="0" id="ixv-15023" unitRef="usd">2199</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c5" decimals="0" id="ixv-15024" unitRef="usd">25159</us-gaap:IncomeTaxesPaidNet>
    <silo:ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments contextRef="c0" decimals="0" id="ixv-15025" unitRef="usd">6227</silo:ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments>
    <us-gaap:StockIssued1 contextRef="c5" decimals="0" id="ixv-15026" unitRef="usd">135100</us-gaap:StockIssued1>
    <us-gaap:NatureOfOperations contextRef="c0" id="ixv-12752">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;N&lt;b&gt;OTE 1 &#x2013; &lt;span style="text-decoration:underline"&gt;ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Silo Pharma, Inc. (the &#x201c;Company&#x201d;)
was incorporated in the State of New York on July 13, 2010, under the name Gold Swap, Inc. On January 24, 2013, the Company changed its
state of incorporation from New York to Delaware. On December 19, 2023, the Company changed its state of incorporation from the State
of Delaware to the State of Nevada.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research.&#160;The Company seeks to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications
such as depression, post-traumatic stress disorder (&#x201c;PTSD&#x201d;), Alzheimer&#x2019;s, Parkinson&#x2019;s, and other rare neurological
disorders. The Company&#x2019;s mission is to identify assets to license and fund the research which the Company believes will be transformative
to the well-being of patients and the health care industry.&#160;The Company was previously engaged in the development of a streetwear
apparel brand, NFID (see below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 21, 2019, the Company filed an amendment
to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter,
on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name
from Uppercut Brands, Inc. to Silo Pharma, Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 8, 2020, the Company incorporated a new
wholly-owned subsidiary, Silo Pharma Inc.,&#160;in the State of Florida. The Company has also secured the domain name www.silopharma.com.
The Company had been exploring opportunities to expand the Company&#x2019;s business by seeking to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. In July 2020, through the Company&#x2019;s newly formed subsidiary, the Company entered into a commercial evaluation license
and option agreement with University of Maryland, Baltimore (&#x201c;UMB&#x201d;) (see Note 8) pursuant to which, among other things, UMB
granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to certain technology.
The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master License Agreement with
UMB (see Note 8). The Company plans to actively pursue the acquisition and/or development of intellectual property or technology rights
to treat rare diseases, and to ultimately expand the Company&#x2019;s business to focus on this new line of business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2021, the Company entered into
and closed on an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company (the
&#x201c;Buyer&#x201d;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the Company&#x2019;s
NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form of a promissory note
amounting to $60,000. The promissory note bore 8% interest per annum and matured on October 1, 2023. On November 8, 2023 and effective
on October 1, 2023, the Company and the Buyer entered into a First Amendment Promissory Note which increased the interest rate to 9% per
annum and extended the maturity date to December 30, 2023 for no consideration. Accordingly, the results of operations of this component,
for all periods presented, are separately reported as &#x201c;discontinued operations&#x201d; on the accompanying consolidated statements
of operations and comprehensive loss (see Note 4). On December 30, 2023, the buyer defaulted on the promissory note (See Note 4).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 14, 2022, the Company filed a Certificate
of Amendment to the Amended and Restated Articles of Incorporation (the &#x201c;Certificate of Amendment&#x201d;) with the Secretary of
State of the State of Delaware to effect a 1-for-50 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) with respect to the outstanding
shares of the Company&#x2019;s common stock. The Certificate of Amendment became effective on September 14, 2022. The Reverse Stock Split
was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split was deemed effective
at the open of business on September 15, 2022. All share and per share data in the consolidated financial statements have been retroactively
adjusted to reflect the effect of the reverse stock split.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ProceedsFromNotesPayable contextRef="c38" decimals="0" id="ixv-15027" unitRef="usd">60000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromSaleOfNotesReceivable contextRef="c38" decimals="0" id="ixv-15028" unitRef="usd">60000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:AccountsPayableInterestBearingInterestRate contextRef="c39" decimals="2" id="ixv-15029" unitRef="pure">0.08</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:LongTermDebtMaturityDate contextRef="c39" id="ixv-15030">2023-10-01</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:AccountsPayableInterestBearingInterestRate contextRef="c40" decimals="2" id="ixv-15031" unitRef="pure">0.09</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:LongTermDebtMaturityDate contextRef="c40" id="ixv-15032">2023-12-30</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-12771">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2 &#x2013; &lt;span style="text-decoration:underline"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation and Principles of Consolidation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S.
GAAP&#x201d;), the instructions to Form 10-K, and the rules and regulations of the United States Securities and Exchange Commission (the
&#x201c;SEC&#x201d;) for financial information. The Company&#x2019;s consolidated financial statements include financial statements for Silo
Pharma, Inc. and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc. All intercompany transactions
and balances have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with, Accounting Standard Codification
(&#x201c;ASC&#x201d;) 205-20 &#x201c;Discontinued Operations&#x201d; establishes that the disposal or abandonment of a component of an entity
or a group of components of an entity should be reported in discontinued operations if the disposal represents a strategic shift that
has (or will have) a major effect on an entity&#x2019;s operations and financial results. As a result, the NFID, LLC component&#x2019;s
results of operations have been classified as discontinued operations on a retrospective basis for all periods presented. Accordingly,
the results of operations of this component, for all periods, are separately reported as &#x201c;discontinued operations&#x201d; on the
consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As reflected in the accompanying consolidated
financial statements, the Company generated a net loss of $3,700,683 and used cash in operations of $3,224,498 during the year ended December
31, 2023. Additionally, the Company has an accumulated deficit of $10,871,811 on December 31, 2023. As of December 31, 2023, the Company
had working capital of $6,905,568.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The positive working capital serves to mitigate
the conditions that historically raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company
believes that the Company has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months
from the date of this filing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible
that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements,
which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the
actual results could differ significantly from estimates. Significant estimates during the years ended December 31, 2023 and 2022 include
the collectability of notes receivable, the percentage of completion of research and development projects, valuation of equity investments,
valuation allowances for deferred tax assets, the fair value of warrants issued with debt, and the fair value of shares and stock options
issued for services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid investments with a maturity
of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial institutions.
The Company&#x2019;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to
$250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of such financial
institutions, the Company evaluates at least annually the rating of the financial institutions in which it holds deposits. On December
31, 2023 and 2022, the Company had cash in excess of FDIC limits of approximately $2,805,000 and $10,868,000, respectively. During the
year ended December 31, 2023, the Company transferred funds to other high quality financial institutions to mitigate its risk to ensure
that its exposure is limited or reduced to the FDIC protection limits. In connection with the early termination of a certificate of deposit,
in 2023, the Company paid a penalty of $166,034, which is reflected on the accompanying consolidated statement of operations and comprehensive
loss during the year ended December 2023. Any material loss that we may experience in the future could have an adverse effect on our ability
to pay our operational expenses or make other payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Short-Term Investments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s portfolio of short-term investments
consists of marketable debt securities which are comprised solely of  highly rated U.S. government securities with maturities
of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate
such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending
upon changing liquidity requirements. These debt securities are classified as current assets in the consolidated balance sheet and recorded
at fair value, with unrealized gains or losses included in accumulated other comprehensive income and as a component of the consolidated
statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification
method and are reported in other income (expense), net in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;An impairment loss may be recognized when the
decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary
declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis
of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and
the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security,
such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required
to sell the security before recovery of its amortized cost basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recorded $6,227 of unrealized loss
on short-term investments as a component of other comprehensive loss for the year ended December 31, 2023, respectively. The Company did
not recognize any unrealized gains or losses on short-term investments during the year ended December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments, at Fair Value&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Realized gain or loss is recognized when an investment
is disposed of and is computed as the difference between the Company&#x2019;s carrying value and the net proceeds received from such disposition.
Realized gains and losses on investment transactions are determined by specific identification. Net unrealized appreciation or depreciation
is computed as the difference between the fair value of the investment and the cost basis of such investment. Net unrealized gains or
losses for equity investments are recognized in operations as the difference between the carrying value at the beginning of the period
and the fair value at the end of the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note Receivable&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recorded as part of general
and administrative expenses. As of December 31, 2023, the Company recognized an allowance for loss on the note receivable and accrued interest
receivable in an amount equal to the estimated probable losses, and accordingly, the Company recorded bad debt expense of $69,600, which
represents the note receivable principal balance of $60,000 and accrued interest receivable of $9,600, which is recorded in loss from
discontinued operations on the accompanying consolidated statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Prepaid Expenses&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prepaid expenses and other current assets of $15,970
and $135,894 on December 31, 2023 and 2022, respectively, consist primarily of costs paid for future services which will occur within
a year. On December 31, 2023 and 2022, prepaid expenses and other assets &#x2013; non-current amounted to $64,983 and $70,821, respectively,
and consist primarily of costs paid for future services which will occur after a year. Prepaid expenses may include prepayments in cash
and equity instruments for consulting, research and development, license fees, public relations and business advisory services, and legal
fees which are being amortized over the terms of their respective agreements, which may exceed a year of service.&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies ASC Topic 606, Revenue from
Contracts with Customers (&#x201c;ASC 606&#x201d;). ASC 606 establishes a single comprehensive model for entities to use in accounting for
revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records interest and dividend income
on an accrual basis to the extent that the Company expects to collect such amounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the license and royalty income, revenue is
recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the licensee
that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related license
agreement (see Note 8).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Product sales were recognized when the NFID products
were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately reported
as &#x201c;discontinued operations&#x201d; on the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cost of Revenues&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary components of cost of revenues on
license fees includes the cost of the license fees. Payments made to the licensor that are related to future periods are recorded as prepaid
expense to be amortized over the term of the related license agreement (see Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based compensation is accounted for based
on the requirements of ASC 718 &#x2013; &#x201c;Compensation &#x2013; Stock Compensation&#x201d;, which requires recognition in the financial
statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the
period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting
period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award
based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under Accounting
Standards Update (&#x201c;ASU&#x201d;) 2016-09 Improvements to Employee Share-Based Payment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income tax assets and liabilities arise
from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates,
which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current,
depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to
an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected
to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the provisions of Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 740-10, &#x201c;Uncertainty in Income Taxes&#x201d;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#x201c;more-likely-than-not&#x201d; threshold. The Company does not believe it has any uncertain tax positions as
of December 31, 2023 and 2022 that would require either recognition or disclosure in the accompanying consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 730-10, &lt;i&gt;&#x201c;Research
and Development-Overall,&#x201d;&lt;/i&gt; research and development costs are expensed when incurred. During the years ended December 31, 2023
and 2022, research and development costs were $845,092 and $1,286,434, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Leases are accounted for using ASU 2016-02, &#x201c;&lt;i&gt;Leases
(Topic 842)&#x201d;&lt;/i&gt;. ASU 2016-02 sets out the principles for the recognition, measurement, presentation and disclosure of leases for
both parties to a contract (i.e., lessees and lessors). The standard requires lessees to apply a dual approach, classifying leases as
either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee.
This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis
over the term of the lease. A lessee is also required to recognize a right-of-use asset and a lease liability for all leases with a term
of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to
existing guidance for operating leases today. As of December 31, 2023 and 2022, the Company has no leases. The Company will analyze any
lease to determine if it would be required to record a lease liability and a right of use asset on its consolidated balance sheets at
fair value upon adoption of ASU 2016-02. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term
leases that have a term of 12 months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Net Loss per Common Share&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic loss per share is computed by dividing net
loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted
loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock,
common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially
dilutive securities which include stock options and stock warrants are excluded from the computation of diluted shares outstanding if
they would have an anti-dilutive impact on the Company&#x2019;s net losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following potentially dilutive shares have
been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the years ended December 31,
2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,429&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,429&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management does not believe that any recently
issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-12777">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation and Principles of Consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S.
GAAP&#x201d;), the instructions to Form 10-K, and the rules and regulations of the United States Securities and Exchange Commission (the
&#x201c;SEC&#x201d;) for financial information. The Company&#x2019;s consolidated financial statements include financial statements for Silo
Pharma, Inc. and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc. All intercompany transactions
and balances have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with, Accounting Standard Codification
(&#x201c;ASC&#x201d;) 205-20 &#x201c;Discontinued Operations&#x201d; establishes that the disposal or abandonment of a component of an entity
or a group of components of an entity should be reported in discontinued operations if the disposal represents a strategic shift that
has (or will have) a major effect on an entity&#x2019;s operations and financial results. As a result, the NFID, LLC component&#x2019;s
results of operations have been classified as discontinued operations on a retrospective basis for all periods presented. Accordingly,
the results of operations of this component, for all periods, are separately reported as &#x201c;discontinued operations&#x201d; on the
consolidated statements of operations.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <silo:LiquidityPolicyTextBlock contextRef="c0" id="ixv-12814">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As reflected in the accompanying consolidated
financial statements, the Company generated a net loss of $3,700,683 and used cash in operations of $3,224,498 during the year ended December
31, 2023. Additionally, the Company has an accumulated deficit of $10,871,811 on December 31, 2023. As of December 31, 2023, the Company
had working capital of $6,905,568.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The positive working capital serves to mitigate
the conditions that historically raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company
believes that the Company has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months
from the date of this filing.&lt;/p&gt;</silo:LiquidityPolicyTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-15033" unitRef="usd">-3700683</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-15034" unitRef="usd">-3224498</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-15035" unitRef="usd">-10871811</us-gaap:RetainedEarningsAccumulatedDeficit>
    <silo:WorkingCapital contextRef="c3" decimals="0" id="ixv-15036" unitRef="usd">6905568</silo:WorkingCapital>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-12824">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible
that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements,
which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the
actual results could differ significantly from estimates. Significant estimates during the years ended December 31, 2023 and 2022 include
the collectability of notes receivable, the percentage of completion of research and development projects, valuation of equity investments,
valuation allowances for deferred tax assets, the fair value of warrants issued with debt, and the fair value of shares and stock options
issued for services.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-12832">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid investments with a maturity
of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial institutions.
The Company&#x2019;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to
$250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of such financial
institutions, the Company evaluates at least annually the rating of the financial institutions in which it holds deposits. On December
31, 2023 and 2022, the Company had cash in excess of FDIC limits of approximately $2,805,000 and $10,868,000, respectively. During the
year ended December 31, 2023, the Company transferred funds to other high quality financial institutions to mitigate its risk to ensure
that its exposure is limited or reduced to the FDIC protection limits. In connection with the early termination of a certificate of deposit,
in 2023, the Company paid a penalty of $166,034, which is reflected on the accompanying consolidated statement of operations and comprehensive
loss during the year ended December 2023. Any material loss that we may experience in the future could have an adverse effect on our ability
to pay our operational expenses or make other payments.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c3" decimals="0" id="ixv-15037" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <silo:CashSPICInsuredAmount contextRef="c3" decimals="0" id="ixv-15038" unitRef="usd">250000</silo:CashSPICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount contextRef="c41" decimals="0" id="ixv-15039" unitRef="usd">2805000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount contextRef="c42" decimals="0" id="ixv-15040" unitRef="usd">10868000</us-gaap:CashFDICInsuredAmount>
    <silo:PenaltyFromEarlyTerminationOfCD contextRef="c0" decimals="0" id="ixv-15041" unitRef="usd">166034</silo:PenaltyFromEarlyTerminationOfCD>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0" id="ixv-12840">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Short-Term Investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s portfolio of short-term investments
consists of marketable debt securities which are comprised solely of  highly rated U.S. government securities with maturities
of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate
such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending
upon changing liquidity requirements. These debt securities are classified as current assets in the consolidated balance sheet and recorded
at fair value, with unrealized gains or losses included in accumulated other comprehensive income and as a component of the consolidated
statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification
method and are reported in other income (expense), net in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;An impairment loss may be recognized when the
decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary
declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis
of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and
the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security,
such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required
to sell the security before recovery of its amortized cost basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recorded $6,227 of unrealized loss
on short-term investments as a component of other comprehensive loss for the year ended December 31, 2023, respectively. The Company did
not recognize any unrealized gains or losses on short-term investments during the year ended December 31, 2022.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c0" decimals="0" id="ixv-15042" unitRef="usd">-6227</us-gaap:UnrealizedGainLossOnInvestments>
    <silo:EquityInvestmentsAtFairValuePolicyTextBlock contextRef="c0" id="ixv-12880">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments, at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Realized gain or loss is recognized when an investment
is disposed of and is computed as the difference between the Company&#x2019;s carrying value and the net proceeds received from such disposition.
Realized gains and losses on investment transactions are determined by specific identification. Net unrealized appreciation or depreciation
is computed as the difference between the fair value of the investment and the cost basis of such investment. Net unrealized gains or
losses for equity investments are recognized in operations as the difference between the carrying value at the beginning of the period
and the fair value at the end of the period.&lt;/p&gt;</silo:EquityInvestmentsAtFairValuePolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0" id="ixv-12888">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recorded as part of general
and administrative expenses. As of December 31, 2023, the Company recognized an allowance for loss on the note receivable and accrued interest
receivable in an amount equal to the estimated probable losses, and accordingly, the Company recorded bad debt expense of $69,600, which
represents the note receivable principal balance of $60,000 and accrued interest receivable of $9,600, which is recorded in loss from
discontinued operations on the accompanying consolidated statement of operations.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <silo:BadDebtExpense contextRef="c0" decimals="0" id="ixv-15043" unitRef="usd">69600</silo:BadDebtExpense>
    <us-gaap:ReceivableWithImputedInterestFaceAmount contextRef="c3" decimals="0" id="ixv-15044" unitRef="usd">60000</us-gaap:ReceivableWithImputedInterestFaceAmount>
    <us-gaap:InterestReceivableCurrent contextRef="c3" decimals="0" id="ixv-15045" unitRef="usd">9600</us-gaap:InterestReceivableCurrent>
    <silo:PrepaidExpensesPolicyTextBlock contextRef="c0" id="ixv-12895">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Prepaid Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prepaid expenses and other current assets of $15,970
and $135,894 on December 31, 2023 and 2022, respectively, consist primarily of costs paid for future services which will occur within
a year. On December 31, 2023 and 2022, prepaid expenses and other assets &#x2013; non-current amounted to $64,983 and $70,821, respectively,
and consist primarily of costs paid for future services which will occur after a year. Prepaid expenses may include prepayments in cash
and equity instruments for consulting, research and development, license fees, public relations and business advisory services, and legal
fees which are being amortized over the terms of their respective agreements, which may exceed a year of service.&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</silo:PrepaidExpensesPolicyTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-15046" unitRef="usd">15970</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="0" id="ixv-15047" unitRef="usd">135894</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c3" decimals="0" id="ixv-15048" unitRef="usd">64983</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c4" decimals="0" id="ixv-15049" unitRef="usd">70821</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0" id="ixv-12904">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies ASC Topic 606, Revenue from
Contracts with Customers (&#x201c;ASC 606&#x201d;). ASC 606 establishes a single comprehensive model for entities to use in accounting for
revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records interest and dividend income
on an accrual basis to the extent that the Company expects to collect such amounts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the license and royalty income, revenue is
recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the licensee
that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related license
agreement (see Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Product sales were recognized when the NFID products
were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately reported
as &#x201c;discontinued operations&#x201d; on the consolidated statements of operations.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <silo:CostOfRevenuesPolicyTextBlock contextRef="c0" id="ixv-12920">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cost of Revenues&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary components of cost of revenues on
license fees includes the cost of the license fees. Payments made to the licensor that are related to future periods are recorded as prepaid
expense to be amortized over the term of the related license agreement (see Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:CostOfRevenuesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock contextRef="c0" id="ixv-12953">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based compensation is accounted for based
on the requirements of ASC 718 &#x2013; &#x201c;Compensation &#x2013; Stock Compensation&#x201d;, which requires recognition in the financial
statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the
period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting
period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award
based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under Accounting
Standards Update (&#x201c;ASU&#x201d;) 2016-09 Improvements to Employee Share-Based Payment.&lt;/p&gt;</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-12960">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income tax assets and liabilities arise
from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates,
which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current,
depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to
an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected
to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the provisions of Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 740-10, &#x201c;Uncertainty in Income Taxes&#x201d;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#x201c;more-likely-than-not&#x201d; threshold. The Company does not believe it has any uncertain tax positions as
of December 31, 2023 and 2022 that would require either recognition or disclosure in the accompanying consolidated financial statements.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-12970">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 730-10, &lt;i&gt;&#x201c;Research
and Development-Overall,&#x201d;&lt;/i&gt; research and development costs are expensed when incurred. During the years ended December 31, 2023
and 2022, research and development costs were $845,092 and $1,286,434, respectively.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-15050" unitRef="usd">845092</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-15051" unitRef="usd">1286434</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-12978">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Leases are accounted for using ASU 2016-02, &#x201c;&lt;i&gt;Leases
(Topic 842)&#x201d;&lt;/i&gt;. ASU 2016-02 sets out the principles for the recognition, measurement, presentation and disclosure of leases for
both parties to a contract (i.e., lessees and lessors). The standard requires lessees to apply a dual approach, classifying leases as
either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee.
This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis
over the term of the lease. A lessee is also required to recognize a right-of-use asset and a lease liability for all leases with a term
of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to
existing guidance for operating leases today. As of December 31, 2023 and 2022, the Company has no leases. The Company will analyze any
lease to determine if it would be required to record a lease liability and a right of use asset on its consolidated balance sheets at
fair value upon adoption of ASU 2016-02. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term
leases that have a term of 12 months or less.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-12986">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Net Loss per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic loss per share is computed by dividing net
loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted
loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock,
common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially
dilutive securities which include stock options and stock warrants are excluded from the computation of diluted shares outstanding if
they would have an anti-dilutive impact on the Company&#x2019;s net losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following potentially dilutive shares have
been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the years ended December 31,
2023 and 2022:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,429&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,429&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-15052">The following potentially dilutive shares have
been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the years ended December 31,
2023 and 2022:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,429&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,429&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c43"
      decimals="INF"
      id="ixv-15053"
      unitRef="shares">28849</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c44"
      decimals="INF"
      id="ixv-15054"
      unitRef="shares">28849</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c45"
      decimals="INF"
      id="ixv-15055"
      unitRef="shares">404580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c46"
      decimals="INF"
      id="ixv-15056"
      unitRef="shares">404580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="INF"
      id="ixv-15057"
      unitRef="shares">433429</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c5"
      decimals="INF"
      id="ixv-15058"
      unitRef="shares">433429</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-13074">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management does not believe that any recently
issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-13083">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2013; &lt;span style="text-decoration:underline"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS
AND FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Fair Value Measurements and Fair Value of Financial
Instruments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;FASB ASC 820 - Fair Value Measurements and Disclosures,
defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether
or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent
information available to the Company on December 31, 2023 and 2022. Accordingly, the estimates presented in these financial statements
are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies
a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable
inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest
priority to unobservable inputs (Level 3 measurement).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; padding-right: 0.8pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.6in; padding-right: 0.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unobservable inputs which reflect the reporting entity&#x2019;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying value of certain financial instruments,
including cash and cash equivalents, prepaid expenses and other current assets, notes receivable, and accounts payable and accrued expenses
are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company analyzes all financial instruments
with features of both liabilities and equity under the Financial Accounting Standard Board&#x2019;s (the &#x201c;FASB&#x201d;) accounting
standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest
level of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table represents the Company&#x2019;s
fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,140,880&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Equity investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s short-term investments and
equity investments are level 1 measurements and are based on redemption value at each date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Short-Term Investments &#x2013; Debt Securities,
at Fair Value&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes activity in the
Company&#x2019;s short-term investments, at fair value for the periods presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Balance, beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%"&gt;Additions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,147,107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unrealized losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Balance, end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,140,880&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Equity Investments, at Fair Value&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes activity in the
Company&#x2019;s equity investments, at fair value for the periods presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance, beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sales at original cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(171,407&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unrealized loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(331,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Balance, end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,118&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 31, 2023 and 2022, equity instruments,
at fair value consisted of 1,559 shares of common equity securities of one entity, Home Bistro, Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company
received 1,559 shares of Home Bistro, Inc. common stock with grant date fair value of $85,733, or $54.99 per share, in exchange for entering
into a lock up and leak out agreement which was recorded as other income from equity shares earned for services in the accompanying consolidated
statement of operations and comprehensive loss. The Company measures equity securities received for services at fair value on the date
of receipt.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company
sold its equity investments in Aikido Pharma, Inc. with cost of $171,407 for gross proceeds of $66,707 and the Company recorded a net
realized loss on equity investments amounting to $104,700 as reflected in the accompanying consolidated statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equity investments are carried at fair value with
unrealized gains or losses which are recorded as net unrealized gain (loss) on equity investments in the accompanying consolidated statement
of operations and comprehensive loss.&#160;Realized gains and losses are determined on a specific identification basis which is recorded
as net realized gain (loss) on equity investments in the consolidated statement of operations and comprehensive loss. The Company reviews
equity investments, at fair value, for impairment whenever circumstances and situations change such that there is an indication that the
carrying amounts may not be recovered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 825-10 &#x201c;Financial Instruments&#x201d;
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0" id="ixv-15059">The following table represents the Company&#x2019;s
fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and 2022.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,140,880&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Equity investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:ShortTermInvestments contextRef="c51" decimals="0" id="ixv-15060" unitRef="usd">4140880</us-gaap:ShortTermInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c54" decimals="0" id="ixv-15061" unitRef="usd">3118</us-gaap:EquityMethodInvestments>
    <silo:ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock contextRef="c0" id="ixv-15062">The following table summarizes activity in the
Company&#x2019;s short-term investments, at fair value for the periods presented:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Balance, beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%"&gt;Additions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,147,107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unrealized losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Balance, end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,140,880&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;The following table summarizes activity in the
Company&#x2019;s equity investments, at fair value for the periods presented:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance, beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sales at original cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(171,407&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unrealized loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(331,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Balance, end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,118&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</silo:ScheduleOfSummarizesActivityInTheCompanysShortTermInvestmentsAndEquityInvestmentsAtFairValueTableTextBlock>
    <silo:AdditionsOfShortTermInvestments contextRef="c59" decimals="0" id="ixv-15063" unitRef="usd">4147107</silo:AdditionsOfShortTermInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c59" decimals="0" id="ixv-15064" unitRef="usd">-6227</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ShortTermInvestments contextRef="c61" decimals="0" id="ixv-15065" unitRef="usd">4140880</us-gaap:ShortTermInvestments>
    <us-gaap:EquitySecuritiesFvNi contextRef="c62" decimals="0" id="ixv-15067" unitRef="usd">3118</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c63" decimals="0" id="ixv-15068" unitRef="usd">419995</us-gaap:EquitySecuritiesFvNi>
    <silo:AdditionsofEquitySecurities contextRef="c65" decimals="0" id="ixv-15069" unitRef="usd">85733</silo:AdditionsofEquitySecurities>
    <silo:EquitySecuritiesSalesAtOriginalCost contextRef="c65" decimals="0" id="ixv-15070" unitRef="usd">171407</silo:EquitySecuritiesSalesAtOriginalCost>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c64" decimals="0" id="ixv-15071" unitRef="usd">-3118</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c65" decimals="0" id="ixv-15072" unitRef="usd">-331203</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNi contextRef="c62" decimals="0" id="ixv-15073" unitRef="usd">3118</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c47"
      decimals="0"
      id="ixv-15074"
      unitRef="shares">1559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c48"
      decimals="0"
      id="ixv-15075"
      unitRef="shares">1559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c49"
      decimals="0"
      id="ixv-15076"
      unitRef="shares">1559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue contextRef="c49" decimals="0" id="ixv-15077" unitRef="usd">85733</silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c5"
      decimals="2"
      id="ixv-15078"
      unitRef="usdPershares">54.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c50" decimals="0" id="ixv-15079" unitRef="usd">171407</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c50" decimals="0" id="ixv-15080" unitRef="usd">66707</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c50" decimals="0" id="ixv-15081" unitRef="usd">-104700</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c0" id="ixv-13432">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span style="text-decoration:underline"&gt;DISPOSAL OF THE DISCONTINUED
OPERATIONS OF THE NFID BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2021, the Company entered into
and closed on an Asset Purchase Agreement (see Note 1) with NFID, LLC, an unrelated party, a Florida limited liability company, whereby
the Company sold certain assets, properties, and rights in connection with its NFID trademark name, logos, domain, and apparel clothing
and accessories for a purchase price of $60,000 in the form of a promissory note amounting to $60,000. The promissory note bore 8% interest
per annum and matured on October 1, 2023. On November 8, 2023 and effective on October 1, 2023, the Company and the Buyer entered into
a First Amendment Promissory Note which increased the interest rate to 9% per annum and extended the maturity date to December 30, 2023
for no consideration. As of December 31, 2023, the Company recognized an allowance for loss on the note receivable and accrued interest
receivable in an amount equal to the estimated probable losses, and accordingly, the Company recorded bad debt expense of $69,600, which
represents the note receivable principal balance of $60,000 and accrued interest receivable of $9,600, which is recorded in loss from
discontinued operations on the accompanying consolidated statement of operations. As of December 31, 2022, the note receivable had a principal
balance of $60,000 and accrued interest receivable of $6,010 for a total outstanding receivable balance of $66,010 (see Note 5).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 205-20 &#x201c;Discontinued Operations&#x201d;
establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should be reported in discontinued
operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#x2019;s operations and financial
results. As a result, the component&#x2019;s results of operations have been classified as discontinued operations on a retrospective basis
for all periods presented. Accordingly, the results of operations of this component, for all periods, are separately reported as &#x201c;discontinued
operations&#x201d; on the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The summarized operating result of discontinued
operations of the NFID Business included in the Company&#x2019;s consolidated statements of operations for the years ended December 31,
2023 and 2022 is as follows:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Product sales, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt"&gt;Cost of sales&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating and other non-operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(69,600&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(84&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Loss from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(69,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,163&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromNotesPayable contextRef="c38" decimals="0" id="ixv-15082" unitRef="usd">60000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c67" decimals="0" id="ixv-15083" unitRef="usd">60000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c68" decimals="2" id="ixv-15084" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c69" id="ixv-15085">2023-10-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c70" decimals="2" id="ixv-15086" unitRef="pure">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c71" id="ixv-15087">2023-12-30</us-gaap:DebtInstrumentMaturityDate>
    <silo:ProvisionForDoubtfulAccountsDiscontinuedOperations contextRef="c0" decimals="0" id="ixv-15088" unitRef="usd">69600</silo:ProvisionForDoubtfulAccountsDiscontinuedOperations>
    <us-gaap:NotesReceivableNet contextRef="c3" decimals="0" id="ixv-15089" unitRef="usd">60000</us-gaap:NotesReceivableNet>
    <us-gaap:InterestReceivableCurrent contextRef="c3" decimals="0" id="ixv-15090" unitRef="usd">9600</us-gaap:InterestReceivableCurrent>
    <us-gaap:NotesReceivableNet contextRef="c4" decimals="0" id="ixv-15091" unitRef="usd">60000</us-gaap:NotesReceivableNet>
    <us-gaap:InterestReceivableCurrent contextRef="c4" decimals="0" id="ixv-15092" unitRef="usd">6010</us-gaap:InterestReceivableCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-15093" unitRef="usd">66010</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c0" id="ixv-15094">The summarized operating result of discontinued
operations of the NFID Business included in the Company&#x2019;s consolidated statements of operations for the years ended December 31,
2023 and 2022 is as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Product sales, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt"&gt;Cost of sales&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating and other non-operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(69,600&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(84&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Loss from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(69,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,163&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c5" decimals="0" id="ixv-15095" unitRef="usd">1079</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c5" decimals="0" id="ixv-15096" unitRef="usd">-1079</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense contextRef="c0" decimals="0" id="ixv-15097" unitRef="usd">69600</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense contextRef="c5" decimals="0" id="ixv-15098" unitRef="usd">84</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-15099" unitRef="usd">-69600</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c5" decimals="0" id="ixv-15100" unitRef="usd">-1163</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0" id="ixv-13520">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 5 &#x2013; &lt;span style="text-decoration:underline"&gt;NOTE RECEIVABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 31, 2023 and 2022, note receivable consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Principal amount of note receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued interest receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,600&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,010&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(69,600&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Note receivable &#x2013; current&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;66,010&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2021, the Company executed a
note receivable agreement with NFID, LLC in connection with an Asset Purchase Agreement (see Note 4). The promissory note bore 8% interest
per annum and matured on October 1, 2023. On November 8, 2023 and effective on October 1, 2023, the Company and the Buyer entered into
a First Amendment Promissory Note which increased the interest rate to 9% per annum and extended the maturity date to December 30, 2023
for no consideration. The outstanding principal and accrued interest shall be due and payable on maturity. As of December 31, 2023, the
Company recognized an allowance for loss on the note receivable and accrued interest receivable in an amount equal to the estimated probable
losses, and accordingly, the Company recorded bad debt expense of $69,600, which represents the note receivable principal balance of $60,000
and accrued interest receivable of $9,600, which is recorded in loss from discontinued operations on the accompanying consolidated statement
of operations. As of December 31, 2022, this note receivable had outstanding principal receivable of $60,000 and accrued interest receivable
of $6,010 for a total receivable balance of $66,010 which is reflected in the accompanying consolidated balance sheet as note receivable
&#x2013; current.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0" id="ixv-15101">On December 31, 2023 and 2022, note receivable consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Principal amount of note receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued interest receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,600&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,010&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(69,600&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Note receivable &#x2013; current&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;66,010&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:NotesReceivableNet contextRef="c3" decimals="0" id="ixv-15102" unitRef="usd">60000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet contextRef="c4" decimals="0" id="ixv-15103" unitRef="usd">60000</us-gaap:NotesReceivableNet>
    <us-gaap:InterestReceivableCurrent contextRef="c3" decimals="0" id="ixv-15104" unitRef="usd">9600</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="c4" decimals="0" id="ixv-15105" unitRef="usd">6010</us-gaap:InterestReceivableCurrent>
    <us-gaap:NotesReceivableGross contextRef="c3" decimals="0" id="ixv-15106" unitRef="usd">69600</us-gaap:NotesReceivableGross>
    <us-gaap:NotesReceivableGross contextRef="c4" decimals="0" id="ixv-15107" unitRef="usd">66010</us-gaap:NotesReceivableGross>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses contextRef="c3" decimals="0" id="ixv-15108" unitRef="usd">69600</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:ReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-15109" unitRef="usd">66010</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate contextRef="c72" decimals="2" id="ixv-15110" unitRef="pure">0.08</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:LongTermDebtMaturityDate contextRef="c72" id="ixv-15111">2023-10-01</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:AccountsPayableInterestBearingInterestRate contextRef="c73" decimals="2" id="ixv-15112" unitRef="pure">0.09</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:LongTermDebtMaturityDate contextRef="c73" id="ixv-15113">2023-12-30</us-gaap:LongTermDebtMaturityDate>
    <silo:ProvisionForDoubtfulAccountsDiscontinuedOperations contextRef="c0" decimals="0" id="ixv-15114" unitRef="usd">69600</silo:ProvisionForDoubtfulAccountsDiscontinuedOperations>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c74" decimals="0" id="ixv-15115" unitRef="usd">60000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestReceivableCurrent contextRef="c3" decimals="0" id="ixv-15116" unitRef="usd">9600</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c75" decimals="0" id="ixv-15117" unitRef="usd">60000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestReceivableCurrent contextRef="c4" decimals="0" id="ixv-15118" unitRef="usd">6010</us-gaap:InterestReceivableCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-15119" unitRef="usd">66010</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0" id="ixv-13628">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 &#x2013; &lt;span style="text-decoration:underline"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Shares Authorized&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 4, 2023, stockholders of the Company
approved a decrease to the number of authorized shares of the Company&#x2019;s common stock from 500,000,000 shares to 100,000,000 shares.
On December 4, 2023, the Company filed a Certificate of Amendment (the &#x201c;Amendment&#x201d;) to its Certificate of Incorporation with
the Delaware Secretary of State to decrease its authorized shares of common stock from 500,000,000 shares to 100,000,000 shares. On December
19, 2023, the Company reincorporated as a Nevada corporation and filed Articles of Incorporation with the Nevada Secretary of State on
such date. The Company has 105,000,000 shares authorized which consist of 100,000,000 shares of common stock and 5,000,000 shares of
preferred stock.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Series C Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 9, 2021, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &#x201c;Certificate of Designations&#x201d;)
with the Delaware Secretary of State, designating 4,280 shares of preferred stock as Series C Convertible preferred stock. The Company
had designated 4,280 shares of preferred stock as Series C Convertible preferred stock. Each share of Series C Convertible Preferred Stock
had a par value of $0.0001 per share and a stated value of $1,000 (the &#x201c;Series C Stated Value&#x201d;). Each share of Series C Convertible
preferred stock was convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number
of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price. &#x201c;Series C Conversion
Price&#x201d; means $15.00, subject to adjustment in the event of stock split, stock dividends, subsequent right offerings and similar
recapitalization transactions. Notwithstanding anything herein to the contrary, after the date that the Company&#x2019;s stockholder approval
is obtained and deemed effective, the Company may deliver a written notice to all holders (the &#x201c;Forced Conversion Notice Date&#x201d;)
to cause each holder to convert all or part of such holder&#x2019;s Series C Convertible preferred stock pursuant to Section 6 (&#x201c;Forced
Conversion&#x201d;), it being agreed that the &#x201c;Conversion Date&#x201d; shall be deemed to occur no later than the earlier of (i) two
(2) trading days and (ii) the number of trading days comprising the standard settlement period following the Forced Conversion Notice
Date; provided, however, a holder shall only be required to convert pursuant to a Forced Conversion to the extent that such conversion
would not cause a holder to exceed its beneficial ownership limitation. On March 31, 2022, the Company notified holders of the remaining
227 shares of its Series C Convertible preferred stock of its election to force the conversion to its Series C Convertible preferred stock
into shares of the Company&#x2019;s common stock (see below). As of December 31, 2022, there were &lt;span style="-sec-ix-hidden: hidden-fact-126"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-127"&gt;no&lt;/span&gt;&lt;/span&gt; shares of the Series preferred stock
issued and outstanding. On December 19, 2023, the Company changed its state of incorporation from the State of Delaware to the State of
Nevada and since there were no shares of Series C Convertible Stock outstanding at the time or the reincorporation the Company did not
designate Series C Convertible Stock in Nevada and it was deemed cancelled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Conversion of Series C Convertible Preferred
Stock into Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 31, 2022, the Company notified holders
of the remaining 227 shares of its Series C Convertible preferred stock of its election to force the conversion to its Series C Convertible
preferred stock into shares of the Company&#x2019;s common stock pursuant to the Certificate of Designations unless such conversion would
cause the holder to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On March 31, 2022, the Company
converted the remaining 227 Series C Convertible preferred stock into 15,167 shares of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sale of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 26, 2022, the Company entered into
an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Laidlaw &amp;amp; Company (UK) Ltd., as representative of the several
underwriters identified therein (the &#x201c;Underwriters&#x201d;), relating to the public offering (the &#x201c;Offering&#x201d;) of 1,000,000
shares of the Company&#x2019;s common stock (the &#x201c;Firm Shares&#x201d;), at public offering price of $5.00 per share. Under the terms
of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 45 days following the closing of the Offering,
to purchase up to an additional 150,000 shares of common stock at the public offering price to cover over-allotments, if any. On September
28, 2022, the Underwriters fully exercised their over-allotment option and purchased an additional 150,000 shares (the &#x201c;Option Shares,&#x201d;
together with the Firm Shares, the &#x201c;Shares&#x201d;). On September 29, 2022 the Company closed the Offering and issued the Shares
for aggregate net proceeds of $4,940,948, after deducting underwriting discounts and commissions and offering expenses. The Company intends
to use the net proceeds from the offering for research and development activities, sales and marketing, general working capital purposes,
potential acquisitions of other companies, products or technologies, and to repay certain indebtedness. Concurrently with the closing
of the Offering, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock to the representative
of the Underwriters or its designees, at an exercise price of $6.25 per share (the &#x201c;Representative&#x2019;s Warrants&#x201d;). The
Representative&#x2019;s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and
conditions of the Representative&#x2019;s Warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Common Stock Issued for Services&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 29, 2022, the Company entered into a
one-year consulting agreement with an entity for investor relations services. In connection with this consulting agreement, the Company
issued 20,000 restricted common shares of the Company to the consultant. These shares vest immediately. These shares were valued at $135,100,
or $6.755 per common share, based on contemporaneous common share sales by the Company. In connection with this consulting agreement,
during the years ended December 31, 2023 and 2022, the Company recorded stock-based professional fees of $90,067 and $45,033, respectively.
which was amortized into stock-based professional fees over the term of the agreement.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock Repurchase Plan&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 26, 2023, the Company&#x2019;s Board
of Directors authorized a stock repurchase plan to repurchase up to $1.0&#160;million of the Company&#x2019;s issued and outstanding common
stock, from time to time, with such plan to be in place until December 31, 2023. On January 9, 2024, the Board of Directors of the Company
approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the Company&#x2019;s
common stock until March 31, 2024. Through December 31, 2023, the Company purchased 252,855 shares of common stock for a cost of $471,121,
which is reflected in treasury stock on the accompanying consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 18, 2021, the Company&#x2019;s board
of directors (&#x201c;Board&#x201d;) approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) to
incentivize employees, officers, directors and consultants of the Company and its affiliates. 170,000 shares of common stock are reserved
and available for issuance under the 2020 Plan, provided that certain exempt awards (as defined in the 2020 Plan), shall not count against
such share limit. The 2020 Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of cash,
stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock
units, stock appreciation units and other stock or cash-based awards.&#160;The 2020 Plan shall terminate on the tenth anniversary of the
date of adoption by the Board. Subject to certain restrictions, the Board may amend or terminate the Plan at any time and for any reason.
An amendment of the 2020 Plan shall be subject to the approval of the Company&#x2019;s stockholders only to the extent required by applicable
laws, rules or regulations. On March 10, 2021, the 2020 Plan was approved by the stockholders. On&#160;September 15, 2023, our Board of
Directors adopted the Silo Pharma, Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan which was approved by the Company&#x2019;s
stockholders on December 4, 2023. The Amended and Restated Omnibus Equity Incentive Plan (i) increases the number of shares of common
stock that may be issued under such plan by 300,000 shares to 470,000 shares and (ii) includes clawback provisions to comply with recent
developments of applicable law.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 29, 2021 and effective January 1,
2022, the Board granted an aggregate of 6,849 incentive stock options under the 2020 Plan, to two non-employee board members, exercisable
at $7.30 per share which expire on December 26, 2026 and vest on the first anniversary date of the grant date. These options were valued
at $30,224 on the grant date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of
0.75%, expected dividend yield of 0%, expected term of 2 years using the simplified method and expected volatility of 115% based on historical
volatility. The Company recorded the fair value of the unvested stock options, in the amount of $30,224, as deferred compensation which
is being amortized over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 27, 2022, pursuant to an Employment
Agreement (see Note 8), an aggregate of 16,000 incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $10.00
per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests
on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023. The 16,000 stock options had a fair value of $94,915 which were valued
at the grant date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of 1.18%, expected
dividend yield of 0%, expected term of 2 years using the simplified method and expected volatility of 117% based on historical volatility.
The Company recorded the fair value of the stock options, in the amount of $94,915, as deferred compensation which is being amortized
over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2023 and 2022,
the Company amortized $14,125 and $111,014 of the deferred compensation which was recorded as compensation expenses in the accompanying
consolidated statement of operations and comprehensive loss. As of December 31, 2023, there was no remaining deferred compensation related
to these issuances. As of December 31, 2022, the deferred compensation related to these issuances had a balance of $14,125.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock option activities for the years ended December
31, 2023 and 2022 are summarized as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,849&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.89&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;42,870&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,610&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,610&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 26, 2022, concurrently with the closing
of the Offering as discussed above, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock
to the representative of the Underwriters or its designees, at an exercise price of $6.25 per share (the &#x201c;Representative&#x2019;s
Warrants&#x201d;). The Representative&#x2019;s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant
to the terms and conditions of the Representative&#x2019;s Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Warrant activities for the years ended December
31, 2023 and 2022 are summarized as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;347,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;57,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6.25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14.05&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14.05&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c76"
      decimals="0"
      id="ixv-15120"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c77"
      decimals="0"
      id="ixv-15121"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c78"
      decimals="0"
      id="ixv-15122"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c79"
      decimals="0"
      id="ixv-15123"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c0"
      decimals="0"
      id="ixv-15124"
      unitRef="shares">105000000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c80"
      decimals="0"
      id="ixv-15125"
      unitRef="shares">100000000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c81"
      decimals="0"
      id="ixv-15126"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <silo:PreferredStockShareDesignated
      contextRef="c82"
      decimals="0"
      id="ixv-15127"
      unitRef="shares">4280</silo:PreferredStockShareDesignated>
    <silo:PreferredStockShareDesignated
      contextRef="c3"
      decimals="0"
      id="ixv-15128"
      unitRef="shares">4280</silo:PreferredStockShareDesignated>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c83"
      decimals="4"
      id="ixv-15129"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c83" decimals="0" id="ixv-15130" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="c84" id="ixv-15131">share of Series C Convertible
preferred stock was convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number
of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c85"
      decimals="2"
      id="ixv-15132"
      unitRef="usdPershares">15</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c86"
      decimals="0"
      id="ixv-15133"
      unitRef="shares">227</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c89"
      decimals="0"
      id="ixv-15134"
      unitRef="shares">227</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c90"
      decimals="0"
      id="ixv-15135"
      unitRef="shares">227</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c91"
      decimals="0"
      id="ixv-15136"
      unitRef="shares">15167</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c92"
      decimals="0"
      id="ixv-15137"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c93"
      decimals="2"
      id="ixv-15138"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c94"
      decimals="0"
      id="ixv-15139"
      unitRef="shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c95"
      decimals="0"
      id="ixv-15140"
      unitRef="shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c96" decimals="0" id="ixv-15141" unitRef="usd">4940948</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c97"
      decimals="0"
      id="ixv-15142"
      unitRef="shares">57500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c97"
      decimals="2"
      id="ixv-15143"
      unitRef="usdPershares">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c98"
      decimals="0"
      id="ixv-15144"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c98" decimals="0" id="ixv-15145" unitRef="usd">135100</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <silo:RestrictedCommonSharePrice
      contextRef="c98"
      decimals="3"
      id="ixv-15146"
      unitRef="usdPershares">6.755</silo:RestrictedCommonSharePrice>
    <us-gaap:ProfessionalFees contextRef="c26" decimals="0" id="ixv-15147" unitRef="usd">90067</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c14" decimals="0" id="ixv-15148" unitRef="usd">45033</us-gaap:ProfessionalFees>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c99" decimals="-5" id="ixv-15149" unitRef="usd">1000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="c100"
      decimals="-6"
      id="ixv-15150"
      unitRef="usd">1000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="c0"
      decimals="0"
      id="ixv-15151"
      unitRef="shares">252855</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <silo:CommonStockPurchaseCost contextRef="c3" decimals="0" id="ixv-15152" unitRef="usd">471121</silo:CommonStockPurchaseCost>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c101"
      decimals="0"
      id="ixv-15153"
      unitRef="shares">170000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="c102"
      decimals="0"
      id="ixv-15154"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="c103"
      decimals="0"
      id="ixv-15155"
      unitRef="shares">470000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <silo:AggregateOfIncentiveStockOptions
      contextRef="c104"
      decimals="0"
      id="ixv-15156"
      unitRef="shares">6849</silo:AggregateOfIncentiveStockOptions>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c105"
      decimals="2"
      id="ixv-15157"
      unitRef="usdPershares">7.3</us-gaap:SharesIssuedPricePerShare>
    <silo:StockOptionValue contextRef="c104" decimals="0" id="ixv-15158" unitRef="usd">30224</silo:StockOptionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c104"
      decimals="4"
      id="ixv-15159"
      unitRef="pure">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c104"
      decimals="2"
      id="ixv-15160"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c104" id="ixv-15161">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c104"
      decimals="2"
      id="ixv-15162"
      unitRef="pure">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:DeferredCompensationEquity contextRef="c105" decimals="0" id="ixv-15163" unitRef="usd">30224</us-gaap:DeferredCompensationEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="c106"
      decimals="0"
      id="ixv-15164"
      unitRef="shares">16000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c107"
      decimals="2"
      id="ixv-15165"
      unitRef="usdPershares">10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c0"
      decimals="0"
      id="ixv-15166"
      unitRef="shares">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c108"
      decimals="0"
      id="ixv-15167"
      unitRef="shares">5000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c109"
      decimals="0"
      id="ixv-15168"
      unitRef="shares">5000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c110"
      decimals="0"
      id="ixv-15169"
      unitRef="shares">16000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c110" decimals="0" id="ixv-15170" unitRef="usd">94915</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c110"
      decimals="4"
      id="ixv-15171"
      unitRef="pure">0.0118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c110"
      decimals="2"
      id="ixv-15172"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c110" id="ixv-15173">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c110"
      decimals="2"
      id="ixv-15174"
      unitRef="pure">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="c110" decimals="0" id="ixv-15175" unitRef="usd">94915</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationEquity contextRef="c3" decimals="0" id="ixv-15176" unitRef="usd">14125</us-gaap:DeferredCompensationEquity>
    <us-gaap:DeferredCompensationEquity contextRef="c4" decimals="0" id="ixv-15177" unitRef="usd">111014</us-gaap:DeferredCompensationEquity>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent contextRef="c111" decimals="0" id="ixv-15178" unitRef="usd">14125</us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-15179">Stock option activities for the years ended December
31, 2023 and 2022 are summarized as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,849&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.89&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;42,870&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,610&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,849&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,610&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c113"
      decimals="INF"
      id="ixv-15180"
      unitRef="shares">12849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c113"
      decimals="2"
      id="ixv-15181"
      unitRef="usdPershares">3.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c114" id="ixv-15182">P2Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c113" decimals="0" id="ixv-15183" unitRef="usd">42870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c115"
      decimals="INF"
      id="ixv-15184"
      unitRef="shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c115"
      decimals="1"
      id="ixv-15185"
      unitRef="usdPershares">10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c116"
      decimals="INF"
      id="ixv-15186"
      unitRef="shares">28849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c116"
      decimals="2"
      id="ixv-15187"
      unitRef="usdPershares">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c115" id="ixv-15188">P6Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c116" decimals="0" id="ixv-15189" unitRef="usd">20130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c118"
      decimals="INF"
      id="ixv-15190"
      unitRef="shares">28849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c118"
      decimals="2"
      id="ixv-15191"
      unitRef="usdPershares">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c117" id="ixv-15192">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c118" decimals="0" id="ixv-15193" unitRef="usd">8610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c118"
      decimals="INF"
      id="ixv-15194"
      unitRef="shares">28849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c118"
      decimals="2"
      id="ixv-15195"
      unitRef="usdPershares">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c117" id="ixv-15196">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c118" decimals="0" id="ixv-15197" unitRef="usd">8610</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c112"
      decimals="0"
      id="ixv-15198"
      unitRef="shares">57500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c112"
      decimals="2"
      id="ixv-15199"
      unitRef="usdPershares">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-15200">Warrant activities for the years ended December
31, 2023 and 2022 are summarized as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;347,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;57,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6.25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14.05&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;404,580&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14.05&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c119"
      decimals="INF"
      id="ixv-15201"
      unitRef="shares">347080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c119"
      decimals="1"
      id="ixv-15202"
      unitRef="usdPershares">15.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c120" id="ixv-15203">P4Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c121"
      decimals="INF"
      id="ixv-15204"
      unitRef="shares">57500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c121"
      decimals="2"
      id="ixv-15205"
      unitRef="usdPershares">6.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted contextRef="c121" id="ixv-15206">P5Y</silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c122"
      decimals="INF"
      id="ixv-15207"
      unitRef="shares">404580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c122"
      decimals="2"
      id="ixv-15208"
      unitRef="usdPershares">14.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c121" id="ixv-15209">P3Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c124"
      decimals="INF"
      id="ixv-15210"
      unitRef="shares">404580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c124"
      decimals="2"
      id="ixv-15211"
      unitRef="usdPershares">14.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c123" id="ixv-15212">P2Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable
      contextRef="c123"
      decimals="INF"
      id="ixv-15213"
      unitRef="shares">404580</silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfOptionsExercisable>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable
      contextRef="c123"
      decimals="2"
      id="ixv-15214"
      unitRef="shares">14.05</silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercisable>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable contextRef="c123" id="ixv-15215">P2Y3M18D</silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsExercisable>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0" id="ixv-14034">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span style="text-decoration:underline"&gt;CONCENTRATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Customer concentration&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2023 and 2022,
one licensee accounted for 100% total revenues from customer license fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Vendor concentrations&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2023 and 2022,
one licensor accounted for 100% of the Company&#x2019;s vendor license agreements (see below) related to the Company&#x2019;s biopharmaceutical
operations.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c125"
      decimals="2"
      id="ixv-15216"
      unitRef="pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c126"
      decimals="2"
      id="ixv-15217"
      unitRef="pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c127"
      decimals="2"
      id="ixv-15218"
      unitRef="pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c128"
      decimals="2"
      id="ixv-15219"
      unitRef="pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-14074">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 &#x2013; &lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Employment Agreements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Eric Weisblum&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 17, 2020, the Company entered into an
employment agreement (&#x201c;Employment Agreement&#x201d;) with Eric Weisblum to serve as Chief Executive Officer and Chief Financial Officer
of the Company. The term of the Employment Agreement continued for a period of one year from the date of execution date thereof and automatically
renewed for successive one-year periods at the end of each term until either party delivers written notice of their intent not to renew
at least six months prior to the expiration of the then effective term. The Employment Agreement provided for a base salary of $120,000
and 152,619 vested shares of the Company&#x2019;s common stock in April 2020. On January 18, 2021, the Company and Mr. Weisblum entered
into the first amendment (the &#x201c;Amendment&#x201d;) to the Employment Agreement, effective as of January 1, 2021. Pursuant to the Amendment
Mr. Weisblum&#x2019;s base salary was increased from $120,000 per year to $180,000 per year and all the terms and provisions of the Employment
Agreement remained in full force and effect.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 12, 2022, the Company entered into
a new employment agreement with Eric Weisblum (the &#x201c;2022 Weisblum Employment Agreement&#x201d;) pursuant to which Mr. Weisblum&#x2019;s
(i) base salary will be $350,000 per year, (ii) Mr. Weisblum was paid a one-time signing bonus of $100,000, and (iii) Mr. Weisblum shall
be entitled to receive an annual bonus of up to $350,000, subject to the sole discretion of the Compensation Committee of the Board of
Directors of the Company (the &#x201c;Compensation Committee&#x201d;), and upon the achievement of additional criteria established by the
Compensation Committee from time to time (the &#x201c;Annual Bonus&#x201d;). In addition, pursuant to the 2022 Weisblum Employment Agreement,
upon termination of Mr. Weisblum&#x2019;s employment for death or Total Disability (as defined in the 2022 Weisblum Employment Agreement),
in addition to any accrued but unpaid compensation and vacation pay through the date of his termination and any other benefits accrued
to him under any Benefit Plans (as defined in the 2022 Weisblum Employment Agreement) outstanding at such time and the reimbursement of
documented, unreimbursed expenses incurred prior to such termination date (collectively, the &#x201c;Weisblum Payments&#x201d;), Mr. Weisblum
shall also be entitled to the following severance benefits: (i) 24 months of his then base salary; (ii) if Mr. Weisblum elects continuation
coverage for group health coverage pursuant to COBRA Rights (as defined in the 2022 Weisblum Employment Agreement), then for a period
of 24 months following Mr. Weisblum&#x2019;s termination he will be obligated to pay only the portion of the full COBRA Rights cost of
the coverage equal to an active employee&#x2019;s share of premiums (if any) for coverage for the respective plan year; and (iii) payment
on a pro-rated basis of any Annual Bonus or other payments earned in connection with any bonus plan to which Mr. Weisblum was a participant
as of the date of his termination (together with the Weisblum Payments, the &#x201c;Weisblum Severance&#x201d;). Furthermore, pursuant to
the 2022 Weisblum Employment Agreement, upon Mr. Weisblum&#x2019;s termination (i) at his option (A) upon 90 days prior written notice
to the Company or (B) for Good Reason (as defined in the 2022 Weisblum Employment Agreement), (ii) termination by the Company without
Cause (as defined in the 2022 Weisblum Employment Agreement) or (iii) termination of Mr. Weisblum&#x2019;s employment within 40 days of
the consummation of a Change in Control Transaction (as defined in the Weisblum Employment Agreement), Mr. Weisblum shall receive the
Weisblum Severance; provided, however, Mr. Weisblum shall be entitled to a pro-rated Annual Bonus of at least $200,000. In addition, any
equity grants issued to Mr. Weisblum shall immediately vest upon termination of Mr. Weisblum&#x2019;s employment by him for Good Reason
or by the Company at its option upon 90 days prior written notice to Mr. Weisblum, without Cause. In September 2023 and October 2022,
the Company paid a bonus of $200,000 and $100,000 to Mr. Weisblum, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Daniel Ryweck&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 27, 2022, the Board appointed Daniel
Ryweck as Chief Financial Officer of the Company. On September 28, 2022, the Company entered into an employment agreement (the &#x201c;Ryweck
Employment Agreement&#x201d;) with Mr. Ryweck. Pursuant to the terms of the Ryweck Employment Agreement, which was amended on October
12, 2022, Mr. Ryweck will (i) receive a base salary at an annual rate of $60,000 (the &#x201c;Base Compensation&#x201d;) payable in equal
monthly installments, and (ii) be eligible to receive an annual discretionary bonus. The term of Mr. Ryweck&#x2019;s engagement under
the Ryweck Employment Agreement commenced on September 28, 2022 and continues until September 28, 2023, unless earlier terminated in
accordance with the terms of the Ryweck Employment Agreement. The term of Mr. Ryweck&#x2019;s Employment Agreement is automatically renewed
for successive one-year periods until terminated by Mr. Ryweck or the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Dr. James Kuo&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 27, 2022, the Company and Dr. James
Kuo entered into an employment agreement (&#x201c;Kuo Employment Agreement&#x201d;) for Dr. Kuo to serve as the Vice President of Research
&amp;amp; Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for a
period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days prior to the applicable renewal date.
Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled to a
bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#x201c;Board&#x201d;) and shall
be payable at the Company&#x2019;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options were granted
under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i)
6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023. The 16,000 stock options
had a fair value of $94,915 which valued at grant date using Binomial Lattice option pricing model with the following assumptions: risk-free
interest rate of 1.18%, expected dividend yield of 0%, expected term of 2 years using the simplified method and expected volatility of
117% based on calculated volatility. The Company recorded the fair value of the stock options, in the amount of $94,915, as deferred compensation
which is being amortized over the vesting period. During the years ended December 31, 2023 and 2022, the Company amortized $14,125 and
$80,790 of the deferred compensation which was recorded as compensation expenses in the consolidated statement of operations and comprehensive
loss, respectively. As of December 31, 2023 and 2022, the deferred compensation had a balance of $0 and $14,125, respectively (see Note
6).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;License Agreements between the Company and
Vendors&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;University of Maryland, Baltimore - License
Agreement for Development and Use of Central Nervous System-Homing Peptides&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Commercial Evaluation License and Option Agreement
with the University of Maryland, Baltimore&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective as of July 15, 2020, the Company, through
its wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1) and University of Maryland, Baltimore (&#x201c;UMB&#x201d;) (collectively as
&#x201c;Parties&#x201d;), entered into a commercial evaluation license and option agreement (&#x201c;License Agreement&#x201d;), granting
the Company an exclusive, non-sublicensable, non-transferable license to with respect to the exploration of the potential use of central
nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory
pathology. The License Agreement also granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing
license (&#x201c;Exclusive Option&#x201d;) with respect to the subject technology. The License Agreement had a term of six months from the
effective date however if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation
period (as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company exercised
its Exclusive Option on January 13, 2021 and entered into a Master License Agreement on February 12, 2021. Both parties may terminate
this agreement within thirty days by giving written notice.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;University of Maryland, Baltimore - License
Agreement for Development and Use of Joint-Homing Peptides&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Commercial Evaluation License and Option Agreement
with the University of Maryland, Baltimore&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#x201c;UMB&#x201d;) (collectively as &#x201c;Parties&#x201d;),
entered into a commercial evaluation license and option agreement (&#x201c;License Agreement&#x201d;), which granted the Company an exclusive,
non-sublicensable, non-transferable license with respect to the exploration of the potential use of joint-homing peptides for use in the
investigation and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate
and obtain an exclusive, sublicensable, royalty-bearing license (&#x201c;Exclusive Option&#x201d;) with respect to the subject technology.
On July 6, 2021, the Company entered into a First Amendment Agreement (&#x201c;First Amendment&#x201d;) with UMB to extend the term of the
original License Agreement by an additional six months such that the First Amendment was effective until February 25, 2022. On January
28, 2022, the Parties entered into a second amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#x201c;Second
Amendment&#x201d;) to extend the term of the original license agreement until December 31, 2022. On June 22, 2022, the Parties entered
into a third amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#x201c;Third Amendment&#x201d;). The
Third Amendment expanded the scope of the license granted in the License Agreement to add additional patent rights with respect to an
invention generally known as &lt;i&gt;Peptide-Targeted Liposomal Delivery for Treatment Diagnosis, and Imaging of Diseases and Disorders&lt;/i&gt;.
In consideration of the licenses granted under this Third Amendment, the Company agreed to pay a one-time, non-refundable fee of $2,500
which was recorded as research and development expense in the consolidated statement of operations and comprehensive loss during the year
ended December 31, 2022. On December 16, 2022, the Company and UMB entered into a fourth amendment to License Agreement (the &#x201c;Fourth
Amendment&#x201d;) to extend the term of the License Agreement until March 31, 2023. In addition, the parties agreed in the Fourth Amendment
to allow the Company to extend the term of the License Agreement to June 30, 2023 by paying UMB a fee of $1,000 on or before February
28, 2023. This fee was paid and the term of the License Agreement was extended to June 30, 2023. In February 2023, upon payment of the
extension fee of $1,000, the Company recorded license fees of $1,000 which are included in research and development expenses on the accompanying
consolidated statement of operations and comprehensive loss. On June 28, 2023, the Company and UMB entered into a fifth amendment to License
Agreement (the &#x201c;Fifth Amendment&#x201d;) to extend the term of the License Agreement until September 30, 2023. The Company may at
its option extend this Agreement until December 31, 2023, by providing written notice to University on or before August 31, 2023, and
by paying an additional license fee of $2,500. This fee was paid and the term of the License Agreement was extended to December 31, 2023.
In August 2023, upon payment of the extension fee of $2,500, the Company recorded license fees of $2,500 which are included in research
and development expense on the accompanying consolidated statement of operations and comprehensive loss. As of December 31, 2023, the
Company decided not to extend this License Agreement and will not continue to pursue this license.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Master License Agreement with the University
of Maryland, Baltimore&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As disclosed above, effective as of February 12,
2021, the Company and University of Maryland, Baltimore (&#x201c;UMB&#x201d;), entered into the Master License Agreement (&#x201c;Master
License Agreement&#x201d;) which grants the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual
property: (i) to make, have made, use, sell, offer to sell, and import certain licensed products and: (ii) to use the invention titled,
&#x201c;Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other
neuroinflammatory pathology&#x201d; and UMB&#x2019;s confidential information to develop and perform certain licensed processes for the
therapeutic treatment of neuroinflammatory disease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Master License Agreement will remain in effect
on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under the
Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity,
or other legally enforceable market exclusivity, if applicable, or (c) 10 years after the first commercial sale of a Licensed Product
in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the Master License
Agreement shall expire 15 years after the Master License Agreement Effective Date in which (a) there were never any patent rights, (b)
there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable
market exclusivity or (c) there was never a first commercial sale of a Licensed Product.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company may assign, sublicense, grant, or
otherwise convey any rights or obligations under the Master License Agreement to a Company affiliate, without obtaining prior written
consent from UMB provided that it meets the terms defined in the Master License Agreement. The Company may grant sublicenses of some or
all of the rights granted by the Master License Agreement, provided that there is no uncured default or breach of any material term or
condition under the Master License Agreement, by Company, at the time of the grant, and that the grant complies with the terms and conditions
of the Master License Agreement. The Company shall be and shall remain responsible for the performance by each of the Company&#x2019;s
sublicensee. Any sublicense shall be consistent with and subject to the terms and conditions of the Master License Agreement and shall
incorporate terms and conditions sufficient to enable Company to comply with the Master License Agreement. The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#x2019;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#x2019;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Master License Agreement, the
Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments
depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company paid to UMB a
license fee of $75,000, payable as follows: (a) $25,000 was due and paid within 30 days following the effective date; and (b) $50,000
on or before the first anniversary of the effective date, which was paid in February 2022. The license fee is non-refundable and is not
creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection
with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid
$25,000 license fee on February 17, 2021 and $50,000 in February 2022 which was recorded as prepaid expense and is being amortized over
the 15-year term. During the years ended December 31, 2023 and 2022, the Company recognized license fees of $5,000 and $5,000, respectively,
from the amortization of prepaid license fees, which is included in costs of revenues on the accompanying consolidated statements of operations.
On December 31, 2023, prepaid expense and other current assets &#x2013; current amounted to $5,000 and prepaid expense &#x2013; non-current
amounted to $55,625. On December 31, 2022, prepaid expense and other current assets &#x2013; current amounted to $5,000 and prepaid expense
&#x2013; non-current amounted to $60,625 as reflected in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Milestone&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Receipt of New Drug Application (&#x201c;NDA&#x201d;) (or foreign equivalent) approval for a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Achievement of First Commercial Sale of Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Royalty Payments Terms&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3%
on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000;
and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5%
on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;minimum
annual royalty payments, as follows:&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Minimum&lt;br/&gt;
 Annual&lt;br/&gt;
 Royalty&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prior to First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Year of First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;First calendar year following the First Commercial Sale&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Second calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Third calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 10, 2023, the Company entered into
a Third Amendment to Master License Agreement (the &#x201c;Third Amendment&#x201d;) with UMB, pursuant to which the parties agreed to an
amended and restated schedule of diligence milestones for the Master License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2021, in connection with the Company&#x2019;s
Sublicense Agreement with Aikido Pharma Inc. (see below - &lt;i&gt;Patent License Agreement with Aikido Pharma Inc.&lt;/i&gt;), the Company paid 25%
of its sublicense income to UMB, pursuant to the Master License Agreement, which amounted to $12,500. During the years ended December
31, 2023 and 2022, the Company recognized license fees of $838 and $838, respectively, from the amortization of the sublicense fee. On
December 31, 2023, prepaid expense and other current assets &#x2013; current amounted to $838 and prepaid expenses &#x2013; non-current
amounted to $9,358. On December 31, 2022, prepaid expense and other current assets &#x2013; current amounted to $838 and prepaid expenses
&#x2013; non-current amounted to $10,196 as reflected in the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;License Agreements between the Company and
Customer&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Customer Patent License Agreement with Aikido
Pharma Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 5, 2021, the Company and its subsidiary
Silo Pharma, Inc., entered into a patent license agreement (&#x201c;License Agreement&#x201d;) (collectively, the &#x201c;Licensor&#x201d;)
with Aikido Pharma Inc. (&#x201c;Aikido&#x201d; or the &#x201c;Customer&#x201d;), as amended on April 12, 2021, pursuant to which the Licensor
granted Aikido an exclusive, worldwide (&#x201c;Territory&#x201d;), sublicensable, royalty-bearing license to certain intellectual property:
(i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise certain licensed
products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused by cancer (&#x201c;Field
of Use&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The License Agreement also provided that, if the
Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective as
of July 15, 2020, it would grant Aikido a non-exclusive sublicense (&#x201c;Right&#x201d;) to certain UMB patent rights in the field of
neuroinflammatory diseases occurring in patients diagnosed with cancer (&#x201c;Field&#x201d;). Pursuant to the License Agreement, Aikido
agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $500,000 and (ii) royalty payments equal
to 2% of net sales (as defined in the License Agreement) in the Field of Use in the Territory. In addition, Aikido agreed to issue the
Licensor 500 shares of Aikido&#x2019;s newly designated Series M Convertible Preferred Stock which were to be converted into an aggregate
of 625,000 shares of Aikido&#x2019;s common stock. On April 12, 2021, the Company entered into an amendment to the License Agreement (&#x201c;Amended
License Agreement&#x201d;) with Aikido dated January 5, 2021 whereby Aikido issued an aggregate of 625,000 restricted shares of Aikido&#x2019;s
common stock instead of the 500 shares of the Series M Convertible Preferred Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the License Agreement, the Company
is required to prepare, file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the
licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed
patents. The Company may terminate the License Agreement upon 30 day written notice if Aikido fails to pay any amounts due and payable
to the Company or if Aikido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal
or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (&#x201c;Patent Challenge&#x201d;)
against the Company (except as required under a court order or subpoena). Aikido may terminate the Agreement at any time without cause,
and without incurring any additional penalty, (i) by providing at least 30 days&#x2019; prior written notice and paying the Company all
amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed
to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $500,000 on January
5, 2021 which was recorded as deferred revenue to be recognized as revenues over 15 years, the estimated term of the UMB Master License
Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prior to the April 12, 2021, issuance of the common
stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible Preferred
stock which was equivalent into Aikido&#x2019;s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based
quoted trading price of Aikido&#x2019;s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note
3) and deferred revenue of $531,250 to be recognized as revenues over the estimated term of the UMB Master License. Accordingly, the Company
recorded a total deferred revenue of $1,031,250 ($500,000 cash received and $531,250 value of equity securities received) to be recognized
as revenues over the 15-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2023 and 2022,
the Company recognized license fee revenues of $68,750 and $68,750, respectively. On December 31, 2023, deferred revenue &#x2013; current
portion amounted to $68,750 and deferred revenue &#x2013; long-term portion amounted to $756,250. On December 31, 2022, deferred revenue
&#x2013; current portion amounted to $68,750 and deferred revenue &#x2013; long-term portion amounted to $825,000 as reflected in the consolidated
balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Right shall be, to the full extent permitted
by and on terms and conditions required by UMB, for a term consistent with the term of patent and technology licenses that UMB normally
grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after
the execution of such UMB license, for consideration to be agreed upon and paid by Aikido, which consideration shall in no event exceed
110% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant Aikido a nonexclusive
sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including
any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly,
on April 6, 2021, the Company entered into the Sublicense Agreement with Aikido pursuant to which it granted Aikido a worldwide exclusive
sublicense to its licensed patents under the Master License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Customer Sublicense&#160;Agreement with
Aikido Pharma Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 6, 2021 (the &#x201c;Sublicense Agreement
Effective Date&#x201d;), the Company entered into the Sublicense Agreement with Aikido pursuant to which the Company granted Aikido an
exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and
(ii) in connection therewith to (A) use an invention known as &#x201c;Central nervous system-homing peptides in vivo and their use for
the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#x201d; which was sublicensed to the Company
pursuant to the Master License Agreement&#160;and (B) practice certain patent rights (&#x201c;Patent Rights&#x201d;) for the therapeutic
treatment of neuroinflammatory disease in cancer patients. &#x201c;Licensed Products&#x201d; means any product, service, or process, the
development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent
Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent
Rights.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Sublicense Agreement, Aikido agreed
to pay the Company (i) an upfront license fee of $50,000, (ii)&#160;the same sales-based royalty payments that the Company is subject
to under the Master License Agreement and (iii) total milestone payments of up to $1.9 million. The Sublicense Agreement shall continue
on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the last to expire
claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new chemical entity,
orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii) 10 years after
the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the Sublicense Agreement.
Furthermore, the Sublicense Agreement shall expire 15 years after the Sublicense Agreement Effective Date with respect to any country
in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity, orphan drug exclusivity,
regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and (ii) there was never a commercial
sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The Company collected the upfront license
fee of $50,000 in April 2021. During the years ended December 31, 2023 and 2022, the Company recognized revenue of $3,352 and $3,352,
respectively. On December 31, 2023, deferred revenue &#x2013; current portion amounted to $3,352 and deferred revenue &#x2013; long-term
portion amounted to $37,430, and on December 31, 2022, deferred revenue &#x2013; current portion amounted to $3,352 and deferred revenue
&#x2013; long-term portion amounted to $40,782 as reflected in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Sponsored Study and Research Agreements
between the Company and Vendors&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Investigator-Sponsored Study Agreement with
University of Maryland, Baltimore&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 5, 2021, the Company entered into an
investigator-sponsored study agreement (&#x201c;Sponsored Study Agreement&#x201d;) with the University of Maryland, Baltimore. The research
project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (&#x201c;MS&#x201d;).
More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the
CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and
progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March
1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of the
Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. In 2021, the Company
paid $40,737 and recorded research and development expense of $40,737. This project has been postponed until further notice and the second
payment is not due.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sponsored Research Agreement with The Regents
of the University of California&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 1, 2021 (the &#x201c;Effective Date&#x201d;),
the Company entered into a sponsored research agreement (the &#x201c;Sponsored Research Agreement&#x201d;) with The Regents of the University
of California, on behalf of its San Francisco Campus (&#x201c;UCSF&#x201d;) pursuant to which UCSF shall conduct a study to examine psilocybin&#x2019;s
effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson&#x2019;s Disease, chronic
pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a total fee of $342,850 to conduct the research over
the two-year period. The Agreement was effective for a period of two years from the Effective Date, subject to renewal or earlier termination
as set forth in the Sponsored Research Agreement. During the years ended December 31, 2022 and 2021, pursuant to the Sponsored Research
Agreement, the Company paid to UCSF $181,710 and $100,570, respectively, which were recorded to prepaid expense and other current assets
&#x2013; current to be amortized over the two-year period. During the year ended December 31, 2023, the Company paid the remaining amount
due of $60,570. During the years ended December 31, 2023 and 2022, the Company recorded research and development expenses of $71,427 and
$178,568, respectively, from the amortization of the prepaid research and development fees. On December 31, 2023 and 2022, prepaid research
and development fees amounted to $0 and $10,857, respectively which is reflected in prepaid expenses and other current assets &#x2013;
current on the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sponsored Research Agreement with University
of Maryland, Baltimore&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 6, 2021, the Company and University of
Maryland, Baltimore (&#x201c;UMB&#x201d;) entered into a sponsored research agreement (&#x201c;July 2021 Sponsored Research Agreement&#x201d;)
pursuant to which UMB shall&#160;evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome. The research
pursuant to the July 2021 Sponsored Research Agreement shall commence on September 1, 2021 and will continue until the substantial completion
thereof, subject to renewal upon written consent of the parties. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#x2019; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, the Company shall relinquish any and all rights it may have in the Results (as
defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated
early, the Company, among other things, will pay all costs incurred and accrued by UMB as of the date of termination. On June 7, 2022,
the Company and UMB amended the July 2021 Sponsored Research Agreement whereby both parties agreed to make changes to the original project
work and budget. The amendment had no effect on the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the July 2021 Sponsored
Research Agreement, UMB granted the Company an option (the &#x201c;Option&#x201d;) to negotiate and obtain an exclusive license to any UMB
Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#x2019;s rights in any Joint Arising IP (as defined in the
July 2021 Sponsored Research Agreement) (collectively, the &#x201c;UMB IP&#x201d;). The Company may exercise the Option by giving UMB written
notice within 60 days after it receives notice from UMB of the UMB IP. Pursuant to the July 2021 Sponsored Research Agreement, the Company
shall pay UMB the fees below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 7%; text-align: center"&gt;1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92,095&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Paid upon execution of the July 2021 Sponsored Research Agreement&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;92,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;92,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company paid the first payment of $92,095
on September 1, 2021 and on August 31, 2022, the Company paid the second payment of $92,095. These payments were recorded to prepaid expense
and other current assets &#x2013; current to be amortized into research and development expense during the years ended December 31, 2022
and 2021. During the years ended December 31, 2023 and 2022, the Company recorded research and development expenses of $0 and $187,090,
respectively, from the amortization of these prepaid research and development fees and other expenses. On December 31, 2023 and 2022,
the Company owed UMB $92,095 which was included in accounts payable on the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sponsored Research Agreement with Columbia
University&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 1, 2021, the Company entered into a
sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets
currently under development, including assets related to the potential treatment of patients suffering from Alzheimer&#x2019;s disease.
The term of the option will commence on the effective date of this agreement and will expire upon the earlier of (i) 90 days after the
date of the Company&#x2019;s receipt of a final research report for each specific research proposal as defined in the agreement or (ii)
termination of the research. If the Company elects to exercise the option, both parties will commence negotiation of a license agreement
and will execute a license agreement no later than 3 months after the date of the exercise of the option. Columbia University and the
Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer&#x2019;s disease to post-traumatic stress
disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University
for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after
the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project. The Company
paid the first payment of $430,825 in November 2021 and the second payment of $430,825 in July 2022, which were recorded to prepaid expense
and other current assets &#x2013; current to be amortized over the estimated project timeline of twelve months. On October 13, 2022, the
Company entered into an amendment to the Columbia Agreement (the &#x201c;Columbia Amendment&#x201d;), pursuant to which the parties agreed
to extend the payment schedule, whereby the third payment of $430,825 was due in March 2023. In August 2023, the Company paid $100,000
of this balance and $330,825 of such payment remains unpaid as of December 31, 2023, which is included in accounts payable on the accompanying
consolidated balance sheet. The remaining payment of $143,607 is due upon completion. As of December 31, 2022, accrued expenses related
to this sponsored research agreement was $143,607.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2023 and 2022,
the Company recorded research and development expense of $287,218 and $646,236, respectively, from the amortization of the prepaid research
and development fees. As of December 31, 2023, the Company estimates that this research project is approximately 90% complete.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research Agreement with Reprocell&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 25, 2022, (the &#x201c;Effective Date&#x201d;),
the Company entered into a research agreement (the &#x201c;Reprocell Research Agreement&#x201d;) with Reprocell Europe Ltd. (&#x201c;Reprocell&#x201d;)
pursuant to which Reprocell shall conduct a study to assess the binding of a peptide on healthy and rheumatoid arthritis synovial tissue.
Pursuant to the Reprocell Research Agreement, the Company shall pay Reprocell a total fee of $41,306 to conduct the research over a three-month
period. During the year ended December 31, 2022, pursuant to the Reprocell Research Agreement, the Company paid to Reprocell $21,172 which
was recorded as prepaid expense and other current assets &#x2013; current to be amortized over the three-month period. During the year
ended December 31, 2023 and 2022, the Company recorded research and development expense of $19,835 and $33,252 from the amortization of
the prepaid research and development fees and the payment pf other fees. As of December 31, 2023 and 2022, accounts payable and accrued
expenses related to this research agreement were $5,891 and $20,134, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research Agreements with Upperton Pharma Solutions&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 16, 2023, (the &#x201c;Effective Date&#x201d;),
the Company entered into research agreements (the &#x201c;Upperton Research Agreements&#x201d;) with Upperton Pharma Solutions (&#x201c;Upperton&#x201d;)
pursuant to which Upperton shall conduct a study to support the development and feasibility of Prucalopride nasal solutions. Pursuant
to the Upperton Research Agreements, the Company shall pay Upperton an aggregate total fee of 242,932 British Pound (GBP) (approximately
$261,462) to conduct the research, which will expensed over the research period. During the year ended December 31, 2023, pursuant to
the Upperton Research Agreements, the Company paid Upperton $177,903. During the year ended December 31, 2023, the Company recorded research
and development expense of $212,428 from the amortization of the prepaid research and development fees. As of December 31, 2023, accounts
payable and accrued expenses related to this research agreement were $34,525.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research Agreement with AmplifyBio&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 16, 2023, (the &#x201c;Effective Date&#x201d;),
the Company entered into a research agreement (the &#x201c;AmplifyBio Research Agreement&#x201d;) with AmplifyBio, LLC. (&#x201c;AmplifyBio&#x201d;)
pursuant to which AmplifyBio shall conduct a study in rates to investigate intranasal administration of a novel drug product. Pursuant
to the AmplifyBio Research Agreement, the Company shall pay AmplifyBio a total fee of $229,000 to conduct the research. During the year
ended December 31, 2023, pursuant to the AmplifyBio Research Agreement, the Company paid AmplifyBio $182,980 which was recorded as prepaid
expense and other current assets &#x2013; current to be amortized over the research period. During the year ended December 31, 2023, the
Company recorded research and development expense of $182,980 from the amortization of the prepaid research and development fees. As of
December 31, 2023, accounts payable and accrued expenses related to this research agreement were $0.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2023 and 2022,
the Company entered into other research and development agreements. In connection with such agreements, the Company recorded research
and development expenses of $71,204 and $241,288, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 31, 2023, future amounts due under
sponsored study and research agreements between the Company and vendors is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;725,244&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;725,244&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Joint Venture Agreement with Zyl&#xf6; Therapeutics,
Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 22, 2021 (&#x201c;Effective Date&#x201d;),
the Company entered into a Joint Venture Agreement (&#x201c;JV Agreement&#x201d;) with Zyl&#xf6; Therapeutics, Inc. (&#x201c;ZTI&#x201d;)
pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (&#x201c;Joint Venture&#x201d;),
to, among other things, focus on the clinical development of ketamine using ZTI&#x2019;s Z-pod&#x2122; technology (&#x201c;Venture&#x201d;).
Pursuant to the JV Agreement, the Company shall act as the manager (&#x201c;Manager&#x201d;) of the Joint Venture. The Joint Venture shall
terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days
of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Joint
Venture at any time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the JV Agreement, (A)
the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute
(1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets
with respect to its Z-pod&#x2122; technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4)
reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in
the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI,
subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either
party own more than 60% of the interest in the Joint Venture. As of December 31, 2023 and 2022 and as of the current date of this report,
the joint venture entity has not been formed yet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Furthermore, pursuant to the terms of the JV Agreement,
ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#x201c;License Agreement&#x201d;) with Albert Einstein
College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating that the patented
technology (the &#x201c;Patented Technology&#x201d;) licensed to ZTI pursuant to the License Agreement is needed to advance the development
of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant to the JV Agreement,
ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development of psilocybin using ZTI&#x2019;s
Z-pod&#x2122; technology on the same terms and conditions set forth in the JV Agreement, which option expired 24 months after the JV Effective
Date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Amended Service Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 10, 2021 (&#x201c;Effective Date&#x201d;),
the Company entered into an Amendment Agreement (&#x201c;Amended Service Agreement&#x201d;) to a certain service agreement dated on September
8, 2020 with the University of Texas (&#x201c;University&#x201d;) at Austin whereby the University will provide advisory service and assist
the Company on identifying license and sponsored research opportunities for the Company. The Company shall pay the University $5,000 per
quarter starting on the Effective Date. Any cost incurred will be reimbursed only after prior written consent by the Company. The term
of the Amended Service Agreement is for 36 months unless earlier terminated by either party upon giving a written notice as defined in
the agreement. During the years ended December 31, 2023 and 2022, the Company paid $25,000 and $25,000, respectively, related to this
agreement which in included in professional fees on the accompanying consolidated statements of operations.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OfficersCompensation contextRef="c129" decimals="0" id="ixv-15220" unitRef="usd">120000</us-gaap:OfficersCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="c129"
      decimals="0"
      id="ixv-15221"
      unitRef="shares">152619</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:OfficersCompensation contextRef="c130" decimals="0" id="ixv-15222" unitRef="usd">120000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation contextRef="c131" decimals="0" id="ixv-15223" unitRef="usd">180000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation contextRef="c132" decimals="0" id="ixv-15224" unitRef="usd">350000</us-gaap:OfficersCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses contextRef="c133" decimals="0" id="ixv-15225" unitRef="usd">100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent contextRef="c134" decimals="0" id="ixv-15226" unitRef="usd">350000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent contextRef="c135" decimals="0" id="ixv-15227" unitRef="usd">200000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:PaymentsToEmployees contextRef="c136" decimals="0" id="ixv-15228" unitRef="usd">200000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees contextRef="c137" decimals="0" id="ixv-15229" unitRef="usd">100000</us-gaap:PaymentsToEmployees>
    <us-gaap:OfficersCompensation contextRef="c138" decimals="0" id="ixv-15230" unitRef="usd">60000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation contextRef="c139" decimals="0" id="ixv-15231" unitRef="usd">30000</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c140"
      decimals="0"
      id="ixv-15232"
      unitRef="shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c141"
      decimals="2"
      id="ixv-15233"
      unitRef="usdPershares">10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:LeaseExpirationDate1 contextRef="c140" id="ixv-15234">2032-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c141"
      decimals="0"
      id="ixv-15235"
      unitRef="shares">6000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c142"
      decimals="0"
      id="ixv-15236"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c143"
      decimals="0"
      id="ixv-15237"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c144"
      decimals="0"
      id="ixv-15238"
      unitRef="shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c144" decimals="0" id="ixv-15239" unitRef="usd">94915</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c145"
      decimals="2"
      id="ixv-15240"
      unitRef="pure">1.18</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c146"
      decimals="0"
      id="ixv-15241"
      unitRef="pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c147"
      decimals="0"
      id="ixv-15242"
      unitRef="pure">2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c148"
      decimals="0"
      id="ixv-15243"
      unitRef="pure">117</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="c144" decimals="0" id="ixv-15244" unitRef="usd">94915</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:OtherDeferredCostsNet contextRef="c149" decimals="0" id="ixv-15245" unitRef="usd">14125</us-gaap:OtherDeferredCostsNet>
    <us-gaap:OtherDeferredCostsNet contextRef="c150" decimals="0" id="ixv-15246" unitRef="usd">80790</us-gaap:OtherDeferredCostsNet>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense contextRef="c144" decimals="0" id="ixv-15247" unitRef="usd">0</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense contextRef="c151" decimals="0" id="ixv-15248" unitRef="usd">14125</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c152" decimals="0" id="ixv-15249" unitRef="usd">2500</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsForFees contextRef="c153" decimals="0" id="ixv-15250" unitRef="usd">1000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees contextRef="c154" decimals="0" id="ixv-15251" unitRef="usd">1000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees contextRef="c155" decimals="0" id="ixv-15252" unitRef="usd">1000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees contextRef="c156" decimals="0" id="ixv-15253" unitRef="usd">2500</us-gaap:PaymentsForFees>
    <silo:ExtensionFee contextRef="c157" decimals="0" id="ixv-15254" unitRef="usd">2500</silo:ExtensionFee>
    <us-gaap:PaymentsForFees contextRef="c158" decimals="0" id="ixv-15255" unitRef="usd">2500</us-gaap:PaymentsForFees>
    <silo:CommercialSaleTerm contextRef="c159" id="ixv-15256">P10Y</silo:CommercialSaleTerm>
    <silo:LicenseAgreementExpire contextRef="c0" id="ixv-15257">P15Y</silo:LicenseAgreementExpire>
    <silo:SublicenseIncomeReceivablePercentage contextRef="c0" decimals="2" id="ixv-15258" unitRef="pure">0.25</silo:SublicenseIncomeReceivablePercentage>
    <silo:SublicenseIncomeReceivablePercentage
      contextRef="c159"
      decimals="2"
      id="ixv-15259"
      unitRef="pure">0.15</silo:SublicenseIncomeReceivablePercentage>
    <us-gaap:PaymentsForFees contextRef="c160" decimals="0" id="ixv-15260" unitRef="usd">75000</us-gaap:PaymentsForFees>
    <silo:DueToRelatedPartieCurrent contextRef="c159" decimals="0" id="ixv-15261" unitRef="usd">25000</silo:DueToRelatedPartieCurrent>
    <us-gaap:FeesPaidOnAcceptancesResold contextRef="c161" decimals="0" id="ixv-15262" unitRef="usd">50000</us-gaap:FeesPaidOnAcceptancesResold>
    <us-gaap:PaymentsForFees contextRef="c162" decimals="0" id="ixv-15263" unitRef="usd">25000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees contextRef="c161" decimals="0" id="ixv-15264" unitRef="usd">50000</us-gaap:PaymentsForFees>
    <us-gaap:LongTermDebtTerm contextRef="c163" id="ixv-15265">P15Y</us-gaap:LongTermDebtTerm>
    <us-gaap:PaymentsForFees contextRef="c164" decimals="0" id="ixv-15266" unitRef="usd">5000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees contextRef="c165" decimals="0" id="ixv-15267" unitRef="usd">5000</us-gaap:PaymentsForFees>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c166" decimals="0" id="ixv-15268" unitRef="usd">5000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c166" decimals="0" id="ixv-15269" unitRef="usd">55625</us-gaap:PrepaidExpenseOtherNoncurrent>
    <silo:ScheduleOfMilestonePaymentsTableTextBlock contextRef="c0" id="ixv-15270">On December 31, 2022, prepaid expense and other current assets &#x2013; current amounted to $5,000 and prepaid expense
&#x2013; non-current amounted to $60,625 as reflected in the consolidated balance sheets.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Milestone&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Receipt of New Drug Application (&#x201c;NDA&#x201d;) (or foreign equivalent) approval for a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Achievement of First Commercial Sale of Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</silo:ScheduleOfMilestonePaymentsTableTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c167" decimals="0" id="ixv-15271" unitRef="usd">5000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c167" decimals="0" id="ixv-15272" unitRef="usd">60625</us-gaap:PrepaidExpenseOtherNoncurrent>
    <silo:MilestoneBalanceDescription contextRef="c225" id="ixv-15273">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</silo:MilestoneBalanceDescription>
    <silo:MilestonePayment contextRef="c225" decimals="0" id="ixv-15274" unitRef="usd">50000</silo:MilestonePayment>
    <silo:MilestoneBalanceDescription contextRef="c226" id="ixv-15275">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</silo:MilestoneBalanceDescription>
    <silo:MilestonePayment contextRef="c226" decimals="0" id="ixv-15276" unitRef="usd">100000</silo:MilestonePayment>
    <silo:MilestoneBalanceDescription contextRef="c227" id="ixv-15277">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</silo:MilestoneBalanceDescription>
    <silo:MilestonePayment contextRef="c227" decimals="0" id="ixv-15278" unitRef="usd">250000</silo:MilestonePayment>
    <silo:MilestoneBalanceDescription contextRef="c228" id="ixv-15279">Receipt of New Drug Application (&#x201c;NDA&#x201d;) (or foreign equivalent) approval for a Licensed Product</silo:MilestoneBalanceDescription>
    <silo:MilestonePayment contextRef="c228" decimals="0" id="ixv-15280" unitRef="usd">500000</silo:MilestonePayment>
    <silo:MilestoneBalanceDescription contextRef="c229" id="ixv-15281">Achievement of First Commercial Sale of Licensed Product</silo:MilestoneBalanceDescription>
    <silo:MilestonePayment contextRef="c229" decimals="0" id="ixv-15282" unitRef="usd">1000000</silo:MilestonePayment>
    <silo:SalesOfLicensedProductsPercentage
      contextRef="c159"
      decimals="2"
      id="ixv-15283"
      unitRef="pure">0.03</silo:SalesOfLicensedProductsPercentage>
    <us-gaap:SalesCommissionsAndFees contextRef="c159" decimals="0" id="ixv-15284" unitRef="usd">50000000</us-gaap:SalesCommissionsAndFees>
    <silo:SalesOfLicensedProductsPercentage contextRef="c0" decimals="2" id="ixv-15285" unitRef="pure">0.05</silo:SalesOfLicensedProductsPercentage>
    <us-gaap:SalesCommissionsAndFees contextRef="c0" decimals="0" id="ixv-15286" unitRef="usd">50000000</us-gaap:SalesCommissionsAndFees>
    <silo:ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock contextRef="c0" id="ixv-14284">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;minimum
annual royalty payments, as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Minimum&lt;br/&gt;
 Annual&lt;br/&gt;
 Royalty&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prior to First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Year of First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;First calendar year following the First Commercial Sale&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Second calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Third calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</silo:ScheduleOfMinimumAnnualRoyaltyPaymentsTableTextBlock>
    <silo:MinimumAnnualRoyaltyPaymentsDescription contextRef="c225" id="ixv-15287">Prior to First Commercial Sale</silo:MinimumAnnualRoyaltyPaymentsDescription>
    <silo:MinimumAnnualRoyaltyPaymentsDescription contextRef="c226" id="ixv-15288">Year of First Commercial Sale</silo:MinimumAnnualRoyaltyPaymentsDescription>
    <silo:MinimumAnnualRoyaltyPaymentsDescription contextRef="c227" id="ixv-15289">First calendar year following the First Commercial Sale</silo:MinimumAnnualRoyaltyPaymentsDescription>
    <us-gaap:RoyaltyExpense contextRef="c227" decimals="0" id="ixv-15290" unitRef="usd">25000</us-gaap:RoyaltyExpense>
    <silo:MinimumAnnualRoyaltyPaymentsDescription contextRef="c228" id="ixv-15291">Second calendar year following the First Commercial Sale</silo:MinimumAnnualRoyaltyPaymentsDescription>
    <us-gaap:RoyaltyExpense contextRef="c228" decimals="0" id="ixv-15292" unitRef="usd">25000</us-gaap:RoyaltyExpense>
    <silo:MinimumAnnualRoyaltyPaymentsDescription contextRef="c229" id="ixv-15293">Third calendar year following the First Commercial Sale</silo:MinimumAnnualRoyaltyPaymentsDescription>
    <us-gaap:RoyaltyExpense contextRef="c229" decimals="0" id="ixv-15294" unitRef="usd">100000</us-gaap:RoyaltyExpense>
    <silo:SublicenseIncomePercentage
      contextRef="c168"
      decimals="2"
      id="ixv-15295"
      unitRef="pure">0.25</silo:SublicenseIncomePercentage>
    <silo:SublicenseAgreementAmountPaid contextRef="c168" decimals="0" id="ixv-15296" unitRef="usd">12500</silo:SublicenseAgreementAmountPaid>
    <us-gaap:ProceedsFromLicenseFeesReceived contextRef="c159" decimals="0" id="ixv-15297" unitRef="usd">838</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived contextRef="c169" decimals="0" id="ixv-15298" unitRef="usd">838</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c170" decimals="0" id="ixv-15299" unitRef="usd">838</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c170" decimals="0" id="ixv-15300" unitRef="usd">9358</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c171" decimals="0" id="ixv-15301" unitRef="usd">838</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c171" decimals="0" id="ixv-15302" unitRef="usd">10196</us-gaap:PrepaidExpenseOtherNoncurrent>
    <silo:NonrefundableCashPayment contextRef="c172" decimals="0" id="ixv-15303" unitRef="usd">500000</silo:NonrefundableCashPayment>
    <silo:NetSalePercentage
      contextRef="c172"
      decimals="2"
      id="ixv-15304"
      unitRef="pure">0.02</silo:NetSalePercentage>
    <silo:LicensorShare
      contextRef="c172"
      decimals="0"
      id="ixv-15305"
      unitRef="shares">500</silo:LicensorShare>
    <silo:AggregateOfConvertedShares
      contextRef="c172"
      decimals="0"
      id="ixv-15306"
      unitRef="shares">625000</silo:AggregateOfConvertedShares>
    <silo:AggregateOfConvertedShares
      contextRef="c173"
      decimals="0"
      id="ixv-15307"
      unitRef="shares">625000</silo:AggregateOfConvertedShares>
    <silo:LicensorShare
      contextRef="c173"
      decimals="0"
      id="ixv-15308"
      unitRef="shares">500</silo:LicensorShare>
    <silo:NonrefundableCashPayment contextRef="c173" decimals="0" id="ixv-15309" unitRef="usd">500000</silo:NonrefundableCashPayment>
    <silo:RevenueTerm contextRef="c173" id="ixv-15310">P15Y</silo:RevenueTerm>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c174"
      decimals="0"
      id="ixv-15311"
      unitRef="shares">500</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:CommonStockDividendsShares
      contextRef="c175"
      decimals="0"
      id="ixv-15312"
      unitRef="shares">625000</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c175"
      decimals="2"
      id="ixv-15313"
      unitRef="usdPershares">0.85</us-gaap:CommonStockDividendsPerShareCashPaid>
    <silo:TradingPrice contextRef="c175" decimals="0" id="ixv-15314" unitRef="usd">531250</silo:TradingPrice>
    <us-gaap:EquityMethodInvestments contextRef="c176" decimals="0" id="ixv-15315" unitRef="usd">531250</us-gaap:EquityMethodInvestments>
    <us-gaap:DeferredRevenue contextRef="c176" decimals="0" id="ixv-15316" unitRef="usd">531250</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="c177" decimals="0" id="ixv-15317" unitRef="usd">1031250</us-gaap:DeferredRevenue>
    <us-gaap:Cash contextRef="c177" decimals="0" id="ixv-15318" unitRef="usd">500000</us-gaap:Cash>
    <silo:SecuritiesReceived contextRef="c177" decimals="0" id="ixv-15319" unitRef="usd">531250</silo:SecuritiesReceived>
    <silo:RevenueTerm contextRef="c172" id="ixv-15320">P15Y</silo:RevenueTerm>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c172" decimals="0" id="ixv-15321" unitRef="usd">68750</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c178" decimals="0" id="ixv-15322" unitRef="usd">68750</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueCurrent contextRef="c177" decimals="0" id="ixv-15323" unitRef="usd">68750</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c177" decimals="0" id="ixv-15324" unitRef="usd">756250</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c179" decimals="0" id="ixv-15325" unitRef="usd">68750</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c179" decimals="0" id="ixv-15326" unitRef="usd">825000</us-gaap:DeferredRevenueNoncurrent>
    <silo:ConsiderationFeePayablePercentage
      contextRef="c172"
      decimals="2"
      id="ixv-15327"
      unitRef="pure">1.10</silo:ConsiderationFeePayablePercentage>
    <silo:UpfrontLicenseFees contextRef="c180" decimals="0" id="ixv-15328" unitRef="usd">50000</silo:UpfrontLicenseFees>
    <us-gaap:PaymentsForFees
      contextRef="c180"
      decimals="-5"
      id="ixv-15329"
      unitRef="usd">1900000</us-gaap:PaymentsForFees>
    <silo:FirstCommercialSale contextRef="c180" id="ixv-15330">P10Y</silo:FirstCommercialSale>
    <silo:AgreementShallExpire contextRef="c180" id="ixv-15331">P15Y</silo:AgreementShallExpire>
    <us-gaap:PaymentsForFees contextRef="c181" decimals="0" id="ixv-15332" unitRef="usd">50000</us-gaap:PaymentsForFees>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c182" decimals="0" id="ixv-15333" unitRef="usd">3352</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c180" decimals="0" id="ixv-15334" unitRef="usd">3352</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueCurrent contextRef="c183" decimals="0" id="ixv-15335" unitRef="usd">3352</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c183" decimals="0" id="ixv-15336" unitRef="usd">37430</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c184" decimals="0" id="ixv-15337" unitRef="usd">3352</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c184" decimals="0" id="ixv-15338" unitRef="usd">40782</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OtherNotesPayable contextRef="c3" decimals="0" id="ixv-15339" unitRef="usd">81474</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable contextRef="c185" decimals="0" id="ixv-15340" unitRef="usd">40737</us-gaap:OtherNotesPayable>
    <silo:SponsoredStudyAgreement contextRef="c186" decimals="0" id="ixv-15341" unitRef="usd">40737</silo:SponsoredStudyAgreement>
    <us-gaap:RepaymentsOfOtherDebt contextRef="c187" decimals="0" id="ixv-15342" unitRef="usd">40737</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c187" decimals="0" id="ixv-15343" unitRef="usd">40737</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsForFees contextRef="c188" decimals="0" id="ixv-15344" unitRef="usd">342850</us-gaap:PaymentsForFees>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c189" decimals="0" id="ixv-15345" unitRef="usd">181710</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c190" decimals="0" id="ixv-15346" unitRef="usd">100570</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c3" decimals="0" id="ixv-15347" unitRef="usd">60570</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c191" decimals="0" id="ixv-15348" unitRef="usd">71427</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c192" decimals="0" id="ixv-15349" unitRef="usd">178568</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseCurrent contextRef="c193" decimals="0" id="ixv-15350" unitRef="usd">0</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c189" decimals="0" id="ixv-15351" unitRef="usd">10857</us-gaap:PrepaidExpenseCurrent>
    <silo:ScheduleOfShallPayUMBFeesTableTextBlock contextRef="c0" id="ixv-15352">Pursuant to the July 2021 Sponsored Research Agreement, the Company
shall pay UMB the fees below:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 7%; text-align: center"&gt;1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92,095&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Paid upon execution of the July 2021 Sponsored Research Agreement&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;92,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;92,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</silo:ScheduleOfShallPayUMBFeesTableTextBlock>
    <us-gaap:PaymentsForFees contextRef="c230" decimals="0" id="ixv-15353" unitRef="usd">92095</us-gaap:PaymentsForFees>
    <silo:PaymentDescription contextRef="c230" id="ixv-15354">Paid upon execution of the July 2021 Sponsored Research Agreement</silo:PaymentDescription>
    <us-gaap:PaymentsForFees contextRef="c231" decimals="0" id="ixv-15355" unitRef="usd">92095</us-gaap:PaymentsForFees>
    <silo:PaymentDescription contextRef="c231" id="ixv-15356">Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</silo:PaymentDescription>
    <us-gaap:PaymentsForFees contextRef="c232" decimals="0" id="ixv-15357" unitRef="usd">92095</us-gaap:PaymentsForFees>
    <silo:PaymentDescription contextRef="c232" id="ixv-15358">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</silo:PaymentDescription>
    <us-gaap:RepaymentsOfOtherDebt contextRef="c194" decimals="0" id="ixv-15359" unitRef="usd">92095</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:RepaymentsOfOtherDebt contextRef="c195" decimals="0" id="ixv-15360" unitRef="usd">92095</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c196" decimals="0" id="ixv-15361" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c197" decimals="0" id="ixv-15362" unitRef="usd">187090</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c198" decimals="0" id="ixv-15363" unitRef="usd">92095</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c199" decimals="0" id="ixv-15364" unitRef="usd">92095</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <silo:SponsoredResearchAgreementDescription contextRef="c191" id="ixv-15365">the Company shall pay a total of $1,436,082 to Columbia University
for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after
the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project.</silo:SponsoredResearchAgreementDescription>
    <us-gaap:RepaymentsOfOtherDebt contextRef="c200" decimals="0" id="ixv-15366" unitRef="usd">430825</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:RepaymentsOfOtherDebt contextRef="c201" decimals="0" id="ixv-15367" unitRef="usd">430825</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:RepaymentsOfOtherDebt contextRef="c202" decimals="0" id="ixv-15368" unitRef="usd">430825</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:RepaymentsOfOtherDebt contextRef="c203" decimals="0" id="ixv-15369" unitRef="usd">100000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:RepaymentsOfOtherDebt contextRef="c191" decimals="0" id="ixv-15370" unitRef="usd">330825</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:AccountsPayableCurrent contextRef="c204" decimals="0" id="ixv-15371" unitRef="usd">143607</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c205" decimals="0" id="ixv-15372" unitRef="usd">143607</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c191" decimals="0" id="ixv-15373" unitRef="usd">287218</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c192" decimals="0" id="ixv-15374" unitRef="usd">646236</us-gaap:ResearchAndDevelopmentExpense>
    <silo:ResearchProjectEstimatePercentage contextRef="c0" decimals="2" id="ixv-15375" unitRef="pure">0.90</silo:ResearchProjectEstimatePercentage>
    <us-gaap:PaymentsForFees contextRef="c206" decimals="0" id="ixv-15376" unitRef="usd">41306</us-gaap:PaymentsForFees>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c207" decimals="0" id="ixv-15377" unitRef="usd">21172</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c208" decimals="0" id="ixv-15378" unitRef="usd">19835</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c209" decimals="0" id="ixv-15379" unitRef="usd">33252</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c210" decimals="0" id="ixv-15380" unitRef="usd">5891</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c207" decimals="0" id="ixv-15381" unitRef="usd">20134</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ProceedsFromFeesReceived contextRef="c211" decimals="0" id="ixv-15382" unitRef="gbp">242932</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:ProceedsFromFeesReceived contextRef="c211" decimals="0" id="ixv-15383" unitRef="usd">261462</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:ProceedsFromFeesReceived contextRef="c212" decimals="0" id="ixv-15384" unitRef="usd">177903</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c213" decimals="0" id="ixv-15385" unitRef="usd">212428</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c214" decimals="0" id="ixv-15386" unitRef="usd">34525</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:PaymentsForFees contextRef="c215" decimals="0" id="ixv-15387" unitRef="usd">229000</us-gaap:PaymentsForFees>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c216" decimals="0" id="ixv-15388" unitRef="usd">182980</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c217" decimals="0" id="ixv-15389" unitRef="usd">182980</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c218" decimals="0" id="ixv-15390" unitRef="usd">0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c217" decimals="0" id="ixv-15391" unitRef="usd">71204</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c219" decimals="0" id="ixv-15392" unitRef="usd">241288</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-15393">On December 31, 2023, future amounts due under
sponsored study and research agreements between the Company and vendors is as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;725,244&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;725,244&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="0" id="ixv-15394" unitRef="usd">725244</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="0" id="ixv-15395" unitRef="usd">725244</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c220" decimals="0" id="ixv-15396" unitRef="usd">225000</us-gaap:DefinedContributionPlanCostRecognized>
    <silo:JointVentureInterestRate
      contextRef="c220"
      decimals="2"
      id="ixv-15397"
      unitRef="pure">0.51</silo:JointVentureInterestRate>
    <silo:JointVentureInterestRate
      contextRef="c221"
      decimals="2"
      id="ixv-15398"
      unitRef="pure">0.49</silo:JointVentureInterestRate>
    <silo:JointVentureInterestRate contextRef="c0" decimals="2" id="ixv-15399" unitRef="pure">0.60</silo:JointVentureInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c220" id="ixv-15400">P24M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:PaymentsForDepositsWithOtherInstitutions contextRef="c222" decimals="0" id="ixv-15401" unitRef="usd">5000</us-gaap:PaymentsForDepositsWithOtherInstitutions>
    <us-gaap:ProfessionalFees contextRef="c223" decimals="0" id="ixv-15402" unitRef="usd">25000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c224" decimals="0" id="ixv-15403" unitRef="usd">25000</us-gaap:ProfessionalFees>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-14626">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 9 &#x2013; &lt;span style="text-decoration:underline"&gt;INCOME
TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains deferred tax assets and
liabilities that reflect the net tax effects of temporary differences between the carrying amounts of the assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. The deferred tax assets on December 31, 2023 and 2022 consist of net
operating loss carry-forwards. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of
the attainment of future taxable income. As of December 31, 2023 and 2022, the Company had not recorded a liability for any unrecognized
tax positions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The items accounting for the difference between
income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2023 and 2022 was as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Income tax benefit at U.S. statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(777,143&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(820,796&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Income tax benefit &#x2013; state&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(240,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(254,056&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,510&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;988,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;940,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s approximate net deferred tax
asset as of December 31, 2023 and 2022 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Deferred Tax Asset:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-bottom: 1.5pt"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;2,538,565&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;1,550,388&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Total deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,538,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,550,388&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,538,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,550,388&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The net operating loss carryforward was approximately
$9,231,000 on December 31, 2023. Future utilization of the net operating loss carryforward to offset future taxable income is subject
to an annual limitation as a result of ownership changes that may occur in the future. The net operating loss carry forwards may be available
to reduce future years&#x2019; taxable income. Net loss carryforwards in the amount of $9,231,000 from 2018 onwards can be carried over
indefinitely, subject to annual usage limits. Management believes that it appears more likely than not that the Company will not realize
these tax benefits due to the Company&#x2019;s continuing losses for income taxes purposes. Accordingly, the Company has provided a 100%
valuation allowance on the deferred tax asset benefit related to the U.S. net operating loss carry forwards to reduce the asset to zero.
Management will review this valuation allowance periodically and will make adjustments as necessary. In 2023, the valuation allowance
increased by $988,177.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-15404">The items accounting for the difference between
income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2023 and 2022 was as
follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Income tax benefit at U.S. statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(777,143&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(820,796&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Income tax benefit &#x2013; state&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(240,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(254,056&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,510&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;988,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;940,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="0" id="ixv-15405" unitRef="usd">-777143</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="0" id="ixv-15406" unitRef="usd">-820796</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="0" id="ixv-15407" unitRef="usd">-240544</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c5" decimals="0" id="ixv-15408" unitRef="usd">-254056</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c0" decimals="0" id="ixv-15409" unitRef="usd">29510</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c5" decimals="0" id="ixv-15410" unitRef="usd">133994</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" id="ixv-15411" unitRef="usd">988177</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="0" id="ixv-15412" unitRef="usd">940858</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-15413">The Company&#x2019;s approximate net deferred tax
asset as of December 31, 2023 and 2022 was as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Deferred Tax Asset:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-bottom: 1.5pt"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;2,538,565&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;1,550,388&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Total deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,538,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,550,388&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,538,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,550,388&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-15414" unitRef="usd">2538565</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="0" id="ixv-15415" unitRef="usd">1550388</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" id="ixv-15416" unitRef="usd">2538565</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" id="ixv-15417" unitRef="usd">1550388</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c3" decimals="0" id="ixv-15418" unitRef="usd">2538565</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c4" decimals="0" id="ixv-15419" unitRef="usd">1550388</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-15420" unitRef="usd">9231000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c233" decimals="0" id="ixv-15421" unitRef="usd">9231000</us-gaap:OperatingLossCarryforwards>
    <srt:FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent contextRef="c3" decimals="2" id="ixv-15422" unitRef="pure">1</srt:FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="0" id="ixv-15423" unitRef="usd">0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" id="ixv-15424" unitRef="usd">988177</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-14779">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10 &#x2013; &lt;span style="text-decoration:underline"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock Repurchase Plan&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 9, 2024, the Board of Directors of the
Company approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the
Company&#x2019;s common stock until March 31, 2024. From January 1, 2024 to March 23, 2024, the Company purchased 62,607 shares of common
stock for a cost of $95,682.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="c234"
      decimals="-6"
      id="ixv-15425"
      unitRef="usd">1000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c235"
      decimals="0"
      id="ixv-15426"
      unitRef="shares">62607</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c235" decimals="0" id="ixv-15427" unitRef="usd">95682</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ShortTermInvestments
      contextRef="c4"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReceivablesNetCurrent
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredStockDesignated
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:PreferredStockDesignated
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockPreferredValue
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="c4"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="c0"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c0"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PenaltyFromEarlyTerminationOfCD
      contextRef="c5"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c5"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c0"
      decimals="2"
      id="hidden-fact-15"
      unitRef="usdPershares">-1.18</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c5"
      decimals="2"
      id="hidden-fact-16"
      unitRef="usdPershares">-1.71</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c5"
      decimals="2"
      id="hidden-fact-17"
      unitRef="usdPershares">0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c0"
      decimals="2"
      id="hidden-fact-18"
      unitRef="usdPershares">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="hidden-fact-19"
      unitRef="shares">2284240</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-20"
      unitRef="shares">3079874</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c6"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c9"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c10"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c13"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c16"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c17"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c18"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c13"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c14"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c16"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c17"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c18"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c13"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c16"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c17"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c18"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="c13"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="c16"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="c17"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="c18"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="c5"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c13"
      id="hidden-fact-42"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c15"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c16"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c17"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c19"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c22"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c23"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c25"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c26"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c28"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c29"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c30"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="c25"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="c26"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="c27"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="c29"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="c30"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c25"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c26"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c27"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c28"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c30"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c25"
      id="hidden-fact-66"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c25"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c27"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c31"
      id="hidden-fact-72"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c31"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:ProvisionForDoubtfulAccountsDiscontinuedOperations
      contextRef="c5"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="c0"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:AmortizationOfPrepaidStockbasedExpense
      contextRef="c5"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="c0"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:EquitySharesEarnedForServices
      contextRef="c0"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities
      contextRef="c0"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities
      contextRef="c5"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="c0"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c0"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity
      contextRef="c5"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c0"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments
      contextRef="c5"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="c0"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c52"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c53"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c54"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c55"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c56"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c51"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c52"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c53"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c55"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c56"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c57"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c58"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:AdditionsOfShortTermInvestments
      contextRef="c60"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c60"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c57"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:AdditionsofEquitySecurities
      contextRef="c64"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:EquitySecuritiesSalesAtOriginalCost
      contextRef="c64"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c66"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="c0"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="c5"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="c0"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="c0"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="c4"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReceivablesNetCurrent
      contextRef="c3"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1 contextRef="c115" id="hidden-fact-111" xsi:nil="true"/>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted
      contextRef="c115"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c117"
      id="hidden-fact-113"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c117"
      id="hidden-fact-114"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <silo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1 contextRef="c117" id="hidden-fact-115" xsi:nil="true"/>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted
      contextRef="c117"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c119"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
      contextRef="c122"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c122"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c123"
      id="hidden-fact-120"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c123"
      id="hidden-fact-121"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermYearsGranted contextRef="c123" id="hidden-fact-122" xsi:nil="true"/>
    <silo:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
      contextRef="c124"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c124"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable
      contextRef="c123"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c87"
      id="hidden-fact-126"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c88"
      id="hidden-fact-127"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:RoyaltyExpense
      contextRef="c225"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RoyaltyExpense
      contextRef="c226"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-15564">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-15565">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-15566">0001514183</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
